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Non-melanoma skin (NMSC) cancer is the most common human malignancy. Cutaneous 
squamous cell carcinoma (cSCC) and its precursor, actinic keratosis (AK) affect tens of 
thousands of people each year in the UK. Merkel cell carcinoma is a rare, yet aggressive type of 
NMSC recently linked with Merkel Cell Polyomavirus (MCPyV). In spite of the clinical burden of 
NMSC, key molecular regulatory patterns remain largely unknown. The aims of this thesis were to 
investigate genome-wide genetic, epigenetic and transcriptional changes in AK and cSCC, and 
assess the prevalence of MCPyV and its effect on methylation in NMSC.  
Copy-number analysis revealed that AK harbours significantly more genomic aberrations 
compared to skin, the majority of which occurs on chromosomes 8 and 9. Transcriptional profiling 
has found 292 and 308 genes as differentially expressed in AK compared to non-sunexposed and 
sun-exposed skin, respectively, and gene-set enrichment analysis (GSEA) revealed dysregulation 
of PPAR pathway in this lesion.  
Expression profiling of cSCC and AK has revealed 346 differentially expressed genes, and GSEA 
detected dysregulation in several canonical pathways including TGF-β and MAPK pathway. 
Aberrant methylation in cSCC cell lines occurs in the promoters of many developmental genes. A 
total of 1085 hyper- and 833 hypomethylated genes were detected in cSCCs, and GSEA revealed 
dysregulation of critical signalling pathways (WNT, MAPK signalling pathways). Methylation 
analysis of AK revealed a total of 4194 differentially methylated genes, and implicated FOXF2, 
PITX2, RUNX1 and SMAD3 transcription factors in this lesions. 
MiRNA profiling of cSCC and normal skin revealed significant dysregulation of 38 miRNAs 
including several of viral origin.  
MCPyV was shown to be common in NMSC, yet MCPyV nor human papillomavirus does not 
affect cSCC methylation. 
Taken together, this work provides novel insight into molecular regulation of cSCC oncogenesis, 
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1. General Introduction 
1.1. Cancer biology 
"Utque malum late solet immedicabile cancer  
Serpere, et illaesas vitiatias addere partes: 
Sic letalis hiems paulatim in pectora venit, 
Vitalesque vias et respiramina clausit." 
 
“As when a cancer in the body feeds, 
And gradual death from limb to limb proceeds; 
So does the chilness to each vital part 
Spread by degrees, and creeps into her heart;” 
Ovid, Metamorphoses 
1.1.1. Cancer: Historical Connotations  
The term “cancer” has rather famously originated in ancient Greece, where the resemblance of 
malignant tumours to the shape of a crab (“karkinos”)  lead Hippocrates to name malignancies 
after a sea decapod crustacean (Koss and Melamed, 2006) (Figure 1.1, 1.2). Further latinisation 
of the word by Celsus of ancient Rome gave grounds to the modern English meaning of cancer:  
a malignant neoplasm characterised by uncontrolled proliferation of body cells and capacity to 




Figure 1.1 Herakles and Hydra. Attic Black Figure by Diosophos (approx. 500 BC). Musée du 
Louvre, Paris, France, Figure taken from http://www.theoi.com 
 
Figure 1.2 Invasive ductal carcinoma of the breast (macroscopic view). Figure taken from Rosai: 
Surgical Pathology, 9th edition. 
In spite of vast medical progress and therapeutic advances achieved in the past six decades, the 
term ‘cancer’ in medical context is still, perhaps rightfully, associated with anxiety and fear, and 
represents a common health concern (Trumbo et al., 2007). Given the recent cancer 
epidemiology statistics, which suggest that 1.4 million people are diagnosed with cancer each 
year in the United States alone (Jemal et al., 2006), and one in four deaths are attributable to 
cancer in the United Kingdom (Statistics, 2010), it may be deduced that cancer is a disease that 
has reached epidemic proportions, and controlling the onset of novel cases and disease 
progression in currently affected people is of utmost importance not only from the public health 
perspective, but also for individual’s welfare: Cancer is associated with considerable mortality 
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(Ferlay et al., 2007), and also with significant suffering, namely during the advanced stage of the 
disease (Nilmanat et al., 2010). 
Cancer is not a modern disease, although it is often ascribed to modern technology and pollutants 
it produces, or modern lifestyle (McKinnell, 1998). Conversely, paleopathological evidence 
suggests that cancer existed already in dinosaurs of the Mesozoic era (250 million years ago) 
(Rehemtulla, 2010), and has plagued mankind since the dawn of civilisation (David and 
Zimmerman, 2010). Traits of multiple myeloma (bone marrow cancer) in fossil bones have been 
discovered in prehistoric American Indians (Morse et al., 1974), nasopharyngeal carcinoma has 
been reported in an Egyptian mummy (Strouhal, 1978), osteosarcoma has been identified in 
remains of a Celtic warrior from Bern region in Switzerland (McKinnell, 1998, Ortner et al., 2010), 
and ample evidence of other malignant tumours has been discovered in skeletons and mummies 
from many regions of practically all eras (Capasso, 2005).  
The value of available historical evidence of cancer epidemiology in the past, albeit limited, is 
relevant to questions about current cancer rates: Are those on an unequivocal rise due to 
environmental changes, better diagnostics or rather due to an increase in life expectancy? A 
study comparing age and gender distribution of cancer between ancient Egypt, modern age 
(1400-1800) German population and recent English population (early 20th century) suggests that 
there are no significant differences in cancer distribution when adjusted for age and gender 
(Nerlich et al., 2006), indicating that prolonged life expectancy is possibly one of the key factors in 
current trends of cancer incidence. Should current economic growth of Western societies 
continue, with the accessibility of modern medicine, research and nutrition for the general 
population, it may be reasonable to presume that life expectancy will continue to rise alongside 
cancer incidence. This vision underscores the need for effective cancer control and prevention, 
and unweaving the molecular background and regulation of cancer may provide effective tools for 
achieving this goal. 
1.1.2. Molecular Mechanisms of Cancer 
German biologist Theodore Boveri has hypothesised already in 1914 that cancer may be a 
disease of a single cell originating at the genetic level (Ried, 2009). The genetic element of 
cancer has been noticed in the Middle Ages, when references to ‘cancer houses’ or ‘cancer 
families’ were made (Tannock, 2005), but only the recent advances in molecular technologies 
have been able to clarify the anchoring of cancer in the genome. 
Cancer cells acquire intrinsic properties distinct from those of normal cells in the original tissue, 
and their malignant characteristics are manifested in cellular morphology, inherent functional 
properties and regulatory mechanisms. The transformation of a normal cell into a malignant one 
involves complex and dynamic changes of the genome which do not occur simultaneously, but 
rather represent the outcome of a multi-step process (Hanahan and Weinberg, 2000).  
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Over two hundred distinct types of cancer have been described and cathegorised, with diverse 
epidemiology, prognosis, sequelae, risk factors and therapeutic options. In order to define 
fundamental biological properties shared by various cancers, the following eight cellular features 
were proposed as key physiological alterations determining malignant growth in the vast majority 
of tumours: self-sustenance in proliferative signals, unresponsiveness to growth-inhibitory signals, 
resistance to apoptosis, unlimited potential for replication, sustained angiogenesis, capacity to 
invade the host tissue, propensity to form distant metastasis, energy metabolism reprogramming, 
and escaping immune destruction (Hanahan and Weinberg, 2011). Additionally, two so-called 
“enabling characteristics” were proposed as traits that make the acquisition of the remaining eight 
features of malignancy possible: genomic instability, which can orchestrate cancerous capabilities 
by random mutations and chromosomal rearrangements, and tumour-promoting inflammation, 
capable of promoting tumour progression by various biological means, including the production of 
growth factors, proangiogenic signals, extracellular matrix-modifying molecules, and by inducing 
epithelial-mesenchymal transition (EMT). 
While the concept of above-described “cancer hallmarks” has been widely accepted as the basis 
of tumourigenesis, it is important to stress that many of those features, such as sustained 
angiogenesis or limitless replicative potential, are shared by both malignant and benign tumours 
(Lazebnik, 2010). While the chief characteristic of cancer cells remains their ability to destroy the 
host through invasion and metastasis, benign tumours may also occasionally be fatal, and may 
even share certain molecular characteristics with their malignant counterparts (for example, 
germline mutation of the RB gene has been described in both retinoma, a benign ocular tumour, 
and histologically distinct malignant retinoblastoma (Abouzeid et al., 2009)). Additionally, many 
human malignancies are very lethal while not generating metastases, such as the most common 
primary brain tumour glioblastoma multiforme. Thus, while those eight physiological traits 
described as key for malignant transformation may indeed represent crucial determining changes 
in many if not most cancers, the individual nature of each tumour type (and perhaps tumour 
subtype) strongly implicates that the relative importance of particular tumourigenic features varies 
significantly between different malignancies.  
From a clinically practical point of view, cancer is essentially a disease of disrupted cell growth 
and proliferation (Jones and Thompson, 2009). Although cellular proliferation alone does not 
necessarily lead to cancer, if it is sustained in an environment rich in growth factor, pro-
inflammatory factors and agents capable of DNA damage, the neoplastic risk is severely 
potentiated (Coussens and Werb, 2002). Cells capable of uncontrolled proliferation usually 
harbour changes in genes and proteins that govern diverse metazoan growth-regulating 
processes, namely the cell cycle. Growth-regulating processes are evolutionarily conserved, and 
the molecular heterogeneity of distinct cancers is the mark of stochastic evolutionary forces that 





Figure 1.3 Key physiological processes representing currently accepted hallmarks of cancer. 
1.1.2.1. Cell Cycle, Tumour Suppressor Genes and Oncogenes 
Precise balance between cell division and cell death must be maintained in tissue homeostasis. 
Mammalian cell cycle represents a process consisting of a series of sequential, highly 
coordinated steps that involve cell growth, nutrients accumulation, DNA replication and ultimate 
cell division. The vital importance of this mechanism warrants tight regulation and control 
mechanisms. Clonal autonomy in vertebrates is restricted by several tiers of regulatory 
mechanisms, and the disruption of each one must occur for cancers to arise (Evan and Vousden, 
2001). Uncontrolled replication alone may not be sufficient for the genesis of human 
malignancies, and tumour cell resistance to cell death (apoptosis) is another important factor in 
the tumourigenic process. Unconstrained cell division is nonetheless one of key features of both 
benign and malignant tumours, thus the dysregulation of the cell cycle is a prominent 
characteristic of most cancers (Weber and Ashkar, 2000).  
Cell cycle is a mechanism regulated by the needs of the whole organism, promoted by cell-
extrinsic growth factors and cell-intrinsic protein kinases (Weber, 2007), and inhibited by products 
of genes that prevent progression of the cell cycle. Those genes belong among tumour-
suppressor genes, and include genes such as p21, p27 and p57 (cip/kip family of genes, 
regulated by a tumour suppressor p53), Rb and p16INK4a and p14arf (Table 1.1). Dysregulation 
of the cell cycle may occur due to mutations in these cell cycle inhibitors, leading to uncontrolled 
proliferation and ultimately tumour formation. For example, patients with Li-Fraumeni syndrome, a 





























mutations in Rb, the first tumour suppressor gene identified in 1980’s, are the molecular cause of 
retinoblastoma, malignant tumour of the eye retina most commonly diagnosed in young children1.  
Tumour suppressors are not exclusively cell cycle inhibitors, but represent a distinct category of 
genes. Their translational products include proteins that generally have repressive effects on cell 
properties that, if uninhibited, would lead to a tumour formation, and are abrogated in cancer cells. 
Conversely, oncogenes contribute to tumour formation by attributing cellular features that will 
potentiate the cell to become malignant. The loss of both alleles (two-hit hypothesis) is usually 
required for the phenotype of tumour suppressor loss (Rook and Burns, 2010), while a single 
allele loss of an oncogene can be sufficient for phenotypic presentation, although there are 
exceptions to this rule.  
Oncogenes are evolutionarily conserved molecules, mostly belonging among growth factors, 
growth factor receptors (GFR) or down-stream effectors of GFR (Neal and Hoskin, 2009). It is 
generally estimated that between five to seven genes must be abolished in a cell to develop 
cancerous phenotype, and those must include both activated oncogenes and inactivated tumour 
suppressors, yet there are tumours in which a single genetic mutation represents the direct cause 
of the disease: the vast majority of chronic myeloid leukemia cases are characterised by a 
cytogenetic abnormality t(9, 22) translocation, the so-called “Philadelphia chromosome”. This 
genetic mutation leads to the formation of the BCR-ABL oncogene, resulting in subsequent 
dysregulation of molecular signalling which enhances proliferative potential and apoptosis 
resistance in progenitor cells of the haematopoietic system. The ultimate result is a dramatic 
increase in the number of myeloid cell (Arora and Scholar, 2005). 
Both oncogenes and tumour suppressors are regulated by genetic and epigenetic mechanisms. 
Genetic changes include changes in the DNA sequence by mutation (base substitution, insertion, 
or deletion, chromosomal rearrangement), or aberrant copy number of DNA segments (Stratton, 
2011), while epigenetic changes occur mainly due to three mechanisms: promoter methylation or 
demethylation, histone modification and microRNA (miRNA) dysregulation. In summary, the 
genetic cause of cancer can be a single driving change (such as mutation), or more likely a 
combination of genetic and epigenetic changes capable of causing cellular phenotype that will 
lead to a tumour formation. 
1.1.2.2. Retinoblastoma gene 
Since its seminal discovery as the first tumour suppressor gene in 1986 (Friend et al., 1986, Lee 
et al., 1987), the mechanistic characterisation of the RB gene has focused namely on its function 
in cell cycle progression control. Its capacity to arrest cell cycle in the G1 phase was thought to 
represent the main mechanism through which RB executes its tumour suppressor function. 
However, it has become clear that in addition to G1 checkpoint, RB posseses crucial capacity in 
                                                       
1 As described above, this mutation is detected also in retinoma, a benign tumour of the eye. 
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other processes, including tissue differentiation during both embryogenesis and adult life, 
apoptosis, cell cycle arrest maintenance and preserving chromosomal stability (Burkhart and 
Sage, 2008).  
Rb protein (pRb) is able to bind and thus inhibit E2F transcription factors during the G1 phase. 
E2F regulates several downstream genes, many of which are involved in key cell cycle regulatory 
processes. The expression of E2F target genes is repressed by this complex through recruiting 
additional corepressors that modulate chromatin (Gordon and Du, 2011). Those include histone 
deactylases, DNA methyltransferase 1 (DNMT1), and heterochromatin protein 1A  (HP1A) 
(Burkhart and Sage, 2008).  
The coupling of pRb and E2F is inhibited by various cyclin-dependent kinases (CDKs). Mitogens 
produced during G1 phase induce activation of cyclin D/Cdk4-Cdk6, and cyclin E/Cdk2, which 
leads to pRb phosphorylation and E2F release. Upon activation of downstream genes, the cell 
progresses from G1 to S phase. The phosphorylation of pRb and subsequent cell cycle 
progression is conversely inhibited by antigrowth signals through down-regulating cyclin protein 
levels, or by inducing cyclin-dependent kinase inhibitors, such as INK4A or CIP/KIP family genes. 
Thus, the Rb protein serves as a cell cycle “switch” that is controlled by both growth promoting 
and growth inhibiting molecules. 
Dysregulation of this pathway has been described in many cancers, including sporadic breast, 
bladder, prostate, lung, liver, oesophageal, brain cancer, melanoma and leukaemia. The 
mechanisms of RB inactivation include not only DNA mutation, but also hyperphosphorylation by 
overexpressed cyclins and CDKs, DNA methylation, miRNAs, and sequestration by viral 
oncoproteins. In cervical squamous cell carcinoma (SCC) and head and neck SCC, human 
papillomavirus (HPV) 16 is suspected to induce malignant transformation by inactivating RB via 
the expression of the E7 oncoprotein (Wittekindt et al., 2012).  
The currently known communication network of pRb is vast and still expanding, and contains 
many binding partners and target proteins involved in diverse cellular proceses (Figure 1.4). This 
clearly demonstrates that the role of the RB gene is by no means linear, and its precise 






Figure 1.4 The role of RB in various critical cellular processes. Figure taken from (Burkhart and 
Sage, 2008). 
1.1.2.3. P53 gene family 
The P53 gene, also known as the “guardian of the genome”, is the most commonly mutated gene 
in human cancers. One of its key functions as an archetypal checkpoint regulator is to ensure that 
a replicating cell arrests in G1 phase in response to DNA damage, and repairs its genome prior to 
cell cycle progression (Sherr, 1996). The loss of p53 leads to decreased fidelity during DNA 
replication, aberrant chromosome segregation due to multiple centrosomes, and unless changes 
are severe enough to induce a mitotic catastrophe, the ultimate result is a rapidly proliferating cell 
with a highly unstable genome, resistant to apoptosis and capable of progession towards 
malignancy.  
In addition to regulating cell cycle progression, the plethora of p53 downstream effectors regulate 
other important mechanisms such as cellular metabolism, senescence, cell motility, and to some 
effect response to cancer therapy (Lai et al., 2012, Barbieri et al., 2006). Generally speaking, cells 
with intact p53 show greater response to anticancer therapies (O'Connor et al., 1997). 
Similar to the RB gene, inactivation of P53 occurs through multiple mechanisms distinct in various 
tumour types. Mutations in the DNA-binding domain are typical for colon, breast, lung, bladder, 
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brain, pancreas and other cancers, inactivation by viral oncogenes has been described in cervical 
cancer and lymphomas, p53 mislocalisation to the cytoplasm leads to breast cancer and 
neuroblastoma (Vogelstein et al., 2000). Epigenetic modifications of P53 include DNA 
methylation, targeting by miRNA and by non-coding RNA, and chromatin organisation (Saldana-
Meyer and Recillas-Targa, 2011). 
P63, described in 1997 as a member of p53 family, is a molecule that posseses both tumour 
suppressor and oncogenic properties. Its full length isoform contains the transactivation domain 
(TAp63), and is capable of inducing cell cycle arrest and apoptosis (Gressner et al., 2005). On the 
other hand, the amino-deleted p63 isoforms (ΔNp63) play an important role in development and 
epidermal organisation, and exhibit oncogenic properies (Yang et al., 1999, Mills et al., 1999).  
In contrast to p53, mutations of p63 are rare in human cancers. In fact, p63 can even be 
overexpressed in certain cancers, such as bladder cancer or cervical carcinoma. Many tumours 
show simultaneous upregulation of both TAp63 and ΔNp63 isoforms, with the latter being more 
abundant at the protein level (Melino, 2011). While the ratio of individual isoforms seems to 
determine the cell fate, the loss of endogenous p63 leads to increased invasiveness and 
metastatic potential of squamous cell lines, and the acquisition of mesenchymal properties 
(Barbieri et al., 2006). 
P73 bears many similarities to P63: it is rarely mutated in cancers, and also transcribed in various 
isoforms which display antagonistic effects; the TAp73 isoform shows properties analogous to 
tumour suppressor gene by inducing cell cycle arrest, apoptosis and protecting against genomic 
instability, while the ΔNp73 isoform has oncogenic features (Conforti et al., 2012). The ultimate 
regulatory effect imposed by both p63 and p73 seems to depend on precise ratio of various 
isoforms and other transcription factors. Precise details of this process remain to be elucidated, 
and may serve as the basis of future targeted cancer therapies. 
Other important tumour suppressor genes and malignancies associated with their hereditary 
alterations are listed in Table 1.1. 
Gene	   Associated	  hereditary	  
syndrome	  
Major	  hereditary	  tumour	  types	   Chromosomal	  
location	  
APC	   FAP	   Colon,	  thyroid,	  stomach,	  intestine	   5q21	  
ATM	   Ataxia	  telangiectasia	   Leukaemias,	  lymphomas,	  brain	  
cancer	  
11q22-­‐q23	  
BHD	   Birt-­‐Hogg-­‐Dube	  syndrome	   Kidney,	  hair	  follicle	  tumours	   17p11.2	  
BLM	   Bloom	  syndrome	   Leukaemias,	  lymphomas,	  skin	  cancer	   15q26.1	  
BRCA1	  and	  
BRCA	  2	  
Hereditary	  breast	  cancer	   Breast,	  ovarian	  cancer	   17q21	  
13q12.3	  
CDKN2A	   Familial	  malignant	  
melanoma	  
Melanoma,	  pancreas	   9p21	  
CYLD	   Familial	  cylindromatosis	   Pilotrichomas	   16q12.1	  
FANCA	   Fanconi	  anaemia	   Leukaemias	   16q24.3	  
FH	   Hereditary	  leiomyomatosis	   Leiomyoma	   1q42.1	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FHIT	   Muir-­‐Torre	  familial	  cancer	  
syndrome.	  
Non-­‐melanoma	  skin	  cancer,	  colon	  
cancer,	  renal	  cell	  carcinoma	  
3p14.2	  
GPC3	   Simpson-­‐Golabi-­‐Behmel	  
syndrome	  
Embryonal	  cancers	   Xq26.1	  
MEN1	   Multiple	  endocrine	  
neoplasia	  type	  I	  
Parathyroid,	  pituitary	  cancer,	  
carcinoid	  
11q13	  
NF1	   Neurofibromatosis	  type	  1	   Neurofibroma	   17q11.2	  
NF2	   Neurofibromatosis	  type	  2	   Meningioma,	  acoustic	  neuroma	   22q12.2	  
PTCH	   Gorlin	  syndrome	   Skin,	  medulloblastoma	   9q22.3	  
PTEN	   Cowden	  syndrome	   Hamartoma,	  glioma,	  uterus	   13q14.2	  
RB1	   Hereditary	  retinoblastoma	   Retinoblastoma	   13q14	  
STK11	   Peutz-­‐Jeghers	  syndrome	   Intestinal,	  ovarian,	  pancreatic	  cancer	   19p13.3	  
SUFU	   Medulloblastoma	  
predisposition	  
Skin,	  medulloblastoma	   10q24.32	  
TP53	   Li-­‐Fraumeni	  syndrome	   Breast,	  brain,	  leukaemia,	  adrenal	  
cancer	  
17p13	  
TSC1,	  TSC2	   Tuberous	  sclerosis	   Hamartoma,	  kidney	   9q34	  
16p13.3	  
VHL	   Von	  Hippel–Lindau	  
syndrome	  
Kidney	   3p26-­‐p25	  
WT1	   Familial	  Wilms	  Tumour	   Kidney	  tumour	   11p13	  
XPA	   Xeroderma	  pigmentosum	   Skin	  cancer	   9q22.3	  
Table 1.1 Tumour suppressor genes important in human malignancies. Table adapted from 
(Vogelstein and Kinzler, 2004). 
1.1.2.4. Oncogenes 
The term oncogene denotes a gene capable of contributing to malignant transformation under 
certain conditions, such as mutations or viral infection. Proto-oncogene is a gene that becomes 
tumourigenic if its expression becomes excessive, or if it is consitutively activated, as opposite to 
its wild-type counterpart. Oncogene activations can occur due to chromosomal translocations 
(such as the above-described Philadelphia chromosome in CML), gene amplifications, or due to 
intragenic mutations that alter residues with regulatory function of the translated protein (such as 
BRAF mutation changing a valine to a glutamate). In contrast to tumour suppressor genes, an 
activating somatic mutation in a single oncogene allele suffices to provide a selective growth 
advantage to the cell (Vogelstein and Kinzler, 2004). Many oncogenes were first identified during 
studies of virus-induced tumourigenesis (see Chapter 1.1.4.3), and retrovirus-associated 
oncogenes relevant in human tumours are listed in Table 1.2. 
Gene	   Mechanism	  of	  
inactivation	  
Associated	  tumour	  types	   Chromosomal	  
location	  
MYC	   Amplification	   Neuroblastoma,	  medulloblastoma	  




EGFR	   Mutation	   Glioblastoma,	  non-­‐small-­‐cell	  lung	  
cancer	  
7p12	  
RAS	   Mutation	   Pancreatic	  cancer	   12p12.1	  (KRAS)	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RAF	   Mutation	   Melanoma	   7q34	  (BRAF)	  
Table 1.2 Oncogenes first identified in retroviruses as drivers in human cancer. Table adapted 
from (Vogt, 2012). 
1.1.2.5. MYC Oncogene 
The MYC oncogene is a DNA-binding protein known to contribute to the formation of many 
malignant tumours. The gene was first shown to be altered by chromosomal translocation in 
Burkitt lymphoma (Dalla-Favera et al., 1982), and since then found to be translocated or amplified 
in an array of cancers, including multiple myeloma, T-cell leukemia and colon carcinoma.  
MYC interacts with many canonical pathways, including TGFβ, Wnt, Hedgehog, Notch, p53, PI3K, 
and its dysregulation thus disrupts many cellular processes, including metabolism and cell cycle. 
Importantly, MYC is capable of inducing many miRNAs,  including mir-17 cluster which inbihits 
tumour suppressors such as PTEN (Dang, 2012). 
In addition to its implication in the genesis of cancer, MYC was described as one of four genes 
that are capable of reprogramming differentiated fibroblasts to a pluripotent stem cell (Takahashi 
and Yamanaka, 2006). The precise molecular role of MYC in pluripotent reprogramming is not 
entirely clear, but it seems to involve chromatin structure regulation and polycomb-mediated gene 
silencing. However, it is of note that in contrast to its function in pluripotency maintenance, MYC is 
required for terminal differentiation of human epidermal stem cells (Gandarillas and Watt, 1997). 
This data suggests that the concrete role of MYC depends on given cellular context and the 
balance of other regulatory molecules. 
Other important oncogenes are listed in Table 1.3. 











MET	   Hereditary	  papillary	  renal	  
cancer	  
Kidney	  cancer	   7q31	  










Table 1.3 Important oncogenes frequently mutated in human malignancies. Table adapted from 
(Vogelstein and Kinzler, 2004). 
It seems probable that the inhibition of overexpressed oncogenes and functional restoration of 
mutated tumour suppressor genes may abrogate malignant properties of cancerous cells. Many 
compounds that target specific molecular alterations in cancer are currently approved for 
application in clinical practice (see Chapter 1.1.3), and many more are currently being scrutinised 
in preclinical testing and clinical trials. However, the complexness of cellular signalling network 
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suggests that the inhibition of a single molecule is unlikely to achieve full anticancerous effect, 
and that multimodal approach to treatment represents the best clinical practice. 
1.1.3. Cancer therapies based on molecular properties of target tumours 
The fundamental goal of cancer therapy is to permanently eradicate malignant cells, while 
preserving normal cells intact. The non-selective nature of traditionally administered therapeutic 
agents including cytotoxic chemotherapy and radiation treatment, while unequivocally 
therapeutically beneficial, often leads to significant damage in healthy tissues, namely in those 
which contain  rapidly dividing cells, as this cellular feature is directly targeted by those 
therapeutic modalities. The most common tissues adversely affected by chemotherapy therapy 
include the skin, cutaneous adnexa, mucous membranes, gastrointestinal tissue and the 
haematopoietic system. Additionally, radiation treatment may cause damage to healthy tissues its 
beam has to penetrate in order to reach the target tumour mass.  
An important trait of many tumours is their resistance to various anticancer agents; either intrinsic 
or acquired during treatment course. The most frequent causes of acquired resistance to a broad 
range of anticancer chemotherapeutics (multidrug resistance) include the expression of energy-
dependent transporters that recognize and subsequently eliminate chemotherapeutics from the 
cell, resistance to drug-induced apoptosis, and the initiation of drug-detoxifying mechanisms 
(Gottesman, 2002). 
Unravelling molecular mechanisms driving tumourigenesis holds a great promise for personalised 
cancer therapy; however, practically all patients become resistant to those agents at a certain 
stage of their disease. Specific cell-autonomous molecular mechanisms, such as MET 
overexpression, and tumour microenvironment alterations confer resistance to molecular targeted 
therapies (Straussman et al., 2012), suggesting strong compensatory mechanisms are induced 
within cancer cells and the surrounding space in order to overcome the anticancerous effect of 
those drugs. 
Many cancer therapies are designed to target a specific molecular mechanism driving cancer 
cells: radiation therapy targets mainly rapidly dividing cells due to cell cycle dysregulation, 
azacitidine used in the treatment of myelodysplastic syndrome (Kaminskas et al., 2005) reduces 
DNA methylation (Antonsson et al., 1987), targeted therapeutic agents include small molecules 
that inhibit a specific protein that promotes cancer (Mladkova and Chakravarti, 2009). Examples 
include imatinib, which inhibits bcr-abl protein in chronic myeloid leukaemia (Deininger et al., 
2005), bevacizumab, which inhibits vascular endothelial growth factor (Mladkova and Chakravarti, 
2009) and is approved for application in colon, breast, brain, kidney and lung cancer (Cohen et 
al., 2007, Pazdur, 2010), rendering obvious the fact that discovering molecules responsible for 
cancer onset and growth is a feasible route towards novel therapies and potentially better 
perspectives for cancer patients. 
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A list of selected targeted therapeutics currently approved for clinical application is listed in Table 
1.4. 
Drug	  name	   Molecular	  target	   Approved	  indication	  
Bevacizumab	   VEGF	   Metastatic	  kidney	  and	  colon	  cancer,	  
glioblastoma,	  lung	  cancer	  
Brentuximab	  vedotin	   CD30	   systemic	  anaplastic	  large	  cell	  lymphoma,	  
Hodgkin	  lymphoma	  
Cabozantinib	   VEGF	  receptors,	  RET,	  MET,	  
TRKB,	  and	  TIE2.	  
Metastatic	  medullary	  thyroid	  cancer	  
Cetuximab	   EGRF,	  HER-­‐1	   Squamous	  cell	  carcinoma	  of	  the	  head	  and	  
neck,	  colorectal	  cancer	  
Erlotinib	   EGFR	   Non-­‐small	  cell	  lung	  cancer	  and	  pancreatic	  
cancer	  
Ipilimumab	   CTLA-­‐4	   Metastatic	  melanoma	  
Pazopanib	   VEGF	  receptors,	  c-­‐KIT,	  
PDGFR	  
Advanced	  renal	  cell	  carcinoma	  and	  
advanced	  soft	  tissue	  sarcoma.	  
Trastuzumab	   ERBB2	   ERBB2-­‐positive	  breast	  cancer,	  ERBB2-­‐
positive	  gastric	  or	  gastro-­‐oesophageal	  
junction	  carcinoma	  
Vemurafenib	   BRAF	  V600E	   Metastatic	  melanoma	  
Vismodegib	   SMO	   Metastatic	  or	  recurrent	  locally	  advanced	  
basal	  cell	  carcinoma	  
Vorinostat	   HDAC	  inhibitor	   Cutaneous	  T-­‐cell	  lymphoma	  
Table 1.4 Targeted therapeutics currently approved for clinical application in cancer patients. 
1.1.4. Pathogenesis of cancer 
The mechanism by which various oncogenes or tumour-suppressors are dysregulated varies 
considerably between tumour to tumour. However, epidemiologal data provide evidence for some 
general mechanisms responsible for tumour formation: those may result due to the action of an 
environmental factor or due to a leverage of microorganisms. 
1.1.4.1. Chemical carcinogens 
Chemical factors epidemiologically linked to cancer include industrial products, but also the 
products of microorganisms. Examples include cigarette smoking, responsible for approximately 
25% of cancer-related death in the UK (Neal and Hoskin, 2009), leading mainly to lung, oral cavity 
and larynx cancer. Exposure to asbestos is linked to mesothelioma (Peto et al., 1995), aniline 
dyes are associated with cancer of the urinary system (Clayson, 1981), and soot captured in the 
skin rugosity of the scrotum of chimney sweeps leads to cutaneous squamous cell carcinoma 
(Johnson et al., 1992). Aflatoxin produced by Aspergillus flavus, a fungal contaminant of poorly 
stored food, causes hepatocellular carcinoma (Liu and Wu, 2010), and nitrosamines, which are 
the product of intestinal microflora from nitrogenous compounds, have been implicated in gastric 
cancer (Hill et al., 1973).  
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1.1.4.2. Physical carcinogens  
Physical factors are capable of causing DNA damage, such as strand breaks or point mutations. 
Such events occur in human organism on a daily basis; however, the damaged DNA is either 
repaired or the cell is removed and prevented from multiplication. If those mechanisms fail, the 
damaged cell can replicate and promote the genetic error, possibly leading to cancer formation. 
Given that skin and mucosal surfaces are most exposed to the external environment, tumours 
resulting from physical carcinogens are especially common in those areas. 
Ultraviolet radiation: Solar radiation is created in the core of the Sun by nuclear fusion, when two 
hydrogen atoms are fused into helium. This process causes atoms to discharge photons, which 
are absorbed by the adjacent gas molecule (about 1 mm away), and upon photon absorption, the 
gas molecule heats up and releases a photon, which then undergoes the same process until it 
reaches the Sun surface. The time it takes the photon to reach the surface via repeated 
absorptions and re-emissions is about 100,000 years, and another 8 minutes to reach the Earth. 
Approximately 40% of solar radiation that reaches the atmosphere passes down to the earth’s 
surface. In the atmosphere, ultraviolet (UV) radiation  < 200 nm in wavelength (vacuum UV) is 
absorbed by oxygen and nitrogen and turned into heat, UV radiation with wavelengths from 200 to 
300 nm (UVC, most of UVB) is absorbed by ozone (O3), infrared radiation with wavelength > 700 
nm is partially absorbed by carbon dioxide, ozone, and water vapours. About 30% of the sun's 
visible spectrum (wavelengths from 400 nm to 700 nm) is reflected back to space. Ultimately, 
98% of UV radiation that reaches the Earth’s surface is UVA radiation. 
 
Figure 1.5 The electromagenetic spectrum. Figure taken from 
http://www.eclogiteskincare.com/blog/wp-content/uploads/2009/07/uv-light-spectrum.gif. 
The most destructive from of UV radiation is the UVB, albeit needed for vitamin D synthesis, since 
it causes photochemical damage to DNA. Excessive exposure to UVB radiation can lead to 
actinic keratoses (precursors of cSCC – see section 1.3.2.2), cSCC, BCC and melanoma. 
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Sunbeds used for cosmetic tans emit about 3% of UVB and have been linked to an increased risk 
of skin cancer, and have been classified as a human carcinogen by by the International Agency 
for Research on Cancer. Moreover, the vast majority of sunbeds in England exceed safe levels of 
UV radiaton, increasing the risk of skin cancer for users (Tierney et al., 2013). 
Ionising radiation consists of particles capable of detaching electrons from atoms (‘ionising’ them). 
There are both natural and artificial sources of radiation, including cosmic radiation or Radon gas, 
and nuclear power-plants or nuclear medicine. The main effect of ionising radiation includes DNA 
damage, particularly in dividing cells, which can lead to tumour formation. Hiroshima and 
Nagasaki atomic bomb survivors developed leukaemia and many solid cancers (Ozasa et al., 
2011), Chernobyl accident lead to thyroid cancer namely among children in the contaminated 
areas (Reiners et al., 2008), and political prisoners in the former Czechoslovakia sentenced to 
uraninite mining mostly developed lung cancer or leukaemia (Kulich et al., 2011). 
1.1.4.3. Oncogenic viruses 
Viruses are non-cellular organisms unable to reproduce without the host cell. Given that a 
considerable proportion of cancers - estimated at 15% (Parsonnet, 1999) - is linked directly or 
indirectly to viral infection, future preventive measures including vaccines may significantly 
contribute to decreasing the incidence of at least some cancers. 
Retroviruses 
Retroviruses, a group of RNA viruses characterised by reverse transcription, played a seminal 
role in the elucidation of many biological processes, including the molecular mechanism of 
malignant transformation. Following infection of the host cell, the viral RNA genome is transcribed 
by the enzyme reverse transcriptase into a double stranded DNA. This genomic product is then 
integrated into the host genome at almost random sites with the help of the enzyme integrase, 
becoming a provirus (Butel, 2000). The infection is permanent, as the provirus is practically never 
lost from the genome. The provirus may remain inactive, or be actively transcribed by the cellular 
enzyme RNA polymerase II, which ultimately leads to the production of new viruses that can 
infect other host cells, or other hosts. If the virus infects a germline cell, it becomes an 
“endogenous retrovirus” and can be inherited by subsequent generations through classical 
Mendelian inheritance (Groom and Bishop, 2012)2.  
Historically, the very first retrovirus isolated from a neoplastic disease came from the blood of 
chickens affected with erythro-myeloblastic leukaemia, and the filtered product was reported to 
induce the disease in inoculated chickens (Rubin, 2011a). In 1911 Peyton Rous isolated “a 
separable agent” from the spindle cell sarcoma of a Plymouth Rock hen, later called Rous 
sarcoma virus (RSV). This agent was also capable of inducing solid tumours in other inoculated 
                                                       




birds (Rous, 1911), and served as the stepping stone for decades of cancer research to follow. In 
subsequent years, tens of retroviruses were isolated from various animal tumours (mainly avian 
and murine), and eventually it was discovered that malignant transformation incited by 
retroviruses is induced through oncogenes; either endogenous to the virus, or by the acquisition 
of protooncogenes of the cell. Based on this determining feature, oncogenic retroviruses fall into 
two groups: acute transforming retroviruses, and slow transforming retroviruses. 
Acute transforming retroviruses, as their name implies, transform the host cell rapidly because of 
carrying additional genetic information – viral oncogenes (Duesberg and Vogt, 1970). Their 
genome is simple, incapable of viral self-replication, and their high tranformation capacity leads to 
tumours within weeks of infection. The RSV is a prototype of this class, and its src oncogene 
encodes a tyrosine protein kinase critical for regulating signal transduction. Approximately 25 viral 
oncogenes were discovered to date, and it is of important note that these retroviral oncogenes 
were originially derived from normal cellular genes (Butel, 2000). Essentially, these retroviruses 
contain a viral homologue of a cellular proto-oncogene that was “stolen” from the host cell during 
phylogenesis of the retrovirus to promote its replication. 
In contrast to acute transforming retroviruses, slow transforming retroviruses have more complex 
genomes, are not replication-defective, do not carry their own oncogenes and tumours they 
induce require longer periods of time to form. Malignant transformation occurs by several 
mechanisms: cellular protooncogenes are activated by the insertion of a viral long terminal repeat 
(LTR) close to a protooncogene promoter or enhancer, causing overexpression of the cellular 
gene, which then becomes responsible for the tumour formation (Fan and Johnson, 2011). More 
than 70 proto-oncogenes have been described to be activated by the insertion of a retrovirus. 
Other oncogenic mechanisms include coding for auxillary viral oncoproteins (such as tax protein 
coded by HTLV-1), and retrovial envelope (env) proteins that cause lung cancer in sheep infected 
by JSRV.  
In humans, important cancerogenic retroviruses include Human T-cell lymphotropic virus type 1 
(HTLV-1) and HTLV-2. HTLV-1 causes adult T-cell leukaemia-lymphoma in Japan and Caribbean 
regions, HTLV-2 infection can lead to haematologic malignancies. While not directly oncogenic, 
HIV-1 and HIV-2 are retroviruses that cause AIDS in humans, a disease associated with 
increased cancer risk, and thereby indirectly contribute to cancer indicence world-wide. 
DNA viruses 
Genomes of small DNA oncogenic viruses (polyomaviruses, papillomaviruses, adenoviruses) do 
not posses physiological properties essential for the genome replication, nor the components 
necessary for genomic transcription. Thus, malignant transformation by DNA viruses requires 
multiple steps that lead to the transition of a quiescent cell into a proliferating one, and 
subsequent utilisation of the host cell’s transcription and replication machinery by the virus. The 
proliferative state is induced by the products of transforming oncogenes, which are of viral origin 
in contrast to retroviral oncogenes, and are indispensible for viral replication and other functions. 
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DNA viruses hijack the cell cycle for its own replication by targeting key regulatory molecules 
including tumour suppressors pRb and p53. Viruses achieve this goal through various means: 
upon binding to p53, SV40 large T antigen (T-ag) inhibits the DNA binding activity of p53, while 
HPV oncoprotein E6 leads to ubiquitin-mediated degradation of the target protein (Butel, 2000). 
Both T-ag and HPV E7 contain a short region of homology capable of binding to pRb, with 
selectivity towards its active (hypophosphorylated) form. It is of note that DNA oncogenic viruses 
share the ability to inhibit pRb and p53 although they are not evolutionarily too closely related. An 
oncogenic DNA virus may cause a single type of cancer, or multiple tumour types. Moreover, 
some viruses are able to cause tumours in a variety of tissues, and even non-neoplastic diseases 
(see Table 1.5). Given that not all infected hosts develop tumours, it seems very likely that many 
host factors including the immune state play an important role in virus-induced tumourigenesis. 
Other oncogenic viruses include Hepatitis B and C viruses which cause hepatocelular cancer; 
Epstein-Barr virus (human herpes virus 4), which causes infectious mononucleosis, has been 
linked with lymphoma formation, namely in Africa (Parkin, 2006); human herpes virus 8 is the 
causative agent of Kaposi’s sarcoma (Moore and Chang, 1995).  
Recently, a novel DNA polyoma virus has been discovered in samples of Merkel Cell carcinoma 
(MCC), a rare type of skin cancer, and is suspected to be the cause of majority of MCC. It is the 
first example of polyoma virus integrating into the host genome (discussed in more detail in 
Chapter 5). 
Summary of known oncogenic viruses is provided in Table 1.5. 
Characteristic HBV EBV HPV HHV-8 SV40 MCPyV 
Genome size 
(kilobasepairs) 
3.2 172 8 165 5.2 5.4 































































Table 1.5 Key ds-DNA oncogenic viruses and their characteristics. PEL - primary effusion 
lymphoma. Table adapted from (Butel, 2000). 
HPV 
Human papillomavirus (HPV) is a double-stranded DNA virus with more than 100 types 
characterised based on L1 gene homology (figure 1.4). HPV currently represents one of the most 
common sexually transmitted infections globally, and the majority of sexually active individuals 
become infected during their lifetime (Baseman and Koutsky, 2005). However, most infected 
individuals experience an asymptomatic infection course, with the virus clearance occurring in up 
to 90% of cases, and only the remaining 10% individuals with persistent infection are at increased 
risk of developing cancer (Zandberg et al., 2013). 
Commonly, HPV causes viral warts (Orth et al., 1977) (Figure 1.5), but a subset of α-HPV, 
including types 16 and 18, confer a high risk of malignant transformation and account for up to 
70% of cervical cancers (Parkin, 2006), which in recent years has lead to the development of a 
clinically approved vaccine against those HPV types (Saslow et al., 2007). In non-melanoma skin 
cancer, the mechanistic link between HPV infection and tumour formation is still rather elusive 




Figure 1.6 Phylogenetic tree of papillomaviruses according to LT1 gene sequence of 189 
papillomaviruses. Figure taken from (Bernard et al., 2010). 
 
Figure 1.7 Clinical presentation of viral warts in various anatomic locations. 
HPV and genital and non-genital cancers 
The aetiological link between an infectious agent and genital cancers has been first suspected in 
1842, when Rigoni-Stern, an Italian doctor, noticed an epidemiological association between the 
mortality from cervical cancer and sexual activity. Over a century later, HPV particles were first 
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demonstrated in cervical condylomata in 1978, and in 1980, Gissmann and zur Hausen isolated 
HPV DNA from genital warts (Gissmann and Hausen, 1980). It was later shown that HPV 
genotype 16 (HPV-16) and HPV-18 represent key subtypes directly linked to cervical cancer 
onset. In recent years, the association of HPV and human cancer has broadened from genital 
tumours to neoplasia of other anatomical locations (see Table 1.6), including anal, vaginal, vulvar 
and penile cancers, in addition to oropharyngeal cancer (Zandberg et al., 2013). This 
epidemiological trend suggests that HPV vaccines may be effective in preventing malignancies in 
diverse groups of patients. 
Anatomic	  area	   Annual	  no.	  of	  cases	   HPV-­‐associated	   HPV	  16/18	  associated	  
Cervix	   11,845	   11,370	   9000	  
Vagina	   714	   460	   400	  
Vulva	   3062	   1560	   1350	  
Anus	  and	  rectum	  (women)	   2977	   2770	   2590	  
Oropharynx	  (women)	   2306	   1450	   1380	  
Total	  (women)	   20,903	   17,61	   14,72	  
Penis	   1000	   360	   310	  
Anus	  and	  rectum	  (males)	   1618	   1500	   1410	  
Oropharynx	  (males)	   8936	   5630	   5360	  
Total	  (males)	   11,553	   7490	   7080	  
Table 1.6 Tumours attributable to HPV Infection in the United States From 2004 to 2007. Table 
taken from (Zandberg et al., 2013) 
Biology of HPV infection 
HPVs are small DNA viruses that lack envelope. Their double-stranded genome is divided into 
early (E) and late (L) regions, and encodes seven non-structural “early” proteins (E1, E2, E3, E4, 
E5, E6 and E7) and two “late” structural proteins (L1 and L2), which code for proteins that 
constitute the icosahedral viral capsid. Additionally, there is a non-coding regulatory long control 
region (LCR). 
E genes modulate cell functions and regulatory circuits in favour of viral reproduction. Specifically, 
their products alter keratinocyte differentiation, promote apoptosis resistance, induce viral DNA 
replication and thwart immunological clearance of the virus. It is of note that the HPV genome is 
present in the host cell in the form of an episome, and its integration into the host genome is 
rather rare and not necessary for HPV replication (Yuan et al., 2012) 
The life cycle of HPV is closely linked with the differentiation of infected epithelial tissue: the virus 
infects cells in the basal layer of stratified epithelia, and its genome becomes a nuclear episome 
replicated along with nuclear chromosomes. During this early phase following HPV infection, the 
E1 and E2 genes are transcribed in order to regulate viral replication. As the infected cell divides, 
becomes more differentiated and migrates towards suprabasal epithelial layers, L genes are 
activated, major and minor capsid proteins they produce encapsidate viral genomes and a new 
generation of virions is produced. The E6 and E7 oncogenes are expressed during this phase, 
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and affect the cell cycle to stimulate differentiating cells towards a proliferative state in order to 
keep replication of the viral genome going (Longworth and Laimins, 2004). While the oncogenic 
process is doubtless complex and involves many host factors, dysregulation of the cell cycle, 
abrogated apoptosis, inhibited cellular differentiation and chromosomal instability represent key 
HPV-induced features that contribute to the process of malignant transformation.  
Various HPV types are described as “low-risk” or “high-risk” from the perspective of their 
oncogenic potential. So-called high-risk HPV types include previously mentioned HPV-16 and 18, 
and also 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82. Low-risk types include HPV-6, 11, 
40, 42, 43, 44, 53, 54, 61, 72, and 81. These HPV types cause less severe lesions, including 
genital condylomata and laryngeal papillomas (Steben and Duarte-Franco, 2007). 
In most regions, high-risk HPV-16 is more prevalent than other high-risk HPV types, suggesting 
perhaps higher virulence or cellular tropism of this subtype. Moreover, HIV-positive patients co-
infected with HPV demonstrate a considerably increased rate of HPV 16-positive tumours 
compared to HIV-negative counterparts. Thereby the incidence of malignancies associated with 
high-risk HPV types is amplified by HIV-induced immunosuppression. Currently available data 
regarding the effect of antiretroviral therapy on the incidence of HPV-induced neoplasia is 
conflicting, as some studies have confirmed the expected positive impact by demonstrating 
decrease in incidence of these tumours following this treatment, and others reporting no such 
effect. Further examination of HPV co-infection in HIV-infected patients is important not only from 
the epidemiological perspective, but may provide further insight into host-pathogen interaction in 




Figure 1.8 The circular genome of HPV-16. The key cellular targets of E proteins are listed: E6 
ubiquitinates p53, E7 inhibits pRB, E5 up-regulates epidermal growth factor receptor (EGFR). 
Figure taken from (Best et al., 2012). 
Merkel Cell polyomavirus 
The Polyomaviridae family encompasses a group of non-enveloped, icosahedral viruses with a 
circular, double-stranded DNA genome. The viral DNA is associated with histone proteins of the 
host cells (H2A, H2B, H3, H4) in a supercoiled fashion, resembling chromatin. The 
Polyomaviridae are currently divided into three genera and twenty-two different species (Johne et 
al., 2011), of which eleven are human polyomaviruses described to date.  
The first polyomavirus was identified in 1953 as a transmissible agent capable of inducing murine 
tumours, and was aptly named murine polyomavirus (MPyV) (Spurgeon and Lambert, 2013). In 
1960, simian vacuolating virus 40 (SV40) was discovered in rhesus monkey kidney cell cultures. 
Those cell lines were used in the production of human poliovirus vaccines to combat poliomyelitis, 
yet at the same time likely infecting large populations with SV40 as a contaminant of the vaccine. 
The oncogenic potential of SV40, an infectious cause of rodent tumours, desribed later on has 
lead to a significant concern regarding the administration of a vaccine mixed with an agent 
capable of neoplastic transformation; however, to date no unequivocal causative link between 
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SV40 and human cancer has been established (Poulin and DeCaprio, 2006), although the virus 
has been detected in various human tumours listed in Table 1.6.  
Recent technological advances have facilitated rapid discovery of novel viruses. In 2008, a novel 
DNA polymavirus named Merkel Cell polyomavirus (MCPyV) has been reported in 8 out of 10 
Merkel cell carcinoma (MCC) samples (Feng et al., 2008) by a group that has previously 
discovered Kaposi's sarcoma-associated herpesvirus. MCC is a non-melanoma skin cancer 
(described in greater detail in Chapter 1.4) associated with immunosuppression, which suggests 
potential connection with an infectious agent. MCPyV represented the first example of DNA 
polyomavirus integrating into the host genome, and the initial report confirmed its genomic 
integration in 6 of the 8 positive MCC samples. In addition, one metastatic sample tested showed 
an identical clonal pattern to the primary tumour, suggesting causative role of the virus in MCC 
aetiology.  
MCPyV genome contains a conserved replication origin, early genes that code for small and large 
T antigens, and late genes regions coding for VP1, VP2, and VP3 (Figure 1.6) that encode capsid 
proteins. Upon infection, early genes are rapidly transcribed, and late genes are activated later in 
the course of infection to form complete virions. MCPyV genome bears high similarity to the 
African Green Monkey lymphotropic polyomavirus, and is more distantly related to SV40. 
Interestingly, a 22-nucleotide viral miRNA (MCV-miR-M1-5p) is transcribed from the late region. 
The function of this miRNA is perhaps autoregulatory, as it reduces the level of transcripts 
containing sequences from the early region of the viral genome (Seo et al., 2009).  
 




Since its discovery, the presence of MCPyV has been described in various types of lesions and 
populations: it seems highly prevalent in MCCs originating in European or American patients, but 
is less abundant in Australian MCC patients (Garneski et al., 2009b). The virus was not detected 
in neonatal blood spots of 150 children, suggesting the infection does not affect genetic 
transformation in utero (Gustafsson et al., 2012). The virus was also not detected in proliferative 
skin disorders (Foulongne et al., 2008), extracutaneous melanoma (Giraud et al., 2008), lymphoid 
tissue of AIDS patients (Sharp et al., 2009), prostate cancer (Bluemn et al., 2009), or small lung 
cancer (Wetzels et al., 2009), which morphologically resembles MCC. However, 42% of US 
sample population were shown to be seropositive for this virus (Kean et al., 2009), and 
seropositivity increased with advancing age. Specifically, MCPyV seroprevalence is less than 
50% among children younger than 10 years of age, 60% in those 10-19 years of age, reaching 
81% by the sixth decade of life, and is greater among MCC patients compared to controls (Viscidi 
et al., 2011). The virus is also highly prevalent among young homosexual men (79%) in which it 
leads to an asymptomatic infection, and shows no correlation with HIV/AIDS course (Tolstov et 
al., 2011). 
Oncogenic potential of MCPyV 
Mutations leading to premature truncation of large T antigen helicase were detected in MCCs 
positive for MCPyV (Shuda et al., 2008). Among those mutations, multiple pyrimidine dimer 
substitutions were found, supporting the role of UV light in the onset of MCC upon MCPyV 
integration. Large T antigen mRNA transcription increases in a dose-dependent manner with UV-
exposure (Mogha et al., 2010), further corroborating combined viral and environmental aetiology 
of MCC. 
Recently, it was shown that MCPyV may in fact play a role in chronic lymphocytic leukaemia 
(CLL). Patients with CLL are at increased risk of MCC, and the virus was detected in 19 CLL 
samples (Koljonen et al., 2009), 6 of which also possessed novel large T antigen mutations.  
A subset of non-small cell lung carcinoma shown to be positive for the virus expressed increased 
mRNA and protein levels of the BRAF oncogene, while the antiapoptotic BCL-2 gene expression 
was downregulated in those samples (Lasithiotaki et al., 2013). However, this data was 
contradicted in a study that detected no significant differences in transcript levels of the K-ras, 
BRAF, RKIP, p53, RB1, Bcl-2, and Bax genes in between MCPyV positive and negative NSCLC 
(Hashida et al., 2013). 
Molecular data available to date does not indicate clear role of MCPyV in carcinogenesis: 
although the activation of proteinkinase AKT is detectable in the majority of MCCs, its 
phosphorylation is unaffected by MCPyV presence, nor by experimental knock-down of the viral 
large or small T-antigen (Hafner et al., 2012). Moreover, while p53 mutations were detected in 
MCPyV-positive tumours, those tumours expressed increased pRb levels and were associated 
with more favourable clinical outcome (Sihto et al., 2011).  
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A recent study focusing on comparison of cell-cell contacts between Merkel cells and MCC cells 
(Werling et al., 2011) showed connection of normal Merkel cells to keratinocytes by E- and P-
cadherin, desmoglein 2 and desmocollin 2, while the majority of MCCs (90%) contained N-
cadherin, and only 67% and 65% contained E- and P-cadherin, respectively. This switch towards 
N-cadherin is suggestive of epithelial-to-mesenchymal transition, a sign of dedifferentiation and 
aggressiveness of the tumour. Notably, the observed difference was irrespective of MCPyV 
infection. 
Functional studies assessing the role of MCPyV in MCC cell lines indicate that T antigen is 
indispensable for MCPyV positive MCC cells maintenance, and that those cells undergo growth 
arrest or cell death upon T antigen inactivation (Houben et al., 2010). Moreover, this phenomenon 
was not observed in MCPyV negative cell lines. Those results point towards possible future 
therapeutic routes, and additionally suggest that the aetiological background of MCC is 
multifactorial, and MCPyV positive and negative tumours may in fact represent distinct entities 
with shared histological features. 
MCPyV and clinical course of MCC 
Antibodies to large and small T antigen of MCPyV were shown to be relatively specific for MCC-
affected patients, and the rise in their titre seems to predict spread of the disease (Paulson et al., 
2010). The actual presence of the virus in tumour specimen does not seem to affect clinical 
course of the disease (Handschel et al., 2010, Becker et al., 2009, Garneski et al., 2009b), 
although other studies suggest that patients infected with MCPyV show prolonged remission 
(Laude et al., 2010) and better clinical outcome (Bhatia et al., 2010, Sihto et al., 2011). An 
immunohistochemical investigation has shown that the absence of MCPyV is associated with p53 
and KIT expression, however this seemed to represent a negative prognostic feature (Waltari et 
al., 2010). The precise role of MCPyV in cancer onset and progression remains to be elucidated. 
Other human pathogens and cancer 
While virus-induced oncogenesis has received considerable attention during the past century, the 
role of bacteria and parasites in cancer formation has been clarified to a lesser degree. The 
human body is estimated to be colonised by some 1014 microbial cells (Savage, 1977), and 500 
different bacterial species are present in the colon alone (Berg, 1996). While the vast majority of 
human bacteria are considered harmless or even symbiotic (for example, certain intestinal 
bacteria synthesise vitamin K2), epidemiological evidence has implicated bacteria as likely 
culprits in the onset of certain cancers. The mechanisms through which bacteria induce cancer 
include detrimental alterations in host physiology that lead to chronic inflammation, antigen-driven 
lymphoproliferation, increasing the levels of signalling molecules that induce proliferation of 
epithelial cells, and direct mutagenic effects of their toxins (Chang and Parsonnet, 2010).  
Helicobacter pylori is a common human pathogen affecting 50% of the world population, and a 
well-established causative agent of gastric cancer. It leads to 60% of all stomach cancers world-
wide, in addition to countless precancerous lesions (chronic and atrophic gastritis, intestinal 
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metaplasia and dysplasia).  It is the cause of gastric adenocarcinoma, the most common 
malignant tumour of the stomach associated with poor prognosis, and gastric mucosa-associated 
lymphoid tissue (MALT) lymphoma, a less common type of gastric neoplasia which can be 
practically cured by H. pylori eradication in majority of cases (Stathis et al., 2009). 
Other bacteria and parasites associated with cancer are listed in Table 1.7 
Pathogen	   Associated	  Cancer	   Comment	  
Opisthorchis	  viverrini	   Cholangiocarcinoma	   Food-­‐borne	  trematode	  
parasite	  (liver	  fluke)	  endemic	  
to	  Southeast	  Asia	  
Schistosoma	  haematobium	   Bladder	  cancer	   Parasitic	  flatworm	  (blood	  
fluke)	  highly	  prevalent	  in	  Sub-­‐
saharan	  Africa	  
Chlamydia	  pneumonia	   Lung	  cancer	   Bacteria	  associated	  with	  
increased	  risk	  of	  lung	  cancer	  
Streptococcus	  bovis	   Colon	  carcinoma	   Opportunistic	  pathogen;	  
bacteraemia	  strongly	  
associated	  with	  colorectal	  
tumours	  
Salmonella	  typhi	   Gallbladder	  Cancer	   Highly	  prevalent	  in	  developing	  
countries	  
Table 1.7 Bacteria and parasites epidemiologically associated with cancer. 
1.2. Anatomy and biology of the skin 
The skin is a dynamic, resilient organ that acts as the frontline barrier against external noxa 
harmful to the human organism. Specifically, it guards the body against the entry of 
microorganisms, solar radiation damage and excessive fluid loss. In addition to this protective 
role, the skin serves as a sensory organ perceiving external sensations through various receptors, 
regulates the body temperature, modulates the immune system by allergen recognition, and 
serves as the site of vitamin D synthesis.  
Skin is the body’s largest organ (Wysocki, 1999), with the average area of an adult’s skin of 1.7 
m2, four kilograms of weight, and approximately eleven miles of blood vessels. Additional skin-
associated anatomical structures enhance its particular functions: hair and hair follicles contribute 
to the skin’s protective, thermoregulatory and sensory role, sebaceous glands produce lipids and 
sebum for lubrication and protection, sweat glands aid in thermoregulation, and nails 
mechanically protect the distant phalanges. In order to cope with its many functions, the skin and 
its appendages have developed a complex differentiation and regeneration process that 







The skin is composed of three basic components that are of different embryologic origin, and 
serve different functions: the epidermis derived from the ectoderm, the dermis and subcutaneous 
tissue (subcutis, hypodermis) which are of mesodermal origin.  
Subcutis functions as an anchor linking skin to structures below (bones, muscles), and 
predominantly consists of adipocytes, fibroblasts and macrophages, elastin and loose connective 
tissue. It contains nerves and larger blood vessels, and due to the presence of many fat cells, it 
serves as an insulation layer for the body. On top of the subcutis lies the corium, or dermis.  
The dermis is composed of fibroblasts, macrophages, adipocytes, collagen, elastin, 
glycosaminoglycans. It contains additional anatomical structures such as blood and lymph 
vessels, nerve endings, hair follicles, sweat and sebaceous glands. Dermis and epidermis are 
connected by a basement membrane, which consists of extracellular matrix and growth factors, 
and provides a stable anchoring for epidermal keratinocytes.  
The epidermis, sometimes designated as interfollicular epidermis, is the uppermost layer of the 
skin comprised of stratified squamous epithelium. It consists of keratinocytes (the principal 
epidermal components), pigment cells (melanocytes), somatosensory receptors (Merkel cells) 
both derived from the neural crest, and antigen-presenting Langerhans cells.  
Histologically, the epidermis is divided into additional five layers (Figure 1.6): stratum basale is the 
deepest layer separated from the dermis by the basement membrane. This layer contains a pool 
of cells with proliferative potential (stem cells and their immediate progeny, the transient 
amplifying cells), the descendants of which undergo terminal differentiation once they leave this 
compartment (Iglesias-Bartolome et al., 2013). Thus, stratum spinosum contains mitotically 
inactive differentiated keratinocytes which produce keratohyalin granules as they enter stratum 
granulosum, in addition to cornified envelope proteins. Once cellular organelles are destroyed, the 
differentiation process culminates and results in a cornified envelope surrounding each dead, 
flattened, transcriptionally inactive keratinocyte (corneocyte). Stratum lucidum, present only in 
areas of thick skin such as the palms of hands, thereby consists of dead, fully keratinised 
anuclear cells, and is rich in protein-bound lipids and eleidin, a keratohyalin derivative. Stratum 
corneum is the outmost layer composed of multilayered corneocytes that are shed off through 
gradual desquamation. Maintaining the equilibrium between keratinocyte renewal and 
differentiation is crucial for epidermal homeostasis, during wound repair and adaptation to 




Figure 1.10 Structure of the human skin (left) and the epidermis (right). Figure taken from 
(MacNeil, 2007) and http://en.wikipedia.org/wiki/File:Epidermal_layers.png. 
Homeostasis of the epidermis 
In order to maintain its protective and regulatory function, the epidermis is under tight homeostatic 
regulation: periodically, proliferative basal keratinocytes enter the programme of terminal 
differentiation, which leads to their unidirectional, upwards movement alongside loss of 
proliferative potential, keratinisation, cornification and eventual cell death (Fuchs, 2008). The key 
step of the process is the transition from stratum basale to stratum spinosum of the epidermis, 
during which cells entering stratum spinosum undergo profound transcriptional, morphological 
and functional changes. Specifically, basal keratinocytes exit from the cell cycle, switch off the 
expression of keratin 5 (KRT5) and KRT14, markers of epithelial cells with proliferative potential, 
and turn on the expression of KRT1 and KRT10 and additional structural proteins (S100). These 
form a complex system of connections interlinked with cell junctions, leading to increased 
mechanical strength and resistance. The entry into this process is regulated by p63, MYC and the 
canonical Notch signalling pathway (Koster et al., 2004, Blanpain et al., 2006, Gandarillas and 
Watt, 1997). 
During later phases of terminal differentiation, filaggrin precursor profilaggrin accumulates in 
keratinocytic granules. Other proteins such as loricrin, involucrin and trichohyalin are synthesised 
and deposited under the plasma membrane and become crosslinked by transaminases, 
generating a highly resistant envelope, which co-creates a waterproof lipid bilayer between 
individual cells. When the differentiation process is completed, dead keratinocytes are wrapped in 
hydrophobic cornified envelope, and evenetually shed off, while being replaced by differentiating 
cells from the basal layer (Blanpain and Fuchs, 2009).  
Transcriptional regulation of keratinocyte differentiation 
Although our knowledge of transcriptional control during epidermal differentiation is far from 
complete, several molecules were implicated in driving epidermal lineage commitment. The 
depletion of apoptosis-stimulating protein of p53 (iASPP), an oncoprotein and p63 co-regulator, 
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leads to terminal stratification of keratinocytes (Chikh et al., 2011) and iASPP functions as 
inhibitor of senescence in epidermal homeostasis (Notari et al., 2011).  
FOXN1 (WHN) is transcribed early during the differentiation process, where it induces KRT1 
expression while suppressing profilaggrin, loricrin, and involucrin, safeguarding the gradual 
character of the process (Baxter and Brissette, 2002). Additionally, FOXN1 is important for nail 
and hair follicle homeostasis (Potter et al., 2011).  
Homeobox gene Distal less-3, DLX3, is expressed in the suprabasal layers of the epidermis at the 
onset of differentiation, and following activation by p63, it reduces the proliferative potential of 
basal keratinocytes (Di Costanzo et al., 2009).  
Other important regulators include the POU family of transcription factors (OCT1, OCT6, OCT11) 
that activate various differentiation genes (Andersen et al., 1997), KLF4 that promotes epidermal 
differentiation and maintenance (Sen et al., 2012), and OVOL1 that reduces the proliferative 
potential of keratinocytes entering terminal differentiation (Nair et al., 2006).  
MiR-203 is an evolutionarily conserved microRNA highly expressed in the epidermis, in which it 
inhibits the replicative potential and promotes differentiation through targeting p63 (Lena et al., 
2008, Yi et al., 2008). MiR-203 is capable of inducing cell cycle arrest rapidly upon its activation 
(Jackson et al., 2013), and  in the absence of miR-203, cell proliferation is elevated even in 
suprabasal layers of the skin (Yi et al., 2008).  
Additional epigenetic regulators of terminal differentiation in the epidermis include ING5, 
SMARCA5, BPTF, EZH2 and UHRF1, the depletion of which drives keratinocytes towards 
terminal differentiation. This seems to be the result of a complex interplay between these genes 
and their targets, including P63, ITGB6 and epidermal stem cell marker ITGB1 (Mulder et al., 
2012). 
Histone modifications have also been implicated in the modulation of regulators that control 
epidermal differentiation. Tri-methylation of lysine 27 on histone H3 (H3K27me3) marks are 
enriched in promoters of a subset of genes involved in epidermal differentiation in undifferentiated 
keratinocytes, and are lost during calcium-induced differentiation (Sen et al., 2008). Setd8 histone 
methyltransferase was shown to play an essential role in histone modifications at H4, required for 
the survival of epidermal stem cells and in cooperation with MYC, for epidermal differentiation 
(Driskell et al., 2012). Epidermal stem cells are discussed in greater detail in section 1.6. 
1.3. Non melanoma skin cancer: an overview 
1.3.1. Human skin cancer 
Skin cancer is the most common human malignancy (Harris et al., 2001). Based on the cell of 
origin, skin cancer can be divided into two major categories: melanoma and non-melanoma skin 
cancer (NMSC). As this nomenclature suggests, the first type of skin cancer is caused by 
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malignant transformation of melanocytes, and the second by neoplastic transformation of all other 
types of skin cells. Melanoma is less common than NMSC, but is associated with significant 
mortality, leading to more than 2000 deaths a year in the UK only (Neal and Hoskin, 2009).  
Over the past decades, the incidence of NMSC has substantially increased, predominantly in 
Caucasian populations (Rodust et al., 2009), representing now the most common malignancy in 
this ethnic group (Trakatelli et al., 2007). The term NMSC encompasses a diverse cluster of 
malignancies and includes cutaneous lymphoma, adnexal tumours, sarcomas, Merkel-cell 
carcinoma, but mainly basal cell carcinoma (BCC) and squamous cell carcinoma (cSCC) (Madan 
et al., 2010). Approximately 75% of NMSCs are BCCs, and about 20-25%% are cSCCs, which 
makes cSCC the second most common malignancy in humans.  
The overall mortality from non-melanoma skin cancer is rather low compared with melanoma and 
other solid tumours (Clayman et al., 2005), but varies across different types of NMSC. MCC has a 
5-year survival of just 60% (Albores-Saavedra et al., 2010a), while BCC practically never forms 
metastases (Wong et al., 2003) and is associated with excellent prognosis. However, in contrast 
to the vast majority of BCCs, squamous cell carcinoma has a significant propensity to metastasise 
(Cherpelis et al., 2002). Moreover, both tumours are associated with considerable morbidity due 
to local invasion and disfigurement (Corona, 1996) (Figure 1.6). This can substantially impact 
patients’ psychosocial health and wellbeing, since very commonly those lesions are located in 
sun-exposed, and thus usually uncovered areas of the body (such as the head, neck and upper 
extremities), and are frequently multiple.  
 
Figure 1.11 Panel of clinical photos showing disfigurement following treatment of NMSC. 
Although the prognosis of cSCC patients is generally favorable (three-year disease specific 
survival is 100% if a patient has no associated risk factors (Clayman et al., 2005)), because of its 
immense prevalence, cSCC represents a serious burden to national health-care systems 
(Housman et al., 2003). In addition to this, the prognosis of patients with metastatic disease is 
dismal, with less than 20% ten-year survival for patients with disease present in regional lymph 
nodes (Claerhout et al., 2010), and less than 10% for patients with identifiable distant metastases 
(Madan et al., 2010). In recessive dystrophic epidermolysis bullosa (RDEB) patients, a rare 
autosomal recessive blistering disorder caused by mutation in type VII collagen (Dunnill et al., 
1994, Hovnanian et al., 1992), the risk of developing an cSCC is especially high, and cSCC 
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represents the most common cause of premature death in RDEB patients (Fine et al., 2008). 
Fifty-five percent of Hallopeau–Siemens RDEB patients, the most severe form of the disease, die 
from metastatic cSCC by 40 years of age (Pourreyron et al., 2007). Thus it is of imminent 
importance to unweave the biological process of cSCC carcinogenesis, namely its propensities to 
metastasise, in order to provide better therapeutic perspectives for affected patients. 
 
Figure 1.12 Clinical presentation of RDEB patients skin. Figures taken from (Fine, 2010). 
1.3.2. Clinical features of NMSC 
1.3.2.1. Basal cell carcinoma 
BCC is the most common malignancy diagnosed in humans, affecting millions of people every 
year worldwide. This tumour develops most commonly on sun-exposed areas (80% of BCCs 
develop in head and neck area (de Vries et al., 2005)), most likely due to accumulated UV 
damage. Additionally, the disease is associated with Gorlin syndrome; a rare autosomal-dominant 
disease characterised by defects of the skin, eyes, bones and other body systems, in which 
numerous BCCs appear bilaterally and in areas not exposed to UV-light. The underlying cause of 
the Gorlin syndrome is a mutation in tumour suppressor gene PTCH (Devi et al., 2013). 
Macroscopically, BCCs present as pearly, red or pink plaques and nodules, which may ulcerate. 
Although this tumour rarely metastasises, it is capable of local invasion and can lead to severe 
disfigurement. The most common treatment is surgical excision, but radiotherapy, topical 
imiquimod cream and a range of other destructive modalities such as cryotherapy and 
photodynamic therapy are also used. Over the past five years, targeted therapies for the rare 
cases of metastatic or otherwise untreatable BCC have been developed, based on the inhibiton of 
the PTCH tumours suppressor pathway, frequently upregulated in BCC (Goppner and Leverkus, 
2011, Tabs and Avci, 2004, Von Hoff et al., 2009).  
While the highly conserved PTCH pathway plays a crucial role in many processes during 
embryonic development, such as proliferation and differentiation (Merchant and Matsui, 2010), it 
is inactive in the majority of adult tissues. However, stem cells, hair follicles, and skin cells rely on 
the pathway for maintenance (Cowey, 2013). PTCH is a 12-pass transmembrane receptor, and 
Hedgehog (Hh) ligand initiates the pathway signalling by binding to PTCH. Once coupled with Hh, 
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PTCH lifts its inhibitory effect on Smoothened (Smo), a G-coupled receptor. Smo then propagates 
the signal by uninhibiting glioma-associated protein (Gli) through the suppressor of fused 
molecule (Sufu), promoting its oncogenic effects through a variety of target genes involved in cell 
cycle, apoptosis resistance and angiogenesis (Cowey, 2013). Thereby, PTCH functions as a 
tumour suppressor. Other solid tumours shown to harbour abnormal hedgehog pathway signalling 
include medulloblastoma and rhabdomyosarcoma (Merchant and Matsui, 2010). 
A variety of anti-Smo agents were tested and incorporated in clinical research, and vismodegib, 
an orally available inhibitor of Smo, has received FDA drug approval in 2012. The drug 
demonstrated 30-50% overall response rate among patients with metastatic BCC (Cowey, 2013), 
and significantly reduced the number new of BCCs in patients with Gorlin syndrome compared to 
placebo (Tang et al., 2012). Although effective in many patients with locally advanced and 
metastatic BCC, eventually most tumours have developed resistance to vismodegib and 
progressed. Nonetheless, Smo inhibitors represent a clinically relevant treatment modality for 
patients with advanced disease and Gorlin syndrome, highlighting the translational potential of 
molecular analysis in cancer treatment. 
1.3.2.2. Squamous cell carcinoma 
Cutaneous SCC (cSCC) is the second most common skin cancer among Caucasians (Alam and 
Ratner, 2001). In spite of identified environmental factors involved in cSCC development and 
increasing public awareness of these, the incidence of cSCC continues to rise (Madan et al., 
2010). Cutaneous SCCs usually present as hyperkeratotic nodules which are often ulcerated and 
painful. Based on histology, the disease is divided into morphological categories which reflect the 
degree of differentiation within the tumour: well differentiated (WD) cSCCs are eosinophilic, 
showing striking similarity to normal keratinocytes, and display a pattern of layers not unlike 
normal squamous epithelium. Moderately differentiated (MD) cSCC is less similar to normal 
squamous epithelium and the typical architecture of epithelial layers is less defined. Poorly 
differentiated (PD) cSCC lacks epithelial architecture and tumour cells show a high degree of 
morphological atypia. Representative haematoxylin-eosin stained slides are shown in Figure 1.9.  
 
Figure 1.13 Panel of histological specimen representing three histological degrees of cSCC 
differentiation. A – WD, B – MD and C – PD SCC (4x magnification). 
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A proportion of cSCC will behave aggressively and metastasise; cSCC accounts for 20% of skin 
cancer-related deaths, and poor outcome is seen in 16% of tumours with a thickness greater than 
6.0 mm (Brantsch et al., 2008).   
Unlike BCC, precursor lesions for cSCC are recognised. Skin SCCs frequently arise from 
cutaneous areas bearing multiple actinic keratoses (AK), generally regarded as precursor lesions 
for cSCC. These lesions are common, affecting about 23% of the UK population over the age of 
60 years (Harvey et al., 1996). They usually appear as asymptomatic red, scaly papules on sun-
exposed areas (Berman and Cockerell, 2013), with histological evidence of epidermal dysplasia, 
and are more common among Caucasian individuals of advanced age. So-called “field 
cancerisation” is an area of the skin (often chronically sun-exposed) in which multiple AK occur 
(Braathen et al., 2007). Field cancerisation can often be a relatively broad area with no obvious 
macroscopic changes in which pro-neoplastic mutations are already present, and thus represents 
the preneoplastic stage of cSCC development (Rubin, 2011b). Although the precise mechanism 
of field cancerisation development has not been entirely clarified, molecular data acquired from 
tumours of the head and neck, esophagus, and bladder indicate that a single genetic event 
occurs in an individual cells, due to clonal expansion then spreads laterally, replacing normal 
epithelium and creates above-described preneoplastic fields (Dakubo et al., 2007). 
Cumulative UV radiation exposure is the main culprit in AK onset (Schmitt and Miot, 2012). First, 
it induces the initial genetic mutations in skin cells, and then contributes to the growth of 
transformed lesions. UV damage generally leads to apoptosis resistance, genomic alterations, 
inflammatory, and immunosuppressive disruptions which in the epidermal context result in 
keratinocyte transformation, aberrant proliferation and eventual clinical appearance of AKs. 
Sunscreen application significantly reduces the number of newly-formed AKs in a dose-
dependent manner, and may lead to the involution of existing lesions (Thompson et al., 1993). 
Additionally, the impact of seasonal variation on AK diagnosis has been noted, with the peak 
number of newly diagnosed AKs registered during spring months (Hancox et al., 2004). This trend 
may be the reflection of seasonal UV radiation variability and sun exposure. Because AKs can 
progress to malignant cSCC, clinically detected AK must be treated (Braathen et al., 2007). 
There is significant controversy over the rate of progression of an individual AK to cSCC; a 
systematic review of 15 studies found progression rates between 0.025% and 20% per year per 
lesion (Quaedvlieg et al., 2006). About 20-25% of AK will regress over the course of a year, 
although the majority will later reappear, and numbers of prevalent AKs are strongly influenced by 
ongoing sun-exposure. A recent study showed that, although the risk of progression for a specific 
AK was only 2.57% at 4 years, 65% of all primary cSCC arose directly in lesions previously 





Figure 1.14 Clinical and microscropic images of AK. 
The epidemiology, risk factors and molecular basis of cSCC are described in more detail in 
section 1.4.  
1.3.2.3. Merkel Cell carcinoma   
Merkel Cell carcinoma (MCC) is a rare primary neuroendocrine tumour of the skin most 
commonly diagnosed in elderly people. It was first described by Cyril Toker in 1972 as a 
trabecular carcinoma of the skin based on morphological observations (Toker, 1972). During the 
past decades, the incidence of MCC has increased considerably (Hodgson, 2005), and it is 
estimated to affect approximately 400 people a year in the UK (Albores-Saavedra et al., 2010b). 
The tumours occur most frequently on sun-exposed sites, and are increasingly common with 
advancing age, with 95% of MCC diagnosed in people over the age of sixty (Albores-Saavedra et 
al., 2010b). This malignancy is more common in white population compared to dark-skin people 
(Miller and Rabkin, 1999), and is also more prevalent in men than in women. 
In solid organ transplant patients, the incidence of MCC is increased 10-40 fold compared to the 
general population, affected patients are generally younger at the onset (50% are under 50 years 
of age) (Stoff et al., 2010), and 8% of all MCC occur in OTRs (Buell et al., 2002).  
Clinically, MCC is an aggressive skin malignancy, usually presenting as a rapidly enlarging, firm, 
reddish nodule on a sun-exposed site. This tumour is locally invasive and often metastasises, and 
in spite of multidisciplinary treatment approach is associated with a significant mortality (almost 





Figure 1.15 Clinical presentation of MCC on scalp. Left panel shows recurrent tumour. 
 
Figure 1.16 Clinical presentation of MCC of the arm in two different patients. 
MCC was originally thought to arise from Merkel cells, which were first described in 1875. In the 
cytoplasm of these cells, electron-dense Merkel granules are found using electron microscopy, 
and such granules are seen in the cytoplasm of MCC cells, which lead to the postulation that 
Merkel cells are the cell of origin for this malignancy. However, this theory has not been 
conclusively proven so far. 
1.3.2.4. Other NMSCs 
Other NMSCs include cutaneous T-cell lymphoma, a disease with peak incidence among 
populations of thirty-fifty years of age, that often clinically resembles eczema or other benign skin 
lesions. B-cell non-Hodgkin’s lymphoma also affects the skin, albeit rarely, and is associated with 
a favourable prognosis if diagnosed early. Kaposi’s sarcoma is a malignancy of vascular origin 
mostly associated with acquired immune deficiency syndrome; however, it can occur sporadically 
in endemic populations and immunosuppressed patients. The lesions are usually purple plaques 
or nodules that may be ulcerated or bleed (Figure 1.11).  
Other rare cutanoues tumours include sarcomas such as dermatofibrosarcoma protuberans, 
angiosarcoma and liposarcoma; appendageal/adnexal tumours such as hidradenocarcinoma, 
cylindroma and sebaceous carcinoma, and histiocytoses such as Langerhans cell and non-




Figure 1.17 Kaposi’s sarcoma of the shin. Kaposi’s sarcoma is a common cutaneous malignancy 
in AIDS-patients associated with HHV-8. Figure taken from (Mehta et al., 2011). 
1.4. Epidemiology and pathogenesis of cutaneous squamous 
cell carcinoma 
1.4.1. Epidemiology of cSCC 
Skin cancer is currently considered to have reached epidemic proportions (Salasche, 2000). 
Because of prominent differences between national registries in data collection and processing, 
precise figures on cSCC incidence are difficult to obtain. However, a sharp incline in cSCC 
incidence has been observed during the past decades in many areas across the globe and 
suggests that cSCC is an imminent health-problem world-wide. In the UK, there are an estimated 
30,000 new cases per year, and there has been an approximate doubling in incidence over the 
past 15 years. The increase in recorded cases may be due to various factors, including increasing 
UVR exposure and population aging, since cSCC is predominantly a disease of older people. 
CSCC is also numerically and economically a major burden to the NHS and other public health-
care systems.  
1.4.2. Risk Factors for cSCC development 
Individual risk of cSCC development depends upon various genetic, phenotypic and 
environmental factors. The key factors include skin tone, accumulated sun damage to the skin, 
radiation exposure and compromised immune system. 
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1.4.2.1. UVR exposure 
Various lines of evidence corroborate the causative role of ambient solar radiation in cSCC 
carcinogenesis. CSCC occurs mainly on sun-exposed body sites, and its occurrence can be 
effectively prevented by sun protection. It is also well-established that geographical location is 
associated with different trends in cSCC incidence; the relative risk of cSCC is three times as high 
among people born in areas with high amounts of UV radiation as among people who move to 
those areas during adulthood (Alam and Ratner, 2001). Sun-sensitive skin phenotype provides 
further evidence of the role of UVR in that cSCC risk is two to five times as high in people with fair 
skin, hazel or blue eyes and blonde or red hair compared to those with darker features. Thus, it is 
now accepted that exposure to UVR is the most common risk factor for cSCC;  UVB radiation is 
principally responsible for the tumour-inducing process with UVA having an additive role in the 
oncogenic mechanism: UVB causes direct damage to RNA and DNA by inducing covalent bond 
formation between adjacent pyrimidines, leading to mutagenic products (cyclopyrimidine dimers 
[(G:C to A:T)], pyrimidine-pyrimidine adducts), while UVA causes indirect damage through the 
formation of reactive oxygen species and by causing DNA damage in deeper strata of the skin 
compared to UVB. A thirty-year follow-up study of psoriasis patients treated with psoralen and 
UVA has described a greatly increased risk of cSCC in those patients (Stern, 2012). Additionally, 
border wavelengths between UVA and UVB of around 315  nm are especially mutagenic to the 
skin (Ikehata et al., 2013). 
In addition to an unequivocal mutagenic effect, UVB radiation has an immunosuppressive 
potential in skin (Phan et al., 2006). It induces the production of immunosuppressive cytokines, 
and profound changes in antigen-presenting cells (Xu and Elmets, 2012). Following a single low 
dose of UVB radiation, Langerhans cells, antigen-presenting cells of the skin and mucosa, are 
reduced by 50% (Murphy et al., 1993), yet epidermal Langerhans cells are essential for the 
generation of UVB-induced regulatory T lymphocytes that mediate local immune reaction. 
Additionally, UVB radiation leads to profound transcriptome changes in the skin, including 
upregulation of genes that encode antimicrobial peptides, inflammatory molecules, and genes that 
play a role in activation of innate defense and early adaptive immune pathways (Kennedy Crispin 
et al., 2013).  
1.4.2.2. Ionising radiation 
Ionising radiation has also been implicated in the development of cSCC. Originally it was 
suggested that exposure to therapeutic radiation is associated with the development of BCC, but 
not cSCC. Nonetheless, it was subsequently demonstrated that the risk of cSCC may be 
increased with radiotherapy, especially in individuals prone to sunburn and particularly if 
experienced by individuals younger than 20 years of age. 
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1.4.2.3. Human papillomavirus (HPV) infection 
HPV infection has also been associated with cutaneous SCC. The first link was observed in 
patients with epidermodysplasia verruciformis (McGregor and Proby, 1996, Orth, 1986) (Figure 
1.12), a rare inherited skin disorder, who are prone to beta-HPV infection and up to 60% of those 
develop cSCC, which is in most cases HPV-positive.  
Based on PCR testing of tumours from immunocompetent (IC) patients with cSCC, 30-50% of 
these are positive for HPV, while immunosuppressed (IS) patients show 65-90% HPV positivity in 
their cSCCs (Harwood and Proby, 2002). However, a more sensitive technique using reverse 
hybridisation shows almost equal distribution of HPV infection in both IC and IS patients (Purdie 
et al., 2009). Within a month of transplantation, 80% of patients are seropositive for at least one 
HPV type, mostly beta-HPV, and the majority retain this serostatus (Antonsson et al., 2013). 
Interestingly, sun exposure of  more than four hours a day is associated with increased HPV 
seropositivity among transplant patients (Sampogna et al., 2012). In addition, the risk of cSCC is 
associated with seropositivity for beta-HPV types (Bavinck et al., 2010, Karagas et al., 2006, 
Proby et al., 2011). For the actual cSCC risk, high viral load may be a more important factor than 
infection with a specific HPV type (Neale et al., 2013). 
While thus far no clear hierarchy of specific HPV types in cSCC has been conclusively defined, 
there is a trend towards beta types oncogenic in EV, notably HPV-5, -8, -36 and -38 (Casabonne 
et al., 2007), which fits well with functional studies showing additional pro-carcinogenic activities 
for HPV8 and -38 E6 and E7 proteins (Storey and Simmonds, 2009). On the other hand, high-
throughput sequencing of cSCC transcriptome has failed to detect HPV expression in any 
cutaneous SCC sample (Arron et al., 2011, Ganzenmueller et al., 2012). The rather striking 
variability of HPV findings suggests that the role of HPV may be indirect in the pathogenic 
process, potentially by facilitating UV-related carcinogenesis by prevention of UV-induced 
apoptosis or impairing DNA repair (Madan et al., 2010). 
 




Cutaneous SCC is the most common post-transplant malignancy in Caucasian organ transplant 
recipients (Reichrath and Nurnberg, 2008).  The risk of cSCC increases 65 to 250 fold in 
comparison with non-transplant population (Madan et al., 2010). CSCC occurs more frequently in 
organ transplant recipients compared to BCC, while in non-transplant population the ratio of BCC 
and cSCC is reversed. Additionally, the biological characteristics of cutaneous SCC are more 
aggressive in OTR patients in comparison to the general population: cSCCs generally develop at 
younger age, starting three to five years after transplantation, demonstrating high frequency of 
local recurrence (13.4%) during the first 6 months after excision and a high frequency of lymph 
node metastasis (7%) during the second year after excision (Reichrath and Nurnberg, 2008). 
Moreover, cSCCs in OTRs grow rapidly to a greater size (>2 cm diameter) and often demonstrate 
an aggressive histological growth pattern, being frequently associated with perineural invasion or 
invasion of the cartilage, fat, or bone (Reichrath and Nurnberg, 2008). Furthermore, cSCCs in 
patients with diseases affecting the immune system, such as HIV/AIDS or non-Hodgkin 
lymphoma, also show an aggressive profile (Madan et al., 2010). It is of interest that transplant 
patients with a history of non-melanoma skin cancer prior to transplantation are at an increased 
risk of metastatic non-melanoma skin cancer post transplantation, and that transplant patients 
with cSCC are at higher risk of internal malignancies compared to OTR free of this skin cancer 
(Wisgerhof et al., 2012). The overall incidence of malignancy in transplant patients ranges from 7-
15%, thus the majority of transplant patients remain cancer free, yet those patients who develop 
skin malignancies are also at increased risk of other tumours. This suggests potential intrinsic 
genetic factors are “unmasked” by immunosuppression, increasing the overall susceptibility to 
cancer.  
1.4.2.5. Other risk factors 
Smoking is another risk factor for the development of cSCC. While the evidence associating 
smoking with basal cell carcinoma and melanoma remains controversial, the association between 
smoking and cSCC has been confirmed by several studies (De Hertog et al., 2001, Grodstein et 
al., 1995, Aubry and MacGibbon, 1985, Karagas et al., 1992, Lear et al., 1998). Other risk factors 
include exposure to arsenic (Petter and Haustein, 2000), coal tar, insecticides, herbicides and 
petroleum products (Gallagher et al., 1996), and high-fat diet, particularly in people with previous 
history of skin cancer (Ibiebele et al., 2007). 
 
1.4.3. Molecular genetic basis of SCC 
1.4.3.1. Cytogenetic abnormalities 
Chromosomal aberrations are frequently observed in both precursors (90% of actinic keratoses) 
and neoplastic skin lesions (95% of cSCCs) (Ashton et al., 2005). Aneuploidy rates are estimated 
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to reach 25-80% in cSCC (Carless and Griffiths, 2008), with a substantial difference in aneuploidy 
rates between well (46%) and moderately (75%) differentiated cSCC (Pilch et al., 1994). 
Aneuploidy rates for AK have been estimated at 69%, and 89-92% for cSCC in situ, which is 
higher than those reported for both cutaneous cSCC and AK, suggesting that DNA aneuploidy 
may not be a good prognostic marker of cutaneous cSCC (Ashton et al., 2005). 
A variety of methods have been used to investigate the cytogenetic alterations associated with 
cSCC. In one study, karyotypic analysis of 13 short-term cultured primary tumours together with 
10 previously published cSCC cases detected recurrent numerical gains, of which the most 
frequent was the loss of chromosome 21 found in 41% of cases (Jin et al., 1999). These data are 
comparable to karyotypic findings in other squamous cell carcinomas, such as SCC of the head 
and neck, breast, and lung (Ashton et al., 2005).  
Fluorescence in situ hybridisation (FISH) of interphase chromosomes highlighted 3p21 deletion 
as a recurrent aberration in cSCC (Dobler et al., 1999), while polymorphic microsatellite marker 
analysis  identified 9p, 13q and 17 as other frequent targets of deletion (Quinn et al., 1994). 
Metaphase comparative genomic hybridisation (CGH) was used in three studies to investigate the 
genetic changes associated with cSCC. Overall, frequent recurrent gains of genetic material at 
3q, 8q, 17q and 20q and losses at 3p, 4q9p, and 18q were observed, with each study also 
identifying further recurrent changes specific to their subset of cSCCs (Ashton et al., 2005, 
Carless and Griffiths, 2008).   
More recently, higher resolution array-based techniques have been used to more accurately map 
the genetic events to particular chromosomal regions. One such study (Purdie et al., 2009) used 
single nucleotide polymorphism (SNP) microarrays to map the genomic instability in 60 tumours, 
revealing a previously unidentified mechanism of loss of heterozygosity (LOH) in cSCC known as 
uniparental disomy (UPD). UPD is a phenomenon whereby mitotic non-dysjunction or mitotic 
recombination causes the loss of one allele and subsequent duplication of the remaining allele, 
resulting in LOH without loss of genetic material (copy number neutral LOH). The most frequent 
aberrations identified in this study were LOH at 3p and 9p. In contrast, another study using high 
resolution array CGH to analyse 16 cSCC identified gain at 3q as the most common event 
(Salgado et al., 2010). Genome-wide SNP analysis of 13 cSCCs collected from transplant 
patients detected various chromosomal aberrations in 6 cSCC samples, with 9p21 loss as the 
most common (Hameetman et al., 2013).  
Many of the gross chromosomal aberrations associated with skin carcinogenesis are merely a 
consequence of genomic instability and may be irrelevant to tumour progression. In addition to 
large-scale chromosomal gains and losses, high resolution microarray-based techniques are able 
to detect focal deletions and gains and may therefore facilitate the identification of genes critical 
for cSCC onset.   
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1.4.3.2. Specific genetic abnormalities in cSCC 
The above-mentioned SNP microarray analysis of 60 SCC (Purdie et al., 2009) identified 9 
tumours with microdeletions at 9p23 within the locus of the candidate tumour suppressor gene, 
protein tyrosine phosphatase receptor type D (PTPRD; (Sato et al., 2005, Stallings et al., 2006)), 
which were associated with greater aggressiveness of tested tumours. Deletions of PTPRD were 
subsequently shown to be associated with metastatic cSCC, and somatic mutations of the gene 
were found in 37% of cSCC tumours (Lambert et al., 2012).  
Deletions at the CDKN2A locus at 9p21.2-9p21.3 were detected in both studies using SNP arrays 
(Purdie et al., 2009, Hameetman et al., 2013), alongside deletions within the Fragile histidine triad 
(FHIT) gene at 3p14.2, both of which have been previously associated with cSCC development 
(Kubo et al., 1997, Brown et al., 2004).  
Array-comparative genomic hybridisation (aCGH) identified a focal amplification at the locus of 
the CKS1B gene at 1q21.1-q21.3 as a marker of aggressive clinical behavior in cSCC (Salgado et 
al., 2010). CKS1B is a member of the highly conserved cyclin kinase subunit 1 (CKS1) protein 
family whose amplification has previously been shown to correlate with poor prognosis in multiple 
myeloma (Chang et al., 2006). Another aCGH study has revealed the loss of 17p.13.3-17q25.3, 
where p53 is located, in almost half of tested cSCC samples (Li et al., 2012), and gains of 7p21 
and 7q31 corresponding to SKTS5 in 10% of samples (Fleming et al., 2013). 
Whole-exome sequencing of 11 cSCCs has revealed mutations in Notch genes in majority of 
these tumours, mostly consistent with UV damage. These mutations were cSCC specific, as 
whole-exome sequencing of five BCC samples did not identify mutations in either NOTCH1 or 
NOTCH2. In cSCC, there was no association with histological subtype or p53 mutations (Wang et 
al., 2011).  
Other studies have used a candidate gene approach to investigate tumour suppressor genes and 
oncogenes implicated in carcinogenesis in other organs. UV signature p53 mutations have been 
detected in an overwhelming majority of cSCC, but are also present in actinic keratoses and sun-
exposed normal skin, and thus would appear to be an early event in UVB-induced skin 
carcinogenesis (Benjamin and Ananthaswamy, 2007). Mutational activation of the ras oncogene 
is a characteristic event in human carcinogenesis, but its role in cSCC remains controversial. 
Considerable variation exists in the reported frequency of activating ras mutations in these 
tumours, ranging from 67% of cSCC from a group of patients with the rare genetic disorder 
xeroderma pigmentosum (XP, (Daya-Grosjean et al., 1993)) to 0% of tumours in another cohort of 
XP patients (Sato et al., 1994) and from 0% to approximately 20% in the general population. 
However, studies among melanoma patients treated with RAF inhibitors that seem to develop 
keratoacanthomas and cSCC has shown a higher frequency of activating RAS mutations among 
patients treated with these agents (Oberholzer et al., 2012, Su et al., 2012b). 
Focal amplification of the c-myc oncogene is another recurrent event in human carcinogenesis 
which has been implicated in cSCC development. To date, this aberration has been identified in a 
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high proportion of tumours, ranging from 50% in a series of renal transplant recipient cSCCs 
(Pelisson et al., 1996)  to 63% in the general population (Toll et al., 2009).  
One study investigated the genetic basis behind the reduced expression of thrombospondin-1 
(TSP-1) in cSCC, an anti-angiogenic matrix glycoprotein. FISH analysis of normal skin and 5 
cSCCs revealed that loss of expression correlated with loss of one copy of chromosome 15, the 
location of TSP-1 (Burnworth et al., 2007). 
Tetraspanin CD151 was shown to be elevated in human cSCC compared to other cutaneous 
tumours, and seems to regulate keratinocyte proliferation through interaction with STAT3 and 
integrins (Li et al., 2013b), suggesting it may be a potential player in early cSCC carcinogenesis. 
The apparent genetic heterogeneity and overall lack of consensus on the role of specific genes in 
cSCC tumourigenesis and progression suggests that additional molecular mechanisms including 
epigenetic modifications may drive the onset of this malignancy. 
1.5. Epigenetics and cancer 
1.5.1. Overview 
In 1942, Conrad Waddington originated the term ‘epigenetics’ to describe the interaction between 
the genome and the environment, which ultimately determines the cellular phenotype (Dawson 
and Kouzarides, 2012). Although cells of the same organism have practically identical DNA that 
remains generally constant throughout the cell’s lifetime, the physiological functions and 
properties of cells vary greatly and even change on a single cell level. This dynamic regulation is 
partly due to the genomic and epigenomic interplay. 
Epigenetics as a scientific field represents the exploration of heritable changes that are not 
mediated at the DNA sequence level (Cheung and Lau, 2005). Epigenetic regulation is a relatively 
highly conserved mechanism that is capable of underpinning different phenotypic expression of 
an organism in spite of the inherited DNA code: for example, mice in Figure 1.19 are identical in 





Figure 1.19 Variation in the fur coat colour due to epigenetic alteration. All depicted mice are 
genetically identical. Figure taken from (Morgan et al., 1999). 
There are several molecular mechanisms that mediate epigenetic regulation, and include namely 
DNA methylation and chromatin or histone modifications (Cheung and Lau, 2005), RNA 
interference (RNAi) and prions (Yool and Edmunds, 1998). Several other important 'epigenetic 
factors' have also been described to play a role in many processes, such as intracardiac 
hemodynamic forces during heart and the cardiac conduction system development (Hove et al., 
2003, Reckova et al., 2003), but the central mechanisms currently understood as epigenetic 
regulators are DNA methylation, histone modification and RNAi. 
Epigenetic regulation has been linked to several physiological processes, such as embryonic 
development (Reik et al., 2001), control of the circadian rhythm (Masri and Sassone-Corsi, 2010), 
placental development (Maltepe et al., 2010), ageing (Rakyan et al., 2010, Gronniger et al., 
2010), as well as diseases: cancer (Esteller, 2008), obesity, depression, cardiovascular diseases 
(Chen et al., 2011), neurodegenerative prion diseases (Tatzelt and Schatzl, 2007) and many 
more. 
From the perspective of a therapeutic intervention, drugs affecting or altering epigenetic 
regulation already have an established role in the clinical setting: DNA methyltransferase (DNMT) 
inhibitor 5-aza-2′-deoxycytidine (decitabine) and 5-azacytidine is currently approved for clinical 
application in haematological cancers (Piekarz and Bates, 2009), suberoylanilide hydroxamic acid 
(vorinostat) and romidespin are histone deacetylases (HDAC) inhibitors currently approved for 
clinical application in cutaneous T-cell lymphoma patients (Zain et al., 2010). Many more agents 
acting on the epigenetic level of regulation have been assessed or are currently being tested in 
preclinical trials (Helin and Dhanak, 2013). 
All above-mentioned factors corroborate the attractiveness of studying epigenetic mechanisms in 
both organic processes and disease. During the past decade, epigenetics have become a highly 
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influential field of research, with important discoveries spanning diverse areas of research: from 
epidemiology (Heijmans et al., 2008), through environmental sciences (Kundakovic et al., 2013) 
to evolutionary paterns of commercially important invertebrate (Nanty et al., 2011). Linking 
epigenetic modifications with cellular functions provides novel insight into multiple levels of 
regulation, and novel targets for therapeutic intervention.  
1.5.2. DNA methylation 
One of key epigenetic mechanisms acting in higher organisms is DNA methylation (Deeb et al., 
2010). This process occurs on DNA level and involves the addition of methyl group to 5' carbon of 
the cytosine ring (Figure 1.14). This process is mediated by methyl-transferase enzymes. The 
genome-wide distribution of methylated cytosines represents an additional level of regulatory 
information that affects cellular phenotype in addition to the DNA sequence. While DNA 
methylation patterns can be transmitted from one generation to another, it is still flexible enough 
to adapt for different somatic cell types, or environmental impulses (Laird, 2003). 
 
Figure 1.20 The enzymatic process of C5’ methylation. Methylation of the 5’-carbon in the 
cytosine ring is carried out by methyltransferase enzymes. S-adenosylmethionine serves as the 
donor of the methyl group. 
The process of methylation occurs in vertebrates most commonly at CpG sites: regions found in 
the genome which are rich in a symmetrical cytosine-guanine sequence, since methyl-
transferases recognise 5'-CpG-3' motif (Laird, 2003). However, non-CpG methylation that targets 
CpA, CpT, and CpC dinucleotides (Ziller et al., 2011) has been shown to occur in both embryonic 
stem cells (Ramsahoye et al., 2000) and to a lesser extent, somatic cells (Ziller et al., 2011). CpG 
regions usually exhibit lower level of methylation in comparison with the rest of the genome, which 
is normally more methylated. 
Methylation often occurs in the promoter region of a given gene, upstream from the transcriptional 
start site, since about 60% of CpG islands in the human genome are found within promoter 
regions (Antequera, 2003). Several proteins such as MeCP2, MBD1, MBD2, MBD3 and MBD4 
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share the methyl-CpG-binding domain (MBD), which is a specific structure capable of binding to 
methylated CpG (Ballestar and Wolffe, 2001). Upon binding of MBD proteins, several transcription 
repressors including HDACs are recruited to the CpG site and transcription of the gene is thus 
blocked (Jones and Takai, 2001). Abnormal methylation can, for example, thereby lead to the 
suppression of tumour-suppressor genes (Zhang et al., 2006b), or conversely, aberrant 
demethylation of an oncogene promoter can be linked to cancer initiation (Koslowski et al., 2011). 
CpG methylation is absent in mitochondrial DNA (Hong et al., 2013). 
1.5.3. Non-CpG methylation 
Although described as potentionally important regulatory mechanism in mammalian cells over two 
decades ago (Woodcock et al., 1987), and as pivotal in embryonic stem cells over a decade ago 
(Ramsahoye et al., 2000), non-CpG methylation remains largely underexplored in most 
organisms. It has been so far mostly studied in plants, but recent studies show 20-25% non-CpG 
methylation in stem cells, namely in CpA context. The observed non-CpG methylation disappears 
with differentiation, indicating that non-CpG methylation is involved in the maintenance of the 
pluripotent state (Lister et al., 2009). In non-small cell lung carcinoma, non-CpG methylation of 
p53 exon 5 is more prevalent compared to normal lung tissue (Kouidou et al., 2005). In Burkitt’s 
lymphoma, overall non-CpG methylation was shown to be generally low, but significantly enriched 
at non-CpG sites within genes (Kreck et al., 2013). 
Recent data evaluating non-CpG methylation across various mammalian tissues has estimated 
the overall prevalence of non-CpG methylation at approximately 7.5% of all non-CpG cytosines 
(Yan et al., 2011). Additionally, high levels of non-CpG methylation occur in oocytes, but not in 
sperm, and change dramatically during early post-conception development (Tomizawa et al., 
2011). In post-developmental cells, non-CpG methylation is much more common in neurons, 
which are non-dividing cells (Kozlenkov et al., 2013), suggesting its role cannot be exclusively 
linked to pluripotency maintenance, but more likely linked to tight regulation of specific cellular 
processes.  
1.5.4. Hydroxymethylation 
In spite of early hypotheses that considered DNA methylation to represent a relatively stable 
epigenetic mark, it became gradually clear that it is a highly dynamic modification that is either 
added or removed through an enzymatic process (Dawson and Kouzarides, 2012). 
A set of so-called TET (ten-eleven translocation) proteins with mammalian DNA hydroxylase 
properties has been shown to catalytically convert 5’-methylcytosine to 5’-hydroxymethylcytosine 
(5’hmC) using molecular oxygen (Thomson et al., 2013, Tahiliani et al., 2009). Further oxidation 
of 5’hmC into 5-formylcytosine and 5-carboxylcytosine creates nucleoside intermediates that are 
eventually excised through the mechanism of base-excision repair, resulting in DNA 
demethylation (Thomson et al., 2013). 
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Current line of evidence suggest an important role of hydroxymethylation in preimplantation 
embryos (Inoue and Zhang, 2011), DNA methylation fidelity control (Williams et al., 2011), mouse 
embryonic stem cells maintenance through Nanog expression (Ito et al., 2010), differentiation 
(Ficz et al., 2011) and transcriptional regulation in mouse embryonic stem cells (Wu et al., 2011, 
Xu et al., 2011). High levels of  5’hmC were detected in human cerebellar neurons (Kriaucionis 
and Heintz, 2009), while the loss of of this epigenetic mark was described in melanoma 
epigenome (Lian et al., 2012) and in Alzheimer’s disease (Chouliaras et al., 2013). Given that 
various hematopoietic malignancies are clearly linked to TET-mediated oncogenesis (Moran-
Crusio et al., 2011, Lorsbach et al., 2003, Figueroa et al., 2010a), and changes in 5’hmC in 
response to carcinogens were described in the liver (Thomson et al., 2013), it seems plausible 
that a congruent interplay of mechanisms regulating DNA methylation plays a role in both 
physiological regulation and disease. 
1.5.5. MicroRNAs 
The classically translated genes are not the only molecules capable of regulating gene expression 
in the cell. MicroRNAs (miRNA) are non-coding single stranded RNA molecules, approximately 22 
nucleotides in length, capable of regulating gene expression by binding to the 3’ untranslated 
region (UTR) of messenger RNA (mRNA) and thus repressing translation. Each miRNA can 
target multiple genes and it is estimated that the expression of up to a third of all human protein-
coding genes is possibly regulated by miRNAs (Esquela-Kerscher and Slack, 2006). Additionally, 
miRNA can accelerate target mRNA degradation and thus indirectly reduce the eventual amount 




Figure 1.21 Basic processing of miRNAs. miRNP=microRNA ribonucleoprotein complex, 
PABP=poly(A)-binding protein. Figure taken from (Shyu et al., 2008). 
MiRNAs are incorporated into RNA-induced silencing complex (RISC), and then guide effector 
complexes (miRNPs) to the target mRNA site through hybridisation with targtet mRNA 3'UTR 
sequence, leading to direct inhibition of protein translation.MiRNPs are also able to deadenylate 
target mRNA and thus accelerate its degradation. See Figure 1.21. 
MiRNAs are capable of affecting many fundamental cellular processes in both animals and plants 
(Shyu et al., 2008), and have been linked to a range of diseases including schizophrenia, 
cardiomyopathy and cancer. Examples of tumour suppressor miRNAs include the miR-15a and 
miR-16-1, shown to be frequently deleted in B-cell chronic lymphocytic leukaemia and leading to 
overexpression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) (Calin et al., 2002, 
Cimmino et al., 2005). MiR-21 has an anti-apoptotic function and is upregulated in glioblastomas 
and breast cancer (Chan et al., 2005, Iorio et al., 2005).  
In skin pathology, miR-99a that regulates the expression of Insulin-like growth factor 1(IGF-1R) 
has been found to be downregulated in psoriasis (Lerman et al., 2011), and hematopoietic-
specific miR-142-3p has been found in psoriatic lesions (Joyce et al., 2011), suggesting a 
complex regulatory interplay in the genesis of this lesion. MiRNA dysregulation in skin cancer is 
described in greater detail in section 1.5.7. 
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1.5.6. Histone modification 
Histones allow the packaging of DNA within the nucleus. The complex of DNA and histones is 
called a nucleosome, and is formed by the octamer of histones H2A, H2B, H3 and H4 in pairs. 
The formation of histones is mediated by so-called histone-chaperone proteins, and this process 
is essential for genome stability and preservation of epigenetic information following DNA 
replication, repair and gene transcription (Burgess and Zhang, 2013). Approximately 146bp of 
DNA are wrapped around the core of histones to form a nucleosome. This complex allows dense 
packaging of DNA and is called chromatin. Chromatin is a highly dynamic cellular structure 
critically important in regulating transcription, DNA replication, repair, and recombination, and any 
alterations to chromatin structure can lead to severe perturbations of those processes (English et 
al., 2006). 
Heterochromatin, considered to represent a transcriptionally inactive form of DNA packaging, is 
often found in segments of repetitive DNA elements, including rRNA genes, centromeres, 
telomeres and interspersed transposable elements (Bierhoff et al., 2013). Euchromatin, on the 
other hand, is considered transcriptionally active, although it has gradually become clear that this 
distinction is not sufficient to cover chromatin complexity: For example, heterochromatin becomes 
transcriptionally permissive during S-phase of the cell cycle, and its relative active transcription 
strongly correlates with developmental stages of tissue (He et al., 2012). 
Histone modification is important in many processes such as DNA repair, mitosis and apoptosis 
and histones are heavily modified post-translation. The N-terminal end of the histone protrudes 
from the complex, containing about 28% of aminoacids of the histone core, and is a subject to 
various modifications: acetylation, methylation, sumoylation, ubiquitination, phosphorylation, 
namely at lysine residues. Given that both the aminoacid sequence of histones and the character 
of the regulatory marks is evolutionarily conserved, it seems plausible that these are critical for 
the maintenance of cellular functions in eukaryotes (Thompson et al., 2013). 
The acetylation of positively charged lysine residues leads to a local opening of the chromatin, 
which allows transcription factors and chromatin remodelling factors to access it and ultimately 
results in gene transcription. The process of acetylation is facilitated by histone acetyltransferases 
(HATs) and conversely removed by histone deacetylases (HDACs) (Zhao et al., 2013b). Histone 
methylation occurs on arginine or lysine residues and can lead to both transcriptional activation 
and suppression (Cloos et al., 2008). Histone methylation depends on the activity of histone 
methyltransferases and is removed by histone demethylases. Perturbations of histone 
posttranslational modifications have been associated with cancer. 
One of the most explored histone modifications includes trimethylated lysine 4 of histone 3 
(H3K4me3). This epigenetic mark is induced by the Trithorax group of proteins (Coskun et al., 
2012), and has been associated with practically all active gene promoters. Although the role of 
this modification has not been entirely clarified yet, because not all genes whose promoters bear 
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it are transcribed, it is presumed to render gene “poised for activation”, possibly due to promoter 
demethylation (Bernstein et al., 2006). 
Conversely, H3K27me3 is found in promoters of transcriptionally silenced genes, and H3K27me3 
pre-marked genes are targeted by DNA methylation (Severson et al., 2013). This mark is induced 
by the Polycomb group complex and has been linked to silencing genes important in embryonic 
development. Irrespective of other epigenetic marks present in the gene promoter, if H3K27me3 
is present, the gene is always silenced (Wang et al., 2008). 
Trimethylation of histone H3 on Lys36 (H3K36me3) is induced by SETD2 trimethyltransferase (Li 
et al., 2013a). It is preferentially enriched in exones compared to intrones, and may play a role in 
alternative splicing, because its levels are lower in alternatively spliced exones (Kolasinska-
Zwierz et al., 2009). Possibly, it may play a role in transcription elongation and might prevent 
transcription from cryptic start sites within the coding region (Carvalho et al., 2013).  
The H3K36me3 mark has recently been implicated in human DNA mismatch repair, because it 
recruits recognition protein hMutS-α onto chromatin. Cells that lack SETD2 show microsatellite 
instability and an increased rate of spontaneous mutations, which is typical for cells deficient in 
DNA mismatch repair (Li et al., 2013a), indicating that perturbations in this modification may be 
linked to cancer susceptibility (Li, 2013). 
The role of histone modification in embryonic stem cells and pluripotency regulation is described 
in detail in Chapter 1.6. 
1.5.7. Epigenetics and non-melanoma skin cancer 
From the non-melanoma skin cancer perspective, previous epigenetic studies have focused 
mainly on DNA methylation of cSCC, BCC and Merkel Cell Carcinoma (MCC).  Studies assessing 
methylation in Merkel Cell carcinoma, a rare yet very aggressive form of skin cancer, are limited 
to date. A study using methylation-specific polymerase chain reaction (PCR) has revealed 
methylation of p14ARF promoter in 42%, and p16INK4a methylation in a single sample 
(Toyoshima et al., 2008). Another study using the same technique but a substantially higher 
number of samples (21 vs. 98) found methylation of RASSF1A gene and CDKN2A in 42 and 9 
MCC samples, respectively. Other genes tested (TP73, PTPRG and FHIT) were not found to be 
methylated (Helmbold et al., 2009a). The same group looked at RASSF1A and p16 gene 
promoter methylation to find out that those genes are methylated in 94% and 56% of samples 
tested, respectively (Helmbold et al., 2009b). 
Methylation analysis of p16, a putative tumour suppressor, in basal cell carcinoma detected 
methylation in 7/28 tested samples (Soufir et al., 1999) using methylation restriction analysis. 
Another study looking at methylation at different histological areas of BCC showed that p16 
methylation diminished in tumour cells that were located at the invasive front (Svensson Mansson 
et al., 2007), underscoring the role of histological heterogeneity in molecular studies of cancer.  
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The promoter region of another tumour suppressor, T-cadherin, has been found to be methylated 
in 6 of 25 BCC samples using methylation-specific PCR (Takeuchi et al., 2002b). The methylation 
status of Gli1, an oncogene that is overexpressed in BCC, was not altered in this tumour (Ghali et 
al., 1999).  
14-3-3sigma is a cell cycle inhibitor regulated by p53. A study assessing methylation status of 14-
3-3sigma in 41 BCC samples using methylation-specific PCR showed that 28 (68.3%) samples 
are hypermethylated in the gene promoter region and in 22 cases this was concordant with 
reduced protein expression (Lodygin et al., 2003). Elsewhere, a study of methylation of a panel of 
selected genes in 68 BCC samples using the same technique has shown that LAMA3, LAMC2, 
CDH1 and CDH3 genes are methylated in more than 30% of the samples, LAMB3, P16, 
RASSF1A, CDH13, CDH1, CDH3 and beta IG-H3 were methylated in more than 0% but less than 
30% of the samples, while Cyclin D2 (CYCD2), TJP2a and CLDN7 were not methylated in any 
sample tested. This study also found a difference in methylation of LAMA3 and CDH1 (p value = 
0.02 and 0.04, respectively) when they stratified for sun-exposure of the samples tested; 
however, given that the number of samples from sun-exposed sites was 61 and only 7 from sun-
protected areas, the validity of this testing is limited (Sathyanarayana et al., 2007). Fragile 
histidine triad (FHIT) gene is a pro-apoptotic molecule and its inactivation plays a role in cellular 
DNA damage survival. Methylation-specific polymerase chain reaction and combined bisulphite-
dependent restriction analysis (COBRA) of this gene methylation status in 17 BCCs has shown 
that in 15/17 of samples this gene is hypermethylated, and this was confirmed by COBRA which 
reported methylation in 88% of the samples (Goldberg et al., 2006). The decreased expression of 
FHIT was confirmed on the protein level using immunohistochemistry.  
The Patched (PTCH) gene is an important regulator during embryonic development, but also 
functions as a tumour suppressor. Mutations in this gene are associated with Gorlin syndrome, 
and since its mutation in sporadic BCC has been reported, a few studies have attempted to 
evaluate the methylation status of PTCH in BCC. A study using methylation-specific PCR found 
no difference in PTCH promoter methylation using samples treated with RNALater or culture 
media for an unspecified period of time (Cretnik et al., 2007), while another study has shown that 
the source material is a key factor in methylation studies in BCC: five of 16 BCCs showed 
methylation of PTCH when fresh frozen samples were used, while only two of 16 samples 
showed methylation of the gene when identical paraffin-embedded samples were used (Heitzer et 
al., 2010) and high-resolution melting technology was applied.  
Methylation-specific high-resolution melting (MS-HRM) analysis of AKAP12 gene in 85 BCC 
samples showed 0% methylation in 11, and 10% methylation in 74 of BCC samples, while 78 of 
adjacent normal tissue samples showed 0% and 7 of them were methylated in 10% degree. 
Although this difference was significant in terms of statistical difference (p value < 0.01), the 
biological significance of this difference is questionable, because 10% degree of methylation 
difference may not be sufficient to lead to actual biological difference in cell regulation. 
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Methylation studies in cSCC have so far identified several potential targets of aberrant 
methylation, including putative tumour-suppressor genes. T-cadherin promoter methylation was 
detected in 12 out of 28 invasive squamous cell carcinomas (Takeuchi et al., 2002a). A study 
assessing  promoter hypermethylation of the E-cadherin in 9 cases of spongiotic dermatitis 
(control), 9 cases of actinic keratosis, 8 cases of squamous cell carcinoma in situ, and 7 cases of 
invasive squamous cell carcinoma gene detected E-cadherin hypermethylation in 6 of 7 cases 
(85%) of invasive squamous cell carcinoma, 4 of 8 cases (50%) of squamous cell carcinoma in 
situ, 4 of 9 cases (44%) of actinic keratosis, and 2 of 9 cases (22%) of control, suggesting that 
this gene promoter hypermethylation increases with more malignant profile of cutaneous lesions. 
Using the same sample panel, death-associated protein kinase promoter methylation was found 
in 1 squamous cell carcinoma in situ and 1 control. P16 promoter hypermethylation was detected 
in 1 invasive squamous cell carcinoma and 1 control only, suggesting no difference in methylation 
between cSCC and control. However, a subsequent study exploring methylation of p16 in 36 
cSCC cases found 13 (36%) samples to be aberrantly hypermethylated (Brown et al., 2004). In 
addition, this study found hypermethylation of p14 in 16 of 38 (42%) cSCC cases. In recessive 
dystrophic epidermolysis bullosa cSCC, two out of eight cSCC samples exhibited p16 methylation 
(Arbiser et al., 2004).  
In skin cancer, microarray profiling of mycosis fungoides (MF) and benign inflammatory conditions 
showed 49 miRNAs to be differentially expressed at the tumour stage MF compared to benign 
inflammatory dermatoses. The most significant differentially expressed were miR-155 and miR-
92a and both were upregulated (van Kester et al., 2011). Mir-211, which has tumour suppressor 
properties, is silenced in melanoma (Levy et al., 2010), mir-125b is down-regulated in metastatic 
melanoma (Glud et al., 2010), and mir-21 is up-regulated in Sezary syndrome (van der Fits et al., 
2011).  
Basal cell carcinoma profiling has identified an array of dysregulated miRNAs, including let-7 
involved in cell proliferation, UV-induced miR-21 upregulation (Heffelfinger et al., 2012), miR-17 
regulated by the MAPK/ERK axis (Sand et al., 2012b) and other miRNAs involved in critical 
cellular processes. 
In cSCC, miRNA profile is affected by UV radiation. Mir-21 and mir-184 expression is significantly 
increased in SCC, while mir-203 expression was shown to be downregulated in this tumour 
(Dziunycz et al., 2010), as well as the expression of miR-124 and miR-214 which regulate ERK1 
and ERK2, respectively (Yamane et al., 2013). 
These data support the role of epigenetic changes in non-melanoma skin cancer, and justify an 
integrative exploration of various epigenetic mechanisms in this very common cancer. 
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1.6. Stem Cells 
In recent years, stem cells have attracted wide-spread interest not only from the scientific 
community, but also from a large number of media outlets and the general public. This 
considerable public attention largely owns to the proclaimed immense potential and promise of 
stem cells in tissue repair and regenerative biology (Pera and Trounson, 2004), thereby 
conceivably spelling a new era in human medicine. In mammals, one single zygote gives rise to 
over 200 types of adult cells (Boyer et al., 2005), and exploiting this property for therapeutic 
purposes is extremely tempting. Nevertheless, while raising hope among many patients, the 
question of potential clinical application of stem cells derived from human embryos has ignited a 
fierce ethical controversy, even leading to a presidential veto to a bill allowing federal funding for 
embryonic stem cell research in the USA (Dolgin, 2006). However, stem cells are attractive not 
only from the perspective of tissue engineering and cellular therapy, but also in the study of 
embryogenesis, developmental biology, disease modelling and cancer research. 
Defining stem cells 
Stem cells (SC) are essential for normal embryonic development and homeostasis of an 
organism, since SC play a fundamental role in the initiation and progress of prenatal growth, 
subsequent organogenesis and in the maintenance and regeneration of mature tissues. The 
definition of stem cells is commonly based on their capacity of self-renewal and concurrent 
differentiation towards multiple types of tissues. Mammalian ontogenesis is characterised by 
gradual restriction of cellular developmental potential, and thus determines the “stemness” of cells 
at various stages of embryogenesis: totipotent (or omnipotent) stem cells have the potential to 
create an entire organism, and arise upon egg fertilisation and zygote formation. Totipotency is 
maintained up to the eight-cell stage of the morula. Once the cells reach the blastocyst stage, 
consisting of outer trophoblast cells (trophoectoderm) and undifferentiated inner cell mass (ICM), 
totipotency is lost, and the cells of the ICM are pluripotent; they possess the capacity to generate 
all three primary germ layers: the endoderm, mesoderm, and ectoderm. Multipotent stem cells are 
even more limited in terms of tissues those can generate; usually within the tissue lineage3. The 
hierarchy of stem cells is shown in Figure 1.22. 
 
 
                                                       




Figure 1.22 Hierarchy of stem cells. Figure taken from (Wobus and Boheler, 2005). 
1.6.1. Embryonic stem cells 
Embryonic stem cells (ESCs) are derived from the blastocyst, which represents the pre-
implantation stage of mammalian embryos. As described above, ICM contains the pluripotent 
ESCs, which under physiological conditions develop into the actual organism, and the 
surrounding trophoblast is determined to become a part of the placental chorion. 
Historically, pluripotency was first demonstrated in 1964 in embryonal carcinoma cells, when upon 
in vivo implantation, single cell grafts formed various clonal lines including well differentiated 
somatic tissues (Kleinsmith and Pierce, 1964). In 1981, two research groups independently 
demonstrated pluripotent cells derived from early mouse embryos that were expanded in vitro 
while retaining their pluripotency (Evans and Kaufman, 1981, Martin, 1981). Upon insertion into 
murine blastocyst, these cells contributed to the embryogenesis and germ line formation, and this 
ability of murine ESCs lead to the generation of chimeric mouse models using homologous 
recombination (Capecchi, 1989).  
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Human ESCs (hESCs) were first derived and maintained in vitro in 1998 (Thomson et al., 1998), 
using 4-5 days old preimplantation embryos. Those cells possess certain defining characteristics 
that set them apart from somatic cells: instrinsic transcriptional hierarchy allowing the 
maintenance of pluripotency during self-renewal, a defining epigenetic state that keeps chromatin 
available for immediate cell fate decisions, and a cell cycle characterised by an extremely short 
G1 phase and the nearly absent checkpoint controls (Boheler, 2009). 
1.6.1.1. Pluripotency maintenance in ESC 
Pluripotency is transcriptionally governed by three key molecular regulators: OCT4, NANOG and 
SOX2. These transcription factors share a substantional segment of their target genes, and form 
a highly regulated circuitry in which these three genes control the transcription of one another, in 
addition to regulating other genes involved in pluripotency maintenance (Boyer et al., 2005). 
These genes are capable of both positive and negative regulation of transcription, creating a 
highly complex interaction network. This network consists of nuclear factors critical for 
maintenance of the ESCs in undifferentiated state and that possess a role in differentiation, 
representing a certain “cellular module” of pluripotency (Wang et al., 2006). Additional 
transcription factors implicated in pluripotency maintenance are listed in Table 1.8. 
Transcription	  Factor	   Function	   Genomic	  location	  
Comment	  
Oct4	   Core	  circuitry	   6p21.31	  
Homeobox	  gene	  
Sox2	   Core	  circuitry	   3q26.3-­‐q27	  
Nanog	   Core	  circuitry	   12p13.31	  
Homeobox	  gene	  
Tcf3	   Wnt	  signaling	  to	  core	  circuitry	   19p13.3	  
Stat3	   Lif	  signaling	  to	  core	  circuitry	   17q21.31	  
Smad1	   BMP	  signaling	  to	  core	  circuitry	   4q31	  
Smad2	  
Smad3	  
TGF-­‐β/Activin/Nodal	  signaling	   18q21.1	  
15q22.33	  
c-­‐Myc	   Proliferation	   8q24.21	  
Oncogene	  
Esrrb	   Steroid	  hormone	  receptor	   14q24.3	  
Sall4	   Embryonic	  regulator	   20q13.2	  
Zinc-­‐finger	  protein	  
Tbx3	   Mediates	  LIF	  signaling	   12q24.1	  
T-­‐box	  gene	  
Zfx	   Self-­‐renewal	   Xp21.3	  
Zinc-­‐finger	  protein	  
Ronin	   Metabolism	   16q22.1	  
Klf4	   LIF	  signaling	   9q31	  
Zinc-­‐finger	  protein	  
Prdm14	   ESC	  identity	   8q13.3	  
Zinc-­‐finger	  protein	  




Key epigenetic mechanisms involved in the maintenance of ESCs include nuclear architecture, 
defined chromatin structure, chromatin dynamics and histone modifications (Meshorer and Misteli, 
2006). Nuclei of ESCs are characterised predominantly by euchromatin, and once differentiation 
is started and progresses, ESCs accumulate transcriptionally inactive heterochromatin. Thus, 
regulators of chromatin structure play an important role in embryonic development and in 
pluripotency maintenance.  
Trithorax group (TrxG) and Polycomb group (PcG) protein complexes represent key molecular 
factors that regulate chromatic structure and contribute to pluripotency maintenance. In murine 
ESC, PcG proteins which possess H3K27-specific trimethylase activity directly repress 
developmental regulators that would lead to differentiation if their expressin were not inhibited, 
and all those regulators contain trimethylated lysine 27 on histone H3 (Boyer et al., 2006). In 
hESC, target genes of PcG are activated during cell differentiation, and OCT4, SOX2, and 
NANOG regulate a significant portion of these genes (Lee et al., 2006b). Conversely, trxG 
proteins have H3K4 trimethylase activity, and trimethylation of H3K4 (H3K4me3) leads to active 
chromatin state permisive for gene expression (Schuettengruber et al., 2007). The pattern of 
these two marks colocalising in ESC in clusters of developmental genes, such as homeobox 
genes, was named “bivalent domains”. Based on the presence of these marks, genes can be 
divided into three clusters: expressed genes, genes poised for expression, or repressed genes 
(Mikkelsen et al., 2007). Bivalency predisposes genes for both activation and inactivation, and 
during commitment towards differentiation, genes important in unrelated lineages lose their 
expression-permisive mark (Pietersen and van Lohuizen, 2008). 
1.6.1.2. Concerns regarding clinical application of hESC 
HESC are capable of long-term proliferation in vitro (Amit et al., 2000), and escape senescence 
through telomerase expression. However, long-term culture conditions lead to profound genomic 
and epigenetic changes of hESC lines (Maitra et al., 2005). Moreover, hESCs normally require a 
feeder layer in order to maintain undifferentiated phenotype. Traditionally, hESCs are thereby 
cultured on a a layer of gamma-irradiated murine fibroblasts that provide necessary stimuli for the 
maintanence of undifferentiated state, yet convey the risk of contamination with murine 
pathogens, including retroviruses, which renders them unsuitable for application in humans. In 
addition, other concerns regarding ESC application include tissue integration of transplanted 
hESC derivates, immunogenicity and graft rejection, as cells gradually become immunologically 
incompatible as differentiation progresses (Drukker et al., 2002), and tumourigenicity of hESC, 
discussed in greater detail in the following segment. 
1.6.1.3. Human embryonic stem cells and cancer 
The intimate link between ESC and cancer is highlighted by the historical fact that the field of 
embryonic stem cells research was initiated by experiments with embryonic carcinoma. The 
unique properties of hESC – indefinite proliferation and self-renewal – contribute to the 
tumourigenicity of hESC, and also represent hallmarks of cancer cells. Other shared traits include 
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high telomerase activity, expression of oncogenes and lack of contact inhibition (Ben-David and 
Benvenisty, 2011). 
Teratocarcinoma and teratoma are tumours comprised of both plutipotent stem cells and 
differentiated tissues, and the initial comparison of ESC with embryonic carcinoma cell lines 
demonstrating many shared properties was considered a validation of ESC pluripotency 
(Knoepfler, 2009). The most concerning discovery for regenerative medicine is the fact that ESC, 
a physiological counterpart of embryonic carcinoma cells, cause tumours. It seems likely that the 
removal of ICM from the embryo and establishment of ESC in an artificial environment of cell 
culture endows the ICM cells with novel properties, some of which are tumourigenic to a lesser or 
greater degree.  
The so-called “teratoma assay”, a transplantation of pluripotent stem cells into mice in which the 
formation of benign tumours (teratomas) is then observed, is considered a demonstration of 
pluripotency of both ESC and iPSC (Wesselschmidt, 2011). Moreover, hESC can form aggressive 
undifferentiated tumours in mice (Shih et al., 2007), suggesting that tumourigenicity of ESC is 
considerably influenced by the host tissue, and thus highly unpredictable. Many regulatory 
elements and pathways are shared by ESC and cancer cells (Sperger et al., 2003, Ben-Porath et 
al., 2008), and established oncogenes such as MYC are required for the generation of iPSCs. If 
levels of MYC are lowered in iPSC, pluripotency of those cells decreases (Knoepfler, 2009). It 
may be deducted that the greater pluripotency, the greater tumourigenic potential, and if a stem 
cell were completely deprived of its ability to cause tumours, it would no longer be a stem cell. If 
we consider cancer a type of tissue, and ESC cells capable of differentiation into any kind of 
tissue, then inevitably these cells must be able to cause cancer.  
Genome-wide expression profiling of hESC and human germ cell tumours has demonstrated 
many similarities between hESC and the human embryonal carcinoma cell, and a certain degree 
of transcriptome similarity with seminoma, a testicular tumour derived from germ cells (Sperger et 
al., 2003). Further expression data analysis has revealed that histologically poorly differentiated 
tumours overexpress ESC genes, and repress PcG-regulated genes, and key ESC markers 
(Nanog, Oct4, Sox2 and c-Myc) are more commonly overexpressed in poorly differentiated 
tumours in comparison with well-differentiated tumours (Ben-Porath et al., 2008). 
1.6.1.4. Human embryonic stem cells in current clinical practice 
In spite of serious ethical, religious and social dilemmas associated with human embryonic stem 
cells (hESC), laboratory results demonstrating that those can been successfully differentiated into 
clinically relevant tissues in vitro, including cardiomyocytes and dopamine neurons (Murry and 
Keller, 2008), encouraged clinical application of tissues engineered from those cells. In 2009, a 
clinical trial using oligodendrocytes derived from hESCs in patients with spinal injury began in the 
USA, and preliminary results have shown no serious adverse effects nor significant neurological 
improvement (Watson and Yeung, 2011), yet the study is still ongoing. Another clinical study of 
hESC-derived retinal pigment epithelium in patients suffering from macular dystrophy and dry 
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age-related macular degeneration has demonstrated no adverse effects and modest improvement 
in the vision of selected patients (Schwartz et al., 2012). Nonetheless, while the therapeutic 
potential of stem cells seems practically unlimited, it still remains to be translated into effective 
clinical practice. 
1.6.2. Induced pluripotent stem cells 
Ever since the first hESC cell lines were derived from a human blastocyct in a process that 
required desctruction of the embryo, significant ethical concerns were raised over hESC (Vogel 
and Holden, 2008), and other above-described doubts regarding their clinical application inspired 
the creation of customised, personalised stem cells for individual patients using somatic-cell 
nuclear transfer (SCNT) (Robinton and Daley, 2012). SCNT has been previously used for “Dolly 
the sheep” cloning (Campbell et al., 1996), and pluripotent stem cells generated using SCNT 
would possess a patient’s genome and be used for generating any required tissue due to their 
pluripotency. However, since this procedure technically creates a human clone, although proven 
feasible for generating “personalised” ESC (Noggle et al., 2011), requirement of human oocytes 
and other technical and ethical considerations make SCNT-derived ESC unlikely for therapeutic 
use. 
Induced pluripotent stem cells (iPSC) represent an alternative source of personalised stem cells. 
In 2006, Takahashi and Yamanaka introduced pluripotency in differentiated murine fibroblasts 
through the ectopic coexpression of four transcription factors by viral transduction (Takahashi and 
Yamanaka, 2006). IPSC derived from human differentiated cells quickly followed (Yu et al., 2007, 
Takahashi et al., 2007). The four factors used for reprogramming towards pluripotency included 
OCT4, SOX2, KLF4 and c-MYC used by Yamanaka’s group, while Thomson’s group avoided 
using c-MYC and KLF4, known oncogenes, and applied Nanong and Lin28 instead.  
In spite of apparently shared traits between hESC and iPSC, the reprogramming process leads to 
copy-number variation (CNV) in the early passages of iPSC, leading to genetic mosaicism and 
selective disadvantage, as CNV decreases with further passaging (Hussein et al., 2011). 
Additionally, iPSC contain protein-coding point mutations (Gore et al., 2011) and aberrant 
methylation (Lister et al., 2011),   
1.6.3. Mesenchymal stem cells 
Mesenchymal stem cells, or multipotent mesenchymal stromal cells (MSCs) are multipotent 
progenitor cells capable of both self-renewal and differentiation towards cells with terminal 
functions. MSCs represent prototypical adult stem cells (in contrast to embryonic stem cells), and 
are distributed in various body tissues (Williams and Hare, 2011).  
MSCs were first isolated from guinea-pig bone marrow as fibroblast-like cells capable of forming 
colonies (Friedenstein et al., 1970), and later were shown as able to differentiate into mesoderm-
derived tissues (Friedenstein et al., 1974), and later emerged as important regulators of bone 
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marrow microenvironment and haematopoietic stem cells niche (Mendez-Ferrer et al., 2010, 
Zhang et al., 2003). Outside of bone marrow, MSCs were shown to be present in most if not all 
adult tissues, and in addition to bone marrow, were isolated from adipose tissue, synovial 
membrane, the bronchi, umbilical cord blood, and peripheral blood. While MSCs from various 
sources are indeed heterogeneous, these cells share certain surface markers and mesodermal 
differentiation potential. 
 In terms of their multilineage potential, MSCs were shown to differentiate into osteoblasts, 
chondrocytes, adipocytes (Pittenger et al., 1999), myogenic cells, astrocytes and cardiomyocytes 
(Williams and Hare, 2011). 
Mesenchymal stem cells are critical for tissue repair and regeneration. MSCs are rapidly recruited 
into the site of injury to promote healing and regeneration by differentiation and paracrine 
signalling (Hocking and Gibran, 2010). Given that tumours can be described, cum grano salis, as 
“wounds that never heal” (Dvorak, 1986), it is conceivable that the dramatic changes surrounding 
malignant tissue formation would attract MSCs in a manner similar to tissue wounds. The 
involvement of MSCs in cancer formation is described in the following segment. 
1.6.3.1. Mesenchymal stem cells in cancer 
Mesenchymal stem cells are an intergral part of stem cell niches of various organs. In spite of 
their potential and capacity to differentiate into various tissues such as fibroblasts, osteoblasts, 
and adipocytes (da Silva Meirelles et al., 2006, Pittenger et al., 1999), it has been shown that 
MSC are not inherently tumourigenic (Ljujic et al., 2013), but can contribute to pro-tumourigenic 
tissue microenvironment (Stagg, 2008). MSC can induce a local immunosuppressive effect or 
stimulate proinflammatory environment, and thus indirectly promote tumour growth (Uccelli et al., 
2008). Bone-marrow derived MSC are recruited to the site of tumour formation, where 
proangiogenic stimuli these cells produce lead to increased tumour vasculature formation (Roorda 
et al., 2009). Higher tumour incidence has been reported if various tumour cell lines were co-
implanted with MSC (Djouad et al., 2006, Yu et al., 2008), and most importantly, a higher 
recurrence rate of haematologic malignancies has been noted among patients co-transplanted 
with MSC (Ning et al., 2008). Additionally, stromal MSC have been shown to promote breast 
cancer metastases (Karnoub et al., 2007), and differentiate into carcinoma-associated fibroblasts 
that further sustain tumour growth (Mishra et al., 2008).  
However, there is evidence showing antitumour effects of MSC, suggesting their role in cancer 
formation and growth may be context-dependent: in Kaposi sarcoma model, MSC were recruited 
to sites of tumour formation as expected, but inhibited tumour growth through Akt inactivation 
(Khakoo et al., 2006). A study in hepatoma and breast carcinoma model has shown similar effects 
due to Wnt pathway inactivation by MSC (Qiao et al., 2008a, Qiao et al., 2008b). 
These data suggest that the ultimate effect of MSC on tumour biology may be highly dependent 
on individual molecular properties of given tumour cells, systemic and local immunological 
response and further factors that remain to be unravelled. 
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1.6.4. Human epidermal stem cells 
Epidermal stem cells (EpSC) are located in epidermal niches, and their primary role in skin 
homeostasis is the replenishment of lost cutaneous cells (Shen et al., 2013). While there are 
extensive data describing the biology of  EpSC in mouse skin, very little is known about human 
EpSC.  
While keratin 15 is routinely used to isolate epidermal stem cells from murine hair follicles, it is not 
equivalently efficient marker for human EpSC (Ohyama, 2007), for which other markers have 
been proposed, including CD200 (Ohyama et al., 2006, Garza et al., 2011).  
Interfollicular epidermis that predominates in humans compared to mice may contain EpSC in so-




Figure 1.23 Panel of skin samples stained with methylene blue depicting rete ridges. a) 5x 
magnification b) 10x magnification c) + d) 40x magnification. Suggested EpSC are present at the 
demarcating edge of rete ridges and stain very darkly. 
These cells were suggested to express high levels of beta1-integrin, melanoma chondroitin 
sulfate proteoglycan and Lrig1 (Boehnke et al., 2012). Alternative markers proposed included α6 
integrin and low expression of CD71 (Webb et al., 2004). This methodological discrepancy may 
be due to the conceptual definition of stem cells, and technological limitations of antibody staining. 
Currently, there is no definite consensus with respect to the location, identifying markers and 
biological characteristics of human interfollicular EpSC. 
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Cancer stem cells 
One of the central questions in cancer biology is the cell of origin of cancer, which to date has not 
been answered. Given that each subtype of cancer is markedly different in terms of intrinsic 
histological features, propensity to metastasise and response to therapy, it may be conceived that 
such variety reflects different cells of origin for these tumours, each driving the distinct phenotype 
ultimately harboured by cells of the tumour (Visvader, 2011). Such cell of origin is expected to be 
a normal cell that acquires tumourigenic mutations which form a hierarchically organised tumour 
mass by clonal evolution, and this mass is then maintained by a distinct subpopulation of cells 
capable of both self-renewal and generating other cells of the neoplasia. This concept presumes 
the existence of two distinct populations within malignancies: cell of origin (tumour-initiating 
cell(s)), which leads to tumour formation and cancer stem cells (CSC), responsible for subsequent 
tumour sustenance. This concept is depicted in Figure 1.15.  
 
Figure 1.24 Hierarchical structure of tissue cells linked with neoplastic initiation and progression. 
According to this model, only the CSCs sustain tumourigenesis, and are distinct from the cell of 
origin. Figure taken from (Visvader, 2011). 
The theory of a single cell of origin of cancer has been postulated in 1976: acquired genetic 
variability of the original tumourigenic cell allows for clonal selection towards more aggressive 
sublines, and this evolution-like selection process leads to the genetic and biological variety within 
tumours (Nowell, 1976). This parallel with Darwinian selection process suggests that cancer is a 
quasi-species endowed with adaptive properties (Greaves and Maley, 2012). According to this 
theory, tissue is the environmental context for cancer evolution, and various genetic subclones 
within the tumour represent adaptive solutions to (micro)environmental constraints: hypoxia, 
space limitations, immune system, nutrition, and most importantly cancer therapeutics. The 
genotoxic character of many therapeutic agents provides selective pressure for the growth of 
clones that gain further mutations accounting for treatment resistance and increased 
aggressiveness of many recurrent cancers. Presuming that mutagenic processes are random and 
non-purposeful, clonal evolution oversees the interplay between “driver” lesions that drive clonal 
expansion and confer a selective advantage, “passenger” or “hitchhiker” lesions which remain 
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selectively neutral, and “mutator” lesions that lead to other genetic changes in the context of 
tissue microenvironment. Importantly, epigenetic changes which are much more readily inducible 
compared to genomic mutations may be key drivers of clonal evolution (Siegmund et al., 2009) 
and tumour heterogeneity (Varley et al., 2009). Single-cell sequencing in breast cancer has 
shown clonal evolution of the tumour based on genetic genealogy of dominant clones and rare, 
intermediate clones that seem to have been overcome in competition with ultimately prevalent 
clones (Navin et al., 2011), and data from leukemia further confirmed evolutionary pattern of 
cancer development and its clonal architecture (Anderson et al., 2011, Campbell et al., 2008, 
Ding et al., 2012). The clonal and evolutionary character of metastases was described in 
pancreatic carcinoma, demonstrating that metastatic clones are the progeny of non-metastatic 
parental clones within the primary tumour mass (Yachida et al., 2010), and in renal cell carcinoma 





Figure 1.25 Clonal evolution of cancer. Change of colour indicates mutation. Figure adapted from 
(Greaves and Maley, 2012). 
In consistence with this model, cancer stem cells would represent a subclone with distinct 
evolutionary advantage that allows CSC to supercede “ecological pressure” of radiation and 
chemotherapy and eventually reform the tumour mass. However, cancer stem cells would not be 
necessarily equal to the cell of origin of cancer, although this feature is often attributed to CSC4. 
The first CSC were identified in acute myeloid leukemia as a rare cell subpopulation definable by 
surface markers and capable of inducing tumour in nonobese diabetic (NOD)-severe combined 
                                                       
4 This may be perhaps due to mostly semantic reasons rather than biological evidence. 
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immunodeficient (SCID) mice (Lapidot et al., 1994). This approach became a paradigm for CSC 
studies, in which putative CSCs are isolated from ‘bulk’ cancer cells using fluorescence-activated 
cell sorting (FACS) using antibodies against defined cellular surface markers, and subsequently 
transplanted into immunocompromised mice (Rosen and Jordan, 2009). However, this 
experimental approach does not take into account tumour microenvironment and the immune 
system as critical contributors to tumourigenesis capable of conferring phenotypic and functional 
differences to cancer cells (Polyak et al., 2009). Additionally, if cancer is a constantly evolving 
quasi-species, it seems very likely that CSC evolve along each tumour in consistence with 
selective pressure such as cancer therapy (Reya et al., 2001). Distinct pools of CSCs were 
identified in various sections of glioblastoma, yet demonstrating a shared ancestor (Piccirillo et al., 
2009), further corroborating the concept of CSC as a subclone within a clonal hierarchy. 
In spite of widespread debates and doubts about the sole existence of CSC (Rosen and Jordan, 
2009), these have been reported in various tumours using a variety of surface markers (Magee et 
al., 2012, Karamboulas and Ailles, 2013), summarised in Table 1.5. 
Tumour	   Positive	  surface	  marker	   Negative	  surface	  marker	  
Breast	  cancer	   CD44	   CD24	  
Colon	  cancer	   CD44,	  EpCAM	  
CD133	  
	  
Glioblastoma	   CD133	   	  
Head	  and	  neck	  SCC	   CD44	   	  
Leukemia	   CD34	   CD38	  
Liver	  cancer	   CD133,	  CD44	  
CD133,	  CD24	  
	  
Lung	  cancer	   CD133	   	  
Melanoma	   ABCB5	   	  
Ovarian	  cancer	   CD44,	  MyD88	  
CD133	  
	  
Pancreatic	  cancer	   CD44,	  CD24,	  EpCAM	   	  
Prostate	  cancer	   CD44,	  α2β1,	  CD133	   	  
Table 1.9 Various tumours in which CSC have been identified using defined surface markers. 
In cutaneous SCC, CD133 has been proposed as a marker for CSC based on short term primary 
cSCC cultures transplanted into mice, which represents a novel technological approach (Patel et 
al., 2012). However, this marker was not validated in a subsequent study, which proposed beta-1 
integrin as a CSC marker in cSCC instead (Dallaglio et al., 2013). It is important to note that both 
studies used primary cSCC rather than stable cell lines. 
While the concept of cancer stem cells has received considerable attention during the past 




1.7. Analytical approaches to large scale genomic data 
While collection of data used to represent major hindrance in scientific progress in the past,  
emerging novel tools in genomic and epigenomic exploration enable generation of large amounts 
of data within a relatively short time; however, such data often become serious analytical 
challenges. Novel tools are constantly being developed to enable more precise and less 
computer-skills demanding analysis of large-scale genomic data. 
1.7.1. Microarrays 
Since their first introduction over fifteen years ago, microarrays have by now become a practically 
indispensible tool in many research areas (Brown and Botstein, 1999, Diehn et al., 2000), 
including gene expression, DNA copy number variation, DNA methylation profiling, and more 
recently, microRNA profiling. Microarrays are usually comprised of a glass slide with fragments of 
nucleic acids mounted on to precise locations on the slide. Upon DNA or RNA hybridisation, 
corresponding short molecules coupled with a light-emitting element bind to their corresponding 
counterparts in the hybridised material. Eventually, those features form spots that are read by a 
special reader and processed as an image in a computer. 
Due to complexity and data scale of microarray experiments, standard statistical approaches and 
tools are not be adequate for accurate data processing (Zhang, 1999). Instead, microarray data 
processing depends on a number of computational steps, including data extraction, data storage, 
quality control, data normalisation and feature annotation. The analytical precision depends on 
many factors, such as background noise and quality of the input material.  
Many internal and external factors need to be taken into account in microarray data analysis: 
given that data are acquired by image processing and spot quantification after laser illumination, 
the process of data acquisition is thereby a major source of variability, since the chemistry of the 
fluorescent labels depends on many stochastic factors (including the humidity and temperature of 
the surrounding environment). Hybridisation is also dependent on various random elements such 
as pipetting precision, and the task of proper analysis is to remove all those confounding factors 
to the maximum extent possible. Both pre- and post-hybridisation steps can lead to substantial 
microarray data variability (Ahmed et al., 2004). 
1.7.2. Image analysis and quality control of microarray data 
Image analysis is the first step of microarray data processing that fundamentally determines all 
subsequent downstream steps (Kadanga et al., 2008). Key steps in overcoming issues of 
background noise, spot shape, size and position include spot detection, signal to background 
segmentation, and detecting signal intensity and signal quality (Wang et al., 2001). 
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Following this first task in microarray data processing, quality control removes spots or whole 
arrays from the set on which the nucleic acid has not hybridised properly, or arrays that bear a 
manufacturing defect. This is usually conducted through an array of visual assessments of the 
data, or through quality scores generated for individual array spots. Only those spots and arrays 
that pass a rigorous quality control should undergo the next step of normalisation. 
1.7.3. Normalisation  
This process removes experimental sources of variability (systemic bias). It is an essential pre-
processing procedure that can remove noise, systematic variation due to different characteristics 
of fluorescent probes, slide scanner efficiency or labelling methods (Bilban et al., 2002). If the 
probes intensity is properly normalised, systemic variation is removed and the data become more 
robust. Also, normalisation allows comparison of data derived from different experiments. 
Various normalisation methods exist that take into account individual spot size, signal-to-noise 
ratios, background noise and saturation status (Kadanga et al., 2008). A global method of 
adjustment is applied to the whole dataset, such as quantile normalisation (Gagnon-Bartsch and 
Speed, 2012). Application-specific methods, on the other take into account details of a given 
experiment, such as batch number.  
 
Figure 1.26 Boxplots of methylation data pre-normalisation. Y axis=beta values (methylation 
level). Yellow boxes=normal skin, red boxes=cSCC cell lines (non-RDEB), pink boxes=cSCC cell 






Figure 1.27 Boxplots of methylation data post-quantile normalisation. Y axis=beta values 
(methylation level). Yellow boxes=normal skin, red boxes=cSCC cell lines (non-RDEB), pink 
boxes=cSCC cell lines (RDEB), brown boxes=PHK. All boxplots now display even beta-values. 
1.7.4. Downstream analysis 
Once the data has been normalised, the process of identifying differentially expressed or 
methylated genes involves non-parametric (Bayesian) statistics, multiple comparisons and 
adjustment of p-values for given false discovery rate (usually 0.05).  
Genes and samples can be clustered into groups based on the mathematically defined similarity 
between the individual values. The process of unsupervised hierarchical clustering can be very 
useful in finding groups of tumours sharing common features, on the other hand, those results 




Figure 1.28 Horizontal and vertical clustering of normalised methylation data based on Pearson’s 
correlation. Dendrograms display relative distance between the correlation values. Yellow 
boxes=normal skin, red boxes=cSCC cell lines (non-RDEB), pink boxes=cSCC cell lines (RDEB), 
brown boxes=PHK. Primary normal human keratinocytes (PHK) cluster with normal skin samples. 
1.7.5. Bioconductor 
In the recent year, a specialised tool for the analysis of microarray data was developed by the 
efforts of biostatisticians concentrated around the statistical language R. The project 
Bioconductor, a statistical tool for processing high-throughoutput genomic data is an open-source, 
command-line driven programme that uses several hundred of packages (coded programs) for 
processing raw input data (Gentleman et al., 2004). Currently, Bioconductor is capable of 
processing SNP, expression, methylation microarray data and sequencing data with dedicated 
packages using standardised statistical approaches. 
The main advantage of open-source software is its availability for anyone with internet access, 
complete user control over each step of analytical pipeline, and also transparency and 
reproducibility of results at every stage of data proccesing in comparison with “black box” 
proprietary software. The main disadvantage is a high demand on user’s computational and 
statistics knowledge, and the process of data analysis can often be rather time-consuming. In 
spite of these inherent drawbacks, Bioconductor provides robust, transparent, comprehensive and 
up-to-date tools for data analysis that are especially useful for analysing microarray data. 
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1.8. Hypothesis and Aims 
Dysregulation of diverse epigenetic processes is a hallmark of malignant onset and progression in 
many tumours. A significant proportion of cSCC arises from precursor lesions (AK), and this 
process may be at least partially mediated by a variety of epigenetic changes. In order to test this 
hypothesis, I aimed at answering the following questions: 
1. Is dysregulated methylation an integral component of the pathological progression from 
normal skin to cSCC, and if so, is this reflected in changes in the tissue expression 
profiles? 
2. Are there fundamental differences in methylation and expression profiles between 
standard cultured keratinocytes and established cSCC cell lines, and if so, how do these 
compare to clinical samples? 
3. Is there a transdifferentiation or dedifferentiation pattern in cSCC methylation compared 
to normal keratinocytes that allows cancer cells to obtain novel cancer-specific 
properties? 
4. Which miRNAs are differentially expressed between non-tumour skin adjacent to cSCC 
and clinical samples of cSCC, and are these responsible for changes in the expression 
profile? 
To answer these questions, I carried out the following experiments: 
i. A genome-wide methylation examination of normal skin, AK and cSCC tumour biopsies 
accompanied by integration with genome-wide expression profiling after stratification for 
age, immune status and gender. Key differences in methylation between the normal skin 
and cSCC were validated using a whole-genome bisulfite sequencing. 
ii. A genome-wide methylation profiling of cSCC cell lines, cultured keratinocytes, 
accompanied by genome-wide expression profiling and integration of the obtained data. 
iii. A comparative analysis of methylation pattern of cSCC cell lines and cultured 
keratinocyte with a variety of differentiated and undifferentiated tissues including ESC. 
iv. MiRNA microarray profiling of cSCC samples and matched adjacent normal skin coupled 
with microarray expression data.  
This approach will provide novel insights into epigenetic regulation of critical cellular processes in 
this skin malignancy and may identify novel targets directly involved in their onset and 
progression. 
Human papillomavirus (HPV) is commonly present in non-melanoma skin cancer, and I 
hypothesised that HPV may cause pro-oncogenic changes in methylation in cSCC samples. 
Additionally, I hypothesised that a new DNA polyoma virus (MCPyV) discovered in a different type 
of non-melanoma skin cancer (Merkel cell carcinoma) may be present in higher proportion in non-
melanoma skin cancer samples of organ transplant recipients, and lead to epigenetic changes in 
cSCC samples. This hypothesis leads to the following questions: 
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5. Is HPV presence in cSCC associated with unique changes in methylation? 
6. Is MCPyV more prevalent in non-melanoma skin samples of transplant recipients? 
7. Are there unique methylation changes in cSCC samples that harbour the virus? 
To answer these questions, I carried out the following experiments: 
v. Genome-wide methylation profiling of HPV-positive and negative cSCC samples. 
vi. MCPyV profiling of various non-melanoma skin lesions derived from both transplant and 
non-transplant patients. 
vii. Genome-wide methylation profiling of MCPyV-positive and negative cSCC samples. 
This approach may identify distinct molecular changes in MCPyV-positive tumours with potential 
implications for prevention or therapeutic options.  
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2. General Materials and Methods 
This chapter describes materials and methods that are common to the majority of the work 
presented in this thesis. Methods that pertain uniquely to specific chapters are outlined within 
these individual chapters. 
2.1. Tumour Samples 
Tumour samples were obtained from consented patients between 1995-2013 in Dermatology 
clinics at Barts and the London NHS Trust (London, United Kingdom). Prior to collection, all 
patients provided informed written consent in accordance with ethical approval from the East 
London and City Health Authority local ethics committee.  
During the procedure, patients received a local anaesthetic to the tumour area, and 4-6mm punch 
biopsy was excised from the tumour mass and immediately snap-frozen in liquid nitrogen. 
Samples were subsequently stored in -80°C. Adjacent normal skin was collected during 
subsequent tumour excision procedure in the operating theatre, and was also immediately snap-
frozen in liquid nitrogen and stored in -80°C.  
Paraffin-embedded tumour samples were obtained from the Department of Pathology, Barts and 
the London NHS Trust (London, United Kingdom). 
2.1.1. Histological Staining of Tumour Sections 
2.1.1.1. Haematoxylin & Eosin staining 
Tumour biopsies were embedded in OCT (optimal cutting temperature compound, VWR, UK), 
mounted on cork discs and labelled. Samples were cross-sectioned with an OTF5000 cryostat 
(Bright Instrument Company Ltd., UK) into 10 µm thick slices and immediately mounted on 
Superfrost plus slides (VWR, United Kingdom) and stored in -80°C prior to staining. Sections 
were equilibrated to ambient temperature for approximately 2 minutes, continuously rehydrated in 
100%, 90% and 70% ethanol for 2 minutes each and washed 5x in distilled water. Slides were 
then submerged in haematoxylin for 4 minutes in Mayer’s haematoxylin solution  (Sigma-Aldrich, 
United Kingdom) to stain the basophilic elements of cells. Slides were then submerged in running 
tap water for 8-10 minutes, washed once in 1% hydrochloric acid solution for differentiation and 
counterstained with eosin Y (Sigma-Aldrich, United Kingdom) for 1 minute. Slides were then 
washed in distilled water and dehydrated by a series of ethanol of increasing concentration (70%, 
90% 100%) and fixed in xylene. Sections were mounted in DPX mountant (Sigma-Aldrich, United 




Figure 2.1 H&E stained section of a cSCC sample.  
2.1.1.2. Acid fuchsine and Toluidine blue staining 
Acid fuchsine solution was prepared by dissolving 0.25 g of acid fuchsine powder (Sigma-Aldrich, 
United Kingdom) in 50.0 ml of distilled water. Toluidine blue dye solution was prepared by 
dissolving 0.5 g in 50.0 ml of distilled water. 
Sections mounted to Superfrost plus slides (VWR, United Kingdom) and stored at -80°C prior to 
staining were equilibrated to ambient temperature for approximately 2 minutes, continuously 
rehydrated in 100%, 90% and 70% ethanol for 2 minutes each and washed 5x in distilled water. 
Slides were covered with toluidine blue solution for 2 minutes to stain basophilic structures, 
washed in distilled water and covered with acid fuchsine solution for additional 2 minutes to 
counterstain eosinophilic elements in the cells. Sections were then washed in distilled water to 
remove excessive stain, air-dried and mounted in DPX mountant (Sigma-Aldrich, United 





Figure 2.2 Acid fuchsine and toluidine blue-stained section of a cSCC sample. 
2.2. DNA-based techniques 
2.2.1. Agarose gel electrophoresis 
The integrity of DNA isolated from fresh-frozen tissue (see below for details) and products of PCR 
reactions were visualised on 1% agarose gel containing ethidium bromide (6 µl of ethidium 
bromide in 100 ml of 1% agarose gel solution) in Syngene G:BOX F3. The gel was prepared by 
mixing 1g of agarose powder (Sigma Aldrich, United Kingdom) and 1% TBE buffer, after brief 
swirling the mixture was microwaved until the agarose powder was fully dissolved. 6 µl of 
ethidium bromide were added to the mixture before pouring it to the gel tanks and inserting well 
combs. Gels were allowed to cool for 1 hour. Ten microliters of PCR products were mixed with 3 
microliters of loading dye and carefully pipetted into gel wells. Pipette tip was changed between 
samples. Six microliters of DNA ladder mixed with loading dye were added into the last well. 
Samples were run in 1x TBE buffer for 1 hour at 100 V (unless otherwise specified). Images of 
products on gels were acquired with GeneSys software. 
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2.2.2. Laser capture microdissection (LCM) of frozen tissue sections with 
subsequent DNA isolation 
Tumour biopsies and adjacent normal skin were embedded in OCT (optimal cutting temperature 
compound, VWR, UK), mounted to cork discs and properly labelled. Samples were cross-
sectioned with OTF5000 cryostat (Bright Instrument Company Ltd., UK) into 10 µm thick slices 
and immediately mounted on pre-chilled 1.0 mm polyethylene napthalate (PEN) coated 
membrane slides (Carl Zeiss Ltd., UK). PEN membrane slides had been pre-treated with 1500 mJ 
of UVB light for 40 minutes in order to enhance adhesion of tissue to the membrane. 
Immediately prior to LCM, samples were fixed with 70% alcohol for 3 minutes, washed in distilled 
water for five times, and stained with 0.5% acid fuchsine solution for 1 minute and counterstained 
with 0.5% toluidine blue solution for another minute to visualise microscopic features. Samples 
were immediately mounted in PALM Microbeam laser capture microscope (Carl Zeiss Ltd., 
Germany) slide holder. 10x magnification was used to detect target cells. Those cells were then 
hand-labelled on computer using a mouse cursor, and excised by the machine’s UV laser.  The 
excised cells were collected with a needle into sterile Eppendorf tubes containing 20 µl Proteinase 
K and 180 ATL tissue lysis buffer (Qiagen, UK), incubated for 24-48 hours at 56°C. DNA was 
extracted using the standard protocol QIAamp DNA micro kit (Qiagen, UK), and eluted in 50 µl of 
sterile water. DNA integrity was assessed by agarose gel electrophoresis: 1 µl of DNA was loaded 
into wells of agarose gel, run for 30 minutes at 100 volts (V), and visualised using UV light 




Figure 2.3 DNA integrity assessment by agarose gel electrophoresis. Agarose gel electrophoresis 
of DNA extracted from cultured cSCC cell lines (MET1, T1, IC1, JG, PS, WB, lanes 3-8 from left) 
and 100 bp ladder in lane 2 (white arrow indicates 1000 bp). This figure demonstrates intact DNA 
integrity. 
2.2.3. DNA isolation from formalin fixed paraffin embedded tissue 
Ten sections of 10 µm thickness were cut onto individual SuperFrost slides (VWR, UK) using a 
microtome. Sections were then deparaffinised using xylene for 2x for 5 minutes, dipped in distilled 
water and dehydrated with 100% ethanol. Samples were then rehydrated with 70% ethanol and 
scraped into 1.5 ml Eppendorf tube using a sterile blade.  20 µl Proteinase K and 180 ATL tissue 
lysis buffer (Qiagen, UK) were added to the tubes, and those were then vortexed 4x for 10 
seconds and incubated for 24-48 hours at 56°C. DNA was extracted using the standard protocol 
QIAamp DNA micro kit (Qiagen, UK), and eluted in 100 µl of sterile water. 
DNA isolated from FFPE tissues is often fragmented (Figure 2.4). To confirm DNA integrity, DNA 
polymerase chain reaction (PCR) was performed using the following set of primers for the β-
globin gene: B1 (5’-GTGTGCTGGCCCATCACTTT-3’) and B19 (5’-
CAAGAAAGCGAGCTTAGTGA-3’). The reaction yields an amplicon of 120 bp in length (Hiyama 
et al., 1990), which was assessed using 1.5% agarose gel electrophoresis described below. Only 





Figure 2.4 Agarose gel electrophoresis of DNA isolated from FFPE samples. From left: Lane 1-6 
contain DNA isolated from FFPE non-melanoma skin cancer samples, lane 9 contains 100 bp 
ladder (white arrow corresponds to 1000 bp). This figure shows high fragmentation of DNA 
isolated from FFPE samples. 
2.2.4. DNA isolation from cultured cells 
2.2.4.1. DNA isolation from primary cells and established cell lines 
Both primary cells and established cell lines were grown to 70%-90% confluency in tissue culture 
flasks. The culture media was removed and replaced with phosphate buffered saline (PBS) for 5 
minutes in order to remove remaining media. The cells were then covered with 0.05% trypsin and 
0.02% EDTA in PBS and incubated at 37°C for 5-20 minutes. Once detachment of cells was 
confirmed under optical inverted microscope, 5-15 ml of culture media were added to the flasks 
and the content was transferred into 15 or 50 ml centrifuge tube and spun at 2500 rpm for 5 
minutes. The supernatant was then removed, and the cell pellet was immediately frozen on dry 
ice and stored in -80°C. DNA was extracted from the cells using QIAamp DNA mini kit (Qiagen, 
UK) following the standard protocol and eluted in 200 µl of sterile water. 
2.2.4.2. DNA isolation from fluorescence-activated cell sorting (FACS) isolated cells 
FACS-sorted cells were allowed to attach in 6-well plates for 12 hours (see below details on 
FACS sorted cells isolation and cell culture). Cells were then washed twice with PBS, incubated 
with 1.5 ml of Accutase® solution (Sigma, United Kingdom) at 37°C until detached from the well 
bottom. 1.5 ml of culture media was added, and the well content was collected into 15 ml 
centrifuge tube. Cells were pelleted by 5 minutes of centrifugation at 1200 rpm, the supernatant 
was removed and cells were immediately frozen on dry ice. Prior to use, DNA was extracted in 
parallel with RNA using the AllPrep DNA/RNA Micro Kit (Qiagen, UK) following a standard 




2.2.5. DNA isolation from tissue samples 
DNA was isolated from fresh frozen tissues stored at -80°C. Between 1g and 5g of tissue was cut 
into small pieces on dry ice, transferred into 1.5 ml pre-chilled Eppendorf tube and covered with 
180 µl ATL lysis buffer and 20 µl Proteinase K (Qiagen, United Kingdom) and repeatedly 
vortexed. Samples were incubated at 56°C for 24-72 hours, with additional 20 µl Proteinase K 
added after 48 hours of incubation. DNA was extracted using the standard protocol QIAamp DNA 
micro kit (Qiagen, UK), and eluted in 100 µl of sterile water. 
2.2.5.1. Archival DNA isolated from skin lesions 
Professor Catherine Harwood, Drs Karin Purdie and Victoria Brown have isolated DNA from 
various skin specimen for the purpose of previous projects using respective total DNA isolation 
protocols (Harwood et al., 2000, Brown et al., 2004). The DNA was stored in -80°C for 3-12 years. 
For the purpose of subsequent DNA polymerase chain reaction (PCR) experiments, DNA integrity 
of the archival nucleic acid isolated from a tissue sample was confirmed using the following set of 
primers: KM29 (5’-GGTTGGCCAATCTACTCCCAGG-3’) and GH21 (5’- 
GGAAAATAGACCAATAGGCAG-3’), which yield an amplicon of 345 bp in length. The PCR 
product was assessed using 1.5% agarose gel electrophoresis (45 minutes at 100 V), and 
visualised with UV light illumination (Figure 2.5). Only those samples that generated the target 
product during this initial step were used in subsequent downstream analysis. 
 
Figure 2.5 Agarose gel of 345 bp PCR product of a reaction using beta-globin primers to assess 




archival cSCC DNA (negative control not shown). Lane 17 contains 100 bp DNA ladder, white 
arrow corresponds to 300 bp, bottom band corresponds to 100 bp. All samples with amplified 
product were included in further analysis of MCPyV presence.  
2.2.6. DNA isolation from blood 
DNA was isolated from blood in collaboration with Drs Abha Gulati and Karin Purdlie. Upon 
collection, 20 ml of blood was mixed with 1.5 ml of EDTA (EDTA concentration 1.8 mg/ml of 
blood) to prevent blood coagulation. DNA was isolated from 1.5 ml of whole blood using the 
Nucleon Blood and Cell Culture (BACC) DNA extraction kit (Amersham Biosciences, United 
Kingdom) following the manufacturer’s protocol. Briefly, following deproteinisation using sodium 
perchlorate, DNA is separated using chloroform and proprietary resin. DNA was eluted in 50 µl of 
EB Buffer (Qiagen, United Kingdom).  
2.2.7. DNA quantification 
2.2.7.1. DNA quantification using spectrophotometry 
DNA concentration was quantified using Nanodrop® 1000 Spectrophotometer (LabTech 
International, UK), which measures concentration of DNA (ng/µl) based on the absorbance at UV 
wavelength of 260nm and the purity of DNA based on the ratio of absorbance at 260nm:280nm. A 
260:280 ratio of 1.8 is considered relatively pure for DNA, whereas lower ratios suggest 
contamination, for example, from protein or phenol. Water was used as a blank reading at the 
beginning of each set of measurements to clean the pedestal and to ensure the machine was 
working correctly. Two µl of DNA from each sample were loaded onto the spectrophotometer to 
determine the concentration and DNA purity. Samples with reading below 10 ng/µl were 
quantified using Qubit™ Fluorometric Quantitation (Life Technologies, UK). 
2.2.7.2. DNA quantification using Qubit™ Fluorometric Quantitation 
Sufficient amount of Qubit™ working solution was prepared diluting the Qubit™ dsDNA HS 
reagent 1:200 in Qubit™ dsDNA HS buffer (Invitrogen, United Kingdom). To prepare standards 
for calibration, 190 µl of working solution was loaded into two 0.5 ml PCR tubes, and 10 µl of each 
standard (Invitrogen, United Kingdom) were added to the working solution and vortexed for 5 
seconds. 199 µl of the working solution were added to individual 0.5 ml PCR tubes and mixed 
with 1 µl of sample DNA and vortexed for 5 seconds. The final volume in each tube is 200 ml. 
Tubes were incubated at room temperature for approximately 2 minutes. 
Qubit™2.0. Fluorometer was then calibrated using two standards prepared during the previous 
step and then all tubes containing sample DNA were read on the fluorometer. The DNA 
concentration of the sample was calculated by the Fluorometer in ng/µl. 
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2.2.8. Bisulfite conversion for methylation profiling and bisulfite 
sequencing 
For methylation microarray profiling and bisulfite sequencing, 550 ng or less of genomic DNA was 
treated with Zymo EZ DNA Methylation-Gold™ Kit (Zymo, United States) following the 
manufacturer’s protocol. Briefly, DNA is denatured at 98°C for ten minutes, followed by 2.5 h 
incubation at 64°C during which bisulfite conversion takes place. Finally, converted DNA is 
purified and cleaned up on column, followed by elution in water. This process converts 
unmethylated cytosines to uracil, leaving methylated cytosines intact. Thereby in sequencing 
analysis, methylated cytosines are displayed as cytosines and unmethylated cytosines as 
thymines. 
2.2.9. Whole-genome Bisulfite Sequencing 
Whole-genome bisulfite sequencing (BS-seq) was carried out in collaboration with Professor 
Vardhman Rakyan5. (BS-seq). This method combining the conversion of unmethylated cytosines 
to uracil with deep sequencing allows the assessment of methylation at a single nucleotide level. 
Unlike DNA methylation microarrays, this approach allows the assessment of methylation in 
repetitive elements that constitute almost a half of all CpGs (Harris et al., 2010). This method has 
been previously utilised to describe differences in methylation patterns of pluripotency and 
differentiation genes in embryonic stem cells (Lister et al., 2009). 
Pooled DNA from 10 laser-capture microdissected paired normal skin and cSCC samples was 
used in this experiment. Libraries were prepared with Ovation® Ultralow Methyl-Seq Library 
Systems (NuGEN, United States) according to the manufacturer’s protocol. Overview of the 
protocol is provided in Figure 2.6. 
                                                       
5 The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of 




Figure 2.6 Overview of steps involved in the preparation of BS-seq libraries. Figure taken from 
NuGEN Ovation® Ultralow Methyl-Seq Library Systems protocol. 
50 ng of pooled DNA was first sonicated with Bioruptor (Diagenode, United Kingdom) to generate 
fragments 200-400 bp longs. Fragment size was assessed with Agilent 2100 Bioanalyzer (Agilent 
Technologies, United States). Agencourt® RNAClean® XP Purification Beads (Beckman Coulter, 
United States) were then added to the DNA, and DNA bound to RNAClean Up XP beads was 
removed from the supernatant with a magnet. DNA was then purified with DNA Clean & 
Concentrator™-5 kit (Zymo, United States). End-repair, ligation of adaptors and final repair was 
carried out with appropriate buffers (NuGEN, United States), and DNA was bisulfite converted 
with Zymo EZ DNA Methylation-Gold™ Kit (Zymo, United States). Libraries were then amplified in 
PCR cycler using Amplification Master Mix with the following cycling conditions: 
Initial	  denaturation	   95°C	  for	  2	  minutes	   1	  cycle	  
Denaturation	   95°C	  for	  15	  seconds	   12	  cycles	  
Annealing	   60°C	  for	  1	  minute	  
Extension	   72°C	  for	  0.5	  minutes	  
Hold	   10°C	    ∞ 
Table 2.1 PCR cycling conditions used to amplify BS-seq libraries. 
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Libraries were then sequenced with Illumina HiSeq 2000 next generation sequencer at Barts and 
the London Genome Centre. This technology binds randomly fragmented DNA to “flowcells”, an 
optically transparent surface that encompasses eight separate lanes (one lane can be used for 
one sample). Each DNA fragment that binds by the adapter to the flowcell is then amplified by 
bridge-PCR into clusters that contain thousands of copies of the fragment. These clusters are 
then sequenced by sequencing-by-synthesis technology that adds complementary bases labelled 
with a fluorescent dye one at a time. Fluorescent dye is then excited with a laser, and image of 
the fluorescence is acquired before the fluorophore is removed and a new base labelled with a 
fluorophore is added. Each base is labelled with a unique dye and DNA sequence is then 
determined by associating respective dyes with paired bases. Once the first-end read is complete, 
DNA templates are regenerated and sequenced from the other end (each read us sequenced 50 
or 100 cycles at each end), which generates paired-end reads. Each lane generates millions of 
reads, which are then processed in silico. 
2.2.10. Data analysis of BS-seq data 
BS-seq data was analysed in collaboration with Dr Thomas Down using in-house C++ based 
software BiFast (Lowe et al., 2013). This programme is freely available 
(https://bitbucket.org/xboxrob/bifast), and combines the previously published BISMARK algorithm 
(Krueger and Andrews, 2011) with BOWTIE (Langmead et al., 2009). BISMARK algorithm 
converts cytosine to thymine and guanine to adenosine in the BS-seq reads and aligns those to 
appropriate segments of the reference genome.  The best alignment is then determined based on 
four different alignment processes run in parallel. BOWTIE, on the other hand, uses a Burrows-
Wheeler and full-text minute space index based approach.  
Raw BS-seq data was mapped to the reference genome using the BiFast algorithm, and the 
number of methylated and unmethylated reads at each CpG site was counted. 
2.2.10.1. Validation of Illumina450K methylation array data with BS-seq data 
For comparison with the Illumina450K methylation data, all CpG sites from the bs-seq dataset 
lying within 50bp of a differentially-methylated probe detected with Illumina 450K methylation data 
were then selected if at least 10 reads from both the cSCC and paired normal skin pools aligned 
properly. Methylation difference between the two pools was then calculated. 
2.3. Polymerase chain reaction 
2.3.1. Primers list 
All primers were ordered from Sigma Aldrich (United Kingdom) and made to a final concentration 
of 100mM. Merkel Cell Polyoma virus (MCPyV) primers were designed based published work 
(Feng et al., 2008, Duncavage et al., 2009). The nucleotide sequence of these primers is 
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complementary to various segments of the viral genome (Figure 2.7). MCVPS1 and LT1 primers 
are complementary to the large T-antigen of MCPyV sequence, LT3 is complementary to the 
small T-antigen and VP1 hybridises to the VP1 region.  
Table 2.2 provides primer sequences, amplicon size and their respective methodological purpose. 
Purpose	   Gene	   Primers	   Amplicon	  size	  
DNA	  integrity	  of	  
DNA	  isolated	  
from	  fresh	  frozen	  
tissue	  
Beta-­‐globin	   KM29(F)	  GGTTGGCCAATCTACTCCCAGG	  
GH21(R)	  GGAAAATAGACCAATAGGCAG	  
345	  bp	  
DNA	  integrity	  of	  
DNA	  isolated	  
from	  FFPE	  tissue	  
or	  archival	  DNA	  
Beta-­‐globin	   B1	  GTGTGCTGGCCCATCACTTT	  	  
B19	  CAAGAAAGCGAGCTTAGTGA	  
120bp	  
MCPyV	  detection	   LT1	   F:TACAAGCACTCCACCAAAGC	  
R:	  TCCAATTACAGCTGGCCTCT	  
439	  bp	  
MCPyV	  detection	   LT3	   F:TTGTCTCGCCAGCATTGTAG	  
R:ATATAGGGGCCTCGTCAACC	  
308	  bp	  
MCPyV	  detection	   VP1	   F:TTTGCCAGCTTACAGTGTGG	  	  
R:TGGATCTAGGCCCTGATTTTT	  
351	  bp	  
MCPyV	  detection	   MCVPS1	   F:	  TCAGCGTCCCAGGCTTCAGA	  
R:	  TGGTGGTCTCCTCTCTGCTACTG	  
109	  bp	  
Table 2.2 Primers used in PCR reactions. 
 
Figure 2.7 Genome of Merkel Cell Polyomavirus. Attachment sites of LT1, LT3 and MCVPS1 
primers are shown in grey. VP1 primer binds to the VP1 genomic region. Figure taken from 
(Duncavage et al., 2009). 
Standard PCR reactions were conducted in a 25 or 50 µl total reaction volume using AmpliTaq 
Gold® DNA Polymerase. Table 2.3 lists components for reaction yielding a total of 50 µl. Cycling 
parameters for each reaction are listed in the following subsection. PCR amplification was carried 
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out using the MJ Research DNA Engine Dyad thermal cycler (Genetic Research Instrumentation, 
United Kingdom). 
Component	   Volume	  per	  reaction	  (µl)	   Concentration	  in	  
Master	  Mix	  
Water	   27.75	   -­‐	  
10x	  Buffer	  mix	   5	   1x	  
25	  mM	  MgCl2	  	   6	   3	  mM	  
10	  mM	  dATP	   1	   200	  µM	  
10	  mM	  dCTP	   1	   200	  µM	  
10	  mM	  dGTP	   1	   200	  µM	  
10	  mM	  dTTP	   1	   200	  µM	  
Primer	  1	   2.5	   0.5	  µM	  
Primer	  2	   2.5	   0.5	  µM	  
AmpliTaq	  Gold	  DNA	  	  
Polymerase,	  LD	  
0.25`	   1.25	  
Units/reaction	  
DNA	  template	   2	   100	  ng/reaction	  
Total	  volume	   50	   -­‐	  
Table 2.3 Standard PCR sample mix for a total of 50 microliters of final volume. 
2.3.1.1. PCR cycling parameters 
Taq	  activation	   95°C	  for	  10	  minutes	   1	  cycle	  
Denaturation	   95°C	  for	  1.1	  minutes	   60	  cycles	  
Annealing	   	   60°C	  for	  1.1	  minutes	  
Extension	   72°C	  for	  1.1	  minutes	  
Final	  extension	   72°C	  for	  7	  minutes	   1	  cycle	  
Hold	   4°C	    ∞ 
Table 2.4 B1/B19 primers cycling conditions. 
Taq	  activation	   95°C	  for	  10	  minutes	   1	  cycle	  
Denaturation	   95°C	  for	  1	  minute	   60	  cycles	  
Annealing	   55°C	  for	  1	  minute	  
Extension	   72°C	  for	  1	  minute	  
Final	  extension	   72°C	  for	  10	  minutes	   1	  cycle	  
Hold	   4°C	    ∞ 
Table 2.5 KM28/G21 beta-globin primers cycling conditions. 
Taq	  activation	   95°C	  for	  10	  minutes	   1	  cycle	  
Denaturation	   94°C	  for	  0.5	  minute	   60	  cycles	  
Annealing	   50°C	  for	  0.5	  minute	  
Extension	   68°C	  for	  1	  minute	  
Final	  extension	   72°C	  for	  10	  minutes	   1	  cycle	  
Hold	   4°C	    ∞ 
Table 2.6 LT1, LT3 and VP1 primers cycling conditions. 
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Taq	  activation	   95°C	  for	  10	  minutes	   1	  cycle	  
Denaturation	   94°C	  for	  0.5	  minute	   60	  cycles	  
Annealing	   55°C	  for	  0.5	  minute	  
Extension	   68°C	  for	  1	  minute	  
Final	  extension	   72°C	  for	  10	  minutes	   1	  cycle	  
Hold	   4°C	    ∞ 
Table 2.7 MCVPS1 primers cycling conditions. 
2.3.2. Positive and negative control for PCR 
Placental DNA (Sigma Aldrich, United Kingdom) was included in PCR reactions assessing DNA 
integrity with beta-globin primers to serve as positive control. A total 100 ng of placental DNA 
were included in each batch of samples amplified with PCR using beta-globin primers to confirm 
proper run of the reaction.  
Plasmid vectors were used as positive control in reactions detecting the presence of MCPyV. Two 
plasmids were obtained from the University of Pittsburgh Cancer Institute, United States, and the 
plasmid sequences were homologous to regions that overlapped with the primer sequences. 100 
ng of plasmid were used as positive control for each batch of PCR reactions. 
Negative control consisted of PCR mastermix with no DNA to exclude contamination with DNA or 
plasmid and false positive reactions. 
PCR products were visualised on agarose gel as described above, and stored at -20°C. 
2.4. RNA based techniques 
RNA isolation was carried out in a dedicated laboratory area. Prior to RNA isolation, the area and 
applicable instruments were cleaned with RNase ZAP (Ambion, United States) in order to remove 
rnases from all surfaces. A centrifuge dedicated to RNA isolation only was used for all steps 
involving centrifugation. If appropriate, RNA lysis buffer was premixed with β-mercaptoethanol to 
inhibit rnases present in the sample. On-column DNase I treatment (Qiagen, United Kingdom) 
was carried out according to manufacturer’s instructions in order to minimise contamination with 
genomic DNA. 
2.4.1. Total RNA and miRNA isolation from tissue samples 
MiRNAs were isolated using miRNeasy Mini Kit (Qiagen, United Kingdom). Fresh frozen tissue 
biopsies were cut in half on dry ice.  One half was transferred back into the original labelled 
cryovial, another half was ground using a pre-chilled pestle and mortar and scraped into a pre-
chilled 1.5 ml Eppendorf tube. 700 µl of QIAzol lysis reagent (Qiagen, United Kingdom) were 
added to the tube, vortexed for 1 minutes and transferred into QIAshredder spin column (Qiagen, 
United Kingdom) placed in a 2 ml collection tube for homogenisation. The samples were then 
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spun for 2 minutes at maximum speed in a dedicated centrifuge. The homogenate was incubated 
at room temperature for 5 minutes, followed by the addition of 140 µl of chloroform. After 15 
seconds of shaking, the sample was further incubated at room temperature for 3 minutes, then 
centrifuged at 12000g for 15 minutes at 4°C. The aqueous phase was then transferred into a new 
1.5 ml Eppendorf tube, mixed with equal amount of pure ethanol and loaded into miRNeasy Mini 
spin column followed by the standard manufacturer’s protocol. Total RNA and miRNA were eluted 
in 50 µl of water, kept on ice during RNA quantification and stored in -80°C to prevent RNA 
degradation. 
2.4.2. mRNA isolation from cultured cells  
2.4.2.1. mRNA isolation from primary cells and established stable cell lines 
Cells were pelleted as described in Chapter 2.2.4.1. RNA was extracted from the pellets using 
RNeasy Mini kit (Qiagen, United Kingdom) following the standard protocol and eluted in 100 µl of 
sterile water. Briefly, 350 µl of RTL lysis buffer were mixed with the pellet on ice by pipetting and 
transferred into QIAshredder spin column (Qiagen, United Kingdom) placed in a 2 ml collection 
tube for homogenisation. The samples were then spun for 2 minutes at maximum speed in a 
dedicated centrifuge. This homogenate was mixed with equal amount of prechilled 100% ethanol, 
and mRNA was extracted and cleaned up following on-column treatment with DNAse (Qiagen, 
United Kingdom). 
2.4.2.2. mRNA isolation from fluorescence-activated cell sorting (FACS) isolated cells 
Cells were pelleted as described in Chapter 2.2.4.2. RNA was extracted in parallel with DNA 
isolation using the AllPrep DNA/RNA Micro Kit (Qiagen, UK) following a standard protocol. Briefly, 
buffer RTL Plus was mixed with beta-mercaptoethanol to inhibit RNAses, and a total of 350 µl 
were added to the pellet to disrupt cells. This lysate was homogenised using QIAshredder spin 
column (Qiagen, United Kingdom), placed in AllPrep DNA spin column and spun for 30 seconds 
at 10 000g. DNA was isolated from this column, and RNA was isolated from the flow-through by 
mixing it with equal volume of 70% ethanol and followed by standard steps of on-column clean-
up, DNase treatment and elution. 
RNA was eluted from the column into 50 µl of water. 
2.4.3. Laser capture microdissection (LCM) of frozen tissue with 
subsequent mRNA isolation 
This procedure was carried out in collaboration with Dr Sally Lambert. Fresh frozen samples were 
cut on microtome into 8 µm sections that were mounted on RNase ZAP (Ambion, United States) 
and UV-light pre-treated PEN slides (described in Chapter 2.2.1). Samples were immediately 
covered with pre-chilled 70% ethanol for two minutes, stained with pre-chilled cresyl violet and 
dehydrated in a series of ethanol washes of increasing ethanol concentration.  
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Following laser-capture microdissection of target cells, isolated cells were collected in Eppendorf 
tubes containing 350 µl of RTL buffer mixed with beta-mercaptoethanol, and RNA was extracted 
using RNeasy Micro Kit (Qiagen, United Kingdom) with on-column DNase treatment.  
RNA was eluted from the column into 14 µl of water. 
2.4.4. RNA quality control 
To ensure that RNA is not degraded, 200 ng of total RNA were run on 1.5% agarose gel 
containing ethidium bromine for 30 minutes at 70 V, and were visualised with UV light illumination. 
2.4.5. RNA quantification 
2.4.5.1. RNA quantification using spectrophotometry 
RNA concentration was quantified using Nanodrop® 1000 Spectrophotometer (LabTech 
International, UK), which measures concentration of RNA (ng/µl) based on the absorbance at UV 
wavelength of 260nm and the purity of RNA based on the ratio of absorbance at 260nm:280nm. A 
260:280 ratio of 2.0 is considered relatively pure for RNA, whereas lower ratios suggest 
contamination, for example, from protein or guanidine which is rather common occurrence when 
using column-based kits. Water was used as a blank reading at the beginning of each set of 
measurements to clean the pedestal and to ensure the machine was working correctly. 1.5 µl of 
RNA from each sample were loaded onto the spectrophotometer to determine total RNA 
concentration and RNA purity.  
2.4.5.2. RNA quantification and quality control using Agilent Bioanalyser  
Agilent 2100 Bioanalyser Chipreader (Agilent, United Kingdom), uses electrophoresis to quantify 
DNA, RNA or protein in multiple samples simultaneously using a chip. Each chip consists of 16 
wells, 12 of which are used for samples, 1 for ladder and 3 for matrix reservoir. Samples move 
from the well through a series of microchannels filled with fluorescent dye and polymer due to 
electric current, followed by electrokinetic injection into separation channel that separates the 
sample based on their molecular weight, and provides a scanned image of the components 
(Figure 2.8). In addition, the software provides a proprietary RIN value that describes RNA quality. 




Figure 2.8 Agilent Bionanalyser RNA 6000 Nano ladder. This ladder contains a mixture of six 
RNA fragments of known size and concentration (150 ng/µl), and is used as a reference for the 
data analysis of experimental samples. RNA peaks of experimental samples are compared to the 
ladder fragments to determine RNA concentration. 
 
Figure 2.9 Agilent Bioanalyser output for a sample of RIN 8.1. This figure shows two distinct 
ribosomal peaks corresponding to 18S and 28S and a mostly flat baseline between the internal 
marker (left-most peak) and 18S. A smaller peak next to the internal marker corresponds to 5S. 




Figure 2.10 Agilent Bioanalyser output for a sample of RIN 1. Peaks corresponding to 18S, 28S or 
5S are almost completely absent. The most prominent peak corresponds to internal marker. Such 
RNA is likely highly degraded. 
2.4.6. cDNA synthesis for RT-PCR  
Three hundred nanograms of total mRNA were used for first-strand cDNA synthesis with 
qScript™ cDNA SuperMix (Quanta BioSciences, United States). RNA template was mixed with 
qScript cDNA SuperMix (5X) and RNase-free water in 0.2 µl tubes on ice to make a total of 20 µl 
per reaction. Each tube was briefly vortexed and centrifuged to collect the mixture on the bottom 
of the tube. Samples were then incubated in PCR cycler as follows: 
Time	   Temperature	  
5	  minutes	   25°C	  
30	  minutes	   42°C	  
5	  minutes	   85°C	  
Hold	   4°C	  
Table 2.8 Cycling conditions for first-strand cDNA synthesis. 
2.4.7. Primer design 
Primer for reverse-transcriptase – polymerase chain reaction (Q-PCR) were designed with 
Primer3 software (Untergasser et al., 2012). Ensembl genome browser was then used to retrieve 
exons sequence, and the sequences of two adjacent exons were entered into Primer3. Primers 
that yield product between 85-150 bp with melting temperature (Tm) close to 60°C were selected 
for the experiment. Complementarity of selected primer to the proper gene were confirmed with 
USCS genome browser. All primers were obtained as custom oligonucleotides from Sigma 
Aldrich (United Kingdom), and resuspended in distilled water to make 100 nM solution. Primers 
are listed in Table 2.9. 






CAAAGGAACAGCAGAGAAGC	   ATTGAGTAAGACAGGTCCATAAGG	   59°C	  
CD44	   GAAGAAAGCCAGTGCGTCTC	   CACGTGGAATACACCTGCAA	   59°C	  
ESA	   CCTCCACGTTCCTCTATCCA	   AAGCAGTTTACGGCCAGCTT	   59°C	  
GAPDH	   AATGAAGGGGTCATTGATGG	   AAGGTGAAGGTCGGAGTCAA	   59°C	  
Table 2.9 Primers used for QPCR reactions. 
2.4.8. Reverse-transcriptase – polymerase chain reaction (Q-PCR) 
QPCR was carried out with MESA Blue qPCR MaterMix Plus or SYBR© Assay (Eurogentec, 
United Kingdom). All reagents were thawed on ice and mixed by repeated inversion prior to the 
experiment. 6.5 µL of 2x reaction buffer were mixed with 2.5 µL of 100 nM reverse and forward 
primers, two microliters of the final cDNA product generated with the previous reaction to make a 
total of 13.5 µL reaction volume. Master mix containing all components except for the cDNA 
template was carefully pipetted into wells of 96-well PCR plate according to a pre-designed 
layout, cDNA was added at the end and the plate was sealed. All procedures were carried out in 
laminar flow hood with no illumination to prevent contamination and unnecessary exposure to 
light. All reactions were performed in triplicate, and a triplicate blank control containing no cDNA 
template was included on each 96 well PCR plate. 
QPCR data were obtained with the AB7500 Fast Realtime PCR System (Applied Biosystems, 
United Kingdom) and extracted with the system’s software. Dissociation curve was obtained for 
each experiment. Cycling condition for the three-step protocol are describe in Table 2.10. 
MeteorTaq	  activation	   95°C	  for	  5	  minutes	   1	  cycle	  
Denaturation	   95°C	  for	  15	  seconds	   40	  cycles	  
Annealing	   60°C	  for	  20	  seconds	   	  
Extension	   72°C	  for	  40	  seconds	   	  
Table 2.10 Cycling conditions for three-step qPCR protocol. 
2.5. Antibody-based techniques 
The following mouse monoclonal antibodies were used in subsequent antibody-based techniques: 
Antibody	   Source	   Clone	   Conjugate	  




CD44	   BD	  Pharmingen™	   G44-­‐26	   Phycoerythrin	  (PE)	  
ESA	   Miltenyi	  Biotec	   HEA-­‐125	   Allophycocyanin	  (APC)	  
Table 2.11 Antibodies used in FACS and immunocytochemistry 
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2.5.1. Fluorescence-activated cell sorting 
Cells were cultured in a monolayer until reaching 70% confluency. After removing the media and 
washing the cells in PBS, cells were detached with Accutase® (Sigma Aldrich, United Kingdom) 
to minimise damage to surface epitopes. Cells were incubated with 5-10 mL Accutase at 37°C in 
5% CO2 incubator for 3 to 5 minutes. The maximum incubation time was 10 minutes. Accutase 
was then deactivated with warm media, and 25 ml of cold PBS was added to the cellular 
suspension. Cells were transferred into 50 mL Falcon tube and centrifuged at 1500 rpm for 5 
minutes at 4°C. The supernatant was then removed and cells were resuspended in 0.5 ml of cold 
PBS. 5 µl of each antibody were added to the cells (1:100 dilution) and were incubated at 4°C in 
darkness for 15 minutes. Cells were then diluted with cold PBS and centrifuged at 1500 rpm for 5 
minutes at 4°C. Supernatant was removed and the cell pellet resuspended in 300-500 µl of cold 
PBS. Cells were passed through 100 um Cell strainer (BD Sciences, United Kingdom) to 50 mL 
Falcon tube. 10 uL of DAPI nuclear dye (Sigma Aldrich, United Kingdom) was added to the 
suspension to exclude dead cells. Cells were then transferred into polypropylene tubes and 3% 
triple-positive and negative cells were sorted with the BD FACSAria™ I machine (BD Biociences, 
United Kingdom) into pre-chilled culture media. Immediately after isolation of cells, these were 
transferred into 50 ml Falcon tube containing cold media and centrifuged at 1500 rpm for 5 
minutes at 4°C.  
Cell pellet was then resuspended in 2 ml fresh, cold media and transferred into 6-well plate 
containing 2 ml of chilled pre-cultured media. Combining fresh and pre-cultured media in 1:1 ratio 
has significantly increased the viability of sorted cells. Cells were placed to 37°C in 5% CO2 
incubator and the media was allowed to gradually warm up in the incubator to minimise stress to 
cells. 
2.5.1.1. Compensation for PE and FITC 
Because the emission spectrum of PE and FITC partially overlaps (Figure 2.11), compensation 
was carried out with Becton Dickinson Compensation Beads (BD Biociences, United Kingdom). 
These beads show either strong positive fluorescence peak from the antibody, or a completely 
negative peak. Unlabelled cells can create false positive signal by autofluorescence, while the 
beads completely block the fluorescent signal. Compensation is then computed by subtracting 




Figure 2.11 Overlap of FITC and PE emission spectrum. PE is an orange fluorophore, yet the 
emission spectrum of the green fluorophore FITC does slightly overlap into the emission spectrum 
of PE. In effect, samples labelled with FITC will appear positive for PE to some extent, and 
thereby compensation is required if these two fluorophores are combined in an experiment.  
Figure taken from http://www.lifesci.dundee.ac.uk/cast/flow-cytometry-core-facility/techniques-4. 
2.5.2. Fluorescent immunocytochemistry   
Stable cSCC cell lines were cultured to 50-70% confluency. Cells were detached with Accutase©, 
mixed with warm media and centrifuged in 50 mL Falcon tube at 1500 rpm for 5 minutes at room 
temperature. Cells were then resuspended in 5 mL of warm media, and 200 uL were mixed with 
300 uL of 0.4% Trypan blue solution, and 20 uL were transferred to a haemocytometer chamber 
and cells were counted in four corner squares and the centre square under a light microscope. 
Cells were then seeded onto sterile Vectashield coverslips (Vector Laboratories, United States) in 
a 12-well plate at 5x104 density, and allowed to attach overnight in an incubator. Media was 
replaced with PBS, and cells were washed twice for 5 minutes. Cells were then fixed with 1 mL of 
4% PFA for 10 minutes at room temperature, and subsequently washed twice with PBS for 5 
minutes each. 
Cells were then permeabilised with 0.1% Triton X-100 in PBS (PBS-T) for 5 minutes at room 
temperature, and washed twice with PBS for 5 minutes each. Cells were then blocked with 500 µl 
of 5% goat serum dissolved in PBS for 1 hour at room temperature, and incubated with 
fluorophore-labelled primary antibody at 4°C in darkness overnight. Primary antibody was diluted 
in 5% goat serum in PBS 1:250. 
Primary antibody was then removed and cells were washed three times with PBS (5 minutes each 
wash). DAPI stain (500 ug/mL) was added to each well, and after 10 minute-incubation, cells 
were washed again twice. Coverslips were then carefully turned over and mounted onto a glass 
slide with Vectashield Mounting Medium (Vector Laboratories, United States). Slides were 
immediately visualised with 510 Meta inverted confocal microscope (Zeiss, Germany), and stored 
at 4°C in darkness. 
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2.6. Microarray profiling 
2.6.1. Biological material, microarrays and data analysis 
Copy-number variation in clinical tissues (normal skin, AK) was detected with Genome-Wide 
Human SNP Array 6.0 (Affymetrix, United States). Transcriptional profiling of normal skin, AK and 
cSCC clinical samples was carried out with Human Genome U133 Plus 2.0 Array, profiling of 
cSCC cell lines, cultured primary human keratinocytes and cancer stem cells with HumanHT-12 
v3 Expression BeadChip. Methylation profiling of stable cSCC cell lines and primary human 
keratinocytes was carried out with Infinium HumanMethylation27 BeadChip, profiling of skin, AK 
and cSCC clinical specimen, cSCC cancer stem cells and MCPyV positive and negative archival 
cSCC DNA was carried out with Infinium HumanMethylation450 BeadChip Kit. MiRNA profiling of 
cSCC samples and paired normal skin was conducted with miRCURY LNA™ microRNA Array 
(7'th GEN). 
Details regarding biological samples hybridised to each array, array descriptions and 
specifications and detailed analytical steps are provided in respective chapters. 
2.6.2. Analytical approaches common to the processing of all datasets 
Microarray data analysis was conducted in R and Bioconductor (Gentleman et al., 2004). All 
microarrays were initially subjected to stringent quality control (details are provided in respective 
chapters), and only those chips that passed the predefined quality control criteria were 
subsequently normalised. Unless otherwise stated, all data were normalised using quantile 
normalisation. The principle of this algorithm is to unify the distribution of probe levels across all 
samples in the dataset (Bolstad et al., 2003). Clustering of microarray data was achieved using 
Euclidian distance in the gplots package (http://CRAN.R-project.org/package=gplots). Specifics 
and details of the analytical approaches applied are included below and in respective chapters 
where appropriate. 
2.6.2.1. Clustering analysis 
Hierarchical clustering of genome-wide data was performed to detect profile correlation between 
samples using vsn (http://www.bioconductor.org/packages/2.3/bioc/html/vsn.html) package on the 
normalised data matrix. Hierarchical clustering algorithm with Pearson correlation metric was 
applied for this purpose. Furthermore, clustering was quantified and further validated using 
pvclust package (http://www.is.titech.ac.jp/~shimo/prog/pvclust/) in R. This package calculates the 
statistical significance of observed clusters. P-values are calculated for each via multiscale 
bootstrap resampling, and the p-value ranges from 0 to 1, indicating the strength of support for 
the cluster. The level of 0.95 was set as α level of significance for the existence of a given cluster. 
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2.6.2.2. Gene Set Enrichment Analysis 
Gene set enrichment analysis (GSEA) searches for common biological function or pathway 
regulation of given gene or probeset. Using in-house Pearl scripts, each probe was annotated 
with respective pathways it interacts with according to the KEGG database and a chi-square test 
was performed on differentially methylated probes using all probes as the background. An 
analogous approach was applied to Gene Ontology enrichment analysis: Probes were annotated 
with respective GO terms by interrogating GO database (www.geneontology.org) and chi-square 
test was applied in an identical manner. Molecular Signatures Database (MsigDB) was used to 
test for cytogenetic location enrichment (Liberzon et al., 2011). α-level for enrichment analysis 
was set at pvalue<0.05. 
2.7. Tissue culture techniques 
2.7.1. Tissue culture of primary human keratinocytes and cSCC 
Primary human keratinocytes (PHK) were derived from clinical samples or obtained as a gift from 
Drs A. Bahta, P. A. Costa and R. Hannen6.  
PHK were cultured in DMEM/Ham’s F12 medium prepared in a 3:1 ratio by a commercial tissue 
culture company (Gibco, United Kingdom). The medium was supplemented with 10% fetal calf 
serum (FCS, Biosera, United States), L-glutamine (Sigma Aldrich, United Kingdom) and RM+ (for 
composition, see Table 2.12).  
Reagent  Final concentration in culture 
medium 
Hydrocortisone 0.4 µg/ml  
Cholera toxin 10-10 M  
Transferrin 5 µg/ml  
Liothyronine 2 x 10-11 M  
Adenine 1.8 x 10-4 M  




Table 2.12 Composition of RM+ reagent. 
Upon receiving a clinical tissue sample (normal skin biopsy or cSCC biopsy tissue), the specimen 
was placed in trypsin at 37°C for 1 hour, and primary keratinocytes or malignant keratinocytes 
                                                       
6 All members of Department of Cutaneous research, The Blizard Institute, Queen Mary, University of London, UK 
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were scraped off with a sterile scalpel into 100 ml petri dish in a laminar flow hood. Approximately 
500,000 3T3 mouse fibroblasts grown in T25 culture flasks in DMEM medium supplemented with 
10% FCS were treated with mitomycin C for 3 hours to inhibit their proliferative potential. Scraped 
cells were added to those flasks, and grown in DMEM/Ham’s F12 medium until confluent (3-7 
days). Prior to PHK/primary cSCC cells collection, T25 flasks were cleared of 3T3 fibroblasts by 
treatment with versine reagent (0.02% EDTA in PBS, Gibco, United Kingdom).  
2.7.2. Tissue culture of primary cSCC cell lines 
Primary cutaneous cSCC cell lines derived from patient tumours collected at Barts and The 
London Dermatology clinic were obtained in cryovials from long-term storage in liquid nitrogen 
tanks. Vials were quickly thawed (< 1 minute) in a 37°C water bath, added to 50 ml Falcon tube 
containing 20 ml pre-warmed DMEM/F12 medium supplemented with 10% FCS and centrifuged 
at 1500 rpm for 5 minutes. The supernatant was subsequently removed, and the pellet was 
resuspended in 7 ml of 10% FCS-supplemented DMEM/F12 medium in T25 culture flask and 
placed in 37°C, 5% CO2 incubator. Primary cSCC cell lines were grown without 3T3 feeders. 
2.7.3. Collection and long-term storage of cultured cells  
Prior to cell collection, culture medium was removed, cells were carefully washed with PBS and 
incubated with 0.05% trypsin and 0.02% EDTA solution in PBS in 37°C, 5% CO2 incubator until 
cells detached from the flask. Trypsin was inactivated by the addition of culture media, and cell 
suspension was then transferred into 15 ml Falcon tube and following 5 minutes of centrifugation 
at 1500 rpm and supernatant removal, either resuspended in culture media and re-seeded for 
further tissue culture, immediately frozen for isolation of nucleic acids, or resuspended in 1.2-1.5 
ml of freezing media (70% DMEM/F12 tissue culture medium, 20% FCS, 10% DMSO), and this 
suspension was transferred into a cryovial. Cryovials were placed in a Nalgene Mr. Frosty 
Freezing Container that provides -1°C/min cooling (Fisher Scientific, United Kingdom) when 
placed in -80°C freezer. Cryovials were then transferred to liquid nitrogen tanks for long-term 
storage.  
2.7.4. Culture of embryonic stem cells 
Human embryonic stem cells (hESC) were cultured in collaboration with Dr Cleo Bishop7. HESC 
H9 cells were cultured under licence from Stem Cell Technologies. HESC cells were cultured on a 
monolayer of mitomycin-treated mouse embryonic fibroblasts (MEF) in hESC media. The hESC 
medium was prepared fresh every two weeks, and changed every day. The composition of hESC 
media is listed in Table 2.13. PBS, beta-mercaptoethanol and L-glutamine were mixed separately 
                                                       




and prepared fresh each time. The medium was then filtered through 0.22uM filter and stored at 
4°C for a maximum of 14 days. 
Solution Volume for 
250 ml 
DMEM/F12 Medium 200 ml 
Knockout Serum Replacer (KO)   50 ml  
Non-Essential Amino Acids (100 X)  2.5 ml  
L-Glutamine (100 X) 2.5 ml 
PBS with Ca2+ and Mg2+ 2.5 ml 
Beta-Mercaptoethanol  3.5µl 
bFGF (2 ug/ml) 500µl 
Table 2.13 Composition of hESC medium (total volume of 250 ml). 
Prior to hESC passaging, mitomycin C-inactivated MEFs were plated onto gelatin-coated wells of 
6-well plate (1 mL of 0.1% sterile aqueous gelatin solution per well) and allowed to attach in MEF 
media overnight. Composition of the MEF media is provided in Table 2.14. 
Reagent Volume 
DMEM high glucose (without L-glut) 500mL 
Fetal Bovine Serum 50mL 
100 x L-Glutamine 5mL 
Sodium Pyruvate 5mL 
Non-essential amino acids 5mL 
β-mercaptoethanol 3.5uL 
Table 2.14 Composition of the MEF medium. 
MEFs were kept as a feeder layer for a maximum of 10 days, and were inspected visually the 
next day after seeding to confirm proper morphology before hESC were passaged. 
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Prior to passaging, hESC colonies were inspected under the microscope and differentiated 
colonies were manually removed from culture. Then 10-20 uL of fresh Dispase were added to 
each well, and cells were incubated at 37°C for a maximum of 30 minutes. Plates were examined 
under the microscope every 5-10 minutes, and once colonies dislodged, these were transferred 
into 10 mL Falcon tube and allowed to settle by gravity. Cells were then washed with 5 ml of 
warm medium three times. MEF medium was replaced with warm hESC medium in new MEF-
covered plates, and washed hESC colonies were resuspend in 5mL hESC medium and gently 
disrupted with a 5mL pipette. Cells were then seeded into new wells, gently swirled to ensure 
even distribution of cells and allowed to settle overnight. Medium was changed the next day.  
2.7.5. Cryopreservation of hESC 
Only colonies of cells of proper morphology maintained in fully established culture were 
cryopreserved. Colonies were cryopreserved 7-8 days post-passaging to ensure the colonies 
reached their maximum size and the best recovery upon thawing. 10-20uL of fresh Dispase were 
added to the media and incubated at 37oC until the colonies fully detached. Colonies were then 
transferred to a 50 ml or 15 ml Falcon tube, depending on the number of colonies. Cells were 
then allowed to settle by gravity or by centrifugation at 300rpm for 1 minute at room temperature. 
Cells were then washed twice with 5mL hESC medium as described in the general hESC 
passaging step. HESC colony pellet was then resuspended in 5mL of hESC medium and 
centrifuged at 300rpm for 5 minutes at room temperature. The supernatant was carefully removed 
and the pellet was then resuspended with 500uL per well of hESC medium.  
10 mL of CRYO medium was prepared by mixing 6 mL of Knockout serum, 2 mL of normal hESC 
medium and 2 mL of DMSO. 500 uL of this mixture per well were added drop by drop to to 
resuspended hESC colonies. 1 mL of the 1:1 medium/CRYO medium mixture was added to 
cryovials. Cryovials were placed in a Nalgene Mr. Frosty Freezing Container and placed in -80°C 
freezer. Cryovials were then transferred to liquid nitrogen tanks for long-term storage. 
2.7.6. Thawing of cryopreserved hESC 
The average recovery of hESC after cryopreservation is 1-10%. Wells were coated with 0.1% 
gelatin and MEFs plated one day before thawing of hESC. On the day of thawing, MEF medium 
was replaced with warm hESC medium and MEFs were incubated at 37oC. Cryovials were 
thawed in water bath, the the content was transferred into 4 ml of warm media in a 15mL Falcon 
tube. Thawed colonies were allowed to settle by gravity in water bath to keep colonies warm. The 
supernatant was carefully removed and the pellet was washed with 5 mL hESC medium. Medium 
was removed from wells containing MEFs, and colonies were added drop by drop to each well. 
The plate was gently swirled to ensure even distribution of cells across all wells, and placed at 




2.8. Standard buffers and reagents 
DMEM/Ham’s F12 medium composition 
3 volumes of Ham’s F12 medium, 1 volume of Dulbecco's modified eagle's medium (DMEM), fetal 
calf serum (10%), 4mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin. 
10x TBE buffer (1 L) 
108 g Tris-base, 55 g boric acid, 200 ml 0.5M EDTA (pH 8.0), distilled water to 1000 mL. 
1x TBE buffer (1 L) 
100 mL of 10x TBE buffer were mixed with 900 mL of distilled water. 
10x PBS 
80 g of NaCl, 2 g of KCl, 14.4 g of Na2HPO4, 2.4 g of KH2PO4 are mixed with 800 mL distilled 
water. 
0.1% Triton X-100 solution in PBS (PBS-T) 
10 mL of 10x PBS were added to 90 mL of distilled water and 0.1 ml of Triton X-100 were added 
to the mixture. 
4% Paraformaldehyde 
200 mL of distilled water heated to 60°C, 10 g of laboratory-grade paraformaldehyde, 50 µl of 10N 
sodium hydroxide, 25 mL of 10X PBS, distilled water to 250 mL. 
Orange G Loading Dye 
100 mg Orange G, 7.5 mL glycerol, distilled water to 50mL. 
10x Trypsin-EDTA  
0.5 g of powdered Trypsin, 80 mL of distilled water, 10 mL of 10x PBS and 1 mL of 0.5 M EDTA 
solution, distilled water to 100 ml. 
DAPI stock solution (1 mg/ml) 
1 mg of 4′,6-dimidino-2-phenylindole (DAPI) is dissolved in 1 ml of 1x PBS. Stock solution is 
wrapped in aluminium foil and stored at -80°C for long-term storage, and at 4°C in darkness for 
short-term storage. 
MTT 10x stock solution 
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25 g of 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were dissolved in 50 
mL of 1x PBS to make 5 mg/mL 10x stock solution. 5 mL aliquots of the stock solution were made 
in 15 ml Falcon tubes, wrapped in aluminium foil and frozen at -20°C for long-term storage. 
Trypan blue 0.4% solution 
4 mg of Trypan blue powder were dissolved in 80 mL of 1x PBS and warmed up with stirring until 
fully dissolved. 1x PBS is added to 100 mL.  
141 
 
3. Somatic Copy Number Alterations and Gene 
Transcription Profiling of Normal Skin and 
Actinic Keratoses 
3.1. Introduction 
A plethora of evidence has established that malignant progression is accompanied by genomic 
instability and subsequent genomic changes. Such genomic changes lead to transcriptional 
differences between normal, premalignant and malignant tissues, promoting malignant 
progression (Bayani et al., 2002). As described previously, up to 60% of cSCC are reported to 
arise from precursor actinic keratoses (AK) – a common clinical manifestation of intraepithelial 
keratinocyte dysplasia, yet the genetic basis of AK is practically unknown. 
Microarray expression profiling is a well-established technique capable of reporting a genome-
wide transcriptome, and thus provide novel insights into cellular processes at an mRNA level 
(Conway and Schoolnik, 2003). High-density oligonucleotide microarrays were originally designed 
to capture single-nucleotide polymorphisms, but can be applied in detection of both genotype and 
copy number variation data (Bignell et al., 2004). SNP is a variation of a single nucleotide in a 
DNA sequence that may occur in both coding and non-coding regions of DNA, and is present in at 
least 1% of the general population. The most common cause of SNP is point mutation leading to 
a nucleotide substitution. SNP may or may not effect gene expression or the coded protein 
structure or function, depending on its character (synonymous versus missense and nonsense) 
and location in the genome (gene, regulatory sequence, intergenic region). For example, 
synonymous SNP do not change the protein structure, since the coded amino acid is identical due 




Figure 3.1 Illustration of Single Nucleotide Polymorphism (SNP). Each version represents a single 
nucleotide substitution in a DNA sequence, and thereby up to four SNP versions may exist in a 
population, with different percentual distribution for each nucleotide. If SNP occurs outside of a 
gene sequence, it is categorised as “linked SNP” and has no effect on protein production. SNPs 
in the regulatory sequences of genes, on the other hand, can alter gene expression levels, while 
SNPs in the gene coding regions can alter the amino acid sequence of the gene protein. Figure 
taken from http://learn.genetics.utah.edu/content/pharma/snips/. 
Unlike SNP, Copy-number variation (CNV) is a form of structural change that alters the amount of 
genomic material in a cell by either loss or gain of a region of DNA (copy number imbalance), or 
leads to copy-neutral loss of heterozygosity (LOH), also known as uniparental disomy in which 
two copies of a genomic region inherited from one parent exist in the absence of a copy from the 
other parent. Seemingly phenotypically neutral CNV are common in the human population and 
have been linked with evolution and phenotypic diversity (Henrichsen et al., 2009), while 
uniparental disomy has been linked with cancer development in humans due to aberrant 
imprinting or homozygosity of mutated or methylated genes (Fu et al., 2008). For the purpose of 
this work, the term “somatic copy number alteration” (SCNA) is used to refer to an alteration in the 
number of copies of a region of DNA (loss or gain) that is acquired in somatic cells. CNV 
commonly refers to a different copy number of a germline, rather than somatic DNA (Moubayed et 
al., 2007). 
SNP arrays allow the detection of gains and losses of small genomic regions, LOH and 
uniparental disomy. Oligonucleotide probes hybridise with fluorescence-labelled DNA fragments 
and the intensity thereby reflects the number of copies of given DNA regions. Additionally, SNP 
arrays are able to distinguish parental alleles based on SNPs. 
The purpose of this experiment was to find shared genomic changes that underpin AK onset and 
progression to cSCC and to define the extent to which these genomic changes determine 
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transcriptional changes in their respective lesions. Any discrepancies between these profiles 
might indicate a potential role for epigenomic changes.  
3.2. Materials and Methods 
3.2.1. Patients and tissue samples 
Skin, AK and tumour samples were collected between 1995-2007 in the dermatology clinics at 
Barts and the London NHS Trust (London, United Kingdom) by Dr Abha Gulati8 or Professor 
Harwood9 from consenting study participants (clinical details are provided in Appendix 18): fresh 
frozen biopsies of normal skin, AK and cSCC were obtained at the time of surgical excision. 
Tumour samples and a subset of AK biopsies were immediately snap-frozen in liquid nitrogen. 
Two 4 mm biopsies were obtained from skin samples, one of which was also immediately snap-
frozen in liquid nitrogen, and the other was split in half: one half was fixed in formalin and 
embedded in paraffin, the other half was submerged in RNALater RNA preserving agent (Qiagen, 
United Kingdom) for up to 4 hours prior to freezing in liquid nitrogen. Venous blood was drawn 
from patients for genotyping. All samples were stored at -80°C until processed. All participating 
patients provided informed consent in accordance with ethical approval from the East London and 
City Health Authority local ethics committee.  
3.2.1.1. Sun-exposed, non-sunexposed skin and actinic keratoses 
Sun-exposed skin was defined as a sample collected from an area usually not covered by 
commonly worn clothes, such as the outer upper arm or scalp (see Figure 3.2). Non-sunexposed 
skin, on the other hand, was collected from an area usually not exposed to sunlight, such as inner 
upper arm and buttocks. AKs were collected from confluent areas of keratinocyte intraepithelial 
neoplasia (KIN). AKs were defined clinically and confirmed histopathologically. 
                                                       
8 Cutaneous Department, Blizard Institute of Cell and Molecular Science, Queen Mary, University of London 
9 Barts and the London School of Medicine and Dentistry; Blizard Institute of Cell and Molecular Science, 




Figure 3.2 Broad areas of keratinocyte intraepithelial neoplasia. Arrows point to individual lesions. 
Photos prepared in collaboration with Dr Abha Gulati. 
Each skin and AK sample was evaluated by a dermatopathologist in a blinded manner to confirm 
its histological structure.  
DNA isolation from blood, skin and AK samples was conducted in collaboration with Dr Abha 
Gulati. DNA was isolated from those samples either with DNEasy Micro or Mini kit (Qiagen, 
United Kingdom) following laser-capture microdissection of the sample (described in Chapter 2) 
or by microdissection under light microscope, during which the epidermis was separated using a 
scalpel. 
If the total DNA yield was below 25 ng/ µl, DNA was amplified using either Illustra Genomiphi v2.0 
DNA Amplification kit (GE Healthcare, USA) or Repli-g Mini kit (Qiagen, United Kingdom) 
following the manufacturers’ protocols. 
3.2.2. Affymetrix GeneChip Human Mapping 250K Nsp SNP Array 
Affymetrix GeneChip Human Mapping 250K Nsp SNP Array (Affymetrix, USA) contains 250 000 
oligonucleotide sequence probes complementary to corresponding genomic regions. Prior to 
hybridisation to the microarray, DNA is digested with restriction enzyme Nsp I and ligated to Nsp-
specific adaptors. Adaptor specific primers were then used to amplify the adaptor-linked DNA 
during a PCR. The PCR products are purified using ultra-free MC filtration column (Millipore, UK) 
and finally, purified PCR products are fragmented using DNase I, labelled with biotin-labelled 
reagent and hybridised to the array. The array is then washed, stained with GeneChip Fluidics 
Station 450 (Affymetrix, USA) and scanned with a GeneChip Scanner 30007G (Affymetrix, USA). 
Array processing was carried out by Dr Tracy Chaplin10.  
                                                       
10Cancer Research UK, Medical Oncology Laboratory, Barts and the London School of Medicine and 
Dentistry, Queen Mary, University of London. 
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Data acquisition from the SNP array consisted of image analysis by GeneChip Operating 
Software (Affymetrix, USA) generating probe cell intensity data. SNP allele calls were generated 
by GeneChip Genotyping Analysis Software (Affymetrix, USA). The raw values were then 
preprocessed and normalised in Bioconductor in collaboration with Fios Genomics11. I analysed 
the data using the following packages: ggplot2, gviz, and glm regression analysis function in R. 
Numeric coding of SCNA is the following: CN0 = homozygous deletion, CN1=heterozygous 
deletion, CN2=uniparental disomy, CN3=heterozygous gain, CN4=double gain. 
Size of SCNA was divided into 5 categories (XS, S, M, L, XL) based on the following cut-off 
criteria: XS < 10K bp, S < 100 K bp, M < 1 MB bp, L < 10 MB bp, XL > 10 MB.  
3.3. Results 
3.3.1. Somatic copy number alteration in normal skin and actinic 
keratoses 
3.3.1.1. Experimental design and comparison strategy  
SNP array profiling data from a total of 38 patients were included in the study. Each of those 
patients provided a blood sample, AK, sun-exposed and non-sunexposed skin biopsy. Only 
arrays that passed quality control and samples with histological verification of tissue 
characteristics were included in the analysis. I focused on somatic mutations potentially relevant 
to non-melanoma skin onset, specifically progression from normal skin to premalignancy (AK). 
Data variables included: chromosome, SNP coordinates (start, end), size in bp, copy number 
(CN0-4), raw data filename, SNP name, chip type, scan date, immune status, tissue type, gender, 
patient ID, extraction kit, histology, and microdissection type. 
In order to exclude genomic changes due to germline mutations, I compared alterations detected 
in blood with changes in other tissues in a patient-specific manner. Identical genomic changes 
detected in blood and other tissue samples in the same patient were considered germline 
mutations and excluded from further analysis. From a total of 749 regions detected in AK, 28 
(3.7%) were excluded as germline mutations, 18 of a total 167 in NSE (10%) and 29 of a total of 
161 in SE (17%). Additionally, the vast majority of blood SCNAs were random and showed no 
common pattern. I detected a total of 3 SCNAs in 4 patients (more than 10% of sample 
population). One patient had only a single SCNA in blood, and one patient had no detectable 
SCNAs in any of the samples analysed. These two patients were excluded from downstream 
analysis due to suspected technical issues (improper hybridisation), leaving data from a total of 
36 individuals. 
                                                       
11 Fios Genomics Ltd., Edinburgh, Scotland. 
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3.3.1.2. Characteristics of analysed samples 
There were a total of 27 (75%) male and 9 (25%) female study participants. Of 27 males, 15 
(55%) were immunocompetent and 12 (44%) were organ transplant recipients (OTR). Among 9 
females, 2 (22%) were immunocompetent and 7 (78%) were OTR. OTR patients represented 
47% of all study participants. 
Somatic SCNAs detected in individual patients are summarised in Table 3.1 along with patient 
characteristics. 
Patient	  ID	   NSE	  SCNAs	   SE	  SCNAs	   AK	  SCNAs	   Immune	  
Status	  
Gender	  
10	   2	   3	   10	   IC	   Male	  
45	   20	   0	   104	   IC	   Male	  
19	   0	   1	   0	   IC	   Female	  
11	   13	   2	   1	   IC	   Male	  
53	   0	   0	   3	   IC	   Male	  
29	   1	   3	   38	   IC	   Male	  
26	   4	   3	   4	   IC	   Male	  
47	   0	   2	   3	   IC	   Male	  
20	   35	   3	   4	   IC	   Male	  
52	   1	   2	   217	   IC	   Female	  
1	   8	   3	   22	   IC	   Male	  
41	   2	   1	   4	   IC	   Male	  
16	   0	   2	   11	   IC	   Male	  
46	   4	   6	   25	   IC	   Male	  
25	   0	   28	   4	   IC	   Male	  
3	   2	   2	   44	   IC	   Male	  
50	   3	   4	   2	   IC	   Male	  
24	   0	   1	   0	   OTR	   Female	  
28	   0	   0	   13	   OTR	   Male	  
14	   4	   4	   1	   OTR	   Male	  
5	   0	   1	   1	   OTR	   Female	  
33	   0	   4	   0	   OTR	   Female	  
21	   2	   0	   2	   OTR	   Female	  
36	   1	   1	   1	   OTR	   Female	  
27	   1	   1	   12	   OTR	   Female	  
31	   0	   0	   2	   OTR	   Female	  
18	   3	   7	   2	   OTR	   Male	  
51	   4	   8	   66	   OTR	   Male	  
34	   1	   12	   7	   OTR	   Male	  
9	   12	   2	   7	   OTR	   Male	  
43	   3	   5	   8	   OTR	   Male	  
15	   11	   2	   91	   OTR	   Male	  
7	   2	   11	   0	   OTR	   Male	  
44	   4	   5	   4	   OTR	   Male	  
22	   0	   1	   0	   OTR	   Male	  
37	   4	   3	   6	   OTR	   Male	  




Table 3.1 Summary of detected somatic SCNAs and clinical characteristics of study participants. 
147 
 
3.3.1.3. SCNA distribution in males and females, transplant recipients and 
immunocompetent patients 
The relative distribution of SCNAs detected in individual patients along with their baseline 
characteristics are shown in Figure 3.3 and Figure 3.4. If stratified by immune status, the overall 
number of SCNAs is relatively equal between the two groups (except for three outliers). If 
stratified by gender, except for those outliers, the relative contribution of individual males and 
females is also evenly distributed.  
 
Figure 3.3 Total number of SCNAs contributed by individual patients. Pink dot - female, green dot 
- male. Upper panel – immunocompetent patients, lower panel – immunosuppressed patients. 
Two female participants were immunocompetent, one of which contributed the majority of SCNAs 
detected in females. 
 
Figure 3.4 Total number of SCNAs contributed by individual patients. Red dot - OTR, blue dot - 
IC. Upper panel - females, lower panel - males. 
 
The cumulative percentage of SCNAs per tissue per gender is shown in Figure 3.5. It 
demonstrates that for both groups, the majority of SCNA was contributed from AKs. Similar trend 











































Figure 3.5 Cumulative percentage of SCNA in SE, NSE and AK in both genders. 
 
 
Figure 3.6 Cumulative percentage of SCNA in SE, NSE and AK in OTR and IC patients. 
Summary baseline statistics for all four groups (males, females, OTR, IC) are provided in Table 
3.2. Although the mean levels of SCNA fluctuate across the groups, median ranges are similar. 
Given the uneven distribution of samples across all groups and the uneven contributions of 
individual samples, median is a more accurate statistic for evaluating SCNA distribution across 
groups and tissue types. 
 
Group Statistic AK SCNAs NSE SCNAs SE SCNAs Total 
Males Median 6 3 3 15 
 Mean 17.96 5.26 4.48 27.67 
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   Mode	   4	   0	   2	   13 
	   Total	   484	   142	   121	   747 
	   %	   64.8	   19	   16.2	   - 
	   	   	   	   	    
Females	   Median	   7	   2	   2	   24.33 
	   Mean	   48.29	   10.6	   8.68	   67.98 
	   Mode	   4	   0	   1	   2 
	   Total	   235	   6	   10	   251 
	   %	   93.6	   2.4	   3.99	   - 
      
OTR Median 4 2 2 16 
	   Mean	   29.18	   5.65	   3.7	   38.53 
	   Mode	   4	   0	   2	   N/A 
	   Total	   496	   96	   63	   655 
	   %	   75.7	   14.6	   9.6	   - 
	   	   	   	   	    
IC	   Median	   2	   2	   2	   13 
	   Mean	   11.77	   2.74	   3.58	   18.1 
	   Mode	   0	   0	   1	   13 
	   Total	   223	   52	   68	   343 
	   %	   65	   15	   20	   - 
Table 3.2 Summary statistics of SCNA distribution per gender and immune status. 
I then plotted chromosomal distribution of detected SCNAs in each sample type (SE/NSE/AK) 
stratified by  gender and immune status (Figure 3.7). The distribution across individual 
chromosomes  varied (males versus females, OTR versus IC), although changes on chromosome 
9 dominated in all groups.  
I then tested the presence of at least 1 SCNA per tissue (SE, NSE, AK) type per group (males vs. 
females, OTR vs. IC) with Chi square test, which showed no statistically significant difference for 
comparison of immunocompetent and immunosuppressed patients, but detected borderline 
significance for AK in comparison of males versus females, with statistically significant increase in 
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risk difference for AK in males as shown in Table 3.3, suggesting that AK collected from male 
patients are more likely to contain genomic imbalances. 
I finally tested this hypothesis with regression analysis, which confirmed significant differences in 
the total number of SCNAs by tissue type (p<0.0001) and patient ID (p<0.03). Neither immune 
status nor gender were significant factors for SCNA number (p value 0.47 and 0.8, respectively).  
 
 
Figure 3.7 Histogram of SCNAs detected in SE, NSE and AK (KIN) stratified by patientr immune 
status (left) and gender (right). Upper left panel (IC) – immunocompetent, lower left panes (IS) – 
immunosuppressed. Upper right panel (1) - males, lower panel (2) - females. This graph depicts 
higher total number of SCNA regions in immunocompetent patients namely on chromosomes 1, 
6, 9, 16, 18 in AK, and in males on chromosomes 1-15, 19-22. 
 
Comparison	   Tissue	   Pvalue	   Relative	  risk	   Risk	  difference	   95%	  CI	  
Males	  vs.	  
Females	  
NSE	   0.061	   1.75	   0.33	   0.981542	  to	  
4.194966	  
	   SE	   0.4	   1.14	   0.1	   0.855716	  to	  
1.985473	  
	   AK	   0.05	   1.8	   0.42	   1.106989	  to	  
4.956808	  
	   	   	   	   	   	  
OTR	  vs.	  IC	   NSE	   0.88	   0.96	   0.02	   0.61026	  to	  
1.558495	  
	   SE	   0.72	   0.95	   0.04	   0.69163	  to	  
1.319434	  




Table 3.3 Statistical comparison of SCNA as categorical variable between two baseline groups 
(gender, immune status). Risk difference (also known as absolute risk reduction) is the difference 
in percentage of patients with the outcome of interest. It measures the absolute size of difference 
between the two groups. If the confidence interval contains 0, such difference is not considered 
statistically significant. For AK in males, the risk of AK containing SCNA is 1.8 compared to 
females (80% increase), and the risk difference of 42%. 
3.3.1.4. Differences between tissue types 
There were no statistically significant differences between the number of SCNAs in NSE and SE 
(t.test, p value >0.05), yet there were differences between NSE, SE and AK (p value 0.0077, 
ANOVA). Differences in chromosomal distribution of SCNA across the three tissue types are 
shown in Figure 3.8, along with the size of individual chromosomal changes.  
There was no statistically significant difference in somatic copy number alteration type (loss, gain) 
per tissue (linear regression, p value >0.05), but SCNA size was statistically significantly different 
across the tissues (p value < 0.01).  
SCNA size was not different between NSE and SE (t test, p value >0.05), but ANOVA confirmed 
the difference in SCNA size between SE, NSE and AK (p value <0.05). Thus, SCNAs in AK are 





Figure 3.8 Histogram of SCNAs across chromosomes reflecting size and tissue type. KIN=AK. 
Large SCNAs were detected mainly in AK in chromosomes 1, 3, 5, 6, 8, 9, 16 and 18. Extra small 
SCNAs, on the other hand, were detected in NSE on chromosomes 2, 8, 9 and 18, and in SE on 
chromosomes 2, 3, 4, 8, 11, 14 and 16. 
Additionally, copy-number (CN) significantly differed across chromosomes and between patients, 
and was size-dependent (linear regression). The majority of changes detected were monoallelic 
gains (723/1003, 72%), followed by monoallelic losses (221/1003, 22%), biallelic losses (42/1003, 
4.2%) and 17 double gains (1.6%). Figure 3.9 shows that the biallelic losses or double gains were 































Figure 3.9 Distribution of SCNAs per chromosome divided into groups according to SCNA 
characteristic and size in base pairs. RegionStart shows genomic coordinate of SCNA on a 
chromosome, groups reflect change in genomic material (0=biallelic loss, 1=monoallellic loss, 
3=monoallelic gain, 4=biallelic gain). Extent shows a gradient of increasing size of SCNA in base 
pairs. Groups 0 and 4 contain mainly small size SCNAs, while group 3 contains several large 
gains on chromosomes 1, 3, 7, 9 and 20 represented by red dots. 
I summarised the distribution of SCNA size per chromosomal change in Table 3.4, and observed 
that 17 of 27 XS changes (63%) are biallelic loss or double gain SCNAs. In comparison with the 
number of XS monoallelic lesions, this is a highly significant finding (p value<0.0001, Fisher’s 
exact test). The same was true for small (S) lesions as well. 
Size	   CN0	   CN1	   CN3	   CN4	  
XS	   9	   6	   4	   8	  
S	   21	   49	   97	   3	  
M	   11	   144	   468	   4	  
L	   1	   22	   153	   2	  





















XL	   0	   0	   1	   0	  
Table 3.4 Summary of the number of SCNA based on size and the change of genomic material. 
CN0=biallelic loss, CN 1=monoallellic loss, CN3=monoallelic gain, CN4=biallelic gain. 
I then plotted SCNA size distribution as bin value based on XS to XL size classificatioin (Figure 
3.10) rather than individual values shown in Figure 3.9, and observed clustering of large SCNAs 
among monoallelic gains. Those represented a total of 21% of all CN3, while only 10% of CN4, 
9% of CN1 SCNAs, and 2% of CN0, which was also a statistically significant finding (p 
value<0.05). Moreover, I observed clustering of changes across individual chromosomes. 
Specifically, there seemed to be a concentration of M size monoallelic losses across chromosome 
5, p-arm of chromosome 9, 13 and 18. There were also clusters of monoallelic gains on 
chromosome 1, 3, 6, 8, 9, 18 and 20. Distribution of M size SCNAs was equal across groups, 
while all other size categories except for 1 XL SNP showed significant association with CN (small 





Figure 3.10 SCNA distribution across CN groups plotted with SCNA size as bin factor. 0=biallelic 
loss, 1=monoallellic loss, 3=monoallelic gain, 4=biallelic gain. This figure shows XS aberrations 
concentrated in groups 0 and 4, while several M-sized monoallelic losses occurred on 
chromosome 5, 9 and 16. Chromosome 1 contained mainly M- and L-sized monoallelic gains, and 
similar trend was apparent on chromosomes 3, 6, 8, 9 and 16 in group 3.  
The chromosomal distribution of CN and SCNA size stratified by tissue type is shown in Figure 
3.11. It shows that clusters of CN1 on chromosome 5, p-arm of chromosome 9, 13 and 18 were 















































Figure 3.11 Histogram of copy-number change and SCNA size chromosomal distribution across 
all tissue types. Copy-number changes in AK (top left panel) show both prominent monoallelic 
gains and losses on chromosomes 5, 7, 9, 13, 16 and 18. In NSE, similar co-occurrence of loss 
and gain of a genomic material is found on chromosomes 1, 3, 5, 6, 8 and 18. In SE, such finding 
can be observed on chromosomes 3, 5-8. Right panel corresponds to Figure 3.8 and is included 
for reference.  
A more detailed look at distribution of SCNAs per tissue with size and CN factored in is shown in 
Figure 3.12. While it confirmed previous observations, it has also demonstrated that there is 
relatively little overlap between SE and NSE SNPs. While some were clearly identical, the 




Figure 3.12 SCNA distribution across tissue types with chromosomal location. Substantial 
increase in both the number and the size of genomic aberrations is apparent in AK (KIN) samples, 
many of which affect entire chromosomes (e.g. chromosome 1, 5, 8, 9,18, 20). Normal skin 











































































I then identified shared, identical SCNA across NSE and SE samples. There were a total of 11 
(3.9%) shared SCNAs listed in Table 3.5. Three of those shared SCNAs occurred in 1 patient 
(OTR male), two in another patient (OTR male), and 2 of those 11 changes were shared by 2 
patients. 1 SCNA showed monoalelic gain in SE and double gain in NSE of the same patient. 
Given that the majority of the SCNAs shared between NSE and SE occurred in the same patient 
(8/11, 72%), this further confirmed absence of shared genomic traits in those samples, and the 
impact of individual patients as the key contributing factor to the character of SCNAs in each 
tissue. 
 
SNP	   Chr	   Start	   End	   ID	   Gene	   CN	   Tissue	  
SNP_A-­‐4216701	   1	   102430762	   102622376	   ID15	   OLFM3	   1	   NSE/SE	  
SNP_A-­‐1900201	   2	   183794033	   183819678	   ID1	   NCKAP1	   0	   NSE/SE	  
SNP_A-­‐2218448	   2	   36244590	   36422518	   ID15	   -­‐	   3	   NSE/SE	  
SNP_A-­‐4194705	   2	   37814187	   37814499	   ID51	   -­‐	   4	   NSE	  
SNP_A-­‐4194705	   2	   37814187	   37814499	   ID51	   -­‐	   3	   SE	  
SNP_A-­‐2056690	   3	   196918723	   196959312	   ID14	   DLG1	   3	   NSE	  
SNP_A-­‐2056690	   3	   196918723	   196959312	   ID16	   DLG1	   4	   SE	  
SNP_A-­‐1843546	   5	   131806615	   131844802	   ID50	   C5orf56,	  IRF1	   3	   NSE/SE	  
SNP_A-­‐2225884	   7	   68428002	   69429303	   ID43	   AUTS2	   1	   NSE/SE	  
SNP_A-­‐2162694	   12	   65484396	   65540472	   ID37	   WIF1	   1	   NSE/SE	  
SNP_A-­‐4233185	   14	   19336854	   19424016	   ID41	   OR11H12,	  
LOC642426	  
3	   NSE	  
SNP_A-­‐4233185	   14	   19336854	   19456378	   ID10	   OR11H12,	  
LOC642426	  
3	   SE	  
SNP_A-­‐2228752	   15	   19821421	   19943185	   ID14	   -­‐	   3	   NSE/SE	  








3	   NSE/SE	  




3.3.1.5. Differences between males and females 
While the presence of SCNAs did not differ between the two groups, I tested the hypothesis that 
there may be differences in the SCNA size and copy number. However, linear regression -
factoring in patient ID - demonstrated no association between gender and SCNA size or CN. 
Although Figure 3.13 shows rather intriguing differences between the two groups in chromosomal 
distribution, Figure 3.14 and Figure 3.15 display the number of SCNA regions per tissue type per 
person, suggesting the majority of SCNAs in group 2 (females) are derived from a single patient, 
reflecting the low number of female participants in the study. A detailed look at SCNAs 
contributed by remaining female participants is shown in Figure 3.16. 
 
 
Figure 3.13 SCNA region size and CN distribution per gender. 1-males, 2-females. 0=biallelic 
loss, 1=monoallellic loss, 3=monoallelic gain, 4=biallelic gain. This graph shows prominent 
differences in both chromosomal location, size and CN character of SCNAs between males and 




































with a concentration of monoallelic losses on chromosome 16 and clusters of gains on 
chromosomes 1, 6, 8, 9, 16 and 21. Male participants demonstrate greater heterogeneity in both 
the size and character of genomic aberrations on individual chromosomes.  
 
 
Figure 3.14 SCNA distribution per tissue type in individual male patients. Most SCNA events were 
contributed by AK (KIN) samples, with increased proportion of NSE SCNAs in patients 11, 9 and 
20. 





















Figure 3.15 SCNA distribution per individual female participants. Patient 52 contributed the vast 
majority of SCNAs in this group. 
 



















Figure 3.16 SCNAs in female participants, patient 52 not included in the display range (column 
with gradient). Three female patients had detectable SCNAs only in their SE skin. 
I wanted to verify the absence of overlapping differences between the two groups in terms of 
SCNA distribution in AK lesions. As seen in Figure 3.17, while there were some shared traits, 
namely on chromosomes 1, 8 and 9, there seemed to be no obvious pattern among the lesions, 
other than as a reflection of the fact that there were more male participants and thus more SCNAs 
in this group. 
 
Figure 3.17 SCNA distribution across chromosomes in AK. Score=CN, upper panel (1) - males, 
lower panel (2) - females. The size of coloured block corresponds to genomic coordinates of each 
detected SCNA. Overlapping SCNAs are plotted above one another. This graph shows that the 
highest number of overlapping SCNAs was four on chromosome 8 in male patients, in addition to 
differences in copy-number changes of overlapping regions: for example, two overlapping regions 
in male patients on chromosome 20 are monoallelic gains (blue), and 1 smaller overlapping 
SCNA region is a monoallelic loss (green). 
A more detailed look at SCNAs across chromosome 1 in AK is shown in Figure 3.18. While both 
the location and distribution of SCNAs are vastly different between males and females based on 
this plot, as shown in Figure 3.19, the majority of those SCNAs are derived from 1 male and 1 
female patient, further stressing the key role of individual genomic background. 
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Figure 3.18. SCNAs detected on chromosome 1 in AK. Geen=loss, orange=gain. This detailed 
look depicts many short SCNAs on the p-arm in female patients, while such cumulation of short 
SCNAs occurs on the q-arm in male patients.  
 
 
Figure 3.19 SCNAs distributed per chromosome per gender in individual patients. Red-males, 
green-females. Each line in the matrix corresponds to patient ID (y axis), and SCNAs are plotted 
based on their chromosomal coordinates (x axis). Each column corresponds to an individual 
chromosome. This graph illustrates how each individual patient contributed to the overall changes 
detected with the SNP arrays, and that the majority of chromosomal aberrations are in fact short 
(focal), rather than arm-long. For example, it shows large regions of SCNA in patient 52 across 7 
chromosomes, while many shorter SCNAs in patient 45 across 21 chromosomes.  
 




































3.3.1.6. Differences between organ transplant recipients  
I then proceeded to find out if there were differences between organ transplant recipients (OTR) 
and immunocompetent (IC) patients. Given that the numbers of participants in each group were 
almost equal (19 and 17, respectively), such differences would be more representative of trends 
in these two groups. 
There were no significant differences in the number of SCNAs per patient in SE, NSE or AK 
between the two groups (treating SCNA as a continuous variable, T-test, p =0.9, 0.24 and 0.2, 
respectively). 
Linear regression analysis has shown that while the size of the SCNA was independent of 
immune status, CN character (gain or loss) was largely associated with immune status (p value < 
0.0001). A cumulative percentage plot shown in Figure 3.20. While over 80% of SCNAs among IC 
patients were gains, over 40% among OTR (IS) patients were losses. Moreover, both biallelic 
losses and double gains were more common among OTR patients, but this difference was not 
significant (Chi square, p value =0.8). The CN1 (hererozygous deletion) was statistically 
significantly more common among SCNAs detected in OTR patients (p value <0.0001, Chi sq 
test). 
 
Figure 3.20 Cumulative percentage of copy number segregated by immune status. 
IC=immunocompetent, IS=immunosuppresed patients. 0=biallelic loss, 1=monoallellic loss, 















common among immunosuppressed patients. Generally, loss of genomic material represented 
almost 50% of detected chromosomal changes in this group, compared with under 20% among 
immunocompetent patients. 
3.3.1.7. Contribution of individual patients 
The contribution of individual patients towards the total number of genetic changes in each tissue 
type is shown in Figure 3.21. The uneven distribution of individual SCNA changes suggests these 
somatic mutations are predominantly stochastic, and that the extent of genomic changes is 
largely patient driven. 
 
 
Figure 3.21 Total number of SCNA contributed by individual patients. Pink outer line - female, 
green outer line - male. Upper panel (0) - Immunocompetent, lower panel (1) – transplant 
patients. Patients 1, 3, 29, 45, 46 and 52 contributed the vast majority SCNAs in AK (KIN) among 
immunocompetent individuals, while patients 1, 11, 20 and 45 contributed the majority of SCNAs 
in NSE in this group. Patients 25, 46 and 50 contributed the majority of SCNAs in SE. The 
distribution across transplant patients is considerably more even compared with 
immunocompetent individuals. 
The presence of at least 1 SCNA detected in each chromosome per tissue type is shown in 
Figure 3.22. It demonstrates inter-patient heterogeneity in SCNA and relative absence of shared 
patterns among the patients. 
Linear regression analysis has confirmed that SCNA size, CN and chromosomal distribution of 























































depicting major clustering of heterozygous gains in patient 45, 20, 1 and 25, and extensive 
heterozygous gains and losses in patient 52. Hererozygous losses were predominant in patients 
37, 43 and 9. Patients 15 and 29 each had a large SCNA in extent. In order to achieve greater 
data spread, after subtracting those two biggest SCNAs and plotting SCNA size and CN per 
patient, it emerged that while in certain patients lesions clustered along chromosomal locations in 
terms of both size and CN (patient 15, 51), in many there were no patterns (Figure 3.24). 
 
Figure 3.22 Chromosomes showing at least 1 SCNA per lesion in individual patients. Some 
chromosomes were consistently affected by genomic aberration in individual patients (for 







































Figure 3.23 Distribution of copy number per chromosome per patient. Each box corresponds to an 
individual patient. 0=biallelic loss, 1=monoallellic loss, 3=monoallelic gain, 4=biallelic gain. Y axis 
of each box=chromosomal location of SCNA. This graph show key differences in the number and 
character of SCNA across individual patients. Patient 9’s SCNA were almost all monoallelic 
losses, while patient 45’s SCNAs were mostly monoallelic gains. Patient 43’s SCNAs were only 
mono- or biallelic losses, while patient 50’s SCNAs were only monoallelic gains. 
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Figure 3.24 SCNA distribution per chromosome in each patient showing both CN and SCNA size. 
Each box corresponds to an individual patient. 0=biallelic loss, 1=monoallellic loss, 3=monoallelic 
gain, 4=biallelic gain. Y axis of each box=chromosomal location of SCNA. This graph shows more 
detailed differences in the size of SCNAs across all patients.  
3.3.1.8. Multiple overlapping SCNAs in SE, NSE and AK 
I proceeded to find overlapping SCNAs (not necessarily identical in their start or end, but having 
an overlapping segment of the SCNA) that appeared in at least 3 patients in each tissue type (8% 
or more).  
Based on Figure 3.25, such changes occurred on chromosome 15 and 17 in SE, chromosome 15 
in NSE, and chromosome 1, 6, 8, 9, 11, 14, and 15 in AK. Changes are listed in Table 3.6. If there 
were differences in size in the overlapping segment, only the size of the smallest segment is 
listed. If the overlapping change differed in loss/gain, the aberration was listed only if the shared 
genomic material loss or gain was shared by three or more patients. 
A heterozygous loss in a single region (15.q11.1) was shared by NSE and SE, as it was present 
in 2/3 patients that shared the lesion in both tissues. Many of the observed overlaps were due to 
one or two patients accumulating aberrations spanning large chromosomal regions, rather than 
due to specific small changes. Example of this pattern is shown on chromosome 9, where many 
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of SCNAs accumulated, but most differed in their CN, namely on p arm (Figure 3.26 and Figure 
3.27). 
 
Tissue	   Chromosome	   Cytoband	   Size	   CN	   Gene	   Exp	   Id	  
SE	   15	   15q11.1 M	   3	   -­‐	   	   14,51,37	  
	   17	   17q21.31 S	   3	   -­‐	   	   20,36,46	  
	   	   	   	   	   	   	   	  
NSE	   15	   15q11.1 S	   3	   -­‐	   	   14,51,46	  
	   	   	   	   	   	   	   	  
AK	   1	   1q42.12 M	   3	   LIN9	   NS	   45,25,52	  
	   1	   1q43 S	   3	   -­‐	   	   45,25,52,15	  
	   6	   6p22.3 M	   3	   -­‐	   	   29,45,52	  
	   8	   8q12.3 
 
M	   3	   NKAIN3	   NP	   9,29,52	  
	   8	   8q13.2 M	   3	   PREX2	   NP	   10,29,52	  
	   8	   8q22.3 M	   3	   -­‐	   	   27,29,52	  
	   8	   8q23.3 
 
M	   1	   MED30	   NS	   37,43,47	  
	   8	   8q24.11 M	   3	   -­‐	   	   27,29,52	  
	   8	   8q24.12 M	   3	   COL14A1	   NS	   27,29,52	  
	   8	   8q24.21 M	   3	   POUF1B	   NP	   45,29,52	  
	   9	   9p21.2 S	   3	   -­‐	   	   46,1,52	  





	   9	   9p22.2 M	   3	   SYK	   NS	   15,3,52	  
	   9	   9p22.32 S	   3	   -­‐	   	   15,46,52,45	  











	   9	   9q33.1 S	   3	   ASTN2	   NS	   15,46,52	  
	   9	   9q31.2 M	   3	   -­‐	   	   3,52,29	  





	   9	   9q33.1 M	   3	   ASTN2	   NS	   46,15,52	  





















































	   9	   9q34.2 
 
M	   3	   RXRA	   UP	   50,52,45	  
	   11	   11q13.3 
 





	   14	   14q11.2 
 
M	   3	   OR11H12	   NP	   10,45,26	  
	   15	   15q11.1 
 
M	   3,4	   -­‐	   	   16,46,25	  
Table 3.6 SCNAs shared by at least 8% of patients in given tissue type. Exp=expression fold-
change. UP=significantly upregulated in AK compared to SE, DOWN=significantly down-
regulated, NS=statistically non-significant difference, NP=not present on expression array. 
 
 
Figure 3.25 Cumulative SCNAs per chromosome in tissues coloured by individual patient ID. 
Each column corresponds to a chromosome, each color shade represents an individual patient 
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(see Figure 3.27 for legend of patient ID). Size of the SCNA corresponds to size in base-pairs. 
The largest SCNAs were detected in AK (KIN), and many were contributed by a single patient. 
 
 
Figure 3.26 SCNA on chromosome 9 showing cumulation of discrete CN changes on p arm. P 
arm=0 to 50 Mb. 0=biallelic loss, 1=monoallellic loss, 3=monoallelic gain, 4=biallelic gain. Each 
SCNA corresponds to its genomic coordinates. While all CN types are detected on the p-arm, the 
q-arm (from 50 Mb on) shows almost exclusively monoallelic gains.  









Figure 3.27 CN on chromosome 9 painted by patient ID. Patient 52 has contributed to the majority 
of shared changes due to having long ranges of chromosomal aberrations. 
3.3.2. Transcription changes in normal skin and actinic keratoses 
3.3.2.1. Experimental design and comparison strategy  
Expression array profiling was generated from samples obtained from a total of 44 patients. Of 
these, 20 patients had at least one of their lesions profiled by SNP array as detailed in the 
previous section.  
A total of 44 AKs, 20 of which were collected from unique patients, passed the quality control. 16 
NSE samples and 20 SE samples passed the quality control and were included in the study. 
Because SE and NSE skin are considered distinct tissue categories in terms of showing intrinsic 
genomic changes, the comparison with AK was conducted separately for each type of skin 
sample. Due to the relatively low number of paired samples (20), there was insufficient power to 
perform analyses on an individual patient basis. 
3.3.2.2. Transcription profiling and statistical analysis of microarray expression data 
Transcriptional profiling of NSE, SE and AK samples was generated by hybridization of 5 
micrograms of amplified cDNA synthesised with NuGen WT-ovation Pico RNA Amplification 
System to Affymetrix HG U133 Plus 2.0 microarrays (Affymetrix, USA). This chip comprises 
54,675 probes. 
Quality control and data normalisation was carried out by FIOS Genomics in R/Bioconductor 
(described in greater detail in Chapter 4.2.3.1). All arrays that passed the quality control including 
arrays used for cSCC profiling (described in Chapter 4) were normalised together to create a 
large matrix of normalised expression values. 

















Differentially expressed probes were identified using the Limma package in Bioconductor. Multiple 
sampling from the same patient was taken into account in the design matrix for data comparison. 
P value was adjusted to control for false discovery rate of 0.05. Affyemtrix Array processing that 
had been applied to this dataset is described in greater details in Chapter 4.2.3. 
3.3.2.3. Sun-exposed skin vs. non-sunexposed skin 
To validate the hypothesis that the transcriptional profile of non-sunexposed skin differs from sun-
exposed skin, I plotted a heatmap of log transformed expression values of all probes present at 
the microarray (shown in Figure 3.28). Unsupervised hierarchical clustering of the samples shows 
that while not entirely distinct from each other, the transcription profiles of SE and NSE are 
sufficiently distinct to support separate comparisons with AK transcription profiles.  
  
Figure 3.28 Heatmap of unsupervised clustering of NSE and SE samples. Yellow=SE, 
violet=NSE. Each column represent log2 expression levels of all genes in individual samples 
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(corresponding numeric values are inferred from the Color Key). In 8 instances, NSE and SE from 
the same patient clustered together (from the left: numbers 1, 5, 2, 11, 6, 17 38, 14), while in 5 
instances skin samples from the same patient did not form a cluster. Additionally, a small cluster 
of NSE samples is apparent (NSE 2, 8, 4, 15, 12, 11).  
The comparison of expression levels between the two tissue types has shown that there were 20 
differentially expressed probes at the α level of significance 0.01 (after FDR adjustment for 
multiple testing). All but three probes were downregulated in NSE compared to SE, and these 20 
probes represented 12 unique genes (listed in Table 3.7Error! Reference source not found.). 
 
ProbeID	   Symbol	   Description	   Chr	   logFC	  
239260_at	   CORIN	   corin,	  serine	  peptidase	   4	   -­‐1.531329923	  
239261_s_at	   CORIN	   corin,	  serine	  peptidase	   4	   -­‐1.254003291	  
1563271_at	   NA	   NA	   -­‐	   0.931952841	  
243146_at	   NA	   NA	   -­‐	   -­‐1.308232535	  
203000_at	   STMN2	   stathmin-­‐like	  2	   8	   -­‐1.610267694	  
220356_at	   CORIN	   corin,	  serine	  peptidase	   4	   -­‐1.339283341	  
236892_s_at	   NA	   NA	   -­‐	   -­‐1.201225627	  
208227_x_at	   ADAM22	   ADAM	  metallopeptidase	  
domain	  22	  
7	   -­‐0.917965468	  
230197_s_at	   TPPP	   tubulin	  polymerization	  
promoting	  protein	  
5	   1.157156495	  
237390_at	   NA	   NA	   -­‐	   -­‐1.122921918	  
212806_at	   PRUNE2	   prune	  homolog	  2	  
(Drosophila)	  
9	   -­‐1.55127211	  
238018_at	   FAM150B	   family	  with	  sequence	  
similarity	  150,	  member	  B	  
2	   -­‐1.288672304	  
216887_s_at	   LDB3	   LIM	  domain	  binding	  3	   10	   -­‐0.735158481	  
244108_at	   SYNPO2	   synaptopodin	  2	   4	   -­‐1.362182941	  
203001_s_at	   STMN2	   stathmin-­‐like	  2	   8	   -­‐1.353975228	  
241412_at	   BTC	   betacellulin	   4	   1.002060116	  
207092_at	   LEP	   leptin	   7	   -­‐1.631393179	  
231452_at	   HRASLS5	   HRAS-­‐like	  suppressor	  
family,	  member	  5	  
11	   -­‐0.79705052	  
228780_at	   NA	   NA	   -­‐	   -­‐0.941476922	  
228707_at	   CLDN23	   claudin	  23	   8	   0.892999417	  
Table 3.7 Differentially expressed genes in NSE compared to SE. Chr=chromosome. 
LogFC=direction of expression change (negative sign-downregulated in NSE). Adjusted P value 
for all differentially expressed probes is < 0.01. 
I then plotted these probes with corresponding log-transformed expression values in each skin 






Figure 3.29 Heatmap of log2 expression values of differentially expressed probes with 
corresponding gene names in NSE and SE. Lighter shades of red indicate down-regulated genes 
in NSE. Blue=NSE, yellow=SE. 
3.3.2.4. Transcription changes between sun-exposed skin and actinic keratosis 
A comparison between sun-exposed skin samples and AK revealed a total of 437 differentially 
expressed probes (p value <0.0001) between the two tissue types. These probes represent 307 
unique genes. List of differentially DEG symbols along with chromosomal location, log fold 
change, p value and description is provided in Appendix 1. 
Pathway analysis of this probeset revealed 18 pathways (listed in Table 3.8) that were 
significantly overrepresented by differentially expressed probes in this dataset (p value <0.05). 
Many of those point to metabolic disruption in AK with relevance to oncogenic process (PPAR 
pathway). It is of note that given the complexity of metabolic signalling, many of metabolic 




















































































































































































Pathway	   Sample	  genes	   Adjusted	  
pvalue	  	  
3-­‐Chloroacrylic	  acid	  degradation	   ADH1B,	  ADH7	   <0.0001	  
1-­‐	  and	  2-­‐Methylnaphthalene	  degradation	   ADH1B,	  ADH7	   <0.0001	  
Metabolism	  of	  xenobiotics	  by	  cytochrome	  P450	   ADH1B,	  GSTM5	   <0.0001	  
Drug	  metabolism	  -­‐	  cytochrome	  P450	   ADH1B,	  GSTM3	   <0.0001	  
Glycolysis	  /	  Gluconeogenesis	   ENO1,	  HK2,	  	  
ADH1B	  
<0.0001	  
Calcium	  signaling	  pathway	   SLC8A1,	  PLN,	  	  
CALML3	  
<0.0001	  
PPAR	  signaling	  pathway	   SORBS1,	  FABP5	   <0.0001	  
Fatty	  acid	  metabolism	   ALDH3A2,	  ADH1B	   <0.0001	  
Tyrosine	  metabolism	   ADH1B,	  ADH7	   <0.0001	  
Retinol	  metabolism	   ALDH1A2,	  ADH1B	   0.000127	  





Adipocytokine	  signaling	  pathway	   LEP,	  LEPR,	   0.000493	  
Tetrachloroethene	  degradation	   AKR1B10	   0.001094	  
Olfactory	  transduction	   CALML3,	  CCLA3	   0.002772	  
RNA	  polymerase	   POLR3G	   0.007526	  
Neuroactive	  ligand-­‐receptor	  interaction	   NPY1R,	  LEP	   0.012941	  
Cardiac	  muscle	  contraction	   TNNC1,	  SLC8A1	   0.027266	  
Table 3.8 Significantly overrepresented KEGG pathways among differentially expressed probes 
between SE and AK. 
Calcium has been shown to induce apoptosis and found to be dysregulated in prostate cancer 
based on gene expression profiling (Lee et al., 2003a), I thereby plotted heatmap of calcium 
signalling pathway probes. As shown in Figure 3.30, most probes were transcriptionally 
decreased in AK relative to SE, and probes profiling the same gene cluster together with respect 





Figure 3.30 Probes involved in Calcium signalling pathway and their log-transformed expression 
levels in each AK/SE sample. Yellow=SE, green=AK. With the exception of 5 SE samples, the 
transcriptome corresponding to Calcium signalling pathway molecules segregated the two 
tissues. 
Analysis of GO terms has revealed a total of 166 GO terms to be significantly overrepresented by 
this probeset (P value <0.01). The full list is shown in Appendix 2, Figure 3.31 shows selected GO 


































































































































































































































































Calcium Signalling Pathway (SE, AK)














Figure 3.31 Select GO terms and a number of probes annotated with respective term. X axis = 
number of probes. 
3.3.2.5. Transcription changes between nonsun-exposed skin and actinic keratosis 
A comparison between nonsun-exposed skin samples and AK has revealed a total of 453 
differentially expressed probes (p value <0.0001) between the two tissue types. These probes 
represent a total of 292 unique genes. List of differentially DEG symbols along with chromosomal 
location, log fold change, p value and description is provided in Appendix 3. 
Pathway analysis of this probeset revealed 18 pathways (listed in Table 3.9) that were 
significantly overrepresented by differentially expressed probes in this dataset (p value <0.05). 
Similarly to probes differentially expressed between SE and AK, many are involved in various 
metabolic pathways.  
Pathway	   Sample	  genes	   Adjusted	  
pvalue	  	  
3-­‐Chloroacrylic	  acid	  degradation	   ADH1B,	  
ALDH3A2	  
9.79E-­‐14	  
Glycolysis	  /	  Gluconeogenesis	   ADH1B,	  
ALDH3A2	  
1.55E-­‐09	  
Ascorbate	  and	  aldarate	  metabolism	   ALDH3A2	   5.33E-­‐07	  
Biosynthesis	  of	  unsaturated	  fatty	  acids	   SCD	   3.66E-­‐06	  
Arginine	  and	  proline	  metabolism	   GATM,	  ALDH3A2	   2.47E-­‐05	  
Fatty	  acid	  metabolism	   ADH1B,	  
ALDH3A2	  
4.47E-­‐05	  
Arrhythmogenic	  right	  ventricular	  cardiomyopathy	  (ARVC)	   CACNB2,	  SLC8A1	   0.000313845	  
0	   5	   10	   15	   20	   25	   30	  
cell	  juncnon	  
Wnt	  receptor	  signaling	  pathway	  
epidermis	  development	  
cell	  migranon	  
inducnon	  of	  apoptosis	  by	  intracellular	  signals	  
posinve	  regulanon	  of	  MAP	  kinase	  acnvity	  
regulanon	  of	  epithelial	  cell	  diﬀerennanon	  
regulanon	  of	  MAPKKK	  cascade	  
cell	  growth	  
kerannocyte	  migranon	  
mesenchymal-­‐epithelial	  cell	  signaling	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Cardiac	  muscle	  contraction	   TNNC1,	  SLC8A1	   0.000957663	  
PPAR	  signaling	  pathway	   RXRA,	  SCD,	  
ACADL	  
0.001083604	  
Cytokine-­‐cytokine	  receptor	  interaction	   TNFSF9,	  CCL27	   0.001660786	  
Streptomycin	  biosynthesis	   HK2	   0.001663104	  
Tetrachloroethene	  degradation	   EPHX2	   0.001666642	  
Limonene	  and	  pinene	  degradation	   ALDH3A2	   0.00174582	  
Hypertrophic	  cardiomyopathy	  (HCM)	   IGF1,	  SLC8A1	   0.002730482	  
Tight	  junction	   PRKCB,	  MYH14	   0.02073146	  
1-­‐	  and	  2-­‐Methylnaphthalene	  degradation	   ADH1B	   0.02133048	  
Neuroactive	  ligand-­‐receptor	  interaction	   LEPR,	  PARD3	   0.02177456	  
beta-­‐Alanine	  metabolism	   ALDH3A2	   0.02416088	  
Table 3.9 KEGG Pathways dysregulated by differentially expressed probes between NSE and 
AK. 
Probes involved in the Tight junctions pathway are also invoved in processes directly relevant to 
oncogenesis (such as PRKCB:MAPK pathway). Heatmap depicting log transformed expression 
levels of probes involved in this pathway shows clear separation of NSE and AK based on this 
probeset (unsupervised hierarchical clustering) and relatively high differences in absolute 





Figure 3.32 Probles invovled in Tight Junctions pathway differentially expressed between NSE 
and AK. Grey=NSE, green=AK. The transcriptome corresponding to Tight junctions pathway 
molecules completely segregated the two tissues. 
GO term analysis of this set of probes revealed 206 significantly overrepresented GO terms (p 
value <0.01). The full list if provided in Appendix 4, Figure 3.33 shows a list of selected GO terms 
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Figure 3.33 Selected GO terms overrepresented among probes differentially expressed between 
NSE and AK. 
3.3.2.6. Overlap between differentially expressed genes, dyregulated pathways and GO 
terms identified in comparisons between nonsun-exposed skin and actinic 
keratosis and sun-exposed skin and actinic keratosis 
In order to find shared traits of transcriptional differences between skin and AK in general, I 
compared lists of DEG, dysregulated pathways and GO terms identified in previous comparisons. 
A total of 139 unique genes were shared by both comparison groups (45% of SE vs. AK, 47% of 
NSE vs. AK comparison). Table 3.10 lists 15 genes that are directly involved in mechanisms and 
processes relevant to oncogenesis or epidermal regulation. 
 
Gene	   Name	   Comment	   Reference	  
KRT17	   keratin	  17;	  keratin	  17	  
pseudogene	  3	  
Upregulated	  in	  oral	  SCC	   (Toyoshima	  et	  
al.,	  2008)	  
KRT16	   keratin	  16;	  keratin	  type	  16-­‐
like	  
Upregulated	  in	  keratoacanthoma	   (Ito	  et	  al.,	  2008)	  
KRT9	   keratin	  9	   Mutated	  in	  epidermolytic	  
palmoplantar	  keratoderma	  
(Lee	  et	  al.,	  
2003a)	  
KRT6B	   keratin	  6B	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regulanon	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  diﬀerennanon	  
regulanon	  of	  MAPKKK	  cascade	  
response	  to	  molecule	  of	  bacterial	  origin	  
T	  cell	  cosnmulanon	  
posinve	  regulanon	  of	  acnvated	  T	  cell	  
proliferanon	  
protein	  tyrosine	  kinase	  acnvator	  acnvity	  
regulanon	  of	  phosphorylanon	  
lepnn-­‐mediated	  signaling	  pathway	  
cellular	  response	  to	  nutrient	  levels	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S100A2	   S100	  calcium	  binding	  
protein	  A2	  
Dysregulated	  in	  lung	  SCC	   (Strazisar	  et	  al.,	  
2009)	  
S100A9	   S100	  calcium	  binding	  
protein	  A9	  
Upregulated	  in	  cSCC	   (Moubayed	  et	  
al.,	  2007)	  
VSNL1	   visinin-­‐like	  1	   TS	  in	  lung	  SCC	   (Fu	  et	  al.,	  2008)	  
S100A8	   S100	  calcium	  binding	  
protein	  A8	  
Involved	  in	  inflammation	  and	  
cancer	  
(Gebhardt	  et	  al.,	  
2006)	  
TMC8	   transmembrane	  channel-­‐
like	  8	  
Cause	  of	  epidermodysplasia	  
verruciformis;	  linked	  to	  HPV	  and	  
cSCC	  
(Patel	  et	  al.,	  
2008)	  
TMEM49	   transmembrane	  protein	  49	   Cell-­‐cell	  adhesion	  protein	   (Sauermann	  et	  
al.,	  2008)	  
SOX5	   SRY	  (sex	  determining	  
region	  Y)-­‐box	  5	  
Overexpressed	  in	  glioma	   (Ueda	  et	  al.,	  
2007)	  
FOXE1	   forkhead	  box	  E1	  (thyroid	  
transcription	  factor	  2)	  




POU2F3	   POU	  class	  2	  homeobox	  3	   Involved	  in	  keratinocyte	  
differentiation,	  enhances	  HPV	  
replication	  
(Cabral	  et	  al.,	  
2003,	  Beck	  et	  
al.,	  2007,	  
Kukimoto	  et	  al.,	  
2008)	  
DLX2	   distal-­‐less	  homeobox	  2	   Upregulation	  is	  associated	  with	  
poor	  prognosis	  in	  cancer	  
(Tang	  et	  al.,	  
2013,	  Yan	  et	  al.,	  
2013)	  	  
Table 3.10 Differentially expressed genes overlapping between NSE and SE involved in 
processes relevant to cancer or epidermal regulation. TS=tumour suppressor. 
A total of 9 pathways (50%) were shared by both comparison groups, including 1- and 2-
Methylnaphthalene degradation, 3-Chloroacrylic acid degradation, Arrhythmogenic right 
ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Fatty acid metabolism, 
Glycolysis / Gluconeogenesis, Neuroactive ligand-receptor interaction, PPAR signaling pathway 
and Tetrachloroethene degradation. However, many of these pathways were represented by only 
one or two genes hybridised by abundant number of probes withtin the dataset. 
PPAR signalling pathway was represented by entirely different set of genes in both lists: RXRA, 
SCD and ACADL in NSE vs. AK list, and by SORBS1, PPARD, FABP7 and FABP5 in SE vs. AK 
list. 
GO terms comparison has revealed 72 shared terms (35% of NSE vs AK, 43% of SE vs AK list). 
These included many immune system related terms (MHC protein binding, T cell costimulation), 
development (Wnt receptor signaling pathway, epidermis development) and cellular contact (cell 
junction, cell-cell adhesion). GO terms assigned with most probes are listed in Table 3.11. 
GO	  term	   Gene	  (NSE	  vs.	  AK)	   Gene	  (SE	  vs.	  AK)	  
Epidermis	  development	   KRT16,	  POU2F3,	  ALDH3A2,	  
KRT9,	  KRT17,	  SCEL,	  EMP1	  
KRT16,	  KRT9,	  KRT17,	  BNC1,	  
FABP5,	  POU2F3,	  ALDH3A2,	  
SPRR1A,	  SPRR3	  
Wnt	  receptor	  signalling	   CD24,	  WNT16,	  WNT5A,	   WIF1,	  CD24,	  WNT5A,	  DIXDC1,	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pathway	   GPR177,	  CTNND1	   GPR177	  
Cell-­‐cell	  adhesion	   CD24,	  CLEC7A,	  THY1,	  BCL2,	  
LMO7,	  CTNND1	  
CD24,	  CLEC7A,	  BCL2	  
Cell	  junction	   DSC2,	  FBLIM1,	  CLDN23,	  
ENAH,	  SNTB1,	  DLG2,	  GJB2,	  
GJB4,	  DSG3,	  CLDN11,	  GJB6,	  
DENND1A,	  HOMER1	  
GJB2,	  DSC2,	  ENAH,	  FBLIM1,	  
SORBS1,	  GJB6,	  DSG3,	  FBXO45,	  
CLDN11,	  HOMER1,	  RIMS3,	  
SYNM,	  DIXDC1,	  CLCA2	  
Table 3.11 GO terms with most represented probes in shared by differentially expressed genes in 
AK compared to NSE and SE. 
3.3.2.7. Comparison of transcriptional profile between immunocompromised and 
immunocompetent patients  
Comparisons between OTR and IC patients did not detect any statistically transcriptional 
differences between the groups in neither normal skin (both sun-exposed and non-sunexposed) 
or between the AK samples. 
3.3.2.8. Validation of transcriptional changes between skin and AK with quantitative PCR 
In order to validate genes detected by expression profiling microarray, independent separate 
panel of 9 AK, 5 SE and 4 NSE samples was used for quantitative PCR (QPCR) analysis (clinical 
data of this sample set is provided in Appendix 19). Genes included in the validation panel were 
ID4, CCL24, PTPN21, SLC8A1, CORIN, DLX2, TPPP, NPY1R, ADAM23, HIF1A, COMP, 
ACVR2A. 
Of these 12 genes, 6 were differentially expressed between AK and skin. CORIN was 
differentially expressed between SE and NSE (not between skin and AK). Figure 3.34 shows a 
heatmap depicting relative and absolute 2^delta Ct levels of genes that were statistically 





Figure 3.34 Heatmap of normalised Ct values and relative expression of genes used for 
expressed data validation. Relative expression is depicted next to corresponding gene. Whiskers 
= standard error, S = skin, AK = actinic keratosis, purple side colour = AK, light green = non-
sunexposed skin, dark green = sun-exposed skin. With the exception of 1 AK sample, 
unsupervised hierarchical clustering of this gene set segregated normal skin from AK. 
3.4. Discussion and future directions 
3.4.1. Chromosomal aberrations are significantly more frequent in actinic 
keratosis compared to normal skin 
In this chapter, I have shown that AK is a genetically distinct precancerous lesion that 
accumulates significantly more genomic aberrations compared to normal skin irrespective of skin 
sun exposure. Additionally, the base-pair size of aberrations in AK is significantly greater 
compared to aberrations detected in NSE and SE. The majority of SCNA detected in both skin 
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and AK are focal (short), although a full chromosomal arm loss or gain was observed in 6 patients 
in AK. This is in contrast to a large study of copy-number profiling of various cancers which 
described focal SCNAs are less frequent compared to whole-arm losses or gains (Gebhardt et al., 
2006), and also in contrast to findings in cSCC, in which losses of chromosomal arms were also 
common findings (Purdie et al., 2009). This may be due to the fact that AK is a precancerous 
lesion, and that chromosomal aberrations affecting large segments of chromosomes accumulate 
later in its development. Additionally, this may be to related to AK histological grade. 
Focal genomic aberrations detected in multiple patients were found mostly on chromosome 8 and 
9; the most common copy-number change in shared SCNAs in AK is monoallelic gain. This 
finding is largely in accordance with previous studies (Rehman et al., 1994) that detected a high 
frequency of loss of heterozygosity in AK, and described chromosome 9 as one of the hotspots 
for LOH. Additional chromosomes frequently affected by SCNA yet containing few if any 
overlapping regions of genomic imbalance included chromosomes 1, 3, 5, 6 16, and 18. 
Chromosomal aberrations on these chromosomes with the exception of chromosome 16 were 
reported in a recent study that used SNP array to detect genomic imbalances in 11 AK samples 
collected from OTR patients (Patel et al., 2008). This may be a co-incidental observation, or it 
may indicate that these chromosomes have greater propensity towards genomic instability; 
possibly due to less resistance to UV-induced damage. 
Potential genes affected by imbalances present in AK collected from at least 3 patients include 
genes located on q-arm of chromosome 9. SYK (spleen tyrosine kinase) and TSC1 (tuberous 
sclerosis 1) were shown to correspond to amplification hotspots in other neoplasms (Lee et al., 
2003a). Additionally, VAV2 (a guanine nucleotide exchange factor) was shown to activate 
RhoGTPase Rac1, CDC42 and RhoA (Tischkowitz et al., 2007), and the axis of EGFR/VAV and 
Rac1 activation has been demonstrated as critical for invasiveness in head and neck SCC (Patel 
et al., 2007). A subset of amplified genes in chromosome 9 SCNAs was described as up-
regulated in a series of urothelial carcinoma tumours (Harwood et al., 2000): ASTN2, RXRA, 
CORO2A, FUBP3 and BRD3, but our data did not find concordant expression levels of these 
genes.  GAS1 and RXRA showed consistency in transcription with gain of genomic material. 
GAS1 is a Hedgehog pathway member that functions as a tumour suppressor by inhibiting cell 
proliferation and inducing apoptosis (Nindl et al., 2006). RXRA (retinoid X-receptor α) gene is a 
member of the PPAR pathway and has been shown to play an important role in epidermial 
homeostasis and hair growth (Duncavage et al., 2009). Our data warrant further exploration of 
this gene in AK onset.  
3.4.2. Male participants have more genomic aberrations in AK compared 
to females  
Additionally, I detected statistically significant risk difference (42%) in the number of genomic 
aberration in AK collected from male participants compared to AK collected from female patients. 
This observation is most likely explicable by greater environmental exposure to UV light among 
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male participants, or by the relatively lower number of female participants in the study. I detected 
no differences in SCNA size, character or location at gender level. 
3.4.3. Transplant patients are significantly more likely to have a loss of 
genomic material compared to immunocompetent patient 
There were no differences in the number of aberrations in skin or AK based on the immune status 
which is consistent with previous findings (Purdie et al., 2009); however, there are significantly 
more genomic losses among organ transplant recipients (40%) compared to immunocompetent 
patients (20%), among whom heterozygous gains predominate. Although one previous study has 
described LOH to be lower in immunosuppressed individuals compared to immunocompetent 
patients (Rehman et al., 1997), I did not detect such a trend. This difference is most likely 
explicable by a greater precision of SNP microarrays in detecting genome-wide regions of 
genomic aberration. 57% of SCNAs detected across a plethora of human cancer previously 
corresponded to gains (Ibanez-Ventoso et al., 2008), which almost exactly corresponds with the 
distribution observed in OTR patients. Thereby the low frequency of gains observed among 
immunocompetent patients is an unusual finding that requires further validation. Should this 
observation be validated, it may reflect different immunological properties of cells with loss versus 
gain of genomic material, or a potential “snowball” effect genomic instability in case of DNA loss 
that would render such cells more readily as indesirable for an intact immune system. 
Additionally, given that transplant patients with AK and/or cSCC are on average younger 
compared to immunocompetent patient, age variation across groups may also be contributing to 
this difference. 
3.4.4. Sun-exposure does not increase the number of genomic aberrations 
in normal skin 
Additionally, I have shown that there are no statistically significant differences between sun-
exposed and non-sunexposed skin with respect to the character of genomic aberrations. Although 
shared regions of genomic changes can be identified in sun-exposed and non-sunexposed skin, 
such regions of change mostly originate in the same patient, further stressing the over-riding role 
of individual genetic background. 
3.4.5. Important differences in the character of SCNA are evident on 
individual patient level 
The most important factor in the character of SCNAs was patient origin. This finding could be 
ascribed to individual genomic instability, perhaps due to past history of sun-exposure, and 
individual propensity to either lose or gain chromosomal segments. Moreover, this may be also 
explained by chromothripsis of individual chromosomes in individual patients. In corcondace with 
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previous reports, (Zack et al., 2013), individuals with evidence of chromothripsis of one 
chromosome (such as patient 52, 45 and 15) were also likely to demonstrate chromothripsis of 
other chromosomes.  
Some individual lesions show a very high number of SCNAs and some very little or none (namely 
in AK), yet clinically these lesions are classified as equivalent - AK. Stratification by histologial 
grade of AK and patient age, skin type and self-reported history of sun-exposure may clarify 
reasons for the gargantuan interpatient variation. Yet this observation also suggests that other 
mechanisms than a chromosomal change in a specific region drive both the onset and potential 
progression of AK. This may also explain the vast differences in estimates of how many AK 
actually progress towards cSCC. 
3.4.6. Transcriptional profiling of sun-exposed and non-sun exposed skin 
reveals up-regulation of various cancer-related molecules in sun-
exposed skin 
Transcriptional differences between sun-exposed skin and non-sunexposed skin detected peptide 
convertase CORIN to be up-regulated in sun-exposed skin. This enzyme activates atrial 
natriuretic peptide (ANP) to regulate blood pressure, but also promotes trophoblast invasion and 
spiral artery remodelling and preeclampsia during pregnancy (Cui et al., 2012). Another up-
regulated gene, STMN2, is a target of beta-catenin (Lee et al., 2006a), and shown to play a role in 
liver carcinogenesis. Addtionally, both betacellulin and TPPP are regulated by the ERK pathway 
(Hlavanda et al., 2007, Fang et al., 2013), and PRUNE2 is known to play a role in tumour 
differentiation and prognosis (Fang et al., 2013). Although we did not detect differences at a 
genetic level between NSE and SE skin, significant transcriptional differences include genes 
directly relevant in the oncogenic process, suggesting that UV damage leads to transcriptional 
changes with direct oncogenic potential. The lack of corresponding genetic changes suggests that 
this may possibly be through epigenetic alterations, or that such transcriptome changes are later 
reversed through repair mechanisms. 
3.4.7. Transcriptional profiling of AK and normal skin reveals differential 
expression of genes involved in cellular contact, the Wnt and PPAR 
pathway 
A comparison of transcriptional profiling between non-sunexposed skin and AK and sun-exposed 
skin and AK revealed a total of 292 and 307 genes, with critical oncogenic pathways such as the 
PPAR pathway essential for epidermal homeostasis (Van Wynsberghe et al., 2011) affected in 
both genesets.  
Additionally, GO term analysis of both gene sets has discovered Wnt receptor signalling pathway 
dysregulation, in addition to overrepresentation of cell-cell adhesion and cell junction GO terms. 
188 
 
The Wnt receptor signalling pathway has been shown to be dysregulated in colorectal cancer 
(Budinska et al., 2013), cell-cell adhesion loss is the marker of invasiveness of epithelial cancers, 
and cell-junction repression is the hallmark of EMT. FBLIM1 is directly involved in cell motility and 
morphology (Ibragimova et al., 2013), p55 members DLG2 and DLG3 regulate epithelial cell 
polarity (Caruana, 2002). Interestingly, I also discovered differential expression of GJB2, GJB4 
and GJB6, mutations of which are involved in both hearing loss and proliferative skin disorders 
(López-Bigas et al., 2002). These data suggest that AK is a lesion in which the oncogenic process 
is initiated by dysregulating cellular adhesion and disrupting conserved regulatory pathways. 
3.4.8. Strength and limitations of current study 
The strength of our study includes paired genetic analysis of normal skin and AK samples with 
blood samples, which has been shown to be far superior to even a large group of unmatched 
controls (Heinrichs et al., 2010), and validation of transcriptional data using qPCR. 
Factors that were not directly taken into account in this study include age of participants, skin 
type, medication and anatomical location of lesions. Lesions were not collected consistently from 
a single body area, and regional differences in skin may underpin observed changes. Moreover, 
genomic changes were not validated in a separate set of samples. 
Another limitation is the low number of female participants, and the absence of a control group 
that would help elucidate the functional significance of genomic findings. 
Additionally, we could not predict which AK lesions would have progressed to cSCC as all AKs 
were completely removed for analysis.  
In conclusion, these data show that AK is a genetically highly diverse and unstable lesion, which 
shows much greater proportion of heterozygous losses in organ transplant patients compared to 
immunocompetent patients. Additionally, the oncogenic process is initiated in the progression 
from normal skin to AK via disruption of cell contacts and conserved developmental regulatory 
pathways, such as WNT pathway. 
3.4.9. Future directions 
SCNAs detected across multiple lesions and the predominance of chromosomal gains in 
immunocompetent individuals need to be validated in an independent set of AK sampels collected 
from both immunocompromised and immunocompetent patients using a different technique, such 
as FISH. A larger study with more female participants, control lesions from all participants with AK 
and control group will provide insight into the significance of focal SCNA in normal skin of AK 
patients, and additional non-precancerous skin lesions such as warts and seborrhoeic keratosis 
representing hyperproliferative but benign control lesions. Such study would provide distinction 
between SCNA that are entirely benign, relevant for keratinocyte proliferation but not conferring 
malignant potential, and AK-specific.  
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4. Gene Transcription Profiling of Actinic 
Keratosis and Cutaneous Squamous Cell 
Carcinoma  
4.1. Introduction 
As discussed in detail in Chapter 1, previous investigations focusing on unweaving the genetic 
background of cSCC have described various karyotypic changes in this tumour, yet with little 
consensus. Recent investigations from our laboratory using single nucleotide polymorphism 
microarrays revealed loss of heterozygosity at 3p and 9p sites as the most common genetic 
events in 60 cSCCs. In addition, this study has shown that clinically relevant histopatholological 
subtypes of cSCC (well differentiated, moderately differentiated, poorly differentiated) exhibit 
distinct SCNA changes (Purdie et al., 2009). However, none of the previous studies has provided 
conclusive results with respect to cSCC tumourigenesis nor pointed firmly towards novel 
therapeutic options.  
Several previous studies have used microarrays to characterise the cSCC transcriptome, but the 
results of individual studies are largely conflicting (Van Haren et al., 2009). Reasons for this may 
include the use of different methodologies or statistical approaches, as well as the heterogenous 
nature of cSCCs, which commonly show leukocyte and stromal infiltration, making molecular 
studies on tumour tissue more challenging and general findings derived from crude tumour tissue 
less interpretable.   
The purpose of this investigation was to compare the transcriptome profile of tumour cells isolated 
from cSCC tumours and dysplastic keratinocytes isolated from AKs, and to identify differentially 
expressed genes (DEG), potentially dysregulated cancer pathways, and enriched Gene Ontology 
terms within the differentially expressed genes set. In addition, I aimed to examine the association 
between expression profiles and tumour histopathology, patient gender and immune status, and 
concordance of expression changes with known genetic aberrations. I also hypothesised that 
integration of these data with SNP array profiling might identify potential targes for epigenetic 
regulation of cSCC carcinogenesis. Finally, I hypothesised that cSCC acquire stem cell-like 
transcriptional profile due to a degree of dedifferentiation present in those tumours, and that this 




4.2. Materials and Methods 
4.2.1. Histopathology of samples 
Haematoxylin-eosin (H&E) stained slides of tumours included in the study were evaluated by a 
histopathologist12 to ensure intra-observer consistency. Based on histological characteristics, 
tumours were designated as well-differentiated (WD), well-to-moderately differentiated (WMD), 
moderately-differentiated (MD), moderately-to-poorly differentiated (MD/PD) and poorly 
differentiated (PD). Additionally, two cSCC nodal metastases were included in the expression 
data series. 
4.2.2. Expression microarray hybridisation 
Ten nanograms of RNA were used as a template for whole transcriptome amplification and cDNA 
systhesis using the NuGen WT-ovation Pico RNA Amplification System according to the 
manufacturer’s instructions (NuGen, USA).  Five micrograms of amplified cDNA were labelled 
with the FL-ovation Biotin Kit (NuGen, USA) and hybridised to the Affymetrix HGU133 Plus 2.0 
microarrays (Affymetrix, USA), comprising 54,675 probes. 
4.2.3. Statistical analysis 
4.2.3.1. Quality control and data normalisation 
Quality control and data normalisation was conducted by FIOS Genomics. Standard quality 
control checks were performed on all .CEL files using the arrayQualityMetrics package in 
Bioconductor. Arrays were scored on the basis of 6 metrics: maplot, boxplot, heatmap, spatial, rle, 
nuse. Arrays not passing two or more of the quality control checks were removed; 5 of the 40 
arrays (2 AKs, 3 cSCCs) failed the quality control by these criteria and were removed from further 
downstream analysis. In addition, any features present on fewer than 20% of the arrays were 
removed, leaving 36,055 features, which were then normalised using robust multi-array averaging 
(RMA). Array features with an inter-quartile range (IQR) of <0.5 log2 intensity units were 
removed, leaving a total of 24,573 features for downstream analysis. All expression arrays (skin, 
AK, cSCC, nodal metastases) were normalised together and subsets of the normalised matrix 
were used for subsequent tissue-specific analyses. 
4.2.3.2. Detection of Differentially Expressed Genes 
Detection of differentially expressed genes was conducted by FIOS Genomics. Empirical 
Bayesian statistics were used to identify differentially expressed genes using the Bioconductor 
Limma package, taking into account multiple sampling from the same patient. Vertical p value 
                                                       




adjustment for multiple testing was applied to control for false discovery rate of 0.05. Genes with 
adjusted p value < 0.0001 were considered to be differentially expressed genes (DEG). 
4.2.3.3. Integration of expression and SNP microarray data 
Previously published SNP microarray dataset (Purdie et al., 2009) was analyzed with respect to 
loss of heterozygosity or gain of allelic copy number in defined chromosomal locations. Twenty-
one samples that were profiled in the current study were also included in the previous SNP 
experiments. SCNA changes that occurred in at least 10% of the samples (6/60) were considered 
a consistent region of allelic imbalance (Walker et al., 2006). The chromosomal position of each 
DEG was compared with the coordinates of consistent regions of allelic imbalance, and those 
genes located within this region that showed a fold-change consistent with the imbalance 
(decrease in expression in case of deletion, increase in expression in case of gain), were 
considered to correlate with SCNA changes.  
4.2.3.4. Gene set Enrichment          
Gene set enrichment analysis searches for common biological functions or pathway dysregulation 
for a given geneset. I performed pathway analysis in order to identify pathway(s) predominantly 
disrupted in the progression from AK to cSCC. Each probe was annotated with respective 
pathways it interacts with according to the Kyoto Encyclopedia of Gene and Genomes (KEGG) 
database. A chi-square test was performed on DEG using all probes as the background. Similar 
approach was applied to Gene Ontology enrichment analysis. Probes were annotated with 
respective GO terms by interrogating the GO database (www.geneontology.org) and chi-square 
test was applied analogously.  
4.2.3.5. Cluster analysis of expression profiles          
Hierarchical clustering of the samples was performed to detect profile correlation between 
samples on the DEG using distance matrix computation in R, visualising the results with heatmap 
and heatmap.2 functions in the R software. Clustering based on genome-wide transcriptional 
profiling was conducted using Pearson correlation and the VSN package. 
4.2.3.6. Correlation of expression data clinicopathological features by multiple regression 
analysis 
For statistical purposes, MD/PD and PD tumours were grouped together. The top 200 
differentially expressed probes from each tumour were combined according to histological 
stratification and ANOVA testing was applied using Graphpad software. Furthermore, multiple 
regression analysis assessing the expression profile and its correlation with histological subtype, 
immunity status and gender was applied using R. Correlation of histological typing with 
expression profiles was further validated using pvclust package 
(http://www.is.titech.ac.jp/~shimo/prog/pvclust/) in R. 
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4.2.3.7. Quantitative real-time PCR 
QPCR was conducted in collaboration with Dr Karin Purdie: altogether, 13 genes were assessed 
using quantitative real-time PCR. Quantitative RT-PCR was performed on a separate panel of 
samples to those used for expression microarray analysis. Total RNA was extracted directly from 
32 fresh frozen biopsies from 5 normal skin samples, 9 AK, 9 WD SCC and 9 MD SCC using the 
RNeasy Mini kit with on-column DNAse digestion (Qiagen, United Kingdom) according to the 
manufacturer’s instructions.  First strand cDNA was synthesised from 500ng RNA using 
Superscript III First-Strand Synthesis SuperMix, with a combination of 2.5 uM oligo dT and 
random primers (2.5ng/ul) (Invitrogen, UK).  The cDNA was diluted 1:10 prior to real-time 
quantitative PCR (QPCR) analysis.  QPCR reactions were run in triplicate on the ABI 7500 Real 
time PCR machine using 1ul of diluted cDNA and Brilliant II SYBR Green QPCR Mastermix 
(Stratagene, UK) with the two-step cycling protocol recommended by the manufacturer.  The PCR 
primers were intron-spanning with the exception of those for JUN, which has a single exon.  
Relative expression data were calculated by the equation 2∆∆Ct, using the endogenous control 
gene RPS9 as the internal reference.  Data was normalised to the mean Ct value from 5 normal 
(non-lesional) skin samples.  For each sample, cDNA synthesis was also performed in the 
absence of reverse transcriptase to exclude the possibility of genomic contamination. 
QPCR data was normalised using normal skin as a reference. Subsequent values were tested for 
normality using Shapiro-Wilk test in R and difference between AK and SCC was evaluated using 
Mann-Whitney U test. The α-level was set at P<0.05. 
4.2.3.8. Comparison with previously published dataset 
Our raw expression data were compared with previously published mesenchymal stem cells 
expression data (Tsai et al., 2007) and a comprehensive dataset assessing expression levels of 
various cutaneous samples (Riker et al., 2008).  
Additionally, a published set of 15 skin samples (11 skin samples (5 pooled), 5 actinic keratosis (2 
pooled), and 5 invasive cSCC (Nindl et al., 2006) was used for further validation of the results. 
4.2.4. Experimental design and comparison strategy 
In total, 30 fresh frozen cSCCs and 10 fresh frozen AKs were subjected to microarray expression 
profiling. These samples were obtained from a total 32 patients.  In 9 cases, cSCC samples were 
matched with AK from the same individuals.  
I then compared the genome-wide expression profile of 27 cSCC (13 WD, 1 WD/MD, 7MD, 4 
MD/PD, 2 PD) and 8 matched AKs that passed the stringent quality control (Table 4.1). The 
samples were derived from 12 immunocompetent patients, 22 organ transplant recipients (OTR) 
and 1 patient with chronic lymphocytic leukaemia, reflecting the diverse spectrum of patients 




4.3.1. Genome-wide transcription profile of AK and cSCC 
Genome-wide transcription profile of a total of 40 fresh-frozen, laser-capture microdissected 
samples was obtained using HGU133 Plus 2.0 expression microarray. Basic characteristics of the 
samples are shown in Table 4.1. 
Sample	   Histology	   Immune	  Status	   Differentiation	   QC	  
1	   AK	   OTR	   /	   Pass	  
2	   AK	   OTR	   /	   Fail	  
3	   AK	   OTR	   /	   Pass	  
4	   AK	   IC	   /	   Pass	  
5	   AK	   IC	   /	   Pass	  
6	   AK	   OTR	   /	   Pass	  
7	   AK	   OTR	   /	   Pass	  
8	   AK	   OTR	   /	   Pass	  
9	   AK	   IC	   /	   Pass	  
10	   AK	   OTR	   /	   Fail	  
11	   SCC	   OTR	   WD	   Fail	  
12	   SCC	   OTR	   WD	   Pass	  
13	   SCC	   OTR	   MD	   Fail	  
14	   SCC	   OTR	   WD	   Pass	  
15	   SCC	   OTR	   WD	   Pass	  
16	   SCC	   OTR	   WD	   Pass	  
17	   SCC	   OTR	   WD	   Pass	  
18	   SCC	   IC	   WD	   Pass	  
19	   SCC	   OTR	   WD	   Pass	  
20	   SCC	   IC	   WD	   Pass	  
21	   SCC	   IC	   MPD	   Pass	  
22	   SCC	   OTR	   MPD	   Pass	  
23	   SCC	   IC	   WD	   Pass	  
24	   SCC	   IC	   WD	   Pass	  
25	   SCC	   OTR	   WD	   Pass	  
26	   SCC	   OTR	   MPD	   Pass	  
27	   SCC	   OTR	   PD	   Pass	  
28	   SCC	   OTR	   PD	   Pass	  
29	   SCC	   OTR	   WMD	   Pass	  
30	   SCC	   CLL	   MD	   Pass	  
31	   SCC	   OTR	   WD	   Pass	  
32	   SCC	   OTR	   MD	   Pass	  
33	   SCC	   OTR	   MD	   Pass	  
34	   SCC	   OTR	   MD	   Pass	  
35	   SCC	   IC	   MD	   Pass	  
36	   SCC	   OTR	   MPD	   Pass	  
37	   SCC	   IC	   WD	   Pass	  
38	   SCC	   OTR	   WD	   Fail	  
39	   SCC	   IC	   MD	   Pass	  
40	   SCC	   IC	   MD	   Pass	  
Table 4.1. Basic characteristics and quality control outcome of AK and cSCC clinical samples 
hybridised to gene expression microarray. 9 AK are matched with cSCC, samples originated in a 
total of 32 patients. QC=quality control, OTR=organ transplant recipient, IC=immunocompetent. 
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WD=well-differentiated, WMD=well to moderately differentiated, MD=moderately differentiated, 
MPD=moderately to poorly differentiated, PD=poorly differentiated cSCC. 
In order to determine the level of correlation between the transcriptional profile of two sample 
groups (AK and cSCC), I carried out unsupervised hierarchical clustering analysis of all 
normalised probes present on the array that were expressed above the background (passed the 
flitering step). Figure 4.1 demonstrates that genome-wide transcription profile of AK and cSCC is 
generally sufficiently different to warrant comparison on gene level in order to detect differentially 
expressed genes. 1 AK sample derived from a cardiac transplant patient showed rather distinct 
transcription profile and clustered aside both groups. 1 cSCC samples clustered among 4 AK 
samples (well-differentiated sample derived from an immunocompetent patient), and 1 AK formed 
a cluster with 3 cSCC. 
 
Figure 4.1 Hierarchical clustering of AK and cSCC transcription profiles based on Pearson's 
correlation of all features present in the quantile-normalised matrix. This approach of assessing 
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pan-transcriptomic similarity between samples in its essence reveals the first component of 
principal component analysis. Majority of tumours cluster together, with the exception of one well-
differentiated tumour forming a cluster with 4 AK samples. One AK sample has a transcriptional 
profile distinct from the remaining samples. FC=AK. 
4.3.1.1. Differentially Expressed Genes between cSCC and AK 
Analysis of differential gene expression revealed 508 probes to be differentially expressed with p 
value < 0.0001. Unsupervised clustering of those probes showed almost complete separation of 
AK and cSCC (Figure 4.2). This probe-set represents 346 differentially expressed genes 
(excluding genes lacking annotation). Of these genes, 147 (42%) were down-regulated in cSCC 




Figure 4.2 Unsupervised hierarchical clustering of log2-transformed expression values of top 508 
dysregulated probes in AK and cSCC samples. With the exception of 2 tumours (1 MPD and 1 
WD cSCC), this probeset leads to a clear segregation of AK and cSCC. 
4.3.1.2. Upregulated genes are involved in cancer invasion, metastasis, epithelial-
mesenchymal stem cell remodelling and inflammation 
Heatmap of top 50 upregulated genes present among 346 differentially expressed genes based 




Figure 4.3 Heatmap of top 50 upregulated genes based on log fold-change. While differences in 
expression level across individual samples are discernible, namely in the two left-most MD and 
PD cSCC samples, the expression levels of the genes show a large consistency across the two 
tissue types. 
The group of top up-regulated genes contained several proteinases and other factors known to be 
involved in cancer invasion and metastasis, including: metalloproteinases (MMP1, MMP10, 
MMP3), which have been demostrated to play a critical role in cancer initiation and metastases 
(Suomela et al., 2009); parathyroid hormone-like hormone (PTHLH) recently shown to be a 
candidate for breast cancer susceptibility (Ghoussaini et al., 2012); osteopontin (SPP1) whose 
over-expression has been demonstrated to correlate with invasion in ovarian cancer (Matsuura et 
al., 2010) and breast cancer (Cook et al., 2006); and LAMC2 shown to enhance invasion in 
various cancers (Tsubota et al., 2010, Yamamoto et al., 2009). Other up-regulated genes 
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included INHBLA, a poor-prognosis marker in gastric cancer (Wang et al., 2010), and MET, a 
putative oncogene. 
The up-regulation of SERPINE1, PLAU and PLAUR, which are involved in angiogenesis, 
response to hypoxia, keratinocyte migration (Villar et al., 2010) and extracellular matrix 
remodelling, was of significance, since SERPINE1 binds to PLAU, thus activating PLAUR. This 
complex subsequently interacts with various integrins (Tsai et al., 2007), whose down-stream 
effectors activate ACTN1, also highly-upregulated in our dataset (Figure 4.4). This mechanism is 
involved in matrix remodelling in mesenchymal stem cells. Interestingly, significantly up-regulated 
SERPINE1, ANXA1, INHBA were shown to be highly overexpressed in mesenchymal stem cells, 
while another highly up-regulated molecule, HRH1 is expressed in differentiating mesenchymal 
stem cells (Pochampally et al., 2007), and IGF2BP2, a stem cell marker (Fong et al., 2011). 
	  




In addition to molecules described above, several pro-inflammatory cytokines were significantly 
over-expressed in our dataset, including CXCL1, an oncogene linked to several cancers including 
melanoma (Dhawan and Richmond, 2002), and IL8, whose overexpression has been linked to 
more aggressive profile of prostate cancer (Manna et al., 2013). Many genes involved in stromal 
progression of cancer and stromal remodelling were also upregulated as expected. 
The average expression of MMP1, MMP10, MMP3, INHBA, PTHLH and LAMC2 on the array is 
shown in Figure 4.5, and indicates that there is a gradient of expression across histological cSCC 
subtypes in LAMC2 expression levels, and that MPD/PD tumours show the highest range of 
expression levels of these molecules (Figure 4.5), indicating greatest transcriptional hererogeneity 





Figure 4.5 Expression of selected genes across histological subtypes of cSCC. A gradient of 




4.3.1.3. Downregulated genes include genes associated with epidermal differentiation, 
tumour suppressors, and epidermal stem cells. 
Heatmap of top 50 downregulated genes based on log fold-change is shown in Figure 4.6. It 
shows that a subset of 7 cSCC showed level of expression of these genes similar to AK (with one 
exception, all were WD tumours).  
	  
Figure 4.6 Top 50 down-regulated genes based on log fold-change. 7 cSCC tumours (5 WD, 1 
WMD and 1 MPD cSCC) adjacent to the AKs demonstrate expression levels of these genes 
similar to AKs. 
Down-regulated genes included several markers and inducers of epidermal differentiation, such 
as KRT9, FLG, FLG2, LOR, LCE1B, LCE2B, SERPINA12 and SCEL. We also found down-
regulation of several tumour suppressor genes including AZGP1, shown to act as a tumour 
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suppressor in prostate cancer by inhibiting TGB-beta mediated ERK signalling (Kong et al., 2010); 
SCUBE2, also involved in hedgehog signalling (Hollway et al., 2006); SERPINB12 which is down-
regulated in oral squamous cell carcinoma (Shiiba et al., 2010) and highly expressed in 
uppermost layer of normal epidermis; HPGD, a known tumour suppressor in various cancers 
(Mohamed et al., 2011);  IGFBP5, a tumour suppressor in head and neck SCC (Hung et al., 
2008); FRAS1 involved in epidermal adhesion (Short et al., 2007). LGR6, a marker of epidermal 
stem cells (Snippert et al., 2010), was also down-regulated in our study. The average expression 
of LOR, HPGD, FLG2, LGR6, AZGP1 and SERPINA12 is depicted in Figure 4.7. Similarly to 
highly upregulated genes, there seems to be a gradient across histological subtypes, which 





Figure 4.7 Average expression of selected down-regulated genes across different histological 
cSCC subtypes. A gradient from WD to less differentiated cSCC subtypes is apparent in the 
expression levels of FLG2, LOR, AZGP1 and LGR6. FC=AK. 
4.3.2. Transcriptional profiling of matched AK and cSCC 
A comparison between a total of 8 matched AK and cSCC pairs has revealed only 2 genes to be 
differentially expressed with the most stringent p value (<0.0001): MMP10 and PTHLH. Using a 
less stringent p value of < 0.01, 77 unique genes were shown to be differentially expressed 
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between the two tissue types. 48 of these genes (62.5%) were listed among the 346 DEG 
discovered by global comparison of the two tissue types.   
Shared genes included many of those listed among top 50 DEGs with the highest foldchange: 
ACVRA2A, ANXA1, CDH3, HN1, INHBA, ITM2A, KRT9, LAMC2, LRIG6, MET, 
metalloproteinases 1, 3, 10, PLAU, PLAUR. 
4.3.3. Correlation of histopathological classification with expression 
profile 
It was previously shown that genetic profiling of cSCC correlates with histological subtype (Purdie 
et al., 2009). I observed a similar trend in the cSCC transcriptome: as shown in Figure 4.8, which 
plots Pearson’s correlation levels between individual tumour samples based on all microarray 
probes. A cluster of 11 WD tumours and 2 MD tumours is apparent on the right, a cluster of 3 MD, 
1 MPD and 2 WD tumours is seen in the center, and a cluster of 1 WD, 2 MD, 1 MPD and 1 PD 




Figure 4.8 Unsupervised hierarchical clustering of different histological subtypes of cSCC. A 
cluster on the right contains predominantly WD cSCC, middle cluster contains a mix of 
histological subtypes, and a cluster on the left represents mostly MD/PD cSCC. For the purpose 
of this plot, all WD tumours and and 1 WMD cSCC were group into one: W(M)D.  
I then explored the statistical significance of clusters using bootstrap correlation. As shown in 
Figure 4.9, 5 unequivocal clusters are present if the whole microarray values are subjected to 
bootstrap correlation. Except for 1 WD sample in a cluster of 5 higher-grade tumours, and a WMD 
sample clustering with WD samples, as expected, those clusters reflect the histological subtype of 
tumours. 
ANOVA testing also showed that histopathological subtype affects the expression profile (p value 
< 0.0001), and this was confirmed by linear regression analysis, in which histological grade was 
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the only variable to affect expression among those in the model (histological subtype, gender and 
immune status).  
 
 
Figure 4.9 Bootstrap correlation of cSCC histological subtypes. Red frame indicates statistically 
significant clusters. 
Plotting corresponding probes between 4 histologically distinct tumours has revealed a rather 
widespread distribution of expression values between a PD and MPD tumour, unlike in 
comparison between WMD and WD tumour (Figure 4.10). Based on this plot, I suspected that 
significant transcriptional differences may exist between individual histological subtypes. These 




Figure 4.10 Log2 levels of corresponding probes in PD and MPD tumour (low correlation, left 
panel), and WMD and WD tumours (high correlation, right panel). 
Additionally, I calculated Pearson’s correlation between individual histological subtypes as the 
following: WD and MD; WD and MPD; WD and PD; MD and MPD; MD and PD; MPD and PD.  
The correlation boxplot is shown in Figure 4.11 and clearly indicates that similarity between WD 
and higher tumour grades inversely correlates with decreasing tumour differentiation. On the 




Figure 4.11 Correlation of array-wide log2 expression values between different cSCC histological 
subtypes. As tumour become less differentiated, the correlation level with WD cSCC decreases. 
Due to the low number of PD tumours in the dataset, I then regrouped the MPD/PD samples with 
PD samples. As shown in Figure 4.12, correlation level is highest between identical histological 
cSCC types (WD and WD, MD and MD), and gradually decreases as less differentiated tumours 
are correlated with WD and MD samples. P values derived with Student's t-test assessing the 
mean correlation values between each tumour subtype are shown in Table 4.2. These results 
indicate that the similarity level between different histological subtypes is significantly different. 
Subtype	  correlation	   P-­‐value	  (Student’s	  T-­‐test,	  unpaired)	  
WD|WD	  versus	  WD|MD	   0.004	  
WD|WD	  versus	  WD|MD/MPD	   <0.0001	  
MD|MD	  versus	  MD|MPD/PD	   <0.0001	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Table 4.2. P values asessing the hypothesis that correlation levels between tumours of the same 
and different histological typing are the same. These results demonstrate that the level of 
transcriptional similarity is significantly different between these groups. 
 
 
Figure 4.12 Pearson's correlation between distinct histological subtypes. MPD/PD and PD 
tumours were grouped together for this comparison. The level of similarity gradually decreases 
with the comparison of WD and MD tumours to less differentiated subtype(s). 
4.3.3.1. Transcriptional differences between distinct histological subtypes of cSCC 
Based on the results presented in previous chapter, I hypothesised there may be transcriptional 
differences in specific genes between the distinct tumour subtypes. 
The comparison of WD and MD cSCC has not detected any significantly differentially expressed 
genes after adjusting the p value. A comparison between WD and MPD-PD and PD samples 
combined revealed a total of 18 probes that are differentially expressed with the most stringent p 
value (<0.0001, Table 4.3). 
Symbol	   Description	   Chromosome	   logFC	   adj.P.Val	  
NA	   NA	   /	   2.099086068	   <0.0001	  
NA	   NA	   /	   1.337295268	   <0.0001	  
TOPORS	   topoisomerase	  I	  binding,	  
arginine/serine-­‐rich	  
9	   1.116112328	   <0.0001	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EPB41L5	   erythrocyte	  membrane	  protein	  band	  
4.1	  like	  5	  
2	   -­‐1.347575898	   <0.0001	  
NA	   NA	   /	   -­‐1.440668934	   <0.0001	  
GRAMD2	   GRAM	  domain	  containing	  2	   15	   -­‐1.872930679	   <0.0001	  
FGFR2	   fibroblast	  growth	  factor	  receptor	  2	   10	   -­‐1.977345253	   <0.0001	  
FGFR2	   fibroblast	  growth	  factor	  receptor	  2	   10	   -­‐2.012884607	   <0.0001	  
EHF	   ets	  homologous	  factor	   11	   -­‐2.051027316	   <0.0001	  
FGFR2	   fibroblast	  growth	  factor	  receptor	  2	   10	   -­‐2.205722516	   <0.0001	  
NA	   NA	   /	   -­‐2.227342478	   <0.0001	  
EHF	   ets	  homologous	  factor	   11	   -­‐2.295503521	   <0.0001	  
FGFR2	   fibroblast	  growth	  factor	  receptor	  2	   10	   -­‐2.311526316	   <0.0001	  
EHF	   ets	  homologous	  factor	   11	   -­‐2.345541049	   <0.0001	  
EHF	   ets	  homologous	  factor	   11	   -­‐2.426611372	   <0.0001	  
CNGB1	   cyclic	  nucleotide	  gated	  channel	  beta	  1	   16	   -­‐2.924659532	   <0.0001	  
PTPRZ1	   protein	  tyrosine	  phosphatase,	  
receptor-­‐type,	  Z	  polypeptide	  1	  
7	   -­‐3.744986849	   <0.0001	  
Table 4.3. Differentially expressed probes between well-differentiated tumours and moderately-to-
poorly and poorly-differentiated tumours. LogFC reflects direction of change from WD to higher 
grade tumours. 
This probeset has revealed a total of 7 genes to be differentially expressed between the tumour 
subtypes. CNGB1 was previously shown to be up-regulated in metastatic oral SCC (Mendez et 
al., 2007). Protein tyrosine phosphatases are known to play a role in cancer (Motiwala and Jacob, 
2006), and PTPRZ1 is down-regulated by ZEB1 (Rokavec et al., 2012), a known epithelial-to-
mesenchymal transition (EMT) marker, and its loss has been linked to prostate cancer 
metastases (Diamantopoulou et al., 2012). EPB41L5 has been previously linked to epithelial-to-
mesenchymal transition regulation (EMT) (Hirano et al., 2008). The only upregulated gene in the 
set, TOPORS, is known to bind to p53 and acts as a tumour suppressor (Yang et al., 2010). The 
loss of EHF expression has been shown in various invasive cancers, including bladder, oral, 
prostate and breast cancer (Mathsyaraja and Ostrowski, 2012). FGFR2 is an established 
oncogene, involved in MAPK, Ras, PI3K-Akt pathway, yet the loss of its signalling has been 
linked to EMT initiation (Diamantopoulou et al., 2012). In our dataset, FGFR2 levels gradually 




Figure 4.13. FGFR2 log2 expression levels. Black line=median. Higher_grade = MD, MPD or PD 
tumours. WD=well-differentiated. This figure shows gradual progression of FGFR2 expression 
loss during the oncogenic transformation of skin to cSCC. This was a statistically significant 
observation (p value<0.0001, ANOVA). Empty circles=outliers. 
4.3.4. Transcriptional analysis of genes relevant in stem cells 
4.3.4.1. Genes upregulated in Epidermal Stem cells 
I then hypothesised that various epidermal stem cell markers may be differentially expressed in  
cSCC compared to AK due to the dedifferentiation of malignant keratinocytes and potential 
acquisition of stem cell-like properties. This phenomenon has been previously described in 
intestinal tumourigenesis (Sauermann et al., 2008).  
Several genes that were previously shown to be involved in epidermal stem cells were present on 
the microarray. Of these, two upregulated genes were found within our top 508 probes: MAP4, a 
microtubule regulator involved in cell cycle progression, and TCF3, additionally shown to be 
indispensable for skin homeostasis (Nguyen et al., 2009). Other upregulated genes related to 
epithelial cancer stem cells included TNC (tenascin, p = 0.0001), PDPN (podoplanin, p < 0.001), 








FGFR2 log2 expression levels
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ASXL1 and RUNX1 (both p < 0.01), SOX9 (p = 0.07). The full list included MAP4, LRIG1, 
FRMD4A, PHKA2, ASXL1, C20orf111, RUNX1, TNC, SOX9, GAS6, TCF3, BMI1 and PDPN. 
When all probes for these genes present on the array were plotted as a heatmap, there was no 
visible trend in hierarchical clustering, and the majority of genes were expressed at rather low or 
mid-range levels. Interestingly, replicate probes for identical genes did not cluster together, and 
some detected expression levels at the opposite spectrum of intensity (PDPN, TCF3, Figure 
4.14). This is likely due to the presence of different transcripts of those genes. 
 
 
Figure 4.14 Heatmap of log-transformed expression levels of epidermal stem cell markers in AK 
and cSCC. Yellow=AK, black=PD, grey=WD, purple=WMD, light blue=MD, dark blue=MPD. This 
set of markers is not sufficiently differentially expressed across the two tissues to segregate those 
based on unsupervised hierarchical clustering. 
I hypothesised that because the oncogenic process has already begun in AK, the transcriptional 
differences in epidermal stem cell markers are more pronounced in the transition from normal skin 
to AK and cSCC. Thus I plotted the full set of transcription data, including expression profiling 
data from normal skin and RNALater treated AKs described in the previous chapter. The probeset 



























































































































































expression levels between skin, AK and cSCC (Figure 4.15). Additionally, most probes for 
identical genes clustered together. 
	  
Figure 4.15 Epidermal stem and cancer stem cell markers plotted across all study samples. The 
majority of skin, AK and cSCC samples formed distinct  clusters based on this probeset. Light 
green=NSE, dark green=SE, purple=AK, increasing tones of brown = increasing cSCC grade. 
To verify that the observed hierarchical clustering is not due to inherently skewed transcription 
profiles of the tissues and to exclude the posibility that any set of 36 genes would lead to identical 
clustering, I plotted randomly selected 36 probes. Unsupervised hierarchical clustering was less 



































































































































































































































Figure 4.16 Random set of 36 probes plotted across all samples. Light green=NSE, dark 
green=SE, purple=AK, increasing tones of brown = increasing cSCC grade. 
To explore the statistical significance of this observation, I used bootstrap correlation for both 
probesets to calculate if any of the clusters observed are statistically significant: using epidermal 
stem cells marker, I detected a total of 4 significant tumour clusters, 1 AK and 2 normal skin 
clusters. Using random markers, I detected no statistically significant clusters.  
I then further reduced the probeset to include probes with the most apparent gradient. Heatmap of 
this reduced probset has shown that tenascin and podoplanin are much more highly expressed in 
cSCC tumours compared to skin (Figure 4.17).  




































































Figure 4.17 Heatmap of reduced number of probes with the most prominent expression level 
gradient. Boxes highlight podoplanin and tenascin expression levels in tumours. Light 
green=NSE, dark green=SE, purple=AK, increasing tones of brown = increasing cSCC grade. 
This finding is consistent with previous reports that have shown that podoplanin is expressed in 
cSCC, and that its levels increase with increasing tumour grade (Schacht et al., 2005). Our results 
only partially confirm this trend (Figure 4.18), because the levels of PDPN suddenly drop in MPD 
and PD tumours (ANOVA comparing PDPN levels in WD, MD, MPD and PD tumours was not 




Figure 4.18 Podpolanin log2 expression levels across tissue groups. Black line indicates median. 
While PDPN levels gradually increase towards MD tumours, their levels then drop in MPD and PD 
samples. Expression level was stastistically significantly different comparing tumours to AK and 
cSCC (p value <0.0001), but not between different histological tumour subtypes. 
Tenascin C (TNC) has been shown to promote EMT in colon cancer (Takahashi et al., 2013) and 
its increasing levels were previously linked with increased level of dysplasia in AK (Lentini et al., 
2006). As shown in Figure 4.19, TNC levels increase with progression from skin to cSCC, 
suggesting that the process of EMT may contribute to the malignant process. 











Figure 4.19 Log2 expression levels of Tenascin C across our sample series. The median levels 
presented by black line in the boxplot are higher in tumours compared to normal skin and AK (p 
value=0.029, ANOVA). The difference in expression levels between tumour subtypes was not 
statistically significant (p value=0.9). 
Figure 4.17 also shows that LRIG1 levels were decreased in cSCC and a subset of AK compared 
to normal skin. Given that LRIG1 has been shown to represent a marker of epidermal stem cell 
multipotency in mouse skin (Jensen et al., 2009), this observation was contrary to my hypothesis 
that markers of stemcellness increase their expression during the progression from skin to cSCC. 
However, LRIG1 has been previously shown to be decreased in cSCC (Tanemura et al., 2005), 
and its levels inversely correlated with tumour differentiation and poor prognosis. Additionally, it 
has been suspected to be a tumour suppressor gene (Hedman et al., 2002), thus this observation 
is consistent with previous findings. 
4.3.4.2. Other stem cells markers lead to clustering of AKs and WD cSCC 
Many markers described as being related to stem cells (other than epidermal cancer stem cells) 
were also present on the array. Some of those were within our top geneset (CD 47, marker of 
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leukaemia stem cells, while some such as HAS2, umbilical cord stem cells marker, showed non-
significant upregulation (p = 0.47).  
This extended probeset of stem cell markers included CD44, EPCAM, ABCG2, BMI1, CD29, 
Nestin A, Nestin B, STAT3, ABCB1, NOTCH1, NOTCH2, NOTCH3, THY1, WNT2b, CD47, CD59, 
CD24, CD99, CD151, CD209, CD84, CD200, CD14, CD34, CDCP1, HAS2, KRT15, KRT19, 
LRG5, LRP4, MCM2, NRP1, PCNA, PTPRC, SOX10, SOX2, SOX4, SOX6, SOX7, SOX6 and 
SOX9. 
When applied to AK and cSCC samples, this probeset lead to clustering of 5/8 AK samples, and 
10/14 WD/WMD samples (Figure 4.20). 
 
	  
Figure 4.20 Log2 expression levels of stem cell markers. Black=AK, yellow=WD/WMD, 
orange=MD/MPD, red=PD. This probeset generated a cluster of 5 AK samples, and 10 WD 
samples. 
I then reapplied the same probeset to tumour samples in order to observe clustering based on 
differentiation status to confirm the trend of WD tumours to form a cluster. I expected that well-
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differentiated tumours would cluster together, and higher grade tumours would form independent 
clusters based on these markers. As shown in Figure 4.21, three clusters formed: One with 10/14 
WD and 2/7 MD, one with 2 MD, 2 MPD-PD and 1 WD samples, and one with 3 WD, 3 MPD-PD 
and 3 MD samples.  
	  
Figure 4.21 Hierarchical clustering of distinct histological cSCC subtypes based on selected stem 
cell markers. 10/14 WD cSCC form a cluster on the right, 10/13 of less-than-well differentiated 
cSCC form the two remaining clusters (chi square 0.021). 
These data suggests that – although not in quite a linear fashion by increasing from WD through 
MD to PD tumours – differences in stem cell markers expression herald progression from AK 
towards higher grade malignancies.  
Because this clustering trend was similar to that based on overall transcription profile (Figure 4.8), 
I proceeded to verify that this trend would not occur if any set of related probes was used for 
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unsupervised clustering. I used a set of 42 probes involved in Ras signalling, and as shown in 
Figure 4.22, this probeset has not generated the same clusters. 
 
Figure 4.22 Unsupervised hierarchical clustering based on probes relevant in Ras signal 
transduction. 8/14 WD tumours clusterin the top-right cluster, 10/15 cluster in the remaining gour 
clusters (p value=0.09, chi square). Green=AK, light blue=WD, grey blue=MD, sky blue=MPD, 
navy blue =PD. 
4.3.4.3. Genes associated with epithelial-to-mesenchymal transition 
Several genes associated with EMT were present on the array: ACTA2, ACTG2, CDH1, CDH11, 
CDH19, CDH22, CDH24, CDH26, CDH3, CDH5, CDH6, CLDN1, CLDN11, CLDN12, CLDN5, 
CLDN7, CLDN8, CTNNB1, CTNND1, FGFR2, FN1, KRT18, KRT8, KRT9, MUC1, OCLN, SNAI2, 
TCF3, THBS1, THBS2, THBS3, TWIST1, TWIST2, VIM, ZEB1, ZEB2. Loss of keratin 8 and 18 
represent a hallmark of EMT (Lee et al., 1993). Additionally, loss of E-cadherin represents a 
fundamental element of EMT, and SNAI2, ZEB1, ZEB2 repress its transcription by binding to E-
box sequence in its promoter, while TWIST1 and TWIST2 repress E-cadherin promoter by 


































































































































































As shown in Figure 4.23, this probeset is able to distinguish between skin, AK and cSCC, and 
generates statistically significant clusters of cSCC, AK and normal skin based on bootstrap 
correlation, suggesting that EMT markers may contribute to malignant progression in cSCC. 
 
Figure 4.23 Unsupervised clustering of skin, AK and cSCC samples based on EMT probes. Skin, 
AK and cSCC form distinct tumours based on this probeset. Light green=NSE, dark green=SE, 
purple=AK, increasing tones of brown = increasing cSCC grade. 
To explore this hypothesis further, I then looked at the mean levels of EMT markers in AK and 
cSCC subtypes (full list with mean expression values is provided in Appendix 5). E-cadherin 
(CDH1) down-regulation is a hallmark of EMT (Kang and Massague, 2004), and its expression 
level gradually decreases with increasing tumour grade in our dataset (Figure 4.24). Other 
important features of EMT such as decreased expression of claudins and occludins are also 
present in our data; claudin 11 (CLDN11) and cadherin 19, type 2 (CDH19) are differentially 
expressed  between normal skin and AK and between AK and cSCC, while FGFR2 was 
differentially expressed between AK and cSCC only. Although occludin (OCLN) has not appeared 
in skin vs. AK or AK vs. cSCC DEG genelist, mean expression levels between normal skin and 










































































































































































































































































































































Figure 4.24 EMT markers that show decreasing trend across sample series. Loss or decreased 
expression of these markers signifies ongoing EMT. One-way ANOVA results (using log2 
transformed expression values of NSE, SE, AK, WD, MD, MPD/PD for each gene as groups) 
showed statistically significant differences for CDH1, CDH19, OCLN, FGFR2, CLDN1 and 
CLDN11. 
SNAI2 (slug) is a key regulator of EMT, and its mean expression level increases during the 
progression from skin through AK to cSCC (Figure 1.25). Although the difference in expression 
levels between normal skin and AK or AK and cSCC was not significant, ANOVA testing between 
skin, WD and MD, MPD/PD-PD tumours has revealed significant difference in expression levels 























Figure 4.25 SNAI2 (Slug) mean expression level across our sample series. X axis=log2 
transformed expression values. The mean expression level gradually increases during the 
progression of skin to cSCC. 
TWIST1, MUC1 and ZEB2, all important EMT markers, increased their mean expression levels as 
tumour grade increased, yet ANOVA test has revealed that this is not a statistically significant 
observation (p value >0.05).  
4.3.5. QPCR Validation 
To validate the findings of the microarray analysis, thirteen genes were confirmed as either up- or 
down-regulated by quantitative real-time (qRT) PCR using an additional set of cSCC samples.  
These included both downregulated genes (ACVR2A and ID4) and upregulated genes (ADAM10, 
ADAM17, AKT1, ANXA1, INHBA, JUN, MET, MMP10, PAK2, PLK and PTHLH).  In all cases, 
qRT-PCR showed statistically significant up- or downregulation between normal skin and cSCC, 
which was consistent with the microarray findings, suggesting a high level of reliability for the 
genes identified by the array.  In particular, oncogenes JUN, MET and PAK2 were all confirmed to 
be overexpressed in cSCC.  










Figure 4.26 Differential expression of selected genes between AK and cSCC with QPCR. Y axis = 
normalised relative expression. Bold line=median. WD=well differentiated, MD=moderately 
differntiated cSCC, SCC=combined WD and MD values. 
 








































































4.3.6. Gene Enrichment Analysis 
4.3.6.1. Pathway analysis 
KEGG Pathway analysis of the 508 differentially expressed probes showed the enrichment of 36 
pathways (Table 4.4). Among the enriched pathways were several putative oncogenic pathways 
including MAPK, ErbB signalling pathways, TGF-beta pathway, several metabolic and 
biosynthesis-related pathways, and pathways involved in cell-cell interactions such as adherens 
junctions, focal adhesion and tight junctions.   
KEGG	  Pathway	  ID	   Pval	   Adj.Pval(FDR)	  
Epithelial	  cell	  signaling	  in	  Helicobacter	  pylori	  infection	   <0.0001	   <0.0001	  
Carbon	  fixation	  in	  photosynthetic	  organisms	   <0.0001	   <0.0001	  
Cytokine-­‐cytokine	  receptor	  interaction	   <0.0001	   <0.0001	  
Glycolysis	  /	  Gluconeogenesis	   <0.0001	   <0.0001	  
Adherens	  junction	   <0.0001	   <0.0001	  
Focal	  adhesion	   <0.0001	   <0.0001	  
Biosynthesis	  of	  alkaloids	  derived	  from	  ornithine	   <0.0001	   <0.0001	  
Lysine	  and	  nicotinic	  acid	   <0.0001	   <0.0001	  
Colorectal	  cancer	   <0.0001	   <0.0001	  
Biosynthesis	  of	  alkaloids	  derived	  from	  shikimate	  pathway	   <0.0001	   <0.0001	  
Biosynthesis	  of	  phenylpropanoids	   <0.0001	   <0.0001	  
Biosynthesis	  of	  alkaloids	  derived	  from	  histidine	  and	  purine	   <0.0001	   <0.0001	  
Renal	  cell	  carcinoma	   <0.0001	   <0.0001	  
Biosynthesis	  of	  terpenoids	  and	  steroids	   <0.0001	   0.000120652	  
Hematopoietic	  cell	  lineage	   <0.0001	   0.000156804	  
Biosynthesis	  of	  alkaloids	  derived	  from	  terpenoid	  and	  polyketide	   <0.0001	   0.000557965	  
Melanoma	   <0.0001	   0.000685036	  
Complement	  and	  coagulation	  cascades	   <0.0001	   0.000708776	  
Fatty	  acid	  biosynthesis	   0.00014198	   0.000963969	  
Endocytosis	   0.00016526	   0.001065927	  
Adipocytokine	  signaling	  pathway	   0.00018528	   0.001138149	  
Pathways	  in	  cancer	   0.00021031	   0.001191007	  
PPAR	  signaling	  pathway	   0.00021235	   0.001191007	  
ECM-­‐receptor	  interaction	   0.00026501	   0.001373592	  
Biosynthesis	  of	  plant	  hormones	   0.0002662	   0.001373592	  
MAPK	  signaling	  pathway	   0.00037278	   0.001849562	  
Vitamin	  B6	  metabolism	   0.00062582	   0.002853436	  
ErbB	  signaling	  pathway	   0.00062665	   0.002853436	  
Pyrimidine	  metabolism	   0.00064147	   0.002853436	  
TGF-­‐beta	  signaling	  pathway	   0.00096778	   0.004161454	  
Vibrio	  cholerae	  infection	   0.0020501	   0.008531061	  
Toll-­‐like	  receptor	  signaling	  pathway	   0.0025301	   0.01019947	  
Atrazine	  degradation	   0.0043247	   0.01690565	  
SNARE	  interactions	  in	  vesicular	  transport	   0.0056832	   0.02156273	  
Metabolic	  pathways	   0.0060293	   0.02222228	  
Tight	  junction	   0.013217	   0.04736092	  
Table 4.4. Significantly dysregulated pathways in our probeset. 
Because many molecules are involved in several pathways, I calculated the percentage of 
overlap between each pathway by calculating the number of overlapping genes between each 
pathway and dividing it by the total number of genes. As shown in Figure 4.27, there was a 
significant overlap between various metabolic pathways, in addition to an overlap between 
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Pathways in cancer and Endocytosis, Colorectal cancer, Focal adhesion, Adherens junction and 
Epithelial cell signalling in H. pylori. 
 
Figure 4.27 Percentage of overlap between individual pathways in genes represented in those 
pathways. The highest level of overlap is shown between various metabolic pathways. 
4.3.6.2. TGF-beta pathway 
TGF-β pathway plays a critical role and cell proliferation and differentiation, and its disruption can 
have both tumour-promoting and tumour-suppressive effects (Derynck et al., 2001). Additionally, 
mutations in TGFBR1 have been identified in multiple self-healing squamous epithelioma 
(Ferguson-Smith disease), a rare form of familial skin cancer that causes spontaneously 
regressing cSCCs (Reinhart et al., 2000). Figure 4.28 illustrates up- and down-regulated genes 































































































































































































































































































































































































































































































































































Figure 4.28 Dysregulated TGF-beta pathway members with corresponding p value, chromosome, 
fold change and average expression. Up-regulated genes were generally more significantly 
dysregulated compared to down-regulated genes. Average expression=log2 transformed 
expression values, p value=log10 transformed p value (the wider the band, the more significant 




A detailed look at mechanistic links in TGF-beta signalling reveals significant down-regulation of 
IL4, a putative tumour suppressor gene (Cabral et al., 2003), significant up-regulation of JUN 
oncogene (Figure 4.29). 
 
Figure 4.29 TGF-beta pathway members and their respective p values and fold change in cSCC. 
This figure represent KEGG-annotated TGF-beta pathway members and their interactions. Grey 













































































































indicate stimulation/upreguation, black dots indicate inhibitory effect of the linked gene. This 
schema provides an overview of mechanistic links between TGF-beta pathway members and 
various critical cellular regulators including oncogens (JUN) or tumour suppressors (IL4). 
4.3.6.3. RAS/MAPK pathway 
This well-characterised signalling pathway plays a critical role in development (Sundaram, 2006), 
and its dysregulation has been linked to a variety of malignant tumours (Dhillon et al., 2007). 
Figure 4.30 shows upregulation of MYC (c-Myc), as downstream oncogenic effector of this 
pathway in our dataset, possibly due to RRAS2 signalling and PRKCA and PRKACA 
upregulation. Protein kinase C-α (PRKCA) is an EMT promoter (Kyuno et al., 2013), and protein 
kinase, cAMP-dependent, catalytic, alpha (PRKACA) has been previously shown to upregulate c-
Myc through PLK1 (Padmanabhan et al., 2013). This pathway is not dysregulated in SE and NSE 




Figure 4.30 Ras/MAPK pathway signalling with corresponding p value and fold change in cSCC of 
relevant molecules in our dataset. This figure represent KEGG-annotated TGF-beta pathway 
members and their interactions. Arrows indicate stimulation/upreguation, black dots indicate 
inhibitory effect of the linked gene. Significantly dysregulated genes are marked with a black, 
arrow-like shape. This schema provides an overview of mechanistic links between the RAS 













































































































































































































































































4.3.7. Integration of expression changes with previously detected genetic 
aberrations 
Previous microarray studies of cSCC have not systematically correlated gene expression with  
copy number changes.  To address this, regions of copy number aberration previously identified 
in a high resolution SNP microarray study of cSCC in our laboratory in a seriesof 60 cSCC 
(Purdie et al., 2009) were used to identify up- or downregulated genes located in regions of 
common (10% or greater) amplification or deletion, respectively. Table 2.2 provides an overview 
of genes that were found within a location of previously detected SCNA. Of 346 DEG, 236 (68%) 
could be localised within a region of SCNA. Of these, 145 (57%) genes significantly dysregulated 
at the expression level were found to be in corresponding regions of somatic copy number 
change and are highlighted in table 2.2.   
Regions with the highest concordance between genetic aberration and expression change 
included 1pter-1p32.3 (88%), 7pter-7pcen (85%), 11q12.2-11q13.4, 13qcen-13qter, 14q11.2-
14q13.1, 18q12.1-18qter (all 100%) and 19pter-19pcen (87.5%). Conversely, low concordance 
was observed in regions 9pter-9pcen (12.5%), 15qcen-15q15.3 (0%), 19pter-19p13.2 (20%) and 
19qcen-19q13.33 (14%). It is plausible that regulation of expression within these regions may be 
subject to epigenetic regulation. 
 
Location	   SCNA	   No.	  of	  
samples	  
Genes	  
1pter-­‐1p32.3	   G	   6	   SH2D5	  CAP1	  ENO1	  LRRC42	  SNRNP40	  KTI12	  SRM	  
CLIC4	  ZNF593	  LOC727770	  MFAP2	  FBLIM1	  PLOD1	  
SLC9A1	  SPATA6	  KIAA0090	  TCEB3	  
1qcen-­‐1qter	   G	   8	   LGR6	  LAMC2	  ZNF281	  ISG20L2	  S100A11	  NME7	  LCE1B	  
LOR	  SLC30A1	  C1orf74	  C1orf96	  FLG	  FLG2	  S100A10	  
SHC1	  SERTAD4	  PPPDE1	  UCK2	  XPR1	  PFDN2	  RGS5	  
SLC30A1	  RAB3GAP2	  DEGS1	  CAPN8	  LCE2B	  TAGLN2	  
2q21.2-­‐2qter	   L	   6	   DAPL1	  IGFBP5	  ACVR2A	  SLC16A14	  KLF7	  ZAK	  DTYMK	  
CACNB4	  FRZB	  TANC1	  NRP2	  	  
3qcen-­‐3qter	   G	   23	   BOC	  PDIA5	  APOD	  AADACL2	  IGF2BP2	  C3orf57	  
GRAMD1C	  CD47	  TNFSF10	  RUVBL1	  FNDC3B	  PAK2	  SGEF	  
IL1RAP	  PPM1L	  TMEM45A	  





L	   6	   HS3ST1	   WDR1	   ATP8A1	  
	  






G	   12	   PDZD2	  ADCY2	  TARS	  TRIP13	  CCT5	  TRIO	  PRLR	  LPCAT1	  
SEPP1	  




6pter-­‐6p21.1	   G	   6	   ID4	  SERPINB1	  TMEM170B	  KIAA1949	  CMAH	  	  KIAA0240	  
7pter-­‐7pcen	   G	   8	   AZGP1	   INHBA	   GNA12	  H2AFV	   UPP1	   HEATR2	  	  	  YKT6	  
7qcen-­‐7q11.22	   G	   6	   	  
8pter-­‐8pcen	   L	   14	   LONRF1	  PROSC	  EIF4EBP1	  CTSB	   ADAM9	  	  LZTS1	   NRG1	  
EGR3	  BMP1	  
8qcen-­‐8qter	   G	   11	   FAM83A	   PDP1	   MATN2	  
	  
9pter-­‐9pcen	   L	   23	   ANXA1	  GGTA1	   LRRC8A	  MAPKAP1	  CTSL1	  PRPF4	  VAV2	  
C9orf30	  
9qcen-­‐9q21.11	   L	   6	   TYRP1	   B4GALT1	  
	  
9qcen-­‐9qter	   G	   15	   TYRP1	   B4GALT1	  
	  
10pter-­‐10qter	   L	   7	   FAM13C	  PLAU	   PDCD4	   KLF6	   NCRNA00081	  FGFR2	  
LOC283070	   SORBS1	   NOLC1	  ACADSB	  
11pter-­‐11pcen	   L	   8	   C11orf17	   SCUBE2	  BBOX1	  NRIP3	  
11q14.1-­‐11qter	   L	   6	   MMP10	   SIDT2	   MMP1	   MMP3	   CADM1	  CDON
	   SIDT2	   ELMOD1	  
11q12.2-­‐
11q13.4	  
G	   6	   RPS6KA4	   STIP1	  












G	   6	   	  
16p13.11-­‐
16pcen	  
L	   6	   GDE1	   IL4R	   VKORC1	  
	  	  
17pter-­‐17qter	   L	   7	   GAS7	  HN1	  HLF	  KRT9	  RHOT1	  SLC16A3	  CSNK1D	  MBTD1	  
ZNF652	  VAMP2	  KRT10	  THOC4	  SKA2	  SPHK1	  KRT23	  
18q12.1-­‐18qter	   L	   6	   SERPINB1	   BCL2	   KIAA1632	  
	  
19pter-­‐19p13.2	   L	   6	   DAPK3	  ACER1	  TCF3	  LMNB2	  SBNO2	  




L	   6	   PVR	  PLAUR	  CD3EAP	  GLTSCR2	  FTL	  EHD2	  ZNF114	  
19q13.31-­‐
19qter	  
G	   6	   GLTSCR2	  FTL	  EHD2	  ZNF114	  
20pter-­‐20qter	   G	   6	   PCSK2	  SDC4	  CDC25B	  NOP56	  PTPN1	  TPD52L2	  RAB22A	  
22q11.23-­‐
22qter	  
L	   6	   MYH9	  YWHAH	  ZBED4	  APOBEC3A	  SOX10	  BPIL2	  
22qcen-­‐22qter	   G	   11	   RANBP1	  MYH9	  YWHAH	  ZBED4	  APOBEC3A	  SOX10	  
CDC45L	  BPIL2	  
Xp22.33-­‐Xqter	   G	   6	   ITM2A	  PLP1	  SMS	  GNL3L	  PGK1	  PCTK1	  AR	  ATP7A	  
Table 4.5. Integration of genetic changes and expression profiling. Bold genes show concordant 
direction of expression change with copy-number change. 




Figure 4.31 Ideogram of differentially expressed probes with known chromosomal location and 
respective fold change. This figure depicts regional differences in differential gene expression. For 
example, differentially expressed genes on chromosome 13 were all down-regulated, while genes 
on distant p-arm of chromosome 1 were consistently upregulated. On chromosome 18, genes 
located on the p-arm are up-regulated, while chromosomes on the q-arm are donwregulated. 
4.3.8. Comparison with previously published datasets 
4.3.8.1. Comparison with skin and non-melanoma skin cancer expression profiling data 
To validate the specificity of 508 differentially expressed probes detected in our dataset, I used an 
independent previously published dataset (Riker et al., 2008) that consisted of 4 normal skin 
samples, 15 basal cell carcinoma samples, and 11 cSCC samples.   
Unsupervised hierarchical clustering of this dataset post-normalisation showed clustering of 3 




Figure 4.32 Unsupervised hierarchical clustering of normal skin (NS), cSCC and BCC samples 
(previously published dataset). 
I then used the set of 508 probes for cluster analysis of the normalised data, which lead to a 
complete separation of the 11 SCC samples from 4 normal skin samples (Figure 4.33). 
 
Figure 4.33 Clustering of an alternative sample set based on our top differentially expressed 
probes. Normal skin forms an entirely separate cluster based on these data, while in the previous 
figure, it clusters with 3 cSCC samples. 
A comparison with another published dataset (Nindl et al., 2006) consisting of 5 cSCC samples 
and 3 AKs has shown that while overall transcriptional profile of these lesions is unable to 
distinguish between them on a cluster level (Figure 4.34), the top 508 probes derived from our 
dataset lead to clustering of 2/3 AK samples, further confirming the specificity of this probeset. 
 
Figure 4.34 Hierarchical clustering of 8 samples from a previously published dataset. This 




Figure 4.35 Clustering of dataset presented in the previous figure based on top 508 differentially 
expressed probes detected in our dataset. This probeset leads to a cluster formation of 2/3 AK 
samples. Given the low number of samples, it is not possible to assess statistical significance of 
this observation. 
4.3.8.2. Comparison with stem cell data 
I hypothesised that cSCC acquire partial stem-cell like transcriptional profile, and due to higher 
degree of dedifferentiation present in MD and PD histological subtypes, I hypothesised that such 
property would be more pronounced in less differentiated cSCC. I thereby compared the 
expression levels of 4 different mesenchymal stem cells (bone marrow, cord blood, amniotic fluid 
and amniotic membrane) with cSCC expression levels, and calculated the correlation between 
these. The highest correlation between the overall expression profile was with bone marrow stem 
cells (67.2%) and the lowest with amniotic membrane (66.4%). Although this difference was 
significant (p = 0.04, Wilcox test), ANOVA testing for all correlation values did not reach 




Figure 4.36 Correlation between four different MSC (amniotic fluid-AF, amniotic membrane-AM, 
cord blood-CB and bone marrow-BM MSC) and cSCC. BM MSC show the highest correlation. 
q=outliers. 
Pearson’s correlation of MSC with cSCC lead to 2 clusters of cSCC (Figure 4.37). The left cluster 
(samples which show higher correlation with MSC) contains only 2 WD samples, while the right 





Figure 4.37 Pearson’s correlation between MSC and cSCC transcriptional profile. Two clusters 
are formed, and the left cluster which shows higher levels of correlation contains significantly 
more less differentiated tumours. 
4.4. Discussion and future directions 
In this study, we compared the transcriptome profile of tumour cells isolated from cSCC tumours 
and dysplastic keratinocytes isolated from AKs, and identified differentially expressed genes 
(DEG) using gene expression microarrays. We validated the microarray data with an additional 
set of samples using QPCR.  
I explored potentially dysregulated cancer pathways in the transition from AK to cSCC, and I 
examined the association between expression profiles and tumour histopathology, patient gender 
and immune status, and concordance of expression changes with known genetic aberrations. 
Additionally, I demonstrated that cSCC acquire stem cell-like transcriptional profile, and that 
transcriptional correlation with mesenchymal stem cells is significantly more pronounced in less 




4.4.1. Genome-wide transcription of cSCC and AK revealed 346 
differentially expressed genes 
Analysis of differential gene expression revealed 508 probes to be differentially expressed with p 
value < 0.0001, and this probe-set represents 346 differentially expressed genes, of which 147 
(42%) are down-regulated in cSCC compared to AK, while 199 genes (58%) are up-regulated. 
4.4.2. Transcriptome profiles reflect histological subtypes of cSCC   
Histological typing of various tumours is not only of prognostic value, but is associated with 
distinct clinical characteristics and biological behaviour of cSCC. Our data show that the 
histopathological distinction between cSCC subtypes is not merely morphological, but is 
accompanied by a variation in expression profile. Taking into account previously published data 
from our group and others demonstrating distinct genetic profiles of high grade cSCCs (Purdie et 
al., 2009), it is likely that different histological grades of cSCC represent distinct disease subtypes 
and may require tailored therapeutic approaches based on their molecular profile. Such profiling 
may prove especially useful in the administration of targeted inhibitors.  
4.4.3. Pathway Analysis pinpoints TGF-β and MAPK pathway as potential 
mediators of AK to cSCC transition 
Enrichment studies of these data have detected several pathways to be dysregulated in cSCC, 
including pathways previously implicated in cancer. The TGF-β pathway has been previously 
shown to play a key role in the onset of various cancers and its pro- or anti-oncogenic role has 
been demonstrated to be highly context-dependent (Kukimoto et al., 2008) (Ueda et al., 2007). In 
addition, it has been demonstrated that this pathway promotes invasion and metastases via 
epithelial-mesenchymal transition (Miyazono, 2009), and has been linked to skin cancer in mice 
model (Eichberger et al., 2004). The BMP segment of TGF-beta pathway is consistently down-
regulated in our data, while the TGF-beta-SMAD signalling part shows expression level 
inconsistencies, but ultimately leads to up-regulation of JUN and MYC oncogenes. ID4, a putative 
tumour-suppressor (Cabral et al., 2003) (Beck et al., 2007), was highly down-regulated in our 
dataset. ID2 down-regulation has been shown to lead to EMT induction by E-cadherin down-
regulation (Yan et al., 2013), and similar mechanism may relate also to ID4, although data 
describing this mechanism are so far lacking.  
In epidermis, TGF-beta signalling has been linked to EMT via HEY1 activation (Zavadil et al., 
2004), but the expression levels of HEY1 in our dataset shows no significant difference. Although 
the role of TGF-beta in in multiple self-healing squamous epithelioma (Ferguson-Smith disease), 
has been previously characterised (Reinhart et al., 2000), the role of this pathway in sporadic 
cutaneous squamous cell carcinoma has not been fully clarified yet, and our data warrant further 
studies of TGF-beta signalling involvement in AK to cSCC transition. 
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The role of MAPK/Ras signalling pathway in cSCC has been previously implicated (Barnes et al., 
2003); and recent clinical data indicate that a crosstalk between Ras and MAPK pathway may be 
responsible for cSCC development in patients treated with BRAF inhibitors (Su et al., 2012a). Our 
data suggest that EGFR, RRAS2, PRKCA and PRKACA upregulation may lead to increased c-
Myc activity, and this regulation is strongly tumour-intrinsic and absent in normal skin to AK 
progression. 
Erbb pathway has also been shown to be linked to EMT transition via MMP9 upregulation, and 
MET overexpression, a molecule which subsequently leads to EMT. MET and MMP3, both linked 
to EMT, were unequivocally upregulated within the top 508 probes, and MMP9 was upregulated 
in our data (p= 0.003). So far, there are only anecdotal data describing EMT in cSCC (Nakamura 
and Tokura, 2011), and since many additional cell-cell contact pathways are disrupted according 
to our data (Adherens Junctions, Tight Junctions), which are important in EMT,  our data warrant 
further studies of this process in cSCC pathogenesis. 
4.4.4. The role of stem cells markers in AK to cSCC transition 
I detected up-regulation of several genes previously shown to be highly up-regulated in 
mesenchymal stem cells (PLAU, PLAUR, ANXA1, INHBA, SERPINE1, HRH1, IGF2BP2). I also 
showed that various markers of epidermal differentiation such as KRT9, FLG, FLG2, LOR, 
LCE1B, LCE2B, SERPINA12, or SCEL were significantly down-regulated in cSCC samples. 
These data suggest that the oncogenic process of AK transition into cSCC involves several 
degrees of de-differentiation, and that keratinocytes undergo at least partial epithelial-to-
mesenchymal transition (EMT). Although neither TWIST1, SNAI2 nor ZEB1 were significantly 
differentially expressed in our dataset, all showed a trend towards up-regulation with increasing 
cSCC grade. Additional genes involved in EMT (claudin 11 [CLDN11] and cadherin 19, type 2 
[CDH19]) shown consistent down-regulation in progression from normal skin to cSCC, which was 
statistically significant.   
When assessing the expression level of epidermal cancer stem cells-related molecules, several 
genes previously shown to be upregulated in cancer stem cells were also significantly up-
regulated in our dataset (MAP4, PDPN, Tenascin, RUNX1), which indicates that their 
upregulation may not be epidermal cancer stem cells specific. Other markers such as AXL tyroine 
kinase showed no significant difference between AK and cSCC (p= 0.46). 
Various other stem cell markers were present on the array and their expression levels are clearly 
tissue-specific, since 5 AKs form a cluster separating these from cSCC, and WD tumours also 
form a separate cluster when expression levels of stem cells markers are compared. 
When assessing the similarity between expression profile of cSCC and 4 different mesenchymal 
stem cells, bone marrow derived stem cells show the highest similarity. The level of similarity to 
mesenchymal stem cells is relatively consistent across WD tumours, and seems to be 
consistently higher among higher-grade tumours. 
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Taken together, these data suggest that malignant keratinocytes gain partial stem cells 
properties, which may then at least partially drive their malignant profile.  
4.4.5. Integration of SCNA and gene expression data  
Expression data were integrated with known regions of genomic imbalance in cSCC, and 
revealed regions with the highest concordance between genetic aberration and expression 
change, including 1pter-1p32.3 (88%), 7pter-7pcen (85%), 11q12.2-11q13.4, 13qcen-13qter, 
14q11.2-14q13.1, 18q12.1-18qter (all 100%) and 19pter-19pcen (87.5%). Conversely, low 
concordance was observed in regions 9pter-9pcen (12.5%), 15qcen-15q15.3 (0%), 19pter-
19p13.2 (20%) and 19qcen-19q13.33 (14%). Previous works integrating copy-number variation 
and gene expression profiling in various malignancies reported various levels of concordance 
between the loss or gain of genomic material and corresponding gene expression. A study of 
myelodysplastic syndrome, a group of premalignant conditions with high risk of malignant 
transformation reported a various range of altered gene expression and copy-number variation 
correlation, ranging from 0% to 100% (Jensen et al., 2009). Another study of multiple myeloma, 
reported a very high correlation between genomic LOH and gene expression changes (Lu et al., 
2005), which suggests that the level of correspondence between expression and copy-number 
variation data is likely tumour specific, and possibly depends on selected methodology. 
With respect to regions identified as demonstrating low correlation in our dataset, it is plausible 
that regulation of expression within these regions may be subject to epigenetic regulation, either 
due to changes in methylation or miRNA expression. Alternatively, this may be explicable by 
comparing expression data with SNP array data from only partially matching tumours. 
4.4.6. Therapeutic implications 
Significantly dysregulated genes identified in this study include several  which are already being 
targeted therapeutically in other malignancies. For example, several oncogenes are up-regulated 
in cSCC compared to AK; inhibitors to PLK are currently being tested in clinical trials (Degenhardt 
and Lampkin, 2010), and MET inhibitors in pre-clinical studies (Tu et al., 2010). Additionally, 
ADAM10 and ADAM17 are important in maintaining epidermal homeostasis via EGFR signalling, 
and the over-expression of both molecules has been previously linked not only to various types of 
cancer, but also to various skin conditions including atopic dermatitis (ADAM10), and psoriasis 
(ADAM17) (Tanemura et al., 2005). This observation likely links both molecules with more general 
processes such as inflammation and keratinocyte proliferation, rather than specifically with 
malignant transformation. Both molecules show a high degree of similarity in their catalytic site 
structure with other metalloproteinases (MMPs). Although clinical trials of metalloproteinase 
inhibitors have proved unsuccesful to date, further selective inhibitors are being developed (Saftig 
and Reiss, 2011). Once those molecules are available, cSCC represents a relevant candidate for 
preclinical testing based on our results. In addition, many pro-metastatic molecules were up-
regulated in our dataset, such as PTHLH / osteopontin (SPP1), representing attractive therapeutic 
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targets in advanced disease and in prevention of metastatic disease spread. Simultaneous 
inhibition of VEGF and osteopontin has already been proved beneficial in hepatocellular 
carcinoma during in vitro testing (Kou et al., 2010). 
Aurora kinases are serine/treonine protein mitotic kinases that play an improtant role in different 
stages in cell division. So far, aurora kinase family inclues Aurora A, B and C, and all members 
are highly conserved across species. RCC2 (Regulator of chromosome condensation 2) is a 
passenger protein that is involved in alignment of chromosomes on the spindle and centromeric 
targeting of the chromosome passenger complex (Humphries et al., 2009). It is also important in 
Aurora B activation (Rosasco-Nitcher et al., 2008).  
In our expression data, we found a significant upregulation of RCC2 (4.5 fold upregulation, 
pvalue= 0.0004), also, upregulation of Aurora B (3.25 fold upregulation, p value =0.01). 
Additionally, Aurora B is regulated by INCENP that was also upregulated (4.26 fold upregulation, 
p value = 0.0009). Aurora A was also upregualted in our dataset (4.1 fold upregulation, p value = 
0.001). Those data suggest that Aurora kinases are significantly upregulated in cSCC compared 
to AK, and given that there are now available targetted therapies for Aurora kinases that are being 
clinically tested, these represent ideal targets for futher exploration in cSCC with strong 
translational potential. 
4.4.7. Strengths and limitations of our study 
The main advantage of our study is that the transcriptional profile is derived almost exclusively 
from malignant cells and dysplastic keratinocytes isolated from tumours and AKs using 
meticulous laser-capture microdissection. Thus, potentially misleading expression levels from 
stromal leukocytes or non-tumour blood vessel cells should be minimised in our dataset. Although 
our QPCR validation was conducted on non-microdissected samples, it has consistently 
confirmed the expression pattern of our microarray data, yet the levels of transcription differences 
were not as striking as on the array, which may be attributable to the admixture of non-malignant 
cells in the validation samples. 
Limitations of the study include relatively low number of AKs and also the fact that these AKs 
were surgically removed before their actual progression into cSCC, thus it is uncertain whether 
their  molecular features  would enable progression into malignant entities. Additionally, paired 
comparison of 8 AKs and 8 cSCC has shown much more limited numbers of DEG, which is 
possibly due to the low number of samples, or due to more even balance of the two samples. 
Also, the relatively low number of higher grade cSCCs (MD, MPD and PD) has made it difficult to 




4.4.8. Summary and conclusions 
Detailed understanding of molecular changes of AK transition to malignant cSCC has been 
lacking despite previous attempts to elucidate this process. In this study, we show that a complex 
series of changes occur at the molecular level during this progression, and involve dysregulation 
of several hundreds of genes. Specifically, dysregulation of several oncogenic, metabolic and 
regulatory pathways alongside disrupted expression of several tumour suppressors and over-
expression of many oncogenes is involved in this progression.  This study also shows the overall 
transcription profile of cSCCs differs based on tumour histology, irrespective of the gender or 
immune profile. 
In conclusion, our data highlight several known oncogenic targets, as well as potential novel 
factors involved in this process (epidermal stem cell markers, EMT genes). It has uncovered a 
broad spectrum of disrupted molecular pathways and processes that are involved in this 
transition. In particular, it suggests that malignant cells undergo de-differentiation, acquiring an 
expression profile that leads to differences in expression of stem cells markers between 
precancerous and tumour lesions. Finally, our study confirms at the transcriptome level our 
previous data showing distinct genotype of various histopathological subtypes of cSCC.  
4.4.9. Implications for future research  
This study has provided unprecedented insight into trascriptional events in cSCC and has pointed 
towards potential regions of epigenetic regulation in the cSCC cancer genome, therapeutic 
targets and avenues for miRNA profiling. Exploration of these areas is discussed in the following 
chapters. 
Additionally, the correlation of less differentiated cSCC samples with mesenchymal stem cells 
warrants validation with a larger set of MD, MPD and PD tumours and an additional set of 
mesenchymal stem cells. Identification of a “stem cell signature” may provide insight into the 
molecular background of shared cellular properties of MSC and cSCC tumours.  
Our data also indicate that EMT plays an important role in the progression from skin to AK and 
then in less differentiated tumours. Conditional knock-down of the SNAI2 gene identified in our 
data as relevant in this process in both normal human keratinocytes and cSCC cell lines paired 
with ChIP-seq and transcriptional profiling would elucidate its role in the malignant transformation 
in human keratinocytes at molecular levels.  
Further evaluation of cSCC transcriptome in comparison with fresh frozen normal skin would 





5. Genome-wide methylation and transcription 
profiling of Cutaneous Squamous Cell 
Carcinoma Cell Lines 
5.1. Introduction 
As described in Chapter 1.3.2.2, squamous cell carcinoma of the skin is the second most 
common malignant tumour to affect humans preceded only by basal cell carcinoma. Its incidence 
has been increasing at an alarming rate during the past decades, and the neoplasm represents 
an imminent global health-problem associated with considerable morbidity (O'Bryan et al., 2013), 
health-care costs (Vallejo-Torres et al., 2013) and suffering (Koster and Bergsma, 1990). Unlike in 
basal cell carcinoma, in which the PTCH gene has been shown to be critical for its development, 
no single gene or molecular pathway has been implicated as crucial in the development of 
cutaneous squamous cell carcinoma (cSCC). 
Epidermolysis bullosa (EB) is a group of rare inherited blistering skin diseases associated with 
serious body mutilations and mortality. Afflicted patients are at increased risk of developing cSCC, 
with metastatic cSCC representing the most common cause of death in patients reaching 
adulthood. Moreover, EB-associated cSCC exhibits a more aggressive clinical behaviour and is 
more difficult to identify. 
Recessive dystrophic epidermolysis bullosa (RDEB) is caused by mutations in collagen, type VII, 
alpha 1 protein-coding gene. This protein is a predominant constituent of fibrils that anchor 
epidermal basement membrane to the underlying dermis. In RDEB, the absence or reduction of 
these anchoring fibrils leads to skin blistering. RDEB cSCC are at increased risk of developing 
aggressive cSCC (Fine et al., 2009), and tumours appears usually in skin wounds and areas 
affected by long-term scarring, rather than in sun-exposed areas, which indicates that different 
pathophysiological mechanisms play role in the onset of RDEB cSCC compared to UV-induced 
cSCC. Moreover, RDEB cSCC are often multiple, and 80% of patients die from cSCC metastases 
within 5 years following initial tumour presentation (Fine et al., 2009). 
The acquisition of stem cell-like properties and dedifferentiation have recently been shown to 
represent the initial step in colon cancer carcinogenesis (Sauermann et al., 2008), and 
conversely, mesenchymal stem cells (MSC) have been shown to gain tumourigenic properties 
(Rubio et al., 2008), suggesting that certain molecular traits shared between the cell types may at 
least partially underpin oncogenic transformation.  
Cancer cell lines represent a suitable system for basic and translational research (Paz et al., 
2003), and previous studies focusing on aberrant methylation in cancer cell lines have identified 
important mechanism that underpin neoplastic growth (Herman et al., 1995). To date, no 
comprehensive DNA methylation or transcription study of cSCC cell lines has been conducted. 
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As discussed in Chapter 1.6.1, human embryonic stem cells (hESC) represent a unique type of 
cells capable of differentiating into any kind of body tissue. As these cells are derived from a 
blastocyst, all cells in the mass possess identical DNA, yet can differentiate into distinct cell types 
via a myriad of epigenetic and other regulatory changes. In addition to capacity for self-renewal, 
hESC possess migratory abilities that allow the cells to fulfil their developmental function. Such 
features are often ascribed to cancer cells, and various conserved signalling pathways including 
MAPK/ERK, PI3K/Akt, Wnt, TGF-β and NOTCH have been shown to play a critical role in both 
malignant tumours and hESC (Dreesen and Brivanlou, 2007). 
The aims of this study included investigation of potential differences in genome-wide CpG island 
methylation and gene transcription between primary cutaneous squamous cell carcinoma-derived 
cell lines and primary cultured keratinocytes. In the view of distinct clinical characteristics of 
recessive dystrophic epidermolysis bullosa (RDEB)-associated cSCC, I aimed at exploring 
potential differences in methylation patterns between cell lines derived from cSCCs of non-RDEB 
and RDEB patients. Finally, I hypothesised that cSCC cells gain certain unique molecular 
properties normally confined to stem cells in the process of dedifferentiation that at least partially 
determine their malignant properties due to acquiring methylation levels of selected genes 
corresponding to their methylation status in embryonic stem cells.  
5.2. Materials and Methods 
5.2.1. cSCC cell lines and normal human keratinocytes 
A total of nine cSCC lines were used for the detection of differentially methylated and transcribed 
genes. Three early-passage primary normal human keratinocytes derived from three different 
participants served as a normal control in each comparison. Additionally, 3 human embryonic 
stem cells (hESC) samples were used for transcriptional profiling. 
Histological subtyping of original tumour with corresponding cell line, passage number and patient 
characterstic is presented in Table 5.1. 
Illumina	  270Infinium	  HumanMethylation27	  BeadChip	  
Cell	  
Line	  
Histological	  Typing	   Passage	  
No.	  
Patient	  Characteristic	  
NHK1	   Primary	  normal	  human	  keratinocytes	   2	   Healthy	  adult	  
NHK2	   Primary	  normal	  human	  keratinocytes	   2	   Healthy	  adult	  
NHK3	   Primary	  normal	  human	  keratinocytes	   2	   Healthy	  adult	  
T1	   Well-­‐differentiated	   5	   Organ-­‐transplant	  recipient	  
T2	   Well-­‐differentiated	   13	   Organ-­‐transplant	  recipient	  
T8	  3-­‐
1b	  
Poorly-­‐differentiated	   8	   Organ-­‐transplant	  recipient	  
IC1	   Moderately-­‐differentiated	   8	   Immunocompetent	  
patient	  
MET1	   Poorly-­‐differentiated	   11	   Organ-­‐transplant	  recipient	  
MET2	   Poorly-­‐differentiated	  (recurrence	  of	  
MET1)	  
11	   Organ-­‐transplant	  recipient	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EB2	   Poorly-­‐differentiated	   13	   Epidermolysis	  bullosa	  
patient	  
EB3	   Well-­‐differentiated	   17	   Epidermolysis	  bullosa	  
patient	  
GP	   unknown	   22	   Epidermolysis	  bullosa	  
patient	  
Table 5.1 Characteristics of cell lines hybridised to Illumina 27K methylation array. 
5.2.2. DNA Extraction and Bisulphite Modification 
DNA extraction from a subset of samples was conducted in collaboration with Angela McHugh13: 
DNA was extracted from confluent cell cultures at passage numbers indicated in Table 5.1 using 
DNesy Mini extraction kit (Qiagen, United Kingdom) according to the manufacturer's instructions. 
500-1000 ng of DNA yield from each sample were bisulphite modified using the EZ DNA 
Methylation Kit (Zymo Research, CA, USA) according to the manufacturer's instructions in 
collaboration with Cambridge Genomic Services14 and Nadiya Mahmoud15.  
5.2.3. Infinium HumanMethylation27 BeadChip  
Methylation detection was performed using the Illumina Infinium HumanMethylation27 BeadChip 
in collaboration with Cambridge Genomic Services. This platform detects the methylation status of 
27,578 CpG sites spread across 14,495 genes by sequencing-based genotyping of bisulfite-
converted DNA. Bisulfite-converted (unmethylated) and unconverted (methylated) sites are 
evaluated by DNA hybridisation to specific probes attached to beads. There are two probes for 
each CpG site per locus, one for methylated and one for unmethylated sites. This is followed by 
allele-specific base extension with a fluorescent label, which is specific for either the methylated 
or unmethylated allele. Eventual methylation scores (denoted “beta-value”) are generated for 
each site with BeadStudio software (Illumina, Inc., USA) and range from 0 (fully unmethylated) to 
1 (fully methylated). The Illumina Infinium methylation assay was performed according to the 
manufacturer's instructions. Briefly, bisulphite-converted DNA was amplified, fragmented and 
hybridised to the chip arrays, followed by imaging with the Illumina BeadArray reader. Image 
processing and intensity data extraction were performed according to Illumina's instructions.  
5.2.3.1. Quality Control and Normalisation 
Background-corrected beta-values were used to evaluate the quality of individual arrays. This was 
conducted using boxplots of total intensity (calculated as addition of unmethylated and methylated 
                                                       
13 Division of Cancer Research, Medical Research Institute, Jacqui Wood Cancer Centre, University of 
Dundee, Dundee, Scotland. 
14 Cambridge Genomic Services, Department of Pathology, Cambridge University, Cambridge.  
15 Genome Centre, Barts and the London School of Medicine and Dentistry, London. 
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values [I=U+M] for each probe) shown in Figure 5.1, and histograms of beta-values on each chip 
(shown in Figure 5.2). If adequate bimodal distribution of beta-values was observed on histogram, 
the sample was included in further analysis. All twelve samples passed the quality control and 
were included in down-stream analysis.  
Intra-array normalisation was performed in the Illumina BeadStudio software. Beta-values were 
further normalised using a quantile-normalisation strategy to reduce inter-array variation using 
preprocessCore package in R (http://bmbolstad.com/stuff/qnorm.pdf).  
 
 
Figure 5.1  Boxplots showing total intensities of samples hybridised to Illumina 27K beadchip. X 
axis=total locus signal intensity (the sum of unmethylated and methylated probe intensities). 
MET1 sample shows generally lower intensity values compared to the rest of the samples, but 




Figure 5.2 Histograms of raw, background-corrected beta-values in all samples showing 
appropriate bimodal distribution. This pattern confirms suitability of the data for normalisation and 
further downstream analysis. 
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5.2.3.2. Detection of Differentially Methylated Genes 
Significant differences in methylation of specific loci were detected using a genefilter package in 
R. Welch two-sample test was applied to each probe to detect the difference in methylation level 
between the controls and all nine tumour samples. Analogous strategy was applied in detection of 
methylation differences between EB-derived tumours and non-EB tumours. α-level was set at 
pvalue<0.01. Obtained p-values were adjusted for multiple testing using Bonferroni-Holm method. 
5.2.4. Comparison with previously published data 
Previously published methylation profile of 30 normal skin samples obtained from healthy 
volunteers (Gronniger et al., 2010) using the same methylation microarray was used to validate 
primary cultured human keratinocytes as a suitable model for exploring methylation patterns in 
human skin. 
Additionally, methylation profile of a panel of various cultured cell types (fetal lung fibroblasts [1x], 
mesenchymal stem cells [4x], cord blood CD34+ cells [2x], peripheral blood CD34+ cells [3x], 
bone marrow CD34+ cells [3x], peripheral blood mononuclear cells [2x], cord blood mononuclear 
cells [2x], human umbilical vein endothelial cells [1x], cord blood endothelial progenitor cells [1x], 
cord blood CD34- cells [1x], induced pluripotent stem cells [23x], embryonic stem cells [11x] and 
human embryonal carcinoma cells [1x], (Chou et al., 2011)) was used to determine potential stem 
cell-like characteristics of cSCC cell lines. 
5.2.4.1. hESC signature in cSCC cell lines 
I defined the epigenetic hESC signature as genes that are differentially methylated in cSCC 
compared to PHK that show a difference of 20% or more in averaged beta-value in hESC 
compared with PHK, and less than 5% methylation difference in cSCC compared with hESC. In 
order to identify hESC epigenetic signature in cSCC cell lines, the raw methylation data derived 
from 11 hESC samples were normalised with PHK and cSCC data. Probes with missing data in 
any of the 23 samples were filtered out. Mean methylation levels for each probe were calculated 
for each tissue type (hESC, PHK, cSCC). The average methylation difference in percentage 
points for each probe were then calculated by taking the absolute value after subtracting the 
average methylation levels in hESC from PHK and from cSCC (hESC minus PHK, hESC minus 
cSCC) and multiplying it by 100.  
5.2.4.2. Average methylation differences in tissue types 
The average difference in methylation across various tissue types included in a previously 
described dataset (Chou et al., 2011) was calculated by substracting the average methylation 
level for each probe between each tissue type in all permutations. Then the difference was 
averaged for each of those comparisons and multiplied by 100. 
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5.2.5. Transcriptional profiling 
Illumina HumanHT-12 v4 expression array was used for this experiment to allow integration with 
previously used Illumina methylation array. Sample processing and RNA hybridisation was carried 
out in collaboration with Cambridge Genomic Services. A total of 500 ng of mRNA (RIN value >8) 
was amplified with the TotalPrep 96-RNA amplification kit (Applied Biosystems, USA). Briefly, 
mRNA is reverse-transcribed into cDNA prior to amplification, and subsequently amplified by In 
Vitro Transcription (IVT). This process generates biotin-labelled cRNA, which is then hybridised to 
the beadchip following the Direct Hybridisation assay. The microarray is read with Illumina 
BeadStation scanner using iScan software. Table 5.2 lists samples hybridised to the transcription 
profiling array. 
Illumina	  HumanHT12v4	  BeadChip	  1	   	  
Cell	  
Line	  
Histological	  Typing	   Passage	  
No.	  
Patient	  Characteristic	  
PK0	   Normal	  human	  keratinocytes	   0	   Healthy	  adult	  
PK1	   Normal	  human	  keratinocytes	   1	   Healthy	  adult	  
PKA	   Normal	  human	  keratinocytes	   3	   Healthy	  adult	  
T1	   Well-­‐differentiated	   8	   Organ-­‐transplant	  recipient	  
T2	   Well-­‐differentiated	   4	   Organ-­‐transplant	  recipient	  
T8	  3-­‐
1b	  
Poorly-­‐differentiated	   8	   Organ-­‐transplant	  recipient	  
IC1	   Moderately-­‐differentiated	   8	   Immunocompetent	  
patient	  
MET1	   Poorly-­‐differentiated	   12	   Organ-­‐transplant	  recipient	  
MET2	   Poorly-­‐differentiated	  (recurrence	  of	  
MET1)	  
12	   Organ-­‐transplant	  recipient	  
EB2	   Poorly-­‐differentiated	   NA	   Epidermolysis	  bullosa	  
patient	  
EB3	   Well-­‐differentiated	   NA	   Epidermolysis	  bullosa	  
patient	  
GP	   unknown	   NA	   Epidermolysis	  bullosa	  
patient	  
	   	   	   	  
Illumina	  HumanHT12v4	  BeadChip	  2	   	  
Cell	  
Line	  
Histological	  Typing	   Passage	  
No.	  
Patient	  Characteristic	  
P0	   Primary	  normal	  human	  keratinocytes	   0	   Male	  infant	  
PKS	   Primary	  normal	  human	  keratinocytes	   1	   Healthy	  adult	  
PK5	   Primary	  normal	  human	  keratinocytes	   5	   Healthy	  adult	  
T1	   Well-­‐differentiated	   13	   Organ-­‐transplant	  recipient	  
T2	   Well-­‐differentiated	   12	   Organ-­‐transplant	  recipient	  
T8	  3-­‐
1b	  
Poorly-­‐differentiated	   9	   Organ-­‐transplant	  recipient	  
IC1	   Moderately-­‐differentiated	   8	   Immunocompetent	  
patient	  
MET1	   Poorly-­‐differentiated	   14	   Organ-­‐transplant	  recipient	  
MET2	   Poorly-­‐differentiated	  (recurrence	  of	  
MET1)	  
13	   Organ-­‐transplant	  recipient	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HESC1	   Human	  embryonic	  stem	  cells	   NA	   Human	  embryonic	  stem	  
cells	  
HESC2	   Human	  embryonic	  stem	  cells	   NA	   Human	  embryonic	  stem	  
cells	  
HESC3	   Human	  embryonic	  stem	  cells	   NA	   Human	  embryonic	  stem	  
cells	  
Table 5.2 Characteristics of cell lines and cultured cells hybridised to gene expression array. 
5.3. Results 
5.3.1. DNA Methylation Patterns 
All twelve samples (three PHK, nine cSCC cell line samples) were hybridised to Illumina Infinium 
HumanMethylation27 BeadChip arrays after passing quality control and inter-array normalisation 
procedure to remove variation due to experimental and other confounding factors. This resulted in 
a normalised data matrix of beta-values between 0 and 1. Inherent bi-modality of the methylation 
value distribution is captured in Figure 5.3 with a typical high peak of hypomethylated loci and a 
low peak in the hypermethylated loci.  
 
 
Figure 5.3 Bimodal distribution of methylation values across both sample types. This observed 
pattern is expected given the character of the methylation array. nNS=primary human 
keratinocytes, tumours=cSCC cell lines. 
5.3.2. Clustering Analysis of normalised methylation profiles 
Methylation profiles of all samples were correlated using Pearson's correlation algorithm, and 
unsupervised hierarchical clustering of these data lead to a clear separation of RDEB-derived 
tumours from the remaining samples (Figure 5.4). Additionally, normal human keratinocytes also 





Figure 5.4 Unsupervised hierarchical clustering analysis of normal human keratinocyte samples 
and cSCC cell lines based on Pearon’s correlation of their methylome. This graph shows clear 
separation based on the patient source of the original tumour (RDEB, non-RDEB patients), and 
on the original histology. EB=RDEB-cSCC derived cSCC cell line, MD=moderately differentiated 
cSCC, WD=well-differentiated cSCC, PD=poorly differentiated cSCC, NS=primary human 
keratinocytes. 
To further explore these clusters and to quantify the statistical relevance of these, I plotted a 
bootstrap correlation plot shown in Figure 5.5. This figure demonstrates that RDEB-derived 
samples and primary human keratinocytes are entirely distinct  from non-RDEB cSCC cell lines. 
Among these cell lines, MET1 and MET2 cell lines form an unequivocal cluster, as do cell lines 





Figure 5.5 Bootstrap correlation dendrogram quantifying the statistical significance of observed 
clusters. Red value >95 indicates a statistically significant cluster. This figure shows that all 
RDEB-cSCC cell lines, NHK and 5/6 cSCC cell lines form statistically significant clusters based 
on their methylome. 
5.3.3. Differentially Methylated Genes 
5.3.3.1. Methylation levels in primary human keratinocytes compared with cSCC cell lines 
With set α-level, the comparison of normal keratinocytes with cSCC cell lines identified 398 
differentially methylated probes (full list is provided in Appendix 7). A heatmap of this probeset's 
beta-values is depicted in Figure 5.6, and shows a distinct clustering pattern of the 2 sample 
types based on this probeset. A histogram of adjusted p-values for all probes is shown in Figure 
5.7 (top panel), indicating that the vast majority of probes present on the array are not 
differentially methylated. P-values for each probe with corresponding chromosomal location are 





Figure 5.6 Heatmap of beta-values of probes differentially methylated in cSCC cell lines. 




Figure 5.7 Histogram of adjusted p-values for all probes comparing PHK vs. all cSCC cell lines 
combined (above) and non-RDEB cSCC cell lines vs. RDEB-cSCC cell lines (below). Red line 
corresponds to p value of 0.01 (pre-set α level). This figure shows that a significant difference in 
methylation on probe-levels is far more common if all cSCC cell lines are compared with PHK 
than if RDEB-cSCC and non-RDEB-cSCC cell lines are compared. 































Figure 5.8 –Log10 p-values for each probe with corresponding chromosomal location. 
CHR=chromosome, red line corresponds to 0.01 p-value. This plot shows that differentially 
methylated probes are located on all chromosomes but the Y chromosome (far right, yellow). 
Pv=-log10 of a p-value (this converts the most significant p values to the highest integer). 
This probeset represents 371 annotated genes, of which 201 (54%) were hypermethylated and 
170 (46%) hypomethylated relative to normal skin. The observed skew towards hypermethylation 
in tumour cell lines was not statistically significant (binomial test, pvalue=0.054). Chromosomal 




Figure 5.9 Chromosomal positions of differentially methylated genes in all cSCC cell lines. 
Many of these differentially methylated genes have been previously shown to be involved in 
cancer, including CDKN2A, WT1, TP53I3, MRAS, GATA4, SPARCL1. Based on extensive 
literature search, a total of 115 (30%) genes in this set have been previously shown to be involved 
in cancer; either as tumour suppressor, as oncogenes or their role is ambiguous. This set of 
cancer-relevant genes is provided in Appendix 8.  
Based on GO term annotation, many additional genes were shown to play a role in signal 
transduction (CHRNB4, CHRNE, ITPR2, MCHR1, F2RL3, PRLHR, GPR75, FFAR2, GABRA5, 
CD101, CCL8, MAPK8, IP1, NFAM1, CARD9, TAC3, DDAH2, FGD4, PLCL1, TNFRSF11B, 
TANK). 
Four homeobox genes were identified as differentially methylated (BARHL2, PAX4, TGIF2 and 
POU2F2). Homeobox genes encode regulatory nuclear proteins that function as transcription 
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factors that play a critical role during development, and dysregulation of these genes has been 
previously implicated in various cancers (Nunes et al., 2003).  
TWIST1, a prominent inductor of EMT transition, was significantly hypomethylated in cSCC, 
which signifies importance of this process in this malignancy. 
5.3.4. Validation of 27K array with bisulfite sequencing 
DMP detected with 27K array were validated using 10 laser-capture microdissected cSCC 
samples and paired normal skin originating in male RTR patients. As described in Chapter 2, 
methylation levels of regions within 50 bp of DMP were averaged and subtracted to obtain 
differences in methylation. 
Bisulfite sequencing data was available for 349 of 398 differentially methylated genes and the 
methylation levels in skin and cSCC are available in Appendix 20. The same direction of 
methylation difference (hyper- or hypomethylation) was confirmed for 163 genes (46.7%). 81 of 
the validated genes were hypo- and 82 were hypermethylated. 
5.3.4.1. cSCC cell lines derived from RDEB-cSCC tumours versus cell lines derived from 
non-RDEB tumours 
The comparison of cSCC cell lines derived from RDEB-associated tumours with non-RDEB 
tumours lead to the identification of 38 differentially methylated probes, which represent 37 unique 
genes. This geneset is listed in Table 5.3, and contains one homeobox gene (SIX6). Three genes 
in this set (ATP10A, GATA4, KIF5A) overlap with differentially methylated geneset derived from 
the comparison of normal human keratinocytes and all cSCC cell lines. 25 probes (66%) were 
relatively hypermethylated in RDEB-derived tumours and 13 (34%) were relatively 
hypomethylated. This trend towards hypermethylation in RDEB-derived tumours is statistically 
significant (binomial test, p-value 0.027).  
Gene	   CHR	   Gene	  name	   Methylation	  Status	  in	  
RDEB-­‐cSCC	  cell	  lines	  
SLC44A4	   6	   Solute	  carrier	  family	  44,	  member	  4	   Hyper	  
MFRP	   11	   membrane	  frizzled-­‐related	  protein	   Hypo	  
HTR2C	   X	   5-­‐hydroxytryptamine	  (serotonin)	  receptor	  2C,	  G	  protein-­‐coupled	   Hyper	  
C18orf34	  	   18	   coiled-­‐coil	  domain	  containing	  178	   Hyper	  
MGC44505	  	   2	   -­‐	   Hypo	  
SORCS3	   10	   sortilin-­‐related	  VPS10	  domain	  containing	  receptor	  3	   Hyper	  	  
HRC	   19	   histidine	  rich	  calcium	  binding	  protein	   Hypo	  
SIX6	   14	   SIX	  homeobox	  6	   Hyper	  
MGC11271	   19	   -­‐	   Hyper	  	  
RNASE6	   14	   ribonuclease,	  RNase	  A	  family,	  k6	   Hypo	  
PLP1	   X	   proteolipid	  protein	  1	   Hypo	  
GATA4	   8	   GATA	  binding	  protein	  4	   Hyper	  
KIF5A	   12	   kinesin	  family	  member	  5A	   Hypo	  
EYA4	   6	   eyes	  absent	  homolog	  4	   Hyper	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ADRA1A	   8	   adrenoceptor	  alpha	  1	   Hyper	  	  
MEST	   7	   mesoderm	  specific	  transcript	   Hyper	  	  
GALR1	   18	   galanin	  receptor	  1	   Hyper	  	  
VSIG4	   X	   V-­‐set	  and	  immunoglobulin	  domain	  containing	  4	   Hypo	  	  
ATP10A	   10	   ATPase,	  class	  V,	  type	  10A	   Hypo	  	  
DYRK1B	   19	   dual-­‐specificity	  tyrosine-­‐(Y)-­‐phosphorylation	  regulated	  kinase	  1B	   Hyper	  	  
DOK1	   2	   docking	  protein	  1,	  62kDa	   Hyper	  	  
PRDM14	   8	   PR	  domain	  containing	  14	   Hyper	  	  
GLYAT	   11	   glycine-­‐N-­‐acyltransferase	   Hypo	  
FOXG1B	   14	   -­‐	   Hyper	  	  
CYP2E1	   10	   cytochrome	  P450,	  family	  2,	  subfamily	  E,	  polypeptide	  1	   Hyper	  	  
GAD2	   10	   glutamate	  decarboxylase	  2	   Hyper	  	  
GRIA4	   11	   glutamate	  receptor,	  ionotropic,	  AMPA	  4	   Hyper	  	  
GRM6	   5	   glutamate	  receptor,	  metabotropic	  6	   Hyper	  	  
FLJ42486	   14	   -­‐	   Hyper	  	  
C7orf9	   7	   -­‐	   Hypo	  	  
CRMP1	   4	   collapsin	  response	  mediator	  protein	  1	   Hyper	  	  
UNQ9433	   8	   -­‐	   Hyper	  	  
TCEAL7	   X	   transcription	  elongation	  factor	  A	  (SII)-­‐like	  7	   Hypo	  	  
CCDC37	   3	   coiled-­‐coil	  domain	  containing	  37	   Hyper	  	  
OR2B6	   6	   olfactory	  receptor,	  family	  2,	  subfamily	  B,	  member	  6	   Hypo	  	  
DPCR1	   6	   diffuse	  panbronchiolitis	  critical	  region	  1	   Hypo	  
PDGFD	   11	   platelet	  derived	  growth	  factor	  D	   Hyper	  	  
Table 5.3. DMG in RDEB-cSCC derived cell lines compared to non-RDEB cSCC derived cell 
lines. 




Figure 5.10 Heatmap of differentially methylated genes in RDEB-cSCC cell lines.  
Based on extensive literature search, I have observed that many genes in this set were shown to 
be involved in mammalian development and in various disorders including psychiatric, cardiac 
diseases and cancer. For example, SLC44A4 has been demonstrated to be overexpressed in 
various epithelial cancers (Ricart, 2011), DOK1 is a putative tumour suppressor shown to be 
hypermethylated in a variety of cancers (Saulnier et al., 2012), and was hypermethylated in 
RDEB-cSCC cell lines compared to non-RDEB cSCC cell lines. The same was true for GALR1, 
the frequent hypermethylation of which has been detected in head and neck SCC (Misawa et al., 
2008). 
5.3.5. Enrichment Analysis 
5.3.5.1. KEGG pathway analysis 
The comparison of normal keratinocytes and cSCC cell lines methylation profiles showed that the 
most significant dysregulation was seen in the NOD-like receptor signalling pathway. This 
pathway is involved in inflammatory and apoptosis response and NF-kappaB activation, and has 
been implicated in gastric cancer (Hedman et al., 2002) and in NSLCC (Strazisar et al., 2009). 
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Dysregulated pathways directly linked to cancer included Apoptosis and p53 signalling pathway. 
A full list of dysregulated pathways is provided in Table 5.4. 
KEGG	  Pathway	   Adjusted	  P-­‐value	  
NOD-­‐like	  receptor	  signaling	  pathway	   <0.0001	  
Apoptosis	   0.0003	  
Maturity	  onset	  diabetes	  of	  the	  young	   0.0012	  
p53	  signaling	  pathway	   0.0014	  
Lysine	  biosynthesis	   0.0016	  
O-­‐Glycan	  biosynthesis	   0.0048	  
Sphingolipid	  metabolism	   0.0177	  
Amyotrophic	  lateral	  sclerosis	  (ALS)	   0.0265	  
RIG-­‐I-­‐like	  receptor	  signaling	  pathway	   0.0281	  
Table 5.4. Significantly dysregulated pathways in differentially methylated probes in cSCC cell 
lines. 
KEGG pathway analysis of differentially methylated probes in RDEB-cSCC cell lines compared to 
non-RDEB cSCC cell lines has found only 1 pathway – Neuroactive ligand-receptor activation – to 
be dysregulated. 
5.3.6. Comparison of primary human keratinocytes and cSCC cell lines 
with genome-wide DNA methylation profile of human skin 
To explore the similarity of PHK to normal epidermis, I used a published dataset containing 30 
human skin samples hybridised to the same DNA methylation chip (Gronniger et al., 2010). As 




Figure 5.11 Unsupervised hierarchical clustering of genome-wide methylation profile 30 human 
skin samples, cultured primary keratinocytes and cSCC cell lines. Normal human skin=yellow, 
PHK=brown, non-RDEB cSCC cell lines=red, RDEB-cSCC cell lines=pink. This figure shows that 
cultured primary keratinocytes cluster with normal human skin based on Pearon’s correlation of 
their methylomes. 
To confirm the validity of 398 differentially methylated probes in cSCC cell lines, I plotted 
normalised methylation levels across PHK, cSCC cell lines and 30 human skin samples. As 
shown in Figure 5.12, methylation levels of this probeset in PHK are concordant with human skin. 


































































Figure 5.12 Unsupervised hierarchical clustering of 30 skin samples, PHK, non-RDEB cSCC cell 
lines and RDEB-cSCC cell lines based on methylation levels of 398 differentially methylated 
genes identified cSCC cell lines. Normal human skin=yellow, PHK=brown, non-RDEB cSCC cell 
lines=red, RDEB-cSCC cell lines=pink. This graph confirms consistency of PHK and normal skin 
methylation profile. 
5.3.7. Comparison with methylation levels in additional cultured tissues 
I hypothesised that due to the process of dedifferentiation in cSCC cell lines, methylation profiles 
of these cells would cluster with less differentiated cell types. To test this hypothesis, I used 
methylation profiles derived from a panel of tissues hybridised to the same kind of microarray 
chip, and explored the clustering patters of genome-wide methylation profiles of this dataset with 
cSCC cell lines following standard data manipulation (normalisation, data filtering). 
As shown in Figure 5.13, methylation profile of cSCC cell lines and hESC and iPSC is quite 
distinct from the remaining tissues. Additionally, PHK clustered with MSC, fetal lung fibroblasts 
and cord-blood endothelial precursors, rather than forming a distinct cluster. This suggests that 
dedifferentiation in cancer cells occurs due to the gain of unique molecular properties rather than 





Figure 5.13 Clustering of genome-wide methylation profiles of various tissues. cSCC cell lines 
(green=RDEB-cSCC, blue=non-RDEB cSCC) cluster independently of this dataset, while PHK 
(brown) form a cluster with cord-blood endothelial progenitor cells (light pink) and fetal lung 
fibroblasts (navy blue), and a greater cluster with MSC (pink). iPSC and hESC form a distinct 
cluster on the right (light blue and aquamarine), and remaining samples (cord blood CD34+ cells, 
peripheral blood CD34+ cells, bone marrow CD34+ cells, peripheral blood mononuclear cells, 
cord blood mononuclear cells, human umbilical vein endothelial cells, cord blood CD34- cells) 
form a cluster in the middle. 
I then looked at average differences in methylation between selected individual tissue types by 
averaging beta-values for each probe in tissue type, and then calculating average of those 
differences: Primary human keratinocytes, mesenchymal stem cells, fetal lung fibroblasts, cord 
blood endothelial progenitor cells, cord blood CD34+ cells, peripheral blood CD34+ cells, bone 
marrow CD34+ cells, hESC, iPSC, and human umbilical vein endothelial cells. As shown in 
Figure 5.14, cSCC cell lines showed the highest differences in comparison with any additional 



































































































































































































































































































































































































































































































Figure 5.14 Average differences in methylation between all tissue types in percentage points. 
Each colour in the colour key corresponds to a difference in beta-values in percentage points 
(0=0%, 5=5%, 10=10%). The highest differences are between cancer cell lines (SCC=cSCC, 
EBSCC=RDEB cSCC) and the remaining tissues. Conversely, hESC, iPS and bone marrow-
derived CD34+ progenitor cells (BMCD34) show on average 5% differences. Cultured normal 
keratinocytes (NS) show the lowest average differences in comparison with mesenchymal stem 
cells (MSC) and also fetal lung fibroblasts (FLFib). PB34=peripheral blood-derived CD34 positive 
cells, CB34=cord blood CD34+ cells, HUVEC=human umbilical vein endothelial cells, CB 
EPCs=cord blood endothelial progenitor cells. 
5.3.7.1. Human embryonic stem cells signature in cSCC cell lines 
I then plotted the 398 differentially methylated probes in PHK, cSCC cell lines and hESC and 
iPSC cells. Figure 5.15 shows that while the majority of differentially methylated probes in cSCC 
showed consistent levels of methylation in hESC and iPSC, a small subset of probes (highlighted 
in black rectangles) showed methylation levels that were distinct in PHK yet showed practically 





































































Figure 5.15 398 differentially methylated probes in PHK (dark red), cSCC cell lines (pink), RDEB-
cSCC cell lines (purple), hESC (dark blue) and iPSC (light blue). Black rectangles indicate probes 
that show similar methylation levels in cSCC cell lines and hESC/iPSC, yet are differentially 
methylated in PHK.  
I then explored the methylation levels of those probes closer by plotting only cSCC cell line and 
iPSC/hESC probe data. In order to visually explore the differences at more subtle levels, I used 
additional colours for distinct methylation values. As shown in Figure 5.16, a small subset of 




Figure 5.16 Differentially methylated probes in cSCC with corresponding levels in iPSC (light 
blue) and hESC (dark blue). Red rectangle highlights probes that seem to have equivalent 
methylation levels in those samples. 
I then identified probes that show less than 5% difference in methylation levels in hESC compared 
to cSCC cell lines, and more than 20% in hESC compared to PHK (details are described in 
Chapter 5.2.4.1.). This approach resulted in 21 probles (individual methylation levels are shown in 
Figure 5.17) that translated in 20 genes listed in Table 5.5 to be identified as “hESC signature” in 
cSCC cell lines.  
Gene	  and	  Gene	  
name	  




Marker	  of	  muscle	  
differentiation,	  p53	  target	  
(Guan	  et	  al.,	  
2006,	  Botcheva	  et	  
al.,	  2011)	  
Hypermethylated	  
AQP9	  aquaporin	  9	   Upregulated	  in	  mouse	  ESC	  by	  
MAPK	  as	  a	  stress	  response	  






methylates	  the	  5'	  end	  of	  7SK	  
RNA	  







kinase	  inhibitor	  2A	  
Tumour	  suppressor,	  
unmethylated	  in	  hESC	  
(Ohm	  et	  al.,	  2007)	   Hypomethylated	  
DSG1	  desmoglein1	   Supports	  epidermal	  
differentiation	  
(Harmon	  et	  al.,	  
2013)	  
Hypermethylated	  
EDNRB	  endotelin	  B	  
receptor	  
Hypermethylated	  in	  various	  
cancers	  
(Chen	  et	  al.,	  2013,	  








factor	  II	  (thrombin)	  
receptor-­‐like	  3	  
Decreased	  expression	  in	  human	  
gastric	  cancer	  through	  
hypermehtylation	  
(Zhang	  et	  al.,	  
2011)	  
Hypermethylated	  
FAM20B	   Expressed	  in	  haematopoietic	  
cells	  
(Nalbant	  et	  al.,	  
2005)	  
Hypomethylated	  






Expression	  is	  characteristic	  of	  
hepatoblasts	  	  
(Cipak	  et	  al.,	  
2010)	  
Hypermethylated	  
KIAA0753	   Underexpressed	  in	  non-­‐
adherent	  cancer	  cells	  












A,	  12	  	  







Involved	  in	  tumour	  regulation	  
through	  β-­‐catenin	  and	  CYCLIN-­‐
D1	  signaling.	  




amyloid	  A2	  	  
	   	   Hypermethylated	  
SERPINA3	  serpin	  
peptidase	  inhibitor,	  
clade	  A	  (alpha-­‐1	  
antiproteinase,	  
antitrypsin),	  
member	  3	  	  
Hypermethylated	  in	  hESC	   (Kim	  et	  al.,	  2011)	   Hypermethylated	  
SLC22A18	  solute	  
carrier	  family	  22,	  
member	  18	  	  
Paternally	  imprinted,	  putative	  
tumour	  suppressor	  
(Jung	  et	  al.,	  2011,	  
Chu	  et	  al.,	  2011)	  
Hypermethylated	  
SLC43A3	  solute	  
carrier	  family	  43,	  
member	  3	  
Low	  expression	  in	  hESC	  	   (Zhang	  et	  al.,	  
2007,	  Ulloa-­‐
Montoya	  et	  al.,	  
2007)	  
Hypermethylated	  
TSPAN16	   Decreased	  expression	  in	  a	   (Juric	  et	  al.,	  2007)	   Hypermethylated	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tetraspanin	  16	  	   subtype	  of	  acute	  lymphoblastic	  
leukaemia	  	  
ZNF662	   NA	   	   Hypermethylated	  
Table 5.5 Genes that represent hESC signature in cSCC cell lines based on methylation levels. 
 
Figure 5.17 Probes that represent hESC signature in cSCC cell lines. Red samples on the 
left=PHK, pink samples=non-RDEB cSCC cell lines, purple samples=RDEB cSCC cell lines, dark 
blue samples=hESC. 
5.3.8. Transcriptional profiling of cSCC cell lines 
I further explored the impact of methylation changes on transcriptional regulation in six primary 
keratinocytes (PHK), three hESC cell lines and previously described cSCC cell lines. One PHK 
sample has not passed the quality control and was excluded from further study.  
As shown in Figure 5.18, hESC possess a very distinct transcriptional profile. This figure also 
shows that PHK are transcriptionally distinct from cSCC cell lines, and warranted comparative 
detection of differentially transcribed genes. If PHK clustered within cSCC cell lines, this would 

























































































































































































































lines. Unlike in clustering analysis of methylation profiles, transcriptional profiling of cSCC cell 




5.3.8.1. Differentially transcribed genes in cSCC cell lines 
I applied Bayesian statistics to determine differentially expressed probes comparing cSCC cell 
lines and primary human keratinocytes. This probabilistic approach uses various parameters, to 






Figure 5.18 Clustering of transcriptional profiles confirms correlation between samples of the 
same tissue origin. Blue=hESC, green=cSCC cell lines, red=PHK. Orange line indicates a 
cluster of three RDEB-cSCC cell lines.  
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to simple fold-change or non-parametric analysis of microarray expression data (Tang et al., 
2013). Table 5.6 summarizes the results in terms of number of differentially expressed probes 
using various thresholds; Table 5.7 lists the top 31 differentially expressed probes. 
Adjusted	  pvalue	  threshold	   Number	  of	  Differentially	  Expressed	  probes	  
<0.0001	   31	  
<0.001	   199	  
<0.01	   991	  
<0.05	   2510	  
Table 5.6 Differentially expressed probes comparing cSCC cell lines and primary human 
keratinocytes using various cut-off thresholds. 
 
 
geneSymbol	   geneName	   logFC	   AveExpr	   adj.P.Val	  
ITM2A	   integral	  membrane	  protein	  2A	   -­‐3.598319171	   7.199052039	   <0.0001	  
INPP5D	   inositol	  polyphosphate-­‐5-­‐phosphatase,	  
145kDa	  
-­‐2.086989877	   6.421191649	   <0.0001	  
COL22A1	   collagen,	  type	  XXII,	  alpha	  1	   -­‐1.697063889	   6.358206802	   <0.0001	  
SPATA18	   spermatogenesis	  associated	  18	  homolog	  
(rat)	  
-­‐1.365464501	   6.290337707	   <0.0001	  
BNIPL	   BCL2/adenovirus	  E1B	  19kD	  interacting	  
protein	  like	  
-­‐3.190986731	   7.239378147	   <0.0001	  
VWA5A	   von	  Willebrand	  factor	  A	  domain	  containing	  
5A	  
-­‐1.99319546	   6.953819069	   <0.0001	  
C9orf150	   chromosome	  9	  open	  reading	  frame	  150	   -­‐1.730644629	   6.706085831	   <0.0001	  
TWIST1	   twist	  homolog	  1	  (Drosophila)	   1.858724861	   7.461149001	   <0.0001	  
WFDC5	   WAP	  four-­‐disulfide	  core	  domain	  5	   -­‐2.120210188	   6.70350485	   <0.0001	  
SLC20A2	   solute	  carrier	  family	  20	  (phosphate	  
transporter),	  member	  2	  
-­‐1.398189952	   8.628350267	   <0.0001	  
C1orf59	   chromosome	  1	  open	  reading	  frame	  59	   2.562296627	   8.709763244	   <0.0001	  
ATP12A	   ATPase,	  H+/K+	  transporting,	  nongastric,	  
alpha	  polypeptide	  
-­‐2.68372915	   6.702343095	   <0.0001	  
NISCH	   nischarin	   -­‐1.271723362	   7.725084387	   <0.0001	  
TRAK1	   trafficking	  protein,	  kinesin	  binding	  1	   -­‐1.835421466	   8.612845799	   <0.0001	  
COL18A1	   collagen,	  type	  XVIII,	  alpha	  1	   -­‐1.776459729	   6.432226465	   <0.0001	  
FYCO1	   FYVE	  and	  coiled-­‐coil	  domain	  containing	  1	   -­‐1.356963286	   7.534225602	   <0.0001	  
BTG2	   BTG	  family,	  member	  2	   -­‐2.09909291	   7.659728098	   <0.0001	  
HSPC159	   galectin-­‐related	  protein	   -­‐2.331471633	   8.446473019	   <0.0001	  
LRRFIP2	   leucine	  rich	  repeat	  (in	  FLII)	  interacting	  
protein	  2	  
-­‐1.683209918	   9.195168392	   <0.0001	  
C6orf150	   chromosome	  6	  open	  reading	  frame	  150	   2.169262015	   7.314817213	   <0.0001	  
ANKRD35	   ankyrin	  repeat	  domain	  35	   -­‐1.780236775	   6.427049067	   <0.0001	  
HOXB7	   homeobox	  B7	   2.811943742	   8.033126094	   <0.0001	  
CDSN	   corneodesmosin	   -­‐0.919662161	   6.107765422	   <0.0001	  
UPK1B	   uroplakin	  1B	   -­‐1.059026093	   6.223324642	   <0.0001	  
PPFIBP2	   PTPRF	  interacting	  protein,	  binding	  protein	  2	   -­‐2.217955791	   6.778286212	   <0.0001	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(liprin	  beta	  2)	  
SESN1	   sestrin	  1	   -­‐1.050584103	   7.058372163	   <0.0001	  
LY6D	   lymphocyte	  antigen	  6	  complex,	  locus	  D	   -­‐2.083147479	   6.223821922	   <0.0001	  
C7orf10	   chromosome	  7	  open	  reading	  frame	  10	   -­‐2.156236189	   7.871272618	   <0.0001	  
NA	   NA	   -­‐0.830028562	   6.53044291	   <0.0001	  
NA	   NA	   -­‐0.690358656	   6.518646325	   <0.0001	  
GGT6	   gamma-­‐glutamyltransferase	  6	   -­‐1.475120675	   6.239338224	   <0.0001	  
Table 5.7 Most differentially expressed probes in cSCC cell lines compared to primary human 
keratinocytes. LogFC indicates down- or up-regulation in cSCC cell lines; negative sign means 
down-regulation. Most genes on the list are in fact under-expressed in cSCC cell lines. 
Heatmap of this probeset is shown in Figure 5.19. 
 
Figure 5.19 Heatmap of top 31 differentially expressed probes in cSCC cell lines. PHK=brown, 
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5.3.8.2. Comparison of expression profile with methylation data 
To evaluate correlation between methylation and transcription changes, we compared the list of 
differentially methylated genes with differentially expressed genes to assess potential overlap of 
those genelists. 
The comparison of probes with pvalue <0.01 in both lists has discovered only 16 overlapping 
genes (AQP9, CCT6A, DSG1, GABRP, GSN, IVL, KYNU, MACF1, NA, NDRG2, PRKAR1B, 
SERPINA3, SLC43A3, TRIM2, TWIST1, ZNF667), using a less stringent pvalue of <0.05, 95 
genes were found to be present in both lists (95/1384, 6.8% of differentially methylated genes, 
95/2474, 3.8% of differentially expressed genes). This finding confirms previously shown data 
suggesting that the highest differences in methylation do not necessarily translate linearly into 
corresponding transcription changes.  
To further explore the relationship between methylation and expression changes, methylation and 
transcription levels in PHK were paired based on gene ID (entrez ID), and plotted against one 
another. Given that methylation levels gain values from 0 to 1 and transcription levels range from 
6 to 15 after log2-transformation of raw values detected on the array, in order to make the two 
dimensions comparable, transcription values were divided by the highest value, thus the new 
maximum is 1. This operation made the two dimensions easier to compare in a single plot.  
As shown in Figure 5.20, after segregating the methylation and corresponding expression values 
in bins of <1% methylation, 1-5%, 5-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 
70-80%, 80-90%, 90-95%, 95-100% methylation, expression levels generally tend to decrease as 
methylation increases, but increase again in bins with the highest methylation levels. A greater 




Figure 5.20 Methylation and expression levels in PHK. As methylation increases, expression 
generally decreases, but with the highest methylation levels, expression levels increase. 
AvgMET=average methylation, AvgEXP=average expression levels. F1=<1%, F2=1-5%, F3=5-
10%, F4=10-20%, F5=20-30%, F6=30-40%, F7=40-50%, F8=50-60%, F9=60-70%, F10=70-80%, 
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Figure 5.21 Average expression levels of methylation bins. Methylation levels indicated along the 
x-axis. Bimodal pattern of expression levels apparent in this graph. 
Moreover, this trend does not reflect general distribution of expression levels in the samples 
shown as histogram of log2 transformed values in Figure 5.22 and as a cumulative density plot in 
Figure 5.23. 
 
Figure 5.22 Histogram of expression values in a representative sample. X axis = expression 


































the bimodal pattern observed in Figure 5.21 is not a simple repetition of general distribution of 
expression levels in the sample. 
 
Figure 5.23 Cumulative density of log2 intensities of 12 samples on an Illumina HT12 v4 chip. 
Similar to the previous figure, this graph shows that the majority of genes are expressed with log2 
transformed intensity of 6 or less (low level of expression), and that there is no sudden peak of 
high expression by a skew due to the array design as in the methylation array. 
However, this trend requires further exploration as this „bimodal peak“ may be due to several 
factors such as distance from transcription site, the absolute number of genes which cluster into 
given methylation status and other factors. 
5.3.8.3. KEGG pathway and GO term analysis of differentially expressed and differentially 
methylated genes 
Given the expected absence of correlation in methylation and expression levels on individual 
probe level, I then hypothesised that certain critical oncogenic mechanisms may be perturbed at 
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the DNA and mRNA level in independent genes that are involved in shared molecular 
processess. 
To test this hypothesis, I annotated differentially methylated and differentially expressed probes (p 
value <0.01) with their KEGG pathway and GO terms, and identified overlapping pathways and 
GO terms among those detected as enriched in those datasets. 
KEGG pathway analysis in differentially methylated genes is described in 5.3.5.1. In differentially 
expressed genes, this analysis has revealed a total of 28 pathways listed in Table 5.8. 
Description	   Adjusted	  p-­‐value	  
Cell	  cycle	   6.35E-­‐05	  
DNA	  replication	   1.04E-­‐03	  
Bladder	  cancer	   1.74E-­‐03	  
Ribosome	   1.81E-­‐03	  
Purine	  metabolism	   3.88E-­‐03	  
Prion	  diseases	   4.12E-­‐03	  
Progesterone-­‐mediated	  oocyte	  maturation	   6.30E-­‐03	  
Pyrimidine	  metabolism	   1.23E-­‐02	  
Peroxisome	   1.83E-­‐02	  
Pathways	  in	  cancer	   1.83E-­‐02	  
Oocyte	  meiosis	   2.18E-­‐02	  
RNA	  degradation	   2.40E-­‐02	  
Prostate	  cancer	   2.42E-­‐02	  
Lysosome	   2.42E-­‐02	  
Retinol	  metabolism	   2.76E-­‐02	  
Spliceosome	   2.91E-­‐02	  
p53	  signaling	  pathway	   3.34E-­‐02	  
Tight	  junction	   3.34E-­‐02	  
Melanoma	   3.43E-­‐02	  
Ubiquitin	  mediated	  proteolysis	   3.53E-­‐02	  
Adherens	  junction	   3.77E-­‐02	  
Notch	  signaling	  pathway	   3.77E-­‐02	  
Arrhythmogenic	  right	  ventricular	  cardiomyopathy	  (ARVC)	   3.77E-­‐02	  
Proteasome	   3.77E-­‐02	  
MAPK	  signaling	  pathway	   4.01E-­‐02	  
Drug	  metabolism	  -­‐	  other	  enzymes	   4.32E-­‐02	  
Vascular	  smooth	  muscle	  contraction	   4.32E-­‐02	  
Non-­‐small	  cell	  lung	  cancer	   4.92E-­‐02	  
Table 5.8 KEGG pathways enriched in differentially expressed genes (<0.01 p value). 
A total of 4 pathways overlapped between the two sets: Cell cycle, Oocyte meiosis, p53 signalling 
pathway and Pathways in cancer.  
Genes listed in Table 5.9 were involved in each pathway in the datasets. No genes disrupted at  
methylation and transcriptional level in each pathway overlap. 
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Pathway	   DifEXP	  
genes	  
Gene	  name	   DifMET	  
genes	  
Gene	  name	  
Cell	  cycle	   MCM2	   MCM2	  minichromosome	  
maintenance	  deficient	  2,	  mitotin	  (S.	  
cerevisiae)	  
ATM	   ataxia	  telangiectasia	  mutated	  (includes	  
complementation	  groups	  A,	  C	  and	  D)	  
	   MCM4	   MCM4	  minichromosome	  
maintenance	  deficient	  4	  (S.	  
cerevisiae)	  
CDK2	   cyclin-­‐dependent	  kinase	  2	  
	   MCM5	   MCM5	  minichromosome	  
maintenance	  deficient	  5,	  cell	  division	  
cycle	  46	  (S.	  cerevisiae)	  
CDKN2A	   cyclin-­‐dependent	  kinase	  inhibitor	  2A	  
(melanoma,	  p16,	  inhibits	  CDK4)	  
	   CDKN1A	   cyclin-­‐dependent	  kinase	  inhibitor	  1A	  
(p21,	  Cip1)	  
HDAC1	   histone	  deacetylase	  1	  
	   CDK4	   cyclin-­‐dependent	  kinase	  4	   PRKDC	   protein	  kinase,	  DNA-­‐activated,	  catalytic	  
polypeptide	  
	   CDC26	   cell	  division	  cycle	  26	   /	   /	  
	   PLK1	   polo-­‐like	  kinase	  1	  (Drosophila)	   /	   /	  
	   CDC25B	   cell	  division	  cycle	  25B	   /	   /	  
	   PTTG1	   pituitary	  tumor-­‐transforming	  1	   /	   /	  
	   GADD45A	   growth	  arrest	  and	  DNA-­‐damage-­‐
inducible,	  alpha	  
/	   /	  
	   BUB1B	   BUB1	  budding	  uninhibited	  by	  
benzimidazoles	  1	  homolog	  beta	  
(yeast)	  
/	   /	  
	   RAD21	   RAD21	  homolog	  (S.	  pombe)	   /	   /	  
	   POLE4	   polymerase	  (DNA-­‐directed),	  epsilon	  4	  
(p12	  subunit)	  
/	   /	  
Oocyte	  
meiosis	  
CDC26	   cell	  division	  cycle	  26	   PPP3R2	   protein	  phosphatase	  3	  (formerly	  2B),	  
regulatory	  subunit	  B,	  19kDa,	  beta	  isoform	  
(calcineurin	  B,	  type	  II)	  
	   PLK1	   polo-­‐like	  kinase	  1	  (Drosophila)	   CDK2	   cyclin-­‐dependent	  kinase	  2	  
	   PTTG1	   pituitary	  tumor-­‐transforming	  1	   INS	   insulin	  
	   PRKX	   protein	  kinase,	  X-­‐linked	   PPP1CC	   protein	  phosphatase	  1,	  catalytic	  subunit,	  
gamma	  isoform	  
	   IGF1R	   insulin-­‐like	  growth	  factor	  1	  receptor	   ITPR2	   inositol	  1,4,5-­‐triphosphate	  receptor,	  type	  
2	  
	   AURKA	   aurora	  kinase	  A	   /	   /	  




CDKN1A	   cyclin-­‐dependent	  kinase	  inhibitor	  1A	  
(p21,	  Cip1)	  
CASP8	   caspase	  8,	  apoptosis-­‐related	  cysteine	  
peptidase	  
	   CDK4	   cyclin-­‐dependent	  kinase	  4	   ATM	   ataxia	  telangiectasia	  mutated	  (includes	  
complementation	  groups	  A,	  C	  and	  D)	  
	   GADD45A	   growth	  arrest	  and	  DNA-­‐damage-­‐
inducible,	  alpha	  
CDK2	   cyclin-­‐dependent	  kinase	  2	  
	   TNFRSF10B	   tumor	  necrosis	  factor	  receptor	  
superfamily,	  member	  10b	  
CDKN2A	   cyclin-­‐dependent	  kinase	  inhibitor	  2A	  
(melanoma,	  p16,	  inhibits	  CDK4)	  
	   SESN1	   sestrin	  1	   TP53I3	   tumor	  protein	  p53	  inducible	  protein	  3	  
Pathways	  
in	  cancer	  
CDKN1A	   cyclin-­‐dependent	  kinase	  inhibitor	  1A	  
(p21,	  Cip1)	  
CASP8	   caspase	  8,	  apoptosis-­‐related	  cysteine	  
peptidase	  
	   CDK4	   cyclin-­‐dependent	  kinase	  4	   CDK2	   cyclin-­‐dependent	  kinase	  2	  
	   ERBB2	   v-­‐erb-­‐b2	  erythroblastic	  leukemia	  viral	  
oncogene	  homolog	  2,	  
neuro/glioblastoma	  derived	  oncogene	  
homolog	  (avian)	  
CDKN2A	   cyclin-­‐dependent	  kinase	  inhibitor	  2A	  
(melanoma,	  p16,	  inhibits	  CDK4)	  
	   CDH1	   cadherin	  1,	  type	  1,	  E-­‐cadherin	  
(epithelial)	  
PDGFRA	   platelet-­‐derived	  growth	  factor	  receptor,	  
alpha	  polypeptide	  
	   RASSF1	   Ras	  association	  (RalGDS/AF-­‐6)	  domain	  
family	  1	  
STAT5B	   signal	  transducer	  and	  activator	  of	  
transcription	  5B	  
	   MMP9	   matrix	  metallopeptidase	  9	  (gelatinase	  
B,	  92kDa	  gelatinase,	  92kDa	  type	  IV	  
collagenase)	  
HDAC1	   histone	  deacetylase	  1	  
	   IGF1R	   insulin-­‐like	  growth	  factor	  1	  receptor	   FGFR1	   fibroblast	  growth	  factor	  receptor	  1	  (fms-­‐




	   HSP90AA1	   heat	  shock	  protein	  90kDa	  alpha	  
(cytosolic),	  class	  A	  member	  1	  
LAMA4	   laminin,	  alpha	  4	  
	   HSP90AB1	   heat	  shock	  protein	  90kDa	  alpha	  
(cytosolic),	  class	  B	  member	  1	  
DCC	   deleted	  in	  colorectal	  carcinoma	  
	   CTNNB1	   catenin	  (cadherin-­‐associated	  protein),	  
beta	  1,	  88kDa	  
EPAS1	   endothelial	  PAS	  domain	  protein	  1	  
	   FGF11	   fibroblast	  growth	  factor	  11	   /	   /	  
	   TCEB1	   transcription	  elongation	  factor	  B	  (SIII),	  
polypeptide	  1	  (15kDa,	  elongin	  C)	  
/	   /	  
	   LAMB1	   laminin,	  beta	  1	   /	   /	  
Table 5.9 KEGG pathways and corresponding genes disrupted in cSCC cell lines due to 
differential methylation or transcription. DifMET = differentially methylated genes, 
DifEXP=differentially expressed genes. 
Because GO terms annotation can be extensive and too generic for functional comparison (e.g. 
“membrane”), I used only GO terms that fall in the category of “biological processes” and 
“molecular function” for the following analysis. 
The number of significantly enriched GO terms in the list of differentially methylated and 
expressed genes is 92 and 99, respectively. Of those GO terms, 23 overlap.  
The list of overlapping GO terms with corresponding number of annotated genes in each group 
and with overlapping genes is provided in Table 5.10, and a graphical overview is shown in Figure 
5.24. 
GO	  term	   DifEXP	  genes	   DifMET	  
genes	  
Overlap	  
ANATOMICAL_STRUCTURE_DEVELOPMENT	   47	   26	   TWIST1	  
ANATOMICAL_STRUCTURE_MORPHOGENESIS	   16	   9	   TWIST1	  
BIOPOLYMER_METABOLIC_PROCESS	   76	   24	   TWIST1,	  IVL	  
BIOSYNTHETIC_PROCESS	   19	   11	   /	  
CALCIUM_ION_BINDING	   8	   6	   GSN	  
CATABOLIC_PROCESS	   13	   7	   /	  
CATION_BINDING	   14	   8	   GSN	  
ESTABLISHMENT_OF_LOCALIZATION	   36	   22	   AQP9	  
ION_BINDING	   16	   10	   GSN	  
LIPID_METABOLIC_PROCESS	   16	   8	   /	  
MULTICELLULAR_ORGANISMAL_DEVELOPMENT	   41	   28	   TWIST1	  
NEGATIVE_REGULATION_OF_METABOLIC_PROCESS	   13	   7	   GSN,	  TWIST1	  
ORGAN_DEVELOPMENT	   29	   19	   TWIST1	  
POSITIVE_REGULATION_OF_BIOLOGICAL_PROCESS	   33	   17	   /	  
POSITIVE_REGULATION_OF_CELLULAR_PROCESS	   32	   15	   /	  
PROTEIN_METABOLIC_PROCESS	   59	   20	   CCT6A,	  GSN,	  
IVL	  
REGULATION_OF_BIOLOGICAL_QUALITY	   19	   14	   GSN	  
REGULATION_OF_CELLULAR_METABOLIC_PROCESS	   29	   14	   GSN,	  TWIST1	  
REGULATION_OF_METABOLIC_PROCESS	   29	   15	   GSN,	  TWIST1	  
RESPONSE_TO_CHEMICAL_STIMULUS	   16	   12	   AQP9	  
SIGNAL_TRANSDUCTION	   46	   46	   /	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SYSTEM_DEVELOPMENT	   38	   25	   TWIST1	  
TRANSPORT	   31	   20	   AQP9	  
Table 5.10 Overlapping GO terms between differentially methylated (DifMET) and differentially 
expressed (DifEXP) genes. Notably, only four genes overlapped between the two datasets: 
TWIST1, IVL, AQP9 and GSN. 
Given that the number of genes in the differentially expressed group is much higher than in the 
differentially methylated group, the number of annotated genes is inevitably higher in this group. 
 
Figure 5.24 Graphical representation of the number of genes annotated with overlapping GO 
terms in gene expression and gene methylation data. 
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5.3.8.4. Comparison of transcriptional profile of RDEB-cSCC and non-RDEB cSCC cell 
lines 
Given that previous methylation analysis has discovered a subset of of genes that is differentially 
methylated in RDEB-cSCC cell lines, I compared transcriptional profile of the two cSCC line 
types. Because the number of RDEB-cSCC cell lines is relatively low (3), I compared those to 
non-RDEB cSCC cell lines present on the same array chip in order to avoid a batch effect (6). 
The same cell lines were used for methylation profiling. 
Despite of significant differences in methylation between RDEB and non-RDEB cSCC cell lines in 
several methylation loci, only 3 probes were found to be differentially expressed in RDEB-cSCC 
cell lines, and none of these represented an annotated gene.  
5.3.8.5. Comparison of hESC, PHK and cSCC cell lines transcriptional profiles 
Human embryonic stem cells represent the most undifferentiated cellular stage. A comparison 
with PHK has revealed 1092 probes to be differentially expressed in PHK compared with hESC 
on our gene expression array. As expected, among the most overexpressed genes in PHK were 
keratin 5, 6A, 6B, 14, 16, and keratin 17, and conversely, the most under-expressed genes 
included markers of pluripotency such as LIN28, POU5F1 (OCT4), SOX2, both molecules are 
critical for stem cell maintenance, and also podocalyxin that was previously shown to be highly 
expressed in hESC (Tateno et al., 2013).  
Comparison between cSCC cell lines and hESC has revealed 1967 differentially expressed 
probes.  
I applied a similar approach described in 5.2.4.1. to identify “stem cell signatures” in the 
transcriptional profile of cSCC cell lines: I looked for genes that were differentially expressed in 
cSCC cell lines compared to PHK, and in hESC compared to PHK, but not in hESC compared to 
cSCC cell lines. This approach identified 13 genes as a putative transcriptional hESC signature in 
cSCC cell lines. Only 2 of the genes are over-expressed in cSCC cell lines. The genes are listed 
in Table 5.11, and Figure 5.25 shows log2 tranformed expression levels in all samples. 
 







in	  cSCC	  lines	  
ABCA12	   ATP-­‐binding	  cassette,	  sub-­‐
family	  A	  (ABC1),	  member	  
12	  
Downregulated	   7.756347901	   5.781304471	   6.247462963	  
ANKRD13A	   ankyrin	  repeat	  domain	  13A	   Downregulated	   10.20392824	   8.330860529	   9.032076911	  
ARL8B	   ADP-­‐ribosylation	  factor-­‐like	  
8B	  
Downregulated	   10.58582747	   9.015457599	   9.48552854	  
BTG2	   BTG	  family,	  member	  2	   Downregulated	   9.234047781	   6.630964878	   7.13495487	  
C9orf150	   chromosome	  9	  open	  
reading	  frame	  150	  
Downregulated	   8.004069303	   5.876505306	   6.273424674	  
CWH43	   cell	  wall	  biogenesis	  43	  C-­‐
terminal	  homolog	  (S.	  
cerevisiae)	  
Downregulated	   9.744739637	   5.553054785	   6.528415436	  
HSPA4L	   heat	  shock	  70kDa	  protein	  4-­‐
like	  
Downregulated	   8.837667108	   6.654665628	   7.407126652	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HSPC159	   galectin-­‐related	  protein	   Downregulated	   10.19507674	   8.29014429	   7.863605111	  
PLEKHA1	   pleckstrin	  homology	  
domain	  containing,	  family	  A	  
(phosphoinositide	  binding	  
specific)	  member	  1	  
Downregulated	   10.53528504	   9.136564582	   9.683045639	  
RPS26	   ribosomal	  protein	  S26	   Overexpressed	   6.240519279	   7.698226226	   7.16242525	  
SLC20A2	   solute	  carrier	  family	  20	  
(phosphate	  transporter),	  
member	  2	  
Downregulated	   9.676992731	   7.705310222	   8.278802779	  
TRAK1	   trafficking	  protein,	  kinesin	  
binding	  1	  
Downregulated	   9.989411899	   7.494696762	   8.153990433	  
TWIST1	   twist	  homolog	  1	  
(Drosophila)	  
Overexpressed	   6.067105355	   7.960261748	   7.925830216	  
Table 5.11. hESC transcriptional signature in cSCC cell lines. 
 
Figure 5.25 hESC transcriptional signature in cSCC cell lines. Individual rectangles depict log2 
transformed expression values for given probes in each sample. PHK=red, hESC=black, RDEB 
cSCC cell lines=pink, non-REDEB cSCC cell lines=grey. 
I also aimed to identify a unique set of genes that is exclusively over- and undertranscribed in 
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level in PHK compared to hESC, but change transcription levels in cSCC cell lines in comparison 
with both hESC and PHK. This approach removes genes that are differentially expressed due to 
physiological differentiation, or non-malignant undifferentiated state, and leaves genes that 
represent a “cancer-specific” signature. 
Only 29 genes fall within this category (listed in Table 5.12), of which 8 are overexpressed, and 
21 are underexpressed in cSCC cell lines. Figure 5.26 shows log2 transformed expression levels 
for each probe in individual samples. 





in	  cSCC	  lines	  
ACVR2A	   activin	  A	  receptor,	  type	  IIA	   Downregulated	   7.174753382	   7.199160402	   6.302883028	  
ANKRD35	   ankyrin	  repeat	  domain	  35	   Downregulated	   7.762226648	   7.74241036	   5.981989873	  
COL22A1	   collagen,	  type	  XXII,	  alpha	  1	   Downregulated	   7.631004719	   7.598820483	   5.933940829	  
EPHB6	   EPH	  receptor	  B6	   Downregulated	   6.523747094	   6.558252646	   5.626251992	  
EPHX3	   epoxide	  hydrolase	  3	   Downregulated	   7.761661576	   8.312469864	   5.976064913	  
FAM46B	   family	  with	  sequence	  
similarity	  46,	  member	  B	  
Downregulated	   9.935372259	   10.79121751	   7.379594766	  
ITM2A	   integral	  membrane	  protein	  2A	   Downregulated	   9.897791418	   9.068175733	   6.299472246	  
LPHN2	   latrophilin	  2	   Downregulated	   8.362233004	   10.03058091	   6.207604557	  
LZTS1	   leucine	  zipper,	  putative	  tumor	  
suppressor	  1	  
Downregulated	   6.207306169	   6.67818831	   5.720718317	  
NDN	   necdin	  homolog	  (mouse)	   Downregulated	   8.015988227	   9.808595573	   6.15872661	  
NISCH	   nischarin	   Downregulated	   8.678876908	   9.408698212	   7.407153546	  
NYNRIN	   NYN	  domain	  and	  retroviral	  
integrase	  containing	  
Downregulated	   8.469562988	   7.966256456	   6.102175778	  
P4HTM	   prolyl	  4-­‐hydroxylase,	  
transmembrane	  (endoplasmic	  
reticulum)	  
Downregulated	   7.81567745	   8.10233413	   6.581043205	  
PAMR1	   peptidase	  domain	  containing	  
associated	  with	  muscle	  
regeneration	  1	  
Downregulated	   7.481602661	   7.325083649	   5.682580992	  
PAPSS1	   3'-­‐phosphoadenosine	  5'-­‐
phosphosulfate	  synthase	  1	  
Downregulated	   10.26674493	   10.36927448	   9.270910268	  
PPP2R2B	   protein	  phosphatase	  2	  
(formerly	  2A),	  regulatory	  
subunit	  B,	  beta	  isoform	  
Downregulated	   8.714079329	   10.6676766	   6.38705536	  
PRICKLE1	   prickle	  homolog	  1	  
(Drosophila)	  
Downregulated	   8.484905315	   9.864984913	   6.738059773	  
RPS27L	   ribosomal	  protein	  S27-­‐like	   Downregulated	   11.89427539	   12.33474575	   10.83371845	  
SESN1	   sestrin	  1	   Downregulated	   7.846310241	   8.048683661	   6.795726138	  
VWA5A	   von	  Willebrand	  factor	  A	  
domain	  containing	  5A	  
Downregulated	   8.448715664	   7.395725704	   6.455520204	  
ZNF334	   zinc	  finger	  protein	  334	   Downregulated	   6.752018712	   7.310928817	   5.954087262	  
C13orf27	   chromosome	  13	  open	  reading	  
frame	  27	  
Overexpresssed	   8.144870542	   7.938208813	   9.291159212	  
C1orf59	   chromosome	  1	  open	  reading	  
frame	  59	  
Overexpresssed	   6.788040774	   7.233437861	   9.350337401	  
C6orf150	   chromosome	  6	  open	  reading	  
frame	  150	  
Overexpresssed	   5.687870702	   5.561222239	   7.857132716	  
HOXB7	   homeobox	  B7	   Overexpresssed	   5.924168288	   5.672006308	   8.73611203	  
NME2	   non-­‐metastatic	  cells	  2,	  
protein	  (NM23B)	  expressed	  in	  
Overexpresssed	   7.445045761	   7.061602502	   8.365042574	  
RILPL2	   Rab	  interacting	  lysosomal	  
protein-­‐like	  2	  
Overexpresssed	   6.984356728	   6.418957327	   8.098413922	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UQCRB	   ubiquinol-­‐cytochrome	  c	  
reductase	  binding	  protein	  
Overexpresssed	   9.502009046	   9.121772702	   10.59440563	  
WDR66	   WD	  repeat	  domain	  66	   Overexpresssed	   7.46809362	   5.860627283	   10.14745016	  
Table 5.12 List of genes that represent cancer-specific transcriptional signature in cSCC cell lines. 
 
 
Figure 5.26 Log2-transformed transcriptional levels of genes that are differentially expressed in 
cSCC cell lines compared to both hESC and PHK, but not in PHK compared to hESC. Top 
cluster: PHK=red, hESC=black, RDEB cSCC cell lines=pink, non-REDEB cSCC cell lines=grey. 
Left cluster: skyblue=probes that are overexpressed in cSCC cell lines, light 
green=underexpressed probes in cSCC cell lines. 
5.4. Discussion 
I have performed the first genome-wide study of DNA methylation and transcriptional profiling of 
primary cutaneous SCC cell lines generated from non-RDEB and RDEB-cSCC samples using a 
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profile to primary cultured keratinocytes and hESC to test the hypothesis that cSCC cell lines gain 
stem-cell like properties that drive their malignant phenotype. 
5.4.1. 371 genes are differentially methylated between normal primary 
keratinocytes and cSCC cell lines and include homeobox genes 
The comparison of normal primary keratinocytes with cSCC cell lines lead to the identification of 
371 differentially methylated genes. Of these genes, one was previously described to be 
epigenetically silenced in cutaneous SCC (p16, CDKN2A) (Brown et al., 2004). Putative tumour 
suppressor TP53 promoter was also previously shown to be hypermethylated in cSCC, and I 
detected CpG hypermethylation of tumour protein p53 inducible protein 3, TP53-contolled gene, 
which indicates that TP53 regulatory network may be disrupted at multiple levels through various 
molecules. Moreover, I discovered several oncogenes and tumour suppressor genes not 
previously described to be involved in cSCC to be differentially methylated in our samples, 
including MRAS, SERPINA3, SIM1, SPARCL1, REGL, and CCR3. We also discovered differential 
methylation of genes that have not been previously implicated in cancer, but that may play a role 
in cSCC development including SNRK, which is regulated by tumour suppressor 14-3-3 via 
STK11, and was hypermethylated in our tumour samples, so was TANK, a NFkappaB activator. 
DYSF probe, which is upregulated in sarcolemma (the cell membrane of cells that form a striated 
muscle fibers) wound healing, was also hypomethylated, and so was LMLN, a metallopeptidase 
that promotes cellular invasion. Hypomethylation of TWIST1 is a novel finding in cSCC, and 
suggests that EMT may play a prominent role in cSCC carcinogenesis. These genes represent 
potential novel target genes in skin cancer research.  
Four homeobox genes were also differentially methylated in comparison between skin and 
tumours including PAX4, which has previously been implicated in cancer development. 
Methylation of homeobox genes has been previously shown in breast cancer (Tommasi et al., 
2009), testicular cancer (Lind et al., 2006), and lung cancer (Rauch et al., 2007). In addition to 
aberrant methylation, deregulated expression of homeobox genes in cancer has been reported by 
many studies (Abate-Shen, 2002), and our findings warrant further functional evaluation of 
homeobox genes in cSCC. 
5.4.2. Genome-wide methylation profiling of cSCC cell lines distinguishes 
between cSCC cell lines derived from well-differentiated tumours 
and less differentiated cSCCs 
Clustering based on correlation of methylation profile of 9 cSCC cell lines was able to segregate 
RDEB-cSCC cell lines as a distinct group, and segregate additional cSCC cell lines based on 
original tumour histology. This finding was consistent with previous genotyping of cSCC; however, 
transcriptional profiling of cSCC cell lines did not detect such trend. This may be explicable by the 
general lack of correlation between epigenetic and transcriptional differences, or – since in the 
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previous chapter, such trend was indeed detected by gene expression profiling of cSCC clinical 
samples - by transcriptional “homogenisation” of cSCC cell lines due to cell culture, and a greater 
impact of technical processing on cultured cells, such as treatment with trypsin and centrifugation 
prior to RNA collection in comparison with tumour collected from patients. Additionally, both 
observations may be explicable by low number of samples, and are subject to further validation. 
5.4.3. EB cell lines have a distinct methylation profile to non-EB lines but 
not distinct transcriptional profile 
We have shown that DNA methylation pattern is crucially different in tumour cell lines derived 
from EB patients in comparison with non-EB patients and that several developmental and cancer-
related genes are significantly differentially methylated between these neoplastic entities. This 
difference in methylation profile may at least partially corroborate distinct clinical behaviour of EB-
associated SCC. Namely the epigenetic silencing of potential tumour suppressor DOK1, GATA4, 
invasion suppressor CRMP1 and MFRP hypomethylation, a gene implied in Wnt pathway 
signalling, may be accountable for more aggressive propensities of EB SCC. KEGG Pathway 
analysis pointed to differential methylation of Gap junction and several metabolic pathways, and 
GO term analysis further stressed the involvement of metabolism-related genes. GO term 
analysis also pointed to significant overrepresentation of genes involved in neural processes, 
DNA repair and ERK pathway in hypermethylated group of genes.  
Unexpectedly, transcriptional profiling revealed no differentially transcribed genes between the 
two kinds of cSCC cell lines. This may be explained by methylation differences representing a 
mere array artefact due to higher passage number of RDEB-cSCC cell lines, or due to their 
genetics, rather than epigenetics, or due to biased statistical inference caused by including only 
three RDEB-cSCC cell lines in the dataset. Further validation of differences between RDEB and 
non-RDEB cSCC on both epigenetic and transcriptional level is required. 
5.4.4. Validation of 27K methylation array with bisulfite sequencing 
confirms direction of methylation change in 46.7% of tested genes 
Bisulfite sequencing data of laser-capture microdissected samples were used to validate genes 
identified as differentially methylated in cSCC cell lines. 163 genes (46.7%) showed consistent 
direction of methylation change.  Of 163 genes for which the data was validated, 81 of the 
validated genes were hypo- and 82 were hypermethylated. This finding suggests that there may 
be a statistical bias in the methylation data due to only three normal human keratinocytes 
samples used as control, in addition to possible cell culture array artifacts. However, this also 
indicates that many genes detected as differentially methylated in cSCC cell lines represent valid 
targets that correspond with clinical samples. Such finding is important namely for functional 
evaluation of methylation targets in the future. 
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5.4.5. Methylation and transcriptional profiling of cSCC cell lines shows 
little overlap in dysregulated genes, but a notable overlap in 
dysregulated pathways and GO terms 
As expected, there was minimal overlap between dysregulated genes on methylation and 
transcriptional level (6.8% of differentially methylated genes, 3.8% of differentially expressed 
genes). Integration of transcriptional data with methylation based on ranges of methylation 
difference showed expected decrease in gene expression with increasing gene methylation in 
primary human keratinocytes, but expression levels of genes with the highest promoter 
methylation paradoxically increased. This indicates a more complex role of promoter methylation, 
in addition to transcription repression. 
Pathways dysregulated both differentially expressed and methylated genes included  Cell cycle, 
Oocyte meiosis, p53 signalling pathway and Pathways in cancer. Given the minimal overlap of 
genes between the two datasets, this observation suggests that while there may be a common 
regulatory disruption between the transcriptional and epigenetic control mechanisms, it is likely 
conveyed by different genes; possibly in a synergistic manner. 
5.4.6. Comparison of methylation profile of primary normal human 
keratinocytes and cSCC cell lines with additional tissues shows 
concordance of primary normal human keratinocytes with normal 
skin and complete segregation of cSCC cell lines from other 
cultured cell types 
An important finding is the high correlation of primary normal human keratinocytes (PHK) and 
normal skin methylation profile observed in our data. This observation indicates that primary 
keratinocytes cultured for a short period of time largely maintain the methylation profile of 
uncultured cells, and validates this model for further exploration of epigenetic regulation in normal 
skin. 
Based on the correlation of the transcriptome of less differentiated cSCC samples and 
mesenchymal stem cells, I hypothesised that cSCC cell lines may show methylome correlation 
with less differentiated tissue types, and assessed this by a comparison with a series of additional 
cultured samples. While PHK showed correlation a degree of correlation with fetal lung fibroblasts 
(possibly due to the presence of fibroblasts in the keratinocyte cultures), cSCC cell lines formed 
an entirely independent cluster in this analysis, suggesting that their methylome is strictly cancer-
specific. In addition to representing a valid biological finding, this observation may be due to 
technical aspects (batch effect) and due to the array bias, since it evaluates methylation of only a 
limited number of genomic regions, and also due to the low number of cSCC samples. 
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5.4.7. Detection of hESC signature in methylation and transcriptional data 
Based on the observation of shared cellular properties between stem cells and cancer, such as 
dedifferentiation and migration propensity, I hypothesised that a certain subset of genes may 
functionally underpin this observation. To detect these genes, I identified genes that are 
differentially methylated/expressed in cSCC cell lines compared to normal skin, but are not 
differentially methylated/expressed in cSCC cell lines compared to hESC. Using this approach, I 
detected a surprisingly low number of genes corresponding to these criteria on both methylation 
and transcriptional level. At methylation level, one of the signature genes, ACTA2, a maker of 
differentiation and a p53 target, was hypermethylated in both cSCC cell lines and hESC, 
warranting further exploration of its role of dedifferentiation in cancer-specific context. At 
transcriptional level, TWIST1, an EMT driver, was upregulated in both hESC and cSCC cell lines, 
which indicates it may be a direct driver of the less differentiated phenotype of cSCC. 
5.4.8. Conclustions and study limitations 
Overall, our results provide the first genome-wide insight into cSCC methylation profile and 
provides clues with respect to possible molecular mechanisms involved in cSCC oncogenesis. 
We identified several potential targets for further investigation in skin cancer research. Moreover, 
we demonstrated that EB-derived cSCC are an independent subset of cSCC from epigenetics 
perspective and if further studies confirm this hypothesis, EB-derived cSCC may be approached 
as an independent biological entity with specific treatment options. The fact that the methylation 
status of genes in our set was not always concordant with previous results regarding its 
oncogenic or tumour-suppressor character indicates that methylation status of individual genes 
may often be tumour tissue-specific, and in addition to this, methylation has been shown to vary 
across different specimen of the same tumour type. If our findings are validated by further studies, 
these would point to considerations of individual tumour profiling and potentially individually-
tailored medicine for cSCC patients in the future. 
Limitations of our study include the fact that methylation was detected in cell culture samples, 
rather than primary tumours. Whether tissue culture impacts methylation profiling of samples is a 
question addressed in our following experiment (see below).  
5.5. Future directions 
Future steps include validation of differential methylation loci in cSCC cell lines using Illumina 
450K array and an additional set of cell lines for biological validation. Additionally, proposed hESC 
signature genes need to be validated with additional techniques and datasets, including Illumina 
450K and bisulfite sequencing data of cSCC clinical specimen described in the following chapters. 
Finally, if this signature is confirmed, functional analysis of these genes would provide insight into 
the phenotypical characteristics of cSCC tumours.  
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6. Identification of differentially methylated 
genes in a sequential series of normal skin, 
premalignant actinic keratoses and 
malignant cSCC clinical samples   
6.1. Introduction 
As discussed in the previous chapter, profound differences in methylation exist between primary 
human keratinocytes and primary cutaneous cSCC cell lines. To the author's knowledge, no 
comprehensive, genome-wide methylation study has been previously conducted on squamous 
cell carcinomas of the skin or its precursor lesion actinic keratosis, and candidate gene 
methylation studies are limited. Thus far, silencing of CDKN2A locus has been shown to be 
commonly inactivated due to promoter methylation (Brown et al., 2004, Murao et al., 2006) in 
cSCC. Other frequently methylated genes in cSCC include FOXE1 (Venza et al., 2010, Chiles et 
al., 2003b) and E-cadherin (Chiles et al., 2003a). On the other hand, hypermethylation of DAPK 
promoter hs been demonstrated not to be involved in cSCC development (Tyler et al., 2003). 
Methylation profiling studies of other epithelial SCCs are also relatively limited. In head and neck 
SCC, MGMT, DAPK, RARbeta, MLH1, RASSF5 and MST1 genes are hypermethylated in more 
than 50% of samples compared to healthy tissue (Steinmann et al., 2009), and  hypermethylation 
of CRABP2 has been linked to poorer disease-free survival (Calmon et al., 2009). In lung SCC, 
CpG island hypermethylation has revealed 162 sites of differential methylation (Park et al., 2005). 
The difference in methylation profile in Caucasian males suffering from lung SCC seems to be 
accountable for their shorter survival (Piyathilake et al., 2003). Additionally, methylation profiling 
of non-small cell lung cancer (NSCLC) using the 450K methylation array platform and integration 
of the data with gene transcription scores has revealed phenotypically distinct molecular tumour 
subtypes (Walter et al., 2012).  
Methylation profiling of oral SCC revealed differential methylation of p16, cytoglobin and cyclin A1 
and hypermethylation of CKMT1 (Onda et al., 2006). HPV-infected cervical SCCs have been 
associated with hypermethylation of DAPK1, MGMT, CADM1 and CDH13 (Henken et al., 2007) 
and higher methylation of cyclin A1 corresponds to higher tumour grade (Kitkumthorn et al., 2006) 
of this neoplasia. All these data indicate that changes in methylation patterns are associated with 
SCC development, and that concrete alterations are most likely site-specific. Additionally, no data 
on methylation patterns in actinic keratosis exist.  
The aim of this study was to explore methylation differences in a series of clinical samples 
representing progression from normal skin to actinic keratosis and cSCC. Additionally, I aimed to 
validate differences in methylation between normal skin and cSCC using whole genome bisulfite 




6.2.  Materials and Methods 
6.2.1. Clinical samples hybridised to the DNA methylation array 
A total of 60 clinical samples were included in the study. The series consisted of 10 non-sun 
exposed and 10 sun-exposed skin samples, 20 actinic keratosis (AK) samples and 20 cSCC 
samples. The series was derived from 34 individual patients (details are provided in Table 6.1). 
Tissue	   Histology	   Immune	  Status	   Gender	   Patient	  ID	  
cSCC WD IC M M1 
AK  IC M M1 
AK  IC M M2 
NSE  IC M M2 
SE  IC M M2 
cSCC MD OTR M M3 
cSCC WMD OTR M M4 
AK  OTR M M4 
AK  OTR F MF5 
SE  OTR F MF5 
AK  OTR M M6 
cSCC MD CLL F MF7 
AK  IC M M8 
SE  IC M M8 
cSCC MD OTR M M9 
AK  OTR M M9 
NSE  OTR M M9 
cSCC MD OTR M M10 
NSE  OTR M M10 
cSCC SCC OTR M M10 
AK  CLL M M11 
NSE  CLL M M11 
AK  IC M M12 
NSE  IC M M12 
SE  IC M M12 
cSCC WD OTR M M15 
AK  OTR M M15 
NSE  OTR M M15 
SE  OTR M M15 
cSCC WD OTR M M16 
cSCC WD OTR F MF17 
cSCC WD IC M M18 
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cSCC WD IC M M19 
AK  IC M M19 
NSE  IC M M19 
AK  IC M M20 
SE  IC M M20 
NSE  OTR F MF21 
cSCC WD OTR M M22 
cSCC PD OTR M M23 
cSCC WD OTR F MF24 
AK  OTR F MF24 
SE  OTR F MF24 
cSCC WD OTR M M25 
AK  OTR M M26 
NSE  OTR M M26 
AK  OTR M M27 
cSCC WD OTR F MF28 
AK  OTR F MF28 
AK  OTR M M29 
AK  IC M M30 
SE  IC M M30 
cSCC SCC OTR M M31 
cSCC MD IC M M32 
SE  OTR F MF33 
AK  OTR F MF33 
cSCC PD OTR M M34 
AK  IC M M34 
NSE  IC M M34 
SE  IC M M34 
Table 6.1. Characteristics of 60 clinical samples used to detect methylation differences in a series 
of clinical specimen  hybridised to the Illumina 450K methylation array. The histological subtype of 
2 cSCCs was unknown. 
6.2.2. Infinium HumanMethylation450 BeadChip 
DNA processing and hybridisation was carried out in collaboration with Barts and the London 
Genome Centre. DNA isolated from undissected clinical specimen was bisulfite-converted using 
EZ DNA Methylation-Gold™ Kit (Zymo Research, United States), and hybridised to Illumina 450K 
DNA methylation array. The amount of total input DNA ranged from 40 to 550 ng of DNA, and a 
total of 14 ul of bisulfite-converted DNA was then amplified using random hexamer priming and 
Phi29 DNA polymerase followed by end-point fragmentation, and hybridised to the array at 48°C 
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for 17 h, followed by single nucleotide extension according to the manufacturer’s protocol. The 
beadchips were then washed and read using the Illumina iScan system (Illumina, United Stated), 
and the scanned raw intensities were stored in *.idat files.  
Infinium HumanMethylation450 BeadChip is a state-of-art methylation array containing 485,764 
probes that correspond to cytosine sites across the human genome. Probes are 50 bp-long and 
are linked with an address code of 23 bp in length that provides information of a bead location on 
the microarray chip. For Type I probes, the beads (one for the methylated and one for the 
unmethylated locus state) are bound to sequences complementary to either fully methylated or 
unmethylated genes (type I probes used for the older Human Methylation 27k BeadChip assay 
are described in greater in the previous chapter), while Type II probes are bound with a single 
bead type and the methylated or unmethylated state is determined during the single base 
extension following DNA hybridisation. 
The vast majority of these cytosine sites (99.3%) represent CpG dinucleotides, and the remaining 
sites (0.7%) are CNG targets, where “N” is any nucleotide. Additionally, 30.9% of CpGs are 
located in CpG islands, 23% in CpG shores (sequences distant from CpGs up to 2 kb), 9.7% in 
CpG shelves (sequences located from 2-4 kb from CpGs) (Irizarry et al., 2009) and “Open Sea” 
areas which represent isolated CpGs in the genome (Sandoval et al., 2011). Figure 6.1 depicts 
positional relationships of these elements. 
 
6.2.3. Methylation array quality control 
Quality control of raw data was carried out in collaboration with Dr Thomas Down16, the remainder 
of the analyses was carried out by the author. DNA Methylation array quality control (QC) was 
carried out with the Minfi package (Aryee et al., 2014). The raw data values contained withtin idat 
files and a sample sheet containing information about the experimental layout were read into R 
                                                       
16 The Gurdon Institute, University of Cambridge, United Kingdom. 
Figure 6.1 CpG Island and the positional relationship of CpG shore (blue), CpG Shelf (purple) 
and so-called "Open Sea" areas (orange) to CpG islands. CpG islands are defined as 
sequences more than 200 bp in length with CG representing more than half the sequence 
composition. CpG Shores are located within 2 kb distance from a CpG island, while CpG 




and several QC plots using control probes present on the array were generated to determine 
signal quality of each array prior to normalisation (Figure 6.2). Additionally, density plots of 
individual arrays were plotted to observe bimodal distribution of probes (Figure 6.3). A total of 
three samples out of 60 (5%) were excluded from further analysis based on the QC: one AK 
sample (leaving 19 AK samples for further analysis) and 2 tumour samples (leaving 18 tumour 





Figure 6.2 Log2 intensity of bisulfite conversion control probes for either green or red channel 
present on the 450K methylation array. Each sample is evaluated in two different colour channels 
(red or green) and the array contains probes that measure the efficacy of bisulfite conversion 
(each dot in the plot corresponds to a control probe). This plot shows that sample R01C01 is 
poorly bisulfite-converted, while the remaining samples pass this control step. 
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Figure 6.3 Density plot showing bimodal distribution of beta values on the x axis and the density 
on the y axis in a tumour sample (left), AK sample (middle) of proper shape in both plots that 
passes the quality control. A poor quality plot of a tumour sample is shown on the right. This 
sample was excluded from further analysis. 
6.2.4. Removal of probes associated with SNP, raw data normalisation 
and determination of differentially methylated sites 
The array is known to contain probes that are associated with SNP (Yousefi et al., 2013) which 
are likely to affect DNA methylation measurement, and these were filtered out prior to 
normalisation. Additionally, given the mixture of male and female participants in the study, probes 
corresponding to loci on the X and Y chromosome were removed. The raw data wereas then 
normalised using the quantile normalisation function in the preprocessCore R package and the 
differentially methylated regions were called using Welch's t-test using the genefilter package. P 
value was then adjusted using the Benjamini-Hochberg method in the stats package. Density plot 
of all samples pre- and post-quantile normalisation were generated with the affy package and are 




Figure 6.4 Density plot of all samples that passed QC prior to normalisation. All samples show 
proper bimodal distribution of p values, yet a certain level of noise is apparent, whereby the lines 
do not overlap perfectly. SNP probes are filtered in these data. X axis=beta values. 
 
Figure 6.5 Density plot of all samples post-normalisation shows perfect overlap of beta values 
across all samples. Bimodal distribution of beta-values has been maintained post-normalisation. 
6.2.5. Positional gene signature 
Positional gene signature was obtained with Molecular Signature Database (MSigDB) of the 
Broad Institute of Massachussetts Institute of Technology 
(http://www.broadinstitute.org/gsea/msigdb). The database uses an overlap analysis between a 
gene set provided by the user and genes reported to be in cytobands of chromosomes based on 
HUGO, October 2006, and Unigene, build 197. 








































6.2.6. Integration with expression data 
Normalised log2-transformed signal values of expression probles corresponding to differentially 
methylated genes on the Human Genome U133A 2.0 Affymetrix Array were extracted and mean 
log2 ratio calculated to observe correlation between differential methylation status and expression 
changes. 
6.2.7. Correlation with immune status and cSCC histological typing 
Association of methylation values with the immune status of patients and with cSCC histological 
subtype was carried out using the package CpGassoc. This package measures association 
between a phenotype of interest (immune status, histological subtyping). 
6.2.8. Transcription Factor Targets Analysis 
Enrichment for motifs among hyper and hypomethylated promoters was obtained with Molecular 
Signature Database (MSigDB) of the Broad Institute of Massachussetts Institute of Technology 
(http://www.broadinstitute.org/gsea/msigdb). The database uses curated TF binding sites defined 




6.3.1. Hierarchical clustering of normalised beta values separates 


















































































































































































































































































































































































Figure 6.6 Hierarchical clustering of genome-wide methylation profile of all samples based on 
Pearson’s correlation. Normal skin samples (green) form a distinct central cluster, 11 cSCC (blue) 
samples form a cluster on the top, and 11 AK(red) form a mixed cluster on the bottom. 
As shown in Figure 6.6, Pearson’s correlation of samples leads to distinct clustering of 15/20 skin 
samples in the central cluster, 11/18 cSCC samples in the top cluster and 11/19 AK samples in 
the bottom cluster. Although the distinction of samples based on their beta-values is not absolute, 
it is sufficient to expect differentially methylated genes and conduct group-wise comparisons. 
6.3.2. Sun-exposed and non-sunexposed skin are not differentially 
methylated 
I hypothesised that there may be minimal if any differences in genome-wide methylation of sun-
exposed (SE) and non-sun exposed skin (NSE). Yet as shown in Figure 6.7, three sun-exposed 
skin samples formed a cluster on the left. Thus I first compared the methylation profile of 10 NSE 
and 10 SE skin samples. This comparison revealed no statistically significant differences in 
methylation across these two tissue categories. Thereby all further detections of differentially 
methylated genes in group-wise comparisons were conducted with combined NSE and SE data 




Figure 6.7 Hierarchical clustering of sun-exposed (purple) and non-sun exposed (green) skin 
samples based on quantile-normalised beta-values. This graph shows that the sun-exposed and 
non-sunexposed samples are largely interspersed, and show high correlation of their methylation 
profile. The top-right cluster is formed by paired samples from the same patient (WA), and 
similarly the second top-right cluster contains 2 paired samples (AM). The correlation model is not 
aware of patient ID. 
6.3.3. Differentially methylated genes in group-wise comparisons 
The following comparisons were carried out: skin vs. AK, skin vs. cSCC, AK vs. cSCC. The 
number of differentially methylated probes (DMP) detected in each comparison after p value 
adjustment is shown in Table 6.2, along with coefficient of determination for mean beta values 
that describes how well the two variables fit the regression model. 
Cut-­‐off	   DMP	  Skin-­‐AK	   DMP	  Skin-­‐cSCC	   DMP	  AK-­‐cSCC	  
P	  val	  <0.0001	   2	   5137	   0	  
P	  val	  <0.01	   8697	   35175	   0	  










































































































































Coefficient	  of	  determination	  (r2)	   0.9882928	   0.9762108	   0.9922041	  
Table 6.2 Number of differentially methylated probes (DMP) detected in each comparison with a 
different adjusted p value cut-off. 
This largely reflects the high correlation of mean methylation values in AK and cSCC samples 
shown in Figure 6.8. 
 
Figure 6.8 Correlation of mean methylation values in skin, AK and cSCC samples. Top left panel 
shows correlation of mean beta values of skin and cSCC in black, top right panel shows 
correlation of mean beta values in skin and AK in coral red, and bottom left panel shows 
correlation of mean beta values of cSCC and AK. Bottomright panel is a merge of previous three 




Given that the number of DMPs detected in cSCC compared to AK was relatively low following p 
value adjustment, all comparisons are presented individually and individual cut-offs were used in 
each analysis. 
6.3.4. Comparison of genome-wide methylation of normal skin and actinic 
keratosis reveals 1822 hypermethylated and 2372 hypomethylated 
genes 
The 20 skin samples and 19 AK samples originated in a total of 20 patients, and a total of 14 
patients contributed paired skin and an AK sample. The cut-off for differentially methylated probes 
comparing skin with AK was set at <0.01 (adjusted p value). The most stringent p value (<0.0001) 
revealed only 2 differentially methylated probes: for HOXB13 and PARD3B genes.  
P value <0.01 identifies 8697 unique differentially methylated probes in AK. Of those probes, 
4124 (47%) are hypomethylated in AK, and 4564 (53%) are hypermethylated in AK compared to 
normal skin (Figure 6.9). Heatmap of beta values corresponding to this probeset in all AK and 
skin samples is shown in Figure 6.10. 
Hypomethylated probes translated into 1822 unique genes, while hypermethylated probes 
represented 2372 unique genes. 291 genes appeared in both lists due to the presence of multiple 
probes corresponding to various regions of the gene on the array. Gene set enrichment analysis 
of hyper- and hypomethylated genes was then conducted separately. 
 
Figure 6.9 Percentage of differentially methylated probes (DMP) in AK compared to skin. 
EMP=equally methylated probes. Of differentially methylated probes (DMPs), 48% are 




Figure 6.10 Heatmap of all differentially methylated probes (<0.01) in AK (grey) compared to 
normal skin (coral red). With the exception of 2 skin samples and 3 AKs, all samples clustered 
based on their tissue characteristics using this probseset. 
Genomic distribution of DMP shows their presence on all somatic chromosomes, and indicates 





Figure 6.11 Genomic distribution of probes differentially methylated in AK. Outer circle=ideogram 
of individual chromosomes. Second outer cicle=mean beta values in skin, second inner 
circle=mean beta values in AK, inner circle=differences between mean values. For the red and 
green circles, green=0, white = 0.5 red=1 (beta value). For the inner circle, -0.35=yellow, 
0.25=red. 
6.3.5. Functional genomic distribution of differentially methylated probes 
in normal skin versus AK 
Illumina 450K array classifies probes the following way: promoter probes, probes corresponding 
to intergenic sequences (Intergenic), gene body (Body) or 3’-UTR. Many probes have multiple 
functional annotations. 
Functional genomic distribution of hypermethylated and hypomethylated probes presented in 
Figure 6.12 and Table 6.3 revealed differences in the relative representation of probes 
corresponding to intergenic regions, which were far more commonly hypomethylated, in addition 
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to gene body methylation, 3’UTR and promoters that were more commonly hypermethylated in 
AK.  
skin	  vs	  ak	   Hyper	   Hypo	   P	  value	  
Intergenic	   952	   1552	   <0.0001	  
3'UTR	   554	   196	   <0.0001	  
Body	   3876	   2468	   <0.0001	  
Promoter	   2551	   1794	   <0.0001	  
Table 6.3 Functional annotation of hyper- and hypo-methylated probes. P-value based on chi-
square test. 
 
Figure 6.12 Functional genomic distribution of hyper- and hypo-methylated genes. 
Hypomethylation of probes corresponding to intergenic regions is far more common compared 
with hypermethylation. 
6.3.6. CpG islands and the neighbourhood context 
I then looked at the relative representation of probes classified based on their positional 
relationship to CpG islands. Hypomethylated probes corresponded more commonly to “open sea” 
regions (Figure 6.13, p value <0.0001). 
 
Figure 6.13 Probes corresponding to CpG islands and neighbourhood regions. 
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6.3.7. Pathway analysis of genes differentially hypomethylated in normal 
skin versus AK reveals dysregulation of cancer-related and 
metabolic pathways 
The results of KEGG pathway analysis of hypomethylated genes revealed 84 dysregulated 
pathways (full list is presented in Appendix 10). Pathways with more than 20 annotated genes are 
shown in Figure 6.14. Selected pathways directly revelant to the oncogenic process are shown in 
Table 6.4. 
 
Figure 6.14 KEGG Pathways with most annotated hypomethylated genes (skin versus AK). 
 
KEGG	  Pathway	   Annotated	  genes	   p-­‐value	   Adjusted	  p	  value	  
MAPK	  signaling	  pathway	   41	   3.84E-­‐14	   2.38E-­‐12	  
Pathways	  in	  cancer	   39	   4.56E-­‐10	   1.06E-­‐08	  
Tight	  junction	   21	   4.20E-­‐08	   7.10E-­‐07	  
Focal	  adhesion	   34	   3.35E-­‐13	   1.56E-­‐11	  
ErbB	  signaling	  pathway	   16	   1.76E-­‐07	   2.73E-­‐06	  
Cell	  adhesion	  molecules	  (CAMs)	   20	   1.99E-­‐07	   2.85E-­‐06	  
Regulation	  of	  actin	  cytoskeleton	   26	   2.70E-­‐07	   3.59E-­‐06	  
Melanogenesis	   16	   1.64E-­‐06	   1.91E-­‐05	  
Adherens	  junction	   11	   1.27E-­‐04	   7.88E-­‐04	  
Gap	  junction	   12	   1.62E-­‐04	   9.74E-­‐04	  
Wnt	  signaling	  pathway	   16	   2.31E-­‐04	   1.30E-­‐03	  
mTOR	  signaling	  pathway	   8	   7.52E-­‐04	   3.50E-­‐03	  
Endometrial	  cancer	   7	   3.49E-­‐03	   1.12E-­‐02	  
Cell	  cycle	   12	   3.75E-­‐03	   1.18E-­‐02	  
Non-­‐small	  cell	  lung	  cancer	   7	   4.33E-­‐03	   1.34E-­‐02	  
Pancreatic	  cancer	   8	   5.16E-­‐03	   1.55E-­‐02	  
0	   5	   10	   15	   20	   25	   30	   35	   40	   45	   50	  
Cell	  adhesion	  molecules	  (CAMs)	  
Purine	  metabolism	  
Tight	  juncnon	  
Regulanon	  of	  acnn	  cytoskeleton	  




Pathways	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  pathway	  
Neuroacnve	  ligand-­‐receptor	  interacnon	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Renal	  cell	  carcinoma	   8	   5.16E-­‐03	   1.55E-­‐02	  
Hedgehog	  signaling	  pathway	   7	   5.31E-­‐03	   1.57E-­‐02	  
TGF-­‐beta	  signaling	  pathway	   9	   5.58E-­‐03	   1.61E-­‐02	  
Notch	  signaling	  pathway	   6	   8.68E-­‐03	   2.27E-­‐02	  
Table 6.4 Selected dysregulated KEGG pathways. Dysregulation determined by 
overrepresentation in hypomethylated genes (skin versus AK).  
6.3.8. Positional gene signature reveals overrepresentation of 
hypomethylated probes in three or more bands on chromosomes 5, 
6 and 16  
Positional gene signature of hypomethylated genes presented in Table 6.5 revealed 30 cytobands 
with overrepresentation of hypomethylated probes. Most common chromosomes were 
chromosome 6 (5 bands), 5 (4 bands) and 16 (3 bands). 
Chromosomal	  band	   Genes	  in	  band	   Adjusted	  p	  value	  
chr10q25	   9	   1.01E-­‐02	  
chr10q26	   14	   4.25E-­‐02	  
chr11p15	   41	   6.89E-­‐05	  
chr12q24	   22	   2.70E-­‐02	  
chr15q21	   12	   2.70E-­‐02	  
chr16p12	   12	   3.34E-­‐02	  
chr16p13	   29	   2.04E-­‐03	  
chr16q24	   12	   3.39E-­‐02	  
chr1p36	   51	   1.22E-­‐07	  
chr1q32	   16	   4.66E-­‐02	  
chr20q11	   14	   3.51E-­‐02	  
chr20q13	   24	   1.17E-­‐03	  
chr21q22	   23	   5.28E-­‐03	  
chr3p14	   9	   1.72E-­‐02	  
chr3q21	   18	   1.77E-­‐04	  
chr4p16	   22	   6.89E-­‐05	  
chr4q34	   5	   2.91E-­‐02	  
chr5p13	   11	   4.79E-­‐03	  
chr5p14	   6	   2.03E-­‐02	  
chr5p15	   16	   4.79E-­‐03	  
chr5q35	   15	   4.28E-­‐02	  
chr6p21	   36	   2.19E-­‐02	  
chr6q16	   6	   3.39E-­‐02	  
chr6q22	   12	   6.82E-­‐03	  
chr6q25	   10	   3.14E-­‐02	  
chr6q26	   4	   3.39E-­‐02	  
chr7q21	   14	   4.70E-­‐03	  
chr7q32	   9	   2.70E-­‐02	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chr8q24	   24	   1.77E-­‐04	  
chr9q34	   26	   7.68E-­‐04	  
Table 6.5 Positional signature of genes hypomethylated in AK. 
Band 8q23 which has been shown to contain loss of genomic material in AK (see Chapter 3) did 
not overlap with significant loci containing hypomethylated genes. 
6.3.9. Pathway analysis of hypermethylated genes reveals dysregulation 
of additional metabolic and oncogenic pathways 
KEGG Pathway analysis of hypermethylated genes found significant dysregulation of 84 
pathways (full list is presented in Appendix 11). Table 6.6 lists pathways directly relevant in 
cancer; Figure 6.15 shows pathways with 20 or more annotated genes. 
Description	   Annotated	  genes	   p-­‐value	   Adjusted	  p	  value	  
Thyroid	  cancer	   7	   4.70E-­‐04	   1.51E-­‐03	  
p53	  signaling	  pathway	   8	   2.21E-­‐02	   4.83E-­‐02	  
Melanoma	   10	   2.82E-­‐03	   8.07E-­‐03	  
VEGF	  signaling	  pathway	   10	   4.65E-­‐03	   1.29E-­‐02	  
Endometrial	  cancer	   11	   4.50E-­‐05	   1.86E-­‐04	  
mTOR	  signaling	  pathway	   11	   4.50E-­‐05	   1.86E-­‐04	  
Notch	  signaling	  pathway	   12	   2.54E-­‐06	   1.97E-­‐05	  
Non-­‐small	  cell	  lung	  cancer	   13	   2.01E-­‐06	   1.62E-­‐05	  
Hedgehog	  signaling	  pathway	   13	   3.12E-­‐06	   2.23E-­‐05	  
Colorectal	  cancer	   13	   1.03E-­‐05	   6.01E-­‐05	  
ErbB	  signaling	  pathway	   16	   6.24E-­‐06	   4.00E-­‐05	  





Figure 6.15 Dysregulated KEGG Pathways with 20 or more annotated genes hypermethylated in 
AK. 
6.3.10. KEGG Pathways dysregulated in both hypo- and hypermethylated 
genes include critical oncogenic pathways 
Overlapping KEGG pathways included many pathways directly relevant to skin cancer, including 
MAPK, Notch, TGF-beta, ErbB signalling pathway. Interestingly, Jak-STAT, VEGF, PPAR and 
p53 pathways were significantly dysregulated among hypermethylated genes only (highlighted in 
Table 6.7). 
Shared	  KEGG	  Pathways	   Hypomethylated	   Hypermethylated	  
Acute	  myeloid	  leukemia	   ABC	  transporters	   Aminoacyl-­‐tRNA	  biosynthesis	  
Adherens	  junction	   Aldosterone-­‐regulated	  sodium	  
reabsorption	  
Arachidonic	  acid	  metabolism	  
Adipocytokine	  signaling	  pathway	   Amino	  sugar	  and	  nucleotide	  sugar	  
metabolism	  
B	  cell	  receptor	  signaling	  pathway	  
Amyotrophic	  lateral	  sclerosis	  (ALS)	   Cardiac	  muscle	  contraction	   Biosynthesis	  of	  unsaturated	  fatty	  acids	  
Apoptosis	   Complement	  and	  coagulation	  
cascades	  
Circadian	  rhythm	  -­‐	  mammal	  
Arrhythmogenic	  right	  ventricular	  
cardiomyopathy	  (ARVC)	  
Dorso-­‐ventral	  axis	  formation	   Colorectal	  cancer	  
Axon	  guidance	   Drug	  metabolism	  -­‐	  other	  enzymes	   Ether	  lipid	  metabolism	  
Basal	  cell	  carcinoma	   Fructose	  and	  mannose	  metabolism	   Glycerolipid	  metabolism	  
Calcium	  signaling	  pathway	   Galactose	  metabolism	   Glycerophospholipid	  metabolism	  
Cell	  adhesion	  molecules	  (CAMs)	   Glycolysis	  /	  Gluconeogenesis	   Glycosaminoglycan	  biosynthesis	  -­‐	  
chondroitin	  sulfate	  
Cell	  cycle	   Glyoxylate	  and	  dicarboxylate	  
metabolism	  
Homologous	  recombination	  
Chemokine	  signaling	  pathway	   Graft-­‐versus-­‐host	  disease	   Huntington's	  disease	  
Chronic	  myeloid	  leukemia	   Leishmania	  infection	   Inositol	  phosphate	  metabolism	  
Cytokine-­‐cytokine	  receptor	  interaction	   Long-­‐term	  depression	   Jak-­‐STAT	  signaling	  pathway	  
Dilated	  cardiomyopathy	   Natural	  killer	  cell	  mediated	  
cytotoxicity	  
Lysine	  degradation	  
ECM-­‐receptor	  interaction	   Olfactory	  transduction	   Lysosome	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Endocytosis	   Pantothenate	  and	  CoA	  biosynthesis	   Other	  glycan	  degradation	  
Endometrial	  cancer	   Pathogenic	  Escherichia	  coli	  infection	   PPAR	  signaling	  pathway	  
ErbB	  signaling	  pathway	   Peroxisome	   RNA	  degradation	  
Fc	  epsilon	  RI	  signaling	  pathway	   Phenylalanine	  metabolism	   Taurine	  and	  hypotaurine	  metabolism	  
Fc	  gamma	  R-­‐mediated	  phagocytosis	   Proximal	  tubule	  bicarbonate	  
reclamation	  
Thyroid	  cancer	  
Focal	  adhesion	   Pyruvate	  metabolism	   Toll-­‐like	  receptor	  signaling	  pathway	  
Gap	  junction	   Riboflavin	  metabolism	   Ubiquitin	  mediated	  proteolysis	  
Glioma	   Ribosome	   VEGF	  signaling	  pathway	  
GnRH	  signaling	  pathway	   SNARE	  interactions	  in	  vesicular	  
transport	  
Valine,	  leucine	  and	  isoleucine	  
biosynthesis	  
Hedgehog	  signaling	  pathway	   Systemic	  lupus	  erythematosus	   Vasopressin-­‐regulated	  water	  
reabsorption	  
Hematopoietic	  cell	  lineage	   Type	  I	  diabetes	  mellitus	   Vibrio	  cholerae	  infection	  
Histidine	  metabolism	   Type	  II	  diabetes	  mellitus	   alpha-­‐Linolenic	  acid	  metabolism	  
Hypertrophic	  cardiomyopathy	  (HCM)	   Tyrosine	  metabolism	   p53	  signaling	  pathway	  
Insulin	  signaling	  pathway	   	  
Leukocyte	  transendothelial	  migration	  
Long-­‐term	  potentiation	   	  
MAPK	  signaling	  pathway	   	  
Melanogenesis	   	  
Melanoma	   	   	  
Neuroactive	  ligand-­‐receptor	  interaction	  
Neurotrophin	  signaling	  pathway	  
Non-­‐small	  cell	  lung	  cancer	  
Notch	  signaling	  pathway	   	  
O-­‐Glycan	  biosynthesis	   	  
Oocyte	  meiosis	   	  
Pancreatic	  cancer	   	  
Pathways	  in	  cancer	   	  
Phosphatidylinositol	  signaling	  system	  
Progesterone-­‐mediated	  oocyte	  maturation	  
Prostate	  cancer	   	  
Purine	  metabolism	   	  
Regulation	  of	  actin	  cytoskeleton	  
Renal	  cell	  carcinoma	   	  
Small	  cell	  lung	  cancer	   	  
T	  cell	  receptor	  signaling	  pathway	  
TGF-­‐beta	  signaling	  pathway	  
Tight	  junction	   	  
Vascular	  smooth	  muscle	  contraction	  
Wnt	  signaling	  pathway	   	  
mTOR	  signaling	  pathway	   	  
Table 6.7 Dysregulated pathways in both hypo- and hyper-methylated genes in AK. Overlapping 
pathways are listed in the first column. 
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6.3.11. Positional gene signature of hypermethylated genes finds 
overrepresentation in three or more bands on chromosomes 1, 6, 
10, 16, 17 
Positional gene signature of hypermethylated genes found 31 chromosomal bands to contain 




#	  Genes	  in	  
Overlap	  (k)	  
p-­‐value	   FDR	  q-­‐value	  
chr10q22	   17	   8.07E-­‐04	   1.14E-­‐02	  
chr10q25	   10	   7.58E-­‐04	   1.12E-­‐02	  
chr10q26	   19	   4.92E-­‐04	   8.01E-­‐03	  
chr11p15	   40	   5.05E-­‐04	   8.01E-­‐03	  
chr11q13	   47	   7.68E-­‐10	   8.35E-­‐08	  
chr12q13	   29	   1.11E-­‐03	   1.45E-­‐02	  
chr12q24	   30	   1.19E-­‐04	   2.58E-­‐03	  
chr13q34	   8	   4.72E-­‐03	   4.96E-­‐02	  
chr15q22	   14	   2.44E-­‐03	   2.75E-­‐02	  
chr16p13	   43	   2.59E-­‐08	   2.11E-­‐06	  
chr16q22	   24	   3.97E-­‐06	   1.44E-­‐04	  
chr16q24	   15	   1.32E-­‐03	   1.66E-­‐02	  
chr17q11	   18	   5.16E-­‐04	   8.01E-­‐03	  
chr17q21	   37	   9.20E-­‐06	   2.73E-­‐04	  
chr17q25	   31	   1.86E-­‐07	   8.67E-­‐06	  
chr19p13	   51	   1.05E-­‐03	   1.43E-­‐02	  
chr19q13	   73	   2.27E-­‐04	   4.11E-­‐03	  
chr1p34	   30	   4.96E-­‐08	   3.24E-­‐06	  
chr1p36	   72	   1.68E-­‐15	   2.73E-­‐13	  
chr1q32	   26	   8.49E-­‐06	   2.73E-­‐04	  
chr2p23	   15	   1.76E-­‐04	   3.58E-­‐03	  
chr3p14	   13	   1.78E-­‐05	   4.46E-­‐04	  
chr3p21	   35	   3.42E-­‐07	   1.39E-­‐05	  
chr4p16	   18	   2.36E-­‐03	   2.75E-­‐02	  
chr5q35	   19	   1.76E-­‐03	   2.13E-­‐02	  
chr6p21	   76	   9.48E-­‐16	   2.73E-­‐13	  
chr6p25	   9	   4.09E-­‐03	   4.44E-­‐02	  
chr6q24	   16	   1.53E-­‐07	   8.32E-­‐06	  
chr7p22	   17	   1.66E-­‐05	   4.46E-­‐04	  
chr8q24	   25	   8.26E-­‐05	   1.92E-­‐03	  
chr9q34	   28	   2.09E-­‐04	   4.01E-­‐03	  
Table 6.8 Cytobands containing significantly more hypermethylated genes in AK. 
Comparison with regions of genomic gain in AK detected with SNP arrays (details in Chapter 3) 
revealed overlap with 8q24.11, 8q24.12, 8q24.21, 9q34.3, and 11q13.3. Hypermethylated genes 
corresponding to 11q13.3 included TPCN2 (two pore segment channel 2) and MRGPRF (MAS-
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related GPR, member F). Genes corresponding to 9q34.3 included PMPCA (peptidase 
(mitochondrial processing) alpha), SNAPC4 (small nuclear RNA activating complex, polypeptide 
4, 190kDa), SEC16A (SEC16 homolog A (S. cerevisiae)), EXD3 (exonuclease 3'-5' domain 
containing 3), EHMT1 (euchromatic histone-lysine N-methyltransferase 1), and CACNA1B 
(calcium channel, voltage-dependent, N type, alpha 1B subunit). Segment 8q24.21 codes for 
PVT1 (Pvt1 oncogene (non-protein coding)), and ASAP1 (ArfGAP with SH3 domain, ankyrin 
repeat and PH domain 1). 8q24.12 codes for EXT1 (exostosin 1) and TAF2 (TAF2 RNA 
polymerase II, TATA box binding protein (TBP)-associated factor, 150kDa). 8q24.11 did not 
contain annotated hypermethylated genes. 
Cytobands 1p36, 3p14 and 8q24 contained significantly overerepresented individual genes that 
were both hyper and hypomethylated. Bands that overlapped between both hyper and 
hypomethylated genes are shown in Table 6.9. 
Shared	  bands	   Hypo	  only	   Hyper	  only	  
chr10q25	   chr15q21	   chr10q22	  
chr10q26	   chr16p12	   chr11q13	  
chr11p15	   chr20q11	   chr12q13	  
chr12q24	   chr20q13	   chr13q34	  
chr16p13	   chr21q22	   chr15q22	  
chr16q24	   chr3q21	   chr16q22	  
chr1p36	   chr4q34	   chr17q11	  
chr1q32	   chr5p13	   chr17q21	  
chr3p14	   chr5p14	   chr17q25	  
chr4p16	   chr5p15	   chr19p13	  
chr5q35	   chr6q16	   chr19q13	  
chr6p21	   chr6q22	   chr1p34	  
chr8q24	   chr6q25	   chr2p23	  
chr9q34	   chr6q26	   chr3p21	  
	   chr7q21	   chr6p25	  
	   chr7q32	   chr6q24	  
	   	   chr7p22	  
Table 6.9 Shared bands with overrepresentation of hyper- and hypo-methylated genes. Bands 
that contain only hyper- or hypo-methylated genes are presented in additional columns. 
6.3.12.  Integration with expression data reveals generally poor correlation 
between gene expression and methylation 
Mean log2 ratio of expression values of all hyper- and hypomethylated genes revealed generally 
lower expression levels in hypermethylated genes (mean log2 ratio of 0.013 in hypermethylated 




Figure 6.16 Mean log2 expression values of hyper- and hypomethylated genes in AK. The median 
of hypomethylated genes is higher compared to hypermethylated genes (p value<0.001). 
The expression levels of both hyper- and hypomethylated genes separates normal skin from AK 
into two major clusters, in contrast to the clustering obtained with a set of 1500 randomly selected 




















































































Figure 6.17 Clustering of normal skin (green) and AK samples (red) based on the expression 
levels of hyper-, hypomethylated genes and a set of random 1500 genes. Random rows were 
selected in R using the “sample” function. 
I then explored differences in expression based on specific methylation values: all genes were 
grouped according to their methylation level into groups of more than 20% methylation difference, 
and then by 5% differences, creating the following groups: 15-20%, 10-15%, 5-10%, 0-5%, with 
negative sign for hypomethylated genes. As shown in Figure 6.18 and in the notched boxplot in 
Figure 6.20, expression levels generally increase with decreasing degree of methylation, yet this 




Figure 6.18 Mean log2 ratio of expression levels in AK correlated with different levels of 










































































































































































Figure 6.19 Mean log2 ratio of expression levels in AK correlated with different levels of 
methylation not depicting the outliers. Light blue=hypermethylated genes, coral=hypomethylated 
genes. 
I then hypothesised that character of probes with respect to functional genomic distribution 
(promoter, gene body, 3’UTR) may impact expression. 
Indeed, as shown in Figure 6.20 and Figure 6.21, hypermethylation of 3’U regions leads to 
increased gene expression, while promoter and gene body methylation decreases transcription. 
All within-group comparisons (3’UTR hypermethylated vs. 3’UTR hypomethylated etc.) were 








































Figure 6.20 Mean log2 expression values based on functional genomic distribution of probes. 
Hypermethylated probes corresponding to 3'UTR lead to increased expression, while 














































































































































Figure 6.21 Mean log2 expression values based on functional genomic distribution of probes 
(outliers not depicted). Hypermethylated probes corresponding to 3'UTR lead to increased 
expression, while hypermethylated probes corresponding to gene bodies (BD) and promoters 
(PR) decrease expression. 
 
6.3.13. Enrichment for transcription factor binding sites finds possible 
association between FOXF2, PITX2, RUNX1 and SMAD3 and 
expression levels of their target genes 
I then proceeded to determine potential transcription factors involved in AK onset by conducting 
enrichment analysis of TF-binding motifs in hyper- and hypomethylated promoters, and then a 
regression analysis of expression levels of target genes. Motif analysis calculating enrichment of 
transcription factor binding sites in hypermethylated and hypomethylated promoters using the top 






























Expression values corresponding to DMP based on genomic region
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(enriched for in both hyper- and hypomethylated promoters) are listed in Appendix 12 along with 
targeting transcription factors (TF). Motifs unique for genes with hypomethylated and 
hypermethylated promoters and respective TFs are listed in Appendices 13 and 14, respectively. 
Unique TF targeting both hyper- and hypomethylated promoters are listed in Table 6.10. This list 
contains several known oncogenes (JUN, ETS2), and TF strongly associated with cancer (LEF1, 
PITX2, GATA1), or stemness (TCF3, NFATC1), in addition to homeobox genes (POU2F1, 
POU3F2, POU6F1, LHX3), and forkhead DNA-binding proteins (FOXA1, FOXC1, FOXF2). 
FOXF2, JUN, PITX2, TCF3 (upregulated), SP1, GATA3 (downregulated) also demonstrated 
significant dysregulation at a transcriptional level (p value<0.01). 
TF	   Name	  
CEBPB	   	  CCAAT/enhancer	  binding	  protein	  (C/EBP),	  beta	  
	  DBP	   	  D	  site	  of	  albumin	  promoter	  (albumin	  D-­‐box)	  binding	  protein	  
	  ESRRA	   	  estrogen-­‐related	  receptor	  alpha	  
	  ETS2	   	  v-­‐ets	  erythroblastosis	  virus	  E26	  oncogene	  homolog	  2	  (avian)	  
	  FOXA1	   	  forkhead	  box	  A1	  
	  FOXC1	   	  forkhead	  box	  C1	  
	  FOXF2	   	  forkhead	  box	  F2	  
	  GATA1	   	  GATA	  binding	  protein	  1	  (globin	  transcription	  factor	  1)	  
	  GATA3	   	  GATA	  binding	  protein	  3	  
	  GFI1	   	  growth	  factor	  independent	  1	  
	  IRF1	   	  interferon	  regulatory	  factor	  1	  
	  JUN	   	  jun	  oncogene	  
	  LEF1	   	  lymphoid	  enhancer-­‐binding	  factor	  1	  
	  LHX3	   	  LIM	  homeobox	  3	  
	  MAZ	   	  MYC-­‐associated	  zinc	  finger	  protein	  (purine-­‐binding	  transcription	  factor)	  
	  MEF2A	   	  MADS	  box	  transcription	  enhancer	  factor	  2,	  polypeptide	  A	  (myocyte	  enhancer	  
factor	  2A)	  
	  MEIS1	   	  Meis1,	  myeloid	  ecotropic	  viral	  integration	  site	  1	  homolog	  (mouse)	  
	  MLLT7	   	  myeloid/lymphoid	  or	  mixed-­‐lineage	  leukemia	  (trithorax	  homolog,	  Drosophila);	  
translocated	  to,	  7	  
	  MYOD1	   	  myogenic	  differentiation	  1	  
	  NFAT	   NFATC	  
	  PAX4	   	  paired	  box	  gene	  4	  
	  PITX2	   	  paired-­‐like	  homeodomain	  transcription	  factor	  2	  
	  POU2F1	   	  POU	  domain,	  class	  2,	  transcription	  factor	  1	  
	  POU3F2	   	  POU	  domain,	  class	  3,	  transcription	  factor	  2	  
	  POU6F1	   	  POU	  domain,	  class	  6,	  transcription	  factor	  1	  
	  REPIN1	   	  replication	  initiator	  1	  
	  SP1	   	  Sp1	  transcription	  factor	  
	  TAF	   TATA	  Box	  Binding	  Protein	  
	  TCF3	   	  transcription	  factor	  3	  (E2A	  immunoglobulin	  enhancer	  binding	  factors	  E12/E47)	  
	  TCF8	   	  transcription	  factor	  8	  (represses	  interleukin	  2	  expression)	  
	  VSX1	   	  visual	  system	  homeobox	  1	  homolog,	  CHX10-­‐like	  (zebrafish)	  
Table 6.10 Transcription factors that target both hyper- and hypomethylated genes. 
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TF targeting genes with hypomethylated promoters in AK are listed in Table 6.11. This list 
contains additional homeobox genes (CRX, HOXA4, PRRX2), oncogenes (RUNX1) and forkhead 
DNA-binding proteins. CEBPG, FOXD1, FOXM1, NFIL3 and RUNX1 were significantly 
upregulated in AK based on expression array data (p value<0.01), while NR3C1, RXRB, SMAD3, 
STAT5A, STAT5B and TEF were significantly down-regulated in AK. 
TF	   Name	  
CBFA2T2	   	  core-­‐binding	  factor,	  runt	  domain,	  alpha	  subunit	  2;	  translocated	  to,	  2<br>	  
CBFA2T3	  
CEBPA	   	  CCAAT/enhancer	  binding	  protein	  (C/EBP),	  alpha	  
CEBPG	   	  CCAAT/enhancer	  binding	  protein	  (C/EBP),	  gamma	  
CRX	   	  cone-­‐rod	  homeobox	  
CUTL1	   	  cut-­‐like	  1,	  CCAAT	  displacement	  protein	  (Drosophila)	  
FOXD1	   	  forkhead	  box	  D1	  
FOXJ1	   	  forkhead	  box	  J1	  
FOXJ2	   	  forkhead	  box	  J2	  
FOXM1	   	  forkhead	  box	  M1	  
FOXO1A	   	  forkhead	  box	  O1A	  (rhabdomyosarcoma)	  
FOXQ1	   	  forkhead	  box	  Q1	  
GABPA	   	  GA	  binding	  protein	  transcription	  factor,	  alpha	  subunit	  60kDa<br>	  GABPB2	  
GCM1	   	  glial	  cells	  missing	  homolog	  1	  (Drosophila)	  
HOXA4	   	  homeobox	  A4	  
NFE2L1	   	  nuclear	  factor	  (erythroid-­‐derived	  2)-­‐like	  1<br>	  MAFG	  
NFE2L2	   	  nuclear	  factor	  (erythroid-­‐derived	  2)-­‐like	  2	  
NFIL3	   	  nuclear	  factor,	  interleukin	  3	  regulated	  
NKX2-­‐5	   	  NK2	  transcription	  factor	  related,	  locus	  5	  (Drosophila)	  
NR3C1	   	  nuclear	  receptor	  subfamily	  3,	  group	  C,	  member	  1	  (glucocorticoid	  receptor)	  
PRRX2	   	  paired	  related	  homeobox	  2	  
RUNX1	   	  runt-­‐related	  transcription	  factor	  1	  (acute	  myeloid	  leukemia	  1;	  aml1	  oncogene)	  
RXRB	   	  retinoid	  X	  receptor,	  beta	  
SMAD3	   	  SMAD,	  mothers	  against	  DPP	  homolog	  3	  (Drosophila)	  
SRF	   	  serum	  response	  factor	  (c-­‐fos	  serum	  response	  element-­‐binding	  transcription	  
factor)	  
STAT5A	   	  signal	  transducer	  and	  activator	  of	  transcription	  5A	  
STAT5B	   	  signal	  transducer	  and	  activator	  of	  transcription	  5B	  
TCF11<br>	  
MAFG	  
	  v-­‐maf	  musculoaponeurotic	  fibrosarcoma	  oncogene	  homolog	  G	  (avian)	  
TCF1	   	  transcription	  factor	  1,	  hepatic;	  LF-­‐B1,	  hepatic	  nuclear	  factor	  (HNF1),	  albumin	  
proximal	  factor	  
TEF	   	  thyrotrophic	  embryonic	  factor	  
Table 6.11 Transcription factors that target promoters of hypomethylated genes. 
Enriched TF that target genes with hypermethylated promoters are listed in Table 6.12. KLF12 
was significantly upregulated, AR, TEAD1 and ZNF238 were significantly down-regulated in AK. 
The remainder of TF was either not present on the expression array or their expressen level did 
not change in the progression from normal skin to AK. 
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TF	   Name	  
AR	   	  androgen	  receptor	  (dihydrotestosterone	  receptor;	  testicular	  feminization;	  spinal	  
and	  bulbar	  muscular	  atrophy;	  Kennedy	  disease)	  
ATF3	   	  activating	  transcription	  factor	  3	  
ATF4	   	  activating	  transcription	  factor	  4	  (tax-­‐responsive	  enhancer	  element	  B67)	  
CDC5L	   	  CDC5	  cell	  division	  cycle	  5-­‐like	  (S	  
ESR1	   	  estrogen	  receptor	  1	  
FOXO1A	   	  forkhead	  box	  O1A	  (rhabdomyosarcoma)	  
GATA6	   	  GATA	  binding	  protein	  6	  
GTF3A	   	  general	  transcription	  factor	  IIIA	  
HAND1	   	  heart	  and	  neural	  crest	  derivatives	  expressed	  1	  
HSF1	   	  heat	  shock	  transcription	  factor	  1	  
KLF12	   	  Kruppel-­‐like	  factor	  12	  
LMO2	   	  LIM	  domain	  only	  2	  (rhombotin-­‐like	  1)	  
NF1	   	  neurofibromin	  1	  (neurofibromatosis,	  von	  Recklinghausen	  disease,	  Watson	  
disease)	  
NKX2-­‐2	   	  NK2	  transcription	  factor	  related,	  locus	  2	  (Drosophila)	  
NR1H4	   	  nuclear	  receptor	  subfamily	  1,	  group	  H,	  member	  4	  
PBX1	   	  pre-­‐B-­‐cell	  leukemia	  transcription	  factor	  1	  
PCAF	   	  p300/CBP-­‐associated	  factor	  
SPI1	   	  spleen	  focus	  forming	  virus	  (SFFV)	  proviral	  integration	  oncogene	  spi1	  
SREBF1	   	  sterol	  regulatory	  element	  binding	  transcription	  factor	  1	  
SRF	   	  serum	  response	  factor	  (c-­‐fos	  serum	  response	  element-­‐binding	  transcription	  
factor)	  
TAL1	   	  T-­‐cell	  acute	  lymphocytic	  leukemia	  1<br>	  TCF3	  
TCF12	   	  transcription	  factor	  12	  (HTF4,	  helix-­‐loop-­‐helix	  transcription	  factors	  4)	  
TCF1	   	  transcription	  factor	  1,	  hepatic;	  LF-­‐B1,	  hepatic	  nuclear	  factor	  (HNF1),	  albumin	  
proximal	  factor	  
TEAD1	   	  TEA	  domain	  family	  member	  1	  (SV40	  transcriptional	  enhancer	  factor)	  
TFAP4	   	  transcription	  factor	  AP-­‐4	  (activating	  enhancer	  binding	  protein	  4)	  
TITF1	   	  thyroid	  transcription	  factor	  1	  
TLX2	   	  T-­‐cell	  leukemia	  homeobox	  2	  
ZIC3	   	  Zic	  family	  member	  3	  heterotaxy	  1	  (odd-­‐paired	  homolog,	  Drosophila)	  
ZNF238	   	  zinc	  finger	  protein	  238	  
Table 6.12 Transcription factors that target hypermethylated promoters. 
I then hypothesised that regulation of differentially expressed transcription factors may be due to 
methylation changes in the genomic sequence of those factors. As shown in Table 6.13, 10/23 
(43%) TF were significantly differentially methylated, and methylation status correlated with 
expected expression levels in all instances except for 3’UTR methylation of STAT5B, which 












CEBPG	   up	  	   x	   	  
FOXD1	   up	  	   x	   	  
FOXM1	   up	  	   x	   	  
NFIL3	   up	  	   x	   	  
RUNX1	   up	  	   hypomethylated	   Promoter	  
NR3C1	   down	  	   x	   	  
RXRB	   down	  	   hypermethylated	   Body	  
SMAD3	   down	  	   hypermethylated	   Promoter,Body	  
STAT5A	   down	  	   hypermethylated	   Promoter	  
STAT5B	   down	  	   hypermethylated	   3'UTR	  
TEF	   down	  	   X	   	  





	   	   	  
AR	   down	  	   X	   	  
KLF12	   up	  	   hypomethylated	   Body	  
TEAD1	   down	  	   hypermethylated	   Body	  
ZNF238	   down	  	   hypermethylated	   Promoter	  
	   	   	   	  
TF-­‐both	   	   	   	  
FOXF2	   up	  	   X	   	  
GATA3	   down	  	   hypermethylated	   Body	  
JUN	   up	  	   X	   	  
PITX2	   up	  	   hypomethylated	   Promoter,	  
Body	  
SP1	   Down	   X	   	  
TCF3	   up	  	   X	   	  
Table 6.13 Methylation status of transcription factors that target promoters of differentially 
methylated genes. X=methylation status not significantly different in AK. 
I then explored the fold change of target genes of overexpressed TFs based on the hypothesis 
that functionally, target genes of overexpressed TFs with hypomethylated promoters would be up-
regulated. Among target genes with hypomethylated promoters, 26/78 (33%) were upregulated 
(Figure 6.22). This is a higher proportion compared to genes with hypomethylated promoters that 





Figure 6.22 Proportion of upregulated and downregulated targets with hypomethylated promoters 
of overexpressed TFs. NotSig=expression levels available yet not significantly different in AK, 
NoA=gene not present on the expression array (expression levels not available). Targets of 
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Figure 6.23 Cumulative percentage plot showing proportion of upregulated, downregulated 
targets with hypomethylated promoters of down-regulated TFs. NotSig=expression levels in AK 
not significantly different from normal skin, NoA=gene not present on the expression array and 
expression levels not available. The targets of SMAD3 that were significantly dysregulated were 
all overexpressed. 
Among target genes with hypermethylated promoters, one target gene containing a binding motif 
for AR (down-regulated TF) was up-regulated (1/12, 8%) which was not significantly different from 
targets of down-regulated TF with hypomethylated promoters (p=0.14). Targets with 
hypermethylated promoters of up-regulated TF were upregulated in 11/52 instances (21%) but 
this was borderline not significant in comparison with targets with hypomethylated promoters 
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Figure 6.24 Targets with hypermethylated promoters. AR is down-regulated, the remaining TF are 
up-regulated. NotSig=expression levels in AK not significantly different from normal skin, 
NoA=gene not present on the expression array and expression levels not available. 
Cumulative percentage graphs of target genes with hyper- and hypomethylated promoters are 
shown in Figure 6.25. Overexpression of target genes with hypomethylated promoters was more 
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Figure 6.25 Cumulative percentage plot of genes that are targeted by TF that are enriched for by 
both hyper- and hypomethylated genes. Black line separates genes with hypermethylated 
promoters (left) from those with hypomethylated promoters (right). 
Linear regression analysis assessing the association between fold-change of significantly 
differentially expressed target genes which included gene promoter methylation status, TF down- 
or upregulation, targeting of hyper or hypomethylated genes only or both and individual TF in the 
model found highly significant association between promoter methylation status and gene 
expression (p value <0.05), as expected based on previous chi-square results. It also detected 
borderline significant association between expression level and up-regulation of TF (p 
value=0.05) and a significant association between expression levels and  targeting by FOXF2 (p 
value <0.0001), PITX2 (p value =0.01), RUNX1 (p value=0.01) and SMAD3 (p value =0.044). 
6.3.14. Comparison of genome-wide methylation of normal skin and cSCC 
reveals 3512 hypermethylated and 1625 hypomethylated probes 
The cut-off for differentially methylated probes comparing normal skin and cSCC was set at 
adjusted p-value <0.0001 and revealed a total of 5137 DMPs. A total of 18 cSCC samples and 20 
normal skin samples were included in this analysis, and 4 tumours and normal skin samples 
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1625 (32%) were hypomethylated in cSCC (Figure 6.26). Heatmap of beta-values corresponding 
to this probe set are shown Figure 6.27. 
 
Figure 6.26 Percentage of differentially methylated probes (DMP) in cSCC compared to skin. 
DMP=differentially methylated probes. Of DMPs, 68% are hypermethylated in cSCC, 32% are 






Figure 6.27 Heatmap of differentially methylated probes in cSCC.  Dendrograms are based on 
unsupervised clustering of beta-values across all cSCC and normal skin samples.  With the 
exception of 2 cSCC and three skin samples, this probeset was able to distinguish cSCC from 
normal skin. Red samples=cSCC, green samples=normal skin.	  
The hypermethylated probes translated into 1812 unique genes, while hypomethylated probes 
aligned to 819 unique genes. 126 genes appeared in both lists due to the presence of multiple 
probes corresponding to various regions of the gene on the array. Gene set enrichment analysis 




6.3.15. Functional genomic distribution of differentially methylated probes 
Functional genomic distribution of hypermethylated and hypomethylated probes (Figure 6.28, 
Table 6.14) shows that hypermethylated probes correspond predominantly to gene bodies, while 
27% of hypomethylated probes corresponded to intergenic regions. 
Skin	  vs.	  
cSCC	  
Hypo	   Hyper	   P	  value	  
intergenic	   644	   219	   <0.0001	  
Promoter	   582	   1594	   0.001	  
3'UTR	   62	   509	   <0.0001	  
Body	   1109	   3401	   <0.0001	  
Table 6.14 Functional annotation of hyper- and hypomethylated probes in cSCC. P -value based 
on Chi-square test with Yates' correction. 
 
Figure 6.28 Functional genomic distribution of hyper- and hypo-methylated genes. 
Hypomethylation of probes corresponding to intergenic regions is far more common compared 
with hypermethylation. 
6.3.16. CpG islands and the neighbourhood context analysis shows similar 
distribution of both hyper- and hypomethylated probes  
The distribution of probes with respect to their positional relationship to CpG islands has revealed 
no differences in the proportion of probes corresponding to Shelf and Shore, and three 
percentage points increase in probes corresponding to CpG islands among hypermethylated 




6.3.17. Pathway analysis of hyper- and hypomethylated methylated genes 
shows a substantial overlap with pathways dysregulated by hyper- 
and hypomethylated genes in AK 
Pathway analysis of hypermethylated genes revealed a total of 84 dysregulated pathways with p 
value <0.05. A full list is provided in Appendix 15. Seventy (83%) of these overlapped with 
pathways dysregulated through hypermethylated probes in AK. Figure 6.29 displays pathways 
with 20 or more annotated genes. 
 
Figure 6.29 Dysregulated KEGG pathways in genes hypermethylated in cSCC with 20 or more 
annotated genes. 
Table 6.15 lists selected dysregulated pathways in hypermethylated genes that are directly 
relevant in oncogenesis. 
Description	   #	  Genes	  	   Adjusted	  p	  value	  
Pathways	  in	  cancer	   51	   5.31E-­‐15	  
Wnt	  signaling	  pathway	   31	   1.34E-­‐12	  
0	   10	   20	   30	   40	   50	   60	  
Pathways	  in	  cancer	  
Endocytosis	  
Regulanon	  of	  acnn	  cytoskeleton	  
Wnt	  signaling	  pathway	  
MAPK	  signaling	  pathway	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  signaling	  pathway	  
Focal	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Jak-­‐STAT	  signaling	  pathway	  




MAPK	  signaling	  pathway	   29	   5.00E-­‐06	  
Focal	  adhesion	   27	   2.69E-­‐07	  
Jak-­‐STAT	  signaling	  pathway	   23	   4.25E-­‐07	  
Tight	  junction	   19	   7.27E-­‐06	  
ErbB	  signaling	  pathway	   18	   8.73E-­‐08	  
Chronic	  myeloid	  leukemia	   17	   4.67E-­‐08	  
Prostate	  cancer	   17	   5.58E-­‐07	  
PPAR	  signaling	  pathway	   16	   9.88E-­‐08	  
mTOR	  signaling	  pathway	   15	   1.87E-­‐08	  
Pancreatic	  cancer	   15	   6.07E-­‐07	  
Cell	  cycle	   15	   5.26E-­‐04	  
Acute	  myeloid	  leukemia	   14	   5.63E-­‐07	  
Colorectal	  cancer	   14	   7.86E-­‐07	  
Small	  cell	  lung	  cancer	   14	   2.46E-­‐05	  
TGF-­‐beta	  signaling	  pathway	   14	   3.06E-­‐05	  
Apoptosis	   13	   1.60E-­‐04	  
Non-­‐small	  cell	  lung	  cancer	   12	   6.04E-­‐06	  
Epithelial	  cell	  signaling	  in	  Helicobacter	  pylori	  infection	   12	   5.56E-­‐05	  
Adherens	  junction	   12	   1.47E-­‐04	  
VEGF	  signaling	  pathway	   12	   1.60E-­‐04	  
Notch	  signaling	  pathway	   9	   3.01E-­‐04	  
Basal	  cell	  carcinoma	   9	   8.13E-­‐04	  
Hedgehog	  signaling	  pathway	   9	   9.03E-­‐04	  
p53	  signaling	  pathway	   7	   4.13E-­‐02	  
Table 6.15 Selected dysregulated pathways related to cancer in genes hypermethylated in cSCC. 
KEGG pathway analysis of hypomethylated genes revealed 52 dysregulated pathways with p 
value <0.05 (listed in Appendix 16). 45 (87%) of those overlapped with pathways dysregulated in 
genes hypomethylated in AK, and 44 (85%) of those also overlapped with pathways dysregulated 
in hypermethylated genes in cSCC. Table 6.16 lists pathways that overlap between hyper- and 
hypomethylated genes, and those that are uniquely dysregulated in either group. Figure 6.30 lists 




Figure 6.30 Dysregulated pathways in hypomethylated genes in cSCC with 15 or more annotated 
genes. 
Shared	   Hyper	  only	   Hypo	  only	  
Adipocytokine	  signaling	  
pathway	  




Adherens	  junction	   Cardiac	  muscle	  contraction	  
Axon	  guidance	   Amino	  sugar	  and	  nucleotide	  sugar	  
metabolism	  
Cell	  adhesion	  molecules	  (CAMs)	  
Basal	  cell	  carcinoma	   Aminoacyl-­‐tRNA	  biosynthesis	   Glycolysis	  /	  Gluconeogenesis	  
Calcium	  signaling	  pathway	   Apoptosis	   Glycosphingolipid	  biosynthesis	  -­‐	  
lacto	  and	  neolacto	  series	  
Chemokine	  signaling	  
pathway	  
Biosynthesis	  of	  unsaturated	  fatty	  
acids	  




Bladder	  cancer	   Histidine	  metabolism	  
Dilated	  cardiomyopathy	   Cell	  cycle	   Neuroactive	  ligand-­‐receptor	  
interaction	  
ECM-­‐receptor	  interaction	   Chronic	  myeloid	  leukemia	   	  
Endocytosis	   Circadian	  rhythm	  -­‐	  mammal	   	  
Endometrial	  cancer	   Colorectal	  cancer	   	  
ErbB	  signaling	  pathway	   Epithelial	  cell	  signaling	  in	  
Helicobacter	  pylori	  infection	  
	  
Fc	  epsilon	  RI	  signaling	  
pathway	  
Ether	  lipid	  metabolism	   	  
Fc	  gamma	  R-­‐mediated	  
phagocytosis	  
Fatty	  acid	  metabolism	   	  
Focal	  adhesion	   Glioma	   	  
Fructose	  and	  mannose	  
metabolism	  
Glycerolipid	  metabolism	   	  
Gap	  junction	   Glycerophospholipid	  metabolism	   	  
GnRH	  signaling	  pathway	   Glycosaminoglycan	  biosynthesis	  -­‐	  
chondroitin	  sulfate	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Hematopoietic	  cell	  lineage	   	  
Insulin	  signaling	  pathway	   Leukocyte	  transendothelial	  
migration	  
	  
Jak-­‐STAT	  signaling	  pathway	   Lysine	  degradation	   	  
Long-­‐term	  depression	   Lysosome	   	  
Long-­‐term	  potentiation	   Non-­‐small	  cell	  lung	  cancer	   	  
MAPK	  signaling	  pathway	   Notch	  signaling	  pathway	   	  
Melanogenesis	   Oocyte	  meiosis	   	  








Primary	  bile	  acid	  biosynthesis	   	  
Pancreatic	  cancer	   Prostate	  cancer	   	  
Pathways	  in	  cancer	   Purine	  metabolism	   	  
Progesterone-­‐mediated	  
oocyte	  maturation	  
Pyruvate	  metabolism	   	  
Regulation	  of	  actin	  
cytoskeleton	  
Small	  cell	  lung	  cancer	   	  
Renal	  cell	  carcinoma	   Steroid	  biosynthesis	   	  
TGF-­‐beta	  signaling	  
pathway	  
T	  cell	  receptor	  signaling	  pathway	   	  
Thyroid	  cancer	   VEGF	  signaling	  pathway	   	  
Tight	  junction	   Vasopressin-­‐regulated	  water	  
reabsorption	  
	  
Toll-­‐like	  receptor	  signaling	  
pathway	  
Vibrio	  cholerae	  infection	   	  
Type	  II	  diabetes	  mellitus	   p53	  signaling	  pathway	   	  
Ubiquitin	  mediated	  
proteolysis	  
	   	  
Vascular	  smooth	  muscle	  
contraction	  
	   	  
Wnt	  signaling	  pathway	   	   	  
mTOR	  signaling	  pathway	   	   	  
Table 6.16 Dysregulated KEGG pathways in both hyper- and hypomethylated genes, with 
overlapping pathways listed in the first column. 
6.3.18. Positional gene signature of hyper- and hypomethylated genes 
reveals overrepresentation of DMP on chromosomes 1, 3, 16 and 17  
Positional gene signature of hypo- and hypermethylated genes presented in Table 6.17 shows 
overlapping regions on chromosomes 1,3,7 and 8, and a significant overrepresentation of 
hypermethylated genes in multiple bands on chromosomes 3, 11, 12, 16, and 17. 
Shared	   hyper	   hypo	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chr1p36	   chr10q26	   chr10q21	  
chr1q32	   chr11p11	   chr11p15	  
chr3q21	   chr11q13	   chr13q32	  
chr7p22	   chr12q13	   chr20q13	  
chr8q24	   chr12q24	   chr21q22	  
	   chr15q22	   chr2p25	  
	   chr16p13	   chr6q25	  
	   chr16q13	   chr7p12	  
	   chr16q22	   	  
	   chr16q24	   	  
	   chr17p11	   	  
	   chr17p13	   	  
	   chr17q21	   	  
	   chr17q25	   	  
	   chr19p13	   	  
	   chr1p34	   	  
	   chr1q21	   	  
	   chr1q22	   	  
	   chr22q13	   	  
	   chr2p23	   	  
	   chr3p21	   	  
	   chr3p25	   	  
	   chr4p16	   	  
	   chr5q35	   	  
	   chr6p21	   	  
	   chr8p21	   	  
	   chr9q34	   	  
Table 6.17 Positional gene signature of differentially methylated genes in cSCC. 
I then integrated overlapping regions with regions of known genomic changes in cSCC (described 
in greater details in Chapter 4) in order to find regions in which epigenetic changes detected by 
the array may be due to genomic imbalance (Table 6.18). 




Chr1	   	   	   	  
Type	   	   	   	  
G	   1pter-­‐1p32.3	   1p36;	  1p34	   both;	  hyper	  




Chr3	   	   	   	  
G	   3qcen-­‐3qter	   3q21	   both	  
L	   3pter-­‐3pcen	   3p21;	  3p25	   hyper;	  hyper	  
Chr4	   	   	   	  
L	   4pter-­‐4p13	   4p16	   hyper	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Chr5	   	   	   	  
L	   5qcen-­‐5qter	   5q35	   hyper	  
Chr6	   	   	   	  
G	   6pter-­‐6p21.1	   6p21	   hyper	  
Chr7	   	   	   	  
G	   7pter-­‐7pcen	   7p22;	  7p12	   both;	  hypo	  
Chr8	   	   	   	  
L	   8pter-­‐8pcen	   8p21	   hyper	  
G	   8qcen-­‐8qter	   8q24	   both	  
Chr9	   	   	   	  
G	   9qcen-­‐9qter	   9q34	   hyper	  
Chr10	   	   	   	  
L	   10pter-­‐10qter	   10q26;	  10q21	   hyper;	  hypo	  
Chr11	   	   	   	  
L	   11pter-­‐11pcen	   11p11;	  11p15	   hyper;	  hypo	  
G	   11q12.2-­‐
11q13.4	  
11q13	   hyper	  
Chr13	   	   	   	  
L	   13qcen-­‐13qter	   13q32	   hypo	  
Chr16	   	   	   	  
L	   16p13.11-­‐
16pcen	  
16p13	   hyper	  
Chr17	   	   	   	  
L	   17pter-­‐17qter	   17p11;	  17p13	   hyper;	  hyper	  
Chr19	   	   	   	  
L	   19pter-­‐19p13.2	   19p13	   hyper	  
G	   19pter-­‐19pcen	   19p13	   hyper	  
Chr20	   	   	   	  
G	   20pter-­‐20qter	   20q13	   hypo	  
Chr22	   	   	   	  
L	   22q11.23-­‐22qter	   22q13	   hyper	  
G	   22qcen-­‐22qter	   22q13	   hyper	  
Table 6.18 Integration of positional gene signature in cSCC with segments of genomic imbalance 
in cSCC. L=loss of genomic material, G=gain of genomic material. 
6.3.19. Overlap between hypermethylated and hypomethylated DMP in AK 
and cSCC is 34.5% and 49.3%, respectively, with functional genomic 
distribution similar to DMP in cSCC 
As expected, a substantial overlap was detected between DMP in AK and SCC: 802/1625 
(49.3%) of hypomethylated and 1213/3512 (34.5%) of hypermethylated probes. The overlapping 
hyper- and hypomethylated probes translated into 751 and 433 unique genes, respectively.  
As shown in Table 6.19 and Figure 6.31, functional genomic distribution (FGD) of overlapping 





hyper	   hypo	   P	  value	  
Intergenic	   214	   318	   <0.0001	  
Promoter	   670	   309	   0.0008	  
3'UTR	   158	   36	   <0.0001	  
Body	   1123	   551	   0.0003	  
Table 6.19 Functional genomic distribution of DMP overlapping between skin vs. AK and skin vs. 
cSCC. 
 
Figure 6.31 Functional genomic distribution of hyper- and hypomethylated probes overlapping in 
AK and cSCC. As in probes dysregulated in cSCC, hypomethylated probes more commonly 
correspond to intergenic regions, while 3’UTR and body probes are more commonly 
hypermethylated. 
6.3.20. CpG Island and the neighbourhood context of overlapping DMPs 
reveals the predominance of Open Sea probes 
In a stark contrast to both DMPs in AK and cSCC, overlapping probes corresponded mainly to 
Open Sea regions (68% of all overlapping hypomethylated probes), and minimally to CpG islands, 
which represented approximately 30% of DMPs in cSCC. 
 
Figure 6.32 Overlapping probes corresponding to CpG islands and neighbourhood regions. 
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6.3.21. Comparison of overlapping hyper- and hypomethylated genes to 
published signatures of chemical and genetic perturbations shows 
significant overlaps with genes regulated by critical oncogenic 
molecules 
Comparison of overlapping DMPs to curated chemical and genetic perturbations in GSEA based 
on published data revealed 54 hypomethylated genes to overlap with genes upregulated in 
nasopharyngeal carcinoma (Dodd et al., 2006), 44 to correspond to genes upregulated by MAPK8 
(Yoshimura et al., 2005), 36 to be targets of SUZ12 and 21 to be targeted by PRC2 based on 
ChIP on chip data in hESC (Ben-Porath et al., 2008).  
Additional GSEA analysis of curated chemical and genetic perturbations also revealed that eighty 
hypermethylated genes overlapped with TP53 targets in mammary epithelium (Perez et al., 2007) 
and 46 were shown to be downregulated in mouse skin upon RB1 and TP53 knock-down 
(Martinez-Cruz et al., 2008). Additionally, 38 genes were shown to be SOX2 targets in hESC 
(Ben-Porath et al., 2008) and 37 were shown to have their promoter bound by FOXP3 based on 
ChIP-chip analysis (Zheng et al., 2007). These detections were based on significant overlaps with 
curated datasets included in the MsigDB database. 
6.3.22. Integration with expression data based on methylation differences 
reveals decreased gene expression with increased methylation 
As shown in Figure 6.33, similar to AK, increase in methylation leads to decreased gene 
expression, but this trend changes around the extreme values towards increased expression even 
in hypermethylated genes. 
 
Figure 6.33 Mean expression log2 ratio in cSCC correlated with different levels of methylation 






















AK, with increased methylation, expression levels of genes generally decrease, with the exception 
of extreme values (differences greater than 20%) which lead to universal expression increase 
irrespective of hyper- of hypomethylation. Peak observed around 0 is most likely an artifact due to 
the very low number of genes with minimal or no differences in methylation. Figure prepared in 
collaboration with Dr Thomas Down. 
6.3.23. Validation of 450K methylation data 
DMP detected with 450K array were validated using 10 laser-capture microdissected cSCC 
samples and paired normal skin originating in male RTR patients. As described in Chapter 2, 
methylation levels of regions within 50 bp of DMP were averaged and subtracted to obtain 
differences in methylation. 
In case of perfect validation, Figure 6.35 would replicate Figure 6.34. Although Figure 6.35 shows 
a substantial overlap between hyper- and hypomethylated probes and centers around zero, 
important differences are maintained in both hyper- and hypomethylated probes and these probes 
remain well-segregated in areas of higher methylated differences. 
 
Figure 6.34 Histogram of differences in beta-values in DMPs in cSCC based on Illumina 450K 
data. Hypomethylated probes are shown in blue, hypermethylated are shown in yellow. X 



















Figure 6.35 Histograms of bs-seq methylation differences corresponding to DMP in cSCC. 
Hypomethylated regions are shown in blue, hypermethylated are shown in yellow, and 
overlapping areas are shown in purple. Figure prepared in collaboration with Dr Thomas Down. 
6.3.24. Comparison of DMP in cSCC with cSCC cell line methylation array 
data shows 21.3% overlap and absolute consistency in methylation 
direction in overlapping probes 
Overlap between 398 DMP in cSCC cell lines (described in greater details in Chapter 5) and DMP 
in cSCC clinical samples found 85 (21.3%) overlapping probes listed in Table 6.20. All probes 






Methylation	  difference	  (cSCC	  cell	  
lines)	  
Gene	  
cg19884658	   -­‐0.275119943	   -­‐0.806527778	   'KLHL21'	  
cg00283535	   -­‐0.25849724	   -­‐0.385046296	   'ANXA13'	  
cg06615154	   -­‐0.234064056	   -­‐0.420555556	   'S100A3'	  
cg17071957	   -­‐0.223950751	   -­‐0.454351852	   'GSN'	  
cg19664945	   -­‐0.211805094	   -­‐0.6425	   'GPR75'	  
cg02774160	   -­‐0.208095751	   -­‐0.414398148	   'GGT1'	  
cg14423778	   -­‐0.207495748	   -­‐0.622777778	   'MBNL1'	  
cg10725344	   -­‐0.191535391	   -­‐0.550740741	   'UNQ1940'	  
cg19881895	   -­‐0.186313042	   -­‐0.668148148	   'SLC43A3'	  
cg17777592	   -­‐0.179162659	   -­‐0.511388889	   'CAB39L'	  
cg10894512	   -­‐0.155323456	   -­‐0.506851852	   'ACTA2'	  
cg12111714	   -­‐0.149834427	   -­‐0.627592593	   'ATP8A2'	  
cg11928198	   -­‐0.148705114	   -­‐0.520185185	   'SCNM1'	  
cg25545088	   -­‐0.146568608	   -­‐0.355092593	   'ABCC10'	  
cg00891541	   -­‐0.146318331	   -­‐0.483425926	   'SMPD3'	  
















cg02164046	   -­‐0.143679321	   -­‐0.69875	   'SST'	  
cg20585500	   -­‐0.139206272	   -­‐0.119212963	   'GPHA2'	  
cg15901783	   -­‐0.139030221	   -­‐0.53287037	   'KCTD12'	  
cg16708623	   -­‐0.13734916	   -­‐0.566296296	   'TRIM2'	  
cg10261191	   -­‐0.135532024	   -­‐0.715092593	   'MGC39545'	  
cg26185508	   -­‐0.133044738	   -­‐0.505324074	   'CDCP2'	  
cg24475171	   -­‐0.132128841	   -­‐0.546712963	   'C9orf78'	  
cg17568996	   -­‐0.131679975	   -­‐0.795648148	   'NFAM1'	  
cg19297823	   -­‐0.131227901	   -­‐0.432546296	   'GCNT4'	  
cg25400358	   -­‐0.125514123	   -­‐0.338657407	   'GPR137'	  
cg13678049	   -­‐0.124327379	   -­‐0.576574074	   'PARC'	  
cg26523005	   -­‐0.119369449	   -­‐0.30587963	   'ZNF662'	  
cg09106999	   -­‐0.117949134	   -­‐0.378240741	   'CDK2'	  
cg18267381	   -­‐0.117660114	   -­‐0.55212963	   'ZNF659'	  
cg26583078	   -­‐0.117641564	   -­‐0.453148148	   'SORBS2'	  
cg22752533	   -­‐0.115850658	   -­‐0.546574074	   'SLC12A5'	  
cg06092815	   -­‐0.115838579	   -­‐0.636064815	   'SKIP'	  
cg17496921	   -­‐0.114575113	   -­‐0.598472222	   'TSPAN16'	  
cg03289872	   -­‐0.11386	   -­‐0.622175926	   'ZNF667'	  
cg21342728	   -­‐0.109232916	   -­‐0.774259259	   'GPR24'	  
cg24576425	   -­‐0.107214168	   -­‐0.588425926	   'GALNT5'	  
cg14642338	   -­‐0.105964447	   -­‐0.101851852	   'DKFZP586H21
23'	  
cg03355526	   -­‐0.105609264	   -­‐0.515648148	   'ZNF454'	  
cg21697134	   -­‐0.10513978	   -­‐0.758888889	   'FN3K'	  
cg04008913	   -­‐0.101546957	   -­‐0.431666667	   'SNRK'	  
cg02647265	   -­‐0.100980506	   -­‐0.567222222	   'FLJ22471'	  
cg23713520	   -­‐0.099507042	   -­‐0.654027778	   'TM4SF11'	  
cg19713460	   -­‐0.094102444	   -­‐0.642175926	   'SYNGR1'	  
cg13288195	   -­‐0.090652605	   -­‐0.697222222	   'FBXL22'	  
cg26104206	   -­‐0.087918025	   -­‐0.47787037	   'PHYHIP'	  
cg00594952	   -­‐0.08606512	   -­‐0.678472222	   'RIMS3'	  
cg22918700	   -­‐0.085485741	   -­‐0.208472222	   'LOC161247'	  
cg22681784	   -­‐0.077257113	   -­‐0.534166667	   'SPINK2'	  
cg10559803	   -­‐0.076638426	   -­‐0.278333333	   'RALGPS2'	  
cg23807646	   -­‐0.075254238	   -­‐0.448287037	   'SLC26A8'	  
cg13870866	   -­‐0.072867702	   -­‐0.6025	   'TBX20'	  
cg18254848	   0.060475359	   0.525462963	   'CLC'	  
cg11827101	   0.075420942	   0.58712963	   'LOC339789'	  
cg14086122	   0.084213629	   0.446435185	   'MGC7036'	  
cg02110963	   0.086314257	   0.455925926	   'MGC40222'	  
cg11091262	   0.095910565	   0.468611111	   'GALNTL5'	  
cg10054857	   0.097116639	   0.541388889	   'C18orf20'	  
cg05208878	   0.098682565	   0.449351852	   'PRAME'	  
cg14757492	   0.101085904	   0.711666667	   'DDX49'	  
cg27168844	   0.101673966	   0.470092593	   'IL17'	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cg24468890	   0.103874202	   0.233333333	   'HDAC1'	  
cg07816074	   0.10594635	   0.864259259	   'SH3TC1'	  
cg23109897	   0.107002313	   0.171712963	   'PRKDC'	  
cg18740800	   0.11015179	   0.369953704	   'KRT7'	  
cg08675585	   0.110203353	   0.65287037	   'C14orf166B'	  
cg08901867	   0.110438087	   0.43962963	   'TTLL6'	  
cg08886154	   0.114591013	   0.467222222	   'PAX4'	  
cg22988566	   0.117335619	   0.593009259	   'WFDC10B'	  
cg20950277	   0.11793971	   0.623935185	   'TNIP3'	  
cg13435792	   0.122004147	   0.456805556	   'C12orf46'	  
cg06793062	   0.126807469	   0.508333333	   'CNTNAP4'	  
cg00436282	   0.127118992	   0.713055556	   'STATH'	  
cg05429895	   0.129041385	   0.523518519	   'TLR4'	  
cg00958560	   0.143420433	   0.556851852	   'FLJ46481'	  
cg23254045	   0.144069478	   0.471574074	   'TMCO5'	  
cg20287234	   0.147602945	   0.675555556	   'GPR55'	  
cg16001913	   0.148394503	   0.466018519	   'HK1'	  
cg24423088	   0.15170408	   0.641574074	   'KRTAP8	  
cg21032583	   0.159286071	   0.665324074	   'LMLN'	  
cg26757793	   0.161896045	   0.514768519	   'MMP20'	  
cg16812893	   0.178286492	   0.464259259	   'KRTAP15	  
cg02833180	   0.181942487	   0.617777778	   'PLCL1'	  
cg26799474	   0.206382182	   0.836203704	   'CASP8'	  
cg06051311	   0.231622336	   0.662592593	   'TRIM15'	  
Table 6.20 DMP overlapping between cSCC clinical samples and cSCC cell lines. Negative value 
indicates hypermethylation in comparison to normal skin or normal cultured keratinocytes. Genes 
highlighted in bold were validated with bs-sequencing. 
Using bs-seq data to validate this set of genes, I obtained methylation levels for 74 genes, of 
which 32 (43%) showed hyper- or hypomethylation consistent with the microarray results. 
Validated genes are highlighted in bold in Table 6.20. 
 
6.3.25. Comparison of AK and cSCC reveals 81 hypermethylated and 23 
hypomethylated genes in cSCC 
Comparison of cSCC and AK data detected a total of 148 DMP in cSCC, of which 108 were 
hyper- and 40 hypomethylated in cSCC. Full list of DMP with corresponding genes is provided in 




Figure 6.36 Heatmap of probes differentially methylated in cSCC compared to AK. Light blue=AK, 
coral=cSCC. This set of 148 probes leads to almost complete separation of AK and cSCC, with 
the exception of 1 cSCC and 3 AK.  
GO term analysis of hypermethylated genes revealed over-representation of genes involved in 
the synthesis of RNA on a template of DNA and other processes related to gene transcription 
regulation. The most important genes involved in gene transcription included SREBF1, ILF3, 
EHF, MED26, SMARCD2, NOTCH4, LIMD1, NFIX, NFIC, and MED24. Additional GSEA analysis 
detected 11 SMAD2 or SMAD3 targets (ACADVL, BLCAP,CASZ1, EHF, SMAD6, KIAA1737, 
KIAA0182, SREBF1, PPP2R2D, SSBP3, BCL9L) based on published data (Koinuma et al., 
2009), TP63 targets (ZNF385A, ASS1, CASZ1, SMAD6, SEMA6D, CRAMP1L, KLHL21) and 
TP53 targets (BLCAP, ALDH4A1, ZNF385A, SMAD6, KIAA1737, KIAA0182, FAM53B, 
CRAMP1L, KLHL21, LIMD1, TOLLIP) many of which contain DNA binding sites for both TF 
(Perez et al., 2007), and 5 genes down-regulated in invasive breast cancer: ERBB3, SEC61A1, 
PPP2R2D, ILF3, AP2A2 (Wang et al., 2007). 
Analysis of hypomethylated genes detected four genes upregulated in Ewing’s sarcoma: 
ADARB1, SV2B, PCSK2, PBX1 (Riggi et al., 2008) and 2 genes that confer resistance to 




































































































































































































































































6.3.26. Functional genomic distribution of DMP in cSCC compared to AK 
shows hypomethylation of intergenic regions and more frequent 
body and 3’UTR hypermethylation 
Similar to DMPs in cSCC versus normal skin comparison, most hypermethylated probes 
corresponded to gene bodies, and 3’UTR probes were also more commonly hypermethylated. 
Intergenic probes were frequently hypomethylated, and no hypomethylated 3’UTR probe was 
detected. 
 
Figure 6.37 Functional genomic distribution of DMP in cSCC compared to AK. Similar to probes 
dysregulated in cSCC compared to skin, hypomethylated probes more commonly correspond to 
intergenic regions and no 3’UTR probe was detected as hypomethylated, while 3’UTR and body 
probes are more commonly hypermethylated. 
6.3.27. CpG islands and the neighbourhood context analysis of DMP in 
cSCC compared to AK shows few probes corresponding to CpG 
islands, and predominance of Open Sea probes 
As shown in Figure 6.38, probes corresponding to CpG islands were the least prevalent among 
DMPs, while Open Sea probes were the most common, representing 63% of all hypomethylated 
probes. One third of hypermethylated probes corresponded to Shore regions. 
 
Figure 6.38 CpG islands and neighbourhood regions analysis of DMP in cSCC. Both hyper- and 
hypomethylated probes show low representation of CpG islands probes. Almost a third of 
hypermethylated probes corresponded to Shore regions, and the majority of hypomethylated 
probes corresponded to Open Sea regions. 
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6.3.28. Comparison of DMGs with differentially expressed genes reveals 
only a modest overlap 
Only 22 genes (20%) overlapped with DEGs (AK vs. cSCC comparison). Table 6.21 lists 
overlapping genes with methylation status in cSCC and expression fold-change in cSCC. 
Overlaping	  genes	   Methylation	  in	  cSCC	   Expression	  in	  cSCC	  (FC)	  
ACADVL	   Hyper	   -­‐0.59490742	  
ASS1	   Hyper	   -­‐0.97591401	  
C1orf133	   Hypo	   -­‐0.649103	  
CASZ1	   Hyper	   -­‐1.067690085	  
ERBB3	   Hyper	   -­‐0.812783857	  
EXPH5	   Hyper	   -­‐1.137355733	  
ILF3	   Hyper	   0.4488273	  
KIAA0182	   Hyper	   -­‐0.530262499	  
MAML3	   Hypo	   -­‐0.824805407	  
MCM7	   Hyper	   0.769505193	  
MRVI1	   Hyper	   -­‐0.867038372	  
MTHFD2	   Hypo	   0.497488708	  
NFIX	   Hyper	   -­‐0.966907945	  
PBX1	   Hypo	   -­‐0.944261999	  
PCSK2	   Hypo	   -­‐1.784293921	  
PTBP1	   Hyper	   0.654671365	  
SBNO2	   Hyper	   0.824146874	  
SEC61A1	   Hyper	   0.711746567	  
SMAD6	   Hyper	   -­‐0.773196057	  
TPRG1	   Hyper	   -­‐1.172766618	  
VPS37B	   Hyper	   0.55773373	  
ZNRF1	   Hyper	   -­‐0.976904048	  
Table 6.21 Overlap between differentially methylated and differentially expressed genes in cSCC 
compared to AK. Negative foldchange represents down-regulation in cSCC compared to AK. 
6.3.29. Methylation profile of cSCC samples is not associated with cSCC 
subtyping nor with immune status 
The dataset included 9 WD, 1 WMD, 5 MD and 2 PD cSCCs (1 cSCC was of unknown histology 
and was excluded from this analysis). Neither clustering analysis (Figure 6.39) nor association 
calculation using the pvclust and CpGAssoc R packages revealed significant association with 
cSCC histological typing; either with the above-described histological phenotype description or 




Figure 6.39 Correlation of different cSCC subtypes. Light blue=WD, blue=WMD, dark blue=MD, 
black=PD. No distinct clustering pattern of cSCC samples is apparent. The left-most MD cSCC 
originated in PUVA-treated patient. 
CpGAssoc package detected no association between the immune status nor gender and cSCC 
methylation profile, but it detected an association with phenotype cSCC originating in a PUVA 
patient. This indicates that statistically significant difference in the methylation of this tumour 
compared to the remaining samples. 
6.4. Discussion 
This is the first study of genome-wide methylation in normal skin, actinic keratosis and cSCC 
using state-of-the-art Illumina 450K methylation array. Additionally, we generated the first whole-
genome bisulfite sequencing data of laser-capture micro-dissected cSCC and paired normal skin. 
6.4.1. Data processing and normalisation 
Given that the new Illumina 450K array contains two types of probes, it has been previously 
recommended to normalise the two probe types separately (Pidsley et al., 2013), in addition to 
alternative computational approaches such as Subset-quantile Within Array Normalisation 





































































































































differences in methylation between normal and precancerous and cancerous tissues, which are 
maintained even after aggressive normalisation methods applied to the 450K methylation data 
(Morris and Lowe, 2012), thereby quantile normalisation was chosen as a consensus method 
previously applied to 450K methylation data derived from cancer samples (Cahill et al., 2013).  
6.4.2. The absence of differences in methylation between sun-exposed 
and non-sunexposed skin is concordant with the previous literature 
I found no statistically significant differences in methylation between NSE and SE samples. This is 
consistent with previous reports that showed no methylation difference in cultured keratinocytes 
following UV radiation (Lahtz et al., 2013). Although UV light is a known mutagen, it seems likely 
that the vast majority of UV-induced changes in methylation are either immediately repaired, or 
methylation is largely resistant to the effects of UV light, perhaps as an evolutionary advantage. 
This may also indicate that the vast differences in methylation observed in cSCC samples 
compared to normal skin are possibly not due to the direct effect of UV light on methylation 
regulatory patterns. 
In contrast, comparison of the transcriptional profile of NSE and SE has revealed differences 
between the two tissues (details are described in Chapter 3). Probes for all differentially 
transcribed genes are present on the methylation array. The lack of differences detected in 
methylation profiles of SE and NSE skin may be due to differences in half-life of mRNA and the 
stability of methylation changes. They may equally reflect alternative epigenetic regulatory 
mechanisms, such as micro RNA, in response to UVR. This lack of concordance may also be due 
to technical issues, since the transcriptional profile was derived from samples that were treated 
with RNALater, or due to data processing since differences in methylation were detected with 
non-parametric Welch t-test, while transcriptional differences were determined with Bayesian 
statistics.  
6.4.3. Functional genomic distribution of differentially methylated probes 
in AK reveals more common hypermethylation in gene body, 
promoter and 3’UTR regions, and hypomethylation in intergenic 
regions  
Our results indicate that hypermethylated probes correspond more commonly to gene body, 
promoter and 3’-UTR regions. Hypermethylation of gene promoters is commonly observed in 
cancer (Sproul et al., 2012). Hypomethylation of gene bodies and 3’-UTR regions correlates with 
decreased gene expression in breast cancer (Shann et al., 2008), and widespread gene body 
hypomethylation was previously observed in chronic lymphocytic leukaemia using the 450K array 
(Kulis et al., 2012). In our data, we see similar trend for probes corresponding to 3’UTR, in which 
hypomethylation leads to decreased expression in AK, while hypomethylation of gene bodies and 
promoters is associated with increased gene expression.  
Most pronounced differences are apparent in hypomethylation of intergenic regions (26% vs. 12% 
of hypermethylated probes). Our finding is consistent with a previous report in breast cancer, 
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which detected the most marked hypomethylation in intergenic regions (Hon et al., 2012). 
Conversely, intergenic hypermethylation has been reported to be common in prostate cells, and 
such regions were shown to be evolutionarily conserved (Yegnasubramanian et al., 2011). In 
general, CpG methylation occurs in intragenic and intergenic non-coding regions far more 
commonly than in CpG island in 5’-promoters (about 3% of methylation occurs in CpG islands) 
and seems to regulate critical processes in a tissue-specific manner through alternative promoters 
(Maunakea et al., 2010).  
It is important to be mindful of the array design, where 25% of probes correspond to intergenic 
regions, 41% to promoter regions, 31% to gene bodies and 3% to 3’-UTR regions, and many 
probes have multiple annotations. Thereby the most striking finding is that the majority of DMP 
correspond to gene body regions and intergenic sequences, rather than promoters, which 
supports the role of non-CpG methylation in the initial steps of the oncogenic process. 
Overrepresentation of intergenic and gene body probes may also be due to genetic aberrations, 
which are far more common in AK (as described in Chapter 3), or genomic instability.  
6.4.4. Positional gene signature analysis reveals potential hotspots for 
epigenomic dysregulation in AK  
Positional gene signature analysis revealed chromosomes 1, 6, 10, and 16 as containing potential 
“hotspots” for differential methylation. Additionally, hypermethylated genes were common on 
chromosomes 17 and 19, while hypomethylated genes occurred commonly on chromosomes 5, 
7, and 20. Hypomethylation of cancerous genome has been associated with genomic instability 
and shown to preceed genomic damage (Rodriguez et al., 2006), thus these regions may 
represent areas of susceptibility to genomic alterations. Although a part of the positional signature 
for hypermethylated genes overlapped with regions of genomic gain in AK, copy-number variation 
has been previously shown to have minimal if any effect on methylation (Houseman et al., 2009). 
Given that 70% of samples were paired, germline mutations are also unlikely to underpin this 
finding.  
6.4.5. Several oncogenic pathways are dysregulated in genes differentially 
methylated in AK 
KEGG pathway analysis of hyper- and hypomethylated genes revealed that several oncogenic 
pathways are dysregulated among differentially methylated genes in AK. MAPK signaling 
pathway has been previously implicated in cSCC oncogenesis, in addition to Notch, TGF-beta, 
Wnt and mTOR pathway. Several pathways involved in cell-cell interaction were also 
dysregulated (Tight junctions, Focal adhesion, Gap junctions, Regulation of Actin cytoskeleton, 
EMC receptor interaction), all known to be dysregulated among genes driving EMT (Groger et al., 
2012). 
Hypomethylated genes showed over-representation of genes belonging to several metabolic 
pathways, which is concordant with expression data profiling. Hypermethylated genes, on the 
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other hand, showed dysregulation of additional cancer-related pathways such as p53, Jak-STAT, 
PPAR and VEGF pathway. This indicates that methylation differences are not entirely stochastic 
in nature, yet can initiate distinct processes based on changes in methylation levels.  
6.4.6. Poor correlation between gene expression and methylation is 
concordant with previous findings 
Our data confirm that the correlation between gene expression levels and methylation is overall 
rather poor. Although the expression levels generally increase with decreasing methylation, the 
changes are not linear, with a wide spread and many outliers. As described above, 
hypermethylation of 3'UTR region increases gene expression, while hypermethylation of the body 
and the promoter leads to decreased gene expression. The association between promoter 
hypermethylation and transcription repression has been observed before (Herman and Baylin, 
2003). Gene body hypermethylation, on the other hand, has been previously linked with gene 
transcription (Rakyan et al., 2008). This suggests that the relationship between methylation and 
gene expression is likely influenced by additional factors such as chromatin features or sequence 
variations (Wagner et al., 2014).  
6.4.7. Transcription factor analysis shows no correlation between TF 
dysregulation or promoter status of genes targeted, but confirms 
significant association between gene promoter methylation 
independent of TF regulation 
The purpose of this in silico analysis was to identify putative TF involved in AK onset. Our findings 
confirm that promoter hyper- or hypomethylation determines expression levels of a gene, that TF 
overexpression possibly influences target transcription (p value=0.05) and that significant over-
representation of motifs for a transcription factor does influences gene expression levels of 
targets of FOXF2, PITX2, RUNX1 and SMAD3.  
FOXF2, PITX2 and RUNX1 are up-regulated in AK, while SMAD3 is down-regulated in AK. 
SMAD3 is a member of the TGF-beta pathway, and plays a fundamental role in TGF-beta 
induced repression, namely repression of c-myc (Frederick et al., 2004). The expression of 
FOXF2 is regulated by Hedgehog signalling (Jeong et al., 2004) due to Gli-binding domains 
(Madison et al., 2009) and the gene is known to suppress WNT signalling during development 
and promote the production of extracellular matrix (Ormestad et al., 2006). Given that one of the 
ECM molecules with hypomethylated promoter and motif enrichment for FOXF2 overexpressed in 
AK is MMP13, and a critical Hedgehog pathway molecule PTCH1 is down-regulated in AK, I 
propose a direct mechanistic link between down-regulation of PTCH1, FOXF2 and MMP13 
upregulation.  
PITX2 is a homeobox gene that plays a critical role in vertebral left-right asymmetry (Campione et 
al., 1999). It was also shown to be overexpressed in thyroid cancer (Huang et al., 2010) and 
shown to activate canonical WNT signalling pathway in ovarian cancer cells (Basu and Roy, 
2013). In our data, it may be responsible for loop-like upregulation of RUNX1 as this gene 
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possesses hypomethylated promoter with motif enrichment for PITX2. This TF is known to play a 
fundamental role in hematopoiesis (Chen et al., 2009) and is involved in acute myeloid leukaemia 
onset (Miyoshi et al., 1991). In mouse skin, it was shown to promote hair follicle stem cells 
proliferation and the formation of chemically induced skin tumours (Hoi et al., 2010). 
These results warrant further exploration of RUNX1 function in AK oncogenesis. 
6.4.8. Histological subtype does not affect cSCC methylation profile 
Our previous data show that methylation profile of cSCC cell lines is associated with tumour 
histological subtyping (see Chapter 5), which is concordant with results based on SCNA typing of 
cSCC (Purdie et al., 2009). Yet data obtained in this study did not find an association between 
cSCC histology and methylation profile. This may be explicable by the low number of poorly-
differentiated samples, which seem to have the most distinct genomic and transcriptional profile. 
Alternatively, given that the samples were not microdissected and most likely contained additional 
tissue elements such as vessels, it may have diminished methylation differences that are driven 
by keratinocytes only.  
One sample originating in a PUVA-treated patient showed distinct assoctiation of its methylation 
profile with “PUVA” treated as a phenotype in the association model. Long-term PUVA treatment 
is a known carcinogen due to induced DNA damage, yet the mechanism and character of DNA is 
different from that induced by ambient solar exposure (Nataraj et al., 1996) and may thereby be 
reflected in the methylation profile. While this finding may indeed be an array artefact due to 
having only 1 PUVA cSCC, it warrants further investigation of PUVA-induced skin tumours as an 
entity of independent aetiology.  
6.4.9. Comparison of cSCC with normal skin and AK revealed more 
common hypermethylation of DMP 
68% of DMP in cSCC compared to normal skin and 73% of DMP compared to AK were 
hypermethylated. While cancer cells are usually regarded as “globally hypomethylated” and 
hypermethylated in CpG islands compared to normal tissue (Esteller, 2007), recent study of an 
aggressive type of childhood leukaemia failed to detect global hypomethylation  while observing 
expected promoter CpG hypermethylation (Basu and Roy, 2013). DMP corresponding to 
promoters were more commonly hypermethylated in cSCC (28% versus 24% compared to skin, 
27% versus 22% compared to AK, p value<0.05), while global mean beta values were highly 
similar in all three tissues. Similarly, a study in renal cell carcinoma revealed widespread 
hypermethylation, predominantly in gene bodies (Hu et al., 2014) as observed in our data 
(discussed in greater detail in the following section). This observation may be due to the array 
design, or due to tissue and tumour specificity of methylation regulation. 
349 
 
6.4.10. Functional genomic distribution of differentially methylated probes 
in cSCC reveals more common hypomethylation in intergenic 
regions, while gene body and 3’UTR are more commonly 
hypermethylated in comparisons of cSCC to both skin and AK 
Functional genomic distribution in cSCC compared to normal skin revealed massive 
hypomethylation of intergenic regions. This observation held true for comparison of cSCC to AK. 
Hypomethylation of such regions has been previously observed in breast cancer cells (Hon et al., 
2012), and represents a similar proportion as DMP in AK (26%). As in the skin versus AK 
comparison, gene body probes were more commonly hypermethylated in cSCC and in greater 
proportion (59% vs. 49% in AK), in addition to promoter and 3’UTR regions. As discussed in the 
previous section, frequent gene body hypermethylation was recently described in renal cell 
carcinoma (Hu et al., 2014) and may represent a novel area for further exploration in cancer 
epigenetics in addition to promoter methylation. Given that both comparisons (skin vs. AK, skin 
vs. cSCC) were conducted with one set of normal skin samples, it may have introduced statistical 
bias. Additionally, the majority of samples in the skin vs. AK comparison were paired in terms of 
patient origin, while the majority of cSCC samples originated in a different patient cohort, thus 
potential genomic differences may be contributing to this apparent difference in functional 
genomic distribution of DMPs. 
6.4.11. “Open Sea” probes are more commonly differentially methylated in 
AK DMPs compared with cSCC DMPs 
An apparent difference between probes differentially methylated in AK and in cSCC compared to 
normal skin was in the percentage of probes that correspond to Open Sea and Island regions. 
Open Sea probes were far more common among DMP in AK (49% of hyper- and 57% of 
hypomethylated probes in AK, 38% and 35% in cSCC, respectively). Additionally, CpG island 
probes represented 14% and 11% of hyper- and hypomethylated probes in AK, in comparison 
with 29% and 32% in cSCC (p value<0.0001). This observation indicates that important 
differences in methylation occur predominantly in the CpG island and adjacent regions (Island 
and Shore constitute over 50% of both hyper- and hypomethylated probes in cSCC), while in AK, 
changes in methylation occur primarily in Open Sea regions (49% and 57% of hyper- and 
hypomethylated probes). Given that the comparison of cSCC and AK revealed minimal 
differences in methylation and DMP corresponded mainly to Open Sea regions, in addition to 
statistical bias by comparing both to the same set of normal skin samples, from a biological 
perspective this may indicate that Open Sea methylation changes in AK are largely stochastic and 
temporary in nature, and will not necessarily lead to a subsequent malignancy, while methylation 




6.4.12. Pathway analysis of differentially methylated genes in cSCC reveals 
strong overlap with pathway analysis in AK 
In our data, 83% of pathways dysregulated in hypermethylated and 87% of pathways in 
hypomethylated genes in cSCC overlapped with those dysregulated in AK. Given that 34.5% of 
hyper- and 49.3% of hypomethylated probes overlapped between the two datasets, this finding 
may be driven by a statistical bias, but may also point to a molecular consensus in stage-wise 
development of cSCC, as it is likely that critical molecular changes that drive AK development are 
maintained during progression to cSCC. 
6.4.13. Genes that maintain their differential methylation status in both AK 
and cSCC are regulated by polycomb group genes 
In order to detect potential upstream regulators of genes that are differentially methylated in both 
AK and cSCC in the absence of our own ChIP-seq data, I compared these to curated datasets 
available in GSEA. This analysis identified MAPK8, SUZ12 and PRC2 as potential regulators of 
overlapping hypomethylated genes, and TP53, RB1, SOX2 and FOXP3 of overlapping 
hypermethylated genes. 
MAPK8 (JNK1) has been shown to play a role in inducing EMT (van der Velden et al., 2012, 
Tiwari et al., 2013) but has also been described to function as a tumour suppressor in skin cancer 
(She et al., 2002). Given that MAPK8 is down differentially expressed in cSCC, 
overrepresentation of genes up-regulated upon its induction may point towards EMT induction in 
AK and cSCC onset. SUZ12 and PRC2 are polycomb group proteins, and increased levels of 
SUZ12 were described in cSCC cell lines compared to normal keratinocytes (Balasubramanian et 
al., 2010). PRC2 is important for the maintenance of hair follicle stem cells (Millar, 2011) and has 
been linked to lung cancer oncogenesis (Sato et al., 2013). Our data justify further exploration of 
the role of polycomb genes in AK and cSCC. 
TP53 and RB1 are tumour suppressors and hypermethylation of their target genes may represent 
a mechanism of abrogating their tumour suppressor function. SOX2 has been recently described 
as a critical molecule in mouse cSCC oncogenesis (Boumahdi et al., 2014) and is significantly 
overexpressed in our cSCC data (p value 0.0007) but not in AK compared to normal skin (p 
value=0.4). Given that its putative target genes are hypermethylated in both AK and cSCC, it may 
be due to compensatory epigenomic changes to counteract its oncogenic effect. FOXP3 is 
significantly upregulated in AK (p value=0.02) but not in cSCC compared to AK (p value=0.9). 
This may indicate it is consistently upregulated early on in the oncogenic process. This is 
consistent with findings detecting increasing levels of FOXP3 in cutaneous and oral SCC in which 
it has been suggested to lead to immune escape of cancer cells (Schipmann et al., 2014). 
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6.4.14. Positional gene signature analysis detects overlap with regions of 
genomic imbalance in cSCC 
Integration with regions of known genomic imbalance in cSCC detected a substantial overlap 
between genomic loci containing significantly more DMG in cSCC. This finding indicates that an 
important part of observed differences in methylation may be due to genomic changes. 
Conversely, this integration also identifies 12q13, 12q24, 15q22, 16q13, 16q22, 16q24, 17q21, 
17q25 and 2p23 as potential hypermethylation, and 21q22, 2p25 and 6q25 as hypomethylation 
hotspots. While these areas may correspond to areas of genomic instability in this tumour set, it 
has been previously demonstrated that specific regions of the cancer genome are targeted for 
differential methylation in various tumours, and may represent tumour-specific epigenetic 
instability hotspots analogous to genomic imbalances (Lee et al., 2006a).  
In our data set, genes with various cellular functions were detected in those hotspots: 
hypermethylation hotspot 12q13 contained tumour suppressor CDK2, keratin 71 and 80, in 
addition to CTDSP2, integrin-β7 and methyltransferase like 7a which were shown to be down-
regulated in Burkitt lymphoma due to CD40 signalling (Hlavanda et al., 2007). 17q21 contains 
keratin 15 and 19 and histone deacetylase 5 (HDAC5) that has been demonstrated to play a 
critical role in the maintenance of pericentric heterochromatin (Fang et al., 2013). 
Hypomethylation hotspot 6p25 contained c-Myc target 1 (MYCT1) which has been detected as an 
upregulated target of RUNX1-ETO fusion protein in acute myeloid leukaemia (Zhao et al., 2013a) 
and F-box protein 5 (EMI1) shown to be associated with poor prognosis in ovarian carcinoma 
(Budinska et al., 2013) if overexpressed, and overtranscribed due to HPV17 (Heinrichs et al., 
2010). 
6.4.15. Validation of 450K array with bisulfite-sequencing data 
We used bisulfite-sequencing data (described in Chapter 2) to validate findings of methylation 
differences between skin and cSCC using Illumina 450K array. Although differences in 
methylation detected with bs-seq were less prominent namely in areas of less pronounced 
genomic differences, segregation in areas of higher methylation differences was sufficiently 
robust. Additionally, bs-seq data was obtained from pooled laser-capture microdissected samples, 
which may explain less profound differences in methylation. Moreover, previous comparison of 
Illumina 450K array and MeDIP-seq found a correlation of 0.68, a degree of overlap between 
hyper- and hypomethylated genes is thereby expected (Clark et al., 2012). 
6.4.16. Comparison with 27K methylation data obtained in cultured cSCC 
cell lines detects only 21.3% of DMG 
To examine cultured cSCC cell lines and normal human keratinocytes as valid models for 
exploration of methylation regulation in skin cancer, I compared 398 DMP detected in cultured 
cSCC with DMPs (p value 0.01) in cSCC clinical samples. While the methylation direction was 
consistent across all overlapping probes, the overlap was only little over one fifth of DMPs 
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detected in cultured cSCC. This may be due to several factors: cultured cSCC included EB-
derived cSCC which showed differences in epigenomic regulation compared to non-EB cSCCs 
(details are described in the previous chapter). Additionally, the passage number of some of the 
cultured cSCC cell lines was close to 20, and thereby the differences may be due to culture 
artifacts. Lastly, only three PHK were hybridised to the 27K array, and there may be a substantial 
statistical bias due to this low number of control samples. 
6.4.17. Comparison of AK and cSCC reveals 104 differentially methylated 
genes 
Perhaps the most unexpected finding was the absence of major methylation differences between 
AK and cSCC, given that our expression analysis revealed several hundred dysregulated genes. 
Furthermore, the overlap between DEG and DMG was only 20%. While this may be explained by 
different statistical approaches or the use of laser-capture microdissected samples for expression 
profiling, it is also important to stress the relatively low number of AK in the expression analysis (8 
samples), whereas such power issues did not occur in methylation analysis. Additionally, using 
stringent quantile normalisation may have prevented detection of more subtle differences in 
methylation between AK and cSCC. 
Interestingly, many of the hypermethylated genes play a direct role in regulation gene 
transcription. GSEA analysis also detected TP53 and and TP63 targets among hypermethylated 
genes, in addition to SMAD3 and SMAD2 targets.  
Overall, these data indicate that the progression from AK to cSCC requires fewer changes at the 
epigenomic level compared to the progression from normal skin to AK, and that critical oncogenic 
processes are already initiated in AK. 
6.5. Conclusions and future directions 
This study shows that critical steps for the oncogenic process are initiated in premalignant skin 
lesions and lead to dysregulation of several pro-oncogenic pathways. 
In addition to addressing the limitations of this study highlighted in the discussion, future steps 
include exploring differences in methylation based on increasing passage number to determine 
validity of this widely used and economical model in exploring cancer epigenomics. Additionally, 
more detailed analysis of bs-seq data will reveal genome-wide changes in methylation and 
identify areas of non-CpG methylation relevant in cSCC oncogenesis.  
Additionally, detecting copy-number variation in skin, AK and cSCC samples from Illumina 450K 
intensity values (Feber et al., 2014), and comparing those to expression and methylation data 
would reveal which changes detected with the methylation array are due to genuine differences in 
methylation, and which are due to the gain or loss of genomic regions. Additionally, aberrant 
methylation in AK needs to be further validated with additional samples and techniques, such as 
pyrosequencing to confirm epigenetic dysregulation of genes from normal skin through AK to 
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cSCC. Moreover, future statistical analysis should incorporate patient age at biopsy into the 
model to determine the effect of ageing in methylation in both normal skin and premalignant and 
malignant tissues.  
To gain further insight into molecular regulation in cSCC, RNA-seq and chromatin 
immunoprecipitation sequencing would reveal whole transcriptome changes and relevant 
transcriptional targets in AK and cSCC onset, and integration with bisulfite sequencing data would 
identify gene regulatory networks in this malignancy and further characterise the interplay 
between the transcriptome and the epigenome in the progression from AK to cSCC. 
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7. MicroRNA profiling of normal skin and 
cutaneous squamous cell carcinoma 
7.1. Introduction 
As described in Chapter 1.5.5, microRNAs (miRNA) are small, highly conserved molecules that 
act as translational regulators at a post-transcriptional level (Ibanez-Ventoso et al., 2008). Given 
their role in regulating many fundamental cellular processes across species (Van Wynsberghe et 
al., 2011), it is perhaps not too surprising that a large body of evidence has accumulated 
demonstrating that miRNA dysregulation substantially contributes to the onset of majority of 
human malignancies (Croce, 2009). 
The first miRNAs, lin-4 and let-7, were described in a nematode C. elegans (Lee et al., 1993, 
Reinhart et al., 2000) and were shown to regulate C. elegans development through negative post-
transcriptional regulation by binding to 3′ untranslated region (UTR) of the cognate mRNA (Lee et 
al., 2002). Because miRNAs binding to 3’UTR is solely due to imperfect complementarity, miRNA 
are able to silence both tumour suppressors and oncogenes, thus playing an important role in the 
oncogenic process (Ventura and Jacks, 2009). Although the functional role of the majority of 
eukaryotic miRNAs has yet to be elucidated, genome-wide profiling of a variety of tumours has 
shown that miRNA profiling correlates with tumour type and differentiation (Lu et al., 2005), further 
stressing the relevance of this epigenetic mechanism in cancer. 
MiRNAs are generated through a multi-step maturation process (delineated in Figure 7.1) that 
begins with the transcription of primary miRNA (pri-miRNA) by RNA polymerase II. This 
transcription product is several hundred to  several thousand nucleotides long, and is 
subsequently digested into precursor-miRNA (pre-miRNA) by a microprocessor complex 
containing Drosha, a double-stranded RNA-specific endoribonuclease, and DGCR8, also known 
as Pasha, that functions as a molecular anchor capable of distinguishing the ssRNA-dsRNA 
junction (Han et al., 2006). Pre-miRNA is approximately 60-70 nucleotides long with a stem-loop 
structure (Lee et al., 2003b), and is transported from the nucleus into the cytoplasm by Exportin-5, 
a RanGTP-dependent protein. In the cytoplasm, Dicer (an endoribonuclease) forms a complex 
with TRBP, a ds-RNA binding protein, and this complex cleaves the terminal loop, leaving mature, 
double-stranded miRNA approximately 20 base-pair long. The so-called “passenger strand” is 
degraded, while the “guide strand” that is complementary to the target sequence through Watson-
Crick base pairing is incorporated into the RNA induced silencing complex (RISC). This complex 
consists of Dicer, TRBP, protein kinase RNA activator (PACT), mature miRNA and Argonaut 2 




Figure 7.1 The process of miRNA maturation. Figure adapted from (Winter et al., 2009). 
MiRNA profiling of the skin and diseased skin tissue to date has revealed an important role for 
miRNA in the development of cutaneous disorders. Several miRNA were shown to be 
dysregulated in dermatomyositis, including upregulation of miR-146b (Eisenberg et al., 2007), that 
has been implicated in various cancers including squamous cell carcinoma of the lung (Raponi et 
al., 2009) and papillary thyroid carcinoma (Yip et al., 2011). A study comparing miRNA levels in 
basal cell carcinoma and paired clinically normal tissue has found dysregulation of a total of 16 
miRNAs (Sand et al., 2012b), in addition to miR-206 previously shown to play a role in BCC 
(Sonkoly et al., 2012). A summary of examples of miRNAs functionally involved in the 
pathogenesis of various skin conditions is provided in Table 7.1. 
miRNAs	   Putative	  
target	  
Disease	   Cell	  type	   Up/	  
Down	  
Role	   Reference	  





Down	   Induces	  collagen	  
synthesis	  and	  tissue	  
fibrosis	  
(Maurer	  et	  al.,	  2010)	  




Down	   Induces	  collagen	  
synthesis	  and	  tissue	  
fibrosis	  
(Honda	  et	  al.,	  2012)	  




Down	   Activates	  cell	  
proliferation	  and	  leads	  
to	  acanthosis	  seen	  in	  
Gottron's	  papules	  
(Inoue	  et	  al.,	  2013)	  




Down	   Induces	  epidermal	  
differentiation	  by	  
stemness	  suppression	  
(Sonkoly	  et	  al.,	  2012)	  
miR-­‐203	   SOCS-­‐3	   Psoriasis	   Keratino-­‐
cytes	  
Up	   Activates	  proliferation	  
and	  differentiation	  of	  




miR-­‐424	   MEK1	  etc.	   Psoriasis	   Keratino-­‐
cytes	  
Down	   Induces	  keratinocyte	  
proliferation	  
(Ichihara	  et	  al.,	  2011)	  
miR-­‐18a-­‐
5p	  





Up	   Induces	  keratinocyte	  
apoptosis	  
(Ichihara	  et	  al.,	  2014)	  
miR-­‐146a	   -­‐	   Melanoma	   Tumour	  
cells	  




and	  invasion	  of	  tumor	  
cells	  
(Yamashita	  et	  al.,	  2013)	  
Table 7.1 An overview summarising miRNAs involved in skin diseases (excluding cSCC). Table 
adapted from (Jinnin, 2014). 
Previous studies exploring the role of miRNAs in cSCC have shown that miR-361-5p is decreased 
in cSCC and its decrease may play a role in VEGFA upregulation and subsequent tumour 
angiogenesis (Kanitz et al., 2012). MiR-124 and miR-214 that target ERK1 and ERK2, 
respectively, were shown to be downregulated in cSCC due to promoter hypermethylation 
(Yamane et al., 2013). A targeted approach has detected overexpression of miR-21 and miR-31 
and down-regulation of miR-205 (Bruegger et al., 2013). Comparison of 4 cSCCs and 4 normal 
skin samples from healhy donors using TaqMan MicroRNA Low Density Array has revealed 58 
differentially expressed miRNAs, and implicated miR-125b as a regulator of MMP 13 and potential 
tumour suppressor (Xu et al., 2012). Additional study of 7 cSCCs and 7 paired skin samples using 
Agilent miRNA microarrays found 13 upregulated and 18 downregulated miRNAs (Sand et al., 
2012a). 
The purpose of the current study was to detect differences in miRNA expression in a large series 
of paired cSCC samples and clinically normal skin from both immunocompromised and 
immunocompetent patients. Additionally, findings of differences in miRNA expression are paired 
with genome-wide expression and SNP data to detect transcriptional targets potentially regulated 
by miRNAs. 
7.2. Materials and methods 
7.2.1. Patients characteristics and tissue samples 
Matched perilesional normal skin and tumour samples from a total of 27 patients were collected at 
the time of surgery and snap frozen at -70’C in liquid nitrogen. Additional normal skin from area 
distant to the tumour was collected from 3 patients. This set represented a new series of samples 
that were not previously used for genetic or transcriptional profiling. 
Total RNA was isolated from a total of 52 samples, and 40 most appropriate samples (paired 
samples of normal and malignant tissue of the best RIN value) were were labeled with the 
miRCURY LNA™ microRNA Hi-Power Labeling Kit, Hy3TM/Hy5TM and hybridised to the 
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miRCURY LNA™ microRNA Array (7'th GEN) (Exiqon, Denmark). Those 40 samples represented 
a total of 19 cSCCs, 20 perilesional skin samples and 1 distant normal skin, and were collected 
from 17 patients (5 females and 12 males), 13 of whom were immunocompromised (OTR) and 4 
were immunocompetent (IC). Clinical details of samples are provided in Table 7.2. 






A260/A280 A260/A230 RIN 
VH 
Tumour 
WD-cSCC Male RTR RTR 92.80 2.06 1.78 6.2 
VH Skin Perilesional 
skin 
Male RTR RTR 18.40 2.17 0.13 7.3 
BD 
Tumour 
MD-cSCC Female RTR RTR 11.70 2.23 0.97 NA 
BD Skin Perilesional 
skin 
Female RTR RTR 51.10 2.24 0.59 6.2 
BR Lip 
Tumour 















Male RTR RTR 16.30 1.99 0.90 1 
DT 
Tumour 
cSCC Female IC IC 64.60 2.10 0.30 6.1 
DT Skin Perilesional 
skin 
Female IC IC 11.30 2.08 0.04 6.7 
JD 
Tumour 
WD-cSCC Male RTR RTR 9.00 1.63 0.47 NA 
JD Skin Perilesional 
skin 
Male RTR RTR 17.30 2.02 0.72 7.2 
MF 
Tumour 
MD-cSCC Female IC IC 38.10 2.07 1.50 6.8 






cSCC Female RTR RTR 83.30 2.09 1.84 2.9 
TK Skin Perilesional 
skin 
Female RTR RTR 8.90 1.81 0.56 5.7 
VH2 
Tumour 










normal skin  
Male  RTR RTR 12.90 1.68 0.12 2.4 
WH 
Tumour 
WD-cSCC Male IC IC 185.10 2.07 1.99 4.2 
WH Skin Perilesional 
skin 
Male IC IC 36.80 2.05 0.26 2.4 
ML 
Tumour 
MD-cSCC Male RTR RTR 173.20 2.03 1.68 6.9 
ML Skin Perilesional 
skin 
Male RTR RTR 38.00 2.11 1.36 6.9 
CW 
Tumour 
cSCC Male RTR RTR 185.50 2.11 1.51 8.4 
CW Skin Perilesional 
skin 
Male RTR RTR 96.40 2.14 2.12 NA 
MB 
Tumour 
MD-cSCC Female RTR RTR 235.40 2.08 2.02 2.8 
MB Skin Perilesional 
skin 
Female RTR RTR 149.80 2.07 1.84 2.6 
JN 
Tumour 
cSCC Female RTR RTR 453.10 2.05 2.12 4 
JN Skin Perilesional 
skin 





Male RTR RTR 130.30 2.10 1.27 7.8 






MD-cSCC Male IC IC 698.80 2.10 2.19 2.3 
AW Skin Perilesional 
skin 
Male IC IC 155.80 2.07 1.99 2.9 
EC 
Tumour 
MD-cSCC Male RTR RTR 606.30 2.09 2.08 2.3 
EC Skin Perilesional 
skin 
Male RTR RTR 156.30 2.09 2.00 2.6 
PS 
Tumour 
cSCC Male RTR RTR 149.60 2.07 2.08 2.5 
PS Peri Perilesional 
skin 
Male RTR RTR 57.00 2.06 1.96 5.6 
PS NS Distant 
normal skin 
Male RTR RTR 69.50 1.69 0.83 4 
BR NS Distant 
normal skin 
Male RTR RTR 118.00 2.06 1.94 2.7 
JD2 
Tumour 
WD-cSCC Male RTR RTR 140.60 2.08 1.63 2.9 
Table 7.2 Samples hybridised to the miRNA microarrays and used for detection of differences 
between cSCC and clinically normal skin. If histology of cSCC samples was known, it was 
included in the histology section (WD=well differentiated, MD=moderately differentiated). RIN NA 
= RIN value below 1.  
7.2.2. Exiqon microarrays 
The miRCURY LNA™ microRNA Array uses locked nucleic acid (LNA)-modified oligonucleotides. 
LNAs are synthetic, thermostable RNA analogues with the ribose ring “locked” in 3-endo 
conformation by a methylene bridge between 2’-O and 4’-C atoms that allow miRNA profiling at 
uniform melting temperature. This unique feature allows the melting temperature for the array 
probes to be more uniform by varing the LNA content, and thereby allows for more specific 




Figure 7.2 LNA nucleotide structure depicting the methylene bridge (in red) between the 4’-C and 
2’-0 of the ribose ring. Figure adapted from 
http://www.vanderbilt.edu/vicb/DiscoveriesArchives/biomarking_infection_with_BSI.html. 
The array contains a total of 3100 capture probes that cover microRNAs annotated in miRBase 
version 19.0, in addition to relevant viral microRNAs and 25 proprietary miRNAs not listed in 
miRBase. 
Array labelling and hybridisation was carried out by Exiqon (Denmark) according to the 
manufacturer’s protocol. Following RNA quality control, samples were labelled by a two-step 
procedure with red and green dye and hybridised using Tecan HS Pro™ hybridisation station that 
automates both labelling and washing steps of the RNA processing.  Briefly, one microgram of 
total RNA was mixed with spike-in miRNAs that are used for quality control and normalisation, 
and incubated with calf intestinal alkaline phosphatase (CIP) and CIP buffer for 30 minutes at 
37°C in a PCR cycler with a heated lid. This process removes 5’-phosphates from RNA. Samples 
were then incubated at 95°C for 5 minutes and cooled on ice. Samples were then labelled with 
fluorophores by mixing 4 microliters of CIP reaction product with Hy3™ or Hy5™ fluorophores, 
labelling buffer, DMSO and a labelling enzyme and incubating the mix for 1 hour at 16°C in a PCR 
cycler, followed by incubation at 65°C for 15 minutes to stop the enzymatic reaction. Sample were 
then cooled at 4°C and hybridised to microarray slides within 2 hours. 
Prior to hybridisation, equal amounts Hy3™ or Hy5™-labelled portions of a sample were mixed 
on ice and 25 µl of hybridisation buffer were added to the reaction followed by denaturation of the 
mixture at 95°C. Samples were then quickly cooled on ice, while microarray slides were prepared 
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in the Tecan instrument by prewashing with buffer A for at 56°C for 30 seconds followed by 
flushing with 1x hybridisation buffer. 50 µl of previously prepared reaction mixture were then 
injected into the hybridisation station and incubated at 56°C for 16 hours while agitated at medium 
level. Following the incubation, samples were washed twice with Wash buffer A for 1 minute at 
56°C, then for 1 minute at 23°C with Wash buffer C and finally for 30 seconds at at 23°C before 
drying. 
All samples were processed in an environment with ozone control to prevent fluorophore 
degradation.  Arrays were then scanned at 5 µm resolution with GenePix 4000A scanner (Axon 
Instruments, USA) and data were subsequently extracted and processed in silico by the author. 
The raw data is captured as in image in ImaGene® files shown in Figure 7.3 and annotated in 
GAL files. 
 
Figure 7.3 Example of ImaGene files. These files contain the raw data acquired from the 
microarrays for both the red and green channels. 
7.2.3. miRNA microarray data analysis 
Unless specifically stated otherwise, all figures and the entire analysis including quality control 
starting with the raw data was carried out by the author. The analysis was conducted using R, 
Bioconductor and ExiMiR package. Raw data stored in ImaGene TXT files were loaded into R 
and annotated using corresponding GAL file. One array failed data quality control and was 
excluded from further analysis (PS Tum, Figure 7.4). Raw values were normalised using RMA 




Figure 7.4 Boxplots of green (left) and red (right) background values of each individual sample (x 
axis) show a poor quality sample (labelled with red dot). Y axis=fold change. 
MA plots show a correlation between log fold changes (M) and the mean single channel intensity 




Figure 7.5 MA plot selected miRNA microarrays. Empty controls are shown in blue, spike-in 
controls are shown in red. 
An offset equal to 10 was added to the normalised intensities before log-transforming in order to 
unify the lower intensities after log transformation towards zero (Figure 7.6). Offsetting is applies 




Figure 7.6 Normalised intensities before (lower panel) and after (upper panel) offsetting as 
demonstrated by boxplot and densityplot. As shown on the boxplot, “tail” of lower values is 
diminished or disappears in most samples after offsetting. This approach minimises the variation 
of intensities for very low intensities. 
Correlation of samples and unsupervised hierarchical clustering was conducted on the normalised 
data using the VSN package in R using Pearson’s correlation.  
Differentially expressed miRNAs were detected using the lumi package (Du et al., 2008) with 
normalised, log2-transformed values. This package uses Bayesian modelling to detect 
differentially expressed elements and allows p-value adjustment for multiple testing (Benjamini-
Hochberg correction). 
Principal component analysis was conducted on all samples using log-transformed normalised 
values for 50 miRNAs with the highest standard deviation. The miRNA expression values were 
zero-shifted by subtracting the mean (the mean is zero), and the variance was scaled to equal 1. 
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7.2.4. Integration of copy-number variation loci in cSCC with miRNA data 
Known genomic location of differentially expressed miRNAs was obtained in miRBase 
(http://www.mirbase.org). The genomic coordiantes of miRNA genes were then compared with 
coordinates of copy-number variation loci (CNV) described in Chapter 4. If the fold-change of the 
miRNA was concordant with the CNV (gain or loss), it was considered condordant with CNV. 
7.2.5. miRNA target prediction and integration with genetic and 
transcriptional data 
MiRNA target prediction was carried out in silico using Targetscan (Lewis et al., 2005). Although 
other algorithms were evaluated (DIANA, miRDB), it is not recommended to combine various 
target prediction approaches (Witkos et al., 2011) and only genes identified by Targetscan were 
used in subsequent analytical steps. This algorithm evaluates targets based on the presence of a 
conserved octamer or heptamer sites and their complementarity to the seed region of individual 
miRNAs. Additionally, targets that mismatch but compensate by conserved 3’-pairing are also 
included among predicted targets. 
DIANA (DIANA)-microT-CDS as an online tool that predicts miRNA targets based on miRNA 3’-
mRNA binding site complementarity and protein coding sequences (CDS) (Reczko et al., 2012). 
This algorithm uses existing high-throughput immunoprecipitation and sequencing data to 
generate a list of targets, and initial miRNA-mRNA hits based on 4-base pair-long 
complementarity in the seed region starting at seed position 1 or two, and then by the presence of 
G:U base pairs, single nucleotide bulges or mismatched sequences. This approach is less strict 
and inherently less precise than the approach utilised by Targetscan (Marin et al., 2013). 
miRDB is an online annotated database using machine-learning approach that relies on Support 
vector machines (SVMs) to predict miRNA targets based on a large microarray training dataset 
(Wang and El Naqa, 2008). However, this program is limited by using only single 3’-UTR target 
sites for the training dataset rather than multiple target sites, since the presence of multiple 
targets for single miRNA can alter miRNA:mRNA interactions leading to low proficiency of gene 
repression (Garcia et al., 2011). This insight was incorporated in Targetscan prediction algorithm. 
Predicted targets of all differentially expressed miRNAs which are expected to be down-regulated 
were then compared with differentially expressed genes (p value <0.01) between cSCC and AK 
(see Chapter 4 for details). Genes that showed expression changes consistent with genetic 
changes (described in Chapter 4) were excluded. The fold-changes of remaining genes (down-
regulation or up-regulation) were compared with miRNA fold-change, and genes that did not show 
fold-change consistent with miRNA alteration (down-regulation if miRNA was up-regulated and 




7.2.6. Validation of differentially expressed miRNAs 
A subset of miRNAs that were detected as differentially expressed using the microarray were 
validated using three paired sets of cSCC and perilesional skin hybridised to the microarray and 
an additional set of 2 paired cSCC and adjacent normal skin samples listed in Table 7.3. 
Additional pairs are highlighted in italics. 
Sample	   Histology	   Concentration	  
ng/µl	  





WD-­‐cSCC	   185.10	   	   2.07	   1.99	   Male	   IC	   4.2	  
WH	  Skin	   Perilesional	  
skin	  
36.80	   	   2.05	   0.26	   Male	   IC	   2.4	  
MB	  Tumour	   cSCC	   235.40	   	   2.08	   2.02	   Female	   RTR	   2.8	  
MB	  Skin	   Perilesional	  
skin	  
149.80	   	   2.07	   1.84	   Female	   RTR	   2.6	  
JC	  T	   cSCC	   313.80	   	   1.89	   1.34	   Male	   RTR	   8.1	  
JC	  S	   Perilesional	  
skin	  
44.50	   	   2.00	   1.84	   Male	   RTR	   2.4	  
CW	  Tumour	   cSCC	   185.50	   	   2.11	   1.51	   Male	   RTR	   8.4	  
CW	  Skin	   Perilesional	  
skin	  
96.40	   	   2.14	   2.12	   Male	   RTR	   NA	  
BR	  Finger	  
Tumour	  





16.30	   	   1.99	   0.90	   Male	   RTR	   1	  
Table 7.3 A set of samples used for validation of differentially expressed miRNAs. If histology of 
cSCC samples was known, it was included in the “Histology” column (WD=well differentiated). 
RIN NA = RIN value below 1.  
Validation was conducted using miRCURY LNA™ Universal RT microRNA PCR. Exiqon, 
Denmark carried out the total RNA processing and RT-qPCR. This approach utilizes pre-designed 
LNA™ PCR panel for detection of miRNAs with SYBR green, and uses spike-in control (UniSp6 
CP) for normalisation. Only previously validated primers can be hybridised to the PCR plate, thus 
the selection of miRNAs for validation was limited by this technical aspect of the assay. The 
following 11 miRNAs were selected for validation: hsa-miR-142-5p, hsa-miR-1908, hsa-miR-210, 
hsa-miR-383, hsa-miR-423-3p, hsa-miR-498, hsa-miR-605, hsa-miR-628-3p, hsa-miR-638, hsa-
miR-639, hsa-miR-943. 
Total RNA was reverse-transcribed using the miRCURY LNA Universal RT miRNA PCR kit 
according to the manufacturer’s incstructions in a single step. Briefly, 2 µl of total RNA 
(concentration of 5ng/µl) were mixed with synthetic RNA spike-ins, enzyme mix, 5x Reaction 
buffer and nuclease-free water to generate a total volume of 10 µl per reaction. Samples were 
then incubated at 42°C for 60 minutes, followed by 5 minutes incubation at 95°C to inactivate the 
reverse transcriptase and cooled on ice.  
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For the real-time PCR quantification, 20 µl of cDNA generated in the previous step was mixed 
with nunclease-free water and 10 µl of PCR mastermix containing SYBR green and added to 
qPCR 384-well plate pre-loaded with lyophilised primers with a pipetting robot. Each sample was 
tested in triplicate for each miRNA, and the plate contained also contained 4 blank controls 
containing no sample to detect contamination. The plate was then sealed and amplified with 
Roche Lightcycler 480® (Roche Applied Science, Germany). The reaction was carried out initially 
at 95°C for 10 minutes, then by 45 cycles amplified at 95°C for 10 seconds, followed by 
amplification at 60°C for 60 seconds with ramp-rate 1.6ºC/s cooling from 95°C to 60°C to ensure 
proper performance of the system.  
7.2.7. RT-PCR data collection and quality control 
The quality control consisted of melting curve analysis, amplification efficiency and a comparison 
of obtained Cp values to blank controls. Lightcycler 480® software was used to export raw Cp 
values and melting points for each sample. If several melting points were detected or if the 
melting point(s) were outside of the assay specifications (based on in-house database generated 
by Exiqon), these were removed from dataset and not included in the analysis. Additionally, 
reactions with amplification efficiency less than 1.6 and Cp values of 37 or more (blank controls 
have a Cp of 40) were also removed from the dataset.  
7.2.8. RT-PCR data analysis 
The raw Cp values (averaged for each sample) were normalised to averaged spike-in Cp values 
using the ΔCp method: average Cp of the target miRNA was subtracted from averaged Cp values 
of UniSp6 CP (ΔCp). This value was then transformed by exponentiating 2 to –ΔCp. This value 
was then log-transformed to detect fold-change.  
Statistical analysis was performed using two-tailed, unpaired t-test using the GraphPad software. 
7.3. Results 
7.3.1. Correlation of global miRNA profiles detected in cSCC and adjacent 
normal skin samples 
As shown in Figure 7.7, unsupervised hierarchical clustering of all 39 samples lead to a formation 
of several clusters largely based on their histology (cSCC and adjacent normal skin). While the 
separation of the samples based on histological typing is not complete, the fact that normal 
distant skin and skin adjacent to a tumour sample from the same patient clustered together (green 
and orange sample) shows that tissue miRNA profile is likely dependent on genetic background. 
In the right cluster, two tumour samples collected from the same patient (JN) cluster together, 
confirming this trend.  
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Additionally, the left-most cluster contains 13 samples of which 3 (2 skin samples, 1 tumour) are 
derived from a single patient (EC). The fourth sample from this patient (tumour) is within the 
rightmost cluster. Of the 10 remaining samples in the leftmost cluster, 2 pairs are from the same 
patient (BR, BD), and 2 more (TK and AW) have their paired tissue cluster right next to this set of 
13 samples. Only one set of paired samples formed an adjacent cluster (CJ), which suggests that 
the majority of paired samples were sufficiently distinct in their miRNA profile. 
 
Figure 7.7 Unsupervised hierarchical clustering of miRNA profiles based on Pearson's correlation. 
Lightblue=normal adjacent skin, dark blue=cSCC, orange=distant normal skin, green=adjacent 
skin from a patient with distant normal skin. The red line indicates clustering of 2 different tumour 
samples obtained from the same patient. The purple line indicates clustering of paired tissue 
(tumour and adjacent skin) collected from one patient. 
Principal component analysis (PCA) has shown that biological variation between the samples is 
sufficient to form biological classes in the majority of the samples (Figure 7.8). The plot indicated 
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no biological differences between males and females, which was subsequently confirmed by 
comparison of miRNA tissue profile (i.e. cSCC and adjacent normal tissue combined) between 
males and females (data not shown). 
 
Figure 7.8 PCA analysis using 50 miRNA with the highest standard deviation. This plot shows 
good separation of the majority of tumours and clinically normal skin samples. X axis=PCA 1, y 
axis=PCA2. Figure prepared in collaboration with Exiqon, Denmark. Samples names correspond 
to samples listed in Table 7.2. 
7.3.2. Comparison of miRNA profile between immunocompetent and 
immunosuppressed patients 
Comparison of miRNA profile between all OTR and IC-derived tissues has not detected 
significantly differentially expressed miRNAs after p-value adjustment. Although a heatmap of top 
15 differentially expressed miRNAs shown in Figure 7.9 indicates almost complete separation of 
OTR and IC-derived samples, it also indicates considerable variability of individual miRNA 




Figure 7.9 Heatmap of top 15 differentially expressed miRNAs (non-significant) shows separation 
of IC (green) and OTR samples. Green samples=IC patients, purple samples=OTR patients. 
 
Comparison of both skin-only and tumour-only samples obtained from OTR and IC patients has 
not detected any significantly differentially expressed miRNAs after p-value adjustment. A 
heatmap of the top 17 differentially expressed miRNAs detected in comparison between tumours 
obtained from IC patients and OTR patients with p value of 0.01 or less before adjustment for 
multiple testing (Figure 7.10) shows similarly to the previous figure generally adequate separation 
of samples based on log2-transformed expression levels of those miRNAs, but the variability of 





Figure 7.10 Heatmap of top 17 differentially expressed miRNAs (non-significant) comparing OTR-
derived tumours with IC-derived tumours. Green=OTR tumours, orange=IC tumours. 
7.3.3. Comparison of cSCC and adjacent normal skin miRNA profile 
A comparison of all cSCC and skin samples has detected a total of 38 differentially expressed 
miRNAs using a stringent p value cut-off (p value <0.01), 6 of which showed fold-change of 1.5 or 
more, and 76 miRNAs using a less stringent cut-off (p value <0.05). Of those 76 miRNAs, 33 
were upregulated and 43 were down-regulated (Figure 7.11). In the set of 38 miRNAs detected 
with more stringent p-value, 7 miRNAs were upregulated and 31 were down-regulated (Figure 
7.13). The list of 38 differentially expressed miRNAs is provided in Table 7.4, and the full list of all 
76 miRNAs is provided in Appendix 9. 
Name	   logFC	   P.Value	   adj.P.Val	   Chr	  
hsa-­‐miR-­‐1469	   -­‐1.072505836	   5.77436154519119e-­‐10	   1.20972874371755e-­‐06	   15	  
hsv1-­‐miR-­‐H17	   -­‐0.705890727	   1.69129214680814e-­‐09	   1.77162852378153e-­‐06	   -­‐	  
hsa-­‐miR-­‐548ap-­‐5p/hsa-­‐miR-­‐548j	   -­‐1.137583927	   6.37345196612178e-­‐09	   4.45079395634171e-­‐06	   -­‐	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hsa-­‐miR-­‐3656	   -­‐1.010574316	   2.62424656124373e-­‐08	   1.3744491364514e-­‐05	   11	  
hsa-­‐miR-­‐4707-­‐5p	   -­‐0.899529655	   3.54495753467037e-­‐08	   1.48533720702689e-­‐05	   -­‐	  
hsa-­‐miR-­‐371b-­‐5p	   -­‐0.796315305	   7.02535328882583e-­‐08	   2.45301919001502e-­‐05	   -­‐	  
hsa-­‐miR-­‐638	   -­‐0.96944656	   8.79507138186871e-­‐08	   2.63223922071642e-­‐05	   19	  
hsa-­‐miR-­‐4787-­‐5p	   -­‐0.783080099	   1.0748940076033e-­‐07	   2.81487868241115e-­‐05	   -­‐	  
hsa-­‐miR-­‐4708-­‐3p	   -­‐0.819929533	   4.15585920532755e-­‐07	   9.6739167057347e-­‐05	   -­‐	  
hsa-­‐miR-­‐4530	   -­‐0.912825789	   5.83423681553376e-­‐07	   0.000122227	   19	  
hsa-­‐miR-­‐4800-­‐3p	   -­‐0.959652136	   8.73797238933443e-­‐07	   0.000166419	   -­‐	  
hsa-­‐miR-­‐943	   -­‐0.547735401	   1.53754766534614e-­‐06	   0.00026843	   4	  
kshv-­‐miR-­‐K12-­‐3-­‐5p	   -­‐0.582550336	   1.99976954076941e-­‐06	   0.00030663	   -­‐	  
hsa-­‐miR-­‐3960	   -­‐0.745469234	   2.04908076517478e-­‐06	   0.00030663	   9	  
hsa-­‐miR-­‐1909-­‐3p	   -­‐0.625525465	   2.71122173072946e-­‐06	   0.000378667	   -­‐	  
hsa-­‐miR-­‐4505	   -­‐0.965317513	   7.52660351418713e-­‐06	   0.000985515	   14	  
hsa-­‐miR-­‐744-­‐5p	   -­‐0.691696164	   9.56746704377922e-­‐06	   0.00117905	   -­‐	  
hsa-­‐miR-­‐642b-­‐3p	   1.141917999	   1.15649194007355e-­‐05	   0.001275185	   -­‐	  
hsa-­‐miR-­‐605	   -­‐0.513822616	   1.15575701021536e-­‐05	   0.001275185	   10	  
hsa-­‐miR-­‐31-­‐5p	   1.740874987	   1.25833940732504e-­‐05	   0.001318111	   -­‐	  
hsa-­‐miR-­‐21-­‐3p	   0.6724371	   1.42998835672022e-­‐05	   0.001426584	   -­‐	  
hsa-­‐miR-­‐4732-­‐5p	   1.92248161	   2.03475247609164e-­‐05	   0.001937639	   -­‐	  
hsa-­‐miR-­‐4423-­‐5p	   0.443625999	   3.69901561629572e-­‐05	   0.003228932	   -­‐	  
kshv-­‐miR-­‐K12-­‐6-­‐3p	   -­‐0.793278205	   3.57816180117349e-­‐05	   0.003228932	   -­‐	  
hsa-­‐miR-­‐585	   -­‐0.617744304	   3.90871812017574e-­‐05	   0.003275506	   5	  
hsa-­‐miR-­‐125b-­‐1-­‐3p	   -­‐0.349733408	   4.82440516267739e-­‐05	   0.003609689	   -­‐	  
hsa-­‐miR-­‐3195	   -­‐0.694960429	   4.49031145967249e-­‐05	   0.003609689	   20	  
hsv1-­‐miR-­‐H7-­‐3p	   -­‐0.708660707	   4.66662449625971e-­‐05	   0.003609689	   -­‐	  
hsa-­‐miR-­‐495-­‐5p	   0.391768945	   6.69281365222725e-­‐05	   0.004523047	   -­‐	  
hsv2-­‐miR-­‐H10	   -­‐0.713452548	   6.68499148385216e-­‐05	   0.004523047	   -­‐	  
hsa-­‐miR-­‐663a	   -­‐0.749102069	   6.44310090858787e-­‐05	   0.004523047	   20	  
hsa-­‐miR-­‐3687	   -­‐0.865385123	   8.8350480273067e-­‐05	   0.005784196	   21	  
hsa-­‐miR-­‐4516	   -­‐0.697507752	   0.000101523	   0.006445202	   16	  
hsa-­‐miR-­‐4734	   -­‐0.445995207	   0.000112973	   0.006961121	   17	  
hsa-­‐miR-­‐124-­‐5p	   -­‐0.298243171	   0.000127269	   0.007617956	   -­‐	  
hsa-­‐miR-­‐224-­‐3p	   -­‐0.561808414	   0.00013696	   0.007970294	   -­‐	  
hsa-­‐miR-­‐1290	   1.530172368	   0.000147766	   0.008366759	   1	  
hsa-­‐miR-­‐639	   -­‐0.249764274	   0.000178618	   0.009847496	   19	  









Figure 7.12 Bar plot showing fold-change of 38 miRNAs detected to be differentially expressed in 
cSCC with p value <0.01. 
 
A hHeatmap of 38 differentially expressed miRNAs is shown in Figure 7.13. With the exception of 

















































Figure 7.13 Heatmap of 38 miRNAs differentially expressed in cSCC. Orange=normal skin, 
green=cSCC. 
7.3.4. Integration of miRNAs with genetic changes in cSCC 
Previously published data that detected genomic changes in a large set of cSCC described in 
Chapter 3 and 4 were used for integrating known genomic location of 16 miRNAs (Figure 7.14). 
Of those, 10 (62.5%) integrated with genomic changes (Table 7.5). Foldchange of 1 miRNA did 
not correlate with the expected genomic change (down-regulation in a region of genomic gain), 
and genes for the remaining 5 miRNAs were located outside of known copy-number variation loci 
in cSCC. 
Chromosome	   Location	   Change	   miRNA	   FC	  
1	   1pter-­‐1p32.3	   Gain	   hsa-­‐miR-­‐1290	   Up	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4	   4pter-­‐4p13	   Loss	   hsa-­‐miR-­‐943	   Down	  
5	   5qcen-­‐5qter	   Loss	   hsa-­‐miR-­‐585	   Down	  
9	   9qcen-­‐9qter	   Loss	   hsa-­‐miR-­‐3960	   Down	  
10	   10pter-­‐10qter	   Loss	   hsa-­‐miR-­‐605	   Down	  
11	   11q14.1-­‐11qter	   Loss	   hsa-­‐miR-­‐3656	   Down	  
16	   16p13.11-­‐
16pcen	  
Loss	   hsa-­‐miR-­‐4516	   Down	  
17	   17pter-­‐17qter	   Loss	   hsa-­‐miR-­‐4734	   Down	  
19	   19pter-­‐19pcen	   Loss	   hsa-­‐miR-­‐638	   Down	  
19	   19pter-­‐19pcen	   Loss	   hsa-­‐miR-­‐639	   Down	  
Table 7.5 MiRNAs that integrate with genomic changes in cSCC. FC=fold change. 
 
Figure 7.14 Genomic location of 16 miRNAs. 
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7.3.5. miRNA profiling of cSCC detects several viral miRNAs 
The top set of 38 miRNAs contains 5 viral miRNAs, the full set of 76 miRNAs contained additional 
3 viral miRNAs shown in Table 7.6. The majority of those were down-regulated with the exception 
of hsv1-miR-H5-3p. Five of those miRNAs were herpes simplex virus miRNAs, two were Kaposi's 
Sarcoma-Associated Herpesvirus miRNAs, and one human cytomegalovirus miRNAs. 
Name	   logFC	   adj.P.Val	   Comment	  
hsv1-­‐miR-­‐H17	   -­‐0.705890727	   1.77162852378153e-­‐
06	  
Described	  in	  (Jurak	  et	  al.,	  2010)	  
kshv-­‐miR-­‐K12-­‐3-­‐5p	   -­‐0.582550336	   0.00030663	   	  
kshv-­‐miR-­‐K12-­‐6-­‐3p	   -­‐0.793278205	   0.003228932	   	  
hsv1-­‐miR-­‐H7-­‐3p	   -­‐0.708660707	   0.003609689	   	  
hsv2-­‐miR-­‐H10	   -­‐0.713452548	   0.004523047	   Described	  in	  (Umbach	  et	  al.,	  2010)	  
hsv2-­‐miR-­‐H7-­‐3p	   -­‐0.589493933	   0.034912168	   	  
hsv1-­‐miR-­‐H5-­‐3p	   0.283271184	   0.040673136	   	  
hcmv-­‐miR-­‐US25-­‐1-­‐3p	   -­‐0.251550024	   0.048200154	   	  
Table 7.6 Viral miRNAs detected to be differentially transcribed in cSCC. 
7.3.6. Comparison with miRNAs previously described to be dysregulated 
in cSCC 
Several miRNAs previously described as differentially transcribed in cSCC were detected in our 
dataset: up-regulated miRNAs included hsa-miR-21-3p and hsa-miR-21-5p (Bruegger et al., 
2013), hsa-miR-210, hsa-miR-31-5p, hsa-miR-135b-5p (Gastaldi et al., 2014), hsa-miR-130b-3p 
and hsa-miR-766-3p, down-regulated miRNAs included hsa-miR-125b-1-3p (Sand et al., 2012a) 
and hsa-miR-124-5p (Yamane et al., 2013). 
7.3.7. Detection of miRNA targets 
Target prediction was carried out for the top set of 38 miRNAs. Various in silico tools utilising 
different algorithms for miRNA target prediction lead to a variety of targets, and the result of 
targets identified for 5 miRNAs by 3 different algorithms (DIANA, miRDB, Targetscan) is 




Figure 7.15 Number of genes predicted as targets of 5 miRNAs by three different algorithms. 
A list of predicted genes and genes found in the list of differentially expressed probes generated 
with gene expression microarrays using fresh-frozen AK and cSCC samples is shown in Table 
7.7. The AK and cSCC expression data are described in Chapter 3 and 4, respectively. 
MiRNAs not listed have no predicted targets in Targetscan. Targets of only 12 miRNAs were 
identified to be differentially expressed in the expression dataset after subtracting genes that 
showed fold-change concordant with genetic changes and subsequently genes that did not show 
fold-change concordant with miRNA fold-change. This generated a final list of 18 miRNA targets 
listed in Table 7.8. Only one gene, TGFBR3, is targeted by 2 miRNAs. 
Name	   Predicted	   Found	   %	   Final	  list	   %	  of	  found	  
targets	  
hsa-­‐miR-­‐371b-­‐5p	   749	   15	   2.002670227	   1	   6.7	  
hsa-­‐miR-­‐4530	   547	   17	   3.10786106	   5	   35.3	  
hsa-­‐miR-­‐4505	   521	   7	   1.343570058	   2	   28.6	  
hsa-­‐miR-­‐1290	   376	   12	   3.191489362	   3	   25	  
hsa-­‐miR-­‐4708-­‐3p	   305	   14	   4.590163934	   4	   28.6	  
hsa-­‐miR-­‐4516	   260	   5	   1.923076923	   1	   20	  
hsa-­‐miR-­‐605	   260	   11	   4.230769231	   2	   18.2	  
hsa-­‐miR-­‐3960	   257	   1	   2.941176471	   0	   0	  
hsa-­‐miR-­‐4423-­‐5p	   111	   2	   1.801801802	   1	   50	  
hsa-­‐miR-­‐943	   101	   1	   0.99009901	   0	   0	  
hsa-­‐miR-­‐4732-­‐5p	   42	   1	   2.380952381	   0	   0	  
hsa-­‐miR-­‐638	   30	   2	   6.666666667	   0	   0	  
hsa-­‐miR-­‐3656	   21	   0	   0	   0	   0	  
hsa-­‐miR-­‐4707-­‐5p	   20	   0	   0	   0	   0	  
hsa-­‐miR-­‐4734	   18	   0	   0	   0	   0	  
hsa-­‐miR-­‐639	   15	   0	   0	   0	   0	  
hsa-­‐miR-­‐4787-­‐5p	   10	   0	   0	   0	   0	  
hsa-­‐miR-­‐3687	   8	   0	   0	   0	   0	  











hsa-­‐miR-­‐3195	   5	   0	   0	   0	   0	  
hsa-­‐miR-­‐585	   5	   0	   0	   0	   0	  
hsa-­‐miR-­‐1469	   2	   0	   0	   0	   0	  
hsa-­‐miR-­‐4800-­‐3p	   1	   0	   0	   0	   0	  
Table 7.7 List of miRNA targets predicted by Targetscan and the  number of corresponding genes 
found to be dysregulated at the transcriptional level comparing AK and cSCC. 
Name	   Number	  of	  targets	   Target	  genes	  
hsa-­‐miR-­‐1290	  	   3	   HS3ST1	  
TGFBR3	  
PDZD2	  





hsa-­‐miR-­‐4505	   2	   EHD2	  
KLF6	  




hsa-­‐miR-­‐605	   2	   MAPKAP1	  
ETS2	  
hsa-­‐miR-­‐4516	   1	   ACTN1	  
hsa-­‐miR-­‐371b-­‐5p	   1	   DENR	  
hsa-­‐miR-­‐4423-­‐5p	   1	   TGFBR3	  
Table 7.8 Final list of miRNA targets. 
Comparison of miRNA targets with differentially methylated genes identified in the previous 
chapter found no hypermethylated targets, and 2 genes (PDZD2, NRP2) were hypomethylated. 
I hypothesised that the number of genes found in the expression list correlated with the number of 
predicted genes. This was confirmed by Pearson’s correlation (r=0.8956, p value<0.0001, Figure 
7.16). Similarly, the number of predicted genes significantly correlated with the number of final 




Figure 7.16 Scatterplot showing correlation between the numbers of predicted and detected 













Figure 7.17 Scatterplot depicting correlation between the number of predicted genes and final 
miRNA targets. X axis=predicted genes, Y axis=genes detected in list of differentially expressed 
genes. 
To compensate for the fact that miRNAs were evaluated in normal skin and cSCC, while the 
expression list used for target detection was generated by comparison of AK and cSCC, rather 
than normal skin, I used expression data generated with RNAlater-treated skin and AK samples 
(described in Chapter 3) and used average log2-transformed expression levels to observe 
general trends across sun-exposed skin (SE), non-sunexposed skin (NSE), actinic keratosis (AK) 
and cSCC. 
As shown in Figure 7.18, with the exception of KLF6, the expression trend (over or 
underexpression in comparison with cSCC) in skin samples was concordant with changes 












Figure 7.18 Average log2-transformed fold expression of 18 target genes as detected with 
expression arrays described in previous chapters. 
To confirm this trend, I generated a heatmap of targets for hsa-miR-4530 and hsa-miR-4708-3p 
that were detected to have four or more targets. Expression levels across all five sample 

























categories (cSCC, metastatic lymph nodes, AK, NSE, SE) of those targets lead to clustering 




Figure 7.19 Heatmap of log2-transformed expression values for hsa-miR-4530 (left panel) and 
hsa-miR-4708-3p (right panel) targets. Unsupervised clustering of all samples lead to mostly 
uniform clusters of cSCC (purple), lymph node metastases (black), AK (red), NSE (blue) and SE 
(yellow). 
Genomic location of all 18 targets along with expression levels in cSCC, AK, SE and NSE is 
shown in Figure 7.20. Three target genes are located on chromosome 16, two on chromosome 1, 




Figure 7.20 Genomic location of 18 miRNA targets. Innermost circle=cSCC, followed by AK, SE 
and NSE (outermost circle). Letters correspond to ranges of log2-transformed expression levels. 
A=2-3, B=3-4, C=4-5, D=5-6, E=6-7, F=7-8, G=8-9, H=9-10, I=10-11. 
7.3.8. Validation of miRNA microarray 
A novel approach to miRNA validation that uses lyophilised primers bound to wells of PCR plates 
was utilised to validate selected miRNA targets. Only 3 of 11 miRNAs were detected in all 
samples. Moreover, both the number and detected targets were often not equal across biological 




Figure 7.21 Number of miRNAs detected in each cSCC and adjacent normal skin sample in 
microarray validation. This figure shows lower miRNA detection in tumours samples. 
Addtionally, 7 of 11 miRNAs failed quality control (hsa-miR-383, hsa-miR-423-3p, hsa-miR-498, 
hsa-miR-605, hsa-miR-628-3p, hsa-miR-638, hsa-miR-639) and were not analysed further. Of the 
remaining four miRNAs, 2 were significantly differentially expressed (hsa-miR-1908, p 
value=0.03, and hsa-miR-943, p value=0.0016) and concordant with fold-change detected with 
miRNA microarray (Figure 7.22, Figure 7.23). 
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Figure 7.22 Validation of differential expression of has-miR-1908 in skin and cSCC. Bar chart 
showing 2^deltaCt values of hsa-miR-1908 expression in cSCC and skin samples. Down-
regulation is concordant with changes detected with miRNA microarray. Whiskers=SEM. 
 
Figure 7.23 Validation of differential expression of has-miR-943 in skin and cSCC. Bar chart 
showing 2^deltaCt values of hsa-miR-943 expression in cSCC and skin samples. Down-
regulation is concordant with changes detected with miRNA microarray. Whiskers=SEM. 
7.4. Discussion 
In this study, I explored the differences in miRNA transcription in cSCC and adjacent clinically 
normal skin. In comparison with previous studies, this investigation has utilised highly sensitive 
and specific microarrays that contain probes for over 2000 miRNAs and to date, the largest panel 
























7.4.1. Global miRNA profile is sufficient to separate clinically normal skin 
from cSCC 
Pearson’s correlation of the global miRNA profile across all samples did not lead to complete 
separation of cSCC and adjacent normal skin samples, yet histologically equivalent samples 
collected from individual patients clustered together, suggesting a considerable influence of 
individual genetic background in miRNA profiling. Only 1 pair of skin and cSCC samples clustered 
together, which may be explained by proximity of those two clinical samples during collection, as 
the adjacent normal skin sample was usually collected from a surrounding rim of clinically normal 
skin during tumour removal. This may also explain findings in the PCA analysis in which several 
cSCC and normal skin samples clustered together. An alternative explanation includes technical 
issues during microarray processing (such as cross-contamination, environmental factors) that 
were not apparent during data processing. In addition to possible technical issues, the influence 
of low RIN value in several samples was considered as potential driver of this observation, yet 
RIN is likely not a critical factor, as most samples with low RIN clustered appropriately. Moreover, 
previous data have shown that miRNAs are highly stable even in clinical samples yielding RNA of 
low RIN (Jung et al., 2010). 
Additionally, clinically normal skin adjacent to malignant tissue may harbour genetic mutations 
due to field cancerisation, in spite of clinically normal appearance (Kanjilal et al., 1995).  
7.4.2. Several miRNAs are significantly differentially expressed in cSCC 
compared to normal skin 
Our data show that miRNAs are not differentially transcribed in comparison between males and 
females, and I detected no statistically significant differences between immunosuppressed and 
immunocompetent patients. 
Comparison of global miRNA profile of cSCC and adjacent normal skin, on the other hand, has 
detected 38 miRNAs with a p value <0.01, and 76 with a p value <0.05 as differentially expressed. 
Many of those miRNAs were previously implicated in cancer, including miR-943 shown to be up-
regulated in HPV-18 positive Hela cells (Zhang et al., 2013), hsa-miR-744-5p found to be 
deregulated in head and neck cancer (Nurul-Syakima et al., 2011) and breast cancer (Enerly et 
al., 2011). MiR-642b-3p was previously shown to be up-regulated in pancreatic cancer (Ganepola 
et al., 2014), and hsa-miR-605 was previously linked with esophageal (Fassan et al., 2011) and 
gastrointestinal malignancies (Zhang et al., 2012). 
The majority of differentially expressed miRNAs were down-regulated in cSCC. Down-regulation 
of miRNAs is common in cancer (Visone et al., 2007, Song et al., 2011), since miRNAs can 
function as both oncogenes and tumour suppressors. Additionally, miRNA genes are frequently 
located in areas of genomic alterations (Calin et al., 2004) and losses of genomic regions are 
more common in cSCC than gains, which may partially explain this finding.  
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Unsupervised hierarchical clustering of all samples based on expression levels of 38 top miRNAs 
has lead to almost complete segregation of cSCC and normal skin. 3 skin samples clustered with 
cSCC, one with substantial proximity to paired tumour sample (DT). 
Additionally, this set of differentially expressed miRNAs has detected 9 miRNAs previously 
implicated in cSCC. Although we did not detect all miRNAs previously described to be 
dysregulated in cSCC, this may be explained by differences in methodology (using updated 
miRNA microarray for transcriptional profiling and using paired samples), and namely the high 
number of samples utilised in this study. The highest number of paired samples previously used 
for comprehensive miRNA exploration in cSCC was seven specimens; thereby this study 
represents the most comprehensive miRNA evaluation in cSCC to date.  
7.4.3. Majority of differentially expressed miRNAs are concordant with 
genetic changes previously described in cSCC 
Ten of sixteen miRNAs with known genomic location detected in our dataset are concordant with 
genomic alterations previously reported in cSCC (Purdie et al., 2009). A high frequency of 
genomic alterations of loci containing miRNA genes was previously reported in a variety of human 
tumours (Zhang et al., 2006a). The fact that the majority of differentially expressed miRNAs 
(62.5%) with known genomic location in our dataset integrated with known loci of genomic 
changes in cSCC identified by SNP array analysis suggests that miRNAs may be to some extent 
regulated by genetics, and the subsequent impact of miRNAs on transcriptional regulation may in 
fact reflect primary genetic changes, rather than act as an entirely independent epigenetic 
regulatory mechanism in this tumour. Given that genetic changes are notoriously difficult to 
address therapeutically, this stresses the attractiveness of miRNAs as potential clinical targets 
and warrants further exploration of their role in driving cSCC oncogenesis.  
It is important to note that the genomic location of 20 (55%) differentially expressed miRNAs is not 
known, and may increase or decrease the proportion of miRNAs likely to be induced or 
downregulated due to genetic changes. Additionally, further regulatory processes and factors 
likely to play a role in miRNA dysregulation in cancer, since copy-number variation alone could 
not explain dysregulation of 37.5% of miRNAs with known genomic location. 
7.4.4. Several viral miRNAs were found among miRNAs dysregulated in 
cSCC 
Viral miRNAs were not previously detected in cSCC. Although the role of viral miRNAs in cancer 
has not been elucidated to date, it has been hypothesised that these may play a role as direct 
oncogenes, or may have a role in immunomodulation and cell cycle regulation (Pfeffer and 
Voinnet, 2006). Our dataset contains viruses from herpes simplex virus, Kaposi's Sarcoma-
Associated Herpesvirus and cytomegalovirus, viruses which have all previously been implicated 
in cSCC (Zafiropoulos et al., 2003, Claudy et al., 1989). We found that 7/8 viral miRNAs were 
down-regulated in cSCC in comparison with normal skin. This may be explained by episomal 
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latency of viruses, or more likely by their integration to genomic regions that is subsequently lost 
or gained due to copy-number variation in cSCC. An alternative explanation could be 
contamination of our samples with viruses, either during sample collection or during sample and 
mRNA processing, yet this explanation is less likely since the miRNAs are not amplified prior 
hybridisation to the array, and thus the minimal amounts of contaminating miRNAs are unlikely to 
lead to statistically significant differences. Our findings warrant further validation and exploration 
of viral miRNAs in cSCC development and progression. 
7.4.5. Integration of in silico target prediction algorithm and 
transcriptional profiling of cSCC reveals novel miRNA targets in this 
malignancy 
Integration of miRNA targets identified with Targetscan and transcription microarray data lead to 
the identification of 18 transcriptional targets. Among those targets, two genes, PDZD2, NRP2 
were shown to be hypomethylated in cSCC and thereby theoretically of increased expression, yet 
PDZD2 is under-expressed at the transcriptional level, which suggests that this gene is possibly 
down-regulated by hsa-miR-1290. PDZD2 is a putative tumour suppressor found to be frequently 
hypermethylated in myeloid leukemia (Figueroa et al., 2010b), and neuropilin-2 is a member of 
neuropilin transmembrane glycoprotein family and a bona fide oncogene that functions as a 
receptor for VEGF binding and promotes cell migration and survival (Favier et al., 2006). Its 
upregulation in cSCC may be due to promoter hypomethylation, but our data shown in the 
previous chapter indicate that hypomethylation does not necessarily equate to an increase in 
transcription, thereby its upregulation may also be due to miRNA dysregulation, or a combination 
of both mechanisms.  
Additional targets known to be involved in cancer were identified as potential miRNA targets. 
TGFBR3, downregulated in cSCC, is a member of TGF-beta signaling pathway that plays a 
critical role in tumourigenesis by interacting with MAPK p38α/β (Bragado et al., 2013) and its 
down-regulation has been linked with immunoevasion in melanoma and breast cancer (Hanks et 
al., 2013). CYP27B1 is a 25-hydroxyvitamin D3 1-alpha-hydroxylase that catalyses the 
conversion of calcidiol to the active form for vitamin D (calcitriol). Its increased expression has 
been described in a variety of cancers including colon cancer and breast cancer, and it has been 
hypothesised that local conversion of calcidiol into calcitriol may be responsible for tumour 
chemoresistance (Deeb et al., 2007). Ubiquitin-conjugating enzyme E2 H (UBE2H) targets 
proteins for degradation, and has been identified as a putative oncogene in hepatocellular 
carcinoma (Rajendra et al., 2004). Nedd4-binding partner 1 (N4BP1) regulates the function of 
Itch, which then ubiquitylates c-JUN and p63 (Oberst et al., 2007). Upregulation of N4BP1 inhibits 
the degradation of p63 through this mechanism (Graziano and De Laurenzi, 2011) and promotes 
tumourigenesis. 
ETS2 is a transcription factor that has been shown to regulate p53 (Venanzoni et al., 1996) and 
has been shown to interact with MAPK pathway (Coffer et al., 1994). MAPKAP1 is another 
member of MAPK and also mTOR/AKT signalling pathway and has been previously reported to 
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promote epithelial-to-mesenchymal transition (Xu et al., 2013). ACTN1 is another transcriptional 
target unregulated in our dataset, and its inhibition has been shown to increase tumour-free 
survival in mice (Craig et al., 2008), suggesting this gene may possess oncogenic properties. 
Given that the panel of samples used for transcriptional profiling of sun-exposed, non-sunexposed 
skin and a subset of AK was treated with RNALater limited the possibility of comparing 
transcriptional profile of cSCC and normal skin as such comparison is likely to detect false targets 
(Chowdary et al., 2006). In order to correlate the expression levels of miRNA targets detected by 
comparison of AK and cSCC (fresh-frozen samples), trends in expression were displayed by 
using averaged transcriptional data across samples. This approach has confirmed expected 
expression trends in normal skin for 17 of the targets, which suggests that the process of 
oncogenic dysregulation is initiated early on and maintained through the progression from AK to 
cSCC. 
7.4.6. Validation with miRCURY LNA™ Universal RT microRNA PCR 
confirms 2 miRNAs as differentially expressed 
We validated the microarray findings in 3 pairs hybridised to miRNA microarrays and additional 
two pairs of cSCCs and adjacent normal skin pairs with miRCURY LNA™ Universal RT 
microRNA PCR. The selection of potential miRNAs for validation was highly limited by primers 
available for this technology, and only 1 miRNA detected in our data with a p value <0.01 was 
included in the panel of targets. The majority of miRNAs evaluated by this technology failed the 
process of quality control, most likely due to technical issues, as target detection was not equal in 
replicates of the same sample (data not shown). Two miRNAs were validated using this 
approach, including hsa-miR-943 included in top 38 dysregulated miRNAs. 
7.4.7. Additional study limitations 
Limitations of the study include using microarrays for miRNA detection and expression profiling, 
which likely limited the number of miRNAs identified as dysregulated in cSCC and the number of 
transcriptional targets. Moreover, no miRNA targets were functionally validated. Additionally, a 
relatively low number of samples from females and IC individuals were included in the panel. 
7.5. Conclusions and future directions 
This study confirms dysregulation of miRNAs in cSCC, and identified several novel miRNAs as 
dysregulated in this malignancy. The set contained several miRNAs previously implicated in 
cSCC, in addition to novel miRNAs including several viral miRNAs. Genes for the majority of 
detected miRNAs are located in areas of genetic copy-number variation in cSCC and their 
dysregulation is concordant with those changes. Additionally, using an in silico target prediction 
method and previously generated transcriptional data, we identified 18 miRNA targets, many of 
which were previously implicated in cancer. Several of those genes (N4BP1, TGFBR3, PDZD2) 
represent attractive targets for further exploration in cSCC. 
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Future directions include re-validating selected targets using standard qRT-PCR, exploring the 
correlation of global miRNA expression profile with cSCC tumour subtype, and validating selected 
putative miRNA targets using siRNA interference in cSCC cell lines. 
392 
 
8. Viruses and epigenetic regulation in non-
melanoma skin cancer: prevalence of Merkel 
Cell Polyomavirus and the impact of MCPyV 
and human papillomavirus on methylation in 
cSCC 
8.1. Introduction 
As described in Chapter 1, human papillomavirus (HPV) has long been implicated in the 
pathogenesis of cSCC. More recently, DNA polymavirus named Merkel Cell polyomavirus 
(MCPyV) has been detected in a series of Merkel cell carcinoma (MCC) samples (Feng et al., 
2008), and represents the first example of DNA polyomavirus integrating into the host genome. 
High prevalence of the virus in MCC samples was subsequently confirmed by several 
independent studies, ranging from 24 % (Garneski et al., 2009b) to 100 % of tested MCC samples 
(Sastre-Garau et al., 2009). 
Since its discovery, the presence of MCPyV has been described in various types of lesions and 
populations: geographical differences in prevalence of the virus in MCC clinical samples were 
reported between European, American and Australian MCC patients (Garneski et al., 2009b). 
Additionally, the virus was shown to be significantly more common among HIV-positive men 
compared to healthy controls (Wieland et al., 2011). 
Conversely, the virus was not detected in proliferative skin disorders (Foulongne et al., 2008), 
extracutaneous melanoma (Giraud et al., 2008), lymphoid tissue of AIDS patients (Sharp et al., 
2009), prostate cancer samples (Bluemn et al., 2009), or small lung cancer (Wetzels et al., 2009), 
which morphologically resembles MCC. Non-small lung cancer samples from a cohort of 
Japanese patients, on the other hand, contained the virus in 9/32 (28 %) lung SCCs, and 9/45  
(20 %) of lung adenocarcinomas (Hashida et al., 2013). Recently, it was shown that MCPyV may 
in fact play a role in chronic lymphocytic leukaemia: patients with CLL are at increased risk of 
MCC (Koljonen et al., 2009), and the virus was detected in 19 CLL samples, 6 of which also 
possessed novel large T antigen mutations (Koljonen et al., 2009). Chronic lymphocytic 
leukemia/small lymphocytic lymphoma (CLL/SLL) specimen, a type of non-Hodgkin lymphoma 
associated with impaired immune system, were also shown to be positive for the virus in 33 % of 
tested samples, while the virus was not detected in follicular lymphoma samples assessed in the 
same study (Teman et al., 2011). This indicates that the virus may be associated with tumours 
linked with impaired immune system, and such immunosuppression may lead to its reactivation. 
In non-melanoma skin cancer, 3/24 (12.5 %) of basal cell carcinomas were initially reported as 
positive for the virus in a cohort of European patients (Becker et al., 2009), with higher prevalence 
(72 %) subsequently reported among immunocompromised patients (Kassem et al., 2009). Yet a 
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subsequent study of 11 BCC reported no positive samples (Andres et al., 2010) and this was 
confirmed in a series of 10 BCC collected from Japanese patients (Murakami et al., 2011), while 
another study of 41 BCC reported a prevalence of 29 % (Scola et al., 2012).  
Reported positivity for MCPyV in cSCC ranged from 13 % (Garneski et al., 2009a) to 52 % in 
cSCC collected from immuncompromised individuals (Kassem et al., 2009). 4/30 (13 %) of cSCC 
from Japanese patients were positive for the virus (Murakami et al., 2011), while another study of 
60 cSCC found 27 % positive samples (Scola et al., 2012). All these studies were carried out with 
FFPE samples. A large series of  145 fresh-frozen cSCC detected positivity in 38 % of samples, 
and showed a correlation between MCPyV positivity and serum antibodies to the virus (Rollison et 
al., 2012). 
I aimed to verify the high prevalence of MCPyV in a series of MCC samples identified in the Barts 
and the London School of Medicine Pathology Group archive. I hypothesised that there may be 
significant differences in MCPyV positivity in non-melanoma skin cancer in transplant patients. 
Additionally, I hypothesised that there may be a correlation between HPV positivity and MCPyV 
presence in non-melanoma skin cancer samples. In broad terms, viral contributions to 
carcinogenesis may be regarded as epigenetic, thus I aimed to explore the impact of MCPyV 
positivity and HPV on methylation profile in CIS and cSCC samples. 
8.2. Materials and methods 
Formalin-fixed paraffin embedded samples of MCC collected from MCC patients, in addition to 
other benign, premalignant and malignant skin specimen from this patient cohort were obtained 
from the Pathology archive in collaboration with Pairaw Kader. Additional archival samples from 
MCC patients including blood were obtained through searching the experimental records of 
previous studies and the non-melanoma skin cancer archive at the Blizard institute. Table 8.1 lists 
all tissues and samples of MCC patients that were available, in addition to their basic clinical 
characteristics: a total of 8 MCCs, 1 blood sample and 13 non-MCC lesions were available in the 
MCC cohort. Histological sections of all tissues were reviewed and compared to the pathology 
reports to verify histological description of the tissues (Figure 8.1, Figure 8.2).  
 
Patient	   Gender	   Age	   Immune	  
status	  
Lesion	  collected	   Location	  
ML	  	   F	   77	   IC	   AK	  	  1	   -­‐	  
	   	   	   	   AK	  2	   -­‐	  
	   	   	   	   MCC	  primary	   Head	  and	  
neck	  
	   	   	   	   MCC	  recurrent	   Head	  and	  
neck	  




GC	  	   F	   86	   IC	   AK	   -­‐	  
	   	   	   	   SCC	   -­‐	  
	   	   	   	   Primary	  MCC	   Trunk	  
	   	   	   	   Carcinoma	  in	  situ	   -­‐	  
	   	   	   	   Scar	  tissue	   Trunk	  
EN	  	   F	   78	   IC	   Blood	   -­‐	  
	   	   	   	   MCC	  1	  (incisional	  biopsy	  –	  FFPE)	   Lower	  
limb	  
	   	   	   	   MCC	  2	  primary	  (FF)	   Lower	  
limb	  
	   	   	   	   MCC	  2	  metastases	  (FF)	   -­‐	  
AD	   M	   80	   IC	   MCC	  primary	   Upper	  
limb	  
NR	  	   F	   76	   IC	   SCC	   Unknown	  
	   	   	   	   MCC	  primary	   Lower	  
limb	  
	   	   	   	   MCC	  recurrent	   Lower	  
limb	  
JH	   F	   74	   IC	   MCC	   Head	  and	  
neck	  
	   	   	   	   Granulation	  tissue	   Head	  and	  
neck	  
RW	   M	   70	   RTR	   SCC	  1	  (FF)	   -­‐	  
	   	   	   	   SCC	  2	  (FF)	   -­‐	  
	   	   	   	   SCC	  3	   -­‐	  
	   	   	   	   SCC	  4	   -­‐	  
	   	   	   	   AK	   -­‐	  
	   	   	   	   BCC	  1	   -­‐	  
	   	   	   	   BCC	  2	   -­‐	  
	   	   	   	   MCC	  1	  (FF)	   Head	  and	  
neck	  
	   	   	   	   MCC	  1	  nodal	  metastases	   Neck	  
lymph	  
nodes	  
SH	   F	   -­‐	   IC	   MCC	  primary	   Upper	  
arm	  
Table 8.1 Clinical characteristics of MCC patients included in the study and additional non-




Figure 8.1 Haematoxylin and eosin staining of MCC (10x magnification) from a patient included in 
this series. This histological section illustrates small basophilic cells that highly resemble small 
cell lung carcinoma. 
 
Figure 8.2 Merkel cell carcinoma CD56 positive staining. CD56 positivity is a typical 
immunohistochemical feature of MCC. 
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Additional set of 146 archival non-melanoma skin cancer DNA samples previously profiled for 
HPV virus presence was included in the study. This set contained a total of 42 BCC (29 from IC, 
13 from OTR), 6 AK and 84 carcinoma in situ/cSCC (32 from immunocompetent patients, 58 from 
OTR), and 25 viral warts samples (all from OTR patients). 
Detailed methodology including the process of DNA isolation from both fresh-frozen, FFPE 
tissues and DNA quantification is described in Chapter 2. Quality of all DNA samples was tested 
by PCR amplification of beta-globin gene prior to assessment of MCPyV presence. The presence 
of MCPyV was determined by a series of primers that amplify different regions of the virus: 
MCVPS1, VP1, LT1, LT3. All samples were assessed with a minimum of two MCPyV primers. 
HPV profiling was previously conducted on all archival samples using previously published 
method (Purdie et al., 2009). 
8.2.1. Methylation profiling of archival cSCC samples 
In order to determine the impact of MCPyV on DNA methylation in CIS/cSCC, 13 MCPyV positive 
and 15 negative (as detected by PCR amplification) archival cSCC DNA samples were hybridised 
to Infinium HumanMethylation450 array (described in greater details in the previous chapter). 
Table 8.2 provides clinical characteristics including date of collection and histological classification 
of all samples that passed the quality control and were included in the study. Samples hybridised 
in duplicate were labelled as _1 and _2 with corresponding sample code. DNA processing and 
hybridisation to the methylation array was carried out in collaboration with Dr Emily Clemente17. 
Data analysis was carried out by the author. 
All samples were assessed for quality prior to normalisation, and all probes with known SNP and 
those corresponding to allosomes were removed from the dataset. Beta-values corresponding to 
the remaining probes were normalised using quantile normalisation in R, and statistical inference 
was determined by Welch t-test with p value adjustment using Bonferroni-Hochberg method.  






MCPYV	   HPV	   Date	  of	  
collectio
n	  
K16	   K16	   RTR	   L	  shin/calf	   SCC	  WD	   -­‐	   HPV5	   05/03/03	  
K17	   K17	   IC	   R.	  Hand	   SCC	   -­‐	   HPV5	   16/01/02	  
K18	   K18	   IC	   R.	  Cheek	   SCC	  WD	   +	   neg	   03/04/02	  
K20	   K20	   ICP	   L.Ear	   SCC	   +	   DL347	   01/11/02	  
K25	   K25	   RTR	   R	  hand	   SCC	   -­‐	   HPV5,	  14,	  
37	  
23/04/03	  
K26_1	   K26	   RTR	   L.	  Hand	   SCC	   -­‐	   neg	   25/06/03	  
K26_2	   K26	   RTR	   L.	  Hand	   SCC	   -­‐	   neg	   25/06/03	  
K30_1	   K30	   CT	   Chest	   SCC	   +	   neg	   05/02/03	  
K30_2	   K30	   CT	   Chest	   SCC	   +	   neg	   05/02/03	  
                                                       
17 Cambridge genomic Services, Department of Pathology, Cambridge University, Cambridge. 
397 
 
K38_1	   K38	   RTR	   L.	  
Shoulder	  
SCC	   +	   HPV19	   07/01/98	  
K38_2	   K38	   RTR	   L.	  
Shoulder	  
SCC	   +	   HPV19	   07/01/98	  
K39	   K39	   RTR	   Dorsum	  R.	  
Hand	  
SCC	   +	   neg	   28/01/98	  
K40_1	   K40	   RTR	   R.	  
Shoulder	  
SCC	   +	   neg	   26/11/03	  
K40_2	   K40	   RTR	   R.	  
Shoulder	  
SCC	   +	   neg	   26/11/03	  
K42	   K42	   RTR	   L.	  
Forehead	  
SCC	   +	   HPV19	   10/12/97	  
K43_1	   K43	   RTR	   L.	  Ear	   SCC	   +	   HPV24	   29/01/97	  
K43_2	   K43	   RTR	   L.	  Ear	   SCC	   -­‐	   HPV24	   29/01/97	  
K46	   K46	   RTR	   Dorsum	  
L.Hand	  
SCC	   -­‐	   neg	   24/07/96	  
K47	   K47	   RTR	   0	   SCC	   +	   novel	   20/09/95	  
K49	   K49	   RTR	   L.	  
Forearm	  
SCC	   +	   neg	   09/07/96	  
K51_1	   K51	   IC	   Forehead	  	   SCC	   +	   HPV5	   08/03/99	  
K51_2	   K51	   IC	   Forehead	  	   SCC	   +	   HPV5	   08/03/99	  
K52	   K52	   RTR	   Scalp	   SCC	   -­‐	   novel	   14/01/99	  
K60	   K60	   RTR	   R.	  Ear	   CIS	   -­‐	   neg	   22/11/00	  
K63	   K63	   RTR	   Temple	   CIS	   -­‐	   neg	   03/01/01	  
K66_1	   K66	   ICP	   L.	  
Forehead	  
Bowens	   -­‐	   RTRX7	   12/03/01	  
K66_2	   K66	   ICP	   L.	  
Forehead	  
Bowens	   -­‐	   RTRX7	   12/03/01	  
K67	   K67	   RTR	   R.ear	   CIS	   -­‐	   novel	   04/04/01	  
K68	   K68	   RTR	   R.	  hand	   CIS	   -­‐	   novel	   04/04/01	  
K76	   K76	   RTR	   L.	  
Forearm	  
Bowens	   -­‐	   HPV	  5,	  20	   06/06/01	  
K82_1	   K82	   IC	   L	  wrist	   Bowens	   -­‐	   Z95963,	  
VS20-­‐4	  
28/09/01	  
K82_2	   K82	   IC	   L	  wrist	   Bowens	   -­‐	   Z95963,	  
VS20-­‐4	  
28/09/01	  
2H	   2H	   RTR	   Hand	   SCC	   +	   27	   19/02/92	  
6R	   6R	   ICP	   Ear	   SCC	   -­‐	   -­‐	   	  
6T	   6T	   ICP	   Ear	   SCC	   +	   -­‐	   	  
7E	   7E	   RTR	   Hand	   SCC	   -­‐	   10,16,36,1
2r	  
	  
Table 8.2 Clinical characteristics of MCPyV positive and negative NMSC samples hybridised to 
Illumina 450K array. Bowens=Carcinoma in situ (CIS). 
Comparison levels of methylation profile included MCPyV positivity, immune status, HPV positivity 




8.3.1. Five of eight MCC samples were positive for MCPyV 
PCR analysis of 8 MCC tumours detected MCPyV in 5/8 (62.5 %) of tested samples. Mean age at 
diagnosis of patients with MCPyV was 73.4 years (excluding one patient of unknown age at 
diagnosis), MCPyV-negative patients were on average 81.3 years old (p value=0.16).  
All three metastatic MCC were MCPyV positive, and 2/3 nodal metastases of these tumours also 
showed positivity for the virus. One recurrent MCC of a MCPyV-positive primary tumour was 
negative for the virus, while the metastatic lesion was MCPyV-positive (patient ML).  
Two patients with MCPyV-positive MCC and additional NMSC lesions (RW, ML) had detectable 
virus in at at least one additional lesion, while two patients with MCPyV-negative MCC and 
additional lesions (NR, GC) had no detectable virus in any of those lesions tested. Table 8.3 
provides comprehensive results of all samples from MCC patients.  
Patient	   Lesion	  collected	   Location	   MCPyV	  
ML	  	   AK	  	  1	   -­‐	   Positive	  
	   AK	  2	   -­‐	   Negative	  
	   MCC	  primary	   Head	  and	  neck	   Positive	  
	   MCC	  recurrent	   Head	  and	  neck	   Negative	  
	   MCC	  nodal	  metastases	   Head	  and	  neck	   Positive	  
GC	  	   AK	   -­‐	   Negative	  
	   SCC	   -­‐	   Negative	  
	   Primary	  MCC	   Trunk	   Negative	  
	   Carcinoma	  in	  situ	   -­‐	   Negative	  
	   Scar	  tissue	   Trunk	   Negative	  
EN	  	   Blood	   -­‐	   Negative	  
	   MCC	  1	  (incisional	  biopsy	  –	  FFPE)	   Lower	  limb	   Negative	  
	   MCC	  2	  primary	  (FF)	   Lower	  limb	   Positive	  
	   MCC	  2	  metastatic	  (FF)	   -­‐	   Positive	  
AD	   MCC	  primary	   Upper	  limb	   Positive	  
NR	  	   SCC	   Unknown	   Negative	  
	   MCC	  primary	   Lower	  limb	   Negative	  
	   MCC	  recurrent	   Lower	  limb	   Negative	  
JH	   MCC	   Head	  and	  neck	   Negative	  
	   Granulation	  tissue	   Head	  and	  neck	   Negative	  
RW	   SCC	  1	  (FF)	   -­‐	   Negative	  
	   SCC	  2	  (FF)	   -­‐	   Positive	  
	   SCC	  3	   -­‐	   Negative	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   SCC	  4	   -­‐	   Negative	  
	   AK	   -­‐	   Negative	  
	   BCC	  1	   -­‐	   Negative	  
	   BCC	  2	   -­‐	   Negative	  
	   MCC	  1	  (FF)	   Head	  and	  neck	   Positive	  
	   MCC	  1	  nodal	  metastasis	   Neck	  lymph	  nodes	   Negative	  
SH	   MCC	  primary	   Upper	  arm	   Positive	  
Table 8.3 Results of MCPyV testing in a series of MCC samples and additional lesions from MCC 
patients. 
8.3.2. 39 % of AK/CIS/cSCC lesions, 28.6 % of BCC samples and 56 % of 
viral warts are positive for MCPyV 
8.3.2.1. MCPyV in AK/CIS/cSCC lesions 
Of 90 AK/CIS/cSCC18 (58 collected from transplant patients, 32 from immunocompetent 
individuals), 35 were positive for MCPyV (39 %). When stratified by immune status, 23/58 (39 %) 
and 12/32 (37 %) of these lesions were positive for the virus (p value=0.8, chi square).  
8.3.2.2. MCPyV in BCC and viral warts 
A total of 12/42 (28.6 %) BCC samples were positive for MCPyV. This was not statistically 
significantly different compared with cSCC-related lesions (p value=0.07, chi square). 
Stratification by immune status revealed 5/13 (38 %) BCC from immunosuppressed patients and 
7/29 (24 %) of BCC from immunocompetent individuals as positive for the virus, which is not a 
statistically significant difference (p value=0.2, chi square).  
Viral warts (all collected from transplant patients), were positive for MCPyV in 14/25 samples (56 
%). This was statistically significantly higher prevalence compared with BCC (p value=0.02, chi 
square) even after adjustment for immune status, while not statistically significantly different in 
comparison with cSCC-related lesions (p value=0.1, chi square). Figure 8.3 depicts cumulative 
percentage of positive samples across all groups. 
Linear regression did not detect a significant association between HPV positivity and MCPyV 
presence. 
                                                       




Figure 8.3 Cumulative percentage plot of MCPyV-positive NMSC samples. MCC samples showed 
the highest prevalence of the virus, followed by viral warts, cSCC and BCC lesions. 
8.3.3. Quality control of cSCC archival samples hybridised to Illumina 
450K methylation array 
Archival DNA from 5 CIS and 23 cSCC samples was hybridised to Infinium HumanMethylation450 
array (450K array). 8 samples were hybridised in duplicate to the array. 
As shown in Figure 8.4, many samples showed poor quality based on beta-values distribution, 
and a total of 16 samples were subsequently excluded prior to normalisation, leaving 20 samples 
for analysis. Density plot of this sample set is shown in Figure 8.5. Not accounting for duplicate 
samples, 11 of those samples were negative for MCPyV, 9 were positive, 10 were positive for 
HPV and 10 were negative for HPV, 8 were CIS and 12 were cSCCs, 7 were from 


















Figure 8.4 Density plot of beta-values of archival CIS/cSCC samples hybridised to Illumina 450K 
array. This figure shows that several samples do not follow expected pattern of bimodal 
distribution, and these samples were excluded from the dataset prior to normalisation.  


















Figure 8.5 Density plot of archival CIS/cSCC samples that were included in the analysis. 
8.3.4.  Methylation profiling of CIS and cSCC archival samples using 
Illumina 450K methylation array reveals no differences in 
methylation due to MCPyV presence 
Comparison of MCPyV-positive samples and MCPyV-negative CIS/cSCC samples revealed no 
differences in methylation between the two groups, and neither did comparison between HPV-
positive or negative samples, between CIS and cSCC. Borderline significant differential 
methylation in one gene (p value=0.09), ZNF211 was detected by comparison of CIS/cSCC from 
transplant and immunocompetent patients.  
8.4. Discussion and future directions 
This study has found high prevalence of MCPyV in MCC samples, which is concordant with 
previous studies. Additionally, this is the first study that aimed to systematically identify 
differences in methylation between MCPyV positive CIS/cSCC and I detected differnces in 
MCPyV prevalence in a series of archival non-melanoma skin cancer lesions, and detected no 
correlation between HPV and MCPyV presence. Finally, by applying genome-wide methylation 
microarray profiling of archival CIS/cSCC samples, I detected no statistically significant 
differences in methylation in MCPyV or HPV positive and negative samples. 

















8.4.1. MCPyV-positive MCC patients are generally younger and all 
metastatic MCC were MCPyV positive 
Our analysis detected expectedly high prevalence of MCPyV in MCC. Patients with the virus were 
on average almost a decade younger compared to their counterparts with MCPyV-negative 
lesions, and all MCC metastases were in MCPyV-positive patients (2/3 metastases were positive 
for the virus). Given that MCPyV has been shown to integrate in the genome, and although we did 
not confirm integration of the virus, this may indicate that its integration leads to increased 
genomic instability and generates a more aggressive MCC in younger patients. The clinical 
significance of MCPyV presence is widely discussed and significant advances have been made in 
understanding the molecular mechanisms through which it contributes to MCC development. 
However, to date, there is no consensus with respect to its clinical role in the clinical course of this 
tumour. Although our data are limited by the low number of samples and corresponding 
metastases, it warrants further exploration of the prognostic significance of the virus in MCC. 
I also detected presence of the virus in at least one non-MCC lesion in patients with MCPyV-
positive tumours, which indicates that there may be a systemic infection or skin-specific infection 
determining its presence in MCC and additional skin lesions of MCC patients.  
8.4.2. MCPyV prevalence in NMSC is highest in viral warts among NMSC 
samples 
I detected presence of the virus in 39 % of cSCC-related lesions, 28.6 % BCC and 56 % of viral 
warts. Such a high prevalence of the virus in viral warts represent a novel finding, and was 
statistically significant in comparison with the prevalence in BCC. Previously, only 1 viral wart of 
16 samples was found to be positive for the virus using PCR (Mertz et al., 2010). Given that all 
viral warts samples were collected from transplant patients, I was not able to determine if such 
high prevalence is related to immunosuppression. 
The prevalence of MCPyV detected in BCC and cSCC-related lesions represents a range that 
has been previously reported, but the absence of difference in prevalence between transplant and 
immunocompetent patients is in contrast with previously published data (Kassem et al., 2009), 
which reported prevalence of MCPyV in 52 % of cSCC and 72 % of BCC collected from transplant 
patients. This may be explicable by far higher number of CIS/AK/cSCC lesions in our study (35 
versus 58), or by using fresh frozen DNA collected under strict sterile conditions in contrast with 
samples embedded in paraffin. I detected no correlation between MCPyV positivity and HPV 
presence. 
8.4.3. Genome-wide methylation profiling of MCPyV- and HPV-positive 
and negative lesions revealed no differences in methylation 
between the two groups 
This was the first study that attempted to identify potential regions of differential methylation in 
MCPyV- and HPV-positive NMSC samples.  
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Hybridisation of archival DNA to the Illumina450K array revealed not only major issues in quality 
of the produced data, which lead to the exclusion of 16 samples from the dataset, but also to a 
different distribution of beta-values in comparison with DNA freshly isolated from skin, AK and 
cSCC samples described in Chapter 6. While data from freshly isolated DNA show two peaks, 
one in a region of low methylation (0.0 to 0.2) and high methylation (0.8-1.0), data from archival 
samples shows peaks around 0.2 and 0.6, and practically no probes with either complete 
methylation or demethylation, which suggests that in addition to possible hybridisation issues, 
these seems to be loss of methylation and concentration of higher methylation values around 0.6. 
This could be due to poor hybridisation of degraded DNA (possibly due to repeated DNA freezing 
and thawing), or due to general loss of methylation due to long-term storage, although the methyl 
group is bound by a covalent bond. 
This quality issue may explain the absence of significant findings between MCPyV- and HPV-
positive and negative samples, in addition to the coverage of the array, since MCPyV may lead to 
differences in regions not assessed by the array. 
8.4.4. Strengths and limitations of our study 
One of the major strengths of our data is the inclusion of a large number of DNA isolated from 
fresh frozen NMSC lesions under strict sterile conditions which minimalised the risk of 
contamination with MCPyV through handling or paraffin embedding from both transplant and 
immunocompetent patients for which HPV profiling data also existed.  
Limitations include a low number of MCC samples, and using only one technique to detect 
MCPyV, and not validating its prevalence by immunohistochemistry in additional set of samples. 
8.4.5. Future directions 
If a larger series of MCC samples could be collected, the presence of MPCyV could be evaluated 
as a prognostic factor in this malignancy.  
The presence of MCPyV in additional series non-melanoma skin cancer samples (AK, CIS, BCC) 
and warts needs to be confirmed with immunohistochemistry with anti MCPyV large-T (LT) 
antigen antibody. Assessment of MCPyV integration and MCPyV viral load in non-melanoma skin 
cancer samples from both transplant and immunocompetent patients may reveal potential 
differences and provide further insights into the mechanisms by which samples the virus plays a 
possible oncogenic role.  
Given that long-term storage of DNA samples can affect methylation levels, a definitive 
confirmation of no impact of MCPyV on methylation in non-melanoma skin cancer would involve 
profiling a large series of age-matched MCPyV-positive and negative samples with fresh DNA 
isolation using a whole-genome approach, since MCPyV may not affect genes or regions to which 
probes on a microarray correspond. A large number of such samples would be required, since the 
MCPyV is likely to affect a limited number of regions, which may also be entirely stochastic. 
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Additionally, correlation of MCPyV antibodies in patient blood and the presence of the virus in 
normal skin and NMSC samples and warts would show if a systemic infection with MCPyV 
predisposes patients to the development of these lesions. 
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9. Summary of results and concluding remarks 
Epigenetic regulation has been extensively studied in a variety of human solid tumours, yet its 
detailed role in non-melanoma skin cancer has been largely unknown. Previous studies have 
implicated a limited number of differentially methylated genes and differentially expressed 
miRNAs as potentially relevant in non-melanoma skin cancer oncogenesis, but no comprehensive 
genome-wide assessment of epigenetic regulation of non-melanoma skin cancer has been 
carried out. In this work, I assessed genome-wide methylation in normal skin, actinic keratosis 
and cSCC tissues and cell lines, and integrated these data with gene expression and copy-
number variation data in order to gain further insight into molecular regulation of this malignancy. 
Additionally, I explored miRNA regulation in cSCC and the impact of Merkel Cell Polyomavirus 
and human papillomavirus on DNA methylation in this tumour.  
9.1.1. Genomic aberrations are significantly more common in AK 
compared to normal skin, and are largely stochastic in nature and 
have low correspondence with transcriptional changes 
Copy-number variation analysis in normal skin and AK detected significantly more common 
genomic aberrations in AK compared to normal skin. Moreover, the size of regions of genomic 
imbalance was significantly greater compared to normal skin. This is a novel finding, and 
indicates that genetic changes underpin the onset of AK at least to some extent, although most of 
the genetic aberrations were largely stochastic and patient-specific, which may be partially 
explicable by individual dose and character of life-time sun-exposure. Regions of genomic 
changes overlapping in individual patients occurred mostly on chromosomes 8 and 9; 
chromosome 9 is a known hotspot for genetic LOH in AK. Genes potentially affected in AK across 
multiple patients included genes corresponding to amplification hotspots on chromosome 9 (SYK, 
TSC1) and known oncogenes (VAV2), but only two genes showed concordant genomic gain and 
increase in expression in AK: GAS1 and RXRA. The reason why so few genes showed 
expression change concordant with genomic aberrations may be due to the fact that a maximum 
of four AK contained a given region of genomic aberration and are thereby unlikely to propagate 
across all samples evaluated by gene transcription array. Additionally, AK samples in the 
transcription dataset were not entirely matched with samples for which SNP array data were 
available. Comparison of matched-only transcriptional and SNP array data would not be 
statistically appropriate due to the very low number of samples. Comparison of transcriptional and 
SNP data on an individual patient level would not provide information from which any statistical 
inference (and thereby construct validity) could be derived. 
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9.1.2. AK from male patients contain more genomic aberrations compared 
to females, and transplant patients more frequently show loss of 
genomic regions compared to immunocompetent counterparts 
Additionally, this analysis revealed a statistically significant risk difference for genomic aberrations 
in AK in males compared to females (42%), and a significant difference between transplant and 
immunocompetent patients in the character of genomic imbalance: 40% of aberrations in 
transplant patients represented a loss of genomic material, while only 20% of SCNAs in 
immunocompetent patients represented a loss of a chromosomal region, which is a novel finding. 
This may be explicable by differences in the nature of genomic instability in immunosuppressed 
patients, or may be due to the study size. 
9.1.3. Transcriptional profiling of normal skin and AK reveals 
dysregulation of genes involved in epidermal differentiation, cell-
cell adhesions and WNT and PPAR pathways 
Transcriptional profiling of non-sun exposed and sun-exposed skin and AK lesions detected 292 
and 307 differentially expressed genes. A significant proportion of genes in both groups plays a 
role in epidermal development and cellular contact, the loss of which is a hallmark of malignant 
transformation and epithelial-to-mesenchymal transition. This finding indicates that processes that 
show a prominent role in cSCC (dedifferentiation, EMT) are initiated early on in the process of 
malignant transformation and are prominent in precancerous lesions. Therapeutic inhibition of this 
process in AK may thereby be of clinical relevance. 
9.1.4. Transcriptional profiling of AK and cSCC reveals up-regulation of 
genes conferring invasive and metastatic potential in cSCC, and 
expression profiling correlates with histopathological classification  
Comparison of AK and cSCC transcriptomes detected a total of 346 differentially expressed 
genes. Many highly up-regulated genes were shown to play a critical role in cancer invasion, 
including several metalloproteinases (MMP1, MMP3, MMP10), osteopontin (SPP1) and LAMC2. 
Additionally, NT5E (CD73) is highly up-regulated in cSCC, and its upregulation has been linked 
with increased metastatic potential in melanoma (Cui et al., 2012). 
Transcriptional profiling of cSCC has also demonstrated significant transcriptional differences 
between various cSCC histological subtypes. This finding is largely consistent with copy-number 
variation profiling of cSCC samples, which found specific differences in genomic aberrations in 
poorly differentiated cSCC tumours (Purdie et al., 2009). 
9.1.5. Increase in transcription of known stem cell markers heralds 
progression from AK to cSCC and distinguishes well differentiated 
tumours from poorly differentiated subtypes 
Exploration of transcriptional levels of 41 known stem cell markers in AK and cSCC samples has 
shown distinct expression levels in AK, well-differentiated cSCC and poorly differentiated cSCC. 
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This finding indicates that expression of stem cell markers confers a certain degree of malignant 
potential in transformed cells, as evidenced by recent work implying SOX2 in mouse cSCC onset 
(Boumahdi et al., 2014) and NOTCH1 and NOTCH2 in human cSCC (Rehman et al., 1997). 
While this finding warrants further validation by additional techniques in an independent set of 
samples, comparison with transcriptional profiles of 4 independently generated mesenchymal 
stem cells types revealed higher correlation of poorly differentiated tumours with mesenchymal 
stem cells. Given that a subset of cSCC grow and progress rapidly (Rehman et al., 1994), 
evaluation of stem cell markers as biomarkers of cSCC invasiveness is warranted based on these 
observations. 
9.1.6. Methylation profiling of cultured normal keratinocytes shows a high 
degree of correlation with normal skin, but only 21.3% of 
differentially methylated genes detected in cSCC cell lines were 
detected in cSCC clinical specimens 
Cell culture is one of the most common laboratory techniques, and represents an attractive 
method for exploration of the methylome in skin due to the relative scarcity of normal skin 
samples. Comparison of short-term keratinocyte culture methylation data with methylation profiles 
of normal skin samples detected a high degree of correlation between the two tissues, suggesting 
that methylation is largely stable in short-tem keratinocyte culture. 
The comparison of differentially methylated genes detected in cSCC cell lines with DMG detected 
in cSCC clinical samples revealed that only 21.3 % of genes detected in cSCC cell lines are 
differentially methylated in clinical specimens. Given that the number of normal skin (n=20) and 
cSCC samples (n=19) was far greater than the three cultured keratinocytes and 9 cSCC cell lines, 
it seems likely that statistical inference in cSCC cell lines was biased by the low number of control 
samples. On the other hand, all hyper- and hypomethylated genes validated in cSCC clinical 
samples showed concordant direction of change (hyper or hypomethylation),  indicating  that 
these genes are likely to represent genuine methylation targets in cSCC oncogenesis, rather than 
cell culture artifacts.  
9.1.7. Genome-wide methylation profiling of normal skin, AK and cSCC 
revealed widespread gene body hypermethylation and 
hypomethylation of intergenic regions and malignant-transformed 
lesions 
I carried out a systematic analysis of genome-wide methylation data in normal skin, AK and cSCC 
samples. I deteted no differences in methylation in normal skin due to sun-exposure, but found 
important differences in DNA methylation in AK and cSCC compared to normal skin. Our data 
also provide important observations regarding the functional genomic distribution of differentially 
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methylated probes in AK and cSCC; we show that gene body regions are more frequently 
hypermethylated in both AK and cSCC, while intergenic regions are widely hypomethylated in 
those two tissues. The distribution of hyper- and hypomethylated promoters, on the other hand, 
was generally equal.  
Given that previous studies of cSCC epigenetics have been focused largely on differences in 
promoter CpG methylation, this is an entirely novel finding that provides an insight into global 
epigenomic regulatory circuits in AK and cSCC. Gene body methylation has been previously 
described as evolutionarily conserved in both plants and higher organisms (Ibragimova et al., 
2013), and thereby disruption in this pattern is likely to have major impact on the regulation of 
cellular functions. Integration of gene expression and DNA methylation data has revealed that 
gene body hypermethylation is associated with decreased gene transcription. This is contrary to 
previously reported findings, but may be explained by not stratifying gene body methylation by 
percentage, since the correlation between gene body methylation and gene expression has been 
previously reported as “parabolic” with a peak around 70% methylation followed by a sharp drop 
in the highest methylation ranges (Caruana, 2002). By averaging the the mean log2 rations, this 
subtle differentiation has been lost. 
Intergenic hypomethylation been shown to be an important regulatory mark in stem cells (López-
Bigas et al., 2002), and may confer a degree of regulatory plasticity in AK and cSCC, in addition 
to differential promoter and gene body methylation.  
9.1.8. Differential methylation of CpG islands is more frequent in cSCC 
compared with AK, while Open Sea regions are frequently 
differentially methylation in AK 
 Over 50% of both hyper- and hypomethylated probes in cSCC compared to normal skin 
corresponded to CpG island and adjacent regions (Shores). In AK, on the other hand, CpG island 
probes represented 14% and 11% of hyper- and hypomethylated probes. This observation 
suggests that an important shift in positional methylation occurs in cSCC with a concentration of 
differences around CpG islands, while this convergence towards CpG-proximal regions is absent 
in AK. While this observation may be due to higher numbers of genomic aberrations in cSCC 
compared to AK, this may also represent a critical regulatory difference between premalignant 
and malignant skin lesions, with a strong potential for therapeutic targeting.  
9.1.9. Differentially expressed miRNAs are predominantly down-regulated 
in cSCC compared to normal skin, and largely correspond to known 
regions of genomic alterations in cSCC 
The comparison of miRNA microarray profiles of cSCC clinical samples and adjacent normal skin 
has revealed significant differences in the miRNA transcriptome of cSCC and normal skin, 
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including differential expression of several miRNAs of viral origin, including herpes simplex virus, 
Kaposi's Sarcoma- Associated Herpesvirus and cytomegalovirus miRNAs. This observation is a 
novel finding in cSCC, and indicates a possible regulatory role of viruses in this malignancy. 
Most  differentially expressed miRNAs were down-regulated in cSCC compared to normal skin. I 
observed a high concordance of miRNA expression levels and known regions of chromosomal 
instability in cSCC. This indicates that miRNA dysregulation in cSCC may to some extent reflect 
genomic changes, rather than represent an entirely independent regulatory mechanism. Given 
the notorious difficulty of addressing genomic changes in human malignancies therapeutically, 
dysregulated miRNAs that convey malignant properties due to genomic aberrations may 
represent an attractive therapeutic target. 
9.1.10. Merkel cell polyomavirus is common in non-melanoma skin cancer, 
but neither the presence of this virus nor human papillomavirus has 
a significant impact on methylation profiles of archival NMSC 
samples  
I detected high prevalence of MCPyV in MCC samples in accordance with previous literature, and 
explored the presence of the virus in additional series of non-melanoma skin cancer samples. The 
prevalence of the virus detected across cSCC and BCC samples was largely concordant with the 
previous literature, while the unexpectedly high prevalence (56 %) of the virus in viral warts 
collected from organ transplant recipients represents a novel finding. While the absence of viral 
wart samples from immunocompetent patients limits the interpretation of this finding in the context 
of immunosuppression, the prevalence was statistically significantly higher compared to other 
lesions (BCC, cSCC) in transplant patients. Given that all viral warts in our dataset were positive 
for HPV, this finding may indicate a frequent “co-infection” of these two viruses in viral warts, or 
reactivation of MCPyV infection in transplant patients. 
Genome-wide profiling of MCPyV- and HPV-positive and negative samples revealed no 
significant differences in methylation after p value adjustment. However, this analysis has 
detected important changes in the methylation profile of archival NMSC during quality control that 
has indicated substantial loss of methylation in archival DNA. Given this important technical 
aspect, in addition to the relatively low number of samples that passed the quality control and the 
bias of the Illumina Infinium HumanMethylation450 BeadChip towards certain regions of the 
genome, this finding requires further validation using freshly isolated DNA from cSCC samples 
using a whole-genome approach, such as bisulfite sequencing. 
 
In summary, my work has shown that: 
1. Genomic aberrations are significantly more common in AK compared to normal skin, and 
are also greater in size. 
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2. Regions of genomic imbalance in normal skin and actinic keratosis are largely stochastic 
and patient-specific, yet chromosome 8 and 9 contain focal SCNAs that occurred in 
multiple patients and represent potential hotspots for mutations in AK.  
3. Transformation of normal skin to AK involves changes in genes relevant in cellular 
contact, epidermal differentiation and developmental pathways (Wnt pathway). 
4. Transcriptional profiling of cSCC corresponds with histological subtyping. 
5. Transcriptome profiling of poorly differentiated tumours is more highly correlated with that 
of mesenchymal stem cells, and well-differentiated tumours can be segregated from less 
differentiated tumours based on a set of known stem cell markers.  
6. Gene bodies are largely hypermethylated, whilst intergenic regions are predominantly 
hypomethylated in AK and cSCC compared to normal skin. 
7. Most areas of differential methylation in AK correspond to Open Sea regions, while 
differential methylation is largely concentrated in CpG islands and CpG-adjacent regions 
in cSCC. 
8. Differentially expressed miRNAs in cSCC are largely down-regulated and many 
correspond to regions of known genomic alteration in cSCC. 
9. Merkel cell polyomavirus is common in non-melanoma skin cancer and very common in 
viral warts. 




Appendix 1. Differentially expressed genes 
between SE skin and AK. 
 
Symbol	   Chrom	   logFC	   adj.P.Val	   Description	  
PHYHIP	   8	   2.231082407	   3.07E-­‐15	   phytanoyl-­‐CoA	  2-­‐hydroxylase	  
interacting	  protein	  
WIF1	   12	   3.112869365	   3.62E-­‐15	   WNT	  inhibitory	  factor	  1	  
LEPR	   1	   2.278620413	   3.62E-­‐15	   leptin	  receptor	  
NA	   -­‐	   2.301669581	   3.71E-­‐15	   NA	  
ADH1B	   4	   3.094469021	   1.13E-­‐11	   alcohol	  dehydrogenase	  1B	  (class	  
I),	  beta	  polypeptide	  
SP8	   7	   2.683868401	   3.09E-­‐11	   Sp8	  transcription	  factor	  
KRT6B	   12	   -­‐2.263015981	   3.40E-­‐11	   keratin	  6B	  
OASL	   12	   -­‐3.210809595	   5.83E-­‐11	   2'-­‐5'-­‐oligoadenylate	  synthetase-­‐
like	  
SYT17	   16	   1.881900085	   7.77E-­‐11	   synaptotagmin	  XVII	  
BTC	   4	   2.253157435	   1.31E-­‐10	   betacellulin	  
S100A9	   1	   -­‐3.62786163	   2.49E-­‐10	   S100	  calcium	  binding	  protein	  A9	  
GJB2	   13	   -­‐1.451842609	   6.20E-­‐10	   gap	  junction	  protein,	  beta	  2,	  
26kDa	  
KRT16	   17	   -­‐3.317399133	   8.77E-­‐10	   keratin	  16	  
IGFL1	   19	   -­‐3.862180153	   9.24E-­‐10	   IGF-­‐like	  family	  member	  1	  
AGTR1	   3	   2.09561044	   1.12E-­‐09	   angiotensin	  II	  receptor,	  type	  1	  
CCL27	   9	   2.749677886	   1.33E-­‐09	   chemokine	  (C-­‐C	  motif)	  ligand	  27	  
CYP4B1	   1	   2.327667074	   1.77E-­‐09	   cytochrome	  P450,	  family	  4,	  
subfamily	  B,	  polypeptide	  1	  
S100A8	   1	   -­‐2.384712806	   1.79E-­‐09	   S100	  calcium	  binding	  protein	  A8	  
NETO2	   16	   -­‐2.238239202	   2.24E-­‐09	   neuropilin	  (NRP)	  and	  tolloid	  
(TLL)-­‐like	  2	  
DSC2	   18	   -­‐1.879176456	   2.28E-­‐09	   desmocollin	  2	  
HRASLS5	   11	   1.242229366	   4.32E-­‐09	   HRAS-­‐like	  suppressor	  family,	  
member	  5	  
CD24	   6	   -­‐1.525641872	   7.17E-­‐09	   CD24	  molecule	  
ENAH	   1	   -­‐1.963434489	   8.31E-­‐09	   enabled	  homolog	  (Drosophila)	  
PCP4	   21	   2.692812549	   8.40E-­‐09	   Purkinje	  cell	  protein	  4	  
SLC7A5	   16	   -­‐1.710791838	   8.89E-­‐09	   solute	  carrier	  family	  7	  (cationic	  
amino	  acid	  transporter,	  y+	  
system),	  member	  5	  
KRT9	   17	   -­‐4.293852464	   1.86E-­‐08	   keratin	  9	  
PGM5	   9	   1.512594075	   2.40E-­‐08	   phosphoglucomutase	  5	  
C1QTNF7	   4	   1.590847144	   2.50E-­‐08	   C1q	  and	  tumor	  necrosis	  factor	  
related	  protein	  7	  
RNF180	   5	   1.744334828	   2.84E-­‐08	   ring	  finger	  protein	  180	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SOX5	   12	   1.762823808	   2.84E-­‐08	   SRY	  (sex	  determining	  region	  Y)-­‐
box	  5	  
RAB3B	   1	   1.087332509	   3.62E-­‐08	   RAB3B,	  member	  RAS	  oncogene	  
family	  
LOC572558	   9	   1.231956459	   4.21E-­‐08	   hypothetical	  locus	  LOC572558	  




PAMR1	   11	   1.807209462	   4.69E-­‐08	   peptidase	  domain	  containing	  
associated	  with	  muscle	  
regeneration	  1	  
C20orf24	   20	   -­‐0.971755373	   5.26E-­‐08	   chromosome	  20	  open	  reading	  
frame	  24	  
NP	   14	   -­‐1.396470515	   5.37E-­‐08	   nucleoside	  phosphorylase	  
SAMD9	   7	   -­‐1.805519162	   5.94E-­‐08	   sterile	  alpha	  motif	  domain	  
containing	  9	  
S100A2	   1	   -­‐0.737778306	   6.72E-­‐08	   S100	  calcium	  binding	  protein	  A2	  
KIAA0101	   15	   -­‐1.606246695	   9.37E-­‐08	   KIAA0101	  
MAPK6	   15	   -­‐1.007506201	   1.10E-­‐07	   mitogen-­‐activated	  protein	  
kinase	  6	  
SYNCRIP	   6	   -­‐0.890391948	   1.22E-­‐07	   synaptotagmin	  binding,	  
cytoplasmic	  RNA	  interacting	  
protein	  
FBLIM1	   1	   -­‐1.267529986	   1.58E-­‐07	   filamin	  binding	  LIM	  protein	  1	  
CLEC7A	   12	   -­‐1.939579658	   2.00E-­‐07	   C-­‐type	  lectin	  domain	  family	  7,	  
member	  A	  
MAPT	   17	   1.249277745	   2.01E-­‐07	   microtubule-­‐associated	  protein	  
tau	  
MYO1B	   2	   -­‐1.082698883	   2.20E-­‐07	   myosin	  IB	  
WNT5A	   3	   -­‐2.123208376	   2.36E-­‐07	   wingless-­‐type	  MMTV	  integration	  
site	  family,	  member	  5A	  
SORBS1	   10	   1.471180662	   2.36E-­‐07	   sorbin	  and	  SH3	  domain	  
containing	  1	  
TSPAN8	   12	   2.251691671	   2.39E-­‐07	   tetraspanin	  8	  
YARS	   1	   -­‐0.69164725	   3.01E-­‐07	   tyrosyl-­‐tRNA	  synthetase	  
EZH1	   17	   0.712855518	   3.02E-­‐07	   enhancer	  of	  zeste	  homolog	  1	  
(Drosophila)	  
GSTM5	   1	   1.483811062	   4.35E-­‐07	   glutathione	  S-­‐transferase	  mu	  5	  
SLC8A1	   2	   1.489506513	   4.35E-­‐07	   solute	  carrier	  family	  8	  
(sodium/calcium	  exchanger),	  
member	  1	  
SUSD2	   22	   1.692237418	   4.35E-­‐07	   sushi	  domain	  containing	  2	  
TXNDC17	   17	   -­‐1.097147117	   4.44E-­‐07	   thioredoxin	  domain	  containing	  
17	  
C4orf31	   4	   1.792256694	   4.99E-­‐07	   chromosome	  4	  open	  reading	  
frame	  31	  
KCNJ15	   21	   -­‐1.491503047	   5.30E-­‐07	   potassium	  inwardly-­‐rectifying	  




TNNC1	   3	   1.163279276	   5.96E-­‐07	   troponin	  C	  type	  1	  (slow)	  
SYNE1	   6	   0.933865749	   6.23E-­‐07	   spectrin	  repeat	  containing,	  
nuclear	  envelope	  1	  
CDK5R1	   17	   -­‐1.462651258	   6.69E-­‐07	   cyclin-­‐dependent	  kinase	  5,	  
regulatory	  subunit	  1	  (p35)	  
KRT6A	   12	   -­‐2.485070983	   6.74E-­‐07	   keratin	  6A	  
DEFB4	   8	   -­‐4.660702841	   6.95E-­‐07	   defensin,	  beta	  4	  
GSTA3	   6	   1.893145666	   7.02E-­‐07	   glutathione	  S-­‐transferase	  alpha	  
3	  
RPL37	   5	   0.79024293	   8.94E-­‐07	   ribosomal	  protein	  L37	  
KDM5A	   12	   0.763305142	   9.02E-­‐07	   lysine	  (K)-­‐specific	  demethylase	  
5A	  
LYVE1	   11	   1.616716411	   1.05E-­‐06	   lymphatic	  vessel	  endothelial	  
hyaluronan	  receptor	  1	  
HSPB7	   1	   1.275963505	   1.28E-­‐06	   heat	  shock	  27kDa	  protein	  family,	  
member	  7	  (cardiovascular)	  
RABIF	   1	   -­‐0.962535046	   1.31E-­‐06	   RAB	  interacting	  factor	  
PTTG1	   5	   -­‐1.149935326	   1.37E-­‐06	   pituitary	  tumor-­‐transforming	  1	  
TNFRSF21	   6	   -­‐1.785235262	   1.57E-­‐06	   tumor	  necrosis	  factor	  receptor	  
superfamily,	  member	  21	  
FUT3	   19	   -­‐1.541417705	   1.57E-­‐06	   fucosyltransferase	  3	  (galactoside	  
3(4)-­‐L-­‐fucosyltransferase,	  Lewis	  
blood	  group)	  
PDK4	   7	   1.297892027	   1.57E-­‐06	   pyruvate	  dehydrogenase	  kinase,	  
isozyme	  4	  
COMP	   19	   -­‐2.106298131	   1.57E-­‐06	   cartilage	  oligomeric	  matrix	  
protein	  
CAB39L	   13	   0.98206153	   1.59E-­‐06	   calcium	  binding	  protein	  39-­‐like	  
ELL2	   5	   -­‐0.924017765	   1.59E-­‐06	   elongation	  factor,	  RNA	  
polymerase	  II,	  2	  
IFI27	   14	   -­‐1.735121388	   1.67E-­‐06	   interferon,	  alpha-­‐inducible	  
protein	  27	  
POLR3G	   5	   -­‐1.530982615	   1.67E-­‐06	   polymerase	  (RNA)	  III	  (DNA	  
directed)	  polypeptide	  G	  (32kD)	  
PI3	   20	   -­‐3.084617491	   1.74E-­‐06	   peptidase	  inhibitor	  3,	  skin-­‐
derived	  
SCARA5	   8	   2.081592857	   1.83E-­‐06	   scavenger	  receptor	  class	  A,	  
member	  5	  (putative)	  
GTPBP4	   10	   -­‐0.724622232	   1.94E-­‐06	   GTP	  binding	  protein	  4	  
PPARD	   6	   -­‐0.997285688	   2.00E-­‐06	   peroxisome	  proliferator-­‐
activated	  receptor	  delta	  
GJB6	   13	   -­‐1.638101615	   2.04E-­‐06	   gap	  junction	  protein,	  beta	  6,	  
30kDa	  
C10orf99	   10	   -­‐3.221956107	   2.04E-­‐06	   chromosome	  10	  open	  reading	  
frame	  99	  
HOXC6	   12	   1.345349571	   2.04E-­‐06	   homeobox	  C6	  
HOXB5	   17	   0.732636673	   2.27E-­‐06	   homeobox	  B5	  
SNX1	   15	   0.838312	   2.46E-­‐06	   sorting	  nexin	  1	  




CADM2	   3	   0.90329592	   2.53E-­‐06	   cell	  adhesion	  molecule	  2	  
MYH11	   16	   1.731951048	   2.71E-­‐06	   myosin,	  heavy	  chain	  11,	  smooth	  
muscle	  
AP2S1	   19	   -­‐1.0272323	   2.71E-­‐06	   adaptor-­‐related	  protein	  complex	  
2,	  sigma	  1	  subunit	  
PPP4R1	   18	   -­‐0.787571214	   2.74E-­‐06	   protein	  phosphatase	  4,	  
regulatory	  subunit	  1	  
SPINK6	   5	   -­‐4.203949729	   2.88E-­‐06	   serine	  peptidase	  inhibitor,	  Kazal	  
type	  6	  
C2orf67	   2	   0.973109162	   2.91E-­‐06	   chromosome	  2	  open	  reading	  
frame	  67	  
GLRX3	   10	   -­‐0.648886304	   3.07E-­‐06	   glutaredoxin	  3	  
RGMB	   5	   0.889799698	   3.09E-­‐06	   RGM	  domain	  family,	  member	  B	  
HNMT	   2	   0.740542384	   3.45E-­‐06	   histamine	  N-­‐methyltransferase	  
C7orf10	   7	   -­‐1.172716968	   3.49E-­‐06	   chromosome	  7	  open	  reading	  
frame	  10	  
MXD1	   2	   -­‐1.047973839	   3.50E-­‐06	   MAX	  dimerization	  protein	  1	  
ECE2	   3	   -­‐1.04688826	   3.53E-­‐06	   endothelin	  converting	  enzyme	  2	  
C12orf5	   12	   -­‐1.192739366	   3.55E-­‐06	   chromosome	  12	  open	  reading	  
frame	  5	  
GTF3C6	   6	   -­‐0.516190952	   3.58E-­‐06	   general	  transcription	  factor	  IIIC,	  
polypeptide	  6,	  alpha	  35kDa	  
TNFSF9	   19	   -­‐1.411748182	   3.58E-­‐06	   tumor	  necrosis	  factor	  (ligand)	  
superfamily,	  member	  9	  
PTPN21	   14	   0.969044184	   3.63E-­‐06	   protein	  tyrosine	  phosphatase,	  
non-­‐receptor	  type	  21	  
CSRP2	   12	   -­‐1.485645516	   3.72E-­‐06	   cysteine	  and	  glycine-­‐rich	  protein	  
2	  
IL1F9	   2	   -­‐2.806087243	   3.90E-­‐06	   interleukin	  1	  family,	  member	  9	  
HN1	   17	   -­‐0.912186278	   4.24E-­‐06	   hematological	  and	  neurological	  
expressed	  1	  
SCN7A	   2	   1.685879275	   4.48E-­‐06	   sodium	  channel,	  voltage-­‐gated,	  
type	  VII,	  alpha	  
C1orf135	   1	   -­‐1.236369182	   4.60E-­‐06	   chromosome	  1	  open	  reading	  
frame	  135	  
DLX2	   2	   -­‐2.420829236	   4.90E-­‐06	   distal-­‐less	  homeobox	  2	  
SP5	   2	   1.025261467	   5.17E-­‐06	   Sp5	  transcription	  factor	  
N4BP2L1	   13	   1.152328855	   5.34E-­‐06	   NEDD4	  binding	  protein	  2-­‐like	  1	  
ATOH8	   2	   0.983378311	   5.62E-­‐06	   atonal	  homolog	  8	  (Drosophila)	  
SEMA3E	   7	   1.009808824	   5.66E-­‐06	   sema	  domain,	  immunoglobulin	  
domain	  (Ig),	  short	  basic	  domain,	  
secreted,	  (semaphorin)	  3E	  
FAM65C	   20	   -­‐1.523886424	   5.79E-­‐06	   family	  with	  sequence	  similarity	  
65,	  member	  C	  
GSN	   9	   0.968897048	   5.79E-­‐06	   gelsolin	  (amyloidosis,	  Finnish	  
type)	  
TPBG	   6	   -­‐1.037909728	   5.83E-­‐06	   trophoblast	  glycoprotein	  
SLC2A1	   1	   -­‐1.363766571	   5.87E-­‐06	   solute	  carrier	  family	  2	  




HIF3A	   19	   1.653193341	   5.87E-­‐06	   hypoxia	  inducible	  factor	  3,	  alpha	  
subunit	  
ZNF677	   19	   1.588365263	   6.12E-­‐06	   zinc	  finger	  protein	  677	  
TMOD1	   9	   0.966159126	   6.59E-­‐06	   tropomodulin	  1	  
HSPA14	   10	   -­‐0.627767157	   6.84E-­‐06	   heat	  shock	  70kDa	  protein	  14	  
IRAK1	   X	   -­‐0.61437479	   6.90E-­‐06	   interleukin-­‐1	  receptor-­‐
associated	  kinase	  1	  
CASQ2	   1	   1.551476299	   7.09E-­‐06	   calsequestrin	  2	  (cardiac	  muscle)	  
SLC30A9	   4	   -­‐0.985849954	   7.40E-­‐06	   solute	  carrier	  family	  30	  (zinc	  
transporter),	  member	  9	  




DSG3	   18	   -­‐1.21683121	   7.71E-­‐06	   desmoglein	  3	  (pemphigus	  
vulgaris	  antigen)	  
ACTG2	   2	   1.852662859	   7.84E-­‐06	   actin,	  gamma	  2,	  smooth	  muscle,	  
enteric	  
RALA	   7	   -­‐0.633711725	   7.85E-­‐06	   v-­‐ral	  simian	  leukemia	  viral	  
oncogene	  homolog	  A	  (ras	  
related)	  
LEPROTL1	   8	   -­‐0.734055955	   8.25E-­‐06	   leptin	  receptor	  overlapping	  
transcript-­‐like	  1	  
SUB1	   5	   -­‐0.689469551	   8.38E-­‐06	   SUB1	  homolog	  (S.	  cerevisiae)	  
LCE3D	   1	   -­‐3.714293176	   8.63E-­‐06	   late	  cornified	  envelope	  3D	  
FBXO45	   3	   -­‐1.134901057	   8.63E-­‐06	   F-­‐box	  protein	  45	  
SPINK7	   5	   -­‐3.461361864	   8.86E-­‐06	   serine	  peptidase	  inhibitor,	  Kazal	  
type	  7	  (putative)	  
EIF4E	   4	   -­‐0.621215178	   8.91E-­‐06	   eukaryotic	  translation	  initiation	  
factor	  4E	  
TMEM63A	   1	   0.718057727	   9.10E-­‐06	   transmembrane	  protein	  63A	  
KRT17	   17	   -­‐1.570923009	   9.33E-­‐06	   keratin	  17	  
LOC643650	   10	   1.348797179	   9.36E-­‐06	   hypothetical	  protein	  LOC643650	  
SGCG	   13	   1.397768707	   9.36E-­‐06	   sarcoglycan,	  gamma	  (35kDa	  
dystrophin-­‐associated	  
glycoprotein)	  
RAI2	   X	   1.249504217	   9.36E-­‐06	   retinoic	  acid	  induced	  2	  
DENND4C	   9	   0.716868104	   9.68E-­‐06	   DENN/MADD	  domain	  containing	  
4C	  
TNFAIP1	   17	   -­‐0.623608342	   9.93E-­‐06	   tumor	  necrosis	  factor,	  alpha-­‐
induced	  protein	  1	  (endothelial)	  
IRF7	   11	   -­‐0.848459149	   9.93E-­‐06	   interferon	  regulatory	  factor	  7	  
CLDN11	   3	   1.564202995	   1.03E-­‐05	   claudin	  11	  
ADAP2	   17	   -­‐1.377588992	   1.07E-­‐05	   ArfGAP	  with	  dual	  PH	  domains	  2	  
LRRC2	   3	   1.118890303	   1.20E-­‐05	   leucine	  rich	  repeat	  containing	  2	  
ENO1	   1	   -­‐0.681648517	   1.22E-­‐05	   enolase	  1,	  (alpha)	  
CRTAP	   3	   0.840667118	   1.22E-­‐05	   cartilage	  associated	  protein	  
GBP6	   1	   -­‐2.019403844	   1.22E-­‐05	   guanylate	  binding	  protein	  
family,	  member	  6	  
417 
 
TNMD	   X	   1.578061911	   1.25E-­‐05	   tenomodulin	  
FOSL1	   11	   -­‐1.795895435	   1.27E-­‐05	   FOS-­‐like	  antigen	  1	  
EIF6	   20	   -­‐0.696817359	   1.30E-­‐05	   eukaryotic	  translation	  initiation	  
factor	  6	  
ABCA8	   17	   1.43951639	   1.30E-­‐05	   ATP-­‐binding	  cassette,	  sub-­‐family	  
A	  (ABC1),	  member	  8	  
KIAA1199	   15	   -­‐0.646109238	   1.31E-­‐05	   KIAA1199	  
SGSM1	   22	   0.576860422	   1.31E-­‐05	   small	  G	  protein	  signaling	  
modulator	  1	  
ACVR2A	   2	   0.842663084	   1.31E-­‐05	   activin	  A	  receptor,	  type	  IIA	  
MRPS14	   1	   0.697863157	   1.33E-­‐05	   mitochondrial	  ribosomal	  protein	  
S14	  
DLX1	   2	   -­‐2.197751512	   1.33E-­‐05	   distal-­‐less	  homeobox	  1	  
EIF5	   14	   -­‐0.528228744	   1.34E-­‐05	   eukaryotic	  translation	  initiation	  
factor	  5	  
FOXE1	   9	   -­‐1.915008435	   1.37E-­‐05	   forkhead	  box	  E1	  (thyroid	  
transcription	  factor	  2)	  
MAMDC2	   9	   1.428412443	   1.39E-­‐05	   MAM	  domain	  containing	  2	  
AKR1B10	   7	   -­‐2.490402458	   1.41E-­‐05	   aldo-­‐keto	  reductase	  family	  1,	  
member	  B10	  (aldose	  reductase)	  
C12orf56	   12	   -­‐1.764593231	   1.42E-­‐05	   chromosome	  12	  open	  reading	  
frame	  56	  
VSNL1	   2	   -­‐1.07087827	   1.43E-­‐05	   visinin-­‐like	  1	  
FABP7	   6	   3.404045922	   1.47E-­‐05	   fatty	  acid	  binding	  protein	  7,	  
brain	  
TK1	   17	   -­‐0.822452932	   1.47E-­‐05	   thymidine	  kinase	  1,	  soluble	  
C14orf132	   14	   0.990892123	   1.47E-­‐05	   chromosome	  14	  open	  reading	  
frame	  132	  
PLN	   6	   1.951613961	   1.56E-­‐05	   phospholamban	  
GDA	   9	   -­‐1.582776852	   1.58E-­‐05	   guanine	  deaminase	  
CKS2	   9	   -­‐1.093273628	   1.59E-­‐05	   CDC28	  protein	  kinase	  regulatory	  
subunit	  2	  





DCUN1D5	   11	   -­‐0.617839525	   1.66E-­‐05	   DCN1,	  defective	  in	  cullin	  
neddylation	  1,	  domain	  
containing	  5	  (S.	  cerevisiae)	  
OGN	   9	   1.367433668	   1.78E-­‐05	   osteoglycin	  
ERBB4	   2	   1.161623978	   1.78E-­‐05	   v-­‐erb-­‐a	  erythroblastic	  leukemia	  
viral	  oncogene	  homolog	  4	  
(avian)	  
SRXN1	   20	   -­‐1.061824985	   1.79E-­‐05	   sulfiredoxin	  1	  homolog	  (S.	  
cerevisiae)	  
FAM162A	   3	   -­‐0.874927878	   1.81E-­‐05	   family	  with	  sequence	  similarity	  
162,	  member	  A	  
LRRN4CL	   11	   1.418917357	   1.85E-­‐05	   LRRN4	  C-­‐terminal	  like	  
FAM13A	   4	   0.795113822	   1.86E-­‐05	   family	  with	  sequence	  similarity	  
418 
 
13,	  member	  A	  
ADAM23	   2	   -­‐1.999949484	   1.88E-­‐05	   ADAM	  metallopeptidase	  domain	  
23	  
EBNA1BP2	   1	   -­‐0.508891279	   1.93E-­‐05	   EBNA1	  binding	  protein	  2	  
ULBP2	   6	   -­‐1.461372151	   1.95E-­‐05	   UL16	  binding	  protein	  2	  
C1orf56	   1	   -­‐0.615316791	   2.05E-­‐05	   chromosome	  1	  open	  reading	  
frame	  56	  




UTP11L	   1	   -­‐0.469248002	   2.08E-­‐05	   UTP11-­‐like,	  U3	  small	  nucleolar	  
ribonucleoprotein,	  (yeast)	  
BNC1	   15	   -­‐0.906989724	   2.11E-­‐05	   basonuclin	  1	  
TMC8	   17	   -­‐0.983228408	   2.14E-­‐05	   transmembrane	  channel-­‐like	  8	  
MICALL1	   22	   -­‐0.782810129	   2.18E-­‐05	   MICAL-­‐like	  1	  
CALML3	   10	   -­‐1.820669812	   2.22E-­‐05	   calmodulin-­‐like	  3	  
FAM150B	   2	   1.321271756	   2.29E-­‐05	   family	  with	  sequence	  similarity	  
150,	  member	  B	  
OAS2	   12	   -­‐1.765115722	   2.29E-­‐05	   2'-­‐5'-­‐oligoadenylate	  synthetase	  
2,	  69/71kDa	  
CCRN4L	   4	   -­‐1.459167504	   2.31E-­‐05	   CCR4	  carbon	  catabolite	  
repression	  4-­‐like	  (S.	  cerevisiae)	  
N4BP2L2	   13	   0.871362327	   2.33E-­‐05	   NEDD4	  binding	  protein	  2-­‐like	  2	  
NME1	   17	   -­‐0.633154152	   2.37E-­‐05	   non-­‐metastatic	  cells	  1,	  protein	  
(NM23A)	  expressed	  in	  
GINS3	   16	   -­‐0.636997509	   2.40E-­‐05	   GINS	  complex	  subunit	  3	  (Psf3	  
homolog)	  
S100A16	   1	   -­‐0.817695136	   2.41E-­‐05	   S100	  calcium	  binding	  protein	  
A16	  
IFRD2	   3	   -­‐0.760453901	   2.41E-­‐05	   interferon-­‐related	  
developmental	  regulator	  2	  
MPZL2	   11	   -­‐1.430762183	   2.48E-­‐05	   myelin	  protein	  zero-­‐like	  2	  
FILIP1	   6	   1.044050818	   2.48E-­‐05	   filamin	  A	  interacting	  protein	  1	  
PLA2G4D	   15	   -­‐0.982822528	   2.63E-­‐05	   phospholipase	  A2,	  group	  IVD	  
(cytosolic)	  
GLTSCR2	   19	   0.602744463	   2.83E-­‐05	   glioma	  tumor	  suppressor	  
candidate	  region	  gene	  2	  
UBE2F	   2	   -­‐0.781502631	   2.92E-­‐05	   ubiquitin-­‐conjugating	  enzyme	  
E2F	  (putative)	  
PSMD11	   17	   -­‐0.553228174	   2.95E-­‐05	   proteasome	  (prosome,	  
macropain)	  26S	  subunit,	  non-­‐
ATPase,	  11	  
FABP5	   8	   -­‐0.986607334	   2.96E-­‐05	   fatty	  acid	  binding	  protein	  5	  
(psoriasis-­‐associated)	  
PAR5	   15	   1.045987817	   3.00E-­‐05	   Prader-­‐Willi/Angelman	  
syndrome-­‐5	  
C11orf67	   11	   0.560151934	   3.02E-­‐05	   chromosome	  11	  open	  reading	  
frame	  67	  




OBFC1	   10	   -­‐0.745207093	   3.20E-­‐05	   oligonucleotide/oligosaccharide-­‐
binding	  fold	  containing	  1	  
FGFBP2	   4	   1.753642781	   3.41E-­‐05	   fibroblast	  growth	  factor	  binding	  
protein	  2	  
CDC42SE1	   1	   -­‐0.492894535	   3.45E-­‐05	   CDC42	  small	  effector	  1	  
ENSA	   1	   -­‐0.813152838	   3.46E-­‐05	   endosulfine	  alpha	  
ARL4C	   2	   -­‐0.783047254	   3.50E-­‐05	   ADP-­‐ribosylation	  factor-­‐like	  4C	  
C7orf58	   7	   1.076736743	   3.50E-­‐05	   chromosome	  7	  open	  reading	  
frame	  58	  
KIAA0802	   18	   -­‐1.384517901	   3.50E-­‐05	   KIAA0802	  
SFXN1	   5	   -­‐0.553153344	   3.53E-­‐05	   sideroflexin	  1	  
LRRC20	   10	   -­‐1.058692931	   3.64E-­‐05	   leucine	  rich	  repeat	  containing	  
20	  
HK2	   2	   -­‐0.930613232	   3.65E-­‐05	   hexokinase	  2	  
HOMER1	   5	   -­‐0.963991288	   3.70E-­‐05	   homer	  homolog	  1	  (Drosophila)	  
SMOX	   20	   -­‐1.457804841	   3.70E-­‐05	   spermine	  oxidase	  
CNN1	   19	   1.096422885	   3.70E-­‐05	   calponin	  1,	  basic,	  smooth	  
muscle	  
LOC100130097	   1	   1.406252911	   3.72E-­‐05	   hypothetical	  LOC100130097	  
RIMS3	   1	   -­‐1.004627903	   3.75E-­‐05	   regulating	  synaptic	  membrane	  
exocytosis	  3	  
WFS1	   4	   0.611474552	   3.80E-­‐05	   Wolfram	  syndrome	  1	  
(wolframin)	  
RAN	   12	   -­‐0.579047554	   3.82E-­‐05	   RAN,	  member	  RAS	  oncogene	  
family	  
ZNF323	   6	   -­‐1.043961478	   3.82E-­‐05	   zinc	  finger	  protein	  323	  
LEP	   7	   1.744600864	   3.84E-­‐05	   leptin	  
FKBPL	   6	   -­‐0.752997816	   3.90E-­‐05	   FK506	  binding	  protein	  like	  
NPY1R	   4	   1.138944059	   3.92E-­‐05	   neuropeptide	  Y	  receptor	  Y1	  
ABCB6	   2	   -­‐0.717186815	   4.01E-­‐05	   ATP-­‐binding	  cassette,	  sub-­‐family	  
B	  (MDR/TAP),	  member	  6	  
BCL2A1	   15	   -­‐1.380133147	   4.02E-­‐05	   BCL2-­‐related	  protein	  A1	  
SERPINB13	   18	   -­‐2.194013705	   4.02E-­‐05	   serpin	  peptidase	  inhibitor,	  clade	  
B	  (ovalbumin),	  member	  13	  
KANK2	   19	   0.847122796	   4.05E-­‐05	   KN	  motif	  and	  ankyrin	  repeat	  
domains	  2	  
GSPT1	   16	   -­‐0.4513105	   4.05E-­‐05	   G1	  to	  S	  phase	  transition	  1	  
CNTNAP2	   7	   -­‐2.257132986	   4.05E-­‐05	   contactin	  associated	  protein-­‐like	  
2	  
UST	   6	   1.216389885	   4.05E-­‐05	   uronyl-­‐2-­‐sulfotransferase	  
C15orf59	   15	   1.074590895	   4.12E-­‐05	   chromosome	  15	  open	  reading	  
frame	  59	  
SYNM	   15	   1.827257685	   4.12E-­‐05	   synemin,	  intermediate	  filament	  
protein	  
FHL1	   X	   1.168944927	   4.13E-­‐05	   four	  and	  a	  half	  LIM	  domains	  1	  
HIF1A	   14	   -­‐0.886352709	   4.32E-­‐05	   hypoxia	  inducible	  factor	  1,	  alpha	  




RFTN1	   3	   -­‐1.389136874	   4.32E-­‐05	   raftlin,	  lipid	  raft	  linker	  1	  
LDLR	   19	   -­‐0.902604389	   4.32E-­‐05	   low	  density	  lipoprotein	  receptor	  
RPL26L1	   5	   -­‐0.615520382	   4.34E-­‐05	   ribosomal	  protein	  L26-­‐like	  1	  
TMEM198	   2	   -­‐0.754524134	   4.35E-­‐05	   transmembrane	  protein	  198	  
DIXDC1	   11	   0.993157805	   4.72E-­‐05	   DIX	  domain	  containing	  1	  
CLCA2	   1	   -­‐0.857394247	   4.73E-­‐05	   chloride	  channel	  accessory	  2	  
FAM49B	   8	   -­‐0.630998728	   4.78E-­‐05	   family	  with	  sequence	  similarity	  
49,	  member	  B	  
NDRG4	   16	   -­‐1.583361104	   4.96E-­‐05	   NDRG	  family	  member	  4	  
POU2F3	   11	   0.990707472	   5.01E-­‐05	   POU	  class	  2	  homeobox	  3	  
ALDH3A2	   17	   0.903345231	   5.01E-­‐05	   aldehyde	  dehydrogenase	  3	  
family,	  member	  A2	  
CABC1	   1	   0.749168853	   5.05E-­‐05	   chaperone,	  ABC1	  activity	  of	  bc1	  
complex	  homolog	  (S.	  pombe)	  
USP54	   10	   0.667402309	   5.06E-­‐05	   ubiquitin	  specific	  peptidase	  54	  
MARS	   12	   -­‐0.532921537	   5.07E-­‐05	   methionyl-­‐tRNA	  synthetase	  
GSTP1	   11	   -­‐0.769210503	   5.11E-­‐05	   glutathione	  S-­‐transferase	  pi	  1	  
ID4	   6	   1.227801869	   5.29E-­‐05	   inhibitor	  of	  DNA	  binding	  4,	  
dominant	  negative	  helix-­‐loop-­‐
helix	  protein	  
CENPN	   16	   -­‐1.051985247	   5.36E-­‐05	   centromere	  protein	  N	  
CDC45L	   22	   -­‐0.72038759	   5.53E-­‐05	   CDC45	  cell	  division	  cycle	  45-­‐like	  
(S.	  cerevisiae)	  
SPRR1A	   1	   -­‐2.310315099	   5.53E-­‐05	   small	  proline-­‐rich	  protein	  1A	  
SYNPO2	   4	   1.383422642	   5.53E-­‐05	   synaptopodin	  2	  
SLC3A2	   11	   -­‐0.712694004	   5.59E-­‐05	   solute	  carrier	  family	  3	  
(activators	  of	  dibasic	  and	  neutral	  
amino	  acid	  transport),	  member	  
2	  
ZFYVE21	   14	   0.538800228	   5.68E-­‐05	   zinc	  finger,	  FYVE	  domain	  
containing	  21	  
RNASEH1	   2	   -­‐0.458794876	   5.69E-­‐05	   ribonuclease	  H1	  
GPR1	   2	   -­‐1.046417274	   5.69E-­‐05	   G	  protein-­‐coupled	  receptor	  1	  
GSTM3	   1	   1.518028394	   5.71E-­‐05	   glutathione	  S-­‐transferase	  mu	  3	  
(brain)	  
ISCA1	   9	   -­‐0.592527822	   5.90E-­‐05	   iron-­‐sulfur	  cluster	  assembly	  1	  
homolog	  (S.	  cerevisiae)	  
GPRIN1	   5	   -­‐0.985742913	   6.00E-­‐05	   G	  protein	  regulated	  inducer	  of	  
neurite	  outgrowth	  1	  
YWHAZ	   8	   -­‐0.516212708	   6.05E-­‐05	   tyrosine	  3-­‐
monooxygenase/tryptophan	  5-­‐
monooxygenase	  activation	  
protein,	  zeta	  polypeptide	  
SLAMF7	   1	   -­‐1.630383541	   6.20E-­‐05	   SLAM	  family	  member	  7	  
SLC47A1	   17	   1.118856086	   6.23E-­‐05	   solute	  carrier	  family	  47,	  
member	  1	  
DLG2	   11	   1.293612966	   6.26E-­‐05	   discs,	  large	  homolog	  2	  
(Drosophila)	  





BBS2	   16	   0.703925117	   6.28E-­‐05	   Bardet-­‐Biedl	  syndrome	  2	  
GPAM	   10	   1.012206427	   6.41E-­‐05	   glycerol-­‐3-­‐phosphate	  
acyltransferase,	  mitochondrial	  
SPRR3	   1	   -­‐3.083151405	   6.54E-­‐05	   small	  proline-­‐rich	  protein	  3	  
PRUNE2	   9	   1.495218852	   6.56E-­‐05	   prune	  homolog	  2	  (Drosophila)	  
PSMD12	   17	   -­‐0.558586985	   6.60E-­‐05	   proteasome	  (prosome,	  
macropain)	  26S	  subunit,	  non-­‐
ATPase,	  12	  
C6orf162	   6	   0.791423049	   6.60E-­‐05	   chromosome	  6	  open	  reading	  
frame	  162	  
MYD88	   3	   -­‐0.806136188	   6.74E-­‐05	   myeloid	  differentiation	  primary	  
response	  gene	  (88)	  
BCL2	   18	   0.633690207	   6.76E-­‐05	   B-­‐cell	  CLL/lymphoma	  2	  
MBP	   18	   0.901487606	   7.12E-­‐05	   myelin	  basic	  protein	  
KIAA1467	   12	   1.340519463	   7.14E-­‐05	   KIAA1467	  
RCAN1	   21	   -­‐1.064604596	   7.18E-­‐05	   regulator	  of	  calcineurin	  1	  
KPNA2	   17	   -­‐0.723735253	   7.42E-­‐05	   karyopherin	  alpha	  2	  (RAG	  cohort	  
1,	  importin	  alpha	  1)	  
PPIF	   10	   -­‐0.980451637	   7.50E-­‐05	   peptidylprolyl	  isomerase	  F	  
EEF2K	   16	   1.029665644	   7.60E-­‐05	   eukaryotic	  elongation	  factor-­‐2	  
kinase	  
AP1S3	   2	   -­‐1.042497787	   7.60E-­‐05	   adaptor-­‐related	  protein	  complex	  
1,	  sigma	  3	  subunit	  
GNA15	   19	   -­‐0.902996254	   7.62E-­‐05	   guanine	  nucleotide	  binding	  
protein	  (G	  protein),	  alpha	  15	  (Gq	  
class)	  
DKK2	   4	   1.264256705	   7.81E-­‐05	   dickkopf	  homolog	  2	  (Xenopus	  
laevis)	  
SLC7A11	   4	   -­‐1.663131251	   7.81E-­‐05	   solute	  carrier	  family	  7,	  (cationic	  
amino	  acid	  transporter,	  y+	  
system)	  member	  11	  
PRMT2	   21	   0.470093445	   7.87E-­‐05	   protein	  arginine	  
methyltransferase	  2	  
ARPC5L	   9	   -­‐0.67408019	   8.13E-­‐05	   actin	  related	  protein	  2/3	  
complex,	  subunit	  5-­‐like	  
TNPO1	   5	   -­‐0.676331739	   8.17E-­‐05	   transportin	  1	  
UBE2T	   1	   -­‐1.018716341	   8.21E-­‐05	   ubiquitin-­‐conjugating	  enzyme	  
E2T	  (putative)	  
TNXB	   6	   0.787124512	   8.25E-­‐05	   tenascin	  XB	  
DIDO1	   20	   0.530268909	   8.25E-­‐05	   death	  inducer-­‐obliterator	  1	  
CDCA4	   14	   -­‐0.630924316	   8.50E-­‐05	   cell	  division	  cycle	  associated	  4	  
F12	   5	   -­‐1.240004245	   8.62E-­‐05	   coagulation	  factor	  XII	  (Hageman	  
factor)	  
KIAA1377	   11	   1.008937074	   8.78E-­‐05	   KIAA1377	  
DUSP14	   17	   -­‐1.200344537	   9.19E-­‐05	   dual	  specificity	  phosphatase	  14	  
C6orf153	   6	   -­‐0.643117067	   9.30E-­‐05	   chromosome	  6	  open	  reading	  
frame	  153	  




SERPINB3	   18	   -­‐2.843983856	   9.37E-­‐05	   serpin	  peptidase	  inhibitor,	  clade	  
B	  (ovalbumin),	  member	  3	  
GPR177	   1	   0.691612027	   9.38E-­‐05	   G	  protein-­‐coupled	  receptor	  177	  
ADH7	   4	   -­‐2.00723802	   9.42E-­‐05	   alcohol	  dehydrogenase	  7	  (class	  
IV),	  mu	  or	  sigma	  polypeptide	  
PLBD1	   12	   -­‐1.309521543	   9.48E-­‐05	   phospholipase	  B	  domain	  
containing	  1	  
PLCB4	   20	   1.005686208	   9.48E-­‐05	   phospholipase	  C,	  beta	  4	  
FLNC	   7	   0.802395558	   9.65E-­‐05	   filamin	  C,	  gamma	  
LGR5	   12	   1.10048201	   9.65E-­‐05	   leucine-­‐rich	  repeat-­‐containing	  G	  
protein-­‐coupled	  receptor	  5	  
H2AFY	   5	   -­‐0.535907178	   9.65E-­‐05	   H2A	  histone	  family,	  member	  Y	  
TMEM49	   17	   -­‐1.213088689	   9.66E-­‐05	   transmembrane	  protein	  49	  
SEMA3D	   7	   0.925658085	   9.72E-­‐05	   sema	  domain,	  immunoglobulin	  
domain	  (Ig),	  short	  basic	  domain,	  




Appendix 2. Full list of significantly 
overrepresented GO terms comparing AK and SE. 
 
adjustedP	   GO	   Name	   Probes	  
4.55E-­‐39	   GO:0001959	   regulation	  of	  cytokine-­‐mediated	  signaling	  pathway	   7	  
1.32E-­‐38	   GO:0032597	   B	  cell	  receptor	  transport	  into	  membrane	  raft	   6	  
1.32E-­‐38	   GO:0032600	   chemokine	  receptor	  transport	  out	  of	  membrane	  raft	   6	  
1.32E-­‐38	   GO:0032913	   negative	  regulation	  of	  transforming	  growth	  factor-­‐beta3	  
production	  
6	  
1.55E-­‐32	   GO:0002768	   immune	  response-­‐regulating	  cell	  surface	  receptor	  
signaling	  pathway	  
6	  
5.99E-­‐32	   GO:0004024	   alcohol	  dehydrogenase	  activity,	  zinc-­‐dependent	   5	  
5.99E-­‐32	   GO:0033210	   leptin-­‐mediated	  signaling	  pathway	   5	  
9.60E-­‐29	   GO:0042104	   positive	  regulation	  of	  activated	  T	  cell	  proliferation	   7	  
5.54E-­‐28	   GO:0001775	   cell	  activation	   6	  
4.85E-­‐26	   GO:0006069	   ethanol	  oxidation	   5	  
1.95E-­‐24	   GO:0030856	   regulation	  of	  epithelial	  cell	  differentiation	   6	  
1.95E-­‐24	   GO:0043408	   regulation	  of	  MAPKKK	  cascade	   6	  
9.12E-­‐24	   GO:0005432	   calcium:sodium	  antiporter	  activity	   5	  
2.20E-­‐22	   GO:0051924	   regulation	  of	  calcium	  ion	  transport	   7	  
8.12E-­‐22	   GO:0016500	   protein-­‐hormone	  receptor	  activity	   5	  
1.33E-­‐21	   GO:0002237	   response	  to	  molecule	  of	  bacterial	  origin	   6	  
1.33E-­‐21	   GO:0031295	   T	  cell	  costimulation	   6	  
1.74E-­‐20	   GO:0043627	   response	  to	  estrogen	  stimulus	   13	  
3.99E-­‐20	   GO:0001542	   ovulation	  from	  ovarian	  follicle	   5	  
1.33E-­‐19	   GO:0031669	   cellular	  response	  to	  nutrient	  levels	   4	  
1.33E-­‐19	   GO:0051346	   negative	  regulation	  of	  hydrolase	  activity	   4	  
2.81E-­‐19	   GO:0030296	   protein	  tyrosine	  kinase	  activator	  activity	   6	  
2.81E-­‐19	   GO:0042325	   regulation	  of	  phosphorylation	   6	  
9.25E-­‐19	   GO:0007204	   elevation	  of	  cytosolic	  calcium	  ion	  concentration	   13	  
1.72E-­‐16	   GO:0045730	   respiratory	  burst	   6	  
8.31E-­‐16	   GO:0060401	   cytosolic	  calcium	  ion	  transport	   4	  
3.88E-­‐15	   GO:0006112	   energy	  reserve	  metabolic	  process	   5	  
5.84E-­‐15	   GO:0002026	   regulation	  of	  the	  force	  of	  heart	  contraction	   7	  
2.92E-­‐13	   GO:0005666	   DNA-­‐directed	  RNA	  polymerase	  III	  complex	   3	  
2.92E-­‐13	   GO:0015276	   ligand-­‐gated	  ion	  channel	  activity	   3	  
4.30E-­‐13	   GO:0002028	   regulation	  of	  sodium	  ion	  transport	   4	  
4.30E-­‐13	   GO:0015081	   sodium	  ion	  transmembrane	  transporter	  activity	   4	  
4.30E-­‐13	   GO:0043149	   stress	  fiber	  assembly	   4	  
4.98E-­‐13	   GO:0015758	   glucose	  transport	   7	  
1.39E-­‐12	   GO:0042755	   eating	  behavior	   5	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3.35E-­‐12	   GO:0048706	   embryonic	  skeletal	  system	  development	   7	  
5.25E-­‐12	   GO:0008366	   axon	  ensheathment	   4	  
5.25E-­‐12	   GO:0017157	   regulation	  of	  exocytosis	   4	  
5.25E-­‐12	   GO:0048251	   elastic	  fiber	  assembly	   4	  
7.02E-­‐12	   GO:0035094	   response	  to	  nicotine	   5	  
9.03E-­‐12	   GO:0006936	   muscle	  contraction	   13	  
1.78E-­‐11	   GO:0001874	   zymosan	  receptor	  activity	   3	  
1.78E-­‐11	   GO:0001879	   detection	  of	  yeast	   3	  
1.78E-­‐11	   GO:0005859	   muscle	  myosin	  complex	   3	  
1.78E-­‐11	   GO:0018125	   peptidyl-­‐cysteine	  methylation	   3	  
1.78E-­‐11	   GO:0043292	   contractile	  fiber	   3	  
4.81E-­‐10	   GO:0001846	   opsonin	  binding	   3	  
4.81E-­‐10	   GO:0002752	   cell	  surface	  pattern	  recognition	  receptor	  signaling	  
pathway	  
3	  
4.81E-­‐10	   GO:0005924	   cell-­‐substrate	  adherens	  junction	   3	  
4.81E-­‐10	   GO:0006359	   regulation	  of	  transcription	  from	  RNA	  polymerase	  III	  
promoter	  
3	  
4.81E-­‐10	   GO:0009756	   carbohydrate	  mediated	  signaling	   3	  
4.81E-­‐10	   GO:0030241	   skeletal	  muscle	  myosin	  thick	  filament	  assembly	   3	  
4.81E-­‐10	   GO:0042287	   MHC	  protein	  binding	   3	  
5.94E-­‐10	   GO:0030054	   cell	  junction	   26	  
7.53E-­‐10	   GO:0043406	   positive	  regulation	  of	  MAP	  kinase	  activity	   6	  
5.14E-­‐09	   GO:0006006	   glucose	  metabolic	  process	   8	  
7.15E-­‐09	   GO:0021756	   striatum	  development	   3	  
7.15E-­‐09	   GO:0032982	   myosin	  filament	   3	  
1.15E-­‐08	   GO:0008544	   epidermis	  development	   11	  
3.35E-­‐08	   GO:0008629	   induction	  of	  apoptosis	  by	  intracellular	  signals	   6	  
3.40E-­‐08	   GO:0071109	   superior	  temporal	  gyrus	  development	   4	  
6.80E-­‐08	   GO:0002238	   response	  to	  molecule	  of	  fungal	  origin	   3	  
6.80E-­‐08	   GO:0008329	   pattern	  recognition	  receptor	  activity	   3	  
6.80E-­‐08	   GO:0009062	   fatty	  acid	  catabolic	  process	   3	  
6.80E-­‐08	   GO:0030101	   natural	  killer	  cell	  activation	   3	  
6.80E-­‐08	   GO:0045089	   positive	  regulation	  of	  innate	  immune	  response	   3	  
1.19E-­‐07	   GO:0034613	   cellular	  protein	  localization	   4	  
3.74E-­‐07	   GO:0001906	   cell	  killing	   4	  
4.58E-­‐07	   GO:0048268	   clathrin	  coat	  assembly	   3	  
1.02E-­‐06	   GO:0005925	   focal	  adhesion	   12	  
1.06E-­‐06	   GO:0015085	   calcium	  ion	  transmembrane	  transporter	  activity	   4	  
1.06E-­‐06	   GO:0017046	   peptide	  hormone	  binding	   4	  
1.36E-­‐06	   GO:0016055	   Wnt	  receptor	  signaling	  pathway	   11	  
1.64E-­‐06	   GO:0042542	   response	  to	  hydrogen	  peroxide	   7	  
1.77E-­‐06	   GO:0008203	   cholesterol	  metabolic	  process	   8	  
2.36E-­‐06	   GO:0005915	   zonula	  adherens	   3	  
2.36E-­‐06	   GO:0030122	   AP-­‐2	  adaptor	  complex	   3	  
2.36E-­‐06	   GO:0042832	   defense	  response	  to	  protozoan	   3	  
2.36E-­‐06	   GO:0051536	   iron-­‐sulfur	  cluster	  binding	   3	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2.41E-­‐06	   GO:0042632	   cholesterol	  homeostasis	   7	  
2.85E-­‐06	   GO:0005200	   structural	  constituent	  of	  cytoskeleton	   9	  
6.68E-­‐06	   GO:0042221	   response	  to	  chemical	  stimulus	   4	  
9.56E-­‐06	   GO:0003344	   pericardium	  morphogenesis	   2	  
9.56E-­‐06	   GO:0003401	   axis	  elongation	   2	  
9.56E-­‐06	   GO:0007620	   copulation	   2	  
9.56E-­‐06	   GO:0016362	   activin	  receptor	  activity,	  type	  II	   2	  
9.56E-­‐06	   GO:0042030	   ATPase	  inhibitor	  activity	   2	  
9.56E-­‐06	   GO:0045836	   positive	  regulation	  of	  meiosis	   2	  
9.56E-­‐06	   GO:0060029	   convergent	  extension	  involved	  in	  organogenesis	   2	  
9.56E-­‐06	   GO:0060638	   mesenchymal-­‐epithelial	  cell	  signaling	   2	  
9.56E-­‐06	   GO:0060686	   negative	  regulation	  of	  prostatic	  bud	  formation	   2	  
9.56E-­‐06	   GO:0060750	   epithelial	  cell	  proliferation	  involved	  in	  mammary	  gland	  
duct	  elongation	  
2	  
9.56E-­‐06	   GO:0090009	   primitive	  streak	  formation	   2	  
9.76E-­‐06	   GO:0005899	   insulin	  receptor	  complex	   3	  
9.76E-­‐06	   GO:0016944	   RNA	  polymerase	  II	  transcription	  elongation	  factor	  activity	   3	  
9.76E-­‐06	   GO:0048739	   cardiac	  muscle	  fiber	  development	   3	  
9.76E-­‐06	   GO:0090004	   positive	  regulation	  of	  establishment	  of	  protein	  
localization	  in	  plasma	  membrane	  
3	  
1.28E-­‐05	   GO:0016337	   cell-­‐cell	  adhesion	   10	  
1.40E-­‐05	   GO:0006874	   cellular	  calcium	  ion	  homeostasis	   7	  
1.51E-­‐05	   GO:0033198	   response	  to	  ATP	   4	  
1.63E-­‐05	   GO:0008021	   synaptic	  vesicle	   5	  
5.51E-­‐05	   GO:0045121	   membrane	  raft	   11	  
0.0001018
48	  
GO:0006910	   phagocytosis,	  recognition	   3	  
0.0001018
48	  





GO:0050690	   regulation	  of	  defense	  response	  to	  virus	  by	  virus	   3	  
0.0001018
48	  
GO:0050727	   regulation	  of	  inflammatory	  response	   3	  
0.0001034
23	  
GO:0005861	   troponin	  complex	   2	  
0.0001034
23	  
GO:0006776	   vitamin	  A	  metabolic	  process	   2	  
0.0001034
23	  
GO:0008038	   neuron	  recognition	   2	  
0.0001034
23	  
GO:0010800	   positive	  regulation	  of	  peptidyl-­‐threonine	  phosphorylation	   2	  
0.0001034
23	  
GO:0016226	   iron-­‐sulfur	  cluster	  assembly	   2	  
0.0001034
23	  
GO:0017002	   activin	  receptor	  activity	   2	  
0.0001034
23	  
GO:0021761	   limbic	  system	  development	   2	  
0.0001034
23	  





GO:0042312	   regulation	  of	  vasodilation	   2	  
0.0001034
23	  
GO:0042713	   sperm	  ejaculation	   2	  
0.0001034
23	  
GO:0050999	   regulation	  of	  nitric-­‐oxide	  synthase	  activity	   2	  
0.0001034
23	  
GO:0060065	   uterus	  development	   2	  
0.0001034
23	  





GO:0060326	   cell	  chemotaxis	   2	  
0.0001034
23	  
GO:0060744	   mammary	  gland	  branching	  involved	  in	  thelarche	   2	  
0.0001034
23	  
GO:0090103	   cochlea	  morphogenesis	   2	  
0.0001158
64	  
GO:0015297	   antiporter	  activity	   5	  
0.0001239
84	  
GO:0004896	   cytokine	  receptor	  activity	   4	  
0.0001239
84	  
GO:0030315	   T-­‐tubule	   4	  
0.0001239
84	  
GO:0048041	   focal	  adhesion	  assembly	   4	  
0.0001923
38	  
GO:0003779	   actin	  binding	   21	  
0.0004213
55	  
GO:0005901	   caveola	   8	  
0.0006515
26	  
GO:0006939	   smooth	  muscle	  contraction	   3	  
0.0006631
74	  
GO:0001518	   voltage-­‐gated	  sodium	  channel	  complex	   2	  
0.0006631
74	  





GO:0005246	   calcium	  channel	  regulator	  activity	   2	  
0.0006631
74	  
GO:0006027	   glycosaminoglycan	  catabolic	  process	   2	  
0.0006631
74	  
GO:0010873	   positive	  regulation	  of	  cholesterol	  esterification	   2	  
0.0006631
74	  
GO:0019788	   NEDD8	  ligase	  activity	   2	  
0.0006631
74	  
GO:0030510	   regulation	  of	  BMP	  signaling	  pathway	   2	  
0.0006631
74	  
GO:0045080	   positive	  regulation	  of	  chemokine	  biosynthetic	  process	   2	  
0.0006631
74	  
GO:0045116	   protein	  neddylation	   2	  
0.0006631
74	  
GO:0060068	   vagina	  development	   2	  






GO:0046907	   intracellular	  transport	   4	  
0.0014357
28	  
GO:0032728	   positive	  regulation	  of	  interferon-­‐beta	  production	   3	  
0.0014357
28	  
GO:0035098	   ESC/E(Z)	  complex	   3	  
0.0026271
84	  
GO:0001666	   response	  to	  hypoxia	   13	  
0.0028515
2	  
GO:0004364	   glutathione	  transferase	  activity	   4	  
0.0028515
2	  
GO:0050699	   WW	  domain	  binding	   4	  
0.0029367
52	  
GO:0006911	   phagocytosis,	  engulfment	   3	  
0.0029467
2	  
GO:0007494	   midgut	  development	   2	  
0.0029467
2	  
GO:0010820	   positive	  regulation	  of	  T	  cell	  chemotaxis	   2	  
0.0029467
2	  
GO:0018106	   peptidyl-­‐histidine	  phosphorylation	   2	  
0.0029467
2	  





GO:0034374	   low-­‐density	  lipoprotein	  particle	  remodeling	   2	  
0.0029467
2	  
GO:0044224	   juxtaparanode	  region	  of	  axon	   2	  
0.0029467
2	  
GO:0048806	   genitalia	  development	   2	  
0.0029467
2	  
GO:0051546	   keratinocyte	  migration	   2	  
0.0029467
2	  
GO:0060612	   adipose	  tissue	  development	   2	  
0.0029467
2	  
GO:0061036	   positive	  regulation	  of	  cartilage	  development	   2	  
0.0034082
72	  
GO:0031225	   anchored	  to	  membrane	   8	  
0.0037522
24	  
GO:0042470	   melanosome	   9	  
0.0042407
68	  
GO:0005516	   calmodulin	  binding	   11	  
0.0043464
96	  
GO:0021766	   hippocampus	  development	   4	  
0.0056328
16	  
GO:0008023	   transcription	  elongation	  factor	  complex	   3	  
0.0070915
04	  
GO:0004871	   signal	  transducer	  activity	   18	  
0.0078911
84	  
GO:0004867	   serine-­‐type	  endopeptidase	  inhibitor	  activity	   7	  
0.0094517
92	  





GO:0009653	   anatomical	  structure	  morphogenesis	   8	  
0.0100219
84	  




Appendix 3. List of differentially expressed genes 
between NSE and AK 
Symbol	   Chr	   logFC	   adj.P.Val	   Description	  
WIF1	   12	   -­‐4.219315383	   1.65E-­‐21	   WNT	  inhibitory	  factor	  1	  
PHYHIP	   8	   -­‐2.723224136	   2.59E-­‐19	   phytanoyl-­‐CoA	  2-­‐hydroxylase	  interacting	  
protein	  
BTC	   4	   -­‐2.566776274	   5.29E-­‐18	   betacellulin	  
SP8	   7	   -­‐3.684368433	   4.30E-­‐17	   Sp8	  transcription	  factor	  
RAB3B	   1	   -­‐1.686256632	   7.43E-­‐15	   RAB3B,	  member	  RAS	  oncogene	  family	  
TNNC1	   3	   -­‐1.99616603	   8.13E-­‐15	   troponin	  C	  type	  1	  (slow)	  
CCL27	   9	   -­‐3.784777844	   1.08E-­‐14	   chemokine	  (C-­‐C	  motif)	  ligand	  27	  
STMN2	   8	   2.903572234	   1.60E-­‐14	   stathmin-­‐like	  2	  
LEPR	   1	   -­‐2.27096095	   3.40E-­‐14	   leptin	  receptor	  
SYT17	   16	   -­‐2.259664347	   1.69E-­‐13	   synaptotagmin	  XVII	  
NA	   -­‐	   -­‐1.906489491	   2.42E-­‐13	   NA	  
CYP4B1	   1	   -­‐3.000085113	   3.36E-­‐13	   cytochrome	  P450,	  family	  4,	  subfamily	  B,	  
polypeptide	  1	  
SGSM1	   22	   -­‐0.971420925	   1.09E-­‐11	   small	  G	  protein	  signaling	  modulator	  1	  
PAMR1	   11	   -­‐2.396125888	   1.10E-­‐11	   peptidase	  domain	  containing	  associated	  with	  
muscle	  regeneration	  1	  
TPPP	   5	   -­‐1.980729801	   1.51E-­‐11	   tubulin	  polymerization	  promoting	  protein	  
DSC2	   18	   2.222951605	   2.17E-­‐11	   desmocollin	  2	  
SUSD2	   22	   -­‐2.379402544	   2.95E-­‐11	   sushi	  domain	  containing	  2	  
PTPN21	   14	   -­‐1.464634331	   6.87E-­‐11	   protein	  tyrosine	  phosphatase,	  non-­‐receptor	  
type	  21	  
NETO2	   16	   2.540280679	   1.07E-­‐10	   neuropilin	  (NRP)	  and	  tolloid	  (TLL)-­‐like	  2	  
WDR66	   12	   1.890740818	   1.51E-­‐10	   WD	  repeat	  domain	  66	  
IRAK1	   X	   0.912036063	   4.33E-­‐10	   interleukin-­‐1	  receptor-­‐associated	  kinase	  1	  
FBLIM1	   1	   1.600072208	   4.33E-­‐10	   filamin	  binding	  LIM	  protein	  1	  
CLDN23	   8	   -­‐1.551793115	   8.79E-­‐10	   claudin	  23	  
KRT6B	   12	   2.139561146	   1.01E-­‐09	   keratin	  6B	  
IFI27	   14	   2.349345424	   1.07E-­‐09	   interferon,	  alpha-­‐inducible	  protein	  27	  
S100A9	   1	   3.59527943	   1.34E-­‐09	   S100	  calcium	  binding	  protein	  A9	  
C7orf59	   7	   -­‐0.980354962	   1.40E-­‐09	   chromosome	  7	  open	  reading	  frame	  59	  
GALNT6	   12	   2.227691829	   1.47E-­‐09	   UDP-­‐N-­‐acetyl-­‐alpha-­‐D-­‐
galactosamine:polypeptide	  N-­‐
acetylgalactosaminyltransferase	  6	  (GalNAc-­‐T6)	  
SOX5	   12	   -­‐1.982365486	   2.97E-­‐09	   SRY	  (sex	  determining	  region	  Y)-­‐box	  5	  
CMAH	   6	   -­‐1.661418146	   3.17E-­‐09	   cytidine	  monophosphate-­‐N-­‐acetylneuraminic	  
acid	  hydroxylase	  (CMP-­‐N-­‐acetylneuraminate	  
monooxygenase)	  pseudogene	  




CD24	   6	   1.612510574	   4.79E-­‐09	   CD24	  molecule	  
C4orf36	   4	   -­‐1.821983315	   4.92E-­‐09	   chromosome	  4	  open	  reading	  frame	  36	  
MYO1B	   2	   1.291192726	   4.94E-­‐09	   myosin	  IB	  
KRT16	   17	   3.253946738	   5.82E-­‐09	   keratin	  16	  
S100A2	   1	   0.836421013	   6.03E-­‐09	   S100	  calcium	  binding	  protein	  A2	  
ENAH	   1	   2.040161851	   9.71E-­‐09	   enabled	  homolog	  (Drosophila)	  
SNTB1	   8	   -­‐1.349195013	   1.03E-­‐08	   syntrophin,	  beta	  1	  (dystrophin-­‐associated	  
protein	  A1,	  59kDa,	  basic	  component	  1)	  
AQP9	   15	   -­‐1.845478701	   1.19E-­‐08	   aquaporin	  9	  
S100A8	   1	   2.342484273	   1.24E-­‐08	   S100	  calcium	  binding	  protein	  A8	  
AK7	   14	   -­‐1.681348413	   1.48E-­‐08	   adenylate	  kinase	  7	  
DLG2	   11	   -­‐1.933191684	   1.76E-­‐08	   discs,	  large	  homolog	  2	  (Drosophila)	  
OASL	   12	   2.802527	   2.29E-­‐08	   2'-­‐5'-­‐oligoadenylate	  synthetase-­‐like	  
SLC8A1	   2	   -­‐1.722647752	   2.86E-­‐08	   solute	  carrier	  family	  8	  (sodium/calcium	  
exchanger),	  member	  1	  
BFSP1	   20	   1.470967319	   3.23E-­‐08	   beaded	  filament	  structural	  protein	  1,	  filensin	  
WNT16	   7	   -­‐1.499361377	   4.87E-­‐08	   wingless-­‐type	  MMTV	  integration	  site	  family,	  
member	  16	  
GJB2	   13	   1.313995421	   4.99E-­‐08	   gap	  junction	  protein,	  beta	  2,	  26kDa	  
PLLP	   16	   -­‐1.776363663	   6.11E-­‐08	   plasma	  membrane	  proteolipid	  (plasmolipin)	  
POU2F3	   11	   -­‐1.396904523	   6.90E-­‐08	   POU	  class	  2	  homeobox	  3	  
GJB4	   1	   -­‐1.451039476	   7.01E-­‐08	   gap	  junction	  protein,	  beta	  4,	  30.3kDa	  
C1QTNF7	   4	   -­‐1.604042815	   7.08E-­‐08	   C1q	  and	  tumor	  necrosis	  factor	  related	  protein	  7	  
WNT5A	   3	   2.319730967	   7.77E-­‐08	   wingless-­‐type	  MMTV	  integration	  site	  family,	  
member	  5A	  
ADH1B	   4	   -­‐2.470779535	   7.77E-­‐08	   alcohol	  dehydrogenase	  1B	  (class	  I),	  beta	  
polypeptide	  
C1orf135	   1	   1.514852991	   1.01E-­‐07	   chromosome	  1	  open	  reading	  frame	  135	  
TPBG	   6	   1.284329154	   1.05E-­‐07	   trophoblast	  glycoprotein	  
COMP	   19	   2.447918217	   1.11E-­‐07	   cartilage	  oligomeric	  matrix	  protein	  
C14orf13
2	  
14	   -­‐1.275570516	   1.36E-­‐07	   chromosome	  14	  open	  reading	  frame	  132	  
IGFL1	   19	   3.4012611	   1.66E-­‐07	   IGF-­‐like	  family	  member	  1	  
KCNJ15	   21	   1.633086491	   1.79E-­‐07	   potassium	  inwardly-­‐rectifying	  channel,	  
subfamily	  J,	  member	  15	  
CLEC7A	   12	   2.030406535	   2.15E-­‐07	   C-­‐type	  lectin	  domain	  family	  7,	  member	  A	  
OAS1	   12	   1.779846981	   2.43E-­‐07	   2',5'-­‐oligoadenylate	  synthetase	  1,	  40/46kDa	  
IL1F7	   2	   -­‐2.206243299	   2.48E-­‐07	   interleukin	  1	  family,	  member	  7	  (zeta)	  
USP54	   10	   -­‐0.898164344	   2.61E-­‐07	   ubiquitin	  specific	  peptidase	  54	  
RSPH1	   21	   -­‐1.211354255	   3.36E-­‐07	   radial	  spoke	  head	  1	  homolog	  (Chlamydomonas)	  
GPC2	   7	   -­‐1.092117918	   3.36E-­‐07	   glypican	  2	  
ALDH3A2	   17	   -­‐1.203237996	   3.39E-­‐07	   aldehyde	  dehydrogenase	  3	  family,	  member	  A2	  
RGMB	   5	   -­‐1.023182889	   3.69E-­‐07	   RGM	  domain	  family,	  member	  B	  
C9orf122	   9	   -­‐1.651774126	   3.73E-­‐07	   chromosome	  9	  open	  reading	  frame	  122	  
GSTA3	   6	   -­‐2.03753085	   3.85E-­‐07	   glutathione	  S-­‐transferase	  alpha	  3	  
KLK1	   19	   -­‐1.051024035	   3.88E-­‐07	   kallikrein	  1	  




GAL3ST4	   7	   -­‐1.108617438	   4.29E-­‐07	   galactose-­‐3-­‐O-­‐sulfotransferase	  4	  
MYOM2	   8	   -­‐0.949774074	   4.35E-­‐07	   myomesin	  (M-­‐protein)	  2,	  165kDa	  
GPR177	   1	   -­‐0.942933109	   4.82E-­‐07	   G	  protein-­‐coupled	  receptor	  177	  
FAM70A	   X	   -­‐1.184394342	   5.22E-­‐07	   family	  with	  sequence	  similarity	  70,	  member	  A	  
CYP4F12	   19	   -­‐1.365839946	   5.60E-­‐07	   cytochrome	  P450,	  family	  4,	  subfamily	  F,	  
polypeptide	  12	  
PARD3	   10	   -­‐0.952938896	   5.76E-­‐07	   par-­‐3	  partitioning	  defective	  3	  homolog	  (C.	  
elegans)	  
TPPP3	   16	   -­‐1.519503982	   5.92E-­‐07	   tubulin	  polymerization-­‐promoting	  protein	  
family	  member	  3	  
KCTD17	   22	   -­‐0.812674759	   6.15E-­‐07	   potassium	  channel	  tetramerisation	  domain	  
containing	  17	  
KDM5A	   12	   -­‐0.809783527	   7.23E-­‐07	   lysine	  (K)-­‐specific	  demethylase	  5A	  
MAMDC2	   9	   -­‐1.720624428	   7.32E-­‐07	   MAM	  domain	  containing	  2	  
SIPA1L2	   1	   1.232950993	   7.32E-­‐07	   signal-­‐induced	  proliferation-­‐associated	  1	  like	  2	  
CNGA1	   4	   -­‐1.116728665	   7.64E-­‐07	   cyclic	  nucleotide	  gated	  channel	  alpha	  1	  
OAS2	   12	   2.172473846	   8.27E-­‐07	   2'-­‐5'-­‐oligoadenylate	  synthetase	  2,	  69/71kDa	  
GATA3	   10	   -­‐1.681693372	   8.27E-­‐07	   GATA	  binding	  protein	  3	  
SRGAP2P
1	  
1	   -­‐1.072893665	   8.27E-­‐07	   SLIT-­‐ROBO	  Rho	  GTPase	  activating	  protein	  2	  
pseudogene	  1	  
TMEM99	   17	   -­‐1.267083668	   8.58E-­‐07	   transmembrane	  protein	  99	  
C4orf31	   4	   -­‐1.840488526	   8.66E-­‐07	   chromosome	  4	  open	  reading	  frame	  31	  
SLAMF7	   1	   2.203178473	   8.73E-­‐07	   SLAM	  family	  member	  7	  
NPY1R	   4	   -­‐1.437421985	   8.97E-­‐07	   neuropeptide	  Y	  receptor	  Y1	  
EEF2K	   16	   -­‐1.073626963	   9.64E-­‐07	   eukaryotic	  elongation	  factor-­‐2	  kinase	  
KRT9	   17	   3.866831475	   1.08E-­‐06	   keratin	  9	  
LYVE1	   11	   -­‐1.694244949	   1.09E-­‐06	   lymphatic	  vessel	  endothelial	  hyaluronan	  
receptor	  1	  
SAMD9	   7	   1.684078511	   1.36E-­‐06	   sterile	  alpha	  motif	  domain	  containing	  9	  
SLC1A2	   11	   -­‐0.99863391	   1.40E-­‐06	   solute	  carrier	  family	  1	  (glial	  high	  affinity	  
glutamate	  transporter),	  member	  2	  
SLC47A1	   17	   -­‐1.419630899	   1.55E-­‐06	   solute	  carrier	  family	  47,	  member	  1	  
MAP4K4	   2	   0.845137296	   1.61E-­‐06	   mitogen-­‐activated	  protein	  kinase	  kinase	  kinase	  
kinase	  4	  
RXRA	   9	   -­‐0.776589712	   1.61E-­‐06	   retinoid	  X	  receptor,	  alpha	  
DENND4C	   9	   -­‐0.819556405	   1.61E-­‐06	   DENN/MADD	  domain	  containing	  4C	  
TMEM19
8	  
2	   0.935810178	   1.63E-­‐06	   transmembrane	  protein	  198	  
TMEM13
2B	  
12	   -­‐0.817122463	   1.65E-­‐06	   transmembrane	  protein	  132B	  
KIAA0802	   18	   1.690244688	   1.70E-­‐06	   KIAA0802	  
PALLD	   4	   0.812398774	   1.96E-­‐06	   palladin,	  cytoskeletal	  associated	  protein	  
PITX1	   5	   1.476500875	   1.96E-­‐06	   paired-­‐like	  homeodomain	  1	  
SCIN	   7	   -­‐1.498386551	   2.03E-­‐06	   scinderin	  
DIO2	   14	   1.410794715	   2.28E-­‐06	   deiodinase,	  iodothyronine,	  type	  II	  
NP	   14	   1.261825123	   2.54E-­‐06	   nucleoside	  phosphorylase	  
C3orf52	   3	   -­‐1.446020377	   2.58E-­‐06	   chromosome	  3	  open	  reading	  frame	  52	  
IGF1	   12	   1.642505988	   2.60E-­‐06	   insulin-­‐like	  growth	  factor	  1	  (somatomedin	  C)	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SYNE1	   6	   -­‐0.923470207	   2.60E-­‐06	   spectrin	  repeat	  containing,	  nuclear	  envelope	  1	  
C11orf67	   11	   -­‐0.71166701	   2.64E-­‐06	   chromosome	  11	  open	  reading	  frame	  67	  
SRXN1	   20	   1.226778481	   2.64E-­‐06	   sulfiredoxin	  1	  homolog	  (S.	  cerevisiae)	  
KRT6A	   12	   2.457025505	   2.78E-­‐06	   keratin	  6A	  
ENO1	   1	   0.832101885	   2.99E-­‐06	   enolase	  1,	  (alpha)	  
SCARA5	   8	   -­‐2.13153296	   3.26E-­‐06	   scavenger	  receptor	  class	  A,	  member	  5	  
(putative)	  
GTF3C6	   6	   0.545359787	   3.26E-­‐06	   general	  transcription	  factor	  IIIC,	  polypeptide	  6,	  
alpha	  35kDa	  
FAM126A	   7	   1.172415743	   3.50E-­‐06	   family	  with	  sequence	  similarity	  126,	  member	  A	  
DSG3	   18	   1.326400769	   3.53E-­‐06	   desmoglein	  3	  (pemphigus	  vulgaris	  antigen)	  
ABCC1	   16	   0.953360832	   3.53E-­‐06	   ATP-­‐binding	  cassette,	  sub-­‐family	  C	  (CFTR/MRP),	  
member	  1	  
CSRP2	   12	   1.565678105	   3.58E-­‐06	   cysteine	  and	  glycine-­‐rich	  protein	  2	  
PRODH	   22	   -­‐1.301358419	   3.59E-­‐06	   proline	  dehydrogenase	  (oxidase)	  1	  
TXNDC17	   17	   1.053771403	   3.61E-­‐06	   thioredoxin	  domain	  containing	  17	  
ADAM23	   2	   2.279633922	   3.75E-­‐06	   ADAM	  metallopeptidase	  domain	  23	  
C15orf59	   15	   -­‐1.277842281	   3.82E-­‐06	   chromosome	  15	  open	  reading	  frame	  59	  
PRKCB	   16	   -­‐1.109873417	   3.91E-­‐06	   protein	  kinase	  C,	  beta	  
FOXN3	   14	   -­‐0.664094	   4.01E-­‐06	   forkhead	  box	  N3	  
FAM65C	   20	   1.627708704	   4.08E-­‐06	   family	  with	  sequence	  similarity	  65,	  member	  C	  
ZFYVE21	   14	   -­‐0.648223034	   4.44E-­‐06	   zinc	  finger,	  FYVE	  domain	  containing	  21	  
N4BP2L1	   13	   -­‐1.220474683	   4.52E-­‐06	   NEDD4	  binding	  protein	  2-­‐like	  1	  
ADAMTSL
3	  
15	   -­‐1.326651735	   4.53E-­‐06	   ADAMTS-­‐like	  3	  
HUNK	   21	   -­‐1.158573188	   4.62E-­‐06	   hormonally	  up-­‐regulated	  Neu-­‐associated	  kinase	  
ZNF323	   6	   1.222242953	   4.86E-­‐06	   zinc	  finger	  protein	  323	  
SLC20A1	   2	   0.985405179	   4.86E-­‐06	   solute	  carrier	  family	  20	  (phosphate	  
transporter),	  member	  1	  
FUT3	   19	   1.535498932	   5.02E-­‐06	   fucosyltransferase	  3	  (galactoside	  3(4)-­‐L-­‐
fucosyltransferase,	  Lewis	  blood	  group)	  
C12orf5	   12	   1.233765685	   5.07E-­‐06	   chromosome	  12	  open	  reading	  frame	  5	  
ACVR2A	   2	   -­‐0.926137449	   5.42E-­‐06	   activin	  A	  receptor,	  type	  IIA	  
KIAA1467	   12	   -­‐1.615435124	   5.73E-­‐06	   KIAA1467	  
TXNDC5	   6	   0.79115768	   5.80E-­‐06	   thioredoxin	  domain	  containing	  5	  (endoplasmic	  
reticulum)	  
KRT17	   17	   1.689164585	   5.88E-­‐06	   keratin	  17	  
CMPK2	   2	   1.918473793	   5.88E-­‐06	   cytidine	  monophosphate	  (UMP-­‐CMP)	  kinase	  2,	  
mitochondrial	  
THY1	   11	   1.555223084	   6.31E-­‐06	   Thy-­‐1	  cell	  surface	  antigen	  
MPZL1	   1	   0.787156482	   6.71E-­‐06	   myelin	  protein	  zero-­‐like	  1	  
PRSS23	   11	   1.298776439	   6.86E-­‐06	   protease,	  serine,	  23	  
CNTNAP3	   9	   -­‐1.694815043	   6.90E-­‐06	   contactin	  associated	  protein-­‐like	  3	  
IKZF2	   2	   -­‐1.602292506	   6.90E-­‐06	   IKAROS	  family	  zinc	  finger	  2	  (Helios)	  
NDFIP2	   13	   -­‐0.95975278	   7.16E-­‐06	   Nedd4	  family	  interacting	  protein	  2	  
PRO0471	   3	   -­‐1.149151688	   7.16E-­‐06	   hypothetical	  LOC28994	  
EIF5	   14	   0.570378219	   8.19E-­‐06	   eukaryotic	  translation	  initiation	  factor	  5	  
YKT6	   7	   0.855689397	   8.84E-­‐06	   YKT6	  v-­‐SNARE	  homolog	  (S.	  cerevisiae)	  
433 
 
FAM49B	   8	   0.728013526	   8.86E-­‐06	   family	  with	  sequence	  similarity	  49,	  member	  B	  
HK2	   2	   1.05462202	   9.17E-­‐06	   hexokinase	  2	  
LOC64365
0	  
10	   -­‐1.420576304	   9.41E-­‐06	   hypothetical	  protein	  LOC643650	  
FAM164A	   8	   -­‐1.041564905	   9.50E-­‐06	   family	  with	  sequence	  similarity	  164,	  member	  A	  
ZSCAN18	   19	   -­‐1.268761562	   1.02E-­‐05	   zinc	  finger	  and	  SCAN	  domain	  containing	  18	  
NPY5R	   4	   -­‐0.717220478	   1.03E-­‐05	   neuropeptide	  Y	  receptor	  Y5	  
LTA4H	   12	   -­‐0.693645845	   1.03E-­‐05	   leukotriene	  A4	  hydrolase	  
RNF180	   5	   -­‐1.438278345	   1.08E-­‐05	   ring	  finger	  protein	  180	  
SNCG	   10	   -­‐0.796416312	   1.11E-­‐05	   synuclein,	  gamma	  (breast	  cancer-­‐specific	  
protein	  1)	  
PAIP2B	   2	   -­‐1.307247416	   1.11E-­‐05	   poly(A)	  binding	  protein	  interacting	  protein	  2B	  
C20orf24	   20	   0.814091892	   1.26E-­‐05	   chromosome	  20	  open	  reading	  frame	  24	  
WFS1	   4	   -­‐0.683505438	   1.31E-­‐05	   Wolfram	  syndrome	  1	  (wolframin)	  
NEFL	   8	   3.563809174	   1.31E-­‐05	   neurofilament,	  light	  polypeptide	  
SCD	   10	   1.473211644	   1.35E-­‐05	   stearoyl-­‐CoA	  desaturase	  (delta-­‐9-­‐desaturase)	  
IFI6	   1	   2.084578733	   1.40E-­‐05	   interferon,	  alpha-­‐inducible	  protein	  6	  
ADAMDE
C1	  
8	   2.303583223	   1.53E-­‐05	   ADAM-­‐like,	  decysin	  1	  
C1orf59	   1	   1.261547967	   1.59E-­‐05	   chromosome	  1	  open	  reading	  frame	  59	  
SRGAP2	   1	   -­‐0.823368986	   1.60E-­‐05	   SLIT-­‐ROBO	  Rho	  GTPase	  activating	  protein	  2	  
HIF1A	   14	   0.988575604	   1.62E-­‐05	   hypoxia	  inducible	  factor	  1,	  alpha	  subunit	  (basic	  
helix-­‐loop-­‐helix	  transcription	  factor)	  
ARL4C	   2	   0.861624053	   1.62E-­‐05	   ADP-­‐ribosylation	  factor-­‐like	  4C	  
SLC7A5	   16	   1.331999362	   1.64E-­‐05	   solute	  carrier	  family	  7	  (cationic	  amino	  acid	  
transporter,	  y+	  system),	  member	  5	  
DEFB4	   8	   4.24312331	   1.69E-­‐05	   defensin,	  beta	  4	  
ZDHHC11	   5	   -­‐0.973551038	   1.75E-­‐05	   zinc	  finger,	  DHHC-­‐type	  containing	  11	  
LRRC20	   10	   1.162441208	   1.75E-­‐05	   leucine	  rich	  repeat	  containing	  20	  
IFI44	   1	   1.874346514	   1.75E-­‐05	   interferon-­‐induced	  protein	  44	  
AP2S1	   19	   0.989982492	   1.75E-­‐05	   adaptor-­‐related	  protein	  complex	  2,	  sigma	  1	  
subunit	  
ACOT8	   20	   -­‐1.126086831	   1.79E-­‐05	   acyl-­‐CoA	  thioesterase	  8	  
MYH14	   19	   -­‐1.056965442	   1.81E-­‐05	   myosin,	  heavy	  chain	  14	  
ATOH8	   2	   -­‐0.977092297	   1.83E-­‐05	   atonal	  homolog	  8	  (Drosophila)	  
TMEM43	   3	   -­‐0.696412265	   1.96E-­‐05	   transmembrane	  protein	  43	  
IL7	   8	   -­‐1.292088499	   1.96E-­‐05	   interleukin	  7	  
ELL3	   15	   -­‐0.84484672	   1.96E-­‐05	   elongation	  factor	  RNA	  polymerase	  II-­‐like	  3	  
GLTSCR2	   19	   -­‐0.649183801	   1.96E-­‐05	   glioma	  tumor	  suppressor	  candidate	  region	  gene	  
2	  
SGK3	   8	   -­‐0.947213565	   2.04E-­‐05	   serum/glucocorticoid	  regulated	  kinase	  family,	  
member	  3	  
ZNF658	   9	   -­‐0.736340566	   2.05E-­‐05	   zinc	  finger	  protein	  658	  
UBE2F	   2	   0.841113104	   2.05E-­‐05	   ubiquitin-­‐conjugating	  enzyme	  E2F	  (putative)	  
ZNF418	   19	   -­‐1.128254365	   2.05E-­‐05	   zinc	  finger	  protein	  418	  
ID4	   6	   -­‐1.362570731	   2.18E-­‐05	   inhibitor	  of	  DNA	  binding	  4,	  dominant	  negative	  
helix-­‐loop-­‐helix	  protein	  
ZNF204	   6	   -­‐1.253631153	   2.18E-­‐05	   zinc	  finger	  protein	  204	  pseudogene	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BCL2	   18	   -­‐1.259152522	   2.24E-­‐05	   B-­‐cell	  CLL/lymphoma	  2	  
LOC64898
7	  
5	   0.897217074	   2.31E-­‐05	   hypothetical	  LOC648987	  
AGFG2	   7	   -­‐0.879381116	   2.34E-­‐05	   ArfGAP	  with	  FG	  repeats	  2	  
C7orf10	   7	   1.12474032	   2.38E-­‐05	   chromosome	  7	  open	  reading	  frame	  10	  
F2R	   5	   -­‐1.017073706	   2.46E-­‐05	   coagulation	  factor	  II	  (thrombin)	  receptor	  
SCEL	   13	   -­‐2.174886732	   2.47E-­‐05	   sciellin	  
GREM2	   1	   -­‐0.957062849	   2.50E-­‐05	   gremlin	  2,	  cysteine	  knot	  superfamily,	  homolog	  
(Xenopus	  laevis)	  
RHOT1	   17	   -­‐0.738534469	   2.54E-­‐05	   ras	  homolog	  gene	  family,	  member	  T1	  
ETV7	   6	   -­‐1.383878495	   2.56E-­‐05	   ets	  variant	  7	  
MX1	   21	   1.732484456	   2.59E-­‐05	   myxovirus	  (influenza	  virus)	  resistance	  1,	  
interferon-­‐inducible	  protein	  p78	  (mouse)	  
INPP5A	   10	   -­‐0.711644897	   2.61E-­‐05	   inositol	  polyphosphate-­‐5-­‐phosphatase,	  40kDa	  
EBNA1BP
2	  
1	   0.528910812	   2.61E-­‐05	   EBNA1	  binding	  protein	  2	  
MID1	   X	   0.897925333	   2.68E-­‐05	   midline	  1	  (Opitz/BBB	  syndrome)	  
EMP1	   12	   -­‐1.113356273	   2.70E-­‐05	   epithelial	  membrane	  protein	  1	  
SYNCRIP	   6	   0.737268696	   2.73E-­‐05	   synaptotagmin	  binding,	  cytoplasmic	  RNA	  
interacting	  protein	  
C2orf67	   2	   -­‐0.918301066	   2.73E-­‐05	   chromosome	  2	  open	  reading	  frame	  67	  
LMO7	   13	   -­‐0.915816105	   2.73E-­‐05	   LIM	  domain	  7	  
PPP4R1	   18	   0.74107727	   2.73E-­‐05	   protein	  phosphatase	  4,	  regulatory	  subunit	  1	  
EPHX2	   8	   -­‐0.894923191	   2.76E-­‐05	   epoxide	  hydrolase	  2,	  cytoplasmic	  
CLDN11	   3	   -­‐1.566806527	   2.76E-­‐05	   claudin	  11	  
GSTM5	   1	   -­‐1.285096379	   2.94E-­‐05	   glutathione	  S-­‐transferase	  mu	  5	  
MLLT11	   1	   1.40448242	   3.01E-­‐05	   myeloid/lymphoid	  or	  mixed-­‐lineage	  leukemia	  
(trithorax	  homolog,	  Drosophila);	  translocated	  
to,	  11	  
DZIP1L	   3	   -­‐0.812694347	   3.05E-­‐05	   DAZ	  interacting	  protein	  1-­‐like	  
GIPC2	   1	   -­‐1.643298792	   3.11E-­‐05	   GIPC	  PDZ	  domain	  containing	  family,	  member	  2	  
VSNL1	   2	   1.084108398	   3.16E-­‐05	   visinin-­‐like	  1	  
LIPA	   10	   0.715655706	   3.25E-­‐05	   lipase	  A,	  lysosomal	  acid,	  cholesterol	  esterase	  
CBX2	   17	   1.063116422	   3.31E-­‐05	   chromobox	  homolog	  2	  (Pc	  class	  homolog,	  
Drosophila)	  
LASS6	   2	   -­‐0.952986163	   3.33E-­‐05	   LAG1	  homolog,	  ceramide	  synthase	  6	  
N4BP2L2	   13	   -­‐0.56268256	   3.33E-­‐05	   NEDD4	  binding	  protein	  2-­‐like	  2	  
PNRC1	   6	   -­‐0.527615837	   3.64E-­‐05	   proline-­‐rich	  nuclear	  receptor	  coactivator	  1	  
BZW1	   2	   0.57891889	   3.66E-­‐05	   basic	  leucine	  zipper	  and	  W2	  domains	  1	  
ANKRD18
A	  
9	   -­‐1.14711812	   3.66E-­‐05	   ankyrin	  repeat	  domain	  18A	  
CRIP1	   14	   -­‐1.687982033	   3.77E-­‐05	   cysteine-­‐rich	  protein	  1	  (intestinal)	  
RAB31	   18	   1.062321588	   3.82E-­‐05	   RAB31,	  member	  RAS	  oncogene	  family	  
PI3	   20	   2.790989125	   3.88E-­‐05	   peptidase	  inhibitor	  3,	  skin-­‐derived	  
TNFRSF10
B	  
8	   0.934090139	   3.94E-­‐05	   tumor	  necrosis	  factor	  receptor	  superfamily,	  
member	  10b	  
FMNL2	   2	   0.98327065	   3.94E-­‐05	   formin-­‐like	  2	  
TMEM49	   17	   1.351731577	   3.99E-­‐05	   transmembrane	  protein	  49	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RELL1	   4	   -­‐0.78272333	   4.00E-­‐05	   RELT-­‐like	  1	  
GJB6	   13	   1.48765847	   4.19E-­‐05	   gap	  junction	  protein,	  beta	  6,	  30kDa	  
SPINK6	   5	   3.875208272	   4.22E-­‐05	   serine	  peptidase	  inhibitor,	  Kazal	  type	  6	  
LOC64382
7	  
9	   -­‐1.389112034	   4.28E-­‐05	   similar	  to	  cell	  recognition	  molecule	  CASPR3	  
GCET2	   3	   -­‐1.156197605	   4.39E-­‐05	   germinal	  center	  expressed	  transcript	  2	  
CTNND1	   11	   -­‐0.749821965	   4.46E-­‐05	   catenin	  (cadherin-­‐associated	  protein),	  delta	  1	  
MXD1	   2	   0.970792058	   4.55E-­‐05	   MAX	  dimerization	  protein	  1	  
CES1	   16	   -­‐1.241229208	   4.63E-­‐05	   carboxylesterase	  1	  (monocyte/macrophage	  
serine	  esterase	  1)	  
FGFR3	   4	   -­‐0.980242284	   4.64E-­‐05	   fibroblast	  growth	  factor	  receptor	  3	  
RASAL2	   1	   -­‐0.705599039	   4.73E-­‐05	   RAS	  protein	  activator	  like	  2	  
LMBRD1	   6	   -­‐0.547656424	   4.75E-­‐05	   LMBR1	  domain	  containing	  1	  
ACADL	   2	   -­‐0.982992006	   4.82E-­‐05	   acyl-­‐Coenzyme	  A	  dehydrogenase,	  long	  chain	  
TMC8	   17	   0.994419548	   4.83E-­‐05	   transmembrane	  channel-­‐like	  8	  
RPL13	   16	   -­‐0.53256886	   4.91E-­‐05	   ribosomal	  protein	  L13	  
ZNF677	   19	   -­‐1.007706414	   5.26E-­‐05	   zinc	  finger	  protein	  677	  
ANG	   14	   -­‐0.982791559	   5.26E-­‐05	   angiogenin,	  ribonuclease,	  RNase	  A	  family,	  5	  
CTPS	   1	   0.805391343	   5.34E-­‐05	   CTP	  synthase	  
FOXE1	   9	   1.879910169	   5.34E-­‐05	   forkhead	  box	  E1	  (thyroid	  transcription	  factor	  2)	  
GALNTL1	   14	   -­‐1.48864083	   5.36E-­‐05	   UDP-­‐N-­‐acetyl-­‐alpha-­‐D-­‐
galactosamine:polypeptide	  N-­‐
acetylgalactosaminyltransferase-­‐like	  1	  
OBFC1	   10	   0.764686637	   5.38E-­‐05	   oligonucleotide/oligosaccharide-­‐binding	  fold	  
containing	  1	  
DENND1A	   9	   1.013513481	   5.50E-­‐05	   DENN/MADD	  domain	  containing	  1A	  
EPN2	   17	   -­‐0.666432193	   5.58E-­‐05	   epsin	  2	  
ASAH1	   8	   -­‐0.658586556	   5.58E-­‐05	   N-­‐acylsphingosine	  amidohydrolase	  (acid	  
ceramidase)	  1	  
SLC30A9	   4	   0.933845156	   5.60E-­‐05	   solute	  carrier	  family	  30	  (zinc	  transporter),	  
member	  9	  
GTPBP4	   10	   0.645442007	   5.61E-­‐05	   GTP	  binding	  protein	  4	  
TMEM19	   12	   -­‐0.812772988	   5.64E-­‐05	   transmembrane	  protein	  19	  
PGAP1	   2	   -­‐0.807492606	   5.71E-­‐05	   post-­‐GPI	  attachment	  to	  proteins	  1	  
BBS2	   16	   -­‐0.748505371	   5.71E-­‐05	   Bardet-­‐Biedl	  syndrome	  2	  
HOMER1	   5	   0.992829208	   5.75E-­‐05	   homer	  homolog	  1	  (Drosophila)	  
FLJ32255	   5	   1.506250462	   5.75E-­‐05	   hypothetical	  protein	  LOC643977	  
CTSC	   11	   0.829848209	   5.75E-­‐05	   cathepsin	  C	  
STX7	   6	   -­‐0.509832943	   5.88E-­‐05	   syntaxin	  7	  
DLX2	   2	   2.239148577	   6.00E-­‐05	   distal-­‐less	  homeobox	  2	  
BCMO1	   16	   -­‐1.047941839	   6.11E-­‐05	   beta-­‐carotene	  15,15'-­‐monooxygenase	  1	  




12	   1.219422577	   6.32E-­‐05	   transmembrane	  protein	  119	  
PITX2	   4	   1.425008042	   6.47E-­‐05	   paired-­‐like	  homeodomain	  2	  




ZNF273	   7	   -­‐1.050336147	   6.93E-­‐05	   zinc	  finger	  protein	  273	  
GDA	   9	   3.003024332	   7.11E-­‐05	   guanine	  deaminase	  
ARHGAP2
3	  
17	   -­‐0.822234333	   7.11E-­‐05	   Rho	  GTPase	  activating	  protein	  23	  
GLCCI1	   7	   -­‐1.330668512	   7.22E-­‐05	   glucocorticoid	  induced	  transcript	  1	  
PDK4	   7	   -­‐1.126383593	   7.39E-­‐05	   pyruvate	  dehydrogenase	  kinase,	  isozyme	  4	  
HNRPDL	   4	   -­‐0.743594774	   7.58E-­‐05	   heterogeneous	  nuclear	  ribonucleoprotein	  D-­‐like	  
CAB39L	   13	   -­‐0.85196845	   7.58E-­‐05	   calcium	  binding	  protein	  39-­‐like	  
SLC25A27	   6	   -­‐0.841397394	   7.79E-­‐05	   solute	  carrier	  family	  25,	  member	  27	  
HERC6	   4	   1.683644313	   8.01E-­‐05	   hect	  domain	  and	  RLD	  6	  
POLR3G	   5	   1.103392334	   8.01E-­‐05	   polymerase	  (RNA)	  III	  (DNA	  directed)	  
polypeptide	  G	  (32kD)	  
MAPRE1	   20	   0.537458304	   8.05E-­‐05	   microtubule-­‐associated	  protein,	  RP/EB	  family,	  
member	  1	  
CYP39A1	   6	   -­‐1.447370086	   8.17E-­‐05	   cytochrome	  P450,	  family	  39,	  subfamily	  A,	  
polypeptide	  1	  
GNB4	   3	   -­‐0.979380437	   8.19E-­‐05	   guanine	  nucleotide	  binding	  protein	  (G	  protein),	  
beta	  polypeptide	  4	  
NDRG4	   16	   1.625795155	   8.24E-­‐05	   NDRG	  family	  member	  4	  
WDR1	   4	   0.634003715	   8.25E-­‐05	   WD	  repeat	  domain	  1	  
TNFRSF19	   13	   -­‐1.1034056	   8.39E-­‐05	   tumor	  necrosis	  factor	  receptor	  superfamily,	  
member	  19	  
KRT77	   12	   -­‐1.939033838	   8.76E-­‐05	   keratin	  77	  
TMEM64	   8	   0.752127494	   8.76E-­‐05	   transmembrane	  protein	  64	  
CNTNAP2	   7	   2.283007504	   8.85E-­‐05	   contactin	  associated	  protein-­‐like	  2	  
KIF21A	   12	   -­‐0.913919767	   8.97E-­‐05	   kinesin	  family	  member	  21A	  
CD55	   1	   -­‐1.016394607	   9.00E-­‐05	   CD55	  molecule,	  decay	  accelerating	  factor	  for	  
complement	  (Cromer	  blood	  group)	  
MKRN1	   7	   -­‐0.62970988	   9.10E-­‐05	   makorin	  ring	  finger	  protein	  1	  
CLDND1	   3	   -­‐0.768114494	   9.10E-­‐05	   claudin	  domain	  containing	  1	  
PITPNC1	   17	   1.108052369	   9.24E-­‐05	   phosphatidylinositol	  transfer	  protein,	  
cytoplasmic	  1	  
NELL2	   12	   2.354454276	   9.30E-­‐05	   NEL-­‐like	  2	  (chicken)	  
SPRY4	   5	   1.297283639	   9.34E-­‐05	   sprouty	  homolog	  4	  (Drosophila)	  
FRMD4A	   10	   -­‐0.775832194	   9.34E-­‐05	   FERM	  domain	  containing	  4A	  




Appendix 4. Full list of significantly 





GO	   Name	   Prob
es	  
<0.0001	   GO:0001959	   regulation	  of	  cytokine-­‐mediated	  signaling	  pathway	   7	  
<0.0001	   GO:0032597	   B	  cell	  receptor	  transport	  into	  membrane	  raft	   6	  
<0.0001	   GO:0032600	   chemokine	  receptor	  transport	  out	  of	  membrane	  raft	   6	  
<0.0001	   GO:0032913	   negative	  regulation	  of	  transforming	  growth	  factor-­‐beta3	  
production	  
6	  
<0.0001	   GO:0002768	   immune	  response-­‐regulating	  cell	  surface	  receptor	  
signaling	  pathway	  
6	  
<0.0001	   GO:0001775	   cell	  activation	   6	  
<0.0001	   GO:0043627	   response	  to	  estrogen	  stimulus	   15	  
<0.0001	   GO:0004768	   stearoyl-­‐CoA	  9-­‐desaturase	  activity	   5	  
<0.0001	   GO:0003408	   optic	  cup	  formation	  involved	  in	  camera-­‐type	  eye	  
development	  
4	  
<0.0001	   GO:0032273	   positive	  regulation	  of	  protein	  polymerization	   4	  
<0.0001	   GO:0030856	   regulation	  of	  epithelial	  cell	  differentiation	   6	  
<0.0001	   GO:0043408	   regulation	  of	  MAPKKK	  cascade	   6	  
<0.0001	   GO:0045730	   respiratory	  burst	   7	  
<0.0001	   GO:0033210	   leptin-­‐mediated	  signaling	  pathway	   4	  
<0.0001	   GO:0002237	   response	  to	  molecule	  of	  bacterial	  origin	   6	  
<0.0001	   GO:0031295	   T	  cell	  costimulation	   6	  
<0.0001	   GO:0042104	   positive	  regulation	  of	  activated	  T	  cell	  proliferation	   6	  
<0.0001	   GO:0001874	   zymosan	  receptor	  activity	   4	  
<0.0001	   GO:0001879	   detection	  of	  yeast	   4	  
<0.0001	   GO:0031669	   cellular	  response	  to	  nutrient	  levels	   4	  
<0.0001	   GO:0051346	   negative	  regulation	  of	  hydrolase	  activity	   4	  
<0.0001	   GO:0030296	   protein	  tyrosine	  kinase	  activator	  activity	   6	  
<0.0001	   GO:0042325	   regulation	  of	  phosphorylation	   6	  
<0.0001	   GO:0016337	   cell-­‐cell	  adhesion	   16	  
<0.0001	   GO:0048873	   homeostasis	  of	  number	  of	  cells	  within	  a	  tissue	   5	  
<0.0001	   GO:0001730	   2'-­‐5'-­‐oligoadenylate	  synthetase	  activity	   3	  
<0.0001	   GO:0031115	   negative	  regulation	  of	  microtubule	  polymerization	   3	  
<0.0001	   GO:0001846	   opsonin	  binding	   4	  
<0.0001	   GO:0002752	   cell	  surface	  pattern	  recognition	  receptor	  signaling	  
pathway	  
4	  
<0.0001	   GO:0009756	   carbohydrate	  mediated	  signaling	   4	  
<0.0001	   GO:0031334	   positive	  regulation	  of	  protein	  complex	  assembly	   4	  
<0.0001	   GO:0042287	   MHC	  protein	  binding	   4	  
<0.0001	   GO:0046689	   response	  to	  mercury	  ion	   4	  
<0.0001	   GO:0035094	   response	  to	  nicotine	   6	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<0.0001	   GO:0051924	   regulation	  of	  calcium	  ion	  transport	   6	  
<0.0001	   GO:0005432	   calcium:sodium	  antiporter	  activity	   4	  
<0.0001	   GO:0060401	   cytosolic	  calcium	  ion	  transport	   4	  
<0.0001	   GO:0015068	   glycine	  amidinotransferase	  activity	   3	  
<0.0001	   GO:0051371	   muscle	  alpha-­‐actinin	  binding	   3	  
<0.0001	   GO:0051902	   negative	  regulation	  of	  mitochondrial	  depolarization	   3	  
<0.0001	   GO:0002238	   response	  to	  molecule	  of	  fungal	  origin	   4	  
<0.0001	   GO:0006590	   thyroid	  hormone	  generation	   4	  
<0.0001	   GO:0008329	   pattern	  recognition	  receptor	  activity	   4	  
<0.0001	   GO:0016500	   protein-­‐hormone	  receptor	  activity	   4	  
<0.0001	   GO:0046785	   microtubule	  polymerization	   4	  
<0.0001	   GO:0006601	   creatine	  biosynthetic	  process	   3	  
<0.0001	   GO:0060509	   Type	  I	  pneumocyte	  differentiation	   3	  
<0.0001	   GO:0001542	   ovulation	  from	  ovarian	  follicle	   4	  
<0.0001	   GO:0002028	   regulation	  of	  sodium	  ion	  transport	   4	  
<0.0001	   GO:0015081	   sodium	  ion	  transmembrane	  transporter	  activity	   4	  
<0.0001	   GO:0007204	   elevation	  of	  cytosolic	  calcium	  ion	  concentration	   11	  
<0.0001	   GO:0042755	   eating	  behavior	   5	  
<0.0001	   GO:0042832	   defense	  response	  to	  protozoan	   4	  
<0.0001	   GO:0001601	   peptide	  YY	  receptor	  activity	   2	  
<0.0001	   GO:0001602	   pancreatic	  polypeptide	  receptor	  activity	   2	  
<0.0001	   GO:0002741	   positive	  regulation	  of	  cytokine	  secretion	  involved	  in	  
immune	  response	  
2	  
<0.0001	   GO:0003103	   positive	  regulation	  of	  diuresis	   2	  
<0.0001	   GO:0003323	   pancreatic	  B	  cell	  development	   2	  
<0.0001	   GO:0004396	   hexokinase	  activity	   2	  
<0.0001	   GO:0004686	   elongation	  factor-­‐2	  kinase	  activity	   2	  
<0.0001	   GO:0004983	   neuropeptide	  Y	  receptor	  activity	   2	  
<0.0001	   GO:0005110	   frizzled-­‐2	  binding	   2	  
<0.0001	   GO:0005115	   receptor	  tyrosine	  kinase-­‐like	  orphan	  receptor	  binding	   2	  
<0.0001	   GO:0030825	   positive	  regulation	  of	  cGMP	  metabolic	  process	   2	  
<0.0001	   GO:0034755	   iron	  ion	  transmembrane	  transport	   2	  
<0.0001	   GO:0048186	   inhibin	  beta-­‐A	  binding	   2	  
<0.0001	   GO:0048187	   inhibin	  beta-­‐B	  binding	   2	  
<0.0001	   GO:0048850	   hypophysis	  morphogenesis	   2	  
<0.0001	   GO:0060011	   Sertoli	  cell	  proliferation	   2	  
<0.0001	   GO:0060067	   cervix	  development	   2	  
<0.0001	   GO:0070245	   positive	  regulation	  of	  thymocyte	  apoptosis	   2	  
<0.0001	   GO:0070287	   ferritin	  receptor	  activity	   2	  
<0.0001	   GO:0071542	   dopaminergic	  neuron	  differentiation	   2	  
<0.0001	   GO:0004800	   thyroxine	  5'-­‐deiodinase	  activity	   3	  
<0.0001	   GO:0018125	   peptidyl-­‐cysteine	  methylation	   3	  
<0.0001	   GO:0042404	   thyroid	  hormone	  catabolic	  process	   3	  
<0.0001	   GO:0016055	   Wnt	  receptor	  signaling	  pathway	   13	  
<0.0001	   GO:0001578	   microtubule	  bundle	  formation	   5	  
<0.0001	   GO:0043406	   positive	  regulation	  of	  MAP	  kinase	  activity	   6	  
<0.0001	   GO:0030175	   filopodium	   8	  
<0.0001	   GO:0008037	   cell	  recognition	   5	  
<0.0001	   GO:0006112	   energy	  reserve	  metabolic	  process	   4	  
<0.0001	   GO:0006910	   phagocytosis	   4	  
<0.0001	   GO:0002248	   connective	  tissue	  replacement	  involved	  in	  inflammatory	   2	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response	  wound	  healing	  
<0.0001	   GO:0004301	   epoxide	  hydrolase	  activity	   2	  
<0.0001	   GO:0006582	   melanin	  metabolic	  process	   2	  
<0.0001	   GO:0006808	   regulation	  of	  nitrogen	  utilization	   2	  
<0.0001	   GO:0010559	   regulation	  of	  glycoprotein	  biosynthetic	  process	   2	  
<0.0001	   GO:0014042	   positive	  regulation	  of	  neuron	  maturation	   2	  
<0.0001	   GO:0021747	   cochlear	  nucleus	  development	   2	  
<0.0001	   GO:0030338	   CMP-­‐N-­‐acetylneuraminate	  monooxygenase	  activity	   2	  
<0.0001	   GO:0031117	   positive	  regulation	  of	  microtubule	  depolymerization	   2	  
<0.0001	   GO:0032814	   regulation	  of	  natural	  killer	  cell	  activation	   2	  
<0.0001	   GO:0032848	   negative	  regulation	  of	  cellular	  pH	  reduction	   2	  
<0.0001	   GO:0043375	   CD8-­‐positive	   2	  
<0.0001	   GO:0046671	   negative	  regulation	  of	  retinal	  cell	  programmed	  cell	  
death	  
2	  
<0.0001	   GO:0048087	   positive	  regulation	  of	  developmental	  pigmentation	   2	  
<0.0001	   GO:0048743	   positive	  regulation	  of	  skeletal	  muscle	  fiber	  development	   2	  
<0.0001	   GO:0048753	   pigment	  granule	  organization	   2	  
<0.0001	   GO:0060164	   regulation	  of	  timing	  of	  neuron	  differentiation	   2	  
<0.0001	   GO:0060760	   positive	  regulation	  of	  response	  to	  cytokine	  stimulus	   2	  
<0.0001	   GO:0060762	   regulation	  of	  branching	  involved	  in	  mammary	  gland	  
duct	  morphogenesis	  
2	  
<0.0001	   GO:0070059	   apoptosis	  in	  response	  to	  endoplasmic	  reticulum	  stress	   2	  
<0.0001	   GO:0071346	   cellular	  response	  to	  interferon-­‐gamma	   2	  
<0.0001	   GO:0072201	   negative	  regulation	  of	  mesenchymal	  cell	  proliferation	   2	  
<0.0001	   GO:0090037	   positive	  regulation	  of	  protein	  kinase	  C	  signaling	  cascade	   2	  
<0.0001	   GO:0004028	   3-­‐chloroallyl	  aldehyde	  dehydrogenase	  activity	   3	  
<0.0001	   GO:0004030	   aldehyde	  dehydrogenase	  [NAD(P)+]	  activity	   3	  
<0.0001	   GO:0007494	   midgut	  development	   3	  
<0.0001	   GO:0008021	   synaptic	  vesicle	   6	  
<0.0001	   GO:0008544	   epidermis	  development	   11	  
<0.0001	   GO:0015631	   tubulin	  binding	   5	  
<0.0001	   GO:0000085	   G2	  phase	  of	  mitotic	  cell	  cycle	   4	  
<0.0001	   GO:0008629	   induction	  of	  apoptosis	  by	  intracellular	  signals	   6	  
<0.0001	   GO:0001514	   selenocysteine	  incorporation	   3	  
<0.0001	   GO:0002360	   T	  cell	  lineage	  commitment	   3	  
<0.0001	   GO:0030104	   water	  homeostasis	   3	  
<0.0001	   GO:0030166	   proteoglycan	  biosynthetic	  process	   3	  
<0.0001	   GO:0030054	   cell	  junction	   24	  
0.000	   GO:0005886	   plasma	  membrane	   86	  
0.000	   GO:0006911	   phagocytosis	   4	  
0.000	   GO:0000015	   phosphopyruvate	  hydratase	  complex	   2	  
0.000	   GO:0001667	   ameboidal	  cell	  migration	   2	  
0.000	   GO:0002320	   lymphoid	  progenitor	  cell	  differentiation	   2	  
0.000	   GO:0004634	   phosphopyruvate	  hydratase	  activity	   2	  
0.000	   GO:0007442	   hindgut	  morphogenesis	   2	  
0.000	   GO:0009441	   glycolate	  metabolic	  process	   2	  
0.000	   GO:0010044	   response	  to	  aluminum	  ion	   2	  
0.000	   GO:0014031	   mesenchymal	  cell	  development	   2	  
0.000	   GO:0014834	   satellite	  cell	  maintenance	  involved	  in	  skeletal	  muscle	  
regeneration	  
2	  
0.000	   GO:0014896	   muscle	  hypertrophy	   2	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0.000	   GO:0014904	   myotube	  cell	  development	   2	  
0.000	   GO:0022612	   gland	  morphogenesis	   2	  
0.000	   GO:0031014	   troponin	  T	  binding	   2	  
0.000	   GO:0034673	   inhibin-­‐betaglycan-­‐ActRII	  complex	   2	  
0.000	   GO:0043084	   penile	  erection	   2	  
0.000	   GO:0045069	   regulation	  of	  viral	  genome	  replication	   2	  
0.000	   GO:0046549	   retinal	  cone	  cell	  development	   2	  
0.000	   GO:0060463	   lung	  lobe	  morphogenesis	   2	  
0.000	   GO:0060599	   lateral	  sprouting	  involved	  in	  mammary	  gland	  duct	  
morphogenesis	  
2	  
0.000	   GO:0060741	   prostate	  gland	  stromal	  morphogenesis	   2	  
0.000	   GO:0048268	   clathrin	  coat	  assembly	   3	  
0.000	   GO:0007584	   response	  to	  nutrient	   10	  
0.000	   GO:0014911	   positive	  regulation	  of	  smooth	  muscle	  cell	  migration	   4	  
0.000	   GO:0015085	   calcium	  ion	  transmembrane	  transporter	  activity	   4	  
0.000	   GO:0017046	   peptide	  hormone	  binding	   4	  
0.000	   GO:0045121	   membrane	  raft	   12	  
0.000	   GO:0005149	   interleukin-­‐1	  receptor	  binding	   3	  
0.000	   GO:0006600	   creatine	  metabolic	  process	   3	  
0.000	   GO:0017157	   regulation	  of	  exocytosis	   3	  
0.000	   GO:0030122	   AP-­‐2	  adaptor	  complex	   3	  
0.000	   GO:0032469	   endoplasmic	  reticulum	  calcium	  ion	  homeostasis	   3	  
0.001	   GO:0007223	   Wnt	  receptor	  signaling	  pathway	   4	  
0.001	   GO:0030100	   regulation	  of	  endocytosis	   4	  
0.001	   GO:0050699	   WW	  domain	  binding	   5	  
0.001	   GO:0042221	   response	  to	  chemical	  stimulus	   4	  
0.001	   GO:0003014	   renal	  system	  process	   2	  
0.001	   GO:0003344	   pericardium	  morphogenesis	   2	  
0.001	   GO:0003401	   axis	  elongation	   2	  
0.001	   GO:0004024	   alcohol	  dehydrogenase	  activity	   2	  
0.001	   GO:0007620	   copulation	   2	  
0.001	   GO:0016362	   activin	  receptor	  activity	   2	  
0.001	   GO:0030534	   adult	  behavior	   2	  
0.001	   GO:0033033	   negative	  regulation	  of	  myeloid	  cell	  apoptosis	   2	  
0.001	   GO:0045836	   positive	  regulation	  of	  meiosis	   2	  
0.001	   GO:0046835	   carbohydrate	  phosphorylation	   2	  
0.001	   GO:0051434	   BH3	  domain	  binding	   2	  
0.001	   GO:0060029	   convergent	  extension	  involved	  in	  organogenesis	   2	  
0.001	   GO:0060638	   mesenchymal-­‐epithelial	  cell	  signaling	   2	  
0.001	   GO:0060686	   negative	  regulation	  of	  prostatic	  bud	  formation	   2	  
0.001	   GO:0060750	   epithelial	  cell	  proliferation	  involved	  in	  mammary	  gland	  
duct	  elongation	  
2	  
0.001	   GO:0090009	   primitive	  streak	  formation	   2	  
0.001	   GO:0016338	   calcium-­‐independent	  cell-­‐cell	  adhesion	   3	  
0.001	   GO:0005516	   calmodulin	  binding	   13	  
0.001	   GO:0006139	   nucleobase	   9	  
0.001	   GO:0008135	   translation	  factor	  activity	   4	  
0.001	   GO:0032760	   positive	  regulation	  of	  tumor	  necrosis	  factor	  production	   4	  
0.001	   GO:0033198	   response	  to	  ATP	   4	  





0.002	   GO:0030057	   desmosome	   5	  
0.003	   GO:0048146	   positive	  regulation	  of	  fibroblast	  proliferation	   6	  
0.003	   GO:0048706	   embryonic	  skeletal	  system	  development	   5	  
0.003	   GO:0045445	   myoblast	  differentiation	   4	  
0.003	   GO:0004029	   aldehyde	  dehydrogenase	  (NAD)	  activity	   3	  
0.003	   GO:0045821	   positive	  regulation	  of	  glycolysis	   3	  
0.003	   GO:0001733	   galactosylceramide	  sulfotransferase	  activity	   1	  
0.003	   GO:0003834	   beta-­‐carotene	  15	   1	  
0.003	   GO:0004127	   cytidylate	  kinase	  activity	   1	  
0.004	   GO:0004463	   leukotriene-­‐A4	  hydrolase	  activity	   1	  
0.005	   GO:0004657	   proline	  dehydrogenase	  activity	   1	  
0.005	   GO:0004731	   purine-­‐nucleoside	  phosphorylase	  activity	   1	  
0.005	   GO:0004771	   sterol	  esterase	  activity	   1	  
0.005	   GO:0005139	   interleukin-­‐7	  receptor	  binding	   1	  
0.005	   GO:0005275	   amine	  transmembrane	  transporter	  activity	   1	  
0.005	   GO:0005345	   purine	  transmembrane	  transporter	  activity	   1	  
0.005	   GO:0005350	   pyrimidine	  transmembrane	  transporter	  activity	   1	  
0.005	   GO:0006148	   inosine	  catabolic	  process	   1	  
0.005	   GO:0006863	   purine	  transport	   1	  
0.005	   GO:0007529	   establishment	  of	  synaptic	  specificity	  at	  neuromuscular	  
junction	  
1	  
0.005	   GO:0014707	   branchiomeric	  skeletal	  muscle	  development	   1	  
0.005	   GO:0015166	   polyol	  transmembrane	  transporter	  activity	   1	  
0.005	   GO:0015722	   canalicular	  bile	  acid	  transport	   1	  
0.005	   GO:0015791	   polyol	  transport	   1	  
0.007	   GO:0015855	   pyrimidine	  transport	   1	  




Appendix 5. The average expression level of EMT-
associated markers in skin, AK and cSCC 
subtypes. 
Symbol	   NSE	   SE	   AK	   WD	   MD	   MPD/PD	  
CDH26	   3.170518799	   3.177116975	   4.059688057	   4.231849863	   3.448734376	   3.833322814	  
CDH6	   3.592186487	   3.897070071	   3.675378121	   3.532581357	   3.81366408	   3.46229941	  
CDH19	   4.403567759	   5.0485751	   4.150877039	   3.262219893	   3.071648697	   3.0981883	  
CDH24	   4.492057395	   4.3760276	   4.820957304	   5.134630992	   5.040684334	   5.180777477	  
CLDN7	   4.797037209	   5.165910872	   4.859272821	   5.323079378	   5.657939917	   5.247951704	  
CDH11	   5.204319666	   5.716820891	   5.96244819	   5.188902018	   5.184095444	   6.757921243	  
ZEB2	   5.613023876	   5.940128129	   5.767595503	   5.043695386	   5.493680956	   5.775746809	  
MUC1	   5.998372643	   6.135153036	   6.020093853	   5.514333997	   6.206169468	   6.316493795	  
ZEB1	   6.10271899	   6.633469006	   5.92906964	   5.16438705	   5.240731473	   5.442788328	  
THBS1	   6.316411937	   6.73832734	   6.910347733	   6.178691523	   7.136763558	   7.37723831	  
ACTA2	   6.450238905	   6.882459304	   6.302710882	   5.10031612	   5.179194309	   5.059989259	  
CLDN5	   6.526357012	   6.326198891	   6.191996379	   5.715681189	   5.581970554	   5.711427368	  
CDH5	   6.599603651	   6.76305059	   6.757345453	   6.185365825	   6.410189006	   6.143613476	  
TWIST2	   6.615820115	   6.910274758	   6.607720838	   6.030882716	   5.780019879	   5.691582404	  
CLDN8	   6.737020125	   6.859036068	   5.149662542	   3.135776213	   3.184871737	   2.829829192	  
THBS3	   6.975516949	   7.063314246	   6.659644943	   6.308370851	   6.498851921	   6.341135178	  
CDH22	   7.000105888	   6.986488715	   6.657042533	   6.364158638	   6.226154748	   5.981568993	  
CLDN11	   7.062131096	   7.114870082	   5.332968623	   3.425846783	   3.238459836	   3.474215484	  
KRT18	   7.079831145	   7.512552806	   6.988925506	   7.389839345	   8.423051339	   7.868582444	  
VIM	   7.155966312	   7.340963189	   7.047479392	   6.387494029	   6.661332718	   7.113356251	  
CLDN12	   7.173310834	   7.157702405	   7.41074766	   8.120991374	   8.207411782	   8.060856293	  
KRT8	   7.173794177	   7.51373597	   7.314437218	   7.039684421	   7.431681846	   7.353694574	  
ACTG2	   7.328634148	   8.402112958	   6.20259271	   4.739848383	   4.878860731	   4.738136182	  
TCF3	   7.634572469	   6.98052364	   7.848196341	   7.379471938	   7.540295199	   7.799644015	  
TWIST1	   7.778881863	   8.112325734	   8.092087352	   6.950974208	   6.8914464	   7.881007571	  
CDH3	   7.996803555	   7.954140372	   9.024104065	   11.08459005	   10.95878934	   9.966808468	  
KRT9	   8.052802944	   7.557635933	   11.76086034	   7.212578966	   6.91570135	   8.865835797	  
FN1	   8.181694549	   8.542290938	   7.938035099	   7.828426345	   8.231692184	   8.98165685	  
FGFR2	   8.279369451	   8.311614765	   7.943676128	   7.50138596	   7.060636872	   5.81771095	  
CTNNB
1	  
8.346254808	   8.559817594	   8.193543599	   7.86784897	   8.087911518	   7.991561633	  
CDH1	   9.3096953	   9.167568361	   9.275898308	   9.83533432	   9.324487461	   8.37509494	  
SNAI2	   9.332077914	   9.308725643	   9.640616902	   10.09308508	   10.15715279	   10.04635047	  
OCLN	   9.342358153	   9.174887062	   8.816605023	   8.014716469	   7.291643216	   7.395167586	  
CTNND
1	  
9.439118702	   9.236009159	   8.880216726	   8.929163869	   9.125666087	   8.698512498	  
THBS2	   10.45892661	   10.73442033	   10.99829583	   10.79974622	   9.925283459	   10.00357589	  




Appendix 6. RAS/MAPK signaling in progression 
























































































































































































































































































































































































































































































































































Appendix 7. Differentially methylated genes 
between primary human keratinocytes and 
cultured primary cSCC cell lines. 
SYMBOL	   Description	   Chr	   adj.p(“BH”)	  
TRIM2	   tripartite	  motif-­‐containing	  2	   4	   1.22531E-­‐07	  
SPARCL1	   SPARC-­‐like	  1	  (mast9,	  hevin)	   4	   5.50704E-­‐07	  
C1QTNF6	   C1q	  and	  tumor	  necrosis	  factor	  related	  protein	  6	   22	   5.50704E-­‐07	  
AQP12A	   aquaporin	  12A	   -­‐	   5.50704E-­‐07	  
CDKN2A	   cyclin-­‐dependent	  kinase	  inhibitor	  2A	  (melanoma,	  p16,	  
inhibits	  CDK4)	  
9	   6.95756E-­‐07	  
YPEL4	   yippee-­‐like	  4	  (Drosophila)	   11	   5.13957E-­‐06	  
ECE1	   endothelin	  converting	  enzyme	  1	   1	   5.13957E-­‐06	  
RGS17	   regulator	  of	  G-­‐protein	  signalling	  17	   6	   6.69546E-­‐06	  
FGFR1	   fibroblast	  growth	  factor	  receptor	  1	  (fms-­‐related	  tyrosine	  
kinase	  2,	  Pfeiffer	  syndrome)	  
8	   8.67082E-­‐06	  
BARHL2	   BarH-­‐like	  2	  (Drosophila)	   1	   2.32999E-­‐05	  
CASP8	   caspase	  8,	  apoptosis-­‐related	  cysteine	  peptidase	   2	   3.18007E-­‐05	  
TM4SF19	   transmembrane	  4	  L	  six	  family	  member	  19	   3	   3.36019E-­‐05	  
GABRA5	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  alpha	  5	   15	   3.36019E-­‐05	  
TRIM15	   tripartite	  motif-­‐containing	  15	   6	   3.84449E-­‐05	  
NFAM1	   NFAT	  activating	  protein	  with	  ITAM	  motif	  1	   22	   3.84449E-­‐05	  
NEFH	   neurofilament,	  heavy	  polypeptide	  200kDa	   22	   4.32511E-­‐05	  
SEC31L2	   -­‐	   10	   4.32511E-­‐05	  
SH3TC1	   SH3	  domain	  and	  tetratricopeptide	  repeats	  1	   4	   4.80662E-­‐05	  
GAL3ST3	   galactose-­‐3-­‐O-­‐sulfotransferase	  3	   11	   4.80662E-­‐05	  
GDPD5	   glycerophosphodiester	  phosphodiesterase	  domain	  
containing	  5	  
11	   5.51624E-­‐05	  
C18orf20	   chromosome	  18	  open	  reading	  frame	  20	   18	   5.70669E-­‐05	  
MGC39545	   -­‐	   11	   5.70669E-­‐05	  
TMEM22	   transmembrane	  protein	  22	   3	   6.36817E-­‐05	  
GARNL3	   GTPase	  activating	  Rap/RanGAP	  domain-­‐like	  3	   9	   7.0854E-­‐05	  
PRKDC	   protein	  kinase,	  DNA-­‐activated,	  catalytic	  polypeptide	   8	   7.33318E-­‐05	  
FXYD4	   FXYD	  domain	  containing	  ion	  transport	  regulator	  4	   10	   9.27401E-­‐05	  
MBNL1	   muscleblind-­‐like	  (Drosophila)	   3	   9.71679E-­‐05	  
ZDHHC11	   zinc	  finger,	  DHHC-­‐type	  containing	  11	   5	   9.74256E-­‐05	  
DDX49	   DEAD	  (Asp-­‐Glu-­‐Ala-­‐Asp)	  box	  polypeptide	  49	   19	   0.000112091	  
PPP3R2	   protein	  phosphatase	  3	  (formerly	  2B),	  regulatory	  subunit	  
B,	  19kDa,	  beta	  isoform	  (calcineurin	  B,	  type	  II)	  
9	   0.000112091	  
MYH4	   myosin,	  heavy	  chain	  4,	  skeletal	  muscle	   17	   0.000112596	  
CR1	   complement	  component	  (3b/4b)	  receptor	  1	  (Knops	  blood	  
group)	  
1	   0.000119724	  
NDRG2	   NDRG	  family	  member	  2	   14	   0.000136334	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CNTNAP4	   contactin	  associated	  protein-­‐like	  4	   16	   0.000136334	  
FAM50B	   family	  with	  sequence	  similarity	  50,	  member	  B	   6	   0.000136334	  
KIAA0427	   KIAA0427	   18	   0.000146288	  
NIPSNAP1	   nipsnap	  homolog	  1	  (C.	  elegans)	   22	   0.000150924	  
MPST	   mercaptopyruvate	  sulfurtransferase	   22	   0.000150924	  
KYNU	   kynureninase	  (L-­‐kynurenine	  hydrolase)	   2	   0.000178931	  
QTRT1	   queuine	  tRNA-­‐ribosyltransferase	  1	  (tRNA-­‐guanine	  
transglycosylase)	  
19	   0.00020842	  
TGIF2	   TGFB-­‐induced	  factor	  2	  (TALE	  family	  homeobox)	   20	   0.00026328	  
CMTM2	   CKLF-­‐like	  MARVEL	  transmembrane	  domain	  containing	  2	   16	   0.000267798	  
STATH	   statherin	   4	   0.000267798	  
GPR75	   G	  protein-­‐coupled	  receptor	  75	   2	   0.000275936	  
FN3K	   fructosamine	  3	  kinase	   17	   0.000277231	  
PRAME	   preferentially	  expressed	  antigen	  in	  melanoma	   22	   0.000284809	  
TP53I3	   tumor	  protein	  p53	  inducible	  protein	  3	   2	   0.000315786	  
C14orf166B	   chromosome	  14	  open	  reading	  frame	  166B	   14	   0.00032672	  
WFIKKN2	   WAP,	  follistatin/kazal,	  immunoglobulin,	  kunitz	  and	  netrin	  
domain	  containing	  2	  
17	   0.00035364	  
IGSF2	   immunoglobulin	  superfamily,	  member	  2	   1	   0.000373536	  
TM4SF11	   -­‐	   16	   0.000377574	  
C19orf19	   chromosome	  19	  open	  reading	  frame	  19	   19	   0.000433263	  
KRT7	   keratin	  7	   12	   0.000433263	  
EML1	   echinoderm	  microtubule	  associated	  protein	  like	  1	   14	   0.000433263	  
HSPCAL3	   -­‐	   11	   0.000433263	  
SERPINA3	   serpin	  peptidase	  inhibitor,	  clade	  A	  (alpha-­‐1	  
antiproteinase,	  antitrypsin),	  member	  3	  
14	   0.000437043	  
NRTN	   neurturin	   19	   0.000437043	  
B4GALT1	   UDP-­‐Gal:betaGlcNAc	  beta	  1,4-­‐	  galactosyltransferase,	  
polypeptide	  1	  
9	   0.000437043	  
GPR137	   G	  protein-­‐coupled	  receptor	  137	   11	   0.000437043	  
LSAMP	   limbic	  system-­‐associated	  membrane	  protein	   3	   0.000463246	  
NRIP2	   nuclear	  receptor	  interacting	  protein	  2	   12	   0.000540445	  
UCHL1	   ubiquitin	  carboxyl-­‐terminal	  esterase	  L1	  (ubiquitin	  
thiolesterase)	  
4	   0.000559268	  
ZIM2	   zinc	  finger,	  imprinted	  2	   19	   0.000573301	  
SAA2	   serum	  amyloid	  A2	   11	   0.000573301	  
CHRNB4	   cholinergic	  receptor,	  nicotinic,	  beta	  4	   15	   0.00060761	  
C20orf179	   chromosome	  20	  open	  reading	  frame	  179	   20	   0.00060761	  
ACOT8	   acyl-­‐CoA	  thioesterase	  8	   -­‐	   0.000616779	  
KLHL21	   kelch-­‐like	  21	  (Drosophila)	   1	   0.000648082	  
TBC1D3C	   TBC1	  domain	  family,	  member	  3C	   17	   0.000648082	  
TBX20	   T-­‐box	  20	   7	   0.000669432	  
CHAT	   choline	  acetyltransferase	   10	   0.000698374	  
THSD1	   thrombospondin,	  type	  I,	  domain	  containing	  1	   13	   0.000711337	  
GAGE4	   G	  antigen	  4	   X	   0.000751007	  
CHRNE	   cholinergic	  receptor,	  nicotinic,	  epsilon	   17	   0.000756053	  
TMEM35	   transmembrane	  protein	  35	   X	   0.000761818	  
C21orf25	   chromosome	  21	  open	  reading	  frame	  25	   21	   0.000849069	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PLCL1	   phospholipase	  C-­‐like	  1	   2	   0.000860669	  
UNQ1940	   -­‐	   7	   0.000860669	  
SRRM2	   serine/arginine	  repetitive	  matrix	  2	   16	   0.000893946	  
MMP20	   matrix	  metallopeptidase	  20	  (enamelysin)	   11	   0.000917033	  
TNFRSF11B	   tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  11b	  
(osteoprotegerin)	  
8	   0.000917033	  
C9orf78	   chromosome	  9	  open	  reading	  frame	  78	   9	   0.000917033	  
ITK	   IL2-­‐inducible	  T-­‐cell	  kinase	   5	   0.000967419	  
WFDC10B	   WAP	  four-­‐disulfide	  core	  domain	  10B	   20	   0.001032763	  
PRKCB1	   protein	  kinase	  C,	  beta	  1	   16	   0.001078886	  
CCT6A	   chaperonin	  containing	  TCP1,	  subunit	  6A	  (zeta	  1)	   7	   0.001100518	  
KLF3	   Kruppel-­‐like	  factor	  3	  (basic)	   4	   0.001114218	  
MAG	   myelin	  associated	  glycoprotein	   19	   0.001169886	  
SIM1	   single-­‐minded	  homolog	  1	  (Drosophila)	   6	   0.001238979	  
PARC	   -­‐	   6	   0.001347767	  
ATP6V0A1	   ATPase,	  H+	  transporting,	  lysosomal	  V0	  subunit	  a1	   17	   0.001367682	  
SST	   somatostatin	   3	   0.001370235	  
ZIC1	   Zic	  family	  member	  1	  (odd-­‐paired	  homolog,	  Drosophila)	   3	   0.001371336	  
HBII-­‐438B	   -­‐	   15	   0.001381504	  
KRTHB1	   -­‐	   12	   0.001392604	  
FLJ22555	   -­‐	   2	   0.001428385	  
FLJ39501	   -­‐	   19	   0.001428385	  
FMNL1	   formin-­‐like	  1	   17	   0.001428385	  
CNN1	   calponin	  1,	  basic,	  smooth	  muscle	   19	   0.001465384	  
TNFRSF10C	   tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  10c,	  
decoy	  without	  an	  intracellular	  domain	  
8	   0.001465384	  
SYNGR1	   synaptogyrin	  1	   22	   0.001465384	  
LOC339789	   -­‐	   2	   0.001465384	  
F2RL3	   coagulation	  factor	  II	  (thrombin)	  receptor-­‐like	  3	   19	   0.001520969	  
SLC2A3	   solute	  carrier	  family	  2	  (facilitated	  glucose	  transporter),	  
member	  3	  
12	   0.001605272	  
EVC2	   Ellis	  van	  Creveld	  syndrome	  2	  (limbin)	   4	   0.001627908	  
TNFRSF1B	   tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  1B	   1	   0.001722942	  
FAM79B	   family	  with	  sequence	  similarity	  79,	  member	  B	   3	   0.001722942	  
FAM50B	   family	  with	  sequence	  similarity	  50,	  member	  B	   6	   0.001750441	  
RIMS3	   regulating	  synaptic	  membrane	  exocytosis	  3	   1	   0.001750441	  
TBX20	   T-­‐box	  20	   7	   0.001750441	  
PPGB	   protective	  protein	  for	  beta-­‐galactosidase	  
(galactosialidosis)	  
20	   0.001750441	  
PCSK1	   proprotein	  convertase	  subtilisin/kexin	  type	  1	   5	   0.001750441	  
ENTPD1	   ectonucleoside	  triphosphate	  diphosphohydrolase	  1	   10	   0.001750441	  
NA	   neurocanthocytosis	   -­‐	   0.001750441	  
SMPD3	   sphingomyelin	  phosphodiesterase	  3,	  neutral	  membrane	  
(neutral	  sphingomyelinase	  II)	  
16	   0.001750441	  
GCNT4	   glucosaminyl	  (N-­‐acetyl)	  transferase	  4,	  core	  2	  (beta-­‐1,6-­‐N-­‐
acetylglucosaminyltransferase)	  
5	   0.001793302	  
TBC1D3C	   TBC1	  domain	  family,	  member	  3C	   17	   0.00180742	  
PCDHGB7	   protocadherin	  gamma	  subfamily	  B,	  7	   5	   0.00180742	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FLJ46481	   -­‐	   4	   0.00180742	  
OR7C2	   olfactory	  receptor,	  family	  7,	  subfamily	  C,	  member	  2	   19	   0.001841952	  
SKIP	   -­‐	   2	   0.001875265	  
DMRTC1	   DMRT-­‐like	  family	  C1	   X	   0.002067509	  
KRT25A	   -­‐	   17	   0.002124399	  
SNX9	   sorting	  nexin	  9	   6	   0.002145745	  
C10orf35	   chromosome	  10	  open	  reading	  frame	  35	   10	   0.002146706	  
FLJ00060	   -­‐	   19	   0.0021851	  
C22orf15	   chromosome	  22	  open	  reading	  frame	  15	   22	   0.002235644	  
MGC35295	   -­‐	   11	   0.002235644	  
SLC43A3	   solute	  carrier	  family	  43,	  member	  3	   11	   0.002240191	  
RSHL1	   radial	  spokehead-­‐like	  1	   19	   0.002281932	  
GATA4	   GATA	  binding	  protein	  4	   8	   0.00228307	  
PRLHR	   prolactin	  releasing	  hormone	  receptor	   10	   0.002296916	  
LOC122258	   -­‐	   13	   0.002308457	  
TATDN1	   TatD	  DNase	  domain	  containing	  1	   8	   0.002323653	  
TMEM35	   transmembrane	  protein	  35	   X	   0.002339402	  
ZNF662	   zinc	  finger	  protein	  662	   3	   0.002363037	  
SPINK2	   serine	  peptidase	  inhibitor,	  Kazal	  type	  2	  (acrosin-­‐trypsin	  
inhibitor)	  
4	   0.002365943	  
TGM6	   transglutaminase	  6	   20	   0.002365943	  
CLEC4D	   C-­‐type	  lectin	  domain	  family	  4,	  member	  D	   12	   0.002365943	  
FOXD2	   forkhead	  box	  D2	   1	   0.002365943	  
ATP10A	   ATPase,	  Class	  V,	  type	  10A	   15	   0.002365943	  
SLC12A5	   solute	  carrier	  family	  12,	  (potassium-­‐chloride	  transporter)	  
member	  5	  
20	   0.002365943	  
REGL	   regenerating	  islet-­‐derived-­‐like,	  pancreatic	  stone	  protein-­‐
like,	  pancreatic	  thread	  protein-­‐like	  (rat)	  
2	   0.002365943	  
ATP10A	   ATPase,	  Class	  V,	  type	  10A	   15	   0.002365943	  
AQP9	   aquaporin	  9	   -­‐	   0.002382694	  
CDKN2A	   cyclin-­‐dependent	  kinase	  inhibitor	  2A	  (melanoma,	  p16,	  
inhibits	  CDK4)	  
9	   0.002396521	  
GGT1	   gamma-­‐glutamyltransferase	  1	   22	   0.002396521	  
KRTAP15-­‐1	   keratin	  associated	  protein	  15-­‐1	   21	   0.002396521	  
C7orf19	   -­‐	   7	   0.002396521	  
FLJ22471	   -­‐	   12	   0.002396521	  
HK1	   hexokinase	  1	   10	   0.002505553	  
ADORA3	   adenosine	  A3	  receptor	   -­‐	   0.002507667	  
PDILT	   -­‐	   16	   0.002509471	  
PCDHGA12	   protocadherin	  gamma	  subfamily	  A,	  12	   5	   0.00251383	  
MGC40222	   -­‐	   6	   0.00251383	  
FLJ22709	   -­‐	   19	   0.002530686	  
PCSK1	   proprotein	  convertase	  subtilisin/kexin	  type	  1	   5	   0.002692681	  
FBXL22	   F-­‐box	  and	  leucine-­‐rich	  repeat	  protein	  22	   15	   0.002724691	  
H2AFY	   H2A	  histone	  family,	  member	  Y	   5	   0.002779813	  
TRIM2	   tripartite	  motif-­‐containing	  2	   4	   0.002817627	  
ZFP41	   zinc	  finger	  protein	  41	  homolog	  (mouse)	   8	   0.002826726	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DYRK3	   dual-­‐specificity	  tyrosine-­‐(Y)-­‐phosphorylation	  regulated	  
kinase	  3	  
1	   0.00286757	  
PAX4	   paired	  box	  gene	  4	   7	   0.00286757	  
ATP8A2	   ATPase,	  aminophospholipid	  transporter-­‐like,	  Class	  I,	  type	  
8A,	  member	  2	  
13	   0.00286757	  
SLC17A2	   solute	  carrier	  family	  17	  (sodium	  phosphate),	  member	  2	   6	   0.00286757	  
PLA2G4E	   phospholipase	  A2,	  group	  IVE	   15	   0.00286757	  
C14orf166B	   chromosome	  14	  open	  reading	  frame	  166B	   14	   0.00286757	  
OSR1	   odd-­‐skipped	  related	  1	  (Drosophila)	   2	   0.003011307	  
PWCR1	   Prader-­‐Willi	  syndrome	  chromosome	  region	  1	   15	   0.003094661	  
CARD9	   caspase	  recruitment	  domain	  family,	  member	  9	   9	   0.003190814	  
BACE2	   beta-­‐site	  APP-­‐cleaving	  enzyme	  2	   21	   0.003264819	  
ZNF677	   zinc	  finger	  protein	  677	   19	   0.00328739	  
GPR55	   G	  protein-­‐coupled	  receptor	  55	   2	   0.003345195	  
RAB11FIP2	   RAB11	  family	  interacting	  protein	  2	  (class	  I)	   10	   0.003345195	  
ARPP-­‐21	   -­‐	   -­‐	   0.003345195	  
FABP1	   fatty	  acid	  binding	  protein	  1,	  liver	   2	   0.003360546	  
TNIP3	   TNFAIP3	  interacting	  protein	  3	   4	   0.003360546	  
OTUD6A	   OTU	  domain	  containing	  6A	   X	   0.003526384	  
SULT1B1	   sulfotransferase	  family,	  cytosolic,	  1B,	  member	  1	   4	   0.003575538	  
PPGB	   protective	  protein	  for	  beta-­‐galactosidase	  
(galactosialidosis)	  
20	   0.003687649	  
BDH	   -­‐	   3	   0.003689823	  
S100A3	   S100	  calcium	  binding	  protein	  A3	   1	   0.003689823	  
KIAA0753	   KIAA0753	   17	   0.003689823	  
SCNM1	   sodium	  channel	  modifier	  1	   1	   0.003689823	  
ZNF177	   zinc	  finger	  protein	  177	   19	   0.003689823	  
PEX11G	   peroxisomal	  biogenesis	  factor	  11	  gamma	   19	   0.003694372	  
WT1	   Wilms	  tumor	  1	   11	   0.003795811	  
C5orf13	   chromosome	  5	  open	  reading	  frame	  13	   5	   0.003865691	  
EPDR1	   ependymin	  related	  protein	  1	  (zebrafish)	   7	   0.003904573	  
LIMS2	   LIM	  and	  senescent	  cell	  antigen-­‐like	  domains	  2	   2	   0.004127572	  
CKMT2	   creatine	  kinase,	  mitochondrial	  2	  (sarcomeric)	   5	   0.00414173	  
DRP2	   dystrophin	  related	  protein	  2	   X	   0.00414173	  
ZNF96	   zinc	  finger	  protein	  96	   6	   0.00414173	  
C18orf20	   chromosome	  18	  open	  reading	  frame	  20	   18	   0.00414173	  
ZIC1	   Zic	  family	  member	  1	  (odd-­‐paired	  homolog,	  Drosophila)	   3	   0.004149229	  
PLCE1	   phospholipase	  C,	  epsilon	  1	   10	   0.004175697	  
KCTD12	   potassium	  channel	  tetramerisation	  domain	  containing	  12	   13	   0.004175697	  
HNRPDL	   heterogeneous	  nuclear	  ribonucleoprotein	  D-­‐like	   4	   0.004175697	  
KCNS1	   potassium	  voltage-­‐gated	  channel,	  delayed-­‐rectifier,	  
subfamily	  S,	  member	  1	  
20	   0.004175697	  
HNF4A	   hepatocyte	  nuclear	  factor	  4,	  alpha	   20	   0.004256414	  
CLEC4F	   C-­‐type	  lectin	  domain	  family	  4,	  member	  F	   2	   0.004299473	  
ATP10A	   ATPase,	  Class	  V,	  type	  10A	   15	   0.004299473	  
GATA4	   GATA	  binding	  protein	  4	   8	   0.004311008	  
DNASE2B	   deoxyribonuclease	  II	  beta	   1	   0.004311008	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TAC3	   tachykinin	  3	  (neuromedin	  K,	  neurokinin	  beta)	   12	   0.004320452	  
ZNF553	   zinc	  finger	  protein	  553	   16	   0.004320452	  
KRTAP19-­‐2	   keratin	  associated	  protein	  19-­‐2	   21	   0.004320452	  
FCN2	   ficolin	  (collagen/fibrinogen	  domain	  containing	  lectin)	  2	  
(hucolin)	  
9	   0.004320452	  
RALGPS2	   Ral	  GEF	  with	  PH	  domain	  and	  SH3	  binding	  motif	  2	   1	   0.004329614	  
CRYBB3	   crystallin,	  beta	  B3	   22	   0.004338542	  
ITPR2	   inositol	  1,4,5-­‐triphosphate	  receptor,	  type	  2	   12	   0.004440709	  
SLC26A8	   solute	  carrier	  family	  26,	  member	  8	   6	   0.004477576	  
ZNF154	   zinc	  finger	  protein	  154	   19	   0.004488773	  
EDNRB	   endothelin	  receptor	  type	  B	   13	   0.005013812	  
GALNTL5	   UDP-­‐N-­‐acetyl-­‐alpha-­‐D-­‐galactosamine:polypeptide	  N-­‐
acetylgalactosaminyltransferase-­‐like	  5	  
7	   0.005013812	  
LOC161247	   -­‐	   14	   0.005013812	  
PABPC5	   poly(A)	  binding	  protein,	  cytoplasmic	  5	   X	   0.005013812	  
GOLGA2L1	   golgi	  autoantigen,	  golgin	  subfamily	  a,	  2-­‐like	  1	   12	   0.005013812	  
GABRP	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  pi	   5	   0.00502773	  
IL17R	   -­‐	   22	   0.005070832	  
LMLN	   leishmanolysin-­‐like	  (metallopeptidase	  M8	  family)	   3	   0.005070832	  
KIAA1622	   KIAA1622	   14	   0.005151934	  
GPR24	   -­‐	   22	   0.005193852	  
TSPAN16	   tetraspanin	  16	   19	   0.005198224	  
CCDC70	   coiled-­‐coil	  domain	  containing	  70	   13	   0.005198224	  
FCN1	   ficolin	  (collagen/fibrinogen	  domain	  containing)	  1	   9	   0.005198224	  
B3GALT5	   UDP-­‐Gal:betaGlcNAc	  beta	  1,3-­‐galactosyltransferase,	  
polypeptide	  5	  
21	   0.00523292	  
CXorf20	   chromosome	  X	  open	  reading	  frame	  20	   X	   0.005343204	  
CASP10	   caspase	  10,	  apoptosis-­‐related	  cysteine	  peptidase	   2	   0.005363216	  
ABCG4	   ATP-­‐binding	  cassette,	  sub-­‐family	  G	  (WHITE),	  member	  4	   -­‐	   0.005363216	  
CASP8	   caspase	  8,	  apoptosis-­‐related	  cysteine	  peptidase	   2	   0.005363216	  
DKFZP586H21
23	  
-­‐	   11	   0.005363216	  
PRKAR1B	   protein	  kinase,	  cAMP-­‐dependent,	  regulatory,	  type	  I,	  beta	   7	   0.005363216	  
C3orf57	   chromosome	  3	  open	  reading	  frame	  57	   3	   0.005363216	  
CCRK	   cell	  cycle	  related	  kinase	   9	   0.005363216	  
ITR	   -­‐	   13	   0.005363216	  
PLUNC	   palate,	  lung	  and	  nasal	  epithelium	  carcinoma	  associated	   20	   0.005395921	  
MPPED2	   metallophosphoesterase	  domain	  containing	  2	   11	   0.005395921	  
IL17	   -­‐	   6	   0.005395921	  
TNFRSF10C	   tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  10c,	  
decoy	  without	  an	  intracellular	  domain	  
8	   0.005423356	  
ACPT	   acid	  phosphatase,	  testicular	   -­‐	   0.005513466	  
PLCE1	   phospholipase	  C,	  epsilon	  1	   10	   0.005540682	  
GPHA2	   glycoprotein	  hormone	  alpha	  2	   11	   0.005540682	  
TAL1	   T-­‐cell	  acute	  lymphocytic	  leukemia	  1	   1	   0.005540682	  
TBC1D14	   TBC1	  domain	  family,	  member	  14	   4	   0.005540682	  
FAHD2A	   fumarylacetoacetate	  hydrolase	  domain	  containing	  2A	   2	   0.005540682	  
BCHE	   butyrylcholinesterase	   3	   0.005540682	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DNALI1	   dynein,	  axonemal,	  light	  intermediate	  chain	  1	   1	   0.005540682	  
DDAH2	   dimethylarginine	  dimethylaminohydrolase	  2	   6	   0.005540682	  
CPNE6	   copine	  VI	  (neuronal)	   14	   0.005540682	  
CHRFAM7A	   CHRNA7	  (cholinergic	  receptor,	  nicotinic,	  alpha	  7,	  exons	  5-­‐
10)	  and	  FAM7A	  (family	  with	  sequence	  similarity	  7A,	  exons	  
A-­‐E)	  fusion	  
15	   0.005540682	  
PPAP2B	   phosphatidic	  acid	  phosphatase	  type	  2B	   1	   0.005540682	  
FGD4	   FYVE,	  RhoGEF	  and	  PH	  domain	  containing	  4	   12	   0.005540682	  
FFAR2	   free	  fatty	  acid	  receptor	  2	   19	   0.005564938	  
GSN	   gelsolin	  (amyloidosis,	  Finnish	  type)	   9	   0.00562665	  
LAMA4	   laminin,	  alpha	  4	   6	   0.00562665	  
OR2F1	   olfactory	  receptor,	  family	  2,	  subfamily	  F,	  member	  1	   7	   0.005638788	  
MACF1	   microtubule-­‐actin	  crosslinking	  factor	  1	   1	   0.005691612	  
SORBS2	   sorbin	  and	  SH3	  domain	  containing	  2	   4	   0.00586338	  
C1QTNF5	   C1q	  and	  tumor	  necrosis	  factor	  related	  protein	  5	   11	   0.005873138	  
LAT2	   linker	  for	  activation	  of	  T	  cells	  family,	  member	  2	   7	   0.005873138	  
DHRS10	   dehydrogenase/reductase	  (SDR	  family)	  member	  10	   19	   0.005874618	  
CCL8	   chemokine	  (C-­‐C	  motif)	  ligand	  8	   17	   0.005874618	  
COL8A2	   collagen,	  type	  VIII,	  alpha	  2	   1	   0.005874618	  
TANK	   TRAF	  family	  member-­‐associated	  NFKB	  activator	   2	   0.005874618	  
KRTAP8-­‐1	   keratin	  associated	  protein	  8-­‐1	   21	   0.005874618	  
ARPP-­‐21	   -­‐	   -­‐	   0.005891195	  
SCUBE3	   signal	  peptide,	  CUB	  domain,	  EGF-­‐like	  3	   6	   0.005891195	  
FLJ22555	   -­‐	   2	   0.005896161	  
FAM20B	   family	  with	  sequence	  similarity	  20,	  member	  B	   1	   0.005926756	  
FCGBP	   Fc	  fragment	  of	  IgG	  binding	  protein	   19	   0.00597756	  
MFSD7	   major	  facilitator	  superfamily	  domain	  containing	  7	   4	   0.005984572	  
SORBS3	   sorbin	  and	  SH3	  domain	  containing	  3	   8	   0.005984572	  
NANOS1	   nanos	  homolog	  1	  (Drosophila)	   10	   0.005995257	  
G0S2	   G0/G1switch	  2	   1	   0.006090998	  
PCDH8	   protocadherin	  8	   13	   0.006122297	  
SCN7A	   sodium	  channel,	  voltage-­‐gated,	  type	  VII,	  alpha	   2	   0.006122297	  
SRI	   sorcin	   7	   0.006253498	  
P8	   -­‐	   16	   0.006253498	  
KLK4	   kallikrein	  4	  (prostase,	  enamel	  matrix,	  prostate)	   19	   0.006255945	  
AQP2	   aquaporin	  2	  (collecting	  duct)	   -­‐	   0.006274651	  
DCUN1D1	   DCN1,	  defective	  in	  cullin	  neddylation	  1,	  domain	  
containing	  1	  (S.	  cerevisiae)	  
3	   0.006411689	  
C12orf46	   chromosome	  12	  open	  reading	  frame	  46	   12	   0.006411689	  
MT1H	   metallothionein	  1H	   16	   0.006417031	  
BRCA1	   breast	  cancer	  1,	  early	  onset	   17	   0.006417031	  
-­‐	   -­‐	   -­‐	   0.006447459	  
DOCK2	   dedicator	  of	  cytokinesis	  2	   5	   0.006447459	  
GLRA1	   glycine	  receptor,	  alpha	  1	  (startle	  disease/hyperekplexia,	  
stiff	  man	  syndrome)	  
5	   0.006447459	  
CDH9	   cadherin	  9,	  type	  2	  (T1-­‐cadherin)	   5	   0.006469237	  
STAT5B	   signal	  transducer	  and	  activator	  of	  transcription	  5B	   17	   0.006469237	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CDCP2	   CUB	  domain	  containing	  protein	  2	   1	   0.006469237	  
SCGB1D2	   secretoglobin,	  family	  1D,	  member	  2	   11	   0.006512801	  
PPP1CC	   protein	  phosphatase	  1,	  catalytic	  subunit,	  gamma	  isoform	   12	   0.006517318	  
CETN1	   centrin,	  EF-­‐hand	  protein,	  1	   18	   0.006568288	  
CCL13	   chemokine	  (C-­‐C	  motif)	  ligand	  13	   17	   0.006598422	  
TBC1D3	   TBC1	  domain	  family,	  member	  3	   17	   0.00661871	  
PDGFRA	   platelet-­‐derived	  growth	  factor	  receptor,	  alpha	  
polypeptide	  
4	   0.006627551	  
CCR3	   chemokine	  (C-­‐C	  motif)	  receptor	  3	   3	   0.006650815	  
C19orf19	   chromosome	  19	  open	  reading	  frame	  19	   19	   0.006666293	  
TWIST1	   twist	  homolog	  1	  (acrocephalosyndactyly	  3	   7	   0.006741725	  
H2AFY	   H2A	  histone	  family,	  member	  Y	   5	   0.006741725	  
SLC22A18	   solute	  carrier	  family	  22	  (organic	  cation	  transporter),	  
member	  18	  
11	   0.006741725	  
SNRPN	   small	  nuclear	  ribonucleoprotein	  polypeptide	  N	   15	   0.006741725	  
MGC7036	   -­‐	   12	   0.006741725	  
Kua	   -­‐	   20	   0.006756329	  
MAGEC1	   melanoma	  antigen	  family	  C,	  1	   X	   0.006797953	  
ATP6V0C	   ATPase,	  H+	  transporting,	  lysosomal	  16kDa,	  V0	  subunit	  c	   16	   0.006825396	  
MSR1	   macrophage	  scavenger	  receptor	  1	   8	   0.006873407	  
CAB39L	   calcium	  binding	  protein	  39-­‐like	   13	   0.006873407	  
ACTA2	   actin,	  alpha	  2,	  smooth	  muscle,	  aorta	   -­‐	   0.006898194	  
GGTLA4	   gamma-­‐glutamyltransferase-­‐like	  activity	  4	   20	   0.006923809	  
TMEM88	   transmembrane	  protein	  88	   17	   0.007011951	  
AASS	   aminoadipate-­‐semialdehyde	  synthase	   -­‐	   0.007011951	  
GDF5	   growth	  differentiation	  factor	  5	  (cartilage-­‐derived	  
morphogenetic	  protein-­‐1)	  
20	   0.007011951	  
IVL	   involucrin	   1	   0.007046375	  
TLR4	   toll-­‐like	  receptor	  4	   9	   0.007147819	  
ME3	   malic	  enzyme	  3,	  NADP(+)-­‐dependent,	  mitochondrial	   11	   0.007147819	  
GRIA2	   glutamate	  receptor,	  ionotropic,	  AMPA	  2	   4	   0.007162973	  
DYSF	   dysferlin,	  limb	  girdle	  muscular	  dystrophy	  2B	  (autosomal	  
recessive)	  
2	   0.007203188	  
TRIM60	   tripartite	  motif-­‐containing	  60	   4	   0.007215958	  
ZNF80	   zinc	  finger	  protein	  80	   3	   0.007299624	  
TBC1D3	   TBC1	  domain	  family,	  member	  3	   17	   0.007395639	  
-­‐	   -­‐	   -­‐	   0.007421584	  
ATM	   ataxia	  telangiectasia	  mutated	  (includes	  complementation	  
groups	  A,	  C	  and	  D)	  
11	   0.007421584	  
RNH1	   ribonuclease/angiogenin	  inhibitor	  1	   11	   0.007421584	  
HDAC1	   histone	  deacetylase	  1	   1	   0.007496188	  
CST4	   cystatin	  S	   20	   0.007496188	  
MRGPRX4	   MAS-­‐related	  GPR,	  member	  X4	   11	   0.007496188	  
FLJ36004	   -­‐	   12	   0.00750587	  
ZNF659	   zinc	  finger	  protein	  659	   3	   0.00750587	  
CLC	   Charcot-­‐Leyden	  crystal	  protein	   19	   0.00751797	  
ZNF667	   zinc	  finger	  protein	  667	   19	   0.007540398	  
ZNF454	   zinc	  finger	  protein	  454	   5	   0.007550939	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DSG1	   desmoglein	  1	   18	   0.007618564	  
NA	   neurocanthocytosis	   -­‐	   0.007618564	  
ABCC10	   ATP-­‐binding	  cassette,	  sub-­‐family	  C	  (CFTR/MRP),	  member	  
10	  
6	   0.007821999	  
CSNK1A1L	   casein	  kinase	  1,	  alpha	  1-­‐like	   13	   0.007860271	  
SLC5A4	   solute	  carrier	  family	  5	  (low	  affinity	  glucose	  cotransporter),	  
member	  4	  
22	   0.007939866	  
RLN3R1	   -­‐	   5	   0.007949721	  
CDK2	   cyclin-­‐dependent	  kinase	  2	   12	   0.00825271	  
POU2F2	   POU	  domain,	  class	  2,	  transcription	  factor	  2	   19	   0.008391955	  
ITGB1BP2	   integrin	  beta	  1	  binding	  protein	  (melusin)	  2	   X	   0.008391955	  
FAM9B	   family	  with	  sequence	  similarity	  9,	  member	  B	   X	   0.008391955	  
GCM2	   glial	  cells	  missing	  homolog	  2	  (Drosophila)	   6	   0.008400027	  
FLJ23514	   -­‐	   11	   0.008400027	  
MRAS	   muscle	  RAS	  oncogene	  homolog	   3	   0.008411015	  
SARDH	   sarcosine	  dehydrogenase	   9	   0.008497573	  
SLC6A2	   solute	  carrier	  family	  6	  (neurotransmitter	  transporter,	  
noradrenalin),	  member	  2	  
16	   0.00853534	  
ORMDL3	   ORM1-­‐like	  3	  (S.	  cerevisiae)	   17	   0.008660065	  
WT1	   Wilms	  tumor	  1	   11	   0.008660065	  
MGC40178	   -­‐	   13	   0.008660065	  
SLC22A18AS	   solute	  carrier	  family	  22	  (organic	  cation	  transporter),	  
member	  18	  antisense	  
11	   0.008660065	  
PCDHGB4	   protocadherin	  gamma	  subfamily	  B,	  4	   5	   0.008717794	  
MAEL	   maelstrom	  homolog	  (Drosophila)	   1	   0.008717794	  
MEGF10	   multiple	  EGF-­‐like-­‐domains	  10	   5	   0.008721123	  
FAM9A	   family	  with	  sequence	  similarity	  9,	  member	  A	   X	   0.008755454	  
STEAP2	   six	  transmembrane	  epithelial	  antigen	  of	  the	  prostate	  2	   7	   0.008755454	  
GALNT5	   UDP-­‐N-­‐acetyl-­‐alpha-­‐D-­‐galactosamine:polypeptide	  N-­‐
acetylgalactosaminyltransferase	  5	  (GalNAc-­‐T5)	  
2	   0.008828744	  
DNAJB8	   DnaJ	  (Hsp40)	  homolog,	  subfamily	  B,	  member	  8	   3	   0.008830444	  
ADH7	   alcohol	  dehydrogenase	  7	  (class	  IV),	  mu	  or	  sigma	  
polypeptide	  
4	   0.008893124	  
MS4A7	   membrane-­‐spanning	  4-­‐domains,	  subfamily	  A,	  member	  7	   11	   0.008893124	  
FMR1NB	   fragile	  X	  mental	  retardation	  1	  neighbor	   X	   0.008895268	  
XAGE5	   X	  antigen	  family,	  member	  5	   X	   0.008902474	  
CCL7	   chemokine	  (C-­‐C	  motif)	  ligand	  7	   17	   0.008930512	  
CDKN2A	   cyclin-­‐dependent	  kinase	  inhibitor	  2A	  (melanoma,	  p16,	  
inhibits	  CDK4)	  
9	   0.008979211	  
UGT2B4	   UDP	  glucuronosyltransferase	  2	  family,	  polypeptide	  B4	   4	   0.009015415	  
BIRC8	   baculoviral	  IAP	  repeat-­‐containing	  8	   19	   0.009015415	  
REG1A	   regenerating	  islet-­‐derived	  1	  alpha	  (pancreatic	  stone	  
protein,	  pancreatic	  thread	  protein)	  
2	   0.009015415	  
NRTN	   neurturin	   19	   0.009015415	  
RNF2	   ring	  finger	  protein	  2	   1	   0.009015415	  
IRS1	   insulin	  receptor	  substrate	  1	   2	   0.009015415	  
KIF5A	   kinesin	  family	  member	  5A	   12	   0.009015415	  
TTLL6	   tubulin	  tyrosine	  ligase-­‐like	  family,	  member	  6	   17	   0.009015415	  
SNRK	   SNF	  related	  kinase	   3	   0.009015415	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EPAS1	   endothelial	  PAS	  domain	  protein	  1	   2	   0.009015415	  
JM11	   -­‐	   X	   0.00901593	  
DCC	   deleted	  in	  colorectal	  carcinoma	   18	   0.009175824	  
TMCO5	   transmembrane	  and	  coiled-­‐coil	  domains	  5	   15	   0.009187483	  
ZNF76	   zinc	  finger	  protein	  76	  (expressed	  in	  testis)	   6	   0.009259825	  
INS	   insulin	   11	   0.009384921	  
COL11A2	   collagen,	  type	  XI,	  alpha	  2	   6	   0.009384921	  
REG3A	   regenerating	  islet-­‐derived	  3	  alpha	   2	   0.009384921	  
CIB3	   calcium	  and	  integrin	  binding	  family	  member	  3	   19	   0.009384921	  
LYZL6	   lysozyme-­‐like	  6	   17	   0.009467574	  
HIST1H2AA	   histone	  cluster	  1,	  H2aa	   6	   0.009467574	  
ANXA13	   annexin	  A13	   8	   0.009467574	  
CD5L	   CD5	  molecule-­‐like	   1	   0.009467574	  
SPOCK2	   sparc/osteonectin,	  cwcv	  and	  kazal-­‐like	  domains	  
proteoglycan	  (testican)	  2	  
10	   0.009476994	  
KRTAP1-­‐1	   keratin	  associated	  protein	  1-­‐1	   17	   0.009574444	  
MYH1	   myosin,	  heavy	  chain	  1,	  skeletal	  muscle,	  adult	   17	   0.009574444	  
ENDOGL1	   endonuclease	  G-­‐like	  1	   3	   0.009574444	  
C10orf111	   chromosome	  10	  open	  reading	  frame	  111	   10	   0.009582908	  
CSDC2	   cold	  shock	  domain	  containing	  C2,	  RNA	  binding	   22	   0.009615483	  
PHYHIP	   phytanoyl-­‐CoA	  2-­‐hydroxylase	  interacting	  protein	   8	   0.009615483	  
BCDIN3	   bin3,	  bicoid-­‐interacting	  3,	  homolog	  (Drosophila)	   7	   0.009759351	  
FHL5	   four	  and	  a	  half	  LIM	  domains	  5	   6	   0.009759351	  
KCNE1	   potassium	  voltage-­‐gated	  channel,	  Isk-­‐related	  family,	  
member	  1	  
21	   0.00984379	  
DPM2	   dolichyl-­‐phosphate	  mannosyltransferase	  polypeptide	  2,	  
regulatory	  subunit	  




Appendix 8. List of genes from the previous 
appendix shown to be involved in cancer based 
on literature search 
Gene	   Prevalent	  Function	  based	  on	  literature	  
search	  
Methylation	  Status	  in	  cSCC	  
cell	  lines	  
SPARCL1	   Tumour	  Suppressor	   Hyper	  	  
CDKN2A	   Tumour	  Suppressor	   Hyper	  	  
RGS17	   Oncogene	   Hyper	  	  
FGFR1	   Oncogene	   Hyper	  	  
BARHL2	   Tumour	  Suppressor	   Hyper	  	  
CASP8	   Pro-­‐apoptotic	   Hypo	  
NEFH	   Tumour	  Suppressor	   Hyper	  	  
TMEM22	   Oncogene	   Hyper	  	  
PRKDC	   Oncogene	   Hypo	  
ZDHHC11	   Oncogene	   Hypo	  
CR1	   Tumour	  Suppressor	   Hyper	  	  
NDRG2	   Tumour	  Suppressor	   Hyper	  	  
TGIF2	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
PRAME	   Oncogene	   Hypo	  
TP53I3	   Tumour	  Suppressor	   Hyper	  	  
KRT7	   Tumour	  Suppressor	   Hyper	  	  
HSPCAL3	   Oncogene	   Hypo	  
SERPINA3	   Tumour	  Suppressor	   Hyper	  	  
NRTN	   Acts	  as	  both	  TS	  and	  oncogene	   Hypo	  
B4GALT1	   Tumour	  Suppressor	   Hyper	  	  
LSAMP	   Tumour	  Suppressor	   Hyper	  	  
UCHL1	   Tumour	  Suppressor	   Hyper	  	  
TBC1D3C	   Oncogene	   Hypo	  
THSD1	   Tumour	  Suppressor	   Hypo	  
GAGE4	   Oncogene	   Hypo	  
MMP20	   Oncogene	   Hypo	  
C9orf78	   Tumour	  Suppressor	   Hyper	  	  
ITK	   Oncogene	   Hypo	  
PRKCB1	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
CCT6A	   Oncogene	   Hypo	  
SIM1	   Tumour	  Suppressor	   Hyper	  	  
PARC	   Tumour	  Suppressor	   Hyper	  	  
SST	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
ZIC1	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
CNN1	   Tumour	  Suppressor	   Hyper	  	  
TNFRSF10C	   Tumour	  Suppressor	   Hyper	  	  
TNFRSF1B	   Oncogene	   Hyper	  	  
SMPD3	   Tumour	  Suppressor	   Hyper	  	  
TBC1D3C	   Oncogene	   Hypo	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GATA4	   Tumour	  Suppressor	   Hyper	  	  
SPINK2	   Oncogene	   Hyper	  	  
REGL	   Oncogene	   Hypo	  
AQP9	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
GGT1	   Oncogene	   Hyper	  	  
HK1	   Oncogene	   Hypo	  
ADORA3	   Oncogene	   Hypo	  
H2AFY	   Tumour	  Suppressor	   Hyper	  	  
DYRK3	   Oncogene	   Hyper	  	  
PAX4	   Acts	  as	  both	  TS	  and	  oncogene	   Hypo	  
GPR55	   Oncogene	   Hypo	  
FABP1	   Oncogene	   Hypo	  
S100A3	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
WT1	   Tumour	  Suppressor	   Hyper	  	  
EPDR1	   Oncogene	   Hypo	  
LIMS2	   Tumour	  Suppressor	   Hypo	  
PLCE1	   Oncogene	   Hypo	  
KCTD12	   Tumour	  Suppressor	   Hyper	  	  
HNF4A	   Oncogene	   Hypo	  
EDNRB	   Acts	  as	  both	  TS	  and	  oncogene	   Hypo	  
GABRP	   Tumour	  Suppressor	   Hypo	  
TSPAN16	   Tumour	  Suppressor	   Hyper	  	  
B3GALT5	   Oncogene	   Hypo	  
CCRK	   Oncogene	   Hyper	  	  
PLUNC	   Oncogene	   Hypo	  
IL17	   Oncogene	   Hypo	  
TAL1	   Tumour	  Suppressor	   Hyper	  	  
BCHE	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
CPNE6	   Oncogene	   Hypo	  
GSN	   Tumour	  Suppressor	   Hyper	  	  
LAMA4	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
SORBS2	   Tumour	  Suppressor	   Hyper	  	  
LAT2	   Oncogene	   Hypo	  
SORBS3	   Oncogene	   Hyper	  	  
NANOS1	   Oncogene	   Hyper	  	  
G0S2	   Tumour	  Suppressor	   Hyper	  	  
PCDH8	   Tumour	  Suppressor	   Hyper	  	  
SRI	   Oncogene	   Hypo	  
P8	   Tumour	  Suppressor	   Hyper	  	  
KLK4	   Oncogene	   Hypo	  
DCUN1D1	   Oncogene	   Hyper	  	  
MT1H	   Oncogene	   Hypo	  
BRCA1	   Tumour	  Suppressor	   Hypo	  
DOCK2	   Oncogene	   Hyper	  	  
STAT5B	   Tumour	  Suppressor	   Hyper	  	  
SCGB1D2	   Oncogene	   Hypo	  
PDGFRA	   Oncogene	   Hyper	  	  
CCR3	   Oncogene	   Hypo	  
TWIST1	   Tumour	  Suppressor	   Hyper	  	  
SLC22A18	   Tumour	  Suppressor	   Hyper	  	  
MAGEC1	   Oncogene	   Hypo	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MSR1	   Acts	  as	  both	  TS	  and	  oncogene	   Hypo	  
GDF5	   Acts	  as	  both	  TS	  and	  oncogene	   Hypo	  
IVL	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
TLR4	   Oncogene	   Hypo	  
TBC1D3	   Oncogene	   Hypo	  
ATM	   Tumour	  Suppressor	   Hypo	  
HDAC1	   Oncogene	   Hypo	  
DSG1	   Tumour	  Suppressor	   Hyper	  	  
RLN3R1	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
CDK2	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
POU2F2	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
MRAS	   Oncogene	   Hypo	  
SLC6A2	   Tumour	  Suppressor	   Hyper	  	  
MAEL	   Oncogene	   Hypo	  
STEAP2	   Oncogene	   Hyper	  	  
ADH7	   Acts	  as	  both	  TS	  and	  oncogene	   Hypo	  
CCL7	   Oncogene	   Hypo	  
BIRC8	   Oncogene	   Hypo	  
REG1A	   Oncogene	   Hypo	  
RNF2	   Oncogene	   Hyper	  	  
IRS1	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  
DCC	   Acts	  as	  both	  TS	  and	  oncogene	   Hypo	  
REG3A	   Oncogene	   Hypo	  
ANXA13	   Acts	  as	  both	  TS	  and	  oncogene	   Hyper	  	  




Appendix 9. List of 76 miRNAs differentially 
expressed in cSCC compared to normal skin. 
Name logFC AveExpr P.Value adj.P.Val 
hsa-miR-1469 -1.072505836 8.909492183 5.77436154519119e-10 1.20972874371755e-06 
hsv1-miR-H17 -0.705890727 6.293762043 1.69129214680814e-09 1.77162852378153e-06 
hsa-miR-548ap-
5p/hsa-miR-548j 
-1.137583927 6.387216938 6.37345196612178e-09 4.45079395634171e-06 
hsa-miR-3656 -1.010574316 7.992558753 2.62424656124373e-08 1.3744491364514e-05 
hsa-miR-4707-5p -0.899529655 7.154120387 3.54495753467037e-08 1.48533720702689e-05 
hsa-miR-371b-5p -0.796315305 12.95202837 7.02535328882583e-08 2.45301919001502e-05 
hsa-miR-638 -0.96944656 7.528746852 8.79507138186871e-08 2.63223922071642e-05 
hsa-miR-4787-5p -0.783080099 13.39009682 1.0748940076033e-07 2.81487868241115e-05 
hsa-miR-4708-3p -0.819929533 13.73263792 4.15585920532755e-07 9.6739167057347e-05 
hsa-miR-4530 -0.912825789 9.016009311 5.83423681553376e-07 0.000122227 
hsa-miR-4800-3p -0.959652136 12.58479102 8.73797238933443e-07 0.000166419 
hsa-miR-943 -0.547735401 7.141100883 1.53754766534614e-06 0.00026843 
kshv-miR-K12-3-
5p 
-0.582550336 7.324808865 1.99976954076941e-06 0.00030663 
hsa-miR-3960 -0.745469234 13.55820195 2.04908076517478e-06 0.00030663 
hsa-miR-1909-3p -0.625525465 6.088837698 2.71122173072946e-06 0.000378667 
hsa-miR-4505 -0.965317513 8.646416497 7.52660351418713e-06 0.000985515 
hsa-miR-744-5p -0.691696164 7.964567669 9.56746704377922e-06 0.00117905 
hsa-miR-642b-3p 1.141917999 6.608054895 1.15649194007355e-05 0.001275185 
hsa-miR-605 -0.513822616 5.813879982 1.15575701021536e-05 0.001275185 
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hsa-miR-31-5p 1.740874987 6.468657902 1.25833940732504e-05 0.001318111 
hsa-miR-21-3p 0.6724371 5.104375825 1.42998835672022e-05 0.001426584 
hsa-miR-4732-5p 1.92248161 9.252727944 2.03475247609164e-05 0.001937639 
hsa-miR-4423-5p 0.443625999 5.250061222 3.69901561629572e-05 0.003228932 
kshv-miR-K12-6-
3p 
-0.793278205 7.928657316 3.57816180117349e-05 0.003228932 
hsa-miR-585 -0.617744304 5.599632618 3.90871812017574e-05 0.003275506 
hsa-miR-125b-1-
3p 
-0.349733408 5.621494536 4.82440516267739e-05 0.003609689 
hsa-miR-3195 -0.694960429 6.110821849 4.49031145967249e-05 0.003609689 
hsv1-miR-H7-3p -0.708660707 9.884600092 4.66662449625971e-05 0.003609689 
hsa-miR-495-5p 0.391768945 5.66288775 6.69281365222725e-05 0.004523047 
hsv2-miR-H10 -0.713452548 8.522406314 6.68499148385216e-05 0.004523047 
hsa-miR-663a -0.749102069 7.506702693 6.44310090858787e-05 0.004523047 
hsa-miR-3687 -0.865385123 7.2448325 8.8350480273067e-05 0.005784196 
hsa-miR-4516 -0.697507752 10.99051286 0.000101523 0.006445202 
hsa-miR-4734 -0.445995207 5.272286218 0.000112973 0.006961121 
hsa-miR-124-5p -0.298243171 6.10332581 0.000127269 0.007617956 
hsa-miR-224-3p -0.561808414 6.789616544 0.00013696 0.007970294 
hsa-miR-1290 1.530172368 8.672801553 0.000147766 0.008366759 
hsa-miR-639 -0.249764274 5.584202327 0.000178618 0.009847496 
hsa-miR-3182 2.337082252 8.163444664 0.000217911 0.011413106 
hsa-miR-4488 -0.454136103 6.913694905 0.00021514 0.011413106 
hsa-miR-4467 -0.547369411 12.57858681 0.00022758 0.011462915 
hsa-miR-149-3p -0.729607545 7.543904852 0.000229805 0.011462915 
hsa-miR-193b-3p 1.118807996 7.5479942 0.000335596 0.015978967 
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hsa-miR-766-3p 0.207156908 5.142699547 0.000333664 0.015978967 
hsa-miR-498 -0.306547631 6.769322106 0.000430022 0.0200199 
hsa-miR-3920 0.216338628 4.840038311 0.000473974 0.021586409 
hsa-miR-3935 0.43234109 6.381786768 0.000521247 0.022821632 
hsa-miR-130b-3p 0.293904195 5.765020465 0.000531654 0.022821632 
hsa-miR-4750-5p -0.59968878 9.784396476 0.000533776 0.022821632 
hsa-miR-24-2-5p 0.365208776 5.027875459 0.000548958 0.02300134 
hsa-miR-4447 -0.273777285 5.626449958 0.000580342 0.023839532 
hsa-miR-3156-3p 0.395539349 6.820620878 0.000681503 0.027456701 
hsa-miR-135b-5p 0.883937247 5.037672863 0.000851169 0.033645257 
hsv2-miR-H7-3p -0.589493933 9.321282767 0.000899884 0.034912168 
hsa-miR-21-5p 2.246588244 8.033722502 0.000934032 0.03494282 
hsa-miR-423-3p 0.579440254 6.524077005 0.000920679 0.03494282 
hsa-miR-223-3p 1.763572745 7.236146792 0.001020281 0.036254584 
hsa-miR-1307-5p 0.285578386 4.757912697 0.001021012 0.036254584 
hsa-miR-4508 -0.98043825 8.831630896 0.001010704 0.036254584 
hsa-miR-1246 1.419004492 13.60041948 0.001045013 0.03648836 
hsv1-miR-H5-3p 0.283271184 5.040945818 0.001191264 0.040673136 
hsa-miR-1908 -0.467009308 10.32439581 0.001203692 0.040673136 
hsa-miR-4521 0.621576095 5.573759197 0.001249158 0.041539459 
hsa-miR-4286 0.956050588 7.537456837 0.00127756 0.041820135 
hsa-miR-5581-3p 0.599733688 6.679426255 0.001351191 0.043549929 
hsa-miR-3676-3p -0.343569654 7.661996726 0.001404249 0.044574273 
hsa-miR-210 0.71365027 7.068375043 0.001464654 0.045797756 
hsa-miR-142-5p 0.99340117 5.087023745 0.001600617 0.047424561 
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hsa-miR-4732-3p 0.654731845 7.779519857 0.00156408 0.047424561 
hsa-miR-1255b-2-
3p 
0.374734845 5.193972354 0.001588268 0.047424561 
hsa-let-7d-3p -0.3890342 6.9052577 0.001607229 0.047424561 
hsa-miR-4639-3p 0.460282559 9.03155916 0.001691256 0.048200154 
hsa-miR-4320 0.217947719 4.764371146 0.001688837 0.048200154 
hcmv-miR-US25-
1-3p 
-0.251550024 5.384550166 0.001702535 0.048200154 
hsa-miR-93-5p 0.990397389 6.667981642 0.001768337 0.049395534 




Appendix 10. KEGG Pathway analysis of genes 
hypomethylated in AK. 
KEGG	  Pathway	   Annotated	  
genes	  
p-­‐value	   Adjusted	  
p	  value	  
Neuroactive	  ligand-­‐receptor	  interaction	   44	   6.45E-­‐16	   1.10E-­‐13	  
Axon	  guidance	   30	   1.18E-­‐15	   1.10E-­‐13	  
MAPK	  signaling	  pathway	   41	   3.84E-­‐14	   2.38E-­‐12	  
Focal	  adhesion	   34	   3.35E-­‐13	   1.56E-­‐11	  
Calcium	  signaling	  pathway	   29	   4.60E-­‐11	   1.71E-­‐09	  
Type	  II	  diabetes	  mellitus	   15	   1.21E-­‐10	   3.74E-­‐09	  
Hypertrophic	  cardiomyopathy	  (HCM)	   19	   4.01E-­‐10	   1.06E-­‐08	  
Pathways	  in	  cancer	   39	   4.56E-­‐10	   1.06E-­‐08	  
Dilated	  cardiomyopathy	   18	   1.10E-­‐08	   2.28E-­‐07	  
Arrhythmogenic	  right	  ventricular	  cardiomyopathy	  
(ARVC)	  
16	   2.39E-­‐08	   4.45E-­‐07	  
Tight	  junction	   21	   4.20E-­‐08	   7.10E-­‐07	  
ErbB	  signaling	  pathway	   16	   1.76E-­‐07	   2.73E-­‐06	  
Cell	  adhesion	  molecules	  (CAMs)	   20	   1.99E-­‐07	   2.85E-­‐06	  
Regulation	  of	  actin	  cytoskeleton	   26	   2.70E-­‐07	   3.59E-­‐06	  
Leukocyte	  transendothelial	  migration	   18	   5.75E-­‐07	   7.13E-­‐06	  
Melanogenesis	   16	   1.64E-­‐06	   1.91E-­‐05	  
Vascular	  smooth	  muscle	  contraction	   17	   1.84E-­‐06	   2.01E-­‐05	  
Long-­‐term	  depression	   13	   2.20E-­‐06	   2.28E-­‐05	  
Purine	  metabolism	   20	   3.15E-­‐06	   3.08E-­‐05	  
ECM-­‐receptor	  interaction	   14	   3.48E-­‐06	   3.23E-­‐05	  
Insulin	  signaling	  pathway	   18	   5.19E-­‐06	   4.60E-­‐05	  
Olfactory	  transduction	   34	   7.99E-­‐06	   6.75E-­‐05	  
Long-­‐term	  potentiation	   12	   1.27E-­‐05	   1.03E-­‐04	  
Aldosterone-­‐regulated	  sodium	  reabsorption	   9	   2.42E-­‐05	   1.88E-­‐04	  
Glioma	   11	   3.29E-­‐05	   2.45E-­‐04	  
Fc	  epsilon	  RI	  signaling	  pathway	   12	   4.46E-­‐05	   3.19E-­‐04	  
Cardiac	  muscle	  contraction	   12	   5.07E-­‐05	   3.49E-­‐04	  
Histidine	  metabolism	   7	   8.75E-­‐05	   5.81E-­‐04	  
Drug	  metabolism	  -­‐	  other	  enzymes	   9	   1.21E-­‐04	   7.78E-­‐04	  
Adherens	  junction	   11	   1.27E-­‐04	   7.88E-­‐04	  
Gap	  junction	   12	   1.62E-­‐04	   9.74E-­‐04	  
Adipocytokine	  signaling	  pathway	   10	   2.20E-­‐04	   1.28E-­‐03	  
Wnt	  signaling	  pathway	   16	   2.31E-­‐04	   1.30E-­‐03	  
Pantothenate	  and	  CoA	  biosynthesis	   5	   2.49E-­‐04	   1.33E-­‐03	  
T	  cell	  receptor	  signaling	  pathway	   13	   2.50E-­‐04	   1.33E-­‐03	  
Progesterone-­‐mediated	  oocyte	  maturation	   11	   4.33E-­‐04	   2.24E-­‐03	  
Phenylalanine	  metabolism	   5	   4.57E-­‐04	   2.30E-­‐03	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GnRH	  signaling	  pathway	   12	   4.81E-­‐04	   2.35E-­‐03	  
Endocytosis	   17	   6.99E-­‐04	   3.33E-­‐03	  
mTOR	  signaling	  pathway	   8	   7.52E-­‐04	   3.50E-­‐03	  
Natural	  killer	  cell	  mediated	  cytotoxicity	   14	   7.95E-­‐04	   3.61E-­‐03	  
O-­‐Glycan	  biosynthesis	   6	   8.32E-­‐04	   3.68E-­‐03	  
Amyotrophic	  lateral	  sclerosis	  (ALS)	   8	   8.57E-­‐04	   3.71E-­‐03	  
Tyrosine	  metabolism	   7	   9.80E-­‐04	   4.14E-­‐03	  
Chemokine	  signaling	  pathway	   17	   1.06E-­‐03	   4.39E-­‐03	  
Neurotrophin	  signaling	  pathway	   13	   1.10E-­‐03	   4.46E-­‐03	  
Fc	  gamma	  R-­‐mediated	  phagocytosis	   11	   1.20E-­‐03	   4.76E-­‐03	  
ABC	  transporters	   7	   1.30E-­‐03	   4.95E-­‐03	  
Amino	  sugar	  and	  nucleotide	  sugar	  metabolism	   7	   1.30E-­‐03	   4.95E-­‐03	  
Small	  cell	  lung	  cancer	   10	   1.37E-­‐03	   5.08E-­‐03	  
Proximal	  tubule	  bicarbonate	  reclamation	   5	   1.53E-­‐03	   5.59E-­‐03	  
Fructose	  and	  mannose	  metabolism	   6	   1.65E-­‐03	   5.92E-­‐03	  
Ribosome	   10	   1.95E-­‐03	   6.84E-­‐03	  
Glycolysis	  /	  Gluconeogenesis	   8	   2.42E-­‐03	   8.20E-­‐03	  
Phosphatidylinositol	  signaling	  system	   9	   2.42E-­‐03	   8.20E-­‐03	  
Peroxisome	   9	   2.90E-­‐03	   9.63E-­‐03	  
SNARE	  interactions	  in	  vesicular	  transport	   6	   2.98E-­‐03	   9.73E-­‐03	  
Endometrial	  cancer	   7	   3.49E-­‐03	   1.12E-­‐02	  
Cell	  cycle	   12	   3.75E-­‐03	   1.18E-­‐02	  
Non-­‐small	  cell	  lung	  cancer	   7	   4.33E-­‐03	   1.34E-­‐02	  
Pancreatic	  cancer	   8	   5.16E-­‐03	   1.55E-­‐02	  
Renal	  cell	  carcinoma	   8	   5.16E-­‐03	   1.55E-­‐02	  
Hedgehog	  signaling	  pathway	   7	   5.31E-­‐03	   1.57E-­‐02	  
TGF-­‐beta	  signaling	  pathway	   9	   5.58E-­‐03	   1.61E-­‐02	  
Melanoma	   8	   5.63E-­‐03	   1.61E-­‐02	  
Type	  I	  diabetes	  mellitus	   6	   6.28E-­‐03	   1.77E-­‐02	  
Chronic	  myeloid	  leukemia	   8	   6.66E-­‐03	   1.85E-­‐02	  
Prostate	  cancer	   9	   6.98E-­‐03	   1.91E-­‐02	  
Pathogenic	  Escherichia	  coli	  infection	   7	   7.08E-­‐03	   1.91E-­‐02	  
Acute	  myeloid	  leukemia	   7	   7.75E-­‐03	   2.06E-­‐02	  
Notch	  signaling	  pathway	   6	   8.68E-­‐03	   2.27E-­‐02	  
Oocyte	  meiosis	   10	   1.21E-­‐02	   3.14E-­‐02	  
Dorso-­‐ventral	  axis	  formation	   4	   1.41E-­‐02	   3.61E-­‐02	  
Cytokine-­‐cytokine	  receptor	  interaction	   18	   1.49E-­‐02	   3.74E-­‐02	  
Complement	  and	  coagulation	  cascades	   7	   1.61E-­‐02	   3.97E-­‐02	  
Galactose	  metabolism	   4	   1.62E-­‐02	   3.97E-­‐02	  
Pyruvate	  metabolism	   5	   1.76E-­‐02	   4.24E-­‐02	  
Basal	  cell	  carcinoma	   6	   1.81E-­‐02	   4.32E-­‐02	  
Systemic	  lupus	  erythematosus	   11	   1.88E-­‐02	   4.43E-­‐02	  
Apoptosis	   8	   1.94E-­‐02	   4.45E-­‐02	  
Hematopoietic	  cell	  lineage	   8	   1.94E-­‐02	   4.45E-­‐02	  
Leishmania	  infection	   7	   2.00E-­‐02	   4.54E-­‐02	  
Graft-­‐versus-­‐host	  disease	   5	   2.13E-­‐02	   4.70E-­‐02	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Glyoxylate	  and	  dicarboxylate	  metabolism	   3	   2.15E-­‐02	   4.70E-­‐02	  




Appendix 11.  KEGG Pathway analysis of genes 
hypermethylated in AK. 
Description	   Genes	   p-­‐value	   Adjusted	  p	  
value	  
Pathways	  in	  cancer	   56	   1.03E-­‐15	   1.92E-­‐13	  
Wnt	  signaling	  pathway	   35	   2.19E-­‐14	   2.03E-­‐12	  
Focal	  adhesion	   39	   3.45E-­‐13	   2.14E-­‐11	  
Endocytosis	   35	   8.44E-­‐12	   3.93E-­‐10	  
PPAR	  signaling	  pathway	   20	   1.04E-­‐10	   3.88E-­‐09	  
Glycerophospholipid	  metabolism	   21	   1.27E-­‐10	   3.95E-­‐09	  
Jak-­‐STAT	  signaling	  pathway	   29	   8.58E-­‐10	   2.28E-­‐08	  
Melanogenesis	   23	   1.06E-­‐09	   2.47E-­‐08	  
Phosphatidylinositol	  signaling	  system	   19	   4.74E-­‐09	   9.79E-­‐08	  
Calcium	  signaling	  pathway	   29	   2.26E-­‐08	   4.11E-­‐07	  
MAPK	  signaling	  pathway	   37	   2.55E-­‐08	   4.11E-­‐07	  
Axon	  guidance	   24	   2.65E-­‐08	   4.11E-­‐07	  
Basal	  cell	  carcinoma	   15	   5.54E-­‐08	   7.85E-­‐07	  
Vascular	  smooth	  muscle	  contraction	   22	   5.91E-­‐08	   7.85E-­‐07	  
Prostate	  cancer	   19	   7.50E-­‐08	   9.31E-­‐07	  
Adherens	  junction	   17	   1.43E-­‐07	   1.65E-­‐06	  
Regulation	  of	  actin	  cytoskeleton	   31	   1.51E-­‐07	   1.65E-­‐06	  
Chemokine	  signaling	  pathway	   28	   3.40E-­‐07	   3.50E-­‐06	  
Insulin	  signaling	  pathway	   23	   3.58E-­‐07	   3.50E-­‐06	  
Glycosaminoglycan	  biosynthesis	  -­‐	  chondroitin	  
sulfate	  
9	   5.50E-­‐07	   5.12E-­‐06	  
GnRH	  signaling	  pathway	   19	   6.07E-­‐07	   5.37E-­‐06	  
ECM-­‐receptor	  interaction	   17	   8.02E-­‐07	   6.78E-­‐06	  
Non-­‐small	  cell	  lung	  cancer	   13	   2.01E-­‐06	   1.62E-­‐05	  
Notch	  signaling	  pathway	   12	   2.54E-­‐06	   1.97E-­‐05	  
Dilated	  cardiomyopathy	   17	   3.02E-­‐06	   2.23E-­‐05	  
Hedgehog	  signaling	  pathway	   13	   3.12E-­‐06	   2.23E-­‐05	  
Small	  cell	  lung	  cancer	   16	   3.88E-­‐06	   2.67E-­‐05	  
Glycerolipid	  metabolism	   12	   4.08E-­‐06	   2.71E-­‐05	  
ErbB	  signaling	  pathway	   16	   6.24E-­‐06	   4.00E-­‐05	  
Acute	  myeloid	  leukemia	   13	   7.07E-­‐06	   4.38E-­‐05	  
Vasopressin-­‐regulated	  water	  reabsorption	   11	   8.28E-­‐06	   4.97E-­‐05	  
Colorectal	  cancer	   13	   1.03E-­‐05	   6.01E-­‐05	  
Tight	  junction	   20	   1.27E-­‐05	   7.16E-­‐05	  
Chronic	  myeloid	  leukemia	   14	   1.42E-­‐05	   7.75E-­‐05	  
Oocyte	  meiosis	   18	   1.55E-­‐05	   8.24E-­‐05	  
Neurotrophin	  signaling	  pathway	   19	   1.79E-­‐05	   9.24E-­‐05	  
Neuroactive	  ligand-­‐receptor	  interaction	   31	   2.03E-­‐05	   1.02E-­‐04	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Cell	  cycle	   19	   2.24E-­‐05	   1.08E-­‐04	  
Progesterone-­‐mediated	  oocyte	  maturation	   15	   2.33E-­‐05	   1.08E-­‐04	  
TGF-­‐beta	  signaling	  pathway	   15	   2.33E-­‐05	   1.08E-­‐04	  
Adipocytokine	  signaling	  pathway	   13	   2.50E-­‐05	   1.13E-­‐04	  
Fc	  gamma	  R-­‐mediated	  phagocytosis	   16	   2.60E-­‐05	   1.15E-­‐04	  
Pancreatic	  cancer	   13	   4.06E-­‐05	   1.76E-­‐04	  
Endometrial	  cancer	   11	   4.50E-­‐05	   1.86E-­‐04	  
mTOR	  signaling	  pathway	   11	   4.50E-­‐05	   1.86E-­‐04	  
Inositol	  phosphate	  metabolism	   11	   6.50E-­‐05	   2.63E-­‐04	  
Hypertrophic	  cardiomyopathy	  (HCM)	   14	   8.29E-­‐05	   3.26E-­‐04	  
Glioma	   12	   8.46E-­‐05	   3.26E-­‐04	  
B	  cell	  receptor	  signaling	  pathway	   13	   8.58E-­‐05	   3.26E-­‐04	  
Arrhythmogenic	  right	  ventricular	  
cardiomyopathy	  (ARVC)	  
13	   9.88E-­‐05	   3.62E-­‐04	  
T	  cell	  receptor	  signaling	  pathway	   16	   9.91E-­‐05	   3.62E-­‐04	  
Gap	  junction	   14	   1.56E-­‐04	   5.58E-­‐04	  
Long-­‐term	  potentiation	   12	   1.77E-­‐04	   6.10E-­‐04	  
Renal	  cell	  carcinoma	   12	   1.77E-­‐04	   6.10E-­‐04	  
Circadian	  rhythm	  -­‐	  mammal	   5	   2.92E-­‐04	   9.88E-­‐04	  
Apoptosis	   13	   4.44E-­‐04	   1.45E-­‐03	  
Hematopoietic	  cell	  lineage	   13	   4.44E-­‐04	   1.45E-­‐03	  
Thyroid	  cancer	   7	   4.70E-­‐04	   1.51E-­‐03	  
Ubiquitin	  mediated	  proteolysis	   17	   5.81E-­‐04	   1.83E-­‐03	  
Other	  glycan	  degradation	   5	   8.74E-­‐04	   2.71E-­‐03	  
Cytokine-­‐cytokine	  receptor	  interaction	   26	   1.05E-­‐03	   3.20E-­‐03	  
Huntington's	  disease	   20	   1.08E-­‐03	   3.25E-­‐03	  
Lysine	  degradation	   8	   1.41E-­‐03	   4.15E-­‐03	  
Fc	  epsilon	  RI	  signaling	  pathway	   11	   1.95E-­‐03	   5.66E-­‐03	  
Melanoma	   10	   2.82E-­‐03	   8.07E-­‐03	  
Biosynthesis	  of	  unsaturated	  fatty	  acids	   5	   4.10E-­‐03	   1.15E-­‐02	  
VEGF	  signaling	  pathway	   10	   4.65E-­‐03	   1.29E-­‐02	  
Ether	  lipid	  metabolism	   6	   5.50E-­‐03	   1.50E-­‐02	  
Leukocyte	  transendothelial	  migration	   13	   6.44E-­‐03	   1.73E-­‐02	  
Purine	  metabolism	   16	   6.52E-­‐03	   1.73E-­‐02	  
Vibrio	  cholerae	  infection	   8	   6.63E-­‐03	   1.74E-­‐02	  
Cell	  adhesion	  molecules	  (CAMs)	   14	   7.64E-­‐03	   1.97E-­‐02	  
Arachidonic	  acid	  metabolism	   8	   8.19E-­‐03	   2.09E-­‐02	  
RNA	  degradation	   8	   9.07E-­‐03	   2.28E-­‐02	  
Taurine	  and	  hypotaurine	  metabolism	   3	   1.16E-­‐02	   2.89E-­‐02	  
Homologous	  recombination	   5	   1.19E-­‐02	   2.92E-­‐02	  
alpha-­‐Linolenic	  acid	  metabolism	   4	   1.34E-­‐02	   3.23E-­‐02	  
Toll-­‐like	  receptor	  signaling	  pathway	   11	   1.35E-­‐02	   3.23E-­‐02	  
Histidine	  metabolism	   5	   1.38E-­‐02	   3.25E-­‐02	  
Valine,	  leucine	  and	  isoleucine	  biosynthesis	   3	   1.54E-­‐02	   3.59E-­‐02	  
Aminoacyl-­‐tRNA	  biosynthesis	   6	   1.59E-­‐02	   3.61E-­‐02	  
O-­‐Glycan	  biosynthesis	   5	   1.59E-­‐02	   3.61E-­‐02	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Amyotrophic	  lateral	  sclerosis	  (ALS)	   7	   1.63E-­‐02	   3.66E-­‐02	  
Lysosome	   12	   1.88E-­‐02	   4.17E-­‐02	  




Appendix 12. Transcription factors targeting 
genes with both hypermethylated and 
hypomethylated promoters. 
Motif	  Shared	   Transcription	  Factor	  
NKNTTGCNYAAYNN	  	   	  CEBPB:	  CCAAT/enhancer	  binding	  protein	  (C/EBP),	  beta	  
AGCAHAC	  	   	  DBP:	  D	  site	  of	  albumin	  promoter	  (albumin	  D-­‐box)	  binding	  
protein	  
TGACCTY	  	   	  ESRRA:	  estrogen-­‐related	  receptor	  alpha	  
RYTTCCTG	  	   	  ETS2:	  v-­‐ets	  erythroblastosis	  virus	  E26	  oncogene	  homolog	  2	  
(avian)	  
TGTTTGY	  	   	  FOXA1:	  forkhead	  box	  A1	  
NNNNNGTAAATAAACA	  	   	  FOXC1:	  forkhead	  box	  C1	  
RTAAACA	  	   	  FOXF2:	  forkhead	  box	  F2	  
NNANNGTAAACAANNN	  	   	  FOXF2:	  forkhead	  box	  F2	  
NNCWGATARNNNN	  	   	  GATA1:	  GATA	  binding	  protein	  1	  (globin	  transcription	  factor	  1)	  
NGATAAGNMNN	  	   	  GATA1:	  GATA	  binding	  protein	  1	  (globin	  transcription	  factor	  1)	  
NCWGATAACA	  	   	  GATA1:	  GATA	  binding	  protein	  1	  (globin	  transcription	  factor	  1)	  
NNGATARNG	  	   	  GATA3:	  GATA	  binding	  protein	  3	  
TGATTTRY	  	   	  GFI1:	  growth	  factor	  independent	  1	  
NNNNNNNAAATCACWGYNNNN
NNN	  	  
	  GFI1:	  growth	  factor	  independent	  1	  
TTCACTT	  	   	  IRF1:	  interferon	  regulatory	  factor	  1	  
TGANTCA	  	   	  JUN:	  jun	  oncogene	  
CTTTGT	  	   	  LEF1:	  lymphoid	  enhancer-­‐binding	  factor	  1	  
CTTTGA	  	   	  LEF1:	  lymphoid	  enhancer-­‐binding	  factor	  1	  
AATTAATTAA	  	   	  LHX3:	  LIM	  homeobox	  3	  
GGGAGGRR	  	   	  MAZ:	  MYC-­‐associated	  zinc	  finger	  protein	  (purine-­‐binding	  
transcription	  factor)	  
YTATTTTNR	  	   	  MEF2A:	  MADS	  box	  transcription	  enhancer	  factor	  2,	  
polypeptide	  A	  (myocyte	  enhancer	  factor	  2A)	  
RNKCTATTTWTAGMWN	  	   	  MEF2A:	  MADS	  box	  transcription	  enhancer	  factor	  2,	  
polypeptide	  A	  (myocyte	  enhancer	  factor	  2A)	  
TGACAGNY	  	   	  MEIS1:	  Meis1,	  myeloid	  ecotropic	  viral	  integration	  site	  1	  
homolog	  (mouse)	  
TTGTTT	  	   	  MLLT7:	  myeloid/lymphoid	  or	  mixed-­‐lineage	  leukemia	  
(trithorax	  homolog,	  Drosophila);	  translocated	  to,	  7	  
GCANCTGNY	  	   	  MYOD1:	  myogenic	  differentiation	  1	  
TGGAAA	  	   	  NFAT<br>	  NFATC	  
GGGTGGRR	  	   	  PAX4:	  paired	  box	  gene	  4	  
GGATTA	  	   	  PITX2:	  paired-­‐like	  homeodomain	  transcription	  factor	  2	  
NNNNWTATGCAAATNTNNN	  	   	  POU2F1:	  POU	  domain,	  class	  2,	  transcription	  factor	  1	  




NNCATNSRWAATNMRN	  	   	  POU3F2:	  POU	  domain,	  class	  3,	  transcription	  factor	  2	  
GCATAAWTTAT	  	   	  POU6F1:	  POU	  domain,	  class	  6,	  transcription	  factor	  1	  
CAGCTG	  	   	  REPIN1:	  replication	  initiator	  1	  
GGGCGGR	  	   	  SP1:	  Sp1	  transcription	  factor	  
TATAAA	  	   	  TAF<br>	  TATA	  
CAGGTG	  	   	  TCF3:	  transcription	  factor	  3	  (E2A	  immunoglobulin	  enhancer	  
binding	  factors	  E12/E47)	  
CAGGTA	  	   	  TCF8:	  transcription	  factor	  8	  (represses	  interleukin	  2	  
expression)	  
TAATTA	  	   	  VSX1:	  visual	  system	  homeobox	  1	  homolog,	  CHX10-­‐like	  
(zebrafish)	  
YTATTTTNR	  	   MEF2A:	  	  MADS	  box	  transcription	  enhancer	  factor	  2,	  
polypeptide	  A	  (myocyte	  enhancer	  factor	  2A)	  
YCATTAA	   Unknown	  
YATGNWAAT	   Unknown	  
WTTGKCTG	   Unknown	  
WTGAAAT	   Unknown	  
WGTTNNNNNAAA	   Unknown	  
TTANTCA	   Unknown	  
TGACATY	   Unknown	  




GCTNWTTGK	   Unknown	  
GATAAGR	   Unknown	  
CTTTAAR	   Unknown	  
CTGCAGY	   Unknown	  




Appendix 13. Transcription factors targeting 
genes with hypomethylated promoters. 
Motif-­‐Hyper	   Transcription	  Factor	  
	  TGTGGTTW	  	   	  CBFA2T2:	  core-­‐binding	  factor,	  runt	  domain,	  alpha	  subunit	  2;	  
translocated	  to,	  2<br>	  CBFA2T3:	  core-­‐binding	  factor,	  runt	  domain,	  
alpha	  subunit	  2;	  translocated	  to,	  3	  
	  NNATTRCNNAANNN	  	   	  CEBPA:	  CCAAT/enhancer	  binding	  protein	  (C/EBP),	  alpha	  
	  NNTKTGGWNANNN	  	   	  CEBPA:	  CCAAT/enhancer	  binding	  protein	  (C/EBP),	  alpha	  
	  RNRTKDNGMAAKNN	  	   	  CEBPB:	  CCAAT/enhancer	  binding	  protein	  (C/EBP),	  beta	  
	  CTBATTTCARAAW	  	   	  CEBPG:	  CCAAT/enhancer	  binding	  protein	  (C/EBP),	  gamma	  
	  YNNNTAATCYCMN	  	   	  CRX:	  cone-­‐rod	  homeobox	  
	  NATYGATSSS	  	   	  CUTL1:	  cut-­‐like	  1,	  CCAAT	  displacement	  protein	  (Drosophila)	  
	  CTWAWGTAAACANWGN	  	   	  FOXD1:	  forkhead	  box	  D1	  
	  NNNTGTTTATNTR	  	   	  FOXJ1:	  forkhead	  box	  J1	  
	  
NNNWAAAYAAAYANNNNN	  	  
	  FOXJ2:	  forkhead	  box	  J2	  
	  AYMATAATATTTKN	  	   	  FOXJ2:	  forkhead	  box	  J2	  
	  ARATKGAST	  	   	  FOXM1:	  forkhead	  box	  M1	  
	  NRWAAACAAN	  	   	  FOXO1A:	  forkhead	  box	  O1A	  (rhabdomyosarcoma)	  
	  NATTGTTTATWT	  	   	  FOXQ1:	  forkhead	  box	  Q1	  
	  MGGAAGTG	  	   	  GABPA:	  GA	  binding	  protein	  transcription	  factor,	  alpha	  subunit	  
60kDa<br>	  GABPB2:	  GA	  binding	  protein	  transcription	  factor,	  beta	  
subunit	  2	  
	  NNNNNGATANKGNN	  	   	  GATA1:	  GATA	  binding	  protein	  1	  (globin	  transcription	  factor	  1)	  
	  CNNRCCCGCATD	  	   	  GCM1:	  glial	  cells	  missing	  homolog	  1	  (Drosophila)	  
	  AWAATTRG	  	   	  HOXA4:	  homeobox	  A4	  
	  NNNTGAGTCAKCN	  	   	  JUN:	  jun	  oncogene	  
	  TGANNYRGCA	  	   	  NFE2L1:	  nuclear	  factor	  (erythroid-­‐derived	  2)-­‐like	  1<br>	  MAFG:	  v-­‐
maf	  musculoaponeurotic	  fibrosarcoma	  oncogene	  homolog	  G	  
(avian)	  
	  NTGCTGAGTCAKN	  	   	  NFE2L2:	  nuclear	  factor	  (erythroid-­‐derived	  2)-­‐like	  2	  
	  TTAYRTAA	  	   	  NFIL3:	  nuclear	  factor,	  interleukin	  3	  regulated	  
	  CWTAATTG	  	   	  NKX2-­‐5:	  NK2	  transcription	  factor	  related,	  locus	  5	  (Drosophila)	  
	  NWNAGRACAN	  	   	  NR3C1:	  nuclear	  receptor	  subfamily	  3,	  group	  C,	  member	  1	  
(glucocorticoid	  receptor)	  
	  WNTAATCCCAR	  	   	  PITX2:	  paired-­‐like	  homeodomain	  transcription	  factor	  2	  
	  NNGAATATKCANNNN	  	   	  POU2F1:	  POU	  domain,	  class	  2,	  transcription	  factor	  1	  
	  NNNRTAATNANNN	  	   	  POU2F1:	  POU	  domain,	  class	  2,	  transcription	  factor	  1	  
	  TNATTTGCATW	  	   	  POU2F1:	  POU	  domain,	  class	  2,	  transcription	  factor	  1	  
	  NNNNATGCAAATNAN	  	   	  POU2F1:	  POU	  domain,	  class	  2,	  transcription	  factor	  1	  
	  WNNANYYAATTANCNN	  	   	  PRRX2:	  paired	  related	  homeobox	  2	  
	  RACCACAR	  	   	  RUNX1:	  runt-­‐related	  transcription	  factor	  1	  (acute	  myeloid	  
leukemia	  1;	  aml1	  oncogene)	  
471 
 
	  NNGKNTGTGGTTWNC	  	   	  RUNX1:	  runt-­‐related	  transcription	  factor	  1	  (acute	  myeloid	  
leukemia	  1;	  aml1	  oncogene)	  
	  YGAMCTNNASTRACCYN	  	   	  RXRB:	  retinoid	  X	  receptor,	  beta	  
	  TGTCTGTCT	  	   	  SMAD3:	  SMAD,	  mothers	  against	  DPP	  homolog	  3	  (Drosophila)	  
	  CCAWATAWGGMNMNG	  	   	  SRF:	  serum	  response	  factor	  (c-­‐fos	  serum	  response	  element-­‐
binding	  transcription	  factor)	  
	  NAWTTCYN	  	   	  STAT5A:	  signal	  transducer	  and	  activator	  of	  transcription	  5A	  
	  TTCYNRGAA	  	   	  STAT5B:	  signal	  transducer	  and	  activator	  of	  transcription	  5B	  
	  WRGTTAATNATTAACNNN	  	   	  TCF1:	  transcription	  factor	  1,	  hepatic;	  LF-­‐B1,	  hepatic	  nuclear	  factor	  




	  TCF11<br>	  MAFG:	  v-­‐maf	  musculoaponeurotic	  fibrosarcoma	  
oncogene	  homolog	  G	  (avian)	  
	  NCACCTGYYNCNKN	  	   	  TCF3:	  transcription	  factor	  3	  (E2A	  immunoglobulin	  enhancer	  
binding	  factors	  E12/E47)	  
	  ATGTTWAYATAA	  	   	  TEF:	  thyrotrophic	  embryonic	  factor	  
GATTGGY	   Unknown	  
TTCYRGAA	   Unknown	  
TTTGGGAGR	   Unknown	  
CTNATTTGCATAY	   Unknown	  
TNATTTGCATN	   Unknown	  
TTCCCGKAA	   Unknown	  




Appendix 14. Transcription factors targeting 
genes with hypermethylated promoters. 
Motif-­‐hypo	   Transcription	  Factor	  
	  KDMAYYNTGACCT	  	   	  AR:	  androgen	  receptor	  (dihydrotestosterone	  receptor;	  testicular	  
feminization;	  spinal	  and	  bulbar	  muscular	  atrophy;	  Kennedy	  disease)	  
	  TGAYRTCA	  	   	  ATF3:	  activating	  transcription	  factor	  3	  
	  CVTGACGYMABG	  	   	  ATF4:	  activating	  transcription	  factor	  4	  (tax-­‐responsive	  enhancer	  
element	  B67)	  




	  ESR1:	  estrogen	  receptor	  1	  
	  KATTGTTTRTTTW	  	   	  FOXF2:	  forkhead	  box	  F2	  
	  GNNTTGTTTACNTT	  	   	  FOXO1A:	  forkhead	  box	  O1A	  (rhabdomyosarcoma)	  
	  ANGNDGATAANNGN	  	   	  GATA1:	  GATA	  binding	  protein	  1	  (globin	  transcription	  factor	  1)	  
	  WGATARN	  	   	  GATA1:	  GATA	  binding	  protein	  1	  (globin	  transcription	  factor	  1)	  
	  NNNGATWANN	  	   	  GATA6:	  GATA	  binding	  protein	  6	  
	  SNNNCCNCAGGCN	  	   	  GTF3A:	  general	  transcription	  factor	  IIIA	  
	  NNNNGNRTCTGGMWTT	  	   	  HAND1:	  heart	  and	  neural	  crest	  derivatives	  expressed	  1	  
	  RGAANNTTC	  	   	  HSF1:	  heat	  shock	  transcription	  factor	  1	  
	  AGAANRTTCN	  	   	  HSF1:	  heat	  shock	  transcription	  factor	  1	  
	  CAGTGGG	  	   	  KLF12:	  Kruppel-­‐like	  factor	  12	  
	  TCAAAG	  	   	  LEF1:	  lymphoid	  enhancer-­‐binding	  factor	  1<br>	  TCF1:	  transcription	  
factor	  1,	  hepatic;	  LF-­‐B1,	  hepatic	  nuclear	  factor	  (HNF1),	  albumin	  
proximal	  factor	  
	  NMGATANSG	  	   	  LMO2:	  LIM	  domain	  only	  2	  (rhombotin-­‐like	  1)	  
	  CTAWWWATA	  	   	  MEF2A:	  MADS	  box	  transcription	  enhancer	  factor	  2,	  polypeptide	  A	  
(myocyte	  enhancer	  factor	  2A)	  
	  NNGTTGTTTACNTN	  	   	  MLLT7:	  myeloid/lymphoid	  or	  mixed-­‐lineage	  leukemia	  (trithorax	  
homolog,	  Drosophila);	  translocated	  to,	  7	  
	  TGCCAAR	  	   	  NF1:	  neurofibromin	  1	  (neurofibromatosis,	  von	  Recklinghausen	  




	  NF1:	  neurofibromin	  1	  (neurofibromatosis,	  von	  Recklinghausen	  
disease,	  Watson	  disease)	  
	  NANWGGAAAANN	  	   	  NFAT<br>	  NFATC	  
	  TTAAGTRSTT	  	   	  NKX2-­‐2:	  NK2	  transcription	  factor	  related,	  locus	  2	  (Drosophila)	  
	  RRGGTYANTRNM	  	   	  NR1H4:	  nuclear	  receptor	  subfamily	  1,	  group	  H,	  member	  4	  
	  NAAWAATTANS	  	   	  PAX4:	  paired	  box	  gene	  4	  
	  ANCAATCAW	  	   	  PBX1:	  pre-­‐B-­‐cell	  leukemia	  transcription	  factor	  1	  
	  NNNGGGAGTNNNNS	  	   	  PCAF:	  p300/CBP-­‐associated	  factor	  
	  MKVATTTGCATATT	  	   	  POU2F1:	  POU	  domain,	  class	  2,	  transcription	  factor	  1	  








	  SRF:	  serum	  response	  factor	  (c-­‐fos	  serum	  response	  element-­‐binding	  
transcription	  factor)	  
	  GNCCAWATAWGGMN	  	   	  SRF:	  serum	  response	  factor	  (c-­‐fos	  serum	  response	  element-­‐binding	  
transcription	  factor)	  
	  NNNAACAGATGKTNNN	  	   	  TAL1:	  T-­‐cell	  acute	  lymphocytic	  leukemia	  1<br>	  TCF3:	  transcription	  
factor	  3	  (E2A	  immunoglobulin	  enhancer	  binding	  factors	  E12/E47)	  
	  
DGTTAATKAWTNACCAM	  	  
	  TCF1:	  transcription	  factor	  1,	  hepatic;	  LF-­‐B1,	  hepatic	  nuclear	  factor	  
(HNF1),	  albumin	  proximal	  factor	  
	  RCCWGCTG	  	   	  TCF12:	  transcription	  factor	  12	  (HTF4,	  helix-­‐loop-­‐helix	  transcription	  
factors	  4)	  





	  TFAP4:	  transcription	  factor	  AP-­‐4	  (activating	  enhancer	  binding	  
protein	  4)	  
	  RNCAGCTGC	  	   	  TFAP4:	  transcription	  factor	  AP-­‐4	  (activating	  enhancer	  binding	  
protein	  4)	  
	  WCTCAAGTGT	  	   	  TITF1:	  thyroid	  transcription	  factor	  1	  
	  NNNNCAAGNRNN	  	   	  TITF1:	  thyroid	  transcription	  factor	  1	  
	  NNGTAAKTNG	  	   	  TLX2:	  T-­‐cell	  leukemia	  homeobox	  2	  
	  NNNTAATTAGCNNN	  	   	  VSX1:	  visual	  system	  homeobox	  1	  homolog,	  CHX10-­‐like	  (zebrafish)	  
	  NGGGKGGTC	  	   	  ZIC3:	  Zic	  family	  member	  3	  heterotaxy	  1	  (odd-­‐paired	  homolog,	  
Drosophila)	  
	  NNAACATCTGGA	  	   	  ZNF238:	  zinc	  finger	  protein	  238	  
	  AAANWWTGC	   Unknown	  
	  AAAYRNCTG	   Unknown	  
	  TGGNNNNNNKCCAR	   Unknown	  




Appendix 15. KEGG Pathway analysis of genes 
hypermethylated in cSCC 
Description	   #	  of	  Genes	   p-­‐value	   Adjusted	  p	  
value	  
Pathways	  in	  cancer	   51	   2.85E-­‐17	   5.31E-­‐15	  
Endocytosis	   36	   7.33E-­‐16	   6.82E-­‐14	  
Regulation	  of	  actin	  cytoskeleton	   32	   8.13E-­‐11	   2.52E-­‐09	  
Wnt	  signaling	  pathway	   31	   2.15E-­‐14	   1.34E-­‐12	  
Insulin	  signaling	  pathway	   29	   6.41E-­‐14	   2.98E-­‐12	  
MAPK	  signaling	  pathway	   29	   6.45E-­‐07	   5.00E-­‐06	  
Focal	  adhesion	   27	   2.02E-­‐08	   2.69E-­‐07	  
Jak-­‐STAT	  signaling	  pathway	   23	   3.42E-­‐08	   4.25E-­‐07	  
Chemokine	  signaling	  pathway	   21	   1.65E-­‐05	   8.52E-­‐05	  
Glycerophospholipid	  metabolism	   20	   8.89E-­‐12	   3.31E-­‐10	  
Axon	  guidance	   20	   1.26E-­‐07	   1.12E-­‐06	  
Fc	  gamma	  R-­‐mediated	  phagocytosis	   19	   5.12E-­‐09	   8.73E-­‐08	  
GnRH	  signaling	  pathway	   19	   1.03E-­‐08	   1.47E-­‐07	  
Vascular	  smooth	  muscle	  contraction	   19	   9.17E-­‐08	   8.53E-­‐07	  
Neurotrophin	  signaling	  pathway	   19	   4.02E-­‐07	   3.25E-­‐06	  
Tight	  junction	   19	   1.06E-­‐06	   7.27E-­‐06	  
Calcium	  signaling	  pathway	   19	   6.58E-­‐05	   2.99E-­‐04	  
Cytokine-­‐cytokine	  receptor	  interaction	   19	   8.25E-­‐03	   2.10E-­‐02	  
ErbB	  signaling	  pathway	   18	   5.16E-­‐09	   8.73E-­‐08	  
Chronic	  myeloid	  leukemia	   17	   2.01E-­‐09	   4.67E-­‐08	  
Phosphatidylinositol	  signaling	  system	   17	   3.89E-­‐09	   8.04E-­‐08	  
Prostate	  cancer	   17	   4.80E-­‐08	   5.58E-­‐07	  
PPAR	  signaling	  pathway	   16	   6.37E-­‐09	   9.88E-­‐08	  
mTOR	  signaling	  pathway	   15	   7.02E-­‐10	   1.87E-­‐08	  
Pancreatic	  cancer	   15	   5.88E-­‐08	   6.07E-­‐07	  
Cell	  cycle	   15	   1.33E-­‐04	   5.26E-­‐04	  
Ubiquitin	  mediated	  proteolysis	   15	   3.05E-­‐04	   9.78E-­‐04	  
Acute	  myeloid	  leukemia	   14	   5.15E-­‐08	   5.63E-­‐07	  
Colorectal	  cancer	   14	   8.03E-­‐08	   7.86E-­‐07	  
Adipocytokine	  signaling	  pathway	   14	   2.25E-­‐07	   1.91E-­‐06	  
Small	  cell	  lung	  cancer	   14	   3.96E-­‐06	   2.46E-­‐05	  
Progesterone-­‐mediated	  oocyte	  maturation	   14	   5.27E-­‐06	   3.06E-­‐05	  
TGF-­‐beta	  signaling	  pathway	   14	   5.27E-­‐06	   3.06E-­‐05	  
Oocyte	  meiosis	   14	   1.33E-­‐04	   5.26E-­‐04	  
Glioma	   13	   1.03E-­‐06	   7.27E-­‐06	  
Fc	  epsilon	  RI	  signaling	  pathway	   13	   1.00E-­‐05	   5.55E-­‐05	  
Apoptosis	   13	   3.31E-­‐05	   1.60E-­‐04	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Melanogenesis	   13	   1.57E-­‐04	   5.83E-­‐04	  
Toll-­‐like	  receptor	  signaling	  pathway	   13	   1.57E-­‐04	   5.83E-­‐04	  
Leukocyte	  transendothelial	  migration	   13	   6.60E-­‐04	   2.01E-­‐03	  
Non-­‐small	  cell	  lung	  cancer	   12	   8.12E-­‐07	   6.04E-­‐06	  
Epithelial	  cell	  signaling	  in	  Helicobacter	  pylori	  
infection	  
12	   1.05E-­‐05	   5.56E-­‐05	  
Adherens	  junction	   12	   2.93E-­‐05	   1.47E-­‐04	  
VEGF	  signaling	  pathway	   12	   3.35E-­‐05	   1.60E-­‐04	  
Dilated	  cardiomyopathy	   12	   2.22E-­‐04	   7.66E-­‐04	  
T	  cell	  receptor	  signaling	  pathway	   12	   9.72E-­‐04	   2.87E-­‐03	  
Lysosome	   12	   2.58E-­‐03	   7.28E-­‐03	  
Purine	  metabolism	   12	   2.10E-­‐02	   4.70E-­‐02	  
Glycerolipid	  metabolism	   11	   2.09E-­‐06	   1.39E-­‐05	  
Endometrial	  cancer	   11	   3.90E-­‐06	   2.46E-­‐05	  
Melanoma	   11	   8.45E-­‐05	   3.60E-­‐04	  
Gap	  junction	   11	   7.04E-­‐04	   2.11E-­‐03	  
Type	  II	  diabetes	  mellitus	   10	   1.01E-­‐05	   5.55E-­‐05	  
Renal	  cell	  carcinoma	   10	   3.47E-­‐04	   1.10E-­‐03	  
Vasopressin-­‐regulated	  water	  reabsorption	   9	   3.93E-­‐05	   1.83E-­‐04	  
Notch	  signaling	  pathway	   9	   6.80E-­‐05	   3.01E-­‐04	  
Inositol	  phosphate	  metabolism	   9	   2.08E-­‐04	   7.31E-­‐04	  
Basal	  cell	  carcinoma	   9	   2.40E-­‐04	   8.13E-­‐04	  
Hedgehog	  signaling	  pathway	   9	   2.77E-­‐04	   9.03E-­‐04	  
Hypertrophic	  cardiomyopathy	  (HCM)	   9	   5.56E-­‐03	   1.50E-­‐02	  
Hematopoietic	  cell	  lineage	   9	   6.97E-­‐03	   1.80E-­‐02	  
Bladder	  cancer	   8	   1.79E-­‐04	   6.39E-­‐04	  
Fatty	  acid	  metabolism	   8	   1.79E-­‐04	   6.39E-­‐04	  
Lysine	  degradation	   8	   2.51E-­‐04	   8.32E-­‐04	  
ECM-­‐receptor	  interaction	   8	   1.59E-­‐02	   3.90E-­‐02	  
Thyroid	  cancer	   7	   9.39E-­‐05	   3.88E-­‐04	  
Vibrio	  cholerae	  infection	   7	   5.64E-­‐03	   1.50E-­‐02	  
NOD-­‐like	  receptor	  signaling	  pathway	   7	   9.81E-­‐03	   2.43E-­‐02	  
p53	  signaling	  pathway	   7	   1.71E-­‐02	   4.13E-­‐02	  
Long-­‐term	  depression	   7	   1.84E-­‐02	   4.25E-­‐02	  
Long-­‐term	  potentiation	   7	   1.84E-­‐02	   4.25E-­‐02	  
Biosynthesis	  of	  unsaturated	  fatty	  acids	   6	   1.44E-­‐04	   5.60E-­‐04	  
Glycosaminoglycan	  biosynthesis	  -­‐	  heparan	  sulfate	   6	   3.91E-­‐04	   1.21E-­‐03	  
Ether	  lipid	  metabolism	   6	   1.49E-­‐03	   4.27E-­‐03	  
Aldosterone-­‐regulated	  sodium	  reabsorption	   6	   5.26E-­‐03	   1.44E-­‐02	  
Amino	  sugar	  and	  nucleotide	  sugar	  metabolism	   6	   6.63E-­‐03	   1.74E-­‐02	  
Circadian	  rhythm	  -­‐	  mammal	   5	   8.51E-­‐05	   3.60E-­‐04	  
Glycosaminoglycan	  biosynthesis	  -­‐	  chondroitin	  
sulfate	  
5	   1.30E-­‐03	   3.78E-­‐03	  
Fructose	  and	  mannose	  metabolism	   5	   9.38E-­‐03	   2.36E-­‐02	  
Pyruvate	  metabolism	   5	   1.84E-­‐02	   4.25E-­‐02	  
Aminoacyl-­‐tRNA	  biosynthesis	   5	   2.03E-­‐02	   4.60E-­‐02	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Steroid	  biosynthesis	   4	   3.53E-­‐03	   9.81E-­‐03	  
Glycosaminoglycan	  biosynthesis	  -­‐	  keratan	  sulfate	   3	   1.85E-­‐02	   4.25E-­‐02	  




Appendix 16. Dysregulated KEGG pathways in 
genes hypomethylated in cSCC. 
Description	   #	  of	  Genes	  	   p-­‐value	   Adjusted	  
p	  value	  
Neuroactive	  ligand-­‐receptor	  interaction	   26	   2.36E-­‐12	   4.39E-­‐10	  
Long-­‐term	  depression	   12	   2.62E-­‐09	   2.37E-­‐07	  
Pathways	  in	  cancer	   24	   3.82E-­‐09	   2.37E-­‐07	  
Cytokine-­‐cytokine	  receptor	  interaction	   20	   5.10E-­‐08	   2.37E-­‐06	  
Type	  II	  diabetes	  mellitus	   9	   9.52E-­‐08	   3.54E-­‐06	  
Hypertrophic	  cardiomyopathy	  (HCM)	   11	   2.43E-­‐07	   7.54E-­‐06	  
Focal	  adhesion	   16	   4.83E-­‐07	   1.28E-­‐05	  
Dilated	  cardiomyopathy	   10	   4.32E-­‐06	   9.63E-­‐05	  
MAPK	  signaling	  pathway	   17	   4.66E-­‐06	   9.63E-­‐05	  
Regulation	  of	  actin	  cytoskeleton	   15	   5.92E-­‐06	   1.08E-­‐04	  
Arrhythmogenic	  right	  ventricular	  cardiomyopathy	  
(ARVC)	  
9	   6.39E-­‐06	   1.08E-­‐04	  
Melanogenesis	   10	   1.09E-­‐05	   1.69E-­‐04	  
Calcium	  signaling	  pathway	   13	   1.43E-­‐05	   1.94E-­‐04	  
ECM-­‐receptor	  interaction	   9	   1.46E-­‐05	   1.94E-­‐04	  
Endocytosis	   13	   1.92E-­‐05	   2.38E-­‐04	  
Gap	  junction	   9	   2.56E-­‐05	   2.97E-­‐04	  
mTOR	  signaling	  pathway	   7	   2.95E-­‐05	   3.23E-­‐04	  
Hedgehog	  signaling	  pathway	   7	   4.82E-­‐05	   4.98E-­‐04	  
GnRH	  signaling	  pathway	   9	   6.40E-­‐05	   6.26E-­‐04	  
Cell	  adhesion	  molecules	  (CAMs)	   10	   1.15E-­‐04	   1.01E-­‐03	  
Tight	  junction	   10	   1.15E-­‐04	   1.01E-­‐03	  
Chemokine	  signaling	  pathway	   12	   1.23E-­‐04	   1.04E-­‐03	  
Insulin	  signaling	  pathway	   10	   1.38E-­‐04	   1.11E-­‐03	  
Adipocytokine	  signaling	  pathway	   7	   1.54E-­‐04	   1.19E-­‐03	  
Vascular	  smooth	  muscle	  contraction	   9	   1.74E-­‐04	   1.30E-­‐03	  
Fructose	  and	  mannose	  metabolism	   5	   2.73E-­‐04	   1.95E-­‐03	  
Neurotrophin	  signaling	  pathway	   9	   3.45E-­‐04	   2.38E-­‐03	  
Axon	  guidance	   9	   4.11E-­‐04	   2.73E-­‐03	  
Fc	  epsilon	  RI	  signaling	  pathway	   7	   4.29E-­‐04	   2.75E-­‐03	  
Glycolysis	  /	  Gluconeogenesis	   6	   6.87E-­‐04	   4.26E-­‐03	  
ErbB	  signaling	  pathway	   7	   7.68E-­‐04	   4.61E-­‐03	  
Glycosphingolipid	  biosynthesis	  -­‐	  lacto	  and	  neolacto	  
series	  
4	   9.59E-­‐04	   5.57E-­‐03	  
Wnt	  signaling	  pathway	   9	   1.27E-­‐03	   7.14E-­‐03	  
Long-­‐term	  potentiation	   6	   1.31E-­‐03	   7.14E-­‐03	  
Melanoma	   6	   1.41E-­‐03	   7.47E-­‐03	  
Histidine	  metabolism	   4	   1.46E-­‐03	   7.55E-­‐03	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Jak-­‐STAT	  signaling	  pathway	   9	   1.52E-­‐03	   7.65E-­‐03	  
Glyoxylate	  and	  dicarboxylate	  metabolism	   3	   2.40E-­‐03	   1.17E-­‐02	  
Basal	  cell	  carcinoma	   5	   2.54E-­‐03	   1.21E-­‐02	  
Progesterone-­‐mediated	  oocyte	  maturation	   6	   3.72E-­‐03	   1.69E-­‐02	  
TGF-­‐beta	  signaling	  pathway	   6	   3.72E-­‐03	   1.69E-­‐02	  
NOD-­‐like	  receptor	  signaling	  pathway	   5	   4.28E-­‐03	   1.89E-­‐02	  
Aldosterone-­‐regulated	  sodium	  reabsorption	   4	   5.78E-­‐03	   2.50E-­‐02	  
Fc	  gamma	  R-­‐mediated	  phagocytosis	   6	   6.68E-­‐03	   2.82E-­‐02	  
Pancreatic	  cancer	   5	   7.16E-­‐03	   2.89E-­‐02	  
Renal	  cell	  carcinoma	   5	   7.16E-­‐03	   2.89E-­‐02	  
Toll-­‐like	  receptor	  signaling	  pathway	   6	   8.47E-­‐03	   3.35E-­‐02	  
Ubiquitin	  mediated	  proteolysis	   7	   1.01E-­‐02	   3.92E-­‐02	  
Endometrial	  cancer	   4	   1.22E-­‐02	   4.60E-­‐02	  
Cardiac	  muscle	  contraction	   5	   1.24E-­‐02	   4.60E-­‐02	  
Thyroid	  cancer	   3	   1.33E-­‐02	   4.84E-­‐02	  




Appendix 17. Differentially methylated probes in 
cSCC compared to AK. 
cgID	   dm	   Gene	  
cg01025800	   -­‐0.200396164	   PTBP1	  
cg19764731	   -­‐0.195589479	   0	  
cg14209920	   -­‐0.18358751	   NFIX	  
cg18560551	   -­‐0.182056302	   EHF	  
cg07636225	   -­‐0.182024189	   RTN3	  
cg25138553	   -­‐0.178570093	   HSPG2	  
cg16853770	   -­‐0.178547855	   VPS37B	  
cg16324314	   -­‐0.177755179	   0	  
cg10126234	   -­‐0.176811734	   ZFYVE21	  
cg16209517	   -­‐0.175021566	   KIAA1737	  
cg10402698	   -­‐0.172310962	   SMAD6	  
cg00302587	   -­‐0.171827787	   NCOA4	  
cg20984972	   -­‐0.171667827	   NFIC	  
cg12914733	   -­‐0.170301963	   AP2A2	  
cg08545463	   -­‐0.167905792	   EXPH5	  
cg04646674	   -­‐0.167871478	   NFIX	  
cg25580656	   -­‐0.165083285	   ZFYVE21	  
cg24153924	   -­‐0.162354241	   0	  
cg10333594	   -­‐0.160693784	   CRAMP1L	  
cg08983011	   -­‐0.157025628	   BCL9L	  
cg24671153	   -­‐0.156263785	   AGPAT1	  
cg15926004	   -­‐0.15517117	   C1orf133;	  SERTAD4	  
cg05241828	   -­‐0.155010707	   GPT	  
cg08761535	   -­‐0.152455719	   ZNRF1	  
cg00510149	   -­‐0.151391703	   MRVI1	  
cg06026545	   -­‐0.150234961	   ACACA	  
cg07962882	   -­‐0.14816068	   SBNO2	  
cg09957864	   -­‐0.147409351	   GPT	  
cg21467371	   -­‐0.146296511	   ARL16	  
cg04095826	   -­‐0.145737354	   PGBD5	  
cg16130802	   -­‐0.145673851	   BCL9L	  
cg01500055	   -­‐0.14358196	   0	  
cg24182798	   -­‐0.142043711	   0	  
cg26995083	   -­‐0.139705263	   TJAP1	  
cg12280150	   -­‐0.138200533	   HEPHL1	  
cg25312122	   -­‐0.138024814	   PEA15	  
cg07259418	   -­‐0.137423522	   PRICKLE2	  
cg12150931	   -­‐0.137081777	   ZNF385A	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cg18378955	   -­‐0.135948368	   0	  
cg06182584	   -­‐0.133887351	   C6orf136	  
cg17611512	   -­‐0.132961384	   NCRNA00175;	  COL18A1	  
cg04984818	   -­‐0.132273499	   ZFYVE21	  
cg25724837	   -­‐0.13167157	   0	  
cg08648499	   -­‐0.13140215	   PRSS8	  
cg02832224	   -­‐0.128587843	   SSBP3	  
cg26788852	   -­‐0.12835503	   MAPKBP1	  
cg25600446	   -­‐0.127606936	   GPT	  
cg02681400	   -­‐0.127387518	   BRD4	  
cg25352281	   -­‐0.126522736	   PPP2R2D	  
cg07658280	   -­‐0.124536636	   GPT	  
cg01771850	   -­‐0.123739187	   TBCD	  
cg11634930	   -­‐0.123713455	   MKNK2	  
cg17858643	   -­‐0.12321625	   LIMD1	  
cg15801751	   -­‐0.122893301	   MARK2	  
cg14010829	   -­‐0.118459422	   ASS1	  
cg21772826	   -­‐0.116155018	   TPRG1	  
cg03474702	   -­‐0.116115425	   IMPA2	  
cg14711433	   -­‐0.115242424	   EXTL3	  
cg00458395	   -­‐0.113438917	   0	  
cg26543333	   -­‐0.113179716	   NFIC	  
cg01906801	   -­‐0.112316975	   MED24	  
cg13154413	   -­‐0.111544619	   ZFYVE21	  
cg05578673	   -­‐0.111421553	   LRRC8D	  
cg04842880	   -­‐0.109849412	   CASZ1	  
cg13243168	   -­‐0.109262749	   SMARCD2	  
cg22940022	   -­‐0.10919705	   MCM7	  
cg21241411	   -­‐0.108903167	   RGL2	  
cg08727352	   -­‐0.10504797	   RGL2	  
cg25050723	   -­‐0.104796521	   HCCA2	  
cg04085707	   -­‐0.103673315	   MAPK8IP3	  
cg19316405	   -­‐0.103147523	   PDDC1	  
cg23875758	   -­‐0.10215405	   SREBF1	  
cg21098787	   -­‐0.102141888	   BRD4	  
cg13169667	   -­‐0.102093105	   ZC3H3	  
cg00545886	   -­‐0.10202929	   BLCAP	  
cg03691756	   -­‐0.101259196	   0	  
cg19697795	   -­‐0.101115726	   0	  
cg04902929	   -­‐0.100627197	   C1orf203	  
cg25609878	   -­‐0.099414231	   0	  
cg15231749	   -­‐0.097980564	   RGL2	  
cg11835619	   -­‐0.096356557	   ERBB3	  
cg27575890	   -­‐0.09367424	   EIF3D	  
cg17483792	   -­‐0.093262717	   AHCYL2	  
cg25384949	   -­‐0.092098318	   NOTCH4	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cg05131707	   -­‐0.089124556	   PCBP2	  
cg00033551	   -­‐0.084966555	   MGRN1	  
cg06651452	   -­‐0.08304793	   ZBTB7A	  
cg01120851	   -­‐0.082119043	   KLHL21	  
cg00280345	   -­‐0.078973312	   GPT	  
cg07918736	   -­‐0.078817878	   ILF3	  
cg04594691	   -­‐0.077344043	   0	  
cg01678580	   -­‐0.076066838	   MGRN1	  
cg07589968	   -­‐0.0750991	   KCNS1	  
cg05709598	   -­‐0.073360333	   KIAA0182	  
cg14297023	   -­‐0.070897999	   EIF3D	  
cg13219127	   -­‐0.06731669	   TOLLIP	  
cg02924834	   -­‐0.065951124	   KLHDC4	  
cg01320211	   -­‐0.065014444	   SEMA6D	  
cg14152306	   -­‐0.064739891	   BAG5	  
cg26881362	   -­‐0.061450279	   ACADVL	  
cg00287016	   -­‐0.058817462	   MCM7	  
cg01721450	   -­‐0.055341182	   SEC61A1	  
cg01366338	   -­‐0.055036686	   ALDH4A1	  
cg12218406	   -­‐0.053175661	   ARRDC2	  
cg23092788	   -­‐0.049532195	   TMEM175	  
cg20166919	   -­‐0.049411165	   FAM53B	  
cg02012771	   -­‐0.037340442	   NEIL1	  
cg25594549	   -­‐0.030273759	   MED26	  
cg12296218	   0.003293619	   DUT	  
cg21110939	   0.005877681	   SV2B	  
cg13467135	   0.015214722	   KIAA1598	  
cg22933133	   0.033968768	   0	  
cg26389255	   0.034687528	   0	  
cg01192112	   0.041782255	   PHACTR2	  
cg09123524	   0.045813779	   TNXB	  
cg05344955	   0.046286934	   0	  
cg16347868	   0.058811498	   PBX1	  
cg25194822	   0.068693261	   KCNN2	  
cg25181684	   0.078390378	   SH3PXD2A	  
cg05226607	   0.081722682	   SPINK5L2	  
cg21297772	   0.100578072	   SLC5A9	  
cg02854972	   0.102930082	   0	  
cg02388849	   0.105753771	   0	  
cg03110996	   0.107758314	   0	  
cg16278514	   0.108840244	   0	  
cg25446789	   0.110247184	   DTNB	  
cg24189745	   0.11098271	   0	  
cg18151345	   0.111259861	   SLC15A3	  
cg22013055	   0.115167741	   LOC100134259	  
cg11749902	   0.125677021	   0	  
482 
 
cg07586285	   0.126796102	   0	  
cg04043538	   0.127468562	   0	  
cg00251358	   0.129096011	   0	  
cg03033182	   0.142986067	   SCOC	  
cg23817637	   0.147640696	   CLRN3	  
cg23403895	   0.148294837	   PALLD	  
cg17841267	   0.154152093	   0	  
cg04233620	   0.154557754	   ADARB1	  
cg24943066	   0.157966566	   0	  
cg20294319	   0.168065699	   LRCH1	  
cg20694147	   0.169645139	   MTHFD2	  
cg03652336	   0.183082351	   MAML3	  
cg10166664	   0.188049049	   0	  
cg07869023	   0.189498052	   PCSK2	  
cg16346032	   0.198072208	   0	  
cg10575547	   0.203364511	   TRERF1	  
cg18826637	   0.22034533	   0	  
cg10344477	   0.254253167	   B3GNTL1	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Appendix 18. Clinical characteristics of study 
participants that consented to have their lesions 
examined by SNP arrays (Chapter 3). 
Patient	   Age	  at	  
recruitment	  	  





1	   38	   M	   Immunosuppressed	   II	   medium	   	   5	  SCC	  
2	   57	   F	   Immunosuppressed	   II	   medium	   1	  BCC	   6	  SCC	  
3	   58	   M	   Immunosuppressed	   I	   medium	   6	  BCC	   	  
4	   64	   M	   Immunosuppressed	   II	   medium	   5	  BCC	   29	  SCC	  
5	   71	   F	   Immunosuppressed	   II	   medium	   	   1	  SCC	  
6	   76	   F	   Immunosuppressed	   I	   medium	   1	  BCC	   2	  SCC	  
7	   57	   M	   Immunosuppressed	   II	   medium	   3	  BCC	   4	  SCC	  
8	   58	   M	   Immunosuppressed	   I	   high	   14	  
BCC	  
3	  SCC	  
9	   70	   M	   Immunosuppressed	   I	   medium	   23	  
BCC	  
29	  SCC	  
10	   70	   M	   Immunosuppressed	   I	   medium	   	   1	  SCC	  
11	   51	   M	   Immunosuppressed	   I	   medium	   	   2	  SCC	  
12	   73	   M	   Immunosuppressed	   II	   high	   2	  BCC	   6	  SCC	  
13	   66	   M	   Immunosuppressed	   I	   high	   	   1	  SCC	  
14	   69	   M	   Immunosuppressed	   I	   high	   	   4	  SCC	  
15	   79	   M	   Immunosuppressed	   I	   high	   1	  BCC	   2	  SCC	  
16	   52	   F	   Immunosuppressed	   II	   high	   1	  BCC	   6	  SCC	  
17	   54	   F	   Immunosuppressed	   I	   medium	   	   4	  SCC	  
18	   83	   M	   Immunosuppressed	   I	   high	   8	  BCC	   9	  SCC	  
19	   59	   M	   Immunosuppressed	   II	   high	   	   6	  SCC	  
20	   64	   M	   Immunosuppressed	   I	   medium	   1	  BCC	   2	  SCC	  
21	   61	   F	   Immunosuppressed	   II	   medium	   2	  BCC	   5	  SCC	  
22	   68	   F	   Immunosuppressed	   I	   medium	   1	  BCC	   	  
23	   71	   F	   Immunosuppressed	   II	   medium	   4	  BCC	   2	  SCC	  
24	   80	   M	   Immunosuppressed	   II	   high	   6	  BCC	   1	  SCC	  
25	   80	   M	   Immunosuppressed	   I	   medium	   5	  BCC	   2	  SCC	  
26	   45	   M	   Immunosuppressed	   II	   medium	   	   6	  SCC	  
27	   68	   M	   Immunosuppressed	   I	   high	   1	  BCC	   9	  SCC	  
28	   47	   M	   Immunosuppressed	   I	   medium	   	   3	  SCC	  
29	   65	   M	   Immunosuppressed	   II	   high	   	   8	  SCC	  
30	   58	   M	   Immunosuppressed	   II	   medium	   5	  BCC	   11	  SCC	  
31	   57	   M	   Immunosuppressed	   II	   medium	   8	  BCC	   2	  SCC	  
32	   50	   M	   Immunocompetent	   I	   Not	  known	   2	  BCC	   2	  SCC	  
33	   85	   M	   Immunocompetent	   I	   Not	  known	   3	  BCC	   	  
34	   84	   M	   Immunocompetent	   I	   Not	  known	   	   1	  SCC	  
35	   75	   M	   Immunocompetent	   I	   Not	  known	   5	  BCC	   4	  SCC	  
36	   74	   M	   Immunocompetent	   I	   Not	  known	   4	  BCC	   2	  SCC	  
37	   80	   M	   Immunocompetent	   I	   Not	  known	   4	  BCC	   2	  SCC	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38	   77	   M	   Immunocompetent	   II	   Not	  known	   2	  BCC	   	  
39	   83	   M	   Immunocompetent	   II	   Not	  known	   	   1	  SCC	  
40	   82	   M	   Immunocompetent	   II	   Not	  known	   	   1	  SCC	  
41	   77	   M	   Immunocompetent	   I	   Not	  known	   1	  BCC	   	  
42	   89	   M	   Immunocompetent	   I	   Not	  known	   3	  BCC	   1	  SCC	  
43	   71	   M	   Immunocompetent	   I	   Not	  known	   	   4	  SCC	  
44	   71	   M	   Immunocompetent	   I	   Not	  known	   4	  BCC	   	  
45	   82	   M	   Immunocompetent	   I	   Not	  known	   	   1	  SCC	  
46	   85	   M	   Immunocompetent	   I	   Not	  known	   	   2	  SCC	  
47	   85	   M	   Immunocompetent	   I	   Not	  known	   2	  BCC	   1	  SCC	  
48	   71	   M	   Immunocompetent	   II	   Not	  known	   	   1	  SCC	  
49	   80	   M	   Immunocompetent	   I	   Not	  known	   1	  BCC	   1	  SCC	  
50	   79	   M	   Immunocompetent	   I	   Not	  known	   none	  
51	   85	   F	   Immunocompetent	   I	   Not	  known	   1	  BCC	   2	  SCC	  
52	   52	   M	   Immunocompetent	   I	   Not	  known	   	   2	  SCC	  
53	   70	   F	   Immunocompetent	   II	   Not	  known	   	   2	  SCC	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Appendix 19. Clinical characteristics of samples 
used for expression microarray validation 
Sample	  	   Gender	   Site	   Age	  at	  biopsy	   Immune	  Status	  
WD1	   F	   forehead	   75	   IC	  
WD2	   F	   calf	   44	   RT	  
WD3	   M	   leg	   58	   IC	  
WD4	   M	   scalp	   49	   RT	  
WD5	  	   M	   Forehead	   53	   RT	  
WD6	   M	   ear	   63	   RT	  
WD7	   M	   lower	  leg	   59	   RT	  
WD8	   M	   calf	   49	   RT	  
WD9	   F	   cheek	   51	   RT	  
	   	   	   	   	  
MD1	   M	   scalp	   64	   IC	  
MD2	   M	   forehead	   66	   IC	  
	  MD3	  	   M	   ear	   65	   RT	  
MD4	   F	   finger	   71	   RT	  
	  MD5	   M	   ear	   76	   RT	  
	  MD6	   F	   dorsal	  
hand	  
64	   RT	  
	  MD7	   M	   neck	   66	   RT	  
MD8	   M	   shoulder	   61	   RT	  
MD9	   M	   forearm	   71	   RT	  
	   	   	   	   	  
	  AK1	   M	   finger	   42	   RT	  
	  AK2	   M	   scalp	   63	   RT	  
AK3	   F	   arm	   56	   RT	  
	  AK4	   M	   chest	   63	   RT	  
AK5	   F	   temple	   74	   IC	  
AK6	   F	   ear	   46	   RT	  
AK7	   M	   dorsal	  
hand	  
51	   RT	  
	  AK8	   M	   arm	   62	   RT	  
AK9	   M	   ear	   78	   IC	  
	   	   	   	   	  
	  SE1	   M	   forearm	   46	   RT	  
SE2	   M	   forearm	   78	   IC	  
SE3	   F	   forearm	   60	   RT	  
SE4	   M	   forearm	   64	   RT	  




	   	   	   	  
NSE1	   M	   inner	  arm	   62	   RT	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NSE2	   M	   inner	  arm	   63	   RT	  
NSE3	   M	   buttock	   57	   RT	  
NSE4	   M	   inner	  arm	   79	   IC	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Appendix 20. Average methylation levels in 
microdissected paired cSCC and peritumoural 
skin based on bisulfite sequencing  
Gene Name Skin CSCC 
ENSG00000173040 EVC2 0.375 0.57381 
ENSG00000119698 PPP4R4 0.80258 0.835 
ENSG00000157036 EXOG 0.421429 0.414914 
ENSG00000102385 DRP2 0.770536 0.568452 
ENSG00000181215 C4orf50 0.641303 0.63149 
ENSG00000087076 HSD17B14 0.274093 0.262222 
ENSG00000163788 SNRK 0.324745 0.0545185 
ENSG00000171224 C10orf35 0.483334 0.33811 
ENSG00000115386 REG1A 0.805769 0.703297 
ENSG00000213215 OR2F1 0.691867 0.589744 
ENSG00000182931 WFDC10B 0.85 0.63125 
ENSG00000163586 FABP1 0.911905 0.817766 
ENSG00000171812 COL8A2 0.733333 0.778439 
ENSG00000123453 SARDH 0.633333 0.866327 
ENSG00000128309 MPST 0.243056 0.5 
ENSG00000123171 CCDC70 0.658605 0.767928 
ENSG00000134030 CTIF 0.60625 0.425238 
ENSG00000171119 NRTN 0.643147 0.706899 
ENSG00000109787 KLF3 0.25 0.25 
ENSG00000176236 C10orf111 0.165233 0.190322 
ENSG00000075142 SRI 0.947829 0.655555 
ENSG00000043093 DCUN1D1 0.923737 0.848672 
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ENSG00000152910 CNTNAP4 0.38795 0.292509 
ENSG00000123374 CDK2 0.223333 0.309524 
ENSG00000136099 PCDH8 0.0887445 0.296627 
ENSG00000147144 CCDC120 0.8 0.797619 
ENSG00000008311 AASS 0.272506 0.21309 
ENSG00000120251 GRIA2 0.836863 0.831121 
ENSG00000136560 TANK 0.687332 0.541883 
ENSG00000053702 NRIP2 0.765625 0.572288 
ENSG00000109654 TRIM2 0.749074 0.549327 
ENSG00000071626 DAZAP1 0.166667 0.0833333 
ENSG00000186298 PPP1CC 0.139267 0.112324 
ENSG00000003400 CASP10 0.0845828 0.467477 
ENSG00000188191 PRKAR1B 0.5411 0.35988 
ENSG00000133466 C1QTNF6 0.4 0.52381 
ENSG00000134516 DOCK2 0.783413 0.704545 
ENSG00000100285 NEFH 0.299273 0.175947 
ENSG00000188015 S100A3 0.553333 0.9 
ENSG00000198920 KIAA0753 0.203175 0.215 
ENSG00000168329 CX3CR1 0.485853 0.682954 
ENSG00000126950 TMEM35 0.451275 0.50492 
ENSG00000100884 CPNE6 0.541667 0.56875 
ENSG00000100053 CRYBB3 0.583333 0.757143 
ENSG00000124827 GCM2 0.599459 0.410016 
ENSG00000107758 PPP3CB 0.2163 0.255952 
ENSG00000050730 TNIP3 0.651235 0.673136 
ENSG00000077782 FGFR1 0.795 0.814286 
ENSG00000157211 CDCP2 0.845 0.620122 
ENSG00000115129 TP53I3 0.614374 0.698901 
ENSG00000169314 C22orf15 0.874224 0.785185 
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ENSG00000157214 STEAP2 0.872222 0.72735 
ENSG00000197928 ZNF677 0.486012 0.32681 
ENSG00000166069 TMCO5A 0.835318 0.785714 
ENSG00000213339 QTRT1 0.232402 0.444796 
ENSG00000066629 EML1 0.508333 0.5 
ENSG00000205426 KRT81 0.913753 0.769006 
ENSG00000177663 IL17RA 0.629609 0.683333 
ENSG00000136895 GARNL3 0.200556 0.316182 
ENSG00000136574 GATA4 0.416399 0.263889 
ENSG00000100565 C14orf166B 0.749675 0.704365 
ENSG00000107742 SPOCK2 0.529142 0.389369 
ENSG00000157005 SST 0.51462 0.350777 
ENSG00000174740 PABPC5 0.319841 0.462434 
ENSG00000160991 ORAI2 0.320833 0.55 
ENSG00000100739 BDKRB1 0.560714 0.627088 
ENSG00000167978 SRRM2 0.740747 0.781944 
ENSG00000167874 TMEM88 0.703965 0.769676 
ENSG00000023191 RNH1 0.836667 0.913195 
ENSG00000145794 MEGF10 0.344758 0.420737 
ENSG00000143032 BARHL2 0.330197 0.343574 
ENSG00000166961 MS4A15 0.702966 0.725564 
ENSG00000137955 RABGGTB 0.282357 0.182374 
ENSG00000181781 ODF3L2 0.460582 0.778616 
ENSG00000173597 SULT1B1 0.930289 0.961539 
ENSG00000188581 KRTAP1-1 0.68254 0.657143 
ENSG00000071054 MAP4K4 0.291667 0.407857 
ENSG00000180509 KCNE1 0.661668 0.597583 
ENSG00000183778 B3GALT5 0.633734 0.643462 
ENSG00000112214 FHL5 0.555671 0.604305 
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ENSG00000128739 SNRPN 0.627629 0.480176 
ENSG00000181374 CCL13 0.933036 0.771429 
ENSG00000134760 DSG1 0.383643 0.348786 
ENSG00000183640 KRTAP8-1 0.750303 0.669898 
ENSG00000137090 DMRT1 0.577579 0.516667 
ENSG00000162407 PPAP2B 0.240874 0.164154 
ENSG00000119973 PRLHR 0.413046 0.2 
ENSG00000128040 SPINK2 0.349213 0.500539 
ENSG00000100031 GGT1 0.659524 0.488095 
ENSG00000184117 NIPSNAP1 0.140278 0.25 
ENSG00000158691 ZSCAN12 0.391272 0.356385 
ENSG00000166927 MS4A7 0.513095 0.383041 
ENSG00000179407 DNAJB8 0.818182 0.59861 
ENSG00000161958 FGF11 0.246354 0.410678 
ENSG00000115042 FAHD2A 0.5 0.631429 
ENSG00000156345 CDK20 0.664262 0.793931 
ENSG00000105671 DDX49 0.0807144 0.457407 
ENSG00000135898 GPR55 0.827614 0.860019 
ENSG00000108688 CCL7 0.486111 0.522222 
ENSG00000110628 SLC22A18 0.721429 0.786436 
ENSG00000172995 ARPP21 0.531279 0.396635 
ENSG00000145107 TM4SF19 0.466244 0.666943 
ENSG00000173757 STAT5B 0.458334 0.225 
ENSG00000118707 TGIF2 0.33254 0.461508 
ENSG00000169026 MFSD7 0.799713 0.554167 
ENSG00000123689 G0S2 0.1 0.221795 
ENSG00000198183 BPIFA1 0.782027 0.801136 
ENSG00000006071 ABCC8 0.240909 0.426667 
ENSG00000172346 CSDC2 0.496032 0.747024 
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ENSG00000179909 ZNF154 0.533812 0.381667 
ENSG00000104537 ANXA13 0.702852 0.756594 
ENSG00000189401 OTUD6A 0.896429 0.815385 
ENSG00000090920 FCGBP 0.740303 0.777778 
ENSG00000102967 DHODH 0.330631 0.58425 
ENSG00000143194 MAEL 0.727231 0.716932 
ENSG00000130340 SNX9 0.535715 0.258179 
ENSG00000152601 MBNL1 0.715737 0.721548 
ENSG00000139132 FGD4 0.136607 0.217024 
ENSG00000126549 STATH 0.680633 0.711194 
ENSG00000137976 DNASE2B 0.876936 0.741816 
ENSG00000109061 MYH1 0.674151 0.696355 
ENSG00000166948 TGM6 0.841987 0.816239 
ENSG00000135480 KRT7 0.630769 0.588095 
ENSG00000106648 GALNTL5 0.792087 0.808968 
ENSG00000156096 UGT2B4 0.4875 0.531566 
ENSG00000142513 ACPT 0.705426 0.875155 
ENSG00000155495 MAGEC1 1 1 
ENSG00000116016 EPAS1 0.892857 0.817272 
ENSG00000204787 REG1P 0.625714 0.907936 
ENSG00000143479 DYRK3 0.238533 0.224111 
ENSG00000101076 HNF4A 0.667304 0.730914 
ENSG00000100191 SLC5A4 0.803128 0.782252 
ENSG00000176979 TRIM60 0.887984 0.888205 
ENSG00000131730 CKMT2 0.8125 0.645714 
ENSG00000185621 LMLN 0.12384 0.202532 
ENSG00000101843 PSMD10 0.1 0.237075 
ENSG00000184922 FMNL1 0.516667 0.659326 
ENSG00000141977 CIB3 0.729167 0.401786 
492 
 
ENSG00000152977 ZIC1 0.19246 0.205506 
ENSG00000158186 MRAS 0.389593 0.313331 
ENSG00000197681 TBC1D3 0.66157 0.699013 
ENSG00000105695 MAG 0.416239 0.415661 
ENSG00000124134 KCNS1 0.555622 0.616667 
ENSG00000188089 PLA2G4E 0.75696 0.815992 
ENSG00000064012 CASP8 0.33349 0.458256 
ENSG00000121933 ADORA3 0.606429 0.652619 
ENSG00000113100 CDH9 0.841901 0.835137 
ENSG00000122691 TWIST1 0.313244 0.0227273 
ENSG00000155980 KIF5A 0.694286 0.539935 
ENSG00000173714 WFIKKN2 0.788889 0.822222 
ENSG00000183674 LINC00518 0.472559 0.662842 
ENSG00000115896 PLCL1 0.201284 0.172619 
ENSG00000151376 ME3 0.435714 0.398571 
ENSG00000124140 SLC12A5 0.269392 0.320933 
ENSG00000151789 ZNF385D 0.50453 0.336578 
ENSG00000086289 EPDR1 0.680482 0.614013 
ENSG00000161572 LYZL6 0.668791 0.731823 
ENSG00000204897 KRT25 0.395833 0.81713 
ENSG00000100321 SYNGR1 0.238095 0.593687 
ENSG00000175229 GAL3ST3 0.9375 0.643333 
ENSG00000163207 IVL 0.672421 0.7 
ENSG00000065029 ZNF76 0.495059 0.515031 
ENSG00000130167 TSPAN16 0.54482 0.574934 
ENSG00000101441 CST4 0.416667 0.6625 
ENSG00000112769 LAMA4 0.375789 0.340317 
ENSG00000136869 TLR4 0.608164 0.620553 
ENSG00000117298 ECE1 0.25 0.575 
493 
 
ENSG00000189320 FAM180A 0.95 0.609722 
ENSG00000138193 PLCE1 0.533541 0.539285 
ENSG00000196136 SERPINA3 0.937231 0.790641 
ENSG00000104970 KIR3DX1 0.809042 0.493032 
ENSG00000175426 PCSK1 0.263262 0.254901 
ENSG00000143867 OSR1 0.418889 0.56 
ENSG00000167363 FN3K 0.457143 0.655291 
ENSG00000130176 CNN1 0.779762 0.490151 
ENSG00000185686 PRAME 0.626389 0.690284 
ENSG00000167670 CHAF1A 0.0824074 0.115278 
ENSG00000028137 TNFRSF1B 0.50974 0.686963 
ENSG00000085265 FCN1 0.444444 0.780556 
ENSG00000139914 FITM1 0.636233 0.800463 
ENSG00000166527 CLEC4D 0.587446 0.538195 
ENSG00000140932 CMTM2 0.80071 0.597043 
ENSG00000158555 GDPD5 0.53198 0.526191 
ENSG00000163156 SCNM1 0.694394 0.566603 
ENSG00000149735 GPHA2 0.851191 0.821429 
ENSG00000004534 RBM6 0.616667 0.62963 
ENSG00000112659 CUL9 0.503987 0.473642 
ENSG00000253159 PCDHGA12 0.473297 0.373547 
ENSG00000164508 HIST1H2AA 0.863039 0.852002 
ENSG00000166793 YPEL4 0.237922 0.219413 
ENSG00000117971 CHRNB4 0.772511 0.843878 
ENSG00000119737 GPR75 0.844823 0.642337 
ENSG00000101473 ACOT8 0.531061 0.64425 
ENSG00000162367 TAL1 0.543403 0.272421 
ENSG00000112115 IL17A 0.814168 0.753266 
ENSG00000153820 SPHKAP 0.37698 0.252194 
494 
 
ENSG00000121481 RNF2 0.401992 0.573006 
ENSG00000152583 SPARCL1 0.542747 0.529038 
ENSG00000183304 FAM9A 0.833333 0.714286 
ENSG00000129221 AIPL1 0.861111 0.839087 
ENSG00000132932 ATP8A2 0.662637 0.663889 
ENSG00000112053 SLC26A8 0.589849 0.709762 
ENSG00000196344 ADH7 0.397186 0.503788 
ENSG00000116199 FAM20B 0.339598 0.430333 
ENSG00000145888 GLRA1 0.332209 0.166837 
ENSG00000183625 CCR3 0.733889 0.724206 
ENSG00000188629 ZNF177 0.450099 0.394159 
ENSG00000107560 RAB11FIP2 0.0656249 0.376675 
ENSG00000198046 ZNF667 0.5 0.39983 
ENSG00000136819 C9orf78 0.165179 0.401786 
ENSG00000102547 CAB39L 0.155102 0.430952 
ENSG00000179817 MRGPRX4 0.694921 0.750469 
ENSG00000116191 RALGPS2 0.751786 0.701026 
ENSG00000172057 ORMDL3 0.255952 0.254762 
ENSG00000066382 MPPED2 0.659722 0.347283 
ENSG00000132405 TBC1D14 0.608333 0.5625 
ENSG00000176928 GCNT4 0.821429 0.654239 
ENSG00000172350 ABCG4 0.292532 0.308333 
ENSG00000181638 ZFP41 0.162101 0.0911172 
ENSG00000123104 ITPR2 0.136657 0.229279 
ENSG00000147687 TATDN1 0.275788 0.372407 
ENSG00000178187 ZNF454 0.57465 0.5 
ENSG00000114200 BCHE 0.496004 0.5188 
ENSG00000102934 PLLP 0.421474 0.638515 
ENSG00000196542 SPTSSB 0.591843 0.761823 
495 
 
ENSG00000125965 GDF5 0.449711 0.504792 
ENSG00000112246 SIM1 0.292262 0.225062 
ENSG00000166501 PRKCB 0.512346 0.200661 
ENSG00000152749 GPR180 0.299287 0.372301 
ENSG00000185565 LSAMP 0.399662 0.294836 
ENSG00000171954 CYP4F22 0.270269 0.377899 
ENSG00000136827 TOR1A 0.462208 0.811984 
ENSG00000188613 NANOS1 0.25 0.8 
ENSG00000182240 BACE2 0.225397 0.554879 
ENSG00000120896 SORBS3 0.779546 0.896258 
ENSG00000178695 KCTD12 0.218707 0.1875 
ENSG00000135636 DYSF 0.360399 0.236667 
ENSG00000075826 SEC31B 0.497619 0.546212 
ENSG00000203710 CR1 0.518983 0.509613 
ENSG00000188386 PPP3R2 0.761235 0.760268 
ENSG00000165795 NDRG2 0.230159 0 
ENSG00000112337 SLC17A2 0.781041 0.780062 
ENSG00000149311 ATM 0.037037 0.107738 
ENSG00000038945 MSR1 0.70527 0.801996 
ENSG00000103546 SLC6A2 0.563136 0.725866 
ENSG00000128285 MCHR1 0.665 0.841856 
ENSG00000162972 C2orf47 0.379018 0.0971381 
ENSG00000239169 SNORD109B 0.572421 0.561868 
ENSG00000124574 ABCC10 0.675 0.430556 
ENSG00000185883 ATP6V0C 0.7 0.75 
ENSG00000028277 POU2F2 0.693734 0.721889 
ENSG00000073754 CD5L 0.563581 0.769994 
ENSG00000108556 CHRNE 0.382738 0.597959 
ENSG00000205358 MT1H 0.8125 0.764253 
496 
 
ENSG00000152672 CLEC4F 0.893333 0.809709 
ENSG00000164761 TNFRSF11B 0.277748 0.327521 
ENSG00000253953 PCDHGB4 0.45811 0.354898 
ENSG00000137674 MMP20 0.828691 0.700219 
ENSG00000187323 DCC 0.205436 0.249017 
ENSG00000116478 HDAC1 0.373486 0.49079 
ENSG00000125888 BANF2 0.609619 0.558677 
ENSG00000180138 CSNK1A1L 0.875794 0.86009 
ENSG00000182631 RXFP3 0.521516 0.458081 
ENSG00000173535 TNFRSF10C 0.8 0.678449 
ENSG00000146834 MEPCE 0.316942 0.3916 
ENSG00000146731 CCT6A 0.094697 0.26433 
ENSG00000033627 ATP6V0A1 0.430296 0.448106 
ENSG00000182983 ZNF662 0.827679 0.453897 
ENSG00000149435 GGTLC1 0.959375 0.833 
ENSG00000127603 MACF1 0.571925 0.754945 
ENSG00000180035 ZNF48 0.255626 0.332565 
ENSG00000136114 THSD1 0.688624 0.693753 
ENSG00000103569 AQP9 0.392744 0.500641 
ENSG00000125492 BARHL1 0.24854 0.198046 
ENSG00000264424 MYH4 0.671627 0.733929 
ENSG00000134256 CD101 0.823418 0.751754 
ENSG00000106331 PAX4 0.8125 0.451191 
ENSG00000173264 GPR137 0.25 0.25 
ENSG00000022267 FHL1 0.2 0.166667 
ENSG00000064601 CTSA 0.660715 0.660715 
ENSG00000177138 FAM9B 0.808333 0.666664 
ENSG00000104883 PEX11G 0.877273 0.629941 
ENSG00000186970 KRTAP15-1 0.763134 0.662382 
497 
 
ENSG00000188818 ZDHHC11 0.647619 0.469231 
ENSG00000170703 TTLL6 0.333331 0.382916 
ENSG00000134802 SLC43A3 0.388548 0.357576 
ENSG00000072163 LIMS2 0.802745 0.801332 
ENSG00000136542 GALNT5 0.49911 0.404896 
ENSG00000206190 ATP10A 0.85303 0.875 
ENSG00000145945 FAM50B 0.62 0.599921 
ENSG00000188001 TPRG1 0.416667 0.260417 
ENSG00000172016 REG3A 0.908334 0.62627 
ENSG00000136908 DPM2 0.448462 0.525 
ENSG00000136546 SCN7A 0.312843 0.272799 
ENSG00000154277 UCHL1 0.703635 0.544218 
ENSG00000086730 LAT2 0.698512 0.753363 
ENSG00000152795 HNRNPDL 0.222222 0.133333 
ENSG00000169340 PDILT 0.758841 0.736433 
ENSG00000099330 OCEL1 0.342108 0.550323 
ENSG00000177143 CETN1 0.802271 0.85114 
ENSG00000186965 KRTAP19-2 0.971282 0.692505 
ENSG00000171405 XAGE5 0.808333 0.76712 
ENSG00000127533 F2RL3 0.885714 0.65 
ENSG00000254122 PCDHGB7 0.542009 0.45617 
ENSG00000168917 SLC35G2 0.888889 0.612127 
ENSG00000115919 KYNU 0.698956 0.45592 
ENSG00000117016 RIMS3 0.479762 0.36 
ENSG00000059804 SLC2A3 0.444288 0.453846 
ENSG00000091844 RGS17 0.619048 0.42 
ENSG00000180152 AC079753.4 0.690477 0.764812 
ENSG00000269699 ZIM2 0.560328 0.568783 
ENSG00000149090 PAMR1 0.604858 0.520924 
498 
 
ENSG00000108700 CCL8 0.712743 0.783593 
ENSG00000103056 SMPD3 0.679412 0.816667 
ENSG00000179676 LINC00305 0.853401 0.736667 
ENSG00000186564 FOXD2 0.575635 0.473545 
ENSG00000146197 SCUBE3 0.497561 0.329236 
ENSG00000012048 BRCA1 0.0982249 0.499335 
ENSG00000127529 OR7C2 0.759127 0.762047 
ENSG00000167749 KLK4 0.756085 0.426389 
ENSG00000163879 DNALI1 0.699492 0.614105 
ENSG00000177324 BEND2 0.816749 0.780655 
ENSG00000154556 SORBS2 0.579071 0.664394 
ENSG00000197361 FBXL22 0.752628 0.453241 
ENSG00000147166 ITGB1BP2 0.833333 1 
ENSG00000160339 FCN2 0.714286 0.833333 
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